Clustering O 0 1.3818144907418173e-05
of O 0 4.875513468505233e-07
missense O 0 4.819920832233038e-06
mutations O 0 1.863391219103505e-08
in O 0 2.2311574809918966e-08
the O 0 2.9251586965983734e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
gene O 0 1.5609408592354157e-06
in O 0 2.520038577813466e-08
a O 0 1.0084489332484736e-07
sporadic B-Disease 0 7.240931154228747e-06
T I-Disease 0 0.008018651977181435
- I-Disease 0 0.03150701895356178
cell I-Disease 1 0.5654364824295044
leukaemia I-Disease 1 0.999996542930603
. O 0 9.175437298836187e-07

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999685287475586
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 3.092590006303908e-08
is O 0 1.1742620209531651e-09
a O 0 8.105461191121321e-09
recessive B-Disease 0 4.0857553784690026e-08
multi I-Disease 0 0.00013466877862811089
- I-Disease 1 0.9998065829277039
system I-Disease 0 0.00011609301145654172
disorder I-Disease 0 0.04077530652284622
caused O 0 2.077919560861119e-07
by O 0 4.0307810422746115e-09
mutations O 0 3.942578263860241e-09
in O 0 1.3436308954339893e-08
the O 0 3.7921756756986724e-07
ATM O 0 6.510585808428004e-05
gene O 0 2.8548807762263095e-08
at O 0 2.3889623435024987e-07
11q22 O 0 2.0333352495072177e-06
- O 0 1.2811526630684966e-06
q23 O 0 7.584875675092917e-06
( O 0 1.9742022061564057e-07
ref O 0 1.322723733210296e-06
. O 0 5.740128372622166e-09
3 O 0 1.0649149118080459e-07
) O 0 2.6623411031323485e-08
. O 0 4.551812793351928e-08

The O 0 4.809772917724331e-07
risk O 0 4.988082764612045e-07
of O 0 4.7214328446898435e-07
cancer B-Disease 0 1.1950785847147927e-05
, O 0 2.098738605127437e-08
especially O 0 1.074385451715898e-07
lymphoid B-Disease 1 0.990403413772583
neoplasias I-Disease 1 0.9982264637947083
, O 0 1.5134823172502365e-08
is O 0 2.007398247627634e-09
substantially O 0 2.0955146950996095e-08
elevated O 0 6.841020905312689e-08
in O 0 3.629146050343479e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 2.906461986640352e-07
and O 0 1.437707175533376e-09
has O 0 3.0924690586076053e-10
long O 0 2.1698238761302946e-09
been O 0 1.1414948986043782e-09
associated O 0 1.0393929272822788e-08
with O 0 1.5007193709948297e-08
chromosomal O 1 1.0
instability O 1 1.0
. O 0 5.3227417993184645e-06

By O 0 2.705727411012049e-07
analysing O 0 1.3458744433592074e-05
tumour B-Disease 1 0.9999998807907104
DNA O 0 3.2192713206313783e-07
from O 0 8.314342991866397e-09
patients O 0 5.356184940019659e-10
with O 0 1.0656753951510112e-10
sporadic B-Disease 0 2.4749156182224397e-06
T I-Disease 0 0.00013798079453408718
- I-Disease 0 2.7409778340370394e-05
cell I-Disease 0 2.3045551643008366e-05
prolymphocytic I-Disease 0 0.0001456800673622638
leukaemia I-Disease 1 0.78055739402771
( O 0 1.226027563916432e-07
T B-Disease 0 8.201179184652574e-07
- I-Disease 0 9.476768809690839e-07
PLL I-Disease 0 0.00021640327759087086
) O 0 3.351848132382429e-09
, O 0 2.0612861417745876e-10
a O 0 1.8326440365257213e-09
rare O 0 7.390854595001883e-09
clonal B-Disease 0 7.949362839099194e-07
malignancy I-Disease 0 1.8261942386743613e-05
with O 0 2.2822812528744407e-09
similarities O 0 2.530606302286742e-08
to O 0 2.6004978170846016e-09
a O 0 1.291031850314539e-07
mature B-Disease 0 8.351997848876636e-07
T I-Disease 0 5.193623564991867e-06
- I-Disease 0 3.5573787044995697e-06
cell I-Disease 0 1.0171772373723798e-05
leukaemia I-Disease 0 0.0006894085090607405
seen O 0 1.6548840164887224e-07
in O 0 6.048463063734744e-08
A B-Disease 1 0.9999998807907104
- I-Disease 0 0.0012879719724878669
T I-Disease 1 0.9952521324157715
, O 0 1.2239259605806296e-09
we O 0 8.373285953489074e-10
demonstrate O 0 3.0625462166256057e-09
a O 0 1.6755078435792825e-09
high O 0 3.187898833800773e-09
frequency O 0 2.0010182399943233e-09
of O 0 6.280461928298564e-09
ATM O 0 1.072063696483383e-06
mutations O 0 1.1013979062113322e-08
in O 0 1.6396614910263452e-07
T B-Disease 0 9.534114360576496e-05
- I-Disease 0 0.0001278006238862872
PLL I-Disease 0 0.056569281965494156
. O 0 1.06110474007437e-06

In O 0 8.164860219039838e-07
marked O 0 1.5993128954505664e-07
contrast O 0 1.810955474468301e-08
to O 0 2.3043531527378036e-09
the O 0 2.7677524272462506e-08
ATM O 0 4.329534476710251e-06
mutation O 0 2.232578122374207e-09
pattern O 0 2.5640087386591404e-08
in O 0 2.8908589300158383e-08
A B-Disease 1 1.0
- I-Disease 1 0.7548682689666748
T I-Disease 1 0.999995231628418
, O 0 1.621011880281742e-09
the O 0 1.538579708082466e-09
most O 0 7.111843752793945e-11
frequent O 0 6.513724559731315e-10
nucleotide O 0 2.1229058511096355e-09
changes O 0 7.302818766374841e-11
in O 0 3.455720432032905e-10
this O 0 5.606313635553306e-09
leukaemia B-Disease 0 0.0001055575194186531
were O 0 1.4013002669344132e-07
missense O 0 3.4910392514575506e-06
mutations O 0 7.749778774268634e-08
. O 0 9.895985186858525e-08

These O 0 1.577487722670412e-07
clustered O 0 9.927970268108766e-07
in O 0 1.2398853499462348e-08
the O 0 1.7329636392560133e-08
region O 0 4.219288385343134e-08
corresponding O 0 1.5746709891573119e-07
to O 0 1.6464865026932785e-08
the O 0 1.6087788878849096e-07
kinase O 0 1.5863852240727283e-05
domain O 0 1.4176102069995977e-07
, O 0 1.0975591963058307e-10
which O 0 2.6857727847273694e-11
is O 0 3.1291594315696614e-11
highly O 0 2.821079203574328e-10
conserved O 0 1.5423001542558268e-08
in O 0 9.728389649410474e-09
ATM O 0 7.124220246623736e-06
- O 0 8.949114516099144e-08
related O 0 4.1533830597018095e-08
proteins O 0 9.7856531766638e-09
in O 0 1.3972776713444546e-08
mouse O 0 3.493006062171844e-08
, O 0 2.879475824446587e-10
yeast O 0 3.665823200549312e-08
and O 0 1.8375978072526777e-08
Drosophila O 0 1.395072104060091e-06
. O 0 1.135859903911296e-07

The O 0 5.047025410931383e-07
resulting O 0 2.3919946556816285e-07
amino O 0 5.7065523861865586e-08
- O 0 3.4712613228293776e-08
acid O 0 1.5742500636406476e-08
substitutions O 0 1.627760504163689e-08
are O 0 9.595241268200994e-10
predicted O 0 3.0111710458413654e-08
to O 0 4.81558082299216e-09
interfere O 0 1.7321183065632795e-07
with O 0 2.953357380874877e-08
ATP O 0 0.0005498965620063245
binding O 0 1.0586914811483439e-07
or O 0 7.029065329788864e-08
substrate O 0 1.1262421821811586e-06
recognition O 0 3.4989145092367835e-07
. O 0 2.8086861902920646e-07

Two O 0 5.738871209359786e-07
of O 0 3.2335236710423487e-07
seventeen O 0 2.3652958134334767e-06
mutated O 0 1.0672528105715173e-06
T B-Disease 0 6.058692633814644e-06
- I-Disease 0 1.825836534408154e-06
PLL I-Disease 0 0.00022327709302771837
samples O 0 5.383865087082995e-08
had O 0 2.1879026590454487e-08
a O 0 1.4665593184304271e-08
previously O 0 7.53226103711313e-08
reported O 0 3.6644536294261343e-07
A B-Disease 1 0.9999996423721313
- I-Disease 1 0.9443604946136475
T I-Disease 1 0.9996022582054138
allele O 0 5.814870291942498e-07
. O 0 3.3191184911629534e-07

In O 0 1.305460557432525e-07
contrast O 0 1.552636597068613e-08
, O 0 8.90140683384999e-10
no O 0 1.1069298810895134e-09
mutations O 0 1.3539842858012463e-10
were O 0 1.8102120913354725e-09
detected O 0 6.638349869803051e-09
in O 0 1.6320624851573484e-09
the O 0 2.7359872589727274e-08
p53 O 0 2.4868910486475215e-08
gene O 0 6.179434186570631e-10
, O 0 1.2521997327930023e-10
suggesting O 0 3.923262159588603e-09
that O 0 3.0443331189289324e-10
this O 0 1.5362434879762077e-08
tumour B-Disease 1 1.0
suppressor O 0 6.256959022721276e-05
is O 0 7.819646596907148e-10
not O 0 1.784330044829474e-10
frequently O 0 1.6392502910633766e-09
altered O 0 1.1345452577415926e-08
in O 0 1.2674087557229541e-08
this O 0 2.0715522452974255e-07
leukaemia B-Disease 0 0.1389143466949463
. O 0 1.3952263770988793e-06

Occasional O 0 2.4967184799606912e-05
missense O 0 8.2593460319913e-06
mutations O 0 2.6924654505933177e-08
in O 0 2.226612849653975e-08
ATM O 0 3.2001021281757858e-06
were O 0 3.4065955389905866e-08
also O 0 1.2185499276284872e-09
found O 0 3.925208602595376e-09
in O 0 1.76412573438256e-08
tumour B-Disease 1 0.9999998807907104
DNA O 0 1.400172777721309e-07
from O 0 9.058918948312566e-09
patients O 0 7.740076635176507e-11
with O 0 6.915171907317941e-11
B B-Disease 0 2.6583114959066734e-05
- I-Disease 0 1.1870559319504537e-05
cell I-Disease 0 0.00018153437122236937
non I-Disease 0 0.0014740622136741877
- I-Disease 0 0.00011477894440758973
Hodgkins I-Disease 1 0.9999996423721313
lymphomas I-Disease 0 1.596569973116857e-06
( O 0 4.340005688163728e-09
B B-Disease 0 4.9134101232084504e-08
- I-Disease 0 6.0810583235593185e-09
NHL I-Disease 0 4.402907549660995e-08
) O 0 3.565287509665893e-10
and O 0 2.818046074271052e-10
a O 0 2.1138038874823906e-08
B B-Disease 0 1.2196339866932249e-06
- I-Disease 0 3.300671664874244e-07
NHL I-Disease 0 2.3509703623858513e-06
cell O 0 1.716488623060286e-05
line O 0 1.7041832052200334e-06
. O 0 4.824731263397553e-07

The O 0 2.1043788933639007e-07
evidence O 0 2.5042604079317243e-07
of O 0 3.308007379132505e-08
a O 0 8.825673525336697e-09
significant O 0 3.12122261370007e-09
proportion O 0 7.3477592898996136e-09
of O 0 1.1540966404766095e-08
loss O 0 1.7537666963107768e-07
- O 0 5.78486449853699e-08
of O 0 3.114361959433154e-07
- O 0 5.461413934426673e-07
function O 0 8.891471736660606e-08
mutations O 0 6.199811219964602e-10
and O 0 1.7670302721040088e-10
a O 0 2.0431640823659336e-09
complete O 0 3.02874489932492e-08
absence O 0 7.59900018465487e-08
of O 0 1.7617486136600746e-08
the O 0 6.806943453341319e-09
normal O 0 3.2337080568822785e-08
copy O 0 3.067692233571506e-08
of O 0 1.6558368898245135e-08
ATM O 0 3.722575456777122e-07
in O 0 1.3789451802637132e-09
the O 0 1.700365070966825e-09
majority O 0 4.5619599764457064e-10
of O 0 1.5215954718428293e-08
mutated O 0 1.7997923862367315e-07
tumours B-Disease 1 0.9999958276748657
establishes O 0 8.896119396695212e-08
somatic O 0 3.562653461131049e-08
inactivation O 0 4.2789615406491066e-08
of O 0 8.693850972463224e-09
this O 0 8.517873628655082e-10
gene O 0 2.8601426782515205e-10
in O 0 4.683435306240824e-10
the O 0 1.2805496218959433e-08
pathogenesis O 0 1.0056164683192037e-05
of O 0 1.1235923693675431e-06
sporadic B-Disease 0 4.713070666184649e-05
T I-Disease 0 0.00047718448331579566
- I-Disease 0 4.10744032706134e-05
PLL I-Disease 0 0.04120718687772751
and O 0 1.3307605017942592e-09
suggests O 0 7.050842132372281e-09
that O 0 1.5956724830346047e-10
ATM O 0 2.1599834099106374e-07
acts O 0 9.40111810621147e-09
as O 0 2.7096675125903857e-08
a O 0 1.2249937526576105e-06
tumour B-Disease 1 1.0
suppressor O 0 0.0001689911150606349
. O 0 1.4792524893891823e-07

As O 0 1.7568736154771614e-07
constitutional O 0 6.438826716248514e-08
DNA O 0 5.5185353176057106e-08
was O 0 1.8702206006082633e-08
not O 0 2.199071202912961e-10
available O 0 1.2605011479038808e-09
, O 0 9.727550986937672e-10
a O 0 6.137599228850377e-08
putative O 0 8.38431606098311e-06
hereditary O 0 0.15399447083473206
predisposition O 0 0.0008170657674781978
to O 0 6.3456400312134065e-06
T B-Disease 1 0.9582233428955078
- I-Disease 0 0.004568604752421379
PLL I-Disease 1 0.9805418252944946
will O 0 4.980464929360551e-09
require O 0 3.5618838989393e-09
further O 0 7.548883296237818e-09
investigation O 0 1.6570918148772762e-07
. O 0 1.4458286123897324e-08
. O 0 6.572912525371066e-08

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
protein O 0 8.069469186011702e-05
kinase O 0 5.636827609123429e-06
is O 0 3.2130839655586385e-10
involved O 0 3.342506549319779e-10
in O 0 3.9927267048156523e-10
the O 0 1.0289951113406914e-09
modulation O 0 8.846049226463037e-09
of O 0 4.046071033769749e-09
the O 0 2.6135271724569975e-08
Ca2 O 0 1.790128408174496e-05
+ O 0 1.4521182265525567e-06
homeostasis O 0 3.1533691071672365e-06
in O 0 3.43743558062215e-08
skeletal O 0 0.008177392184734344
muscle O 0 1.3586828572442755e-05
cells O 0 8.193039320758544e-06
. O 0 2.737554041232215e-07

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9906457662582397
DM B-Disease 1 1.0
) O 0 5.315349227430488e-08
, O 0 4.3684145190070467e-10
the O 0 2.1910211422948578e-09
most O 0 1.9450026034206758e-09
prevalent O 0 8.27733219921356e-06
muscular B-Disease 1 0.969376802444458
disorder I-Disease 0 0.11423061043024063
in O 0 6.659048068513584e-08
adults O 0 2.6068162739534273e-08
, O 0 3.1522493504354543e-09
is O 0 6.436319033298332e-09
caused O 0 2.4695530953522393e-08
by O 0 8.799653450353162e-09
( O 0 6.355599424523461e-08
CTG O 0 1.1986350727966055e-05
) O 0 3.1003963840703364e-09
n O 0 1.5560726041030648e-08
- O 0 3.327851549883576e-09
repeat O 0 8.786102512203797e-09
expansion O 0 8.0991258144536e-09
in O 0 1.6159830140693998e-09
a O 0 7.964257697778976e-09
gene O 0 1.263232851655971e-09
encoding O 0 3.961150962794591e-09
a O 0 1.9913938942295317e-08
protein O 0 2.0115545851240313e-07
kinase O 0 5.350030278350459e-06
( O 0 1.1558098123032323e-07
DM B-Disease 1 0.9999991655349731
protein O 0 4.7228604671545327e-07
kinase O 0 3.934227663648926e-07
; O 0 2.585580083369621e-10
DMPK O 0 1.0666993830454885e-06
) O 0 6.352369741335906e-10
and O 0 1.241914904248631e-10
involves O 0 4.434240086226282e-09
changes O 0 7.053393979994382e-10
in O 0 7.857461348237393e-09
cytoarchitecture O 0 5.6303379096789286e-06
and O 0 8.870755152656784e-08
ion O 0 9.275539923692122e-05
homeostasis O 0 0.34644976258277893
. O 0 1.250937998520385e-06

To O 0 1.6315409823164373e-07
obtain O 0 2.3918599367789284e-07
clues O 0 2.428843572488404e-06
to O 0 5.589848139919695e-09
the O 0 7.821380876293915e-09
normal O 0 1.0754639134802346e-07
biological O 0 3.2107476499732e-07
role O 0 1.2262965753961907e-07
of O 0 7.956408580866992e-07
DMPK O 0 0.00042946916073560715
in O 0 3.041068907805311e-08
cellular O 0 1.6923586088068987e-07
ion O 0 3.089121207722201e-07
homeostasis O 0 2.6129195248358883e-05
, O 0 1.41732492409119e-09
we O 0 2.041641078420753e-09
have O 0 1.1781066400207152e-10
compared O 0 8.105642268496638e-10
the O 0 1.3336776127914618e-09
resting O 0 3.463761970579071e-07
[ O 0 2.408928310160263e-07
Ca2 O 0 3.6511002576844476e-07
+ O 0 1.9171769949366535e-08
] O 0 3.9501277804276924e-09
i O 0 1.4623323663087717e-09
, O 0 1.1880466055380623e-10
the O 0 4.235700956645161e-10
amplitude O 0 4.20440793291732e-09
and O 0 1.9543355822548847e-10
shape O 0 5.8479296960456395e-09
of O 0 2.8710825716871113e-08
depolarization O 0 6.720640044477477e-08
- O 0 1.1338663341575739e-07
induced O 0 3.7664705132556264e-07
Ca2 O 0 4.0619789842821774e-07
+ O 0 1.8199688867071018e-08
transients O 0 1.555639350669935e-08
, O 0 5.962046828456025e-11
and O 0 7.117231110020938e-11
the O 0 2.296704826321161e-09
content O 0 8.539741358504216e-09
of O 0 4.836312328393433e-08
ATP O 0 6.887249583087396e-06
- O 0 3.63937061820252e-07
driven O 0 5.096480890642852e-07
ion O 0 1.9035684317714185e-07
pumps O 0 1.403014522338708e-07
in O 0 8.787292671286195e-09
cultured O 0 4.3375935092626605e-06
skeletal O 0 0.00039109180215746164
muscle O 0 2.605196414151578e-07
cells O 0 4.1412011597685705e-08
of O 0 2.1286401974407454e-08
wild O 0 9.374367060388522e-09
- O 0 1.659428505718097e-08
type O 0 1.888300360519679e-08
and O 0 2.6249162843328122e-09
DMPK O 0 8.401011655223556e-06
[ O 0 5.571940846493817e-07
- O 0 2.548028419369075e-07
/ O 0 8.537202234037977e-07
- O 0 5.16019724727812e-07
] O 0 5.510057121682621e-07
knockout O 0 7.109315902198432e-06
mice O 0 2.9013210678385803e-06
. O 0 1.0432903252421966e-07

In O 0 2.412549974906142e-06
vitro O 0 3.1722199764772085e-06
- O 0 3.8674383517900424e-07
differentiated O 0 1.5360976135525561e-07
DMPK O 0 1.7042877516360022e-05
[ O 0 8.660775847602054e-07
- O 0 5.758465135841107e-07
/ O 0 1.8929937368739047e-06
- O 0 7.178783221206686e-07
] O 0 4.7090082944123424e-07
myotubes O 0 1.8619969068822684e-06
exhibit O 0 5.452754692214512e-08
a O 0 9.160669556251833e-09
higher O 0 2.8113383621075627e-08
resting O 0 6.958426297387632e-07
[ O 0 5.544499117604573e-07
Ca2 O 0 6.238998366825399e-07
+ O 0 2.8047344002857244e-08
] O 0 6.1530456285652235e-09
i O 0 3.355801636573119e-09
than O 0 6.884695036291077e-10
do O 0 6.654865547517375e-10
wild O 0 5.2269344408273355e-09
- O 0 1.9272228257705137e-08
type O 0 6.016109921347379e-08
myotubes O 0 4.152617293584626e-06
because O 0 2.7673077163115067e-09
of O 0 6.555156861764999e-09
an O 0 2.0800152711331066e-09
altered O 0 3.3633564822110884e-09
open O 0 1.2668310844787811e-08
probability O 0 1.6262060142935297e-08
of O 0 5.198964814212559e-09
voltage O 0 2.4538097775916867e-08
- O 0 2.0923636157021974e-08
dependent O 0 6.993146683953455e-08
l O 0 2.06453822926278e-08
- O 0 1.689557493911309e-09
type O 0 4.4344341532109866e-09
Ca2 O 0 4.801953679134385e-08
+ O 0 6.431728927225322e-09
and O 0 1.988682774012318e-09
Na O 0 5.154720838618232e-06
+ O 0 2.1774997094325954e-07
channels O 0 1.4733701902969187e-07
. O 0 3.523236458136125e-08

The O 0 4.45874093202292e-06
mutant O 0 1.8515495412430027e-06
myotubes O 0 3.6108326639805455e-06
exhibit O 0 4.695980493352181e-08
smaller O 0 2.7635993493646538e-09
and O 0 1.5403532893643046e-09
slower O 0 9.770270281705962e-08
Ca2 O 0 2.7997165830129234e-07
+ O 0 1.252525905215407e-08
responses O 0 7.000587332051111e-10
upon O 0 3.5824669897266403e-09
triggering O 0 1.9704247122831475e-08
by O 0 4.604999936930199e-09
acetylcholine O 0 3.828284036444529e-07
or O 0 3.8753440456673616e-09
high O 0 4.082250271153498e-08
external O 0 9.647677643442876e-07
K O 0 1.024394623527769e-05
+ O 0 1.1658335097308736e-06
. O 0 9.236889297881135e-08

In O 0 3.9284802255679097e-07
addition O 0 5.164179839312055e-08
, O 0 3.3966347512404127e-09
we O 0 1.8507805288336954e-09
observed O 0 2.0201156303301104e-09
that O 0 8.359510306199525e-11
these O 0 1.3371952434226841e-09
Ca2 O 0 1.253192294825567e-06
+ O 0 2.0242558207428374e-07
transients O 0 5.1398391320844894e-08
partially O 0 8.450092181533364e-09
result O 0 3.022238015404355e-10
from O 0 2.435570911618612e-10
an O 0 2.5169089035159686e-10
influx O 0 1.8085692943259346e-09
of O 0 1.1871621907744156e-08
extracellular O 0 4.0146480273506313e-07
Ca2 O 0 3.203990672773216e-07
+ O 0 8.44456593540599e-09
through O 0 5.830074201185198e-10
the O 0 3.131884973583965e-09
l O 0 1.886881761947734e-08
- O 0 8.300572673647366e-09
type O 0 8.748665436542069e-08
Ca2 O 0 7.58522730848199e-07
+ O 0 1.515152376896367e-07
channel O 0 3.8207920738386747e-07
. O 0 4.4550457545255995e-08

Neither O 0 5.824516847496852e-06
the O 0 6.803752938822072e-08
content O 0 3.9358482695206476e-08
nor O 0 4.842478773525727e-08
the O 0 1.3794456243942932e-08
activity O 0 4.0728629358000035e-08
of O 0 3.128101866423094e-08
Na O 0 3.018191364390077e-06
+ O 0 7.349332520334428e-08
/ O 0 2.802713083838171e-08
K O 0 1.9778468640652136e-07
+ O 0 4.510690843062548e-08
ATPase O 0 5.474836939356464e-07
and O 0 1.745215860715632e-09
sarcoplasmic O 0 1.1234766361667425e-06
reticulum O 0 1.5869471781115863e-06
Ca2 O 0 1.0389221642981283e-06
+ O 0 1.0344549394858404e-07
- O 0 6.902426008537077e-08
ATPase O 0 3.577932375264936e-06
are O 0 4.2287104373706086e-10
affected O 0 2.842794666335635e-09
by O 0 8.99662033759796e-09
DMPK O 0 0.004325946792960167
absence O 0 4.002565401606262e-05
. O 0 2.886247784772422e-06

In O 0 2.405436418939644e-07
conclusion O 0 1.851184521228788e-07
, O 0 5.441552097806834e-09
our O 0 1.9311304555458264e-08
data O 0 4.169989153979259e-08
suggest O 0 1.3729018810693105e-08
that O 0 4.933219388547627e-10
DMPK O 0 5.83852033742005e-06
is O 0 3.986085683749252e-09
involved O 0 6.735022317627681e-09
in O 0 6.634198523869372e-09
modulating O 0 3.0772804393564e-07
the O 0 3.0108090243174956e-08
initial O 0 5.786630197235354e-08
events O 0 5.566516136923383e-09
of O 0 1.531305215962675e-08
excitation O 0 2.4487007976858877e-06
- O 0 3.1402964850713033e-06
contraction O 0 1.760180225574004e-06
coupling O 0 2.835794816746784e-07
in O 0 3.4733673714981705e-08
skeletal O 0 0.0003529828099999577
muscle O 0 8.390990160478395e-07
. O 0 5.499379795992354e-08
. O 0 1.6296453964059765e-07

Constitutional O 0 4.043045555590652e-05
RB1 O 1 0.6079054474830627
- O 0 5.5129139582277276e-06
gene O 0 2.1307686282057148e-08
mutations O 0 2.3974371377022408e-09
in O 0 1.920341663463887e-09
patients O 0 6.047096712258337e-10
with O 0 1.6037039474170456e-09
isolated O 0 3.3530350265209563e-06
unilateral B-Disease 0 3.901194759237114e-06
retinoblastoma I-Disease 1 0.9967045187950134
. O 0 5.569912900682539e-06

In O 0 1.0261423710744566e-07
most O 0 1.8988308703171697e-09
patients O 0 3.0311400611715555e-10
with O 0 1.1662973364856555e-10
isolated O 0 9.598069539151766e-08
unilateral B-Disease 0 5.1807834466899294e-08
retinoblastoma I-Disease 0 0.09012386947870255
, O 0 2.6261144370209877e-08
tumor B-Disease 0 5.07786899106577e-06
development O 0 3.453707364542424e-08
is O 0 4.038189505006784e-10
initiated O 0 3.220804511983033e-09
by O 0 1.8041652893874272e-10
somatic O 0 5.925774537729467e-09
inactivation O 0 4.228117589377689e-08
of O 0 4.4805914534151725e-09
both O 0 6.537124175309827e-10
alleles O 0 1.15822418322864e-09
of O 0 1.3101946194638003e-08
the O 0 2.6296285682292364e-07
RB1 O 0 0.0004601115651894361
gene O 0 2.8952356956324365e-07
. O 0 1.2606345478616277e-07

However O 0 3.944070101624675e-07
, O 0 1.2751090183726888e-09
some O 0 5.111021675330285e-11
of O 0 4.864329494758124e-10
these O 0 6.970368726655352e-10
patients O 0 3.2477500688798955e-09
can O 0 2.5019526450620333e-09
transmit O 0 1.1098595678049605e-06
retinoblastoma B-Disease 1 0.9959577918052673
predisposition O 1 0.6669192910194397
to O 0 5.979935480127097e-08
their O 0 1.2225785894770524e-07
offspring O 0 8.361043342119956e-07
. O 0 7.869147822248124e-08

To O 0 2.168608403962935e-08
determine O 0 1.5727103175322554e-08
the O 0 6.60757759618491e-09
frequency O 0 6.768272609036785e-09
and O 0 1.3568281220788236e-10
nature O 0 2.0545760648360556e-08
of O 0 1.7624206094524197e-08
constitutional O 0 1.9784769733632857e-07
RB1 O 0 0.000898483966011554
- O 0 7.902357879174815e-08
gene O 0 4.0014944135968733e-10
mutations O 0 3.777489779310805e-11
in O 0 6.524415036013309e-11
patients O 0 1.1377555148017748e-10
with O 0 1.0346823398066363e-10
isolated O 0 4.609862003235321e-08
unilateral B-Disease 0 1.2808598626179446e-08
retinoblastoma I-Disease 0 2.4652244974276982e-06
, O 0 2.6898805405295434e-10
we O 0 1.451651993056302e-10
analyzed O 0 6.800286556085666e-09
DNA O 0 5.259225499543163e-09
from O 0 2.898581819010815e-09
peripheral O 0 2.9908227361374884e-07
blood O 0 9.339530926411044e-09
and O 0 3.2552294193521902e-09
from O 0 4.02353293793567e-07
tumor B-Disease 0 0.12914495170116425
tissue O 0 0.000155796849867329
. O 0 4.042922512326186e-07

The O 0 4.659449359678547e-07
analysis O 0 9.763971320353448e-07
of O 0 7.335117402362812e-07
tumors B-Disease 1 1.0
from O 0 2.0058536165379337e-07
54 O 0 1.3970303314181365e-07
( O 0 1.3389798603213876e-08
71 O 0 3.3516773356723206e-08
% O 0 1.0571811204229675e-09
) O 0 1.0123268889827841e-10
of O 0 4.0025474601357303e-10
76 O 0 2.589689174214982e-08
informative O 0 1.5542593700956786e-07
patients O 0 1.1461942506230116e-09
showed O 0 5.805852687501556e-09
loss O 0 1.5896630145562085e-07
of O 0 2.56031256640199e-07
constitutional O 0 1.020612103275198e-06
heterozygosity O 1 0.9994221925735474
( O 0 0.00023072661133483052
LOH O 1 0.9999431371688843
) O 0 5.170210926053187e-08
at O 0 3.4477648114261683e-07
intragenic O 0 4.638831887859851e-05
loci O 0 3.0330804747791262e-06
. O 0 4.2551110368549416e-07

Three O 0 7.163395707721065e-07
of O 0 2.4700813128220034e-07
13 O 0 1.4491714637188124e-06
uninformative O 0 0.005038551054894924
patients O 0 4.4696685108647216e-07
had O 0 1.655082826346188e-07
constitutional O 0 8.417640060542908e-07
deletions O 0 2.405047098363866e-06
. O 0 1.1002368864865275e-06

For O 0 8.261925898978006e-08
39 O 0 4.6010249832306727e-08
randomly O 0 1.213100908614706e-08
selected O 0 1.6444973027773813e-07
tumors B-Disease 1 1.0
, O 0 2.7849952743963513e-07
SSCP O 0 0.19297584891319275
, O 0 6.619134751417732e-08
hetero O 0 3.2625898711557966e-06
- O 0 4.6774584205877545e-08
duplex O 0 3.5158399214196834e-07
analysis O 0 4.312034285192112e-09
, O 0 6.233993876669786e-11
sequencing O 0 7.314754912890464e-10
, O 0 1.4457030017567263e-10
and O 0 2.818417166317033e-10
Southern O 0 7.897382303667655e-09
blot O 0 2.736275064307847e-07
analysis O 0 1.3696351608416535e-08
were O 0 2.2877553185196575e-09
used O 0 6.5261357429236e-10
to O 0 1.3645029550701793e-09
identify O 0 4.388754959450125e-08
mutations O 0 2.2015878187175986e-07
. O 0 4.965462494510575e-07

Mutations O 0 1.1526685739227105e-06
were O 0 1.0475774558926787e-07
detected O 0 1.2354161071925773e-07
in O 0 6.1429252795619504e-09
21 O 0 7.117200340189811e-08
( O 0 9.12237929640014e-09
91 O 0 9.227151309687542e-08
% O 0 5.7760192184730386e-09
) O 0 9.492936436927835e-10
of O 0 2.4723007641114236e-08
23 O 0 4.15571266785264e-05
tumors B-Disease 1 1.0
with O 0 0.00044712063390761614
LOH O 1 1.0
. O 0 6.84944961903966e-06

In O 0 1.3858494867236004e-06
6 O 0 4.774031481247221e-07
( O 0 1.4501092771013191e-08
38 O 0 3.083719235519311e-08
% O 0 3.1773059738782194e-09
) O 0 6.541813757365844e-10
of O 0 9.885341434312522e-09
16 O 0 3.224868351026089e-06
tumors B-Disease 1 1.0
without O 1 0.5159943699836731
LOH O 1 1.0
, O 0 5.165635030834892e-09
one O 0 3.2987501619174964e-09
mutation O 0 4.40791986244804e-10
was O 0 8.942320661731173e-09
detected O 0 4.831810063166131e-09
, O 0 2.1690198248602854e-10
and O 0 3.8139144620252807e-10
in O 0 6.0776494947845094e-09
9 O 0 7.443711780297235e-08
( O 0 2.3798603088209802e-09
56 O 0 7.113085676024866e-09
% O 0 3.6055322616412866e-10
) O 0 9.976326015292969e-11
of O 0 1.9328871836421513e-09
the O 0 1.3639056817282835e-07
tumors B-Disease 1 1.0
without O 1 0.9960960745811462
LOH O 1 1.0
, O 0 1.6394753332704681e-09
both O 0 3.993481101360885e-10
mutations O 0 6.045643985430615e-10
were O 0 7.12563297255997e-09
found O 0 4.8863356028050475e-08
. O 0 9.937370037960136e-08

Thus O 0 2.0350967133708764e-06
, O 0 8.608312285218744e-09
a O 0 8.431898734784227e-09
total O 0 6.817507003376022e-09
of O 0 6.9901835431096515e-09
45 O 0 2.0162980618465554e-08
mutations O 0 1.229044421791059e-09
were O 0 5.03220976000307e-09
identified O 0 5.316404028121724e-08
in O 0 1.4217259547422145e-07
tumors B-Disease 1 1.0
of O 0 5.304330261424184e-05
36 O 0 1.9547944248188287e-05
patients O 0 9.581058435514933e-08
. O 0 1.474707147508525e-07

Thirty O 0 1.5952191461110488e-05
- O 0 3.0237407599997823e-07
nine O 0 3.868485265456911e-08
of O 0 5.991727114462719e-09
the O 0 5.7338254144667644e-09
mutations O 0 9.524712130115631e-10
- O 0 7.727236628340961e-09
including O 0 3.380861979263017e-10
34 O 0 1.5665012398358158e-08
small O 0 2.810907728800771e-09
mutations O 0 3.735412812400085e-10
, O 0 1.7205091518146531e-10
2 O 0 5.654844592584141e-09
large O 0 3.7591010304538486e-09
structural O 0 2.707968178583542e-06
alterations O 0 3.281119234088692e-07
, O 0 6.079655445745402e-09
and O 0 6.050064893514673e-09
hypermethylation O 0 3.183593071298674e-05
in O 0 6.324231662802049e-07
3 O 0 4.8748875997262076e-05
tumors O 1 1.0
- O 0 3.1895399388304213e-07
were O 0 1.60413922145608e-08
not O 0 3.4304237228610646e-10
detected O 0 1.9799060169134464e-09
in O 0 3.262388137414973e-10
the O 0 1.500466639825504e-09
corresponding O 0 3.5494746697395385e-08
peripheral O 0 1.1236567161176936e-06
blood O 0 9.721733817968925e-08
DNA O 0 6.923706905581639e-07
. O 0 7.223160736202772e-08

In O 0 1.4547600812875316e-06
6 O 0 5.547027512875502e-07
( O 0 7.832666959473045e-09
17 O 0 1.0715710985209626e-08
% O 0 1.1940423094713992e-09
) O 0 7.164493304179231e-11
of O 0 1.4043083362835773e-10
the O 0 6.511563510613882e-10
36 O 0 1.7965918530649105e-08
patients O 0 1.0409300088554119e-09
, O 0 2.0927924671010345e-10
a O 0 2.9889901664859053e-09
mutation O 0 3.21843246497977e-10
was O 0 7.599446405492927e-09
detected O 0 7.704102245043032e-09
in O 0 3.6522382340642423e-10
constitutional O 0 3.3387870246315288e-09
DNA O 0 1.5518816454118678e-08
, O 0 1.1284063961003454e-10
and O 0 1.198120769263511e-10
1 O 0 3.451255947695131e-09
of O 0 1.0833459684889135e-09
these O 0 1.6625220644606031e-10
mutations O 0 4.2677983369543426e-10
is O 0 1.4561472860830094e-10
known O 0 2.5509280798807765e-10
to O 0 3.452070851395206e-10
be O 0 2.664584997091879e-09
associated O 0 3.049409613709031e-08
with O 0 8.13692135892552e-09
reduced O 0 8.438867666882288e-07
expressivity O 0 0.0002359294448979199
. O 0 9.375512490805704e-07

The O 0 9.713410236145137e-07
presence O 0 9.349710694550595e-08
of O 0 8.905287529614725e-08
a O 0 3.5317544444524174e-08
constitutional O 0 2.3043805086331304e-08
mutation O 0 1.3408320009844488e-09
was O 0 1.449481690229959e-08
not O 0 3.3845265479115483e-10
associated O 0 3.537881099191509e-09
with O 0 9.009129553483319e-11
an O 0 2.857483138996031e-09
early O 0 1.0108156089927434e-07
age O 0 1.8749071273305162e-07
at O 0 6.541532684423146e-07
treatment O 0 8.829364617213287e-08
. O 0 8.549426411263994e-08

In O 0 4.616972262283525e-07
1 O 0 2.406014516509458e-07
patient O 0 1.0675200456944367e-07
, O 0 5.2335185074525725e-09
somatic O 0 6.447569944612042e-07
mosaicism O 0 6.073665645089932e-05
was O 0 1.1157765555935839e-07
demonstrated O 0 5.261844293613649e-09
by O 0 3.676406401531551e-10
molecular O 0 3.4355001066188606e-09
analysis O 0 1.1197879290492097e-09
of O 0 1.5585134294227032e-09
DNA O 0 9.01317775969801e-09
and O 0 3.760987077328082e-09
RNA O 0 8.958641615208762e-07
from O 0 1.2742056298975513e-07
peripheral O 0 3.0637234885944054e-05
blood O 0 2.292361614308902e-06
. O 0 1.6891028735699365e-06

In O 0 4.7025321237015305e-07
2 O 0 4.0763882225292036e-07
patients O 0 2.601192372608807e-09
without O 0 1.881734101871757e-09
a O 0 7.019202108438094e-09
detectable O 0 2.5283296167799563e-07
mutation O 0 1.67053937349948e-09
in O 0 3.785275648482411e-09
peripheral O 0 9.730072633828968e-06
blood O 0 1.9175117813574616e-06
, O 0 9.155886715461747e-08
mosaicism O 1 0.8654851317405701
was O 0 2.077591489069164e-06
suggested O 0 3.870832188113127e-08
because O 0 1.0601454158987167e-09
1 O 0 3.990566543876639e-09
of O 0 2.814459332256547e-09
the O 0 1.637851099189902e-08
patients O 0 1.0946275352807788e-07
showed O 0 2.2573713067686185e-05
multifocal O 1 1.0
tumors B-Disease 1 1.0
and O 0 1.0670071048934915e-07
the O 0 9.837494019393489e-08
other O 0 8.51985593186555e-10
later O 0 2.3998815379400185e-08
developed O 0 2.501476892291521e-08
bilateral B-Disease 0 3.7348188470787136e-06
retinoblastoma I-Disease 0 0.0007249372429214418
. O 0 9.000208933684917e-07

In O 0 2.0516476695320307e-07
conclusion O 0 5.344138571672374e-07
, O 0 7.244419730767504e-09
our O 0 1.0880804701685065e-08
results O 0 4.134222741924987e-09
emphasize O 0 4.12802148019864e-09
that O 0 2.4651128360808627e-10
the O 0 1.5722385615646317e-09
manifestation O 0 3.5283346733194776e-07
and O 0 2.3250679159758647e-09
transmissibility O 0 1.8142350199923385e-06
of O 0 3.4126113490628995e-08
retinoblastoma B-Disease 0 1.4698351833430934e-06
depend O 0 5.681204484631053e-08
on O 0 5.278259163077337e-09
the O 0 1.7734801405211442e-09
nature O 0 9.173853676713861e-09
of O 0 1.370094371289099e-09
the O 0 3.9439679300201647e-10
first O 0 1.1261944710128091e-09
mutation O 0 8.466475437396426e-11
, O 0 1.74691597992771e-11
its O 0 5.386568621701393e-11
time O 0 6.96191881921493e-10
in O 0 5.813517445218963e-10
development O 0 2.7254870360593486e-08
, O 0 4.5351691846384767e-10
and O 0 1.76899286885579e-10
the O 0 9.208629969670312e-10
number O 0 3.896651334933665e-10
and O 0 6.026563970085164e-11
types O 0 2.372725071975168e-10
of O 0 4.4502534990442655e-09
cells O 0 2.9990065986140735e-09
that O 0 9.329586408979296e-11
are O 0 1.1627789703316793e-10
affected O 0 3.0771374337490442e-09
. O 0 5.530091051753061e-09
. O 0 1.22621926834654e-07

Hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.8552654981613159
the I-Disease 0 2.0051005776622333e-05
fifth I-Disease 0 2.997493174916599e-05
component I-Disease 0 1.3429460523184389e-05
of I-Disease 0 1.1456285164967994e-06
complement I-Disease 0 1.6981283579298179e-06
in O 0 1.3588958154286956e-06
man O 0 9.99575640889816e-05
. O 0 2.7394341941544553e-06

I O 0 0.0017860569059848785
. O 0 2.091975875373464e-05

Clinical O 0 0.4147200286388397
, O 0 1.6354449883237976e-07
immunochemical O 0 0.0002479674876667559
, O 0 4.3870979737903326e-08
and O 0 2.2840154656478262e-08
family O 0 2.266359160785214e-06
studies O 0 1.1580523278098553e-06
. O 0 2.423819296382135e-07

The O 0 2.629072071158589e-07
first O 0 3.844762730409457e-08
recognized O 0 6.227561755167699e-08
human O 0 8.957123753816632e-08
kindred O 0 0.00021242303773760796
with O 0 8.874458217178471e-07
hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.9999998807907104
the I-Disease 0 0.00026434316532686353
fifth I-Disease 0 4.254217492416501e-05
component I-Disease 0 1.7604637832846493e-05
of I-Disease 0 1.1327632591928705e-06
complement I-Disease 0 1.8907852563643246e-06
( O 0 4.800489023182308e-06
C5 O 0 0.0013275454984977841
) O 0 2.2350759465439296e-08
is O 0 7.820932346191967e-09
described O 0 2.567082333371218e-07
. O 0 4.0648777144269843e-07

The O 0 5.721685738535598e-06
proband O 0 6.670704169664532e-05
, O 0 1.1365707308641504e-07
a O 0 1.5809607134542603e-07
20 O 0 1.5741680670089409e-07
- O 0 3.445844498628503e-08
year O 0 2.6214051374040537e-08
- O 0 1.7259183948681311e-07
old O 0 5.676010346178373e-07
black O 0 5.032557481854383e-08
female O 0 9.102569720198517e-08
with O 0 2.9675758739244884e-08
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 0 1.6668678881615051e-06
age O 0 1.2620782854355639e-06
11 O 0 2.8101379712097696e-07
, O 0 2.5521753599377917e-09
lacked O 0 1.204831733048195e-06
serum O 0 7.54105258238269e-06
hemolytic O 0 0.0005262650665827096
complement O 0 1.4843358258076478e-06
activity O 0 0.0008816334884613752
, O 0 1.5714262113775135e-09
even O 0 2.555604616816254e-09
during O 0 1.6530132995740132e-07
remission O 0 1.065459491655929e-05
. O 0 2.486673622570379e-07

C5 O 0 0.007726813666522503
was O 0 1.2945500202476978e-05
undetectable O 0 1.7252568795811385e-05
in O 0 1.0713834086573115e-07
her O 0 7.40444576763366e-08
serum O 0 1.2282558259357756e-07
by O 0 5.9757150339123655e-09
both O 0 1.2915855052142433e-08
immunodiffusion O 0 1.0039223525382113e-05
and O 0 1.6619505061044038e-07
hemolytic O 0 0.004971629939973354
assays O 0 4.565527706290595e-05
. O 0 3.5382518035476096e-06

Other O 0 1.2320681364030861e-08
complement O 0 3.573099505160826e-08
components O 0 8.263643991313074e-08
were O 0 7.554501024742422e-09
normal O 0 5.3416517431514876e-08
during O 0 1.8572526627735897e-08
remission O 0 2.2341643557410862e-07
of O 0 1.4561881300778623e-07
lupus O 0 2.316309917205217e-07
, O 0 1.7803060137211446e-09
but O 0 1.3745998117542513e-08
C1 O 0 0.0003586389357224107
, O 0 6.300970056827282e-08
C4 O 0 0.0015360643155872822
, O 0 8.231458537011349e-08
C2 O 0 1.3919032426201738e-05
, O 0 2.4389251507273002e-08
and O 0 6.92747263997262e-08
C3 O 0 0.23144203424453735
levels O 0 3.8437261537183076e-05
fell O 0 0.18434956669807434
during O 0 1.7617874618736096e-05
exacerbations O 0 0.023130491375923157
. O 0 1.6287502830891754e-06

A O 0 2.1130610548425466e-05
younger O 0 2.0114279664085188e-07
half O 0 1.2668799342918646e-07
- O 0 4.560659476737783e-07
sister O 0 1.1369517096682102e-06
, O 0 9.146806867477153e-09
who O 0 3.2865474786092364e-09
had O 0 9.967381231490435e-08
no O 0 6.560837846336653e-07
underlying O 1 0.9999957084655762
disease O 0 0.07080258429050446
, O 0 9.260063826843634e-09
was O 0 1.6314490949298488e-06
also O 0 5.720465434677635e-09
found O 0 6.918133621525158e-09
to O 0 9.088513053256975e-09
lack O 0 2.4498031052644365e-06
immunochemically O 0 0.002957342891022563
detectable O 0 0.002445568097755313
C5 O 0 0.001003770623356104
. O 0 5.677250101143727e-07

By O 0 2.0044590200996026e-06
hemolytic O 0 0.004658122546970844
assay O 0 3.9702335925539955e-06
, O 0 1.629347856635377e-08
she O 0 2.3629361578514363e-08
exhibited O 0 6.839325550345166e-08
1 O 0 1.4319164165499387e-07
- O 0 4.42599485950268e-08
2 O 0 2.8874424629066198e-08
% O 0 1.1950858080922444e-09
of O 0 1.1591833048996136e-09
the O 0 6.217601100644288e-09
normal O 0 1.6581319073338818e-07
serum O 0 4.214414559555735e-07
C5 O 0 6.074683824408567e-06
level O 0 6.734151725140691e-08
and O 0 2.1603907551792645e-10
normal O 0 7.111335964538057e-09
concentrations O 0 4.84505324749307e-09
of O 0 1.8898773657127776e-09
other O 0 3.504821155519977e-10
complement O 0 3.615238597376447e-08
components O 0 1.17438571578532e-06
. O 0 1.8518765898534184e-07

C5 O 0 0.0014241330791264772
levels O 0 1.3405766594587476e-06
of O 0 1.2424189321791346e-07
other O 0 3.3997396009510794e-09
family O 0 1.779770464338526e-08
members O 0 2.2252180653659082e-10
were O 0 4.947733334148552e-09
either O 0 2.1303094399627298e-08
normal O 0 1.2207632948957325e-07
or O 0 2.9428242065421273e-09
approximately O 0 1.86408710689534e-09
half O 0 8.611301005601035e-09
- O 0 2.704359580718574e-08
normal O 0 1.612486322244422e-08
, O 0 1.0521234578009242e-10
consistent O 0 5.0580566401947635e-09
with O 0 3.4223593403659436e-10
autosomal O 0 9.927196487069523e-08
codominant O 0 4.635223831428448e-07
inheritance O 0 2.8990418954322195e-08
of O 0 8.363282510970294e-09
the O 0 2.2009700728631287e-08
gene O 0 6.025847909540971e-08
determining O 0 7.87707631388912e-06
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 3.1589252103003673e-06

Normal O 0 0.0023925674613565207
hemolytic O 1 0.916632354259491
titers O 0 0.0005199118168093264
were O 0 4.876675916420936e-07
restored O 0 3.165983741837408e-07
to O 0 5.8947176029278125e-09
both O 0 9.125808553278603e-09
homozygous O 0 6.182517608976923e-07
C5 B-Disease 1 1.0
- I-Disease 1 0.9999986886978149
deficient I-Disease 1 1.0
( O 0 1.0167078471567947e-05
C5D B-Disease 1 1.0
) O 0 1.6588501239311881e-07
sera O 0 2.3117954697227105e-06
by O 0 8.205492396662351e-10
addition O 0 1.7614519842723553e-09
of O 0 1.9437203846450757e-08
highly O 0 1.3488515548942814e-07
purified O 0 4.334244295023382e-06
human O 0 1.2025644764435128e-06
C5 O 0 0.0002835260529536754
. O 0 6.508415708594839e-07

In O 0 1.3167806400815607e-06
specific O 0 5.157978648639983e-07
C5 O 0 0.00023526408767793328
titrations O 0 2.6272819013684057e-05
, O 0 5.705635075514692e-09
however O 0 7.960536230200432e-09
, O 0 1.6412964320977608e-09
it O 0 2.362248729959049e-10
was O 0 4.460623515001316e-08
noted O 0 4.04746014481816e-09
that O 0 5.904377681220652e-11
when O 0 2.807423460371439e-10
limited O 0 9.54515355644503e-10
amounts O 0 5.297543292925866e-09
of O 0 8.784028437958113e-08
C5 O 0 1.0270612619933672e-05
were O 0 1.8934141365889445e-08
assayed O 0 1.016356804939278e-06
in O 0 5.0293507136700555e-09
the O 0 2.900180096077065e-09
presence O 0 3.272991655478563e-09
of O 0 2.0979022963274474e-08
low O 0 1.5692711485826294e-07
dilutions O 0 2.8709239359159255e-06
of O 0 2.7735029561881674e-07
either O 0 1.0375963483966189e-06
C5D B-Disease 1 1.0
serum O 0 4.0927468944573775e-05
, O 0 9.474490525462897e-09
curving O 0 3.036756623941983e-08
rather O 0 1.0458973687121897e-09
than O 0 1.4626859445865392e-10
linear O 0 4.564677524854233e-09
dose O 0 2.5087874888640727e-08
- O 0 8.997787404041446e-09
response O 0 1.5965380129046025e-09
plots O 0 3.7891638271503325e-08
were O 0 1.0582428267014166e-08
consistently O 0 5.787587298300423e-09
obtained O 0 1.1108877373544601e-08
, O 0 6.658890105981641e-10
suggesting O 0 8.503674209237033e-09
some O 0 7.282875413849865e-10
inhibitory O 0 4.1438173070673656e-07
effect O 0 5.7183083157497094e-08
. O 0 1.0118166926531558e-07

Further O 0 1.0024269840869238e-06
studies O 0 1.8191070694228983e-07
suggested O 0 3.2115618608941077e-08
that O 0 8.997474432170804e-10
low O 0 1.0860469501494663e-07
dilutions O 0 6.347879207169171e-06
of O 0 1.4848736782369087e-06
C5D B-Disease 1 1.0
serum O 0 1.586423059052322e-05
contain O 0 2.8839746590847426e-08
a O 0 1.7591631262803276e-08
factor O 0 8.561449327260107e-09
( O 0 2.9500554776795695e-10
or O 0 3.933074976814055e-10
factors O 0 9.0014777853753e-09
) O 0 1.100154412014831e-09
interfering O 0 2.443436919463693e-08
at O 0 3.992456854007287e-08
some O 0 9.256245769861948e-10
step O 0 1.838526841879684e-08
in O 0 1.0905113256853838e-08
the O 0 6.175091726845494e-08
hemolytic O 0 0.0001571321045048535
assay O 0 8.255518878286239e-06
of O 0 1.7835100152296945e-05
C5 O 0 0.08083118498325348
, O 0 4.079236060050562e-09
rather O 0 6.374426320121529e-09
than O 0 1.424094064894632e-09
a O 0 2.6231658623032672e-08
true O 0 5.556467499445716e-07
C5 O 0 4.692400398198515e-05
inhibitor O 0 1.8654557152331108e-06
or O 0 9.268674006079891e-08
inactivator O 0 2.144063364539761e-05
. O 0 4.1460941702098353e-07

Of O 0 2.720174734349712e-06
clinical O 0 6.69983091938775e-06
interest O 0 1.0635097851263708e-06
are O 0 1.866762744384687e-09
( O 0 2.0499795194695025e-09
a O 0 2.3636697044082666e-09
) O 0 2.36262703845469e-10
the O 0 5.578725814636698e-10
documentation O 0 2.846090012553759e-07
of O 0 4.229323735671642e-07
membranous O 1 1.0
glomerulonephritis B-Disease 1 1.0
, O 0 0.0002395874762441963
vasculitis B-Disease 1 1.0
, O 0 1.1319275472487789e-06
and O 0 1.815521864045877e-05
arthritis B-Disease 1 1.0
in O 0 5.329599389369832e-06
an O 0 7.288023198270821e-07
individual O 0 1.087140731215186e-06
lacking O 0 0.0012559851165860891
C5 O 0 0.001954610925167799
( O 0 1.661027582144925e-08
and O 0 2.227907192065004e-09
its O 0 2.8070554769499267e-09
biologic O 0 5.005361458643165e-07
functions O 0 1.198158550153039e-08
) O 0 3.290177297277097e-10
, O 0 6.696868753985896e-11
and O 0 1.3644085861130861e-10
( O 0 1.0807998052086987e-08
b O 0 1.2057795117925707e-07
) O 0 2.1810351302775643e-09
a O 0 2.3240347424291485e-09
remarkable O 0 4.855278490367709e-08
propensity O 0 4.392096286665037e-07
to O 0 1.1786000619906645e-08
bacterial B-Disease 1 1.0
infections I-Disease 1 1.0
in O 0 1.710760386686161e-07
the O 0 3.841691693651228e-07
proband O 0 3.781806299230084e-05
, O 0 1.2013158245949285e-09
even O 0 2.4289370514907205e-10
during O 0 2.6149868936897747e-09
periods O 0 1.426031985829468e-07
of O 0 1.0299621777676293e-07
low O 0 2.703168888729124e-07
- O 0 9.847609838686822e-09
dose O 0 3.379021862315312e-08
or O 0 2.285740041685358e-09
alternate O 0 9.074587303814496e-09
- O 0 1.923561399053142e-08
day O 0 6.843017530400175e-08
corticosteroid O 0 8.182561032299418e-06
therapy O 0 3.571944762370549e-05
. O 0 9.255742128289057e-08

Other O 0 7.470907803508453e-08
observations O 0 8.875339290170814e-07
indicate O 0 1.0759502089285888e-07
that O 0 1.2484944189594671e-09
the O 0 3.46984485588564e-08
C5D B-Disease 1 1.0
state O 0 1.3717475155772263e-08
is O 0 8.243847271494076e-10
compatible O 0 3.7572087663306775e-09
with O 0 1.393387905057608e-10
normal O 0 7.025928994153219e-08
coagulation O 0 2.966122281122807e-07
function O 0 1.4256443137128372e-07
and O 0 9.222216323934163e-10
the O 0 1.1071225713976673e-08
capacity O 0 7.033638382836216e-08
to O 0 2.9337689610997586e-08
mount O 0 6.097994264564477e-05
a O 0 2.0491518171183998e-06
neutrophilic O 1 0.9846932888031006
leukocytosis O 0 0.003228297457098961
during O 0 3.5077523534710053e-06
pyogenic B-Disease 0 0.369858980178833
infection I-Disease 0 1.1310295121802483e-05
. O 0 1.5741237646693662e-08
. O 0 6.716129519190872e-08

Susceptibility O 0 0.0036184038035571575
to O 0 1.4775108866160735e-05
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 0.000115282426122576
twins O 0 5.55351334696752e-06
: O 0 4.188072999511405e-09
the O 0 4.054012237020288e-09
role O 0 2.7953722891993493e-08
of O 0 1.5140878417696513e-07
genes O 0 1.69837885977131e-08
, O 0 9.703020609208579e-09
HLA O 0 2.047540192506858e-06
, O 0 1.7611730962485694e-09
and O 0 1.8701447057623e-09
the O 0 1.1343822592380093e-07
environment O 0 3.059680466321879e-06
. O 0 2.38895779602899e-07

OBJECTIVE O 0 8.724736835574731e-05
To O 0 9.95696414207714e-09
determine O 0 6.86656198567448e-09
the O 0 1.9287516028754226e-09
relative O 0 5.330588592755703e-08
effects O 0 6.353842252337927e-08
of O 0 6.848916989099507e-09
genetic O 0 6.251658746236899e-09
and O 0 1.820592010481903e-10
environmental O 0 3.1846716375127926e-09
factors O 0 4.478019732800931e-09
in O 0 1.3663233877636571e-09
susceptibility O 0 7.602523055538768e-08
to O 0 1.4647540069745446e-07
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 1 0.999663233757019
AS B-Disease 1 0.9999996423721313
) O 0 1.2722823328203958e-07
. O 0 4.987673563050521e-08

METHODS O 0 0.0001525946572655812
Twins O 0 8.273902494693175e-05
with O 0 3.679216220575654e-08
AS B-Disease 1 0.999994158744812
were O 0 9.748826101940722e-08
identified O 0 1.8058127437825533e-08
from O 0 2.5582185259054313e-09
the O 0 9.72792602027539e-09
Royal O 0 4.44961478933692e-05
National O 0 2.043761924142018e-05
Hospital O 1 0.9984986782073975
for O 0 4.187659783383424e-07
Rheumatic B-Disease 1 1.0
Diseases I-Disease 1 1.0
database O 1 0.9966506361961365
. O 0 1.9267101833975175e-06

Clinical O 0 9.550221147947013e-05
and O 0 1.9951805541040812e-08
radiographic O 0 4.028149760415545e-06
examinations O 0 8.519500624970533e-06
were O 0 4.796296693143631e-08
performed O 0 1.2821088191117269e-08
to O 0 8.281308416790978e-10
establish O 0 2.5240263212822356e-08
diagnoses O 0 1.3261956155474763e-07
, O 0 1.590883980107094e-09
and O 0 2.9526183720207655e-09
disease O 0 7.550080454166164e-07
severity O 0 6.388268047885504e-07
was O 0 9.616301355208634e-08
assessed O 0 2.791972697480105e-08
using O 0 7.706273397189989e-10
a O 0 8.971050569073213e-10
combination O 0 7.108606481232016e-10
of O 0 3.6548186699292273e-09
validated O 0 3.525717318098032e-08
scoring O 0 1.2407588201313047e-07
systems O 0 1.0510412948860903e-06
. O 0 3.6040236750523036e-07

HLA O 0 0.00013054741430096328
typing O 0 6.89670105202822e-06
for O 0 1.4719796581630362e-07
HLA O 0 3.4399063224554993e-06
- O 0 4.0178423432735144e-07
B27 O 0 1.5775253814354073e-06
, O 0 3.053810004871593e-08
HLA O 0 4.431460638443241e-07
- O 0 6.726654788735686e-08
B60 O 0 3.930792331630073e-07
, O 0 6.3947873663039445e-09
and O 0 3.792894887055809e-08
HLA O 0 2.2915375666343607e-05
- O 0 5.701036570826545e-06
DR1 O 0 0.0017438600771129131
was O 0 1.250880217185113e-07
performed O 0 7.469906471158083e-09
by O 0 3.5048435265139233e-09
polymerase O 0 9.732847416898949e-08
chain O 0 9.975308579157627e-09
reaction O 0 4.518470597680846e-10
with O 0 4.1940961120756626e-11
sequence O 0 6.6746865812206124e-09
- O 0 2.472785087803686e-09
specific O 0 5.583846718337782e-10
primers O 0 1.0311647535843349e-08
, O 0 6.173732081116157e-10
and O 0 2.0156971647367072e-09
zygosity O 0 2.560027041909052e-06
was O 0 3.032525626167626e-07
assessed O 0 3.189141466464207e-07
using O 0 8.049216404515391e-08
microsatellite O 0 1.1958173672610428e-05
markers O 0 2.637771785884979e-06
. O 0 5.549154593609273e-07

Genetic O 0 9.051493179867975e-06
and O 0 7.688571557196155e-09
environmental O 0 2.0961303803801457e-08
variance O 0 5.284917836689829e-09
components O 0 2.7182188944152585e-08
were O 0 4.407493037206223e-09
assessed O 0 2.679376187586513e-08
with O 0 4.567139999522851e-10
the O 0 1.0341881129249941e-08
program O 0 2.2597278714897584e-08
Mx O 0 6.385691335708543e-07
, O 0 5.398767197184462e-11
using O 0 1.0555928353639388e-10
data O 0 1.7870626090044084e-09
from O 0 1.855161996244803e-10
this O 0 3.6956421256562066e-10
and O 0 2.0027851599380142e-10
previous O 0 1.5977024148128294e-08
studies O 0 2.4489612115985437e-08
of O 0 1.3017950273308543e-08
twins O 0 1.5808552689122735e-07
with O 0 7.826424841539392e-09
AS B-Disease 1 1.0
. O 0 1.990590590139618e-06

RESULTS O 0 1.510808306193212e-05
Six O 0 2.348352836634149e-06
of O 0 1.2747372011290281e-06
8 O 0 5.255295036477037e-06
monozygotic O 0 0.00016595458146184683
( O 0 5.134869752509985e-06
MZ O 0 0.34161055088043213
) O 0 5.1891799301984065e-08
twin O 0 4.998968847758078e-07
pairs O 0 1.7673759344916107e-08
were O 0 1.405398251108636e-07
disease O 0 3.5139490250912786e-07
concordant O 0 4.352116320660571e-06
, O 0 3.82499720785745e-09
compared O 0 1.0108691661514513e-08
with O 0 3.5152855626385815e-10
4 O 0 5.3501555186130645e-08
of O 0 1.9548668461766283e-08
15 O 0 3.067388121280601e-08
B27 O 0 3.4964560313710535e-07
- O 0 8.357194758445985e-08
positive O 0 3.646381330213444e-08
dizygotic O 0 1.1852675015688874e-05
( O 0 1.4802120062995527e-07
DZ O 0 0.00013017772289458662
) O 0 1.7510950911514556e-08
twin O 0 1.2099113178010157e-07
pairs O 0 3.0806082129686274e-09
( O 0 1.8951475944106733e-09
27 O 0 2.4872468529224534e-08
% O 0 3.9620124958617e-09
) O 0 2.4674742804542404e-10
and O 0 4.4642620156132296e-10
4 O 0 6.263488927515937e-08
of O 0 3.520100335663301e-07
32 O 0 9.868605957308318e-06
DZ O 1 0.9553064703941345
twin O 0 1.0807752005348448e-05
pairs O 0 4.440818557327475e-08
overall O 0 1.8688517400278215e-07
( O 0 3.4406870685899094e-09
12 O 0 2.5851965013146128e-09
. O 0 2.613290417396996e-10
5 O 0 7.04788449823468e-09
% O 0 1.9587960142786187e-09
) O 0 3.273821880256378e-09
. O 0 1.7092199655621698e-08

Nonsignificant O 0 0.0009227180853486061
increases O 0 5.605705837297137e-07
in O 0 1.1010470757355506e-08
similarity O 0 2.0624012719849816e-08
with O 0 1.8942757085138595e-10
regard O 0 5.704590577693125e-09
to O 0 4.0043346416496206e-10
age O 0 3.52774200962358e-08
at O 0 8.681887493366958e-07
disease O 0 7.894024633969821e-07
onset O 0 4.121908659726614e-06
and O 0 3.350133781498954e-10
all O 0 1.563291024408997e-10
of O 0 9.922550558982834e-10
the O 0 2.115085218079571e-09
disease O 0 2.3802415594076365e-09
severity O 0 2.4468029824475934e-09
scores O 0 6.793256512871437e-10
assessed O 0 1.3369427787068844e-09
were O 0 7.160808057626866e-10
noted O 0 3.6594149932511755e-09
in O 0 7.310045013753097e-09
disease O 0 1.1207840771021438e-06
- O 0 2.039308583334787e-06
concordant O 0 0.00034977239556610584
MZ O 0 0.2420264482498169
twins O 0 1.4510522987620789e-06
compared O 0 4.8456197276891544e-08
with O 0 1.462910592664457e-08
concordant O 0 0.00026344272191636264
DZ O 1 0.9928699135780334
twins O 0 0.0001110123994294554
. O 0 1.871833774202969e-06

HLA O 0 0.0012231445871293545
- O 0 7.877511052356567e-06
B27 O 0 7.247037956403801e-06
and O 0 1.5462440217106632e-08
B60 O 0 1.4056007557883277e-06
were O 0 2.6077611181563043e-08
associated O 0 9.550221058418629e-09
with O 0 1.0545289086394405e-09
the O 0 1.8920573552350106e-07
disease O 0 8.602703928772826e-06
in O 0 3.234559642351087e-08
probands O 0 0.00036753647145815194
, O 0 2.04395922409617e-09
and O 0 1.1274770006508561e-10
the O 0 1.26261379129744e-09
rate O 0 1.8024334025312783e-08
of O 0 5.4610995725568046e-09
disease O 0 2.0101925457538528e-08
concordance O 0 9.490175045812066e-08
was O 0 1.7752070036181067e-08
significantly O 0 3.6772922484828996e-09
increased O 0 9.30100796381339e-09
among O 0 2.824526390554638e-09
DZ O 0 0.0001748668437357992
twin O 0 1.8164494974826084e-07
pairs O 0 2.586187930475603e-09
in O 0 1.4807133297267683e-09
which O 0 9.232055120378391e-10
the O 0 1.0991104915092365e-08
co O 0 2.0751583633682458e-06
- O 0 5.264116111902695e-07
twin O 0 8.081457849584694e-07
was O 0 4.960795152442188e-08
positive O 0 2.064986182048756e-09
for O 0 9.43596423219617e-10
both O 0 1.086624568102934e-08
B27 O 0 1.115448321797885e-05
and O 0 1.4718352758791298e-06
DR1 O 1 0.8852296471595764
. O 0 1.8110820292349672e-06

Additive O 0 5.292080004437594e-06
genetic O 0 1.159549185558717e-07
effects O 0 9.456981331368297e-08
were O 0 4.469921766059315e-09
estimated O 0 1.2620455791534368e-09
to O 0 9.774562409470278e-11
contribute O 0 2.0644308484918383e-09
97 O 0 3.0143920071168395e-07
% O 0 8.794615036222808e-10
of O 0 5.853137974298761e-10
the O 0 9.251550636690808e-10
population O 0 1.746943562030978e-10
variance O 0 4.607020542835016e-09
. O 0 1.4113827440098703e-08

CONCLUSION O 0 4.2558855056995526e-05
Susceptibility O 0 9.821117600949947e-06
to O 0 3.682951543737545e-08
AS B-Disease 1 0.655510663986206
is O 0 6.704504951215995e-09
largely O 0 1.498585611159342e-08
genetically O 0 2.282393163355323e-10
determined O 0 2.137671595292545e-09
, O 0 2.525376852080541e-10
and O 0 1.9099594128491049e-10
the O 0 8.703572973445262e-09
environmental O 0 4.5290708072798225e-08
trigger O 0 1.1005410804898474e-08
for O 0 6.006141139991428e-10
the O 0 2.248802388749027e-08
disease O 0 8.173710170922277e-07
is O 0 3.5468674663974298e-09
probably O 0 4.17554474552162e-07
ubiquitous O 0 1.8100702163792448e-06
. O 0 9.390852540036576e-08

HLA O 0 0.0003733135818038136
- O 0 1.4180118341755588e-06
B27 O 0 1.2879295354650822e-06
accounts O 0 3.1619698859230994e-08
for O 0 7.138743485235466e-10
a O 0 5.165398331286042e-09
minority O 0 1.466438304120743e-09
of O 0 1.5855251556118333e-09
the O 0 9.056171812460434e-09
overall O 0 1.838627383676794e-07
genetic O 0 1.150670385641206e-07
susceptibility O 0 4.191255342789191e-08
to O 0 1.4070552722955654e-08
AS B-Disease 1 0.9999853372573853
. O 0 7.306304041776457e-07

Cell O 0 0.00013651377230416983
cycle O 0 5.293301455822075e-06
- O 0 8.410747227571846e-07
dependent O 0 4.277557934528886e-07
colocalization O 0 2.1996036139171338e-06
of O 0 2.798574030293821e-07
BARD1 O 0 0.0008806990226730704
and O 0 3.615107502241699e-08
BRCA1 O 0 3.3657581610668785e-08
proteins O 0 1.5606254066824476e-09
in O 0 1.4552816729462847e-09
discrete O 0 9.37172544013265e-08
nuclear O 0 3.757235617740662e-06
domains O 0 1.2526184036687482e-05
. O 0 3.040828744360624e-07

Germ O 1 0.6166924834251404
- O 0 3.441714579821564e-05
line O 0 2.708404736040393e-07
mutations O 0 7.215873676358342e-09
of O 0 1.981278252571883e-08
the O 0 1.0302548503204889e-07
BRCA1 O 0 4.328005331899476e-07
gene O 0 8.05188538066659e-09
predispose O 0 6.953710141033298e-08
women O 0 6.511812200571399e-10
to O 0 8.567455633823329e-10
early O 0 9.232448405782634e-07
- O 0 2.4648374164826237e-05
onset O 1 0.9999880790710449
breast B-Disease 1 1.0
and I-Disease 1 0.9999891519546509
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 4.017726951133227e-08
compromising O 0 3.1786339604877867e-06
the O 0 1.9413565865988858e-08
genes O 0 4.879059822826548e-09
presumptive O 0 5.764103150340816e-08
function O 0 5.4974056418188866e-09
as O 0 1.7849164368755055e-09
a O 0 4.722369340015575e-08
tumor B-Disease 0 1.1088650353485718e-05
suppressor O 0 9.079964002012275e-06
. O 0 1.1863250648502799e-07

Although O 0 1.377563592086517e-07
the O 0 4.716464374610041e-08
biochemical O 0 3.333095946800313e-06
properties O 0 6.697894605167676e-06
of O 0 1.1549595910764765e-06
BRCA1 O 0 5.839917776029324e-07
polypeptides O 0 9.418908319958064e-08
are O 0 5.302828176567687e-10
not O 0 2.6930380148115773e-10
understood O 0 1.6591183538139376e-08
, O 0 7.017056935509913e-10
their O 0 7.155128156632884e-10
expression O 0 6.865527701904739e-09
pattern O 0 2.3392232151309145e-08
and O 0 2.446653546428479e-09
subcellular O 0 9.851003596850205e-06
localization O 0 1.138440325121337e-06
suggest O 0 1.53427563986952e-08
a O 0 6.739005797840036e-09
role O 0 1.2888932587884483e-08
in O 0 3.5472684345450034e-08
cell O 0 2.937688350357348e-06
- O 0 7.279895157807914e-07
cycle O 0 3.862141511490336e-06
regulation O 0 7.915147648418497e-07
. O 0 1.1035515967705578e-07

When O 0 1.012919028653414e-06
resting O 0 3.087866571149789e-05
cells O 0 2.996195576088212e-07
are O 0 1.2224001810778873e-09
induced O 0 4.2255216214925895e-08
to O 0 1.0216283374830937e-09
proliferate O 0 3.904727563508459e-08
, O 0 1.8177616079029235e-09
the O 0 1.2379287817054774e-08
steady O 0 3.548138920450583e-06
- O 0 8.236857418353338e-09
state O 0 1.323854248447276e-09
levels O 0 7.776398192049783e-09
of O 0 6.5353944478374615e-09
BRCA1 O 0 1.6031657112947073e-09
increase O 0 2.630753948018594e-10
in O 0 1.8236340215693758e-09
late O 0 3.5728069747165137e-07
G1 O 0 1.5587750112899812e-06
and O 0 6.120385864782918e-10
reach O 0 7.074470342871564e-09
a O 0 1.4578626084116308e-09
maximum O 0 4.719927115814926e-09
during O 0 3.75455968537608e-08
S O 0 6.586365657312854e-07
phase O 0 1.4633691307608387e-06
. O 0 2.6218259563393076e-07

Moreover O 0 6.480361662397627e-06
, O 0 1.6894617260732048e-08
in O 0 2.9461784123441248e-08
S O 0 1.1596658850976382e-06
phase O 0 8.603372521065467e-07
cells O 0 2.563275813827204e-07
, O 0 1.364820478855222e-09
BRCA1 O 0 6.0207909768905665e-09
polypeptides O 0 5.151505888534302e-09
are O 0 1.8396931200648226e-10
hyperphosphorylated O 0 1.4442305484863027e-07
and O 0 1.115817993557755e-09
accumulate O 0 3.5108197238287175e-08
into O 0 5.2567212804888186e-08
discrete O 0 2.3776801754138432e-06
subnuclear O 0 4.974351031705737e-05
foci O 0 7.106798148015514e-05
termed O 0 1.908508465930936e-06
" O 0 1.1539378874658723e-06
BRCA1 O 0 9.036364758685522e-07
nuclear O 0 8.812623491394334e-06
dots O 0 4.026575425086776e-06
. O 0 4.0936697587312665e-07

" O 0 3.461295636952855e-05
BRCA1 O 0 2.798215973598417e-05
associates O 0 2.0513069102889858e-05
in O 0 5.404029934652499e-08
vivo O 0 2.581380158517277e-06
with O 0 5.562769356259878e-09
a O 0 3.7823699017280887e-07
structurally O 0 2.5398056095582433e-05
related O 0 3.915059551218292e-06
protein O 0 1.0670211850083433e-05
termed O 0 9.362758646602742e-06
BARD1 O 1 0.9979277849197388
. O 0 2.7093838070868514e-06

Here O 0 3.0019955374882556e-06
we O 0 8.697503517396399e-08
show O 0 3.081825994399878e-08
that O 0 2.806074539396519e-10
the O 0 6.214695869033449e-09
steady O 0 1.0474050213815644e-06
- O 0 1.6664699842294795e-08
state O 0 2.2221864348637155e-09
levels O 0 1.4261252623271048e-08
of O 0 1.8010727131922977e-08
BARD1 O 0 3.241432204958983e-05
, O 0 1.0923177917732119e-09
unlike O 0 8.445383281596719e-10
those O 0 1.1962483781324806e-10
of O 0 3.845486595821512e-09
BRCA1 O 0 5.527085455980796e-09
, O 0 9.594431499282408e-11
remain O 0 2.0738277761722657e-09
relatively O 0 2.7447459860496792e-09
constant O 0 8.268515472309446e-08
during O 0 1.5146872556215385e-07
cell O 0 1.3027173508817214e-06
cycle O 0 1.0798116818477865e-06
progression O 0 1.5394222145914682e-06
. O 0 7.614553965140658e-08

However O 0 1.9016481473954627e-06
, O 0 2.1132863992079365e-07
immunostaining O 0 5.063756907475181e-05
revealed O 0 3.4215515825053444e-06
that O 0 4.958884147754361e-08
BARD1 O 0 0.0005139599088579416
resides O 0 6.4742584982013796e-06
within O 0 1.8849829075406888e-07
BRCA1 O 0 1.2343926414359885e-07
nuclear O 0 1.2660926813623519e-06
dots O 0 1.3239538532161532e-07
during O 0 8.081274671667416e-08
S O 0 6.213850838321378e-07
phase O 0 1.0414035500616592e-07
of O 0 1.9756555502681294e-08
the O 0 1.303860042156657e-08
cell O 0 3.031634676631256e-08
cycle O 0 1.2727454645755643e-08
, O 0 8.561897718584177e-11
but O 0 1.3799283937743212e-10
not O 0 1.8762318088061392e-10
during O 0 1.8388039535466305e-08
the O 0 1.3473281512688118e-07
G1 O 0 6.7917085289082024e-06
phase O 0 9.677514754002914e-07
. O 0 2.380091359555081e-07

Nevertheless O 0 3.443234527367167e-05
, O 0 2.0982268722491426e-07
BARD1 O 0 0.0001286463375436142
polypeptides O 0 8.95040955128934e-07
are O 0 1.5979972900481698e-09
found O 0 1.7357977277754344e-09
exclusively O 0 7.2604655620978065e-09
in O 0 2.9551028291052717e-09
the O 0 1.3024904710334795e-08
nuclear O 0 2.4064596004791383e-07
fractions O 0 1.463168075588328e-07
of O 0 5.089510679567866e-08
both O 0 5.874749575696114e-09
G1 O 0 3.5626743510874803e-07
- O 0 8.672221163408267e-09
and O 0 1.657899595386425e-09
S O 0 2.615008725115331e-07
- O 0 2.9963324266191194e-08
phase O 0 4.3598873844530317e-07
cells O 0 2.9084696961945156e-07
. O 0 4.945641407516632e-08

Therefore O 0 4.329218938892154e-07
, O 0 8.819346142274753e-09
progression O 0 1.1039937675150213e-07
to O 0 3.58069107697645e-09
S O 0 4.2396578692205367e-07
phase O 0 1.9055808309076383e-07
is O 0 3.1035261027767547e-09
accompanied O 0 5.662853297394577e-09
by O 0 9.600038541890399e-10
the O 0 7.0311010347268166e-09
aggregation O 0 1.524288251175676e-08
of O 0 2.743784399683591e-08
nuclear O 0 2.5733625079737976e-06
BARD1 O 0 0.001382277230732143
polypeptides O 0 2.278543206557515e-06
into O 0 1.5885143511695787e-07
BRCA1 O 0 7.031176778582449e-07
nuclear O 0 8.173435162461828e-06
dots O 0 4.22486345996731e-06
. O 0 3.633385290413571e-07

This O 0 2.6642669581633527e-07
cell O 0 6.500277436316537e-07
cycle O 0 6.367466198753391e-07
- O 0 2.68571625383629e-07
dependent O 0 5.507798164217093e-07
colocalization O 0 3.5990954074804904e-06
of O 0 2.903392442021868e-07
BARD1 O 0 0.0010404542554169893
and O 0 2.1639396052819393e-08
BRCA1 O 0 6.511110228757389e-08
indicates O 0 3.0228349601202353e-08
a O 0 3.057276209972315e-09
role O 0 5.0121897743338195e-09
for O 0 4.505735784476883e-09
BARD1 O 0 0.00021173428103793412
in O 0 1.7198425439346465e-07
BRCA1 O 0 7.087573408171011e-07
- O 0 2.04681009563501e-06
mediated O 0 3.034715291505563e-06
tumor B-Disease 0 0.00030786838033236563
suppression O 0 1.2848042388213798e-05
. O 0 2.334038384788073e-07

Ethnic O 0 1.3913478369431687e-06
differences O 0 5.643780696118483e-07
in O 0 2.0770200137576467e-07
the O 0 7.508392059207836e-07
HFE O 0 0.00030469257035292685
codon O 0 4.99026054967544e-06
282 O 0 4.202111995255109e-06
( O 0 4.794362666871166e-07
Cys O 0 0.0017079560784623027
/ O 0 1.1239824743825011e-05
Tyr O 0 3.66877211490646e-05
) O 0 9.307240134148742e-08
polymorphism O 0 8.192096174752805e-07
. O 0 8.267396367500623e-08

Recent O 0 1.0538697097217664e-06
studies O 0 6.607403690850333e-08
have O 0 8.069592771775547e-10
shown O 0 2.5140183268490546e-08
that O 0 1.1698713819896511e-07
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 1 1.0
HH B-Disease 1 1.0
) O 0 3.0935574102386454e-08
is O 0 1.0427224639286692e-09
likely O 0 6.658306128670688e-10
to O 0 8.360758751990716e-10
be O 0 7.540738700129168e-09
caused O 0 9.234511111344545e-08
by O 0 1.6502561095421697e-08
homozygosity O 0 9.308788321504835e-06
for O 0 2.0557640922902465e-08
a O 0 7.509695620910861e-08
Cys282Tyr O 0 8.197369425033685e-06
mutation O 0 7.28112903303213e-09
in O 0 3.900497702602479e-09
the O 0 1.1095033158881051e-07
HFE O 0 0.0017252921825274825
gene O 0 1.0909111836099328e-07
located O 0 2.49156357767788e-07
4 O 0 8.235397785938403e-07
. O 0 2.2492598361623095e-07

5 O 0 2.6132509447052144e-05
Mb O 0 0.00030839303508400917
telomeric O 0 1.5488614735659212e-05
to O 0 4.4632960793933307e-07
HLA O 0 5.805383625556715e-05
- O 0 3.5930800095229642e-06
A O 0 3.523133727867389e-06
. O 0 1.6092178611870622e-07

Population O 0 1.7552684639099425e-08
studies O 0 8.180055743878256e-09
of O 0 4.565914313303665e-09
this O 0 1.877457078691691e-09
polymorphism O 0 2.727005288249984e-08
are O 0 1.5777021356022658e-10
facilitated O 0 2.2041881209133862e-08
by O 0 7.62858942682243e-10
the O 0 5.939386760189791e-09
fact O 0 9.420611846167048e-09
that O 0 2.5193341857132623e-10
the O 0 9.744398177247149e-09
Cys282Tyr O 0 1.4909105630067643e-05
mutation O 0 1.3024010314666157e-08
creates O 0 2.699705881070713e-08
a O 0 8.625507774695507e-08
Rsal O 0 3.012793604284525e-05
restriction O 0 2.7090220555692213e-07
site O 0 8.534858011444157e-07
. O 0 7.460839412942732e-08

We O 0 1.522606538628679e-07
have O 0 2.499586981841162e-09
studied O 0 4.027862487987477e-08
the O 0 3.794674796608888e-08
codon O 0 2.1631643676300882e-07
282 O 0 8.125422255034209e-07
( O 0 1.413376793379939e-07
Cys O 0 0.0006498842849396169
/ O 0 4.023370365757728e-06
Tyr O 0 2.0672869140980765e-06
) O 0 6.436057797820638e-10
polymorphism O 0 1.3576183510721762e-09
in O 0 3.6299435679509884e-11
different O 0 2.470599939907725e-11
ethnic O 0 9.306627690719438e-10
groups O 0 3.3172431468386776e-09
. O 0 5.390153390294472e-08

In O 0 1.164286800303671e-06
agreement O 0 1.629247634582498e-07
with O 0 4.145245480202675e-09
previous O 0 9.584969973275292e-08
observations O 0 4.672473892242124e-07
the O 0 6.145904762888676e-08
Tyr O 0 7.710846148256678e-06
allele O 0 2.072737181890716e-08
appeared O 0 1.5553723642369732e-08
to O 0 6.9692257520515e-10
be O 0 1.7049602840657485e-09
rare O 0 1.3143846011587357e-08
or O 0 3.758128030995067e-08
absent O 0 2.5500071387796197e-07
in O 0 4.041044476821298e-08
Asiatic O 0 4.087060005986132e-05
( O 0 3.5432044853678235e-08
Indian O 0 3.417418952267326e-07
, O 0 6.117704565156146e-09
Chinese O 0 1.210281794783441e-07
) O 0 1.9089989589105016e-09
populations O 0 2.0414852031080954e-09
. O 0 1.2381318192922208e-08

The O 0 1.380619096380542e-06
highest O 0 4.7027612026795396e-07
allele O 0 1.1237381691842074e-08
frequency O 0 1.076196021188025e-08
( O 0 1.3364990225639417e-09
7 O 0 5.3788329346105e-09
. O 0 1.5449100332354249e-10
5 O 0 2.3292534567787015e-09
% O 0 5.578736361755432e-10
) O 0 1.1025002438769249e-10
was O 0 6.125258966704905e-09
found O 0 1.3627760031553748e-09
in O 0 7.429099557754171e-09
Swedes O 0 1.909791990328813e-06
. O 0 5.843332928634482e-07

Saamis O 0 0.0007178785162977874
( O 0 2.833334633578488e-07
2 O 0 1.2786439640422032e-07
% O 0 2.818757227629476e-09
) O 0 3.9371356175266214e-10
and O 0 6.909954275435837e-10
Mordvinians O 0 1.4556177347913035e-06
( O 0 3.0848943399774953e-09
1 O 0 3.432415240922637e-09
. O 0 1.4751086463427043e-10
8 O 0 4.594025160287174e-09
% O 0 3.556396843684695e-10
) O 0 3.807284001955402e-11
had O 0 3.1335625760853247e-10
significantly O 0 4.0819736479846824e-10
lower O 0 3.026837669395377e-09
frequencies O 0 4.235290784748713e-09
of O 0 1.2807988447605112e-08
the O 0 5.857912910300911e-08
Tyr O 0 2.4298384232679382e-05
allele O 0 3.1587273952027317e-07
. O 0 7.891227227219133e-08

Comparisons O 0 4.3697025375877274e-07
with O 0 1.6841972261261162e-09
allele O 0 5.491578747296444e-09
frequencies O 0 4.870134073797772e-09
based O 0 4.448471369045137e-09
on O 0 7.832099413462856e-09
prevalence O 0 1.7778542371615913e-07
estimates O 0 2.121186781778306e-08
of O 0 4.7732441998959985e-08
HH B-Disease 1 0.9999780654907227
showed O 0 1.7366802751439536e-07
some O 0 4.522945629137354e-10
disagreements O 0 2.2020406831302353e-08
with O 0 3.008693572059684e-10
the O 0 6.170839839114706e-09
RFLP O 0 1.6677012126820046e-07
data O 0 7.001992763377984e-09
, O 0 2.059965531486796e-10
particularly O 0 6.052243151088987e-10
in O 0 1.801560500780397e-08
Finns O 0 4.050531515531475e-06
. O 0 6.150397098281246e-07

The O 0 2.047672978733317e-06
newly O 0 5.626929123536684e-06
described O 0 5.105137915961677e-06
HFE O 0 0.005505071487277746
marker O 0 1.7811427142078173e-06
provides O 0 1.2282857397849511e-08
a O 0 3.4853773200893556e-09
new O 0 7.40160044365723e-10
approach O 0 6.468365842948742e-09
to O 0 4.182953428077951e-10
the O 0 3.694502037632219e-09
screening O 0 6.040540956320228e-09
of O 0 9.662062439019792e-08
HH B-Disease 1 0.999997615814209
as O 0 9.930658073642462e-09
well O 0 1.4799707015455965e-09
as O 0 5.599076202678077e-10
studies O 0 6.048253453627694e-09
of O 0 4.573889711423362e-09
the O 0 7.962632331270925e-09
relationship O 0 6.69386466256583e-08
between O 0 4.225602268093098e-08
the O 0 2.1225147861514415e-07
HFE O 0 0.0020865180995315313
Tyr O 0 1.711126242298633e-05
allele O 0 4.169748102356152e-09
and O 0 4.1423742214163894e-10
different O 0 2.9144811009018667e-09
disorders O 1 0.7504034042358398
including O 0 8.394260476052295e-06
cancer B-Disease 1 0.9999997615814209

Autosomal B-Disease 1 0.9999997615814209
dominant I-Disease 1 0.9999915361404419
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999991655349731
associated O 0 3.1727481086818443e-07
with O 0 3.178530549874381e-09
a O 0 3.248445423764679e-08
missense O 0 7.293363779581341e-08
mutation O 0 5.315992646082179e-10
encoding O 0 1.773317825914944e-09
Gly23 O 0 7.358182187999773e-07
- O 0 1.1887606206073542e-06
- O 0 5.421102287073154e-06
> O 0 3.1517454317508964e-06
Val O 0 8.158577657013666e-06
in O 0 2.4565687795075064e-07
neurophysin O 0 0.0008448966545984149
II O 1 0.9998321533203125
. O 0 8.106412678898778e-06

Autosomal B-Disease 1 0.9999998807907104
dominant I-Disease 1 0.9999971389770508
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 1.5830466509214602e-05
ADNDI B-Disease 1 0.999997615814209
) O 0 3.5135865772417674e-08
is O 0 3.5132696751816184e-09
an O 0 4.356420646445258e-08
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 1 0.9999593496322632
by O 0 2.5014539914991474e-06
progressive O 1 0.9999974966049194
degeneration O 1 1.0
of O 0 6.536431556014577e-07
the O 0 2.34610936900026e-07
magnocellular O 0 0.0003716361534316093
neurons O 0 3.536949634508346e-06
of O 0 4.5347846366894373e-07
the O 0 4.0004991319619876e-07
hypothalamus O 0 1.1486050425446592e-05
leading O 0 1.898521020393673e-07
to O 0 3.6760718913342316e-09
decreased O 0 5.077362175143207e-07
ability O 0 2.6737081437744337e-09
to O 0 3.6104871870001887e-10
produce O 0 1.237125624165003e-09
the O 0 2.982072899726518e-08
hormone O 0 7.837243032327024e-08
arginine O 0 4.212003830161848e-07
vasopressin O 0 8.957804311648943e-07
( O 0 2.4783911811709913e-08
AVP O 0 3.7039592371002072e-06
) O 0 6.111430028710174e-09
. O 0 2.2710356262223286e-08

Affected O 0 2.5123651425928983e-07
individuals O 0 3.185917085701817e-09
are O 0 2.9741459295351547e-10
not O 0 1.7306505117886672e-09
symptomatic O 0 3.006081215062295e-07
at O 0 1.6712739636659535e-07
birth O 0 7.358645603972036e-08
, O 0 8.455989242150963e-10
but O 0 1.142871686177216e-09
usually O 0 2.0997477534479003e-08
develop O 0 3.624038754423964e-06
diabetes B-Disease 1 1.0
insipidus I-Disease 1 0.9999709129333496
at O 0 1.5124054698389955e-05
1 O 0 3.27266161548323e-06
- O 0 4.4478929339675233e-07
6 O 0 6.925251909706276e-07
yr O 0 9.156039595836774e-06
of O 0 3.5880969306845145e-08
age O 0 3.3934446719285916e-07
. O 0 2.1704545360989869e-07

The O 0 3.2312009352608584e-06
genetic O 0 2.1567261683230754e-06
locus O 0 5.447016064863419e-07
of O 0 4.2874656713820514e-08
the O 0 1.3530207354506274e-07
disease O 0 3.3792555313993944e-06
is O 0 3.643044266254947e-08
the O 0 5.116793886372761e-07
AVP O 0 0.0002624299086164683
- O 0 1.3047949778410839e-06
neurophysin O 0 1.4524683138006367e-05
II O 0 0.0019248833414167166
( O 0 2.7302954208607844e-07
NPII O 0 0.00019140081712976098
) O 0 5.665294899870332e-09
gene O 0 5.437751360304333e-10
, O 0 6.65198104932152e-11
and O 0 2.899968321035118e-10
mutations O 0 3.170326223767006e-09
that O 0 1.2440539709501763e-09
cause O 0 4.361159824384231e-07
ADNDI B-Disease 1 0.9996505975723267
have O 0 2.7221969123303325e-09
been O 0 2.4125379471939823e-09
found O 0 7.034839932806847e-10
in O 0 9.263487199540066e-10
both O 0 7.030815929454093e-10
the O 0 1.8196287143723566e-08
signal O 0 9.380487853150044e-08
peptide O 0 3.207766141599677e-08
of O 0 2.8569834498171076e-08
the O 0 9.568913839075321e-08
prepro O 0 4.2874558857874945e-05
- O 0 0.00010291705984855071
AVP O 0 0.002885742112994194
- O 0 5.507501100510126e-06
NPII O 0 0.00016065745148807764
precursor O 0 1.2289980304558412e-06
and O 0 1.9846822851832258e-08
within O 0 2.470097797413473e-07
NPII O 0 0.002394008683040738
itself O 0 3.2527475468668854e-06
. O 0 6.952740818633174e-07

An O 0 2.0158574898232473e-06
affected O 0 5.31507566847722e-07
girl O 0 7.467070190614322e-06
who O 0 2.5647961976460465e-08
presented O 0 1.3610679161502048e-07
at O 0 1.5061640397107112e-06
9 O 0 3.1414836598742113e-07
months O 0 3.137363435712359e-08
of O 0 2.6911562756026797e-08
age O 0 7.421907355364965e-08
and O 0 3.601767328831329e-09
her O 0 2.5524396818354944e-08
similarly O 0 2.42568010122568e-08
affected O 0 3.182928809408736e-09
younger O 0 3.5792229180486856e-09
brother O 0 1.2156608875102393e-07
and O 0 5.517100998275737e-09
father O 0 8.931199886319519e-07
were O 0 4.872115155762913e-08
all O 0 1.0840468522843594e-09
found O 0 9.86872028541086e-10
to O 0 6.902604043901306e-10
have O 0 4.1224720859212027e-10
a O 0 8.655514527333708e-09
novel O 0 8.192550637886598e-08
missense O 0 1.4138782944428385e-07
mutation O 0 2.3411816929552742e-09
( O 0 1.7339381042091873e-09
G1758 O 0 5.7291600796816056e-08
- O 0 1.2156688455888798e-07
- O 0 3.064780287331814e-07
> O 0 3.4122669489988766e-07
T O 0 2.8637757054639223e-08
) O 0 2.427251177827827e-10
encoding O 0 4.78375672408049e-10
the O 0 9.980518633767588e-10
amino O 0 4.623473603970751e-09
acid O 0 9.131096989634102e-10
substitution O 0 3.0187023991601336e-09
Gly23 O 0 1.3704135426451103e-06
- O 0 1.698204641797929e-06
- O 0 3.7265858736645896e-06
> O 0 2.797116621877649e-06
Val O 0 1.4463616025750525e-05
within O 0 2.6220211566396756e-06
NPII O 0 0.005774442572146654
. O 0 2.8260153612791328e-06

The O 0 5.458164764604589e-07
mutation O 0 2.5373728007593854e-08
was O 0 8.469814360978489e-08
confirmed O 0 5.107751999133825e-09
by O 0 4.280477750029377e-09
restriction O 0 7.86604132940738e-08
endonuclease O 0 2.0570523702190258e-06
analysis O 0 2.8249544925529335e-07
. O 0 9.092539698940527e-08

A O 0 7.103741518221796e-05
T1 O 0 0.0005511950002983212
- O 0 6.080006187403342e-07
weighted O 0 2.2450402070717246e-07
magnetic O 0 2.2263012056100706e-07
resonance O 0 2.7757045018006465e-07
imaging O 0 9.550986987960641e-07
of O 0 8.067506485076592e-08
the O 0 6.840205060143489e-07
fathers O 0 0.002300718566402793
pituitary O 0 0.0022945001255720854
gland O 0 2.670343974386924e-06
demonstrates O 0 1.7642409488871635e-07
an O 0 1.2255782166903373e-08
attenuated O 0 5.225011136644753e-06
posterior O 0 2.0307159502408467e-05
pituitary O 0 6.855480023659766e-05
bright O 0 3.5917478271585423e-06
spot O 0 1.2261518349987455e-05
. O 0 1.1003386362062884e-06

This O 0 3.4184392916358775e-07
mutation O 0 1.594472465171748e-08
may O 0 1.8240270405200931e-09
be O 0 4.3306758179539884e-10
valuable O 0 2.0598655225967377e-08
for O 0 1.715937530955003e-10
developing O 0 1.4329082365094337e-09
models O 0 4.105313866631377e-09
of O 0 3.695046757457021e-08
dominantly B-Disease 1 0.6593010425567627
inherited I-Disease 1 1.0
neurodegeneration I-Disease 1 1.0
, O 0 1.110430574158272e-07
as O 0 1.1649905484745204e-09
the O 0 7.844129790157695e-10
early O 0 1.0184361798337704e-08
age O 0 1.561346785194928e-08
of O 0 4.899129990576512e-08
onset O 0 0.001206344342790544
of O 0 7.252316436279216e-07
symptoms O 0 8.350583084393293e-05
suggests O 0 6.234692762063787e-08
that O 0 1.206125060937424e-10
this O 0 3.9587094713411375e-10
mutation O 0 2.970619583653189e-10
may O 0 2.3255235237495953e-10
be O 0 1.3459278136451758e-10
particularly O 0 1.0800326188942222e-09
deleterious O 0 2.4104235052391232e-08
to O 0 8.032066567409402e-09
the O 0 1.996344138888162e-07
magnocellular O 0 0.00010691682109609246
neuron O 0 1.5183914911176544e-05
. O 0 3.148645433270758e-08
. O 0 1.4477221554898279e-07

Frequent O 0 1.0793537512654439e-05
inactivation O 0 5.780700303148478e-05
of O 0 0.00010556135384831578
PTEN O 1 0.9999974966049194
/ O 1 0.9858848452568054
MMAC1 O 1 0.9999563694000244
in O 0 4.243814146320801e-06
primary O 1 0.999996542930603
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.0898898835876025e-05

Sporadic B-Disease 1 1.0
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 3.4360530776211817e-07
the O 0 3.483252442038065e-08
most O 0 1.0135657868559633e-09
common O 0 3.4564471285136733e-09
male B-Disease 0 2.3092820100600875e-08
cancer I-Disease 0 3.799743186760907e-09
in O 0 1.0074925338443563e-09
the O 0 1.3065710291471078e-08
Western O 0 4.476630266481152e-08
world O 0 2.5371005296648264e-09
, O 0 4.596650143851022e-11
yet O 0 1.0099874409030818e-10
many O 0 1.4823507005212733e-11
of O 0 1.9416730723254005e-10
the O 0 8.420355523952594e-10
major O 0 4.628184502308841e-09
genetic O 0 3.172733853418208e-09
events O 0 5.257277391201853e-10
involved O 0 1.6687942139270717e-09
in O 0 6.978669864210474e-10
the O 0 6.856196943516579e-09
progression O 0 5.331849592948856e-07
of O 0 4.275916065665797e-09
this O 0 3.356755318151272e-09
often O 0 1.3144597410530423e-08
fatal O 0 8.296749911096413e-06
cancer B-Disease 0 7.392534371319925e-07
remain O 0 2.2212327621673467e-07
to O 0 6.974468558240687e-09
be O 0 1.2554228590033745e-07
elucidated O 0 0.0013089297572150826
. O 0 1.5556727248622337e-06

Numerous O 0 8.323901965923142e-06
cytogenetic O 0 0.004436418414115906
and O 0 1.3849059143922204e-07
allelotype O 0 0.00011153039667988196
studies O 0 1.6538851923542097e-06
have O 0 2.4729549519264538e-09
reported O 0 3.325645181462278e-08
frequent O 0 1.5392821239856858e-08
loss O 0 1.92402055176899e-07
of O 0 3.0768683245696593e-06
heterozygosity O 1 0.9997496008872986
on O 0 9.202979526889976e-06
chromosomal O 0 0.0003324118733871728
arm O 0 0.0008766897371970117
10q O 0 0.000571591779589653
in O 0 2.1077582914585946e-06
sporadic B-Disease 1 0.9999997615814209
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0001378625602228567

Deletion O 0 1.226421954925172e-05
mapping O 0 1.2135357110309997e-06
studies O 0 4.318604496234002e-08
have O 0 1.9467609468915015e-10
unambiguously O 0 5.4094719814656855e-09
identified O 0 7.958228742666051e-09
a O 0 6.982441735914335e-09
region O 0 1.738011512486537e-08
of O 0 1.710907184815369e-07
chromosome O 0 6.561175496244687e-07
10q23 O 0 5.979342745376925e-07
to O 0 2.755625283512586e-09
be O 0 4.81821782472025e-09
the O 0 2.465552562114226e-08
minimal O 0 3.5998987186758313e-06
area O 0 1.7381019290496624e-07
of O 0 3.6880555853713304e-07
loss O 0 4.136362986173481e-05
. O 0 1.1314461971778655e-06

A O 0 1.016698206512956e-05
new O 0 3.789164395584521e-07
tumor B-Disease 0 2.651900467753876e-05
suppressor O 0 7.886178536864463e-06
gene O 0 6.263620377922052e-08
, O 0 1.7324380152672347e-08
PTEN O 0 0.00018349109450355172
/ O 0 1.1081640877819154e-05
MMAC1 O 0 0.030163731426000595
, O 0 1.4908280832059972e-08
was O 0 6.107983381298254e-07
isolated O 0 2.503176688151143e-07
recently O 0 2.8698616816313915e-08
at O 0 2.0794056254658244e-08
this O 0 8.670612561267887e-10
region O 0 6.1863958400465435e-09
of O 0 4.570394906977526e-08
chromosome O 0 1.229605999242267e-07
10q23 O 0 2.2128408261323784e-07
and O 0 1.10636211303472e-09
found O 0 1.2579792763034447e-09
to O 0 1.78052919630467e-10
be O 0 4.0547523671996544e-10
inactivated O 0 1.3011794308681601e-08
by O 0 3.092948341887336e-09
mutation O 0 2.631548312592713e-09
in O 0 6.016543263598351e-09
three O 0 2.5593848818061815e-07
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 1 0.9999938011169434
lines O 0 7.083775017235894e-06
. O 0 5.924296146986308e-07

We O 0 1.7273756611757562e-06
screened O 0 7.1056829256122e-06
80 O 0 8.234603228629567e-06
prostate B-Disease 0 0.0005639107548631728
tumors I-Disease 1 1.0
by O 0 3.180157293058983e-08
microsatellite O 0 4.507312496571103e-06
analysis O 0 3.878370335996806e-08
and O 0 4.1659226068802013e-10
found O 0 5.660736768220431e-09
chromosome O 0 9.296842762296365e-08
10q23 O 0 1.9404409101753117e-07
to O 0 3.920120672518124e-09
be O 0 1.4008320725622525e-08
deleted O 0 4.161440472216782e-07
in O 0 1.2074683475304937e-08
23 O 0 8.638464521482092e-08
cases O 0 1.0648272485980215e-08
. O 0 8.45098284685264e-08

We O 0 3.59023005103154e-07
then O 0 2.7374435163096678e-08
proceeded O 0 4.924133634176542e-08
with O 0 7.478314634212779e-10
sequence O 0 1.6004504388433816e-08
analysis O 0 1.1397288446346465e-08
of O 0 6.675590746851867e-09
the O 0 2.1367879909917065e-08
entire O 0 3.0139228783809813e-06
PTEN O 0 0.0003519656602293253
/ O 0 1.3654196209245129e-06
MMAC1 O 0 2.417777432128787e-05
coding O 0 5.431371050690359e-07
region O 0 3.1003017930686383e-09
and O 0 2.575951674188559e-10
tested O 0 1.3818413080457503e-09
for O 0 4.161340161346061e-10
homozygous O 0 7.651369315908596e-09
deletion O 0 4.895503113999666e-09
with O 0 1.604309046721042e-10
new O 0 4.071276649142419e-09
intragenic O 0 2.1127507352503017e-05
markers O 0 1.844153842966989e-07
in O 0 1.2779064473278368e-09
these O 0 4.0040748494618583e-10
23 O 0 2.3347388022898485e-08
cases O 0 9.657834532106335e-10
with O 0 6.961413667738725e-10
10q23 O 0 9.097738802665845e-05
loss O 0 0.0012962999753654003
of O 0 0.00044738169526681304
heterozygosity O 1 0.9999963045120239
. O 0 6.9417033046192955e-06

The O 0 9.671730367699638e-07
identification O 0 2.5870485842460766e-07
of O 0 2.2622641893121909e-07
the O 0 2.0599939887233631e-07
second O 0 6.606622378058091e-07
mutational O 0 8.168105523509439e-06
event O 0 8.037955723239065e-08
in O 0 2.8730584578084972e-09
10 O 0 5.349132692344938e-09
( O 0 3.5182117219534348e-09
43 O 0 4.741810855080075e-08
% O 0 5.441648198711846e-08
) O 0 6.4771590757573e-08
tumors B-Disease 1 1.0
establishes O 0 3.132193523924798e-05
PTEN O 1 0.9961963891983032
/ O 0 2.7955060431850143e-05
MMAC1 O 0 0.00013064428640063852
as O 0 7.11224457106141e-09
a O 0 5.770755429068686e-09
main O 0 1.3670617526884143e-08
inactivation O 0 6.545040065475405e-08
target O 0 1.2662368931160017e-08
of O 0 8.784326155364397e-09
10q O 0 2.754647312031011e-06
loss O 0 2.5791309781197924e-06
in O 0 4.2208418449263263e-07
sporadic B-Disease 1 0.9999994039535522
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 6.68768677769549e-07
. O 0 3.322754480450385e-07

Risk O 0 1.6576257621636614e-05
reversals O 0 4.8676615733711515e-06
in O 0 1.0032398023440692e-08
predictive O 0 7.274594082673502e-08
testing O 0 1.4821607940973536e-08
for O 0 3.2611009714855754e-07
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 5.275018793327035e-06

The O 0 2.3125841153159854e-07
first O 0 1.1200961047563851e-08
predictive O 0 2.465129433915081e-08
testing O 0 4.017418397950223e-09
for O 0 3.097094136705891e-08
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 5.467944106385403e-07
HD B-Disease 0 1.7501590264146216e-05
) O 0 1.6596048979522493e-09
was O 0 2.8965423393145784e-09
based O 0 2.520521569238099e-10
on O 0 8.05157385208588e-10
analysis O 0 2.619034988882163e-09
of O 0 1.4880008336604078e-09
linked O 0 1.1200234517616536e-08
polymorphic O 0 7.687295244807046e-09
DNA O 0 1.778514757688754e-08
markers O 0 9.220392449549308e-09
to O 0 4.5096026912716525e-10
estimate O 0 5.882015319258471e-09
the O 0 1.3627082795508727e-09
likelihood O 0 4.05850144602482e-08
of O 0 2.1386147963653457e-08
inheriting O 0 3.3353458661622426e-07
the O 0 2.3483876177010643e-08
mutation O 0 1.6794688972865401e-09
for O 0 2.0942672041002197e-09
HD B-Disease 0 8.95399625733262e-06
. O 0 4.143113869758963e-07

Limits O 0 2.56412675980755e-07
to O 0 2.9573243853775466e-09
accuracy O 0 7.873261864688175e-08
included O 0 5.3200426286537095e-09
recombination O 0 4.008608112116008e-09
between O 0 2.342932514665108e-09
the O 0 5.107927414371716e-09
DNA O 0 5.4003614025077695e-08
markers O 0 9.20066423049093e-09
and O 0 1.8100732024350918e-10
the O 0 1.5829961785840396e-09
mutation O 0 9.469789397087425e-10
, O 0 3.0758684488318977e-10
pedigree O 0 2.4921330776805917e-08
structure O 0 2.2754754525067256e-08
, O 0 5.78354530933467e-10
and O 0 1.1936318600191953e-10
whether O 0 2.572735635641976e-10
DNA O 0 5.681570325322127e-09
samples O 0 5.972475292104207e-10
were O 0 1.2202779897663163e-09
available O 0 1.956313111506347e-09
from O 0 6.155369547400369e-09
family O 0 3.1381890863713124e-08
members O 0 1.7910149807676135e-08
. O 0 1.6189538598609943e-07

With O 0 7.262072276859044e-09
direct O 0 5.96216676029826e-09
tests O 0 1.886473061096794e-10
for O 0 1.6128136326454268e-10
the O 0 5.137572145486047e-09
HD B-Disease 0 1.0763160389615223e-06
mutation O 0 9.12986020118467e-10
, O 0 4.295595476544456e-11
we O 0 1.3440498713990223e-10
have O 0 7.244273930728795e-11
assessed O 0 1.1853725112587199e-08
the O 0 3.409733828618755e-09
accuracy O 0 1.4737973685896577e-07
of O 0 7.279850944286181e-09
results O 0 1.0360494684391597e-09
obtained O 0 2.4033674606016575e-08
by O 0 2.589381375983635e-09
linkage O 0 7.54358993049209e-08
approaches O 0 3.568588979874221e-09
when O 0 5.053155671674858e-10
requested O 0 3.321314112625373e-09
to O 0 7.210531616230753e-10
do O 0 2.0685142487764097e-09
so O 0 7.379131750084866e-10
by O 0 5.569497640856014e-10
the O 0 3.196233944180449e-09
test O 0 6.910195082809878e-09
individuals O 0 8.484751568005322e-09
. O 0 7.700066362303915e-08

For O 0 9.136783774010837e-08
six O 0 3.2637231583976245e-08
such O 0 6.508509287073139e-10
individuals O 0 1.5441097289681238e-09
, O 0 1.444080521828539e-09
there O 0 3.657461444817045e-09
was O 0 3.6869717945364755e-08
significant O 0 8.46038084034717e-09
disparity O 0 3.8033125093761555e-08
between O 0 9.480275231510404e-09
the O 0 1.9047263322136132e-08
tests O 0 1.572347407829966e-08
. O 0 6.405813479659628e-08

Three O 0 5.722355922443967e-07
went O 0 6.658133315795567e-07
from O 0 8.371997317624391e-09
a O 0 1.1820175060961446e-08
decreased O 0 5.254661346043576e-07
risk O 0 6.227962590088509e-09
to O 0 1.3375235641266414e-10
an O 0 3.6595182439924656e-10
increased O 0 2.741094240477082e-09
risk O 0 1.7336942548240586e-08
, O 0 3.0355370994605835e-10
while O 0 9.417804314182376e-10
in O 0 6.888964398932274e-10
another O 0 1.5009647968966533e-09
three O 0 1.1974217450916314e-10
the O 0 1.6364699595428078e-09
risk O 0 1.1629043505934078e-08
was O 0 2.475132419021975e-07
decreased O 0 4.828302735404577e-06
. O 0 2.000756467168685e-07

Knowledge O 0 0.00016266937018372118
of O 0 1.0014809959102422e-06
the O 0 5.321222573684281e-08
potential O 0 3.441476437160418e-08
reasons O 0 9.490913832621573e-09
for O 0 1.5319581714301478e-10
these O 0 1.1799820842650632e-10
changes O 0 1.2754318434726741e-10
in O 0 7.975213267563674e-10
results O 0 9.184913940529782e-10
and O 0 2.634002460588647e-10
impact O 0 5.3583333325946114e-09
of O 0 4.2458198068473507e-10
these O 0 1.1162623603233612e-10
risk O 0 2.822749145536818e-09
reversals O 0 1.7497930215881752e-08
on O 0 9.187997584980678e-10
both O 0 4.0831105163618986e-10
patients O 0 1.1875482541778837e-10
and O 0 9.8536311055053e-11
the O 0 5.117298584877972e-09
counseling O 0 1.7581097466745632e-08
team O 0 1.1921672538051098e-09
can O 0 4.088877292307558e-10
assist O 0 1.4316141161430096e-08
in O 0 3.726206454501835e-09
the O 0 1.234823088225312e-08
development O 0 6.600551927249398e-08
of O 0 1.7072098401627045e-08
strategies O 0 9.045244553362863e-09
for O 0 6.210604808210007e-10
the O 0 8.038964161016793e-09
prevention O 0 4.02569675372888e-08
and O 0 1.4649138846412058e-10
, O 0 1.058591062030878e-10
where O 0 2.9001839818576514e-10
necessary O 0 1.479920630487186e-08
, O 0 2.42107511816414e-09
management O 0 5.5493032391495944e-08
of O 0 3.74292463689585e-09
a O 0 6.092121918044313e-09
risk O 0 6.631415416791242e-09
reversal O 0 2.194886050688183e-09
in O 0 1.52653861773544e-10
any O 0 4.989371138464094e-10
predictive O 0 3.0368592085494583e-09
testing O 0 7.628341847087938e-10
program O 0 6.333983559869694e-09
. O 0 1.8321862915726683e-09
. O 0 1.984231801088754e-08

A O 0 7.588891094201244e-06
novel O 0 1.4296815606940072e-06
common O 0 1.4846752094399562e-07
missense O 0 1.8560328953753924e-06
mutation O 0 1.7423463560817254e-08
G301C O 0 4.226070018376049e-07
in O 0 2.1235186054013866e-08
the O 0 5.0386184113904164e-08
N O 0 1.3137550922692753e-06
- O 0 6.63241621623456e-07
acetylgalactosamine O 0 7.296031981240958e-06
- O 0 1.7570959016666166e-06
6 O 0 9.462355592404492e-07
- O 0 3.6340577480586944e-07
sulfate O 0 6.511557444355276e-07
sulfatase O 0 8.14712984720245e-05
gene O 0 9.353313856763634e-08
in O 0 6.791811557604888e-08
mucopolysaccharidosis B-Disease 0 0.00021869613556191325
IVA I-Disease 1 0.9965127110481262
. O 0 4.763357992487727e-06

Mucopolysaccharidosis B-Disease 0 0.08968865871429443
IVA I-Disease 1 0.9999686479568481
( O 0 1.0748753084044438e-05
MPS B-Disease 1 0.9999957084655762
IVA I-Disease 1 1.0
) O 0 5.487654775038209e-08
is O 0 2.5273729775676657e-09
an O 0 1.4520578517362992e-08
autosomal B-Disease 1 0.6564858555793762
recessive I-Disease 1 0.9999716281890869
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 1 0.9927493333816528
by O 0 2.684379580841778e-07
a O 0 9.153003338724375e-05
genetic B-Disease 1 1.0
defect I-Disease 1 0.9999996423721313
in O 0 1.6073282438355818e-07
N O 0 9.980276445276104e-06
- O 0 9.073480100596498e-07
acetylgalactosamine O 0 4.05639257223811e-05
- O 0 6.245956228667637e-06
6 O 0 1.2666672773775645e-05
- O 0 3.2799130167404655e-06
sulfate O 0 1.2607294593180995e-05
sulfatase O 0 0.011735863983631134
( O 0 1.834815634538245e-06
GALNS O 0 0.001742200693115592
) O 0 5.519203227777325e-07
. O 0 3.375637334102066e-07

In O 0 1.8892230002620636e-07
previous O 0 6.140304265045415e-08
studies O 0 2.2253560771900993e-08
, O 0 3.5394789876797006e-10
we O 0 5.762107457840671e-10
have O 0 9.022181612916569e-11
found O 0 5.398646529819473e-10
two O 0 2.520632036429049e-10
common O 0 6.782329697863076e-10
mutations O 0 6.233485394524507e-10
in O 0 5.3941207056595886e-09
Caucasians O 0 2.2424234202844673e-07
and O 0 1.6484881015799147e-08
Japanese O 0 3.919391383533366e-05
, O 0 1.6295592430992656e-08
respectively O 0 3.433150936871243e-07
. O 0 2.1751293388660997e-07

To O 0 3.7775393479932973e-07
characterize O 0 1.5645804296582355e-06
the O 0 5.663039814862714e-08
mutational O 0 5.884548045287374e-06
spectrum O 0 6.232573568354383e-09
in O 0 8.345777541274302e-11
various O 0 5.6112073321124e-11
ethnic O 0 1.821203327034837e-10
groups O 0 2.2629507642757396e-11
, O 0 3.645833288046241e-11
mutations O 0 4.030192846116165e-11
in O 0 4.236024031545327e-10
the O 0 1.9634580183947037e-08
GALNS O 0 3.908966391463764e-05
gene O 0 3.2072138278493867e-09
in O 0 3.2118234738476303e-09
Colombian O 0 9.291964602198277e-07
MPS B-Disease 1 0.999657392501831
IVA I-Disease 1 1.0
patients O 0 2.3664044945803653e-08
were O 0 2.7928872547988703e-09
investigated O 0 2.8780402061556742e-08
, O 0 4.760265515102446e-10
and O 0 2.8961319453735257e-10
genetic O 0 3.5763363381846602e-09
backgrounds O 0 3.4013025729251467e-09
were O 0 2.902869500331917e-09
extensively O 0 3.3798450704836114e-09
analyzed O 0 4.1220027391375424e-09
to O 0 2.1050226839403052e-10
identify O 0 8.932855011245522e-10
racial O 0 6.506994387756038e-10
origin O 0 2.165555929023455e-10
, O 0 1.1273501576702927e-10
based O 0 1.6299771254946194e-10
on O 0 1.904925106543942e-09
mitochondrial O 0 9.334811146288757e-09
DNA O 0 4.3239016811469355e-09
( O 0 1.4642219658966837e-09
mtDNA O 0 6.349950343320643e-09
) O 0 3.990640873308138e-10
lineages O 0 5.168788508314037e-09
. O 0 3.354131417054873e-09

Three O 0 2.9872473987779813e-06
novel O 0 6.52840981274494e-06
missense O 0 1.9622917534434237e-05
mutations O 0 3.381916613420799e-08
never O 0 2.4699817302575866e-08
identified O 0 1.3305378132599799e-08
previously O 0 5.238322220435521e-09
in O 0 3.3473426808150464e-10
other O 0 9.265036654548808e-11
populations O 0 6.525634893561616e-11
and O 0 4.888938559544087e-11
found O 0 1.4373151557833808e-09
in O 0 2.188085268528539e-09
16 O 0 1.1908520392012178e-08
out O 0 8.158315689676954e-10
of O 0 8.577499599482508e-09
19 O 0 1.4078182175580878e-07
Colombian O 0 3.5016992114833556e-06
MPS B-Disease 1 0.9991762042045593
IVA I-Disease 1 1.0
unrelated O 0 8.618548577032925e-07
alleles O 0 1.594778864522084e-09
account O 0 6.532042462481513e-09
for O 0 1.6694755577972842e-09
84 O 0 2.6166253519477323e-07
. O 0 1.9857959898672561e-07

2 O 0 1.8470982467988506e-06
% O 0 1.3227114514791083e-08
of O 0 4.564451483446419e-09
the O 0 4.2815799794482245e-09
alleles O 0 7.440582039386356e-10
in O 0 1.1664024190949362e-09
this O 0 3.4261879999775147e-09
study O 0 4.0185700100892063e-08
. O 0 6.182009570920854e-08

The O 0 2.179337116103852e-06
G301C O 0 7.479913165298058e-06
and O 0 8.710547838575167e-09
S162F O 0 1.4033840898264316e-06
mutations O 0 5.729627439166052e-09
account O 0 3.1244642428873703e-08
for O 0 1.1604360139472192e-08
68 O 0 2.0971976937289583e-06
. O 0 4.769340193888638e-07

4 O 0 4.462573997443542e-06
% O 0 2.2251990472454963e-08
and O 0 5.052021023743691e-09
10 O 0 7.995554796025317e-08
. O 0 1.0780001957755303e-07

5 O 0 4.7071901576600794e-07
% O 0 1.2317415531981624e-08
of O 0 5.857541118814424e-09
mutations O 0 4.1414577323095614e-10
, O 0 3.9466543921840014e-10
respectively O 0 1.819441486361484e-08
, O 0 1.3565906176182807e-09
whereas O 0 1.5145333875921096e-08
the O 0 1.3009535670960304e-08
remaining O 0 1.2860688229920925e-06
F69V O 0 0.0005115754902362823
is O 0 7.159172810133896e-09
limited O 0 2.322377401497988e-09
to O 0 7.621579478644946e-10
a O 0 2.0404545608698754e-08
single O 0 1.4202131026763709e-08
allele O 0 5.569099315039239e-08
. O 0 5.615637732603318e-08

The O 0 1.06142658751196e-06
skewed O 0 2.0287948245822918e-06
prevalence O 0 1.3489622574525129e-07
of O 0 8.786822824902174e-09
G301C O 0 1.2475445032578136e-07
in O 0 1.0815828233035063e-09
only O 0 4.452662960563458e-10
Colombian O 0 2.1666942018327973e-08
patients O 0 3.971369344490938e-10
and O 0 9.841534531762619e-11
haplotype O 0 6.129922347497541e-09
analysis O 0 4.169587175528733e-10
by O 0 6.385372092188035e-11
restriction O 0 5.384537815622537e-10
fragment O 0 3.816739813089498e-09
length O 0 2.6208539782857088e-09
polymorphisms O 0 1.3661546560683746e-08
in O 0 7.886961084224708e-10
the O 0 3.018726957293438e-08
GALNS O 0 0.000467354548163712
gene O 0 4.673623621442857e-08
suggest O 0 2.127110043659286e-08
that O 0 5.683886694640705e-10
G301C O 0 3.038532838672836e-07
originated O 0 1.1727030369002023e-07
from O 0 1.8210766228321518e-08
a O 0 3.7071956171530474e-08
common O 0 2.4007604793041537e-08
ancestor O 0 1.6236974715866381e-06
. O 0 1.840178072143317e-07

Investigation O 0 1.1231434655201156e-05
of O 0 3.417947027628543e-07
the O 0 7.787741651554825e-08
genetic O 0 6.089103976592014e-08
background O 0 3.427810923994912e-08
by O 0 1.2596383935914446e-09
means O 0 1.6443209460703656e-08
of O 0 2.784936192767873e-08
mtDNA O 0 1.3594619474588399e-07
lineages O 0 4.3166421548335165e-09
indicate O 0 9.657815658314917e-10
that O 0 2.8911524216357343e-11
all O 0 4.8186631768087906e-11
our O 0 1.4170573603422554e-09
patients O 0 1.4058734731925426e-10
are O 0 5.000773059538055e-11
probably O 0 8.083260283342497e-09
of O 0 9.82476251465414e-08
native O 0 8.557303772249725e-07
American O 0 1.2152509953011759e-05
descent O 0 0.00021888680930715054

Low O 0 5.2053455874556676e-06
frequency O 0 2.6343323611399683e-07
of O 0 1.616735261222857e-07
BRCA1 O 0 5.773570705969178e-07
germline O 0 9.337500159745105e-07
mutations O 0 1.943230243384164e-09
in O 0 9.968760261713783e-10
45 O 0 2.6797337682182842e-08
German O 1 0.9999960660934448
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 4.3786521928268485e-06
. O 0 1.8689230785184918e-07

In O 0 1.1278248734925e-07
this O 0 2.9344950913667844e-09
study O 0 4.540078979431428e-09
we O 0 5.897526356157812e-10
investigated O 0 2.402510190790963e-08
45 O 0 5.566242933241483e-08
German O 1 0.9864555597305298
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 9.11059050423546e-09
for O 0 1.4944744330946946e-09
germline O 0 1.5362894600912114e-06
mutations O 0 1.0484740853300423e-09
in O 0 1.968534002472211e-09
the O 0 6.334964552934252e-08
BRCA1 O 0 3.388286984318256e-07
gene O 0 5.172864803171251e-08
. O 0 6.304816935198687e-08

We O 0 1.9859439248648414e-07
identified O 0 8.416687080625707e-08
four O 0 4.087820926201857e-08
germline O 0 3.942155217373511e-06
mutations O 0 8.175954135936081e-09
in O 0 3.19891113598203e-09
three O 0 3.731627984393526e-08
breast B-Disease 0 0.000478273315820843
cancer I-Disease 0 4.57847272627987e-05
families O 0 1.3094201278818218e-08
and O 0 4.12665945859203e-09
in O 0 2.5687404558993876e-07
one O 0 0.030214877799153328
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 0.0006791716441512108
. O 0 1.9722726229964849e-10
among O 0 1.38992853684905e-11
these O 0 1.065965544999603e-11
were O 0 1.0324000543349143e-09
one O 0 6.897260540483785e-10
frameshift O 0 2.2547636646663705e-08
mutation O 0 2.006428911904834e-10
, O 0 6.744130254254799e-11
one O 0 4.854365798223625e-10
nonsense O 0 1.1911852482171525e-07
mutation O 0 2.111880448296688e-09
, O 0 8.448928223714347e-10
one O 0 4.433825750993492e-09
novel O 0 2.2520136155890214e-07
splice O 0 1.5293546766770305e-06
site O 0 8.325740452619357e-08
mutation O 0 1.7871614188536e-09
, O 0 7.3968020597448e-10
and O 0 9.770168007960933e-10
one O 0 4.093251249059904e-08
missense O 0 8.093605174508411e-06
mutation O 0 1.7061590540379257e-07
. O 0 2.3049788921980507e-07

The O 0 9.947020771505777e-06
missense O 0 2.4301674784510396e-05
mutation O 0 8.71400871460537e-08
was O 0 2.555482296884293e-07
also O 0 4.56906779078281e-09
found O 0 1.2247906688855892e-08
in O 0 3.3525722642480105e-08
2 O 0 2.388229631833383e-06
. O 0 4.4378217012308596e-07

8 O 0 1.979108219529735e-06
% O 0 1.713659436575199e-08
of O 0 2.282546596177326e-09
the O 0 1.0706062703036423e-09
general O 0 8.289909203540446e-09
population O 0 5.065101671419825e-10
, O 0 2.532250242825995e-10
suggesting O 0 8.298420617336433e-09
that O 0 8.024907821591043e-11
it O 0 1.1709648528590577e-10
is O 0 2.155315925733703e-10
not O 0 1.6631287458324095e-09
disease O 0 5.6610204524076835e-08
associated O 0 2.5187080154864816e-07
. O 0 5.924669039814034e-07

The O 0 3.941528348150314e-07
average O 0 1.0063411082228413e-07
age O 0 2.6227153782087953e-08
of O 0 1.6927008061884408e-07
disease O 0 1.5283416360034607e-05
onset O 0 0.00212761084549129
in O 0 1.1500840280120883e-08
those O 0 2.430054824031913e-09
families O 0 1.3258106612568099e-08
harbouring O 0 8.391997835133225e-05
causative O 0 7.819338497938588e-05
mutations O 0 2.5003416226354602e-08
was O 0 3.197303044544242e-07
between O 0 9.49305345443463e-08
32 O 0 1.5131207646845724e-06
. O 0 3.9481798808083113e-07

3 O 0 4.2220804061798844e-06
and O 0 1.24077303098602e-07
37 O 0 2.5046908831427572e-06
. O 0 4.745755859403289e-07

4 O 0 1.1985240462308866e-06
years O 0 4.419002053168697e-08
, O 0 3.089245970144816e-09
whereas O 0 4.154056298943942e-08
the O 0 4.268454034672686e-08
family O 0 3.5896820804737217e-07
harbouring O 0 6.442575249820948e-05
the O 0 2.924752493527194e-07
missense O 0 2.349441501792171e-06
mutation O 0 3.4851646013578375e-09
had O 0 3.512439006314594e-09
an O 0 1.3089549444345039e-09
average O 0 7.619766151378826e-09
age O 0 1.708274943723609e-08
of O 0 2.0139827938692179e-07
onset O 0 0.0005142774898558855
of O 0 9.84531197900651e-06
51 O 0 1.028166661853902e-05
. O 0 6.530450491482043e-07

2 O 0 3.5592376661952585e-05
years O 0 2.2235924461710965e-06
. O 0 1.1153142622788437e-06

These O 0 8.462983913659627e-08
findings O 0 1.0341511114120294e-07
show O 0 4.0894430952675975e-08
that O 0 2.088419215340309e-09
BRCA1 O 0 2.5048953133932628e-08
is O 0 1.5057333158097208e-09
implicated O 0 1.0442594344794998e-08
in O 0 1.3002210419443827e-09
a O 0 2.9713009830345527e-09
small O 0 2.0531218947184016e-09
fraction O 0 2.1568684616113387e-08
of O 0 6.27054532742477e-06
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.7486094350260828e-07
suggesting O 0 1.1494043050674918e-08
the O 0 6.263029539432807e-10
involvement O 0 5.733409746966345e-09
of O 0 3.608988219383491e-09
another O 0 3.0592124389272612e-09
susceptibility O 0 1.3024705758368782e-08
gene O 0 2.7182485151655555e-09
( O 0 6.69361943650415e-09
s O 0 3.0037341502975323e-07
) O 0 1.1199171012776787e-07

Paternal O 1 0.8668009042739868
transmission O 1 0.9984230995178223
of O 1 0.9994016885757446
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.0002442241820972413

We O 0 2.5145516246993793e-06
report O 0 3.721155508173979e-07
a O 0 1.956310491380009e-08
rare O 0 6.913754901916036e-09
case O 0 1.5078809312285557e-08
of O 0 2.2095301233093778e-07
paternally O 1 0.9999957084655762
transmitted O 1 1.0
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999072551727295
DM B-Disease 1 1.0
) O 0 6.907021656843426e-07
. O 0 2.728317269884428e-07

The O 0 1.5171149243542459e-05
proband O 0 0.00032045828993432224
is O 0 1.847600543669614e-07
a O 0 5.991557827655924e-08
23 O 0 6.991506751319321e-08
year O 0 1.512088587674043e-08
old O 0 1.165933440461231e-06
, O 0 4.5565468553832034e-07
mentally B-Disease 1 1.0
retarded I-Disease 1 1.0
male O 0 6.36861368548125e-05
who O 0 7.314915961842416e-08
suffers O 0 0.004212714731693268
severe O 1 0.9724304676055908
muscular B-Disease 1 1.0
weakness I-Disease 1 1.0
. O 0 1.466870162403211e-05

He O 0 8.151244514920108e-07
presented O 0 5.362865636016068e-07
with O 0 4.239682311890647e-07
respiratory O 1 0.9999997615814209
and O 0 1.117909391723515e-06
feeding O 0 0.14785358309745789
difficulties O 1 0.999961256980896
at O 0 0.0030014333315193653
birth O 0 2.0649911675718613e-05
. O 0 4.498606642755476e-07

His O 0 1.2423540283634793e-05
two O 0 1.2787113519152626e-06
sibs O 1 0.9947628378868103
suffer O 0 3.523442956065992e-06
from O 0 5.988393354527943e-07
childhood O 1 0.9999529123306274
onset O 1 1.0
DM B-Disease 1 1.0
. O 0 1.9900757251889445e-05

Their O 0 6.670953780485434e-07
late O 0 3.4570732623251388e-06
father O 0 9.214327860718186e-07
had O 0 4.504749995248858e-08
the O 0 9.775952491963835e-09
adult O 0 1.3134799026204291e-08
type O 0 1.5659583141314215e-07
of O 0 1.3620338904729579e-05
DM B-Disease 1 1.0
, O 0 6.699139021293377e-08
with O 0 8.564160047797031e-09
onset O 0 0.09203099459409714
around O 0 1.8375807542270195e-07
30 O 0 6.592021861706598e-08
years O 0 4.0588030714161505e-08
. O 0 6.705607802359737e-08

Only O 0 1.065408596900852e-07
six O 0 6.114590167527467e-09
other O 0 1.5578825729445356e-10
cases O 0 3.651882962696362e-10
of O 0 2.568668655555939e-08
paternal O 0 0.00016170235176105052
transmission O 1 0.9998770952224731
of O 1 0.999998927116394
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 7.291871952475049e-06
been O 0 8.71314398409595e-08
reported O 0 1.1088643958601097e-07
recently O 0 1.2317983077991812e-07
. O 0 1.0600290778484123e-07

We O 0 2.356718624696441e-07
review O 0 5.149288639927363e-08
the O 0 5.824275284282976e-09
sex O 0 6.12853101600308e-09
related O 0 1.794348669648116e-08
effects O 0 2.9086388053656265e-07
on O 0 2.638720104641834e-07
transmission O 0 0.00020060095994267613
of O 0 0.0005859910161234438
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 8.277217420982197e-05

Decreased O 0 0.002208138583227992
fertility O 0 2.035216994045186e-06
of O 0 3.090913747172408e-09
males O 0 4.025777489147231e-10
with O 0 5.4876988370144986e-11
adult O 0 5.7241901885163315e-08
onset O 1 0.8669992685317993
DM B-Disease 1 1.0
and O 0 2.3969811024926457e-08
contraction O 0 1.7341216107524815e-07
of O 0 2.96759128382007e-09
the O 0 4.3120009785013735e-09
repeat O 0 1.1354847728739514e-08
upon O 0 2.6813086861920965e-08
male O 0 2.852551084231436e-08
transmission O 0 4.469154379904694e-09
contribute O 0 4.0300796033676534e-10
to O 0 1.364827556527004e-10
the O 0 1.5735077685263832e-09
almost O 0 9.838354131375127e-09
absent O 0 4.629511352050031e-08
occurrence O 0 2.6788038454128582e-08
of O 0 1.4029979844565332e-08
paternal O 0 2.6028023967228364e-06
transmission O 0 4.012501813122071e-05
of O 0 0.0006053312681615353
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 8.203807374229655e-05

Also O 0 6.562902967743867e-07
the O 0 1.6059584595495835e-07
fathers O 0 9.95590198726859e-07
of O 0 5.08202226967569e-08
the O 0 1.4064561071336357e-07
reported O 0 1.4684201232739724e-06
congenitally O 0 0.00010280406422680244
affected O 0 2.2870626281701334e-08
children O 0 3.6855356544407414e-09
showed O 0 3.80836446822741e-08
, O 0 1.571791918841825e-09
on O 0 2.6901297189851903e-08
average O 0 8.688748209806363e-08
, O 0 3.23474913521693e-09
shorter O 0 1.1289375834167004e-07
CTG O 0 8.527913450961933e-05
repeat O 0 3.059045354802947e-07
lengths O 0 1.27188593523897e-06
and O 0 6.177713340882462e-10
hence O 0 1.162693585854413e-08
less O 0 2.077588767690486e-09
severe O 0 3.2295229601686515e-08
clinical O 0 1.731619647671323e-07
symptoms O 0 1.871465826752683e-08
than O 0 1.7489770742784572e-10
the O 0 2.1720720777551605e-09
mothers O 0 3.799786263414262e-09
of O 0 3.893377176211743e-09
children O 0 5.16312326226398e-09
with O 0 1.0201648592556012e-07
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 2.5105589884333313e-05

We O 0 3.1442593240171846e-07
conclude O 0 1.3543882459998713e-06
that O 0 1.179596420541884e-08
paternal O 0 6.749505246261833e-06
transmission O 0 0.00012488465290516615
of O 0 0.005766314920037985
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 7.776488928357139e-07
rare O 0 9.011836610284263e-09
and O 0 3.005516113763207e-10
preferentially O 0 2.9340303520086763e-09
occurs O 0 2.4560795619521514e-09
with O 0 2.8395741313858025e-10
onset O 0 0.10888339579105377
of O 1 0.6630895733833313
DM B-Disease 1 1.0
past O 0 1.1141553386551095e-06
30 O 0 2.1828091334441524e-08
years O 0 1.887089373653339e-09
in O 0 1.1628881191327878e-09
the O 0 1.5429209909711972e-08
father O 0 3.7603942359965004e-07
. O 0 2.899771978093213e-08
. O 0 1.4216867327832006e-07

The O 0 1.4164726053422783e-05
RB1 O 0 0.0021515153348445892
gene O 0 1.0024827190591168e-07
mutation O 0 4.4050558756225655e-09
in O 0 2.828699274814994e-09
a O 0 2.768417672882606e-08
child O 0 3.9001133700367063e-07
with O 0 7.602768050674058e-07
ectopic B-Disease 1 1.0
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 1 1.0
. O 0 2.9312208425835706e-05

The O 0 2.0007129933219403e-05
RB1 O 0 0.007547816261649132
gene O 0 1.2525443082722632e-07
mutation O 0 7.142015423511339e-09
was O 0 2.8953397901432254e-08
investigated O 0 2.1182519560625224e-07
in O 0 1.845170061187673e-08
a O 0 5.276671544152123e-08
child O 0 3.3413343203392287e-07
with O 0 1.7830109300120967e-07
ectopic B-Disease 1 0.9999899864196777
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 0 0.03585517406463623
using O 0 1.0576297881925711e-07
DNA O 0 4.411380771784934e-08
obtained O 0 5.716988837889403e-08
from O 0 5.77882897090376e-09
both O 0 1.5954055854194849e-09
the O 0 3.37763630398058e-08
pineal B-Disease 0 0.4639393091201782
and I-Disease 0 1.893041030598397e-07
retinal I-Disease 1 0.9998308420181274
tumours I-Disease 1 1.0
of O 0 1.3647032574226614e-05
the O 0 4.187818376522046e-06
patient O 0 7.683495641686022e-05
. O 0 8.203040806620265e-07

A O 0 2.5401011953363195e-05
nonsense O 0 1.2539355338958558e-05
mutation O 0 4.3508158853455825e-08
in O 0 1.990163589482563e-08
exon O 0 2.245926822297406e-07
17 O 0 6.885148451374334e-08
( O 0 7.860039730189783e-09
codon O 0 5.313463802281149e-08
556 O 0 4.580771673090567e-08
) O 0 1.5413496035066032e-09
of O 0 1.1521390952395905e-08
the O 0 2.290363596557654e-07
RB1 O 0 0.0011598283890634775
gene O 0 2.2587581582911298e-08
was O 0 1.362649868497101e-07
found O 0 2.4686994670730655e-09
to O 0 2.2581356229345317e-10
be O 0 7.098810428374236e-10
present O 0 1.2132860049973715e-08
homozygously O 0 9.392682841280475e-06
in O 0 2.6522700480313688e-08
both O 0 1.6207158282099954e-08
the O 0 2.7859039164468413e-07
retinal B-Disease 0 4.3339943658793345e-05
and I-Disease 0 7.347874486640649e-08
the I-Disease 0 1.044072905642679e-05
pineal I-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 2.6611103294271743e-06

The O 0 4.872255203736131e-07
same O 0 5.22385761314581e-08
mutation O 0 7.967402737563134e-09
was O 0 2.7754389009260194e-08
present O 0 8.049643618335267e-09
heterozygously O 0 1.4619004105043132e-06
in O 0 9.68575086801593e-09
the O 0 1.0384338722246866e-08
DNA O 0 1.837709895369244e-08
from O 0 1.8898160814018183e-09
the O 0 4.234071315778465e-09
constitutional O 0 8.727061739932651e-09
cells O 0 2.170196466977359e-09
of O 0 1.6836639860073888e-09
the O 0 4.103732464955101e-09
patient O 0 5.4807511418175636e-08
, O 0 4.315652279984761e-10
proving O 0 9.881970441938392e-08
it O 0 1.8709822580120772e-10
to O 0 2.187074549242496e-10
be O 0 5.947999870414833e-10
of O 0 1.487553102919037e-08
germline O 0 3.254540843045106e-06
origin O 0 2.6094585336977616e-07
. O 0 3.570579565348453e-07

The O 0 4.832697868550895e-07
initial O 0 1.514529799351294e-07
mutation O 0 5.613749909372245e-09
was O 0 4.068049364036597e-08
shown O 0 3.3058045190159646e-09
to O 0 1.8693959713544928e-09
have O 0 1.2772680690886773e-09
occurred O 0 1.446491211254397e-07
in O 0 2.9312785532198404e-09
the O 0 3.081426314111013e-08
paternally O 0 6.880605724290945e-06
derived O 0 2.800357151500066e-06
RB1 O 0 0.00014069784083403647
allele O 0 2.7101282285002526e-07
. O 0 1.526441906207765e-07

The O 0 5.579502158070682e-07
mutation O 0 2.7694529336486085e-08
is O 0 2.3157116224581387e-09
in O 0 1.1034264613130063e-09
an O 0 2.0999308958380425e-09
area O 0 2.9830456327317734e-08
of O 0 2.618916461472054e-08
the O 0 6.939427521501784e-08
gene O 0 4.489487892556099e-09
that O 0 5.14642606308513e-10
encodes O 0 6.901857307894943e-09
the O 0 1.1429938107099247e-09
protein O 0 7.147057612399976e-09
- O 0 1.9424113428812007e-09
binding O 0 2.1474506617380484e-09
region O 0 2.7610878916561887e-08
known O 0 3.764455414057011e-08
as O 0 1.1537951039031213e-08
the O 0 1.0858936150270893e-07
pocket O 0 0.0001666906027821824
region O 0 6.696692480545607e-07
and O 0 8.379680949133217e-09
has O 0 1.1291928503354143e-09
been O 0 2.379710428712656e-09
detected O 0 1.0435107888895345e-08
in O 0 2.9691071823378934e-10
other O 0 1.9871082557187947e-10
cases O 0 1.1486059880994048e-09
of O 0 5.306890926704e-08
retinoblastoma B-Disease 0 6.598175968974829e-05
. O 0 1.7427328202757053e-07
. O 0 2.8796441142731055e-07

Low O 0 3.93602476833621e-06
levels O 0 1.351303069441201e-07
of O 0 6.57138343740371e-08
beta O 0 2.173568873331533e-06
hexosaminidase O 0 3.8030188989068847e-06
A O 0 9.295211356175059e-08
in O 0 2.2398032317738625e-09
healthy O 0 1.3080147631683303e-08
individuals O 0 1.3486901873083212e-10
with O 0 2.920645392201493e-10
apparent O 0 3.3111791708506644e-05
deficiency O 1 0.9997982382774353
of O 0 8.946535672293976e-06
this O 0 4.893330896038606e-08
enzyme O 0 4.474982517876924e-07
. O 0 6.720819811789625e-08

Appreciable O 0 0.0004858543979935348
beta O 0 3.1776751711731777e-05
hexosaminidase O 0 3.552090493030846e-05
A O 0 3.9663204915996175e-06
( O 0 5.5684093780428157e-08
hex O 0 1.4393536957868491e-06
A O 0 3.722245480730635e-07
) O 0 2.1037311892513344e-09
activity O 0 1.4518999336132765e-08
has O 0 8.143713481345571e-11
been O 0 4.505621986616859e-10
detected O 0 2.990016456649869e-09
in O 0 4.6481867244096975e-09
cultured O 0 2.018189843511209e-05
skin O 0 9.008039342006668e-06
fibroblasts O 0 0.0010663539869710803
and O 0 1.4018989702435647e-07
melanoma B-Disease 1 0.9999855756759644
tissue O 0 0.00030146530480124056
from O 0 2.0023637148369744e-07
healthy O 0 6.40070879853738e-07
individuals O 0 3.3496164175694787e-10
previously O 0 7.816503888591342e-09
reported O 0 7.266769408431628e-09
as O 0 2.2838315683060273e-09
having O 0 1.4032153217158339e-07
deficiency B-Disease 0 0.4696436822414398
of I-Disease 0 9.650764695834368e-06
hex I-Disease 0 6.734030466759577e-05
A I-Disease 0 5.723338176721882e-07
activity O 0 3.710909979304233e-08
indistinguishable O 0 8.176967547512959e-09
from O 0 2.1053077337018777e-10
that O 0 1.5953674145641195e-11
of O 0 2.3701207663151536e-09
patients O 0 2.622223993498096e-09
with O 0 1.848464279419204e-07
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 6.7495120674720965e-06
TSD B-Disease 1 0.601288914680481
) O 0 7.962043468978663e-08
. O 0 7.451780703604527e-08

Identification O 0 6.312545338005293e-06
and O 0 1.1895789242544197e-07
quantitation O 0 0.0004785072524100542
of O 0 2.5289009499829262e-05
hex O 0 0.00045928420149721205
A O 0 1.2736623830278404e-05
, O 0 1.317582398741024e-08
amounting O 0 9.045003821483988e-07
to O 0 5.6621217936481116e-08
3 O 0 1.2539478575490648e-06
. O 0 2.845118558525428e-07

5 O 0 6.217488589754794e-06
% O 0 1.3899894213409425e-07
- O 0 4.92022820708371e-07
6 O 0 6.630986604250211e-07
. O 0 3.3522533726682013e-07

9 O 0 1.2554962722788332e-06
% O 0 1.3861130021552981e-08
of O 0 3.1800342359389333e-09
total O 0 1.3170446955257376e-08
beta O 0 1.707686010377074e-07
hexosaminidase O 0 5.198878625378711e-07
activity O 0 8.19711516442112e-08
, O 0 2.469899285095778e-10
has O 0 4.7803067060314675e-11
been O 0 1.3267301146591137e-10
obtained O 0 2.7701065885565868e-09
by O 0 5.468479002956883e-09
cellulose O 0 4.343811269791331e-06
acetate O 0 3.7843179256924486e-07
gel O 0 5.208694915381784e-07
electrophoresis O 0 1.334128114649502e-06
, O 0 4.992670454839754e-08
DEAE O 0 7.943874516058713e-05
- O 0 2.485839331711759e-06
cellulose O 0 5.672970019077184e-06
ion O 0 2.055863888017484e-06
- O 0 2.1811501937918365e-06
exchange O 0 1.7943670172826387e-05
chromatography O 0 0.0013142325915396214
, O 0 1.7296241594522144e-07
radial O 0 3.5098803436994785e-06
immunodiffusion O 0 2.7153715564054437e-05
, O 0 5.193298946437608e-08
and O 0 6.207827851767433e-08
radioimmunoassay O 0 0.004652956500649452
. O 0 2.9273801374074537e-06

Previous O 0 0.0001144905763794668
family O 0 8.000037041711039e-07
studies O 0 3.4276805394029e-08
suggested O 0 2.682524868902192e-09
that O 0 3.778498347539738e-11
these O 0 3.3187206455176366e-11
individuals O 0 2.6024912780364673e-10
may O 0 7.00797531116848e-10
be O 0 2.745782934354679e-09
compound O 0 7.783150977047626e-07
heterozygotes O 0 2.562898870905883e-08
for O 0 1.6948241421399501e-10
the O 0 3.97199251267466e-09
common O 0 7.84518139340662e-09
mutant O 0 5.92426260936918e-07
TSD B-Disease 0 0.0010558265494182706
gene O 0 6.138135333344508e-09
and O 0 8.060946909971278e-10
a O 0 7.4151973450398145e-09
rare O 0 1.2625156919909841e-08
( O 0 1.1364511109945852e-08
allelic O 0 1.1420119960803277e-07
) O 0 1.5122703089787137e-08
mutant O 0 1.6927040746850253e-07
gene O 0 6.465359092544531e-08
. O 0 5.3952756928765666e-08

Thus O 0 2.6355742193118203e-06
, O 0 1.6448103323796204e-08
the O 0 8.93463081297341e-09
postulated O 0 1.234450792253483e-06
rate O 0 1.0557494078966556e-07
mutant O 0 4.4497976858792754e-08
gene O 0 1.138776628550886e-09
appears O 0 1.4019432281742183e-09
to O 0 1.0331756977732809e-10
code O 0 2.310337060551504e-10
for O 0 8.237241444497556e-11
the O 0 6.975449107216036e-10
expression O 0 2.8431252907523685e-09
of O 0 2.9737277085217784e-09
low O 0 1.870470356379883e-08
amounts O 0 1.3676198840073539e-08
of O 0 1.7828051568358205e-07
hex O 0 9.559795216773637e-06
A O 0 6.432041118387133e-06
. O 0 1.5092800254024041e-07

Heterozygotes O 0 0.00010483447840670124
for O 0 3.85716845130446e-08
the O 0 3.929217839981902e-08
rare O 0 3.6256171398463266e-08
mutant O 0 5.221257737275664e-08
may O 0 1.3390812902969174e-09
be O 0 3.254321256918047e-10
indistinguishable O 0 1.5338395442654473e-08
from O 0 1.4981503815292285e-09
heterozygotes O 0 1.4768470890658136e-08
for O 0 5.85074932946128e-10
the O 0 8.93616913799633e-08
common O 0 4.57612600257562e-07
TSD B-Disease 0 0.001838598633185029
mutant O 0 1.33913508761907e-05
. O 0 3.2693748153178603e-07

However O 0 1.8276921309734462e-07
, O 0 1.0046281140319024e-08
direct O 0 9.4745303158561e-08
visualization O 0 1.3650454093294684e-05
and O 0 5.3751026740656016e-08
quantitation O 0 0.0027658010367304087
of O 0 7.862778147682548e-06
hex O 0 8.981533028418198e-05
A O 0 2.675697317044978e-07
by O 0 4.661973584951795e-10
the O 0 8.952589780619746e-10
methods O 0 8.12510414505141e-09
described O 0 6.616482028931614e-09
may O 0 1.1091721985323488e-09
prevent O 0 3.0440907572426568e-09
false O 0 5.298779015561195e-08
- O 0 2.4251759711546583e-08
positive O 0 5.52547341214904e-09
prenatal O 0 4.7524682145194674e-07
diagnosis O 0 3.0724066846232745e-07
of O 0 1.1365317931222307e-07
TSD B-Disease 0 0.1300765722990036
in O 0 6.428371079891804e-08
fetuses O 0 2.9753724106740265e-07
having O 0 2.6938316466385004e-08
the O 0 3.1116897503125074e-08
incomplete O 0 7.286692380148452e-06
hex B-Disease 0 5.19395325682126e-05
A I-Disease 0 2.3184868041425943e-05
deficiency I-Disease 0 0.034051988273859024
of O 0 2.879583462345181e-06
the O 0 3.6487679722085886e-07
type O 0 2.3351221898337826e-05
described O 0 1.870231898237762e-07
in O 0 2.614319782878738e-08
the O 0 4.180174073553644e-08
four O 0 1.1194729410135551e-07
healthy O 0 6.867559818601876e-07
individuals O 0 1.664318602934145e-07

The O 0 7.766796443320345e-06
tumor B-Disease 0 0.00010639568063197657
suppressor O 0 2.5684008505777456e-05
gene O 0 1.3172197554922604e-07
Smad4 O 0 2.4719089196878485e-05
/ O 0 2.110185960191302e-06
Dpc4 O 0 8.063811947067734e-06
is O 0 8.56163973050883e-10
required O 0 3.168934004094126e-10
for O 0 6.987087575183182e-10
gastrulation O 0 1.130324562836904e-06
and O 0 3.4712595020636172e-09
later O 0 8.23106631742121e-08
for O 0 2.3211788047206028e-08
anterior O 0 2.289460098836571e-05
development O 0 2.038440106844064e-05
of O 0 7.289156087608717e-07
the O 0 4.995790163775382e-07
mouse O 0 1.3334324648894835e-06
embryo O 0 4.3609520616882946e-07
. O 0 6.148155762275564e-08

Mutations O 0 1.3380731616052799e-06
in O 0 8.661975670065658e-08
the O 0 7.824068575246201e-07
SMAD4 O 1 0.9999703168869019
/ O 1 0.9471750259399414
DPC4 O 1 0.9994128942489624
tumor B-Disease 0 0.00046608815318904817
suppressor O 0 3.59107980330009e-06
gene O 0 4.51578507920658e-09
, O 0 2.385021069528648e-10
a O 0 3.7023606402897258e-09
key O 0 1.1232030061592013e-07
signal O 0 1.0739286437910778e-07
transducer O 0 2.1947704453850747e-07
in O 0 4.958455868120382e-09
most O 0 3.3449953917852326e-09
TGFbeta O 0 4.13022207794711e-05
- O 0 7.786595688230591e-07
related O 0 9.753055110195419e-07
pathways O 0 5.4982677966108895e-08
, O 0 1.1019557488722853e-10
are O 0 5.5162426709776113e-11
involved O 0 9.59908597053527e-10
in O 0 1.4014085447655589e-09
50 O 0 2.199820059445301e-08
% O 0 9.578386972464159e-09
of O 0 2.0263804856313072e-07
pancreatic B-Disease 1 1.0
cancers I-Disease 1 0.9999420642852783
. O 0 1.3031709613642306e-06

Homozygous O 0 0.0007101006340235472
Smad4 O 0 0.007930949330329895
mutant O 0 0.00011434459884185344
mice O 0 3.816971457126783e-06
die O 0 5.345642080101243e-07
before O 0 2.570600372564513e-07
day O 0 1.0348018122385838e-06
7 O 0 2.396127683823579e-06
. O 0 3.99716981291931e-07

5 O 0 1.0858458153961692e-05
of O 0 2.078800662275171e-06
embryogenesis O 0 0.00010751213267212734
. O 0 3.0336532290675677e-06

Mutant O 0 2.92341542262875e-06
embryos O 0 3.926790270725178e-08
have O 0 2.936475507198111e-10
reduced O 0 1.1230540941653544e-09
size O 0 6.158658027999309e-09
, O 0 1.5766801197969471e-09
fail O 0 5.111945711178123e-08
to O 0 1.2551422123863176e-08
gastrulate O 0 3.8225683965720236e-05
or O 0 1.2619467781860294e-07
express O 0 4.685512422497595e-08
a O 0 3.701917705711821e-08
mesodermal O 0 3.114557102890103e-06
marker O 0 2.6192540758529503e-07
, O 0 1.3297785095289782e-09
and O 0 2.457072989514586e-09
show O 0 3.0455564115072775e-07
abnormal O 0 1.0585704330878798e-05
visceral O 0 3.488250285954564e-06
endoderm O 0 0.0001647952594794333
development O 0 7.612485205754638e-06
. O 0 2.5595775809961197e-07

Growth B-Disease 1 1.0
retardation I-Disease 1 1.0
of O 0 1.2892014638055116e-06
the O 0 8.819407071314345e-07
Smad4 O 1 0.9993659853935242
- O 0 5.018711453885771e-05
deficient O 0 1.7291520180151565e-06
embryos O 0 2.682954525212722e-09
results O 0 3.4505764912040604e-10
from O 0 2.8203797630688143e-10
reduced O 0 4.712235490700323e-09
cell O 0 6.705032262743771e-08
proliferation O 0 6.017808118485846e-08
rather O 0 1.8864128037421324e-09
than O 0 6.568094401693259e-10
increased O 0 6.540420205425335e-09
apoptosis O 0 3.673067396903207e-07
. O 0 2.40683100116712e-08

Aggregation O 0 1.3982253221911378e-05
of O 0 9.122467758970743e-07
mutant O 0 7.519573046010919e-06
Smad4 O 0 0.007934711873531342
ES O 0 0.00116263038944453
cells O 0 4.604104208993931e-09
with O 0 1.2280104710882256e-10
wild O 0 1.4752902011139213e-08
- O 0 6.599720592248559e-08
type O 0 1.684516917066503e-07
tetraploid O 0 4.250217898515984e-06
morulae O 0 7.363654003711417e-05
rescues O 0 1.1280178114247974e-05
the O 0 2.909551426455437e-07
gastrulation B-Disease 0 0.00032003421802073717
defect I-Disease 0 4.7924306272761896e-05
. O 0 2.7337608798916335e-07

These O 0 9.654233679157187e-08
results O 0 4.9334030194359e-08
indicate O 0 5.060664776124213e-08
that O 0 1.7558602349865282e-09
Smad4 O 0 1.8109058146364987e-06
is O 0 7.497151233160082e-10
initially O 0 2.3423560868707227e-09
required O 0 6.236280380989001e-10
for O 0 2.111742447574727e-10
the O 0 3.498431766502108e-09
differentiation O 0 3.87171823490462e-08
of O 0 9.998243122311123e-09
the O 0 1.598159649063291e-08
visceral O 0 9.161284708625317e-08
endoderm O 0 1.4716696341565694e-06
and O 0 1.2765252188629006e-09
that O 0 1.5727748270411013e-10
the O 0 3.7320746493207935e-09
gastrulation B-Disease 0 3.384373940207297e-06
defect I-Disease 0 9.979324886444374e-07
in O 0 1.0116484538968962e-08
the O 0 4.325487878986678e-08
epiblast O 0 5.3015184676041827e-05
is O 0 8.44255243492853e-09
secondary O 0 1.0673266359617628e-07
and O 0 4.495263272730199e-09
non O 0 1.8837672541849315e-05
- O 0 2.5801062292885035e-05
cell O 0 1.5891364455455914e-05
autonomous O 0 5.142435838934034e-06
. O 0 1.9129259953842848e-07

Rescued O 0 0.00021246474352665246
embryos O 0 1.06747472727875e-06
show O 0 3.2848953424036154e-07
severe O 0 9.768031077328487e-07
anterior O 0 5.696383595932275e-05
truncations O 0 0.03543463349342346
, O 0 2.085370027771205e-07
indicating O 0 7.256356298057653e-07
a O 0 5.8692197768550614e-08
second O 0 4.884630300239223e-08
important O 0 3.4792019931728646e-08
role O 0 6.109777217488954e-08
for O 0 5.868044539170114e-08
Smad4 O 1 0.9992088675498962
in O 0 2.899197170336265e-06
anterior O 0 0.0019084529485553503
patterning O 0 0.0006236464832909405
during O 0 0.00015027767221909016
embryogenesis O 0 0.0015548747032880783
. O 0 2.91209357783373e-06

Prevalence O 0 0.000263833295321092
of O 0 1.2209490023451508e-06
p16 O 0 8.867894393915776e-06
and O 0 1.5961619226345647e-07
CDK4 O 1 0.8073008060455322
germline O 0 8.684520435053855e-05
mutations O 0 3.469785170295836e-08
in O 0 7.667146917356149e-09
48 O 0 4.334647201176267e-07
melanoma B-Disease 0 0.0043906597420573235
- O 0 9.321763354819268e-05
prone O 0 2.269814103783574e-05
families O 0 1.623438450337744e-08
in O 0 4.907828099476319e-08
France O 0 2.051535375358071e-06
. O 0 1.7770385056792293e-06

The O 0 1.9123372112517245e-05
French O 0 0.00025853089755401015
Familial B-Disease 1 0.9999997615814209
Melanoma I-Disease 1 1.0
Study O 0 5.11979051225353e-05
Group O 0 1.1707022622431396e-06
. O 0 1.7002595598114567e-07

Germline O 0 0.0011454997584223747
mutations O 0 1.0603282873944408e-07
in O 0 1.2331919485575327e-08
the O 0 5.3564964019869876e-08
p16 O 0 1.0700126722440473e-06
and O 0 2.3145471317320698e-08
CDK4 O 0 0.07225744426250458
genes O 0 3.5001953335722646e-08
have O 0 5.364793609352603e-10
been O 0 1.1470187022410983e-09
reported O 0 3.139816184827282e-09
in O 0 4.0030057046891443e-10
a O 0 2.6606239433846213e-09
subset O 0 1.0772047431828469e-07
of O 0 4.220994753723062e-08
melanoma B-Disease 0 0.00010403421038063243
pedigrees O 0 4.663219897338422e-06
, O 0 4.018130717042823e-09
but O 0 4.745570048036996e-10
their O 0 1.107662850330371e-09
prevalence O 0 4.683412768713424e-08
is O 0 2.227302925428276e-10
not O 0 4.772738315672598e-10
well O 0 8.517975658151045e-09
known O 0 1.1429893476133657e-07
. O 0 3.399832451123075e-07

We O 0 3.5724798408409697e-07
searched O 0 1.1168085620738566e-06
for O 0 5.520522261548422e-09
such O 0 5.5362119333324245e-09
germline O 0 5.706579941033851e-06
mutations O 0 1.2782045644144091e-08
in O 0 6.825365161944319e-09
48 O 0 1.4627634925545863e-07
French O 0 1.253903337783413e-05
melanoma B-Disease 1 0.9982389211654663
- O 0 2.1355986973503605e-05
prone O 0 6.596297339456214e-07
families O 0 1.2208437594196653e-09
selected O 0 7.888571462721927e-10
according O 0 2.317120939565598e-09
to O 0 5.260427093922715e-10
two O 0 5.706807804095604e-10
major O 0 3.5959670796614773e-09
criteria O 0 1.407618910320707e-08
families O 0 8.342662116689326e-10
with O 0 3.350114630151779e-10
at O 0 5.6266486581080244e-08
least O 0 4.002442821615659e-09
three O 0 1.0297785957291694e-09
affected O 0 1.1297507374052884e-09
members O 0 6.538944941070213e-10
( O 0 2.5907891387788595e-09
n O 0 3.835438633359445e-08
= O 0 4.821097476792602e-08
20 O 0 6.504504490578711e-09
) O 0 2.335226734206941e-10
or O 0 3.071881915506225e-10
families O 0 8.286249464362072e-11
with O 0 1.3976620208411283e-11
two O 0 3.0634794701001056e-10
affected O 0 2.3375941182735005e-09
members O 0 2.3833476858747815e-10
, O 0 4.959295751838511e-10
one O 0 1.3116692176851075e-09
of O 0 3.1557205737442473e-09
them O 0 1.2383958303274767e-09
affected O 0 1.6608051600641716e-09
before O 0 2.7186217721464345e-09
the O 0 5.711035200306469e-09
age O 0 2.2011505507180118e-08
of O 0 3.670741577366243e-08
50 O 0 1.0677600137398713e-08
( O 0 6.18776085925532e-10
n O 0 7.885040176347502e-09
= O 0 1.083396217183008e-08
28 O 0 4.772513051420901e-09
) O 0 2.5592325481049727e-10
, O 0 4.977069797962308e-11
and O 0 8.789714095458478e-11
one O 0 3.907144885406666e-10
additional O 0 1.694643980698629e-09
minor O 0 2.3495530854233948e-07
criterion O 0 1.0189383829128928e-05
. O 0 7.75665341734566e-07

Sixteen O 0 5.457141924125608e-06
different O 0 4.106404460912927e-08
p16 O 0 6.9901116148685105e-06
germline O 0 4.155795068072621e-06
mutations O 0 8.608361135031828e-09
were O 0 3.722761210411818e-09
found O 0 1.749752120971948e-09
in O 0 1.2007729255358868e-09
21 O 0 2.9126098866072425e-08
families O 0 1.2259703252581744e-09
, O 0 5.106969847012977e-10
while O 0 4.7088035692866015e-09
one O 0 1.7734711477146448e-08
germline O 0 1.3582894098362885e-06
mutation O 0 5.274263692456316e-09
, O 0 2.8024120801717345e-09
Arg24His O 0 2.513529580028262e-05
, O 0 1.719005382483374e-08
was O 0 4.266696294052963e-07
detected O 0 1.379750074192998e-07
in O 0 1.662342974384501e-08
the O 0 3.984461898198788e-07
CDK4 O 0 0.26778051257133484
gene O 0 1.2653092653636122e-06
. O 0 4.088215632691572e-07

The O 0 3.686198795094242e-07
frequency O 0 1.9616037150171906e-07
of O 0 9.168276449145196e-08
p16 O 0 1.96771475202695e-06
gene O 0 1.5687287913124237e-08
mutation O 0 6.144574848931939e-10
in O 0 7.144600466801876e-10
our O 0 3.0349016633124393e-09
sample O 0 1.4559480288056648e-09
( O 0 9.19206433191988e-10
44 O 0 1.6498367116923873e-09
% O 0 6.318667811200385e-10
) O 0 1.7374000849113003e-10
is O 0 3.8673137608968844e-11
among O 0 1.026248183655376e-11
the O 0 3.0553332086569185e-10
highest O 0 9.040726389741849e-09
rates O 0 2.2947606037604373e-09
yet O 0 9.226334141132497e-10
reported O 0 1.680628969324971e-09
and O 0 6.917440925624518e-11
the O 0 3.393604286472396e-09
CDK4 O 0 1.2491195775510278e-05
mutation O 0 1.0019618468248837e-09
is O 0 1.0639734926431998e-10
the O 0 3.3683109079696294e-10
second O 0 3.627725231325485e-09
mutation O 0 5.260527569106443e-10
detected O 0 1.6816870118674387e-09
in O 0 4.098371919614152e-10
this O 0 1.1567538038548264e-09
gene O 0 1.0276658635177682e-08
worldwide O 0 8.029340747839342e-09
. O 0 3.4782335234240236e-08

In O 0 3.88955726293716e-07
summary O 0 4.020404958282597e-06
, O 0 7.94120147418198e-09
our O 0 1.4202021780818086e-08
results O 0 4.286057286861933e-09
show O 0 5.930421487221338e-09
frequent O 0 5.531409552617106e-09
involvement O 0 4.341131898399908e-09
of O 0 7.017649572560458e-09
the O 0 1.663278581531813e-08
p16 O 0 8.948907748163037e-07
gene O 0 1.2136840865650811e-08
in O 0 1.2002629112828345e-08
familial B-Disease 0 3.7775134842377156e-05
melanoma I-Disease 0 8.343236549990252e-05
and O 0 4.586268254058723e-09
confirm O 0 1.6892755638764356e-07
the O 0 4.910056006224295e-08
role O 0 1.2820079575703858e-07
of O 0 5.525548658624757e-07
the O 0 6.807626959925983e-07
CDK4 O 0 0.34816262125968933
gene O 0 6.038595756763243e-08
as O 0 5.463433261354567e-09
a O 0 1.5631620442491112e-07
melanoma B-Disease 0 8.018214430194348e-05
- O 0 2.9033475584583357e-05
predisposing O 0 0.00010357263818150386
gene O 0 1.0164435337856048e-07
. O 0 2.38772717153779e-08
. O 0 1.7577082189745852e-07

Progression O 0 0.0003482899919617921
of O 0 2.9012217055424117e-06
somatic O 0 2.6314191927667707e-05
CTG O 0 0.0011301451595500112
repeat O 0 2.6763379423755396e-07
length O 0 3.9164604004326975e-08
heterogeneity O 0 1.0994925503382547e-07
in O 0 1.6406548342118299e-09
the O 0 6.859401935344067e-09
blood O 0 1.1662355348107667e-07
cells O 0 3.0394687655643793e-07
of O 0 1.7865331756183878e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 1.5403107681777328e-05
. O 0 1.5974518419170636e-07

The O 0 3.980367750955338e-07
genetic O 0 1.8172032412167027e-07
basis O 0 4.1958386987062113e-07
of O 0 3.255360525145079e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0003020073054358363
DM B-Disease 1 1.0
) O 0 4.688039734190852e-09
is O 0 2.054668102324797e-10
the O 0 9.180045057455288e-10
expansion O 0 9.763095221160256e-09
of O 0 1.1817402167935143e-08
an O 0 2.806136478739063e-08
unstable O 0 4.73168256576173e-05
CTG O 0 0.0020483150146901608
repeat O 0 9.910337439578143e-07
in O 0 4.559702659889808e-08
the O 0 7.286439540621359e-08
34 O 0 4.0200271200774296e-07
UTR O 0 0.00011636410636128858
of O 0 6.026997994013072e-07
the O 0 3.5443783872324275e-06
DM B-Disease 1 1.0
protein O 0 1.4903647752362303e-05
kinase O 0 1.2893175153294578e-05
gene O 0 6.4458034465531e-09
on O 0 9.213589002854405e-09
chromosome O 0 9.834418079890384e-08
19 O 0 1.9784354776675173e-07
. O 0 9.831342140387278e-08

One O 0 8.304818948090542e-07
of O 0 1.269015399429918e-07
the O 0 8.245412175256206e-08
principal O 0 4.06194294555462e-06
features O 0 7.208723218354862e-08
of O 0 3.3443853908465826e-07
the O 0 4.198186616122257e-06
DM B-Disease 1 1.0
mutation O 0 5.812714221065107e-08
is O 0 9.255557431586681e-10
an O 0 5.793647783747247e-10
extraordinarily O 0 4.017688581825496e-08
high O 0 3.350859145712093e-08
level O 0 1.7875841251679958e-07
of O 0 1.233759405749879e-07
somatic O 0 1.7793211100070039e-06
mosaicism O 0 0.00029070829623378813
, O 0 3.412648608147606e-09
due O 0 3.2529655413782166e-08
to O 0 1.9387358385358766e-09
an O 0 4.588402990890472e-09
extremely O 0 1.899114288050896e-08
high O 0 2.1065590161128966e-08
degree O 0 3.548974518707837e-07
of O 0 3.9229348658409435e-08
somatic O 0 2.2211139594219276e-07
instability O 0 2.0684213097865722e-07
both O 0 4.349607896081409e-10
within O 0 1.9918715565836465e-09
and O 0 1.6821161130664564e-10
between O 0 9.747199714027488e-10
different O 0 5.128151236988288e-10
tissues O 0 8.719328548068006e-08
. O 0 7.218849873424915e-08

This O 0 2.2234432606182963e-07
instability O 0 1.1695684634105419e-06
appears O 0 1.0711178077826844e-07
to O 0 2.1306456599035073e-09
be O 0 3.1300815273027638e-09
biased O 0 4.298683720094232e-08
towards O 0 6.991356826802075e-09
further O 0 1.850964048699666e-09
expansion O 0 9.04320973660333e-09
and O 0 3.716870422554308e-10
continuous O 0 1.4247500246256095e-07
throughout O 0 1.5455033919309358e-09
the O 0 1.8447116056918844e-09
life O 0 1.0066805167241455e-08
of O 0 2.7464428509205163e-09
an O 0 3.696953299048289e-10
individual O 0 8.54897763691298e-10
, O 0 2.568494583687908e-10
features O 0 8.774007076439716e-10
that O 0 1.0253563970108459e-10
could O 0 2.73348066404111e-10
be O 0 5.757208043633e-10
associated O 0 6.313394251833415e-09
with O 0 5.955367310406245e-10
the O 0 1.0736008704270716e-07
progressive O 0 9.493557513451378e-07
nature O 0 2.1004210282171698e-07
of O 0 5.6172982709767894e-08
the O 0 2.437256512166641e-07
disease O 0 1.3687390492123086e-06
. O 0 5.9529202900421296e-08

Although O 0 1.887281797507967e-07
increasing O 0 3.912742130296465e-08
measured O 0 4.635944250708235e-08
allele O 0 1.0410193818088942e-09
size O 0 1.2933054627239926e-09
between O 0 1.8113726074631131e-09
patients O 0 1.310216379835083e-09
clearly O 0 5.57141266455119e-09
correlates O 0 6.117788586834649e-08
with O 0 5.925971519049611e-11
an O 0 1.2750864253341376e-10
increased O 0 2.226988593534429e-10
severity O 0 5.575866879325986e-09
of O 0 4.429354216739512e-09
symptoms O 0 2.9178588434319863e-08
and O 0 1.4550062543694509e-10
an O 0 1.852100278698643e-10
earlier O 0 5.545763848147089e-10
age O 0 1.1703624736014717e-09
of O 0 1.8945043311902054e-09
onset O 0 5.888180254487452e-08
, O 0 4.926972718699574e-11
this O 0 5.131700273053319e-11
correlation O 0 8.409057339342496e-10
is O 0 1.331774707874489e-11
not O 0 6.4130016401431345e-12
precise O 0 1.074007549561884e-09
and O 0 1.7714070488228373e-10
measured O 0 4.169716127933043e-09
allele O 0 1.7009317565541693e-10
length O 0 3.890517075166855e-10
cannot O 0 2.2455812209720705e-10
be O 0 1.1347756068147419e-10
used O 0 4.632333405751865e-10
as O 0 3.81986969832937e-10
an O 0 5.479773856897907e-10
accurate O 0 4.492505567554872e-08
predictor O 0 2.721991450016503e-07
of O 0 2.8490911851974943e-09
age O 0 4.407302256481671e-08
of O 0 3.452061605457857e-07
onset O 0 0.007395029067993164
. O 0 7.549699603259796e-07

In O 0 2.749558518644335e-07
order O 0 5.071697284364518e-09
to O 0 8.838117460108208e-10
further O 0 4.623023741601173e-09
characterize O 0 1.6012189973935165e-07
the O 0 2.6064581604146042e-08
dynamics O 0 3.431963477851241e-06
of O 0 6.183730420161737e-06
DM B-Disease 1 1.0
CTG O 0 0.06441047787666321
repeat O 0 5.765597848039761e-07
somatic O 0 3.1431048341801215e-07
instability O 0 1.568901524251487e-07
, O 0 7.50437600949283e-10
we O 0 6.204187719127674e-10
have O 0 1.3937201392977272e-10
studied O 0 5.744464903756352e-09
repeat O 0 4.863051294989873e-09
length O 0 1.1895074925050153e-09
changes O 0 6.262106805321466e-11
over O 0 1.3323597780612317e-10
time O 0 1.7050058032097581e-09
in O 0 8.094924730528419e-09
111 O 0 5.075811259303009e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 1.705653174255417e-09
with O 0 5.422666222304473e-12
varying O 0 4.610279658034955e-10
clinical O 0 2.429217360599978e-08
severity O 0 4.886121374170216e-08
and O 0 5.18465581578198e-09
CTG O 0 4.263290611561388e-05
repeat O 0 3.3415279432347234e-08
size O 0 2.0072759010503205e-09
over O 0 1.9836320086508152e-10
time O 0 1.0319531895675027e-09
intervals O 0 8.904671666698505e-09
of O 0 6.339252678344565e-09
1 O 0 2.3929977999159746e-08
- O 0 2.5293758199040894e-08
7 O 0 5.742474229464278e-08
years O 0 3.9931570938733785e-08
. O 0 9.802432288097407e-08

We O 0 3.3995797821262386e-07
have O 0 2.224824324770225e-09
found O 0 1.8432907422649691e-09
a O 0 4.013206211794795e-09
direct O 0 1.1667744992394091e-08
progression O 0 8.850896904277761e-08
of O 0 4.3128896010102835e-09
the O 0 2.9948279411939893e-09
size O 0 4.19439594168125e-09
heterogeneity O 0 2.637584728404363e-08
over O 0 5.828673099728121e-10
time O 0 2.6325774893365406e-09
related O 0 8.13910983055166e-09
to O 0 2.34045383074033e-09
initial O 0 3.143647404613148e-07
CTG O 0 4.492426523938775e-05
repeat O 0 3.178040941520521e-08
size O 0 5.077998466163081e-09
and O 0 2.6632576699547883e-10
the O 0 1.1398609833790374e-09
time O 0 6.317779188691475e-09
interval O 0 8.108990101618474e-08
and O 0 5.565558014453131e-10
always O 0 7.570020166269842e-09
biased O 0 2.599006698744688e-08
towards O 0 1.0306062669940275e-08
further O 0 1.0600650135472733e-08
expansion O 0 2.2376636366061575e-07
. O 0 8.585163868701784e-08

Attempts O 0 1.9279141270089895e-06
to O 0 1.0774776626476523e-08
mathematically O 0 5.570479402194906e-07
model O 0 6.627156068361728e-08
the O 0 2.1849293929676605e-08
dynamics O 0 3.1259062325261766e-06
have O 0 2.171330670819316e-09
proved O 0 4.388424486023723e-07
only O 0 6.188342727142526e-09
partially O 0 5.433112164610066e-07
successful O 0 2.265973009230038e-08
suggesting O 0 8.154322550524284e-09
that O 0 4.35505971563277e-11
individual O 0 9.432973152589952e-11
specific O 0 2.836034185271785e-10
genetic O 0 1.7919913330999293e-09
and O 0 8.964208819683961e-10
/ O 0 4.391908134948608e-07
or O 0 1.557979345534477e-08
environmental O 0 1.0516213677647102e-07
factors O 0 2.8982237054719917e-08
also O 0 5.328631424994512e-10
play O 0 8.113596905445775e-09
a O 0 1.610860067557951e-08
role O 0 4.481602289274633e-08
in O 0 3.4819837679833654e-08
somatic O 0 2.1184146135055926e-06
mosaicism O 0 7.533328607678413e-05
. O 0 6.63540262735296e-08
. O 0 2.0383235721510573e-07

Aspartylglucosaminuria B-Disease 1 1.0
among O 0 2.1278744952724082e-06
Palestinian O 0 0.0002090869384119287
Arabs O 0 1.0798994480865076e-05
. O 0 5.820635351483361e-07

Aspartylglucosaminuria B-Disease 1 1.0
( O 1 0.982102632522583
AGU B-Disease 1 1.0
) O 0 1.6206114139549754e-07
is O 0 5.087877674725405e-09
a O 0 1.444147379459082e-08
rare O 0 4.2318697524024174e-07
disorder B-Disease 1 0.9957908391952515
of I-Disease 1 0.9860155582427979
glycoprotein I-Disease 1 1.0
metabolism I-Disease 1 1.0
caused O 0 3.373404751982889e-06
by O 0 2.424194178729522e-09
the O 0 9.028873648730951e-08
deficiency B-Disease 0 0.3788847029209137
of I-Disease 0 5.805882665299578e-06
the I-Disease 0 4.464502580958651e-06
lysosomal I-Disease 1 0.999984622001648
enzyme I-Disease 0 1.1981870557065122e-05
aspartylglucosaminidase I-Disease 0 7.69725302234292e-05
( O 0 2.3495127265960036e-07
AGA O 0 0.00035429210402071476
) O 0 1.8802430190589803e-07
. O 0 1.4565966921509244e-07

AGU B-Disease 1 1.0
is O 0 1.067344442162721e-06
inherited O 0 4.801973045687191e-05
as O 0 1.9398488859678764e-07
an O 0 5.00932060276682e-07
autosomal O 1 0.7588529586791992
recessive O 0 0.00032454164465889335
trait O 0 4.706791060016258e-06
and O 0 1.8520809774713598e-08
occurs O 0 1.8047217054117937e-07
with O 0 2.2610848748882972e-09
a O 0 1.3612262250717322e-07
high O 0 4.779648747899046e-07
frequency O 0 1.0355445567711286e-07
in O 0 1.3201104209770165e-08
Finland O 0 3.405492066121951e-07
because O 0 9.72197256032814e-09
of O 0 1.0230293412405445e-07
a O 0 3.535216137606767e-07
founder O 0 1.211673952639103e-05
effect O 0 6.471329925261671e-07
. O 0 2.086613335450238e-07

While O 0 7.810245961081819e-07
very O 0 1.2608287747184477e-08
few O 0 2.4616618077288877e-08
patients O 0 1.150937745109104e-08
with O 0 1.539663685434789e-08
AGU B-Disease 1 1.0
have O 0 4.863072433636262e-08
been O 0 1.5175551482116134e-08
reported O 0 9.198505956931058e-09
from O 0 1.135486371595107e-09
non O 0 6.079901027078449e-08
- O 0 2.249042729829398e-08
Finnish O 0 1.0278774880134733e-06
origin O 0 2.2279467160046806e-08
, O 0 3.278714855170506e-09
we O 0 1.5439896472457804e-08
diagnosed O 0 8.225665055761056e-07
the O 0 5.55855130812688e-08
disorder O 0 7.0422688622784335e-06
in O 0 1.0494549229633776e-08
8 O 0 1.1537669308836485e-07
patients O 0 3.1053304372363755e-10
originating O 0 1.8673824708770326e-09
from O 0 1.0878101752709313e-09
3 O 0 5.211514331193712e-09
unrelated O 0 1.3786801922321956e-08
families O 0 4.100060568834607e-10
, O 0 1.4226679556639255e-10
all O 0 6.146684827790239e-10
Palestinian O 0 1.3019312063988764e-06
Arabs O 0 2.4976342771765303e-08
from O 0 8.553120434129369e-10
the O 0 2.826736178462852e-09
region O 0 9.698432279492408e-09
of O 0 8.425600839245817e-08
Jerusalem O 0 0.0001936798362294212
. O 0 1.2953597661180538e-06

The O 0 2.073937594104791e-06
clinical O 0 0.00014894055493641645
diagnosis O 1 0.7032964825630188
of O 0 0.0028501248452812433
AGU B-Disease 1 1.0
is O 0 2.2435463620240625e-07
often O 0 1.6593010299104094e-09
difficult O 0 7.32523020019471e-09
, O 0 7.475590146910349e-10
in O 0 2.0180013216020143e-09
particular O 0 7.0574883714868974e-09
early O 0 6.624691906154112e-08
in O 0 5.042182671388673e-09
the O 0 1.3042355639925063e-08
course O 0 8.940311602145812e-08
of O 0 7.698887749540972e-09
the O 0 1.465756671592544e-08
disease O 0 1.0807754335928621e-07
, O 0 2.300259149823347e-10
and O 0 8.340955703900477e-11
most O 0 1.3247881958111662e-10
of O 0 2.106027796600074e-09
the O 0 1.2408222005433345e-08
patients O 0 3.441704476969676e-09
are O 0 3.183583119348299e-10
diagnosed O 0 4.3699607488179026e-08
after O 0 2.207882410232287e-08
the O 0 5.74123717456132e-08
age O 0 1.4218697685919324e-07
of O 0 1.5252558682732342e-07
5 O 0 9.90943291867552e-08
years O 0 2.994104164599776e-08
. O 0 7.579516392297592e-08

However O 0 4.0877750961954007e-07
, O 0 6.6852363644898105e-09
since O 0 2.466172155379809e-09
these O 0 4.0125000544399825e-10
patients O 0 8.404150153573653e-10
excrete O 0 3.229565948004165e-08
early O 0 6.152283127391911e-09
large O 0 7.912033250789818e-10
amounts O 0 5.201464592374805e-09
of O 0 6.705735700052173e-08
aspartylglucosamine O 0 3.7300419535313267e-06
in O 0 4.754505678050691e-09
urine O 0 3.901152734187008e-09
, O 0 3.451293695277968e-10
biochemical O 0 1.9535958628580374e-08
screening O 0 3.17928838811099e-09
is O 0 4.1030570607780703e-10
easy O 0 5.666613400734377e-09
by O 0 2.263561560411631e-09
urine O 0 6.71862849799254e-08
chromatography O 0 4.941774022881873e-05
. O 0 3.0443047194239625e-07
. O 0 5.773857196800236e-07

Detection O 0 1.1950899533985648e-05
of O 0 1.182502771257532e-07
heterozygous O 0 5.750848686147947e-08
carriers O 0 1.5404530984142184e-09
of O 0 3.825195804552095e-08
the O 0 1.6152678199432557e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.0003169136180076748
ATM O 0 0.00017005487461574376
) O 0 6.806593066954747e-09
gene O 0 1.1553403789221761e-09
by O 0 1.5005983122762245e-09
G2 O 0 3.069775630137883e-06
phase O 0 1.7605495941097615e-06
chromosomal O 0 1.689213422650937e-05
radiosensitivity O 0 7.100625953171402e-05
of O 0 6.596740604436491e-06
peripheral O 0 0.01438894122838974
blood O 0 5.998045890009962e-05
lymphocytes O 0 1.595699905010406e-05
. O 0 8.073061508184765e-07

In O 0 0.0002507020253688097
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.999981164932251
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 3.774304957460117e-08
patients O 0 1.5937631214768544e-09
, O 0 4.2818366907670935e-11
mutations O 0 5.5681882715763464e-11
in O 0 2.2482597727968567e-10
a O 0 1.5127947783355467e-09
single O 0 1.0768238523084506e-09
gene O 0 1.2062285892344704e-10
, O 0 6.042009947915261e-11
ATM O 0 5.010758030721263e-08
, O 0 3.5574401063831473e-11
result O 0 4.0883474383690555e-10
in O 0 6.591264423150278e-09
an O 0 9.344307181891054e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 1.0900123470491963e-08
embraces O 0 7.481271602216566e-09
a O 0 7.484449726646858e-10
variety O 0 2.9892566200118154e-10
of O 0 1.6176089800978843e-08
clinical O 0 2.26643919631897e-06
features O 0 2.6391850482809787e-08
and O 0 2.4706634516036274e-09
manifests O 0 1.1198573446336013e-07
extreme O 0 1.9187448287993902e-06
radiosensitivity O 0 0.0005512073985300958
and O 0 3.9808149665532255e-08
a O 0 3.142400544220436e-07
strong O 0 1.5758519111841451e-07
pre O 0 2.9771068511763588e-05
- O 0 3.1363815651275218e-06
disposition O 0 5.249670357443392e-05
to O 0 1.5124658148124581e-06
malignancy B-Disease 1 0.9845833778381348
. O 0 2.910394186983467e-06

Heterozygotes O 0 1.3392627806751989e-05
for O 0 2.2147911948877663e-08
the O 0 1.0725693044832951e-07
ATM O 0 2.8732833015965298e-05
gene O 0 1.243480518553497e-08
have O 0 5.7009330589608e-10
no O 0 5.571890948630198e-09
clinical O 0 7.15079622182202e-08
expression O 0 2.6732914548688314e-08
of O 0 1.2478067219490185e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999996423721313
T I-Disease 1 1.0
but O 0 1.1111229269999967e-08
may O 0 1.4799037550972116e-08
be O 0 2.757088424232279e-08
cancer B-Disease 0 1.910068931465503e-06
prone O 0 2.1105894632000854e-07
with O 0 5.213927622982339e-10
a O 0 3.497686051900928e-08
moderate O 0 7.979157778947865e-09
increase O 0 7.083891251369323e-10
in O 0 3.255105296418037e-09
in O 0 2.4391903608034227e-08
vitro O 0 6.992132057348499e-06
radiosensitivity O 0 2.6965493816533126e-05
. O 0 2.0921885379721061e-07

We O 0 3.7464050706148555e-07
performed O 0 2.5924870783455845e-07
a O 0 1.3252069663849397e-07
blind O 0 6.700468020426342e-07
chromosomal O 0 2.1589022480839049e-07
analysis O 0 2.8797094486776587e-08
on O 0 4.128771635691919e-08
G2 O 0 3.013451760125463e-06
- O 0 3.8553665149265726e-08
phase O 0 1.9032923148643022e-07
lymphocytes O 0 1.002979654884939e-08
from O 0 7.690287517903016e-09
7 O 0 1.459380314372538e-07
unrelated O 0 1.3256686770546366e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999970197677612
T I-Disease 1 1.0
patients O 0 1.579076602808982e-08
, O 0 1.8917816202446147e-09
13 O 0 9.408727663640093e-08
obligate O 0 9.932685998137458e-07
A B-Disease 1 1.0
- I-Disease 1 0.9999608993530273
T I-Disease 1 0.999998927116394
heterozygotes O 0 6.592624686163617e-07
( O 0 1.928836201869899e-09
parents O 0 2.404735854888429e-10
of O 0 6.518273698574717e-10
the O 0 1.999103105276845e-09
patients O 0 2.887373395932258e-10
) O 0 1.2849940556058925e-10
, O 0 7.368214371972215e-11
and O 0 2.12683204381392e-10
14 O 0 1.6848085593323958e-08
normal O 0 4.120244057048694e-08
controls O 0 1.8190831063691348e-09
following O 0 1.3545249366586631e-09
X O 0 1.557168758381522e-07
- O 0 4.324693492208098e-09
irradiation O 0 1.2082517208966692e-08
with O 0 4.32117064352866e-10
1 O 0 5.4484406319943446e-08
Gy O 0 3.2266893867927138e-06
in O 0 1.515051972766912e-10
order O 0 1.0563703384258716e-10
to O 0 4.523210972440239e-11
evaluate O 0 5.01586194801007e-09
this O 0 2.7285231851692515e-09
cytogenetic O 0 1.842116262196214e-06
method O 0 2.679376187586513e-08
as O 0 7.585308492430443e-10
a O 0 1.507535096756385e-09
tool O 0 3.3938128751742624e-08
for O 0 5.263537938837715e-10
detection O 0 5.7724538038428364e-08
of O 0 8.376025562029099e-08
ATM O 0 0.0002467978629283607
carriers O 0 3.743569436664984e-07
. O 0 3.913541490874195e-07

Both O 0 2.245288123958744e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
homozygotes O 0 0.00015960466407705098
and O 0 2.5249027757467957e-08
heterozygotes O 0 8.8898752892419e-07
showed O 0 1.2184575126639174e-08
significantly O 0 5.839578265387502e-10
increased O 0 2.7732666163515773e-10
levels O 0 2.2791577514169603e-09
of O 0 1.0896215485445282e-08
radiation O 0 1.349694503005594e-05
- O 0 9.79658807409578e-07
induced O 0 4.488661033974495e-06
chromatid O 0 0.0002050651382887736
damage O 0 6.174268492031842e-07
relative O 0 4.229601913152692e-08
to O 0 3.2110011871644417e-10
that O 0 2.35321873098826e-10
of O 0 8.618202151922105e-09
normal O 0 4.717121271369251e-07
controls O 0 1.8487197905869834e-07
. O 0 6.819746545261296e-08

These O 0 7.94344714449835e-08
results O 0 4.668803299523461e-08
show O 0 1.8844936278128444e-08
that O 0 1.4558452221535845e-09
the O 0 3.2820388184973126e-08
G2 O 0 1.0467766514921095e-05
- O 0 2.8452976152948395e-07
phase O 0 1.9168555809301324e-06
chromosomal O 0 4.7342200559796765e-06
radiosensitivity O 0 1.9047027990382048e-06
assay O 0 3.0108953552598905e-08
can O 0 7.281330399733221e-11
be O 0 9.138357431881516e-11
used O 0 2.2909023289496844e-10
for O 0 4.2407774514252594e-10
the O 0 9.605757966824058e-09
detection O 0 3.1440433190255135e-07
of O 0 4.269987130101072e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
heterozygotes O 0 5.671038888976909e-05
. O 0 3.83059926889473e-07

In O 0 1.2181816089196218e-07
combination O 0 5.692789528666253e-08
with O 0 3.407068405181235e-09
molecular O 0 1.6493141856699367e-06
genetic O 0 9.245243859368202e-08
analyses O 0 3.9945284413533955e-08
, O 0 7.99833393960725e-11
this O 0 6.49990825052349e-11
test O 0 1.4982753926418013e-10
may O 0 1.933955773303353e-10
be O 0 8.120075445372521e-11
of O 0 5.0083071023721e-10
value O 0 6.271675179192471e-09
in O 0 8.483710955964341e-10
studies O 0 9.685823698646345e-09
of O 0 9.768645448104962e-09
familial B-Disease 0 4.305950369598577e-07
and I-Disease 0 3.6966592009690658e-09
sporadic I-Disease 0 1.751202580635436e-05
cancers I-Disease 0 2.8417337034625234e-06
aimed O 0 1.9704629039551946e-07
at O 0 8.865832512583438e-08
determination O 0 8.357701197780898e-09
of O 0 5.805000036218644e-09
the O 0 1.765232293671204e-09
potential O 0 1.5687490195759324e-09
involvement O 0 1.8984733785032404e-08
of O 0 3.4366554046982856e-08
ATM O 0 1.0156670214200858e-05
mutations O 0 5.0808952600789326e-09
in O 0 5.171520101043825e-09
tumor B-Disease 0 1.3240792213764507e-05
risk O 0 2.474226050708239e-07
or O 0 1.9145680596466264e-08
development O 0 5.723436515836511e-07
. O 0 1.5950503140516048e-08
. O 0 1.069921324869938e-07

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
: O 0 1.2576133201491757e-07
identification O 0 1.9792725680645162e-08
and O 0 1.0865783828251097e-09
detection O 0 1.453097411285853e-07
of O 0 2.6663335006560374e-07
founder O 0 9.214674355462193e-05
- O 0 3.1396805866279465e-07
effect O 0 2.0006298839803094e-08
mutations O 0 5.257086432841618e-10
in O 0 4.951469789737928e-10
the O 0 7.441238736305422e-09
ATM O 0 1.7743678881743108e-06
gene O 0 7.168228233211948e-10
in O 0 2.540692378705245e-10
ethnic O 0 2.0518573506933535e-09
populations O 0 6.466355007006541e-09
. O 0 1.709370067715099e-08

To O 0 5.4296631191164124e-08
facilitate O 0 3.941595494438843e-08
the O 0 6.508115379944002e-09
evaluation O 0 1.3317480807018e-07
of O 0 4.1104485148935055e-07
ATM O 0 7.852035923860967e-05
heterozygotes O 0 4.5351043809205294e-07
for O 0 8.734518108788336e-10
susceptibility O 0 3.1697474867087294e-08
to O 0 2.426445988579218e-10
other O 0 2.3715981956051735e-10
diseases O 0 3.67582561011659e-06
, O 0 1.823740741757618e-10
such O 0 7.510186222914328e-11
as O 0 2.369444018768263e-08
breast B-Disease 0 1.8555461792857386e-05
cancer I-Disease 0 6.689211886623525e-07
, O 0 1.4274770254729674e-09
we O 0 1.579111952310086e-09
have O 0 1.4771808776181672e-10
attempted O 0 4.041643908436754e-09
to O 0 1.9563568820490929e-10
define O 0 2.8235944693477677e-09
the O 0 1.1082121886829555e-09
most O 0 3.509649515454072e-11
common O 0 5.5646102309347967e-11
mutations O 0 4.6093892591692054e-11
and O 0 3.0836090625374624e-11
their O 0 2.1469581668043247e-10
frequencies O 0 5.3065840610599935e-09
in O 0 9.708874415537139e-08
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
telangiectasia I-Disease 1 1.0
( O 1 0.9999839067459106
A B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
) O 0 1.5731004054941877e-08
homozygotes O 0 1.469823729394193e-07
from O 0 5.318092077821746e-10
10 O 0 7.501486098959731e-10
ethnic O 0 8.165990661446187e-10
populations O 0 3.917504542982897e-09
. O 0 1.599794252626907e-08

Both O 0 6.429193177837078e-08
genomic O 0 2.0887952700832102e-07
mutations O 0 7.731910223185423e-09
and O 0 4.288360777593425e-10
their O 0 1.1870348037845702e-09
effects O 0 8.384400729255503e-08
on O 0 6.092543003433093e-08
cDNA O 0 6.716551865793008e-07
were O 0 3.302988815789831e-08
characterized O 0 6.721191425640427e-08
. O 0 4.7219010923527094e-08

Protein O 0 7.51051402403391e-06
- O 0 3.918545701253606e-07
truncation O 0 1.249166416528169e-06
testing O 0 1.6306971772905854e-08
of O 0 2.748718586076393e-08
the O 0 2.2943810407127785e-08
entire O 0 6.926943001417385e-07
ATM O 0 1.1470758181530982e-05
cDNA O 0 4.440157965746039e-07
detected O 0 2.2524467624407407e-08
92 O 0 1.637457458514291e-08
( O 0 6.181862799436999e-10
66 O 0 7.850554872845805e-09
% O 0 5.028024108177931e-10
) O 0 1.2155014494918959e-10
truncating O 0 9.582316273792912e-09
mutations O 0 1.580472974715974e-10
in O 0 4.409584641873465e-10
140 O 0 1.2728473386403039e-08
mutant O 0 1.712640163020751e-08
alleles O 0 1.0327348975991413e-09
screened O 0 3.1525097199391894e-08
. O 0 3.075754406722808e-08

The O 0 4.1571743167878594e-06
haplotyping O 0 0.00026200691354461014
of O 0 1.2756395335600246e-06
patients O 0 3.325327924130761e-08
with O 0 9.788224675233437e-10
identical O 0 1.553143675891988e-07
mutations O 0 2.8165068499674817e-08
indicates O 0 1.0617652179689685e-07
that O 0 1.348309658366631e-10
almost O 0 7.022144532520258e-10
all O 0 3.906926865360205e-11
of O 0 8.076378454902056e-11
these O 0 1.4939657150270236e-11
represent O 0 8.873449891533269e-11
common O 0 7.74646125023537e-10
ancestry O 0 2.4486657146383095e-09
and O 0 2.0804706568622322e-10
that O 0 1.4343594367804968e-10
very O 0 1.5159719035651165e-09
few O 0 6.01109517717191e-09
spontaneously O 0 2.2012896749856736e-07
recurring O 0 1.3971376574772876e-05
ATM O 0 6.466407648986205e-05
mutations O 0 5.795322621793275e-08
exist O 0 2.249879997862081e-07
. O 0 3.203728056178079e-07

Assays O 0 2.920812903539627e-06
requiring O 0 9.586393012739336e-09
minimal O 0 6.141767983081081e-08
amounts O 0 3.361624756337278e-09
of O 0 3.5599481140735634e-09
genomic O 0 2.295887036041222e-08
DNA O 0 7.299122195547625e-09
were O 0 3.2958114015713136e-10
designed O 0 3.5077574178643545e-10
to O 0 5.942395187030769e-11
allow O 0 1.0903334485279359e-10
rapid O 0 1.6185897067089172e-09
screening O 0 4.484659310577399e-10
for O 0 1.4296477890418657e-10
common O 0 8.924084249350983e-10
ethnic O 0 3.3245084463118246e-09
mutations O 0 3.693743266808269e-08
. O 0 7.393254719545439e-08

These O 0 5.640929501282699e-08
rapid O 0 2.497253603905847e-07
assays O 0 1.4297332029400422e-07
detected O 0 5.04078130347807e-08
mutations O 0 1.4089397426531036e-09
in O 0 1.274603311784972e-09
76 O 0 2.3429025830523642e-08
% O 0 1.8262307222016716e-09
of O 0 4.086376570455741e-09
Costa O 0 7.336055318774015e-08
Rican O 0 2.67501860662378e-07
patients O 0 2.6358233373713347e-09
( O 0 2.053069797502971e-10
3 O 0 1.3340133442341084e-09
) O 0 5.5775103285915506e-11
, O 0 6.087818443800685e-11
50 O 0 6.328364499097461e-10
% O 0 1.584502529183851e-10
of O 0 1.2960118533911213e-09
Norwegian O 0 4.900924068351742e-06
patients O 0 7.750869279732342e-09
( O 0 8.895772452000017e-10
1 O 0 6.658360085509685e-09
) O 0 2.060445009055556e-10
, O 0 5.015914072981076e-11
25 O 0 4.984463397583738e-10
% O 0 1.36479896828412e-10
of O 0 6.33263941285378e-10
Polish O 0 2.8146817498964083e-07
patients O 0 5.227333232937781e-09
( O 0 5.687823545486026e-10
4 O 0 8.617346836103934e-09
) O 0 1.986069919635014e-10
, O 0 3.6845901330018194e-11
and O 0 8.064617723624323e-11
14 O 0 2.2331956284205035e-09
% O 0 4.959324062525639e-10
of O 0 1.1362945029347316e-09
Italian O 0 4.2340008832297826e-08
patients O 0 1.6323582485711086e-09
( O 0 1.6938546398836962e-10
1 O 0 2.5968993622171865e-09
) O 0 9.931709621380236e-11
, O 0 2.6341871392498994e-11
as O 0 9.09701966533838e-11
well O 0 2.6017865639715865e-10
as O 0 2.586433289764045e-10
in O 0 7.757077202796836e-10
patients O 0 6.093083815272848e-10
of O 0 9.34555366427503e-09
Amish O 0 2.9899700166424736e-05
/ O 0 7.394971362373326e-06
Mennonite O 0 2.9031565645709634e-05
and O 0 5.800584013115895e-09
Irish O 0 3.009683950949693e-07
English O 0 6.301450525825203e-07
backgrounds O 0 3.9687765251983365e-07
. O 0 2.558028029397974e-07

Additional O 0 5.906114779463678e-07
mutations O 0 4.457442770444686e-08
were O 0 4.081891802343307e-08
observed O 0 4.380918383617427e-08
in O 0 3.252947067267087e-08
Japanese O 0 7.380428996839328e-06
, O 0 1.2545773309113883e-08
Utah O 0 1.1822518217741163e-06
Mormon O 0 6.406681336557085e-07
, O 0 4.636611650177258e-10
and O 0 3.2207292388619635e-10
African O 0 1.4613266152707638e-08
American O 0 6.542069286297192e-08
patients O 0 1.2901599788506246e-08
. O 0 4.228940042594331e-08

These O 0 6.806424313055004e-09
assays O 0 1.497611279432931e-08
should O 0 3.2680430583909015e-10
facilitate O 0 2.521537423305631e-09
screening O 0 2.3074846478010613e-09
for O 0 9.23214837911246e-09
A B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
heterozygotes O 0 4.30531400752443e-07
in O 0 7.286793390903767e-10
the O 0 4.937568132135084e-10
populations O 0 2.025871553845704e-10
studied O 0 7.522063860676553e-09
. O 0 1.7291756915227552e-09
. O 0 2.6477563253024528e-08

The O 0 9.700018381408881e-06
von B-Disease 1 0.987782895565033
Hippel I-Disease 1 0.9999967813491821
- I-Disease 1 0.9998700618743896
Lindau I-Disease 1 0.9999866485595703
tumor I-Disease 0 0.0015500927111133933
suppressor O 0 3.5403647871135036e-06
gene O 0 1.5421376398094822e-09
is O 0 6.542946046073084e-11
required O 0 3.852782537450139e-10
for O 0 1.3890448791187282e-09
cell O 0 1.330127190612984e-07
cycle O 0 1.9387393024317134e-07
exit O 0 1.9223950431523917e-08
upon O 0 2.4656184649529678e-08
serum O 0 6.145659199319198e-07
withdrawal O 0 6.292850684985751e-07
. O 0 3.8541941194125684e-07

The O 0 3.2371692668675678e-06
inactivation O 0 6.443423899327172e-06
of O 0 7.588859602947196e-07
the O 0 1.3594817573903129e-06
von B-Disease 1 0.9999275207519531
Hippel I-Disease 1 0.9999997615814209
- I-Disease 1 0.9999990463256836
Lindau I-Disease 1 0.9999998807907104
( I-Disease 0 1.9127348423353396e-05
VHL I-Disease 1 0.8705955147743225
) I-Disease 0 4.0167466863749723e-07
tumor I-Disease 0 6.456340997829102e-06
suppressor O 0 3.2907726108533097e-06
gene O 0 4.366867312199929e-09
predisposes O 0 1.7959099096742648e-08
affected O 0 6.381125627896722e-10
individuals O 0 1.464539600704029e-10
to O 0 3.3143071620500564e-10
the O 0 4.57803785991473e-08
human O 0 0.0011229199590161443
VHL B-Disease 1 1.0
cancer I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
and O 0 1.110527003689299e-09
is O 0 4.6005291243211843e-10
associated O 0 5.7141407161509505e-09
with O 0 2.701507240132628e-09
sporadic B-Disease 1 0.9999514818191528
renal I-Disease 1 1.0
cell I-Disease 1 1.0
carcinomas I-Disease 1 1.0
( O 0 0.005391017068177462
RCC B-Disease 1 0.9999998807907104
) O 0 4.4501882712211227e-07
and O 0 2.408521595498314e-07
brain B-Disease 1 0.9994174242019653
hemangioblastomas I-Disease 1 0.9993840456008911
. O 0 1.1839254511869512e-05

VHL O 0 0.0077217696234583855
- O 0 2.8782636945834383e-05
negative O 0 2.360009602853097e-06
786 O 0 6.537718036270235e-06
- O 0 1.3357297348193242e-06
0 O 0 1.9738030232474557e-07
RCC B-Disease 0 0.00011489808821352199
cells O 0 1.727031531117973e-07
are O 0 3.143027615948313e-09
tumorigenic O 0 5.481354492076207e-06
in O 0 1.1055931281589437e-07
nude O 0 0.0006224007229320705
mice O 0 2.05298647415475e-07
which O 0 4.913086604219075e-10
is O 0 2.2509673291981613e-10
suppressed O 0 4.579432832940711e-09
by O 0 4.101007311518856e-10
the O 0 7.970366588949673e-09
reintroduction O 0 1.35501053932785e-07
of O 0 2.4423121658401215e-07
VHL B-Disease 0 0.0002115736569976434
. O 0 6.409663910744712e-07

Remarkably O 0 0.0004515686014201492
, O 0 5.714130058009914e-09
this O 0 5.640213851521025e-10
occurs O 0 4.4096881701705115e-09
without O 0 7.619388675550454e-09
affecting O 0 1.8032586979188636e-08
the O 0 2.371414176138842e-09
growth O 0 1.6669149616177492e-08
rate O 0 8.593302069925812e-09
and O 0 5.559043780856143e-10
cell O 0 3.10072927334204e-08
cycle O 0 3.4013950767075585e-08
profile O 0 1.975304142476375e-09
of O 0 6.204318170333067e-10
these O 0 1.190115089810817e-10
cells O 0 3.0312052867742523e-09
in O 0 1.9444610366292636e-09
culture O 0 2.071682700943711e-07
. O 0 1.2507788937909936e-07

The O 0 5.203072760195937e-06
786 O 0 1.3441057490126695e-05
- O 0 8.546888352611859e-07
0 O 0 5.202400288339959e-08
cell O 0 1.8877781116088954e-08
line O 0 6.954104847523013e-09
, O 0 2.7698093818528946e-10
like O 0 4.83972195652882e-10
many O 0 3.6135322512009793e-10
cancer B-Disease 0 1.3688464584049598e-08
cells O 0 1.476292244007027e-08
, O 0 1.1908354302647695e-09
fails O 0 3.3224942797005497e-08
to O 0 8.0010886804871e-09
exit O 0 8.967277409510643e-08
the O 0 2.8148097186431187e-08
cell O 0 1.446595945253648e-07
cycle O 0 1.0779467629618011e-07
upon O 0 8.496365921928373e-08
serum O 0 1.6430158211733215e-06
withdrawal O 0 5.742440976064245e-07
. O 0 3.127168781702494e-07

Here O 0 3.5660980302054668e-06
, O 0 8.312106558605592e-09
it O 0 3.986274088596531e-10
is O 0 2.0550952606335215e-10
shown O 0 5.684602233380076e-10
that O 0 6.665087926016611e-11
reintroduction O 0 1.3088949923911741e-09
of O 0 6.871851976342214e-10
the O 0 1.1456477988502911e-09
wild O 0 1.4121205538231152e-08
- O 0 9.263247591206891e-08
type O 0 9.936725575698802e-08
VHL B-Disease 0 9.265285189030692e-05
gene O 0 2.02056735787437e-08
restores O 0 3.5021383126832006e-08
the O 0 2.0644979059625257e-09
ability O 0 4.0417518221147475e-09
of O 0 3.142825732993515e-08
VHL O 0 0.001354660140350461
- O 0 2.3917782527860254e-05
negative O 0 1.1820827694464242e-06
RCC B-Disease 0 0.030485084280371666
cancer I-Disease 0 8.063030065841303e-08
cells O 0 1.0986509479948836e-09
to O 0 1.1037100400290711e-10
exit O 0 3.54120932577473e-09
the O 0 2.3864785703153757e-09
cell O 0 1.9388810557074976e-08
cycle O 0 1.5190870783499122e-08
and O 0 1.6723247231453797e-09
enter O 0 4.930129762215074e-07
G0 O 0 0.002832349156960845
/ O 0 1.579501258675009e-05
quiescence O 0 2.4974990083137527e-05
in O 0 1.9200205869651654e-08
low O 0 3.7849028444725263e-07
serum O 0 3.436034148762701e-06
. O 0 1.727626255387804e-07

Both O 0 4.159014224569546e-06
VHL O 0 0.0004984071129001677
- O 0 2.115443066941225e-06
positive O 0 3.587727448461919e-08
and O 0 1.5191684354931567e-08
VHL O 0 0.00012481606972869486
- O 0 9.75791067503451e-07
negative O 0 2.2219190043415438e-07
RCC B-Disease 0 4.89816848130431e-05
cells O 0 3.830204420296468e-08
exit O 0 1.3979494006832738e-08
the O 0 6.08902039900272e-09
cell O 0 5.949367576363329e-08
cycle O 0 6.475232083857918e-08
by O 0 6.155064458113202e-09
contact O 0 1.3647349987877533e-06
inhibition O 0 1.1740099580492824e-05
. O 0 2.0767545549915667e-07

The O 0 1.105235241993796e-05
cyclin O 0 0.00010808499791892245
- O 0 1.8453762322678813e-06
dependent O 0 1.9854942365782335e-06
kinase O 0 2.6108075417141663e-06
inhibitor O 0 1.0146886353368245e-07
, O 0 3.7115080453453686e-10
p27 O 0 8.459481648515066e-08
, O 0 6.391540630090731e-10
accumulates O 0 2.756383565838405e-08
upon O 0 6.7735936859492085e-09
serum O 0 4.923298035919288e-08
withdrawal O 0 1.6874327712912418e-08
, O 0 7.679905600355141e-10
only O 0 4.1408099171746926e-10
in O 0 2.5672897141504336e-10
the O 0 1.8969268378299375e-09
presence O 0 2.6133164521269237e-09
of O 0 1.1765678209485486e-07
VHL B-Disease 0 0.0002956483222078532
, O 0 3.558047412255405e-09
as O 0 1.1451126713524218e-09
a O 0 2.2211357197932102e-09
result O 0 7.528174195137183e-10
of O 0 1.2942283911243635e-09
the O 0 1.6232890587275506e-09
stabilization O 0 1.4062027275940636e-07
of O 0 6.980100408782164e-08
the O 0 1.4555023142293066e-07
protein O 0 6.149915634523495e-07
. O 0 1.738748522939204e-07

We O 0 3.256548097851919e-07
propose O 0 5.965991078937805e-08
that O 0 2.739688476083302e-09
the O 0 1.1286787504616314e-08
loss O 0 4.6385534346882196e-07
of O 0 1.722677325233235e-07
wild O 0 7.354015565397276e-07
- O 0 3.5632288017950486e-06
type O 0 5.695265826943796e-06
VHL B-Disease 0 0.00046821669093333185
gene O 0 1.0492947843943057e-08
results O 0 1.4652863367103919e-09
in O 0 6.210249536842127e-10
a O 0 2.2895711992987344e-09
specific O 0 2.7595805640601156e-09
cellular O 0 2.239471967868667e-07
defect O 0 6.55219665190998e-08
in O 0 3.352046418214627e-09
serum O 0 1.1355169817761634e-06
- O 0 2.578595740487799e-05
dependent O 0 1.4985824236646295e-05
growth O 0 4.424509825184941e-08
control O 0 4.604605141622642e-09
, O 0 1.7864550116986067e-10
which O 0 1.4470438736147173e-10
may O 0 2.750720540234397e-09
initiate O 0 6.982950395695298e-08
tumor B-Disease 0 8.721291123947594e-06
formation O 0 2.1810835733049316e-06
. O 0 7.983604746186757e-07

This O 0 6.184504286466108e-07
is O 0 2.095910467403428e-08
corrected O 0 2.3338581911502843e-07
by O 0 2.7481876774260172e-09
the O 0 1.1855963322204843e-08
reintroduction O 0 1.4502642642355568e-08
of O 0 1.1098796548481005e-08
wild O 0 4.346386361930854e-08
- O 0 1.5297601976271835e-06
type O 0 4.727588020614348e-06
VHL B-Disease 1 0.9672713875770569
, O 0 2.0918334087127732e-07
implicating O 0 0.0011817945633083582
VHL B-Disease 0 0.0005747911054641008
as O 0 1.877676503170278e-08
the O 0 9.593325245305095e-09
first O 0 3.0007189621983343e-08
tumor B-Disease 0 4.387650278658839e-07
suppressor O 0 3.7784545270369563e-07
involved O 0 1.4856703423049566e-08
in O 0 4.0771666043326604e-09
the O 0 1.9506952497749808e-08
regulation O 0 5.80143861839133e-08
of O 0 2.30333903061819e-08
cell O 0 7.911225452517101e-08
cycle O 0 5.096962141237782e-08
exit O 0 1.1195877114289488e-08
, O 0 1.9821154439991773e-10
which O 0 1.0583083714932329e-10
is O 0 3.833971751188159e-10
consistent O 0 1.3001325349648596e-08
with O 0 1.446229802581911e-10
its O 0 2.531106879644085e-09
gatekeeper O 0 6.384784114743525e-07
function O 0 2.9290665892744983e-08
in O 0 2.950659050426907e-09
the O 0 1.3951184030247532e-07
kidney O 0 3.997263411292806e-05
. O 0 7.969610038571773e-08
. O 0 3.67322542160764e-07

Piebaldism B-Disease 1 1.0
with O 0 0.02503238059580326
deafness B-Disease 1 1.0
: O 0 3.952632994241867e-07
molecular O 0 1.7931122329173377e-06
evidence O 0 3.616204651279986e-07
for O 0 7.880183616748582e-09
an O 0 3.845525498036295e-08
expanded O 0 5.036984020989621e-06
syndrome O 1 0.9998602867126465
. O 0 8.597343708061089e-07

In O 0 6.617859185098496e-07
a O 0 2.0057886729318852e-07
South O 0 1.1476785033437409e-07
African O 0 6.0718349459421e-08
girl O 0 6.575764928129502e-07
of O 0 2.491114798885974e-07
Xhosa O 0 0.002318208571523428
stock O 0 7.781674185025622e-07
with O 0 3.2798030957792434e-09
severe O 0 6.0715160543622915e-06
piebaldism B-Disease 1 0.9824787378311157
and O 0 2.5081808416871354e-06
profound O 1 1.0
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 2.0255818071746035e-06
identified O 0 2.8093666060158284e-07
a O 0 2.5957421101452383e-08
novel O 0 7.113820998938536e-08
missense O 0 2.4194844172598096e-07
substitution O 0 1.3878140414647078e-08
at O 0 3.850148999617886e-08
a O 0 7.313196714875403e-09
highly O 0 1.2690487771749304e-08
conserved O 0 2.251642143846766e-07
residue O 0 6.670972538813658e-07
in O 0 1.8596347572952254e-08
the O 0 6.189453927163413e-08
intracellular O 0 7.602335244882852e-06
kinase O 0 4.262033598934067e-06
domain O 0 1.6601667596205516e-07
of O 0 2.3913459656910163e-08
the O 0 5.5973412571574954e-08
KIT O 0 0.0002307122922502458
proto O 0 0.0007524222601205111
- O 0 4.355947021394968e-05
oncogene O 0 0.00022651102335657924
, O 0 8.438048837433598e-08
R796G O 0 1.5160590919549577e-05
. O 0 7.572694471491559e-07

Though O 0 3.0277224141173065e-06
auditory B-Disease 0 0.0012882596347481012
anomalies I-Disease 0 0.0009458180866204202
have O 0 1.0520583515472026e-08
been O 0 2.4515363961086223e-08
observed O 0 3.8258523460399374e-08
in O 0 4.723973034970186e-08
mice O 0 5.961896221151619e-08
with O 0 1.179667696860065e-09
dominant O 0 7.387883442788734e-07
white O 0 8.799624140465312e-08
spotting O 0 9.904387115966529e-05
( O 0 5.7581478358770255e-06
W O 0 0.3935090899467468
) O 0 9.508598353136222e-09
due O 0 3.054427466508969e-08
to O 0 1.2146937677925962e-08
KIT O 1 0.8924665451049805
mutations O 0 1.2082873581675813e-05
, O 0 7.261600785568589e-06
deafness B-Disease 1 1.0
is O 0 2.8688218023376066e-08
not O 0 1.8505792453993308e-09
typical O 0 8.356971648026956e-08
in O 0 2.326479631165057e-08
human O 0 9.899571296045906e-08
piebaldism B-Disease 0 6.584222865058109e-05
. O 0 6.470855282714183e-07

Thus O 0 2.1055886918475153e-06
, O 0 9.926265143178625e-09
the O 0 2.9398467660257666e-08
occurrence O 0 1.359213001705939e-05
of O 0 0.00047423996147699654
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
in O 0 2.285398295498453e-06
this O 0 2.425014145046589e-08
patient O 0 2.5312780849162664e-07
extends O 0 4.257702190813006e-09
considerably O 0 1.1143378442213248e-09
the O 0 1.7291747200776086e-10
phenotypic O 0 1.1545672196078272e-09
range O 0 2.4673671994435153e-09
of O 0 3.727230080130539e-09
piebaldism B-Disease 0 4.6283284405035374e-07
due O 0 7.634196386163694e-09
to O 0 5.657571078288015e-10
KIT O 0 9.63699221756542e-07
gene O 0 2.0146593282532876e-09
mutation O 0 1.3816429944579767e-10
in O 0 1.2222829692820625e-10
humans O 0 1.3465857318095686e-09
and O 0 8.039450771768486e-10
tightens O 0 1.278258210390959e-08
the O 0 2.026769196916689e-09
clinical O 0 7.02997766666158e-08
similarity O 0 2.2677976829754698e-08
between O 0 3.0183471722011745e-08
piebaldism B-Disease 0 5.294745278661139e-06
and O 0 7.540677526840511e-10
the O 0 2.2980489733370746e-10
various O 0 3.533718317960677e-10
forms O 0 2.0031261094288766e-09
of O 0 1.7633270772421383e-06
Waardenburg B-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
. O 0 9.330435091214895e-08
. O 0 3.528105878558563e-07

Cycloheximide O 0 0.000812457175925374
facilitates O 0 2.0482784748310223e-06
the O 0 4.5686167737812866e-08
identification O 0 4.508446238560282e-08
of O 0 7.997400075510086e-08
aberrant O 0 5.120875243846967e-07
transcripts O 0 1.0749097327789059e-06
resulting O 0 3.7926852769487596e-08
from O 0 1.0367971370328632e-08
a O 0 3.3712645119976514e-08
novel O 0 3.6160562899567594e-07
splice O 0 1.6142637377924984e-06
- O 0 8.419110741897384e-08
site O 0 5.674619885098764e-08
mutation O 0 7.76968178684001e-09
in O 0 1.6358715271280744e-08
COL17A1 O 0 0.001869597123004496
in O 0 7.306410054752632e-08
a O 0 2.2237230723476387e-07
patient O 0 2.4847912527548033e-07
with O 0 5.227462906987057e-09
generalized O 0 0.00017607466725166887
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999942779541016
. O 0 4.052347321703564e-06

Patients O 0 2.7894338927580975e-06
with O 0 1.8470643681212096e-08
generalized O 0 0.00012368363968562335
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
often O 0 4.5660993208684886e-08
show O 0 3.0187496946609826e-08
decreased O 0 2.042413882463734e-07
expression O 0 1.0042373155272344e-08
of O 0 1.8987812211435084e-08
type O 0 1.0579824447631836e-06
XVII O 1 0.9986488223075867
collagen O 0 0.008697988465428352
, O 0 8.99290171219036e-08
a O 0 1.292342517444922e-07
transmembrane O 0 5.4137863116920926e-06
hemidesmosomal O 0 3.911917247023666e-06
protein O 0 1.0442001041610638e-07
encoded O 0 5.99312386384554e-08
by O 0 4.573517031758456e-08
COL17A1 O 0 0.00027807021979242563
. O 0 8.795166763775342e-07

This O 0 3.0508527970596333e-07
report O 0 1.6231511779096763e-07
documents O 0 3.3085188988479786e-07
a O 0 6.899529836346119e-08
novel O 0 5.559144256039872e-07
splice O 0 2.2533208721142728e-06
- O 0 1.1825941470533508e-07
site O 0 1.0659778126864694e-07
mutation O 0 3.851520435915745e-09
in O 0 9.234560671700365e-09
COL17A1 O 0 0.00033025600714609027
in O 0 1.7150165732005007e-08
a O 0 4.138753340043877e-08
patient O 0 4.661409036543773e-08
with O 0 1.4019165828216273e-09
generalized O 0 4.60292721982114e-05
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999825954437256
, O 0 4.162667543994303e-09
and O 0 3.5922978480762424e-10
applies O 0 2.9262843259658666e-09
a O 0 1.2177854280537304e-09
new O 0 4.236088702036511e-10
methodology O 0 4.8608374214609285e-08
to O 0 7.243393662648145e-10
define O 0 1.8760012210350396e-08
and O 0 1.2266861970644527e-09
characterize O 0 9.297198033664245e-08
the O 0 2.4751175331516606e-08
resulting O 0 8.25655419589566e-08
mRNA O 0 3.004599307132594e-07
splice O 0 2.7459105922389426e-07
variants O 0 2.2918881015243642e-08
. O 0 1.8485870612039434e-08

Mutational O 0 0.00202453276142478
analysis O 0 3.235403710277751e-06
of O 0 8.386422223338741e-07
COL17A1 O 0 0.0006155759911052883
identified O 0 8.852261430547514e-07
a O 0 1.809647471873177e-07
maternally O 0 1.7192043060276774e-06
inherited O 0 3.4612232866493287e-06
G O 0 1.1852268471557181e-05
- O 0 1.7427572629458155e-06
to O 0 2.6264456209901255e-07
- O 0 3.2696778362151235e-05
T O 0 1.459338454878889e-05
transversion O 0 1.3001918887312058e-05
at O 0 8.37594370750594e-07
the O 0 1.4475855891760148e-07
- O 0 6.721524670183499e-08
1 O 0 1.1439217217912301e-07
position O 0 9.53788230617647e-08
of O 0 2.113034440753836e-07
exon O 0 2.3197771952254698e-06
32 O 0 5.811450023429643e-07
. O 0 1.782193237431784e-07

This O 0 6.483858214778593e-07
acceptor O 0 3.189165909134317e-07
splice O 0 4.32272690886748e-06
- O 0 4.2261103772034403e-07
site O 0 2.096242752713806e-07
mutation O 0 8.649325700105237e-09
led O 0 7.319252759430128e-09
to O 0 1.284808370805024e-09
the O 0 8.576452437125681e-09
formation O 0 3.193816553448414e-07
of O 0 9.17313684567489e-07
aberrant O 0 1.479208890486916e-06
transcripts O 0 6.837446449026174e-07
present O 0 9.989816973643428e-09
at O 0 8.940158124914888e-08
extremely O 0 6.488955506256389e-08
low O 0 3.9761715697750333e-07
levels O 0 6.231832685443806e-07
. O 0 1.550887986923044e-07

Based O 0 1.190967623188044e-06
on O 0 6.073433667097561e-08
our O 0 1.836367857777077e-08
recent O 0 7.0702212973117184e-09
finding O 0 5.0001325746507064e-08
that O 0 3.762242961613538e-09
cycloheximide O 0 1.3619338460557628e-05
stabilized O 0 4.625592919182964e-05
mutant O 0 2.206338876931113e-06
COL17A1 O 0 6.632937584072351e-05
transcripts O 0 1.110091375267075e-06
in O 0 7.055631634500514e-09
keratinocytes O 0 2.0242558207428374e-07
homozygous O 0 9.699949288233256e-09
for O 0 7.71405328503505e-10
a O 0 3.227946265838e-08
frameshift O 0 6.681121362817066e-07
mutation O 0 1.0754486190478474e-09
, O 0 1.4998077779715402e-10
the O 0 3.6241776246725976e-09
effects O 0 2.2526194243255304e-07
of O 0 3.1779231335349323e-07
the O 0 5.097107873552886e-07
splice O 0 4.002768491773168e-06
- O 0 9.479537510515001e-08
site O 0 4.151181443035057e-08
mutation O 0 5.141725933910379e-10
on O 0 2.99321212260395e-09
splicing O 0 2.4665261832979013e-08
of O 0 2.4886324112571856e-08
COL17A1 O 0 1.4035665117262397e-05
transcripts O 0 2.679407486994023e-07
were O 0 1.1971710289770954e-09
determined O 0 4.1869602229738234e-10
using O 0 8.384297145447306e-10
reverse O 0 1.5745111880960394e-08
transcriptase O 0 5.17275609013268e-08
polymerase O 0 2.1834670960174662e-08
chain O 0 4.91243357103599e-09
reaction O 0 4.915645668290836e-10
of O 0 1.0745162981606882e-08
total O 0 9.441500026241556e-08
RNA O 0 4.234073855968745e-07
from O 0 1.4064060138707646e-08
keratinocytes O 0 2.5806468784139724e-07
incubated O 0 4.81389406559174e-07
for O 0 7.184534300819223e-09
2 O 0 2.2372624641775474e-07
. O 0 1.4424851713101816e-07

5 O 0 1.473305110266665e-05
h O 0 2.3487380076403497e-06
in O 0 3.577347484906568e-08
the O 0 4.5681463944902134e-08
presence O 0 7.46926929195979e-08
or O 0 1.3283728605983924e-07
absence O 0 9.342630846731481e-07
of O 0 1.8354526218899991e-06
10 O 0 1.2133389191149035e-06
microg O 0 3.0153203624649905e-05
cycloheximide O 0 2.1233448933344334e-05
per O 0 2.2618378352490254e-06
ml O 0 4.621677817340242e-06
. O 0 1.330680419187047e-07

Using O 0 1.792977286640962e-07
this O 0 6.59931531643565e-09
approach O 0 7.966053772179293e-08
, O 0 7.809603630448692e-09
an O 0 3.8304015959056414e-08
abnormally O 0 4.793398147739936e-06
spliced O 0 1.038107143358502e-06
transcript O 0 6.458004008891294e-06
was O 0 1.943142677873766e-07
identified O 0 6.060933976925753e-09
that O 0 1.4297897588111397e-10
contains O 0 2.923181419145493e-10
an O 0 6.153734743996608e-10
extra O 0 5.882273335089394e-09
264 O 0 5.98249059180489e-08
bases O 0 7.405656976544606e-09
upstream O 0 2.6279190024069976e-07
from O 0 6.880052083602095e-09
exon O 0 3.0211577239924736e-08
32 O 0 7.3446346782191085e-09
, O 0 2.496984008448777e-10
resulting O 0 2.0117332244495856e-09
in O 0 2.6695703425616557e-09
a O 0 4.2943486988633595e-08
premature O 0 2.1178723841330793e-07
termination O 0 4.923199412587564e-07
codon O 0 1.2211911553094978e-06
27 O 0 3.066083081648685e-06
bp O 0 8.389642061956692e-06
downstream O 0 4.862720288656419e-06
from O 0 1.1779768271935609e-07
the O 0 8.462255323138379e-07
cryptic O 0 4.742375676869415e-05
splice O 0 8.031430479604751e-05
site O 0 6.093465799494879e-06
. O 0 4.353779559096438e-07

Three O 0 8.506012250109052e-07
other O 0 1.0970538255605788e-08
splice O 0 4.979290224582655e-07
variants O 0 1.205871136278347e-08
, O 0 1.185016973437314e-09
including O 0 4.1659303784413737e-10
one O 0 2.9260389666774245e-09
derived O 0 2.0572661796336433e-08
from O 0 1.3914081442578663e-08
the O 0 3.826874461765328e-08
skipping O 0 1.3224294548308535e-07
of O 0 2.1848715903161064e-07
exon O 0 1.212002729289452e-07
32 O 0 5.989900841996132e-08
, O 0 2.6449284984408905e-09
were O 0 2.1336276745387295e-08
also O 0 6.046523726155328e-09
identified O 0 3.741363912013185e-07
. O 0 3.6578614981408464e-07

These O 0 4.125370978158571e-08
results O 0 1.2690003714510567e-08
indicate O 0 1.371360358604079e-08
the O 0 2.5982269669100333e-09
usefulness O 0 1.0069727096606584e-07
of O 0 3.796483127871397e-09
cycloheximide O 0 2.9691420877497876e-07
treatment O 0 2.2586235104427033e-09
in O 0 3.8147149328260355e-10
evaluating O 0 6.847036271295792e-09
the O 0 4.1399985661882965e-09
abnormal O 0 9.498486974734988e-08
processing O 0 6.825732867810075e-08
of O 0 8.150220764946425e-08
mRNA O 0 1.4378457535713096e-07
due O 0 6.284322751071159e-08
to O 0 4.9859778528116294e-09
splice O 0 3.9172641663753893e-07
- O 0 9.569768089079389e-09
site O 0 7.87935761081826e-09
mutations O 0 1.7928176998527334e-10
, O 0 1.0518907272993872e-10
because O 0 1.0149141527193706e-09
( O 0 1.3694000600139589e-08
i O 0 2.741504374625947e-07
) O 0 3.3780228392288336e-08
aberrant O 0 2.8330077839200385e-07
splicing O 0 5.9639205574058e-08
often O 0 2.9558637759663497e-09
generates O 0 1.2771615764961552e-08
a O 0 3.3102149910035905e-09
premature O 0 9.205052720062668e-09
termination O 0 3.669768844360988e-08
codon O 0 2.5016582583248237e-08
, O 0 2.6608777403680506e-09
( O 0 2.73799050098944e-09
ii O 0 8.354722353942634e-07
) O 0 3.01666034374648e-08
transcripts O 0 3.230385630104138e-07
with O 0 2.558242950811973e-09
premature O 0 2.38317809930777e-07
termination O 0 2.568762340615649e-07
codons O 0 3.881678267703137e-08
can O 0 1.1549923240039561e-09
occur O 0 5.30617949578982e-09
at O 0 2.0822241708629008e-07
low O 0 3.9835958887124434e-07
or O 0 1.2731436349611158e-08
undetectable O 0 3.591103165945242e-07
levels O 0 2.336765980714972e-08
due O 0 1.300717844543442e-08
to O 0 1.2616364619688625e-09
nonsense O 0 3.445700542670238e-07
- O 0 3.094637435197001e-08
mediated O 0 6.566646959527134e-08
mRNA O 0 2.1517815085303482e-08
decay O 0 1.522428760836192e-08
, O 0 1.3599034398570353e-10
and O 0 9.171446935241079e-11
( O 0 8.028540054993982e-10
iii O 0 3.0804745421164625e-08
) O 0 1.2903168533640041e-09
the O 0 6.700092147760017e-10
levels O 0 4.310307222255005e-09
of O 0 9.493118513503873e-10
these O 0 4.422766874956352e-10
transcripts O 0 8.000512252692715e-08
can O 0 4.939226250222362e-10
be O 0 7.171072069489526e-10
increased O 0 6.05632255457067e-09
by O 0 3.852036556395433e-08
cycloheximide O 0 0.00010768215724965557
. O 0 1.5930793324514525e-06

A O 0 1.1123782314825803e-05
deletion O 0 1.6342800108759548e-06
mutation O 0 4.3576424246793977e-08
in O 0 2.5309683238106118e-08
COL17A1 O 0 0.00021151755936443806
in O 0 2.032453139122481e-08
five O 0 2.342209981520682e-08
Austrian O 0 3.732265895450837e-06
families O 0 3.1587796822662995e-09
with O 0 1.635877100447658e-09
generalized O 0 1.1585556421778165e-05
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999494552612305
represents O 0 8.376344595717455e-08
propagation O 0 6.934623684173857e-07
of O 0 6.562477494753693e-08
an O 0 7.380602085049759e-08
ancestral O 0 1.901436917250976e-05
allele O 0 9.291256333199271e-07
. O 0 4.6119023977553297e-07

Patients O 0 3.341539695611573e-06
with O 0 2.3844050289767438e-08
generalized O 0 0.00012616752064786851
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
, O 0 4.690519617156497e-08
a O 0 9.744342222006708e-09
usually O 0 4.6479118331888e-09
nonlethal O 0 2.9493617148546036e-07
form O 0 7.198816120990159e-08
of O 0 0.0006442557205446064
junctional B-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
, O 0 3.318586294653869e-08
have O 0 4.246575091571003e-09
generalized O 0 1.283198116652784e-07
blistering B-Disease 0 6.76553963785409e-06
, O 0 5.055812266618886e-07
nail B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
, O 0 9.33101910050027e-06
patchy B-Disease 1 1.0
alopecia I-Disease 1 1.0
, O 0 1.8031371382676298e-06
and O 0 0.0001364026393275708
dental B-Disease 1 1.0
abnormalities I-Disease 1 1.0
. O 1 0.9981854557991028

Skin B-Disease 1 0.999036431312561
fragility I-Disease 1 0.9977462887763977
in O 0 4.136590803227591e-08
most O 0 8.732385370358031e-10
cases O 0 4.362760985809899e-10
is O 0 8.982979637917055e-11
due O 0 3.2927969240148514e-09
to O 0 9.175826209961713e-10
mutations O 0 9.409635293167184e-10
in O 0 1.1698022550632459e-09
the O 0 1.4188700880879423e-08
gene O 0 2.516766128835002e-09
encoding O 0 7.38544336797986e-09
type O 0 1.1689089518540641e-07
XVII O 0 0.0014441683888435364
collagen O 0 0.0003677951463032514
( O 0 7.797514626872726e-06
COL17A1 O 0 0.47232693433761597
) O 0 1.416483002003588e-07
. O 0 7.055876949380036e-08

Recently O 0 1.996807441173587e-05
, O 0 4.713541557066492e-08
we O 0 2.668731724497775e-08
reported O 0 4.4382783670471326e-08
five O 0 9.827026303810271e-09
Austrian O 0 2.8888748602184933e-06
families O 0 1.0274816553135224e-08
with O 0 7.208362351462938e-09
generalized O 0 5.052041160524823e-05
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
who O 0 2.1049169163234183e-07
share O 0 2.3567208984331955e-07
the O 0 1.460307572642705e-07
same O 0 6.312819209597365e-07
COL17A1 O 0 0.007561061531305313
mutation O 0 1.6009136061256868e-06
. O 0 5.280401751406316e-07

Affected O 0 4.6215447468966886e-07
individuals O 0 2.344600069648095e-09
in O 0 1.4208489940159552e-09
three O 0 1.1880223471649742e-09
families O 0 8.537962004062649e-10
are O 0 9.821525537301312e-11
homozygous O 0 9.042601112341231e-10
for O 0 7.521716027802938e-10
4003delTC O 0 1.1053695914142736e-07
, O 0 3.2138824934691e-09
whereas O 0 7.8305459894068e-09
those O 0 6.726340595619718e-10
in O 0 1.1530311150309558e-09
two O 0 1.6342771580468707e-09
others O 0 4.991049351588117e-09
are O 0 2.64045740827612e-09
compound O 0 2.752333784883376e-06
heterozygotes O 0 2.639794956849073e-06
. O 0 4.361010326192627e-07

To O 0 3.046921293048399e-08
determine O 0 2.314600244801568e-08
if O 0 4.557891841727724e-09
the O 0 1.1235452568314486e-08
occurrence O 0 3.43503074873297e-07
of O 0 2.049640634993466e-08
4003delTC O 0 2.376430643380445e-07
in O 0 6.884485204139423e-10
these O 0 1.6222821697109424e-10
unrelated O 0 1.8962838410629956e-08
families O 0 1.213755318474341e-09
signifies O 0 6.219451620381733e-09
propagation O 0 4.459364788544917e-08
of O 0 6.743904990003102e-09
an O 0 9.040587833908376e-09
ancestral O 0 8.170576961674669e-07
allele O 0 8.272723839297669e-09
or O 0 1.436603369597833e-08
a O 0 2.764507911479086e-08
mutational O 0 2.2688982426188886e-06
hot O 0 2.385833965945494e-07
spot O 0 8.618123814585488e-08
, O 0 1.5147550991301273e-09
haplotypes O 0 2.7482677467105532e-08
were O 0 3.0917983728784293e-09
determined O 0 2.0744536755046283e-08
for O 0 1.3829071221493905e-08
polymorphisms O 0 1.6134899283315463e-07
both O 0 1.3395570874763507e-08
within O 0 4.5858772068640974e-07
and O 0 2.515798485092091e-07
flanking O 0 0.00030805187998339534
COL17A1 O 1 0.9999212026596069
. O 0 1.3700259842153173e-05

Five O 0 1.3798970030620694e-05
intragenic O 0 0.00015575466386508197
polymorphisms O 0 7.328975698328577e-06
were O 0 1.0576963660469119e-07
chosen O 0 1.9894804026421298e-08
based O 0 4.114958329637375e-08
on O 0 2.2651894937553152e-07
their O 0 1.8295058623607474e-07
informativeness O 0 0.00013439860776998103
. O 0 9.77136664914724e-07

One O 0 5.191714649299684e-07
of O 0 5.9350639958211104e-08
these O 0 1.991959042157987e-09
, O 0 1.245492708967788e-09
not O 0 1.5633900840583692e-09
previously O 0 5.385796342238791e-08
reported O 0 1.3201839976773044e-07
, O 0 8.924752492589505e-09
was O 0 2.163553290301934e-06
2988 O 0 2.0774390577571467e-05
A O 0 4.063616870553233e-06
or O 0 4.687711552264773e-08
C O 0 1.6894671261979965e-06
that O 0 4.842011791517109e-10
introduces O 0 4.999653135939752e-09
a O 0 2.9072244611683118e-09
new O 0 5.317493667611473e-10
restriction O 0 4.9522839162818855e-09
site O 0 1.0438591324657409e-08
for O 0 4.685760224276692e-09
Eco0109 O 0 8.854762199916877e-06
I O 0 9.358628449263051e-05
. O 0 2.586478785815416e-06

All O 0 2.1378728831678018e-07
the O 0 9.298864256379602e-08
4003delTC O 0 7.996650310815312e-07
alleles O 0 1.0861729293765165e-08
showed O 0 4.747219950473891e-09
the O 0 2.6605173619742573e-09
same O 0 6.099761140632154e-09
haplotype O 0 1.908067837064209e-08
for O 0 2.0491654206811205e-10
these O 0 1.2625849254987997e-09
five O 0 3.8973983151890934e-08
polymorphic O 0 2.9404475299088517e-07
markers O 0 9.79671881395916e-07
. O 0 4.192550875359302e-07

Fourteen O 0 3.415306127863005e-05
microsatellite O 0 3.436765473452397e-05
polymorphisms O 0 1.0898667142100749e-06
were O 0 3.110289270580324e-08
selected O 0 1.242707536874832e-08
based O 0 1.2126776027798769e-08
on O 0 2.4760854699934498e-08
their O 0 8.109342530815411e-09
high O 0 3.004519157912e-07
heterozygosity O 0 0.00013118844071868807
and O 0 7.930500700581433e-09
their O 0 1.3669523291071073e-08
location O 0 8.411083740611502e-07
within O 0 4.4514109731608187e-07
10q23 O 0 1.4596363143937197e-05
- O 0 9.489534022577573e-06
q25 O 0 4.6723605919396505e-05
near O 0 8.185357000911608e-05
COL17A1 O 0 0.003562862752005458
. O 0 2.8033816761308117e-06

Three O 0 2.2972500346440938e-07
families O 0 3.080956290091308e-08
shared O 0 2.751719989646517e-07
microsatellite O 0 4.384950443636626e-05
polymorphisms O 0 4.669921963795787e-06
covering O 0 3.917748927051434e-06
at O 0 4.45591422248981e-06
most O 0 1.1103793440270238e-08
19 O 0 1.246396976739561e-07
cM O 0 2.3274699856301595e-07
, O 0 1.5830986521692125e-09
whereas O 0 8.197861944836404e-09
the O 0 1.3709027690822495e-08
others O 0 1.2040686225844865e-09
shared O 0 4.2204448824634255e-09
smaller O 0 1.2177785446709777e-09
regions O 0 6.268121022223738e-10
consistent O 0 3.873727649761349e-08
with O 0 4.826419264247761e-10
cross O 0 1.1542110378570669e-08
- O 0 1.6298171701123465e-08
over O 0 1.180061603989202e-09
events O 0 2.0478849727112447e-09
during O 0 3.1421585333646362e-09
passage O 0 6.032722765780818e-09
of O 0 4.329651914769528e-10
this O 0 1.2699265250493141e-10
mutation O 0 7.111423949712758e-11
through O 0 2.4685239963240235e-10
several O 0 8.244240290444793e-10
generations O 0 4.5256857816866614e-08
. O 0 5.9091181725534625e-08

These O 0 9.795759581265884e-08
results O 0 5.835041605450897e-08
indicate O 0 8.268783346920827e-08
that O 0 7.348736619228191e-10
4003delTC O 0 9.256960709080886e-08
occurs O 0 5.323138374535574e-09
on O 0 8.713389121339787e-09
a O 0 1.4151889438096532e-08
single O 0 1.6768771260444737e-08
ancestral O 0 6.907903866704146e-07
allele O 0 1.1466584126651469e-08
. O 0 6.356287940434413e-09
. O 0 6.214189340880694e-08

The O 0 3.1852252959652105e-06
haptoglobin O 0 0.0002177777059841901
- O 0 6.188798124640016e-06
gene O 0 5.182454287933069e-08
deletion O 0 2.5052830210370303e-07
responsible O 0 1.4749981858130923e-07
for O 0 1.6265664726233808e-07
anhaptoglobinemia B-Disease 0 0.003972169943153858
. O 0 8.249663551396225e-06

We O 0 2.93714037979953e-07
have O 0 1.3534608989118624e-09
found O 0 2.383939934347268e-09
an O 0 1.5885551762906402e-09
allelic O 0 1.404152243367207e-07
deletion O 0 1.2318254505316872e-07
of O 0 2.9356002073654963e-07
the O 0 5.701949135072937e-07
haptoglobin O 0 0.00039474491495639086
( O 0 2.017979113588808e-06
Hp O 0 3.950352038373239e-06
) O 0 4.729830749283792e-09
gene O 0 1.6910921551982483e-09
from O 0 2.406067789451072e-09
an O 0 4.567446865166858e-09
individual O 0 1.2618729172686471e-08
with O 0 1.343910227546985e-08
anhaptoglobinemia B-Disease 0 0.001003855257295072
. O 0 2.6305417577532353e-06

The O 0 2.5425491912756115e-05
Hp O 0 4.867510870099068e-05
gene O 0 5.2117457016720437e-08
cluster O 0 2.1900238067473765e-08
consists O 0 6.0817546554403634e-09
of O 0 4.238792428168381e-08
coding O 0 1.435392050552764e-06
regions O 0 1.715412345504319e-08
of O 0 2.735831685640733e-07
the O 0 3.6066299458070716e-07
alpha O 0 5.609510026260978e-06
chain O 0 6.109964090228459e-08
and O 0 7.694876402730699e-10
beta O 0 7.931456025289663e-08
chain O 0 1.4321931196548121e-08
of O 0 2.7645221667427222e-09
the O 0 2.0473470030424323e-08
haptoglobin O 0 2.754450179054402e-06
gene O 0 8.557840658340865e-09
( O 0 3.2546956241219505e-09
Hp O 0 4.068359515940756e-08
) O 0 1.7112833372578962e-10
and O 0 7.292685899606965e-11
of O 0 5.146693737856367e-09
the O 0 2.039431379330381e-08
alpha O 0 1.0168328117288183e-06
chain O 0 3.55481368785604e-08
and O 0 1.5842163136881027e-09
beta O 0 4.0178807125812455e-07
chain O 0 3.266114489974825e-08
of O 0 6.633439131320529e-09
the O 0 1.213799816213168e-08
haptoglobin O 0 8.71740030561341e-06
- O 0 1.1795849559348426e-06
related O 0 2.9197582307460834e-07
gene O 0 2.0693994073894828e-08
( O 0 1.195451382329793e-08
Hpr O 0 1.532913074697717e-06
) O 0 3.126799708041972e-09
, O 0 3.9999376033605927e-10
in O 0 3.75856323842072e-09
tandem O 0 3.1430300850843196e-07
from O 0 2.9221586927974386e-08
the O 0 9.689690472214352e-08
5 O 0 3.2968713981063047e-07
side O 0 2.1047041798283317e-07
. O 0 5.712846018468554e-07

Southern O 0 5.3121634664421435e-06
blot O 0 8.856636668497231e-06
and O 0 3.964289518876285e-08
PCR O 0 5.459914405037125e-07
analyses O 0 1.202690214086033e-07
have O 0 3.8345787656268726e-10
indicated O 0 1.1114594800076816e-09
that O 0 4.5729604131183876e-11
the O 0 1.1727981918951969e-09
individual O 0 3.140215865116147e-10
with O 0 1.5424016230891624e-10
anhaptoglobinemia B-Disease 0 4.101884201190842e-07
was O 0 1.0404605177427584e-07
homozygous O 0 1.4647525414801521e-09
for O 0 1.5528038577183878e-10
the O 0 1.2362835200008249e-09
gene O 0 5.457223006821721e-10
deletion O 0 8.903461301557059e-10
and O 0 8.304476550868856e-11
that O 0 4.213105905814807e-11
the O 0 8.072244206402956e-09
gene O 0 4.509570494803938e-09
deletion O 0 1.5146518705932976e-08
was O 0 1.3403268894762732e-07
included O 0 9.655426680410528e-09
at O 0 1.0747339018735147e-07
least O 0 6.4590088832972015e-09
from O 0 4.550976928641148e-09
the O 0 6.732186363933579e-08
promoter O 0 3.368518491697614e-06
region O 0 1.055348207046336e-06
of O 0 1.3654828762810212e-05
Hp O 0 5.251532274996862e-05
to O 0 5.563440907963013e-08
Hpr O 0 1.8468077541911043e-05
alpha O 0 6.689856490993407e-07
but O 0 8.756219083139172e-10
not O 0 5.627758814519268e-10
to O 0 4.551853560741392e-09
Hpr O 0 1.0578538422123529e-05
beta O 0 2.9796676699334057e-06
( O 0 6.945637665012327e-08
Hpdel O 0 1.0896612366195768e-05
) O 0 4.82249546962521e-08
. O 0 4.095734951192753e-08

In O 0 5.311549102771096e-07
addition O 0 5.692094262599312e-08
, O 0 4.154268040679199e-09
we O 0 2.3105937163592216e-09
found O 0 1.9605004286660233e-09
seven O 0 3.0162794484311917e-09
individuals O 0 3.9407871410546136e-10
with O 0 1.5813474141257444e-10
hypohaptoglobinemia B-Disease 0 6.262718557081826e-07
in O 0 4.7377941569948234e-09
three O 0 7.468051177461632e-10
families O 0 6.514321304607051e-10
, O 0 1.9480163315765964e-10
and O 0 3.8874314878256655e-10
the O 0 1.62730113828502e-08
genotypes O 0 1.201195516387088e-07
of O 0 3.054415742553829e-08
six O 0 2.6340151393355882e-08
of O 0 3.913413948453126e-08
the O 0 9.935925859849704e-09
seven O 0 1.3566612722115678e-08
individuals O 0 5.771611522042974e-10
were O 0 2.9902331721842756e-09
found O 0 1.6652014211970823e-09
to O 0 4.763819116959667e-09
be O 0 1.6496069576987793e-07
Hp2 O 1 0.8219351768493652
/ O 0 0.010083820670843124
Hpdel O 0 0.49964022636413574
. O 0 2.341873823752394e-06

The O 0 1.5157058896875242e-06
phenotypes O 0 1.6616445464023855e-06
and O 0 1.0782609471959859e-08
genotypes O 0 2.781284820230212e-07
in O 0 3.2856199982944645e-09
one O 0 1.980952291091853e-09
of O 0 1.9520343119694417e-09
these O 0 1.2722345399396318e-10
three O 0 9.725992233811098e-10
families O 0 5.642796230276304e-10
showed O 0 9.784345778030001e-09
the O 0 1.0559967122958369e-08
father O 0 2.1182682985454448e-07
to O 0 7.892473341541972e-09
be O 0 3.253282088166998e-08
hypohaptoglobinemic B-Disease 0 4.9246691560256295e-06
( O 0 1.3319170477643638e-07
Hp2 O 0 1.6409223462687805e-05
) O 0 1.1948198874733862e-08
and O 0 4.778834661323117e-09
Hp2 O 0 0.00017584313172847033
/ O 0 1.2745555977744516e-05
Hpdel O 0 0.0003010258951690048
, O 0 6.210892689040293e-09
the O 0 4.9608519958610486e-08
mother O 0 1.2305795848988055e-07
to O 0 6.867020285739045e-09
be O 0 2.1594289023596502e-08
Hp2 O 0 4.754752808366902e-06
- O 0 1.4733842590430868e-07
1 O 0 1.0446304088418401e-07
and O 0 8.934409656546904e-09
Hp1 O 0 9.178857726510614e-05
/ O 0 2.523189778003143e-06
Hp2 O 0 2.3008240532362834e-05
, O 0 1.6672447866739049e-09
one O 0 8.305811038944455e-10
of O 0 2.1756463297606388e-09
the O 0 1.8638703913609334e-09
two O 0 8.988075284044328e-10
children O 0 6.576205135999658e-10
to O 0 1.06215725104164e-09
be O 0 7.501804510923193e-09
hypohaptoglobinemic B-Disease 0 6.636530997639056e-06
( O 0 1.492143013592795e-07
Hp2 O 0 1.188765418191906e-05
) O 0 5.569563921170584e-09
and O 0 2.694606315856163e-09
Hp2 O 0 3.876968548865989e-05
/ O 0 2.2895476377016166e-06
Hpdel O 0 3.8948004657868296e-05
, O 0 3.637640411113807e-09
and O 0 7.559339820772948e-10
the O 0 2.570034629556517e-09
other O 0 3.156621630751033e-10
child O 0 2.9712103888357433e-09
to O 0 1.3610744753478343e-09
be O 0 2.182659386562591e-08
Hp1 O 0 2.3757360395393334e-05
and O 0 1.238235114442432e-07
Hp1 O 1 0.9928365349769592
/ O 0 0.0005479582468979061
Hpdel O 0 0.001446012407541275
, O 0 7.307856098037746e-09
showing O 0 5.934407454333268e-08
an O 0 6.705183075439436e-09
anomalous O 0 2.5027807168953586e-06
inheritance O 0 4.944697593600722e-06
of O 0 1.2478289136197418e-05
Hp O 0 0.0002631286333780736
phenotypes O 0 2.54351988360213e-07
in O 0 8.018611552529364e-09
the O 0 2.845030877551835e-08
child O 0 1.3361356820951187e-07
with O 0 2.4368185691514554e-08
Hp1 O 1 0.9979851245880127
. O 0 5.662581315846182e-06

The O 0 2.134656097041443e-05
Hp2 O 1 0.957048773765564
/ O 0 0.0009517273865640163
Hpdel O 0 0.00476075429469347
individuals O 0 1.6205859765250352e-08
had O 0 7.159377535259637e-09
an O 0 3.934060188726107e-09
extremely O 0 2.7747297792757308e-08
low O 0 1.4033999207185843e-07
level O 0 6.488324402198486e-07
of O 0 1.7431283083624294e-07
Hp O 0 4.882292614638573e-07
( O 0 1.143820371751758e-09
mean O 0 2.201565152404328e-09
+ O 0 4.14920009461639e-09
/ O 0 2.510356145180026e-09
- O 0 6.2180043336468316e-09
SD O 0 1.2777236690908467e-07
= O 0 1.1079063000352107e-08
0 O 0 3.472423182326878e-10
. O 0 3.599428741174471e-11
049 O 0 1.3777260221559118e-08
+ O 0 1.7310400890480082e-09
/ O 0 8.308552734703767e-10
- O 0 8.809187823644038e-10
0 O 0 3.4939087734109364e-10
. O 0 5.144705841897412e-11
043 O 0 4.0733990402941345e-08
mg O 0 1.7509082184119507e-08
/ O 0 9.512842957803969e-09
ml O 0 5.252178691961262e-09
; O 0 1.5920427476334709e-10
n O 0 5.500468081010013e-09
= O 0 8.372188275984627e-09
6 O 0 3.1201867756180945e-09
) O 0 8.605545442907925e-11
, O 0 2.306857309342103e-11
compared O 0 2.0807604250716594e-10
with O 0 1.4561770192433876e-11
the O 0 1.4822701954742001e-09
level O 0 3.612825949517173e-08
( O 0 4.466621239540558e-10
1 O 0 8.960379660472029e-10
. O 0 3.7706081312816053e-11
64 O 0 3.34731714568548e-10
+ O 0 9.682383783626847e-10
/ O 0 8.754565405943993e-10
- O 0 7.648010003080685e-10
1 O 0 2.0020030078171658e-09
. O 0 2.9830996006730004e-10
07 O 0 6.296873067412889e-08
mg O 0 6.38949870790384e-08
/ O 0 2.4848475277394755e-08
ml O 0 6.512958172777417e-09
) O 0 4.191752847604313e-11
obtained O 0 7.86219422899137e-10
from O 0 4.736807057703629e-10
52 O 0 1.4809060644438432e-08
healthy O 0 8.465611323060784e-09
volunteers O 0 1.1050381942823151e-08
having O 0 9.592194061269765e-08
phenotype O 0 4.6818141186122375e-07
Hp2 O 0 1.03405473055318e-05
, O 0 4.1287377960941285e-09
whereas O 0 3.472148790706342e-08
the O 0 1.779980784988311e-08
serum O 0 9.446955004932533e-07
Hp O 0 2.2864469428895973e-06
level O 0 1.0639404024459509e-07
of O 0 8.522087036055837e-09
an O 0 1.0235690073301384e-09
individual O 0 5.903681987717846e-10
with O 0 1.2611095501213754e-09
Hp1 O 0 0.0006985791260376573
/ O 0 1.9353883544681594e-05
Hpdel O 0 4.77281391795259e-05
was O 0 1.0591029422357678e-06
0 O 0 2.4114217467285926e-07
. O 0 3.819589622366948e-08

50 O 0 9.95197297015693e-07
mg O 0 6.718717031617416e-07
/ O 0 5.327488565853855e-07
ml O 0 1.84135600989066e-07
, O 0 6.224598614323895e-10
which O 0 8.172999083067012e-11
was O 0 3.067971654502344e-09
approximately O 0 1.0074464595888344e-09
half O 0 1.0661639349152097e-09
the O 0 3.05760239349695e-09
level O 0 1.8078586094816274e-07
of O 0 7.161332860050607e-08
Hp O 0 1.0714892368923756e-06
in O 0 9.130178391103527e-09
control O 0 3.9000985907478025e-07
sera O 0 8.5167139332043e-06
from O 0 2.4114259034035967e-08
the O 0 4.569192313397252e-08
Hp1 O 0 1.1239760169701185e-05
phenotype O 0 3.563584272114895e-08
( O 0 8.98862317910698e-10
1 O 0 2.049995284636452e-09
. O 0 1.754995454517072e-10
26 O 0 8.474335011499079e-09
+ O 0 5.420688786728078e-09
/ O 0 1.9742005807898977e-09
- O 0 1.0274536776933019e-09
0 O 0 3.0962107877563483e-10
. O 0 3.9869409856896354e-11
33 O 0 7.949017000186132e-10
mg O 0 4.4681400801493965e-09
/ O 0 2.521267861155252e-09
ml O 0 2.3632324985811692e-09
; O 0 3.85074541697783e-11
n O 0 5.501853195255535e-09
= O 0 1.3685489186343602e-08
9 O 0 7.449902028611177e-09
) O 0 4.464943137438837e-10
, O 0 2.2892381046357713e-10
showing O 0 5.243990575110047e-09
a O 0 2.246800256955339e-08
gene O 0 9.672181278119751e-09
- O 0 3.1564866276312387e-08
dosage O 0 3.1102541697691777e-07
effect O 0 5.501677264874161e-07
. O 0 5.577847446147643e-07

The O 0 1.2118009635742055e-06
other O 0 1.5426444122113026e-08
allele O 0 2.3674520122085596e-08
( O 0 2.674382670875275e-08
Hp2 O 0 7.519716291426448e-06
) O 0 5.92389826081785e-09
of O 0 8.355820035887973e-09
individuals O 0 1.1366195762363418e-09
with O 0 1.2595789300462457e-08
Hp2 O 1 0.9999899864196777
/ O 0 0.019662760198116302
Hpdel O 0 0.006165572442114353
was O 0 3.5787334695669415e-07
found O 0 1.278745220822941e-09
to O 0 1.2685852368576889e-10
have O 0 7.636257598475638e-11
, O 0 4.733635011744397e-11
in O 0 1.9514935500897224e-10
all O 0 7.742679830613497e-10
exons O 0 9.32292465449791e-09
, O 0 2.8251823103175866e-10
no O 0 4.449470791811905e-10
mutation O 0 7.358748332908505e-11
, O 0 3.01014387027454e-11
by O 0 4.097840677896869e-10
DNA O 0 5.964307092654053e-08
sequencing O 0 7.750133335093778e-08
. O 0 6.487370995955644e-08

On O 0 1.2873524610768072e-06
the O 0 3.5083228766552566e-08
basis O 0 2.4200659254347556e-07
of O 0 2.5676547110720094e-08
the O 0 3.770920908863218e-09
present O 0 2.93735102907533e-09
study O 0 5.53305579131802e-09
, O 0 3.511773927211692e-10
the O 0 1.7829225873455812e-09
mechanism O 0 7.865637030590733e-08
of O 0 4.789459140397412e-08
anhaptoglobinemia B-Disease 0 4.000074113719165e-06
and O 0 2.8330460200010066e-09
the O 0 4.848372370247489e-09
mechanism O 0 9.981231130495871e-08
of O 0 3.209289900496515e-08
anomalous O 0 7.078953331074445e-06
inheritance O 0 2.0542313450278016e-06
of O 0 6.5948029259743635e-06
Hp O 0 4.331771924626082e-05
phenotypes O 0 2.0811759782191075e-07
were O 0 5.395193625190586e-08
well O 0 6.635251281750243e-08
explained O 0 2.70897021437122e-06
. O 0 1.4597743529520812e-06

However O 0 9.149346169579076e-07
, O 0 1.736557031506436e-08
the O 0 3.6766628852547e-08
mechanism O 0 8.154930242199043e-07
of O 0 1.1495794751681387e-06
hypohaptoglobinemia B-Disease 0 0.001265990431420505
remains O 0 6.751636101398617e-05
unknown O 0 0.00045808753930032253

ATM O 0 0.0007370937382802367
mutations O 0 5.607363391391118e-07
and O 0 2.834057966083492e-08
phenotypes O 0 2.4989692519739037e-06
in O 0 5.238042831479106e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 2.1539472072618082e-06
in O 0 8.52260750860978e-09
the O 0 1.1241133357486888e-08
British O 0 6.584858169844665e-08
Isles O 0 6.310615390248131e-07
: O 0 1.036624674988218e-09
expression O 0 1.3440069057679693e-09
of O 0 2.844302349203076e-09
mutant O 0 1.5852691603868152e-08
ATM O 0 5.006459105061367e-07
and O 0 3.087918531985423e-10
the O 0 2.17162887672373e-09
risk O 0 1.5658470076118647e-08
of O 0 1.1243754016732055e-07
leukemia B-Disease 1 1.0
, O 0 0.00044132416951470077
lymphoma B-Disease 1 1.0
, O 0 5.9533642343012616e-05
and O 0 0.00011124096636194736
breast B-Disease 1 1.0
cancer I-Disease 1 0.999991774559021
. O 0 8.454386261291802e-06

We O 0 3.9359539982797287e-07
report O 0 4.377452356152389e-08
the O 0 3.1106437425876265e-09
spectrum O 0 6.406788433110933e-09
of O 0 2.5631432976069846e-08
59 O 0 5.049028004577849e-07
ATM O 0 8.307707503263373e-06
mutations O 0 6.419350828679171e-09
observed O 0 3.2446312303591185e-08
in O 0 3.1965345215212437e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.990088939666748
A B-Disease 1 1.0
- I-Disease 1 0.9999984502792358
T I-Disease 1 1.0
) O 0 2.37579769191143e-08
patients O 0 1.7281930331236595e-09
in O 0 1.9474823975684785e-09
the O 0 3.725213559846452e-08
British O 0 2.6571290163701633e-06
Isles O 0 7.476854079868644e-05
. O 0 7.147686460484692e-07

Of O 0 4.411635018186644e-06
51 O 0 3.1636338917451212e-06
ATM O 0 2.442255754431244e-05
mutations O 0 1.1373835206995864e-08
identified O 0 2.6710791800610423e-08
in O 0 3.378388457875303e-09
families O 0 3.834426998139406e-09
native O 0 6.890032544504265e-09
to O 0 4.0410115254019274e-09
the O 0 5.1633325170996613e-08
British O 0 9.482989185016777e-07
Isles O 0 6.238223249965813e-06
, O 0 5.924621238051486e-09
11 O 0 2.140651211846034e-08
were O 0 6.49588738355078e-09
founder O 0 4.831577484765148e-07
mutations O 0 1.7466444957037197e-09
, O 0 5.156802207473277e-10
and O 0 1.5879767500948105e-09
2 O 0 4.7812260817181595e-08
of O 0 1.7426653897700817e-08
these O 0 1.3685663713403073e-09
11 O 0 1.8156244507849806e-08
conferred O 0 2.916429053811953e-08
a O 0 3.417840233055358e-09
milder O 0 1.8399888279674315e-09
clinical O 0 1.5106962791833212e-08
phenotype O 0 2.18479501157276e-09
with O 0 2.6209161577139817e-11
respect O 0 9.071987050468522e-10
to O 0 2.8456752509953276e-09
both O 0 6.351806547399974e-08
cerebellar B-Disease 1 1.0
degeneration I-Disease 1 1.0
and O 0 5.954532298346749e-07
cellular O 0 1.1238088518439326e-05
features O 0 3.7596700508402137e-07
. O 0 1.815175068031749e-07

We O 0 9.287189755013969e-07
report O 0 1.5195051616956334e-07
, O 0 4.891620442037947e-09
in O 0 5.4637978585958535e-09
two O 0 1.1258191712215648e-08
A B-Disease 1 0.9999960660934448
- I-Disease 0 0.0205528661608696
T I-Disease 1 0.9999885559082031
families O 0 1.2440213303932524e-08
, O 0 8.17624579152465e-10
an O 0 3.379419633020575e-09
ATM O 0 4.930881800646603e-07
mutation O 0 1.2591290232677466e-09
( O 0 4.501559125458243e-10
7271T O 0 1.487689349488619e-08
- O 0 3.3777393326772653e-08
- O 0 9.829242486603107e-08
> O 0 2.0352622698283085e-07
G O 0 2.007252390967551e-07
) O 0 2.7120225509769114e-10
that O 0 1.492066192820829e-11
may O 0 1.5495670024900932e-10
be O 0 1.0309591375046168e-10
associated O 0 1.0608736111805683e-09
with O 0 6.272948827046321e-11
an O 0 2.854501912619156e-10
increased O 0 3.429607708937965e-09
risk O 0 1.7146470909779055e-08
of O 0 1.3440927659758017e-07
breast B-Disease 0 0.0005943580763414502
cancer I-Disease 0 1.423961066393531e-06
in O 0 1.2345993560813895e-08
both O 0 4.941320241869107e-09
homozygotes O 0 1.0217846693194588e-06
and O 0 3.739349718756557e-09
heterozygotes O 0 8.726616584908697e-08
( O 0 1.2360028556201996e-09
relative O 0 3.218018207462592e-08
risk O 0 5.2655391158396014e-09
12 O 0 2.1146657758208676e-09
. O 0 1.6459038298943796e-10
7 O 0 3.563773054438002e-09
; O 0 3.0766428293915737e-10
P O 0 1.114263795898296e-06
= O 0 9.314822335682038e-08
. O 0 7.760406206536175e-10
0025 O 0 6.89449109358975e-07
) O 0 1.7635050364450677e-10
, O 0 2.660463863102258e-11
although O 0 8.64151666890578e-11
there O 0 5.741964681504896e-10
is O 0 6.751971204366214e-10
a O 0 4.640046569193146e-09
less O 0 6.9217769294027676e-09
severe O 0 1.1880171086886548e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999594688415527
T I-Disease 1 0.9999974966049194
phenotype O 0 4.525582397718608e-08
in O 0 4.41337966172739e-10
terms O 0 4.475936066228314e-09
of O 0 3.7446743483826594e-09
the O 0 4.63328087008108e-09
degree O 0 1.1420951295804116e-06
of O 0 4.959726425113331e-07
cerebellar B-Disease 1 0.9999923706054688
degeneration I-Disease 1 1.0
. O 0 1.1969591469096486e-06

This O 0 1.8155697034671903e-07
mutation O 0 8.795860928501043e-09
( O 0 2.410744270875398e-09
7271T O 0 2.447014146866877e-08
- O 0 3.8496203558224806e-08
- O 0 1.0331377353622884e-07
> O 0 1.3938975484961702e-07
G O 0 1.1554671175417752e-07
) O 0 7.080163122452632e-10
also O 0 5.6068854420443515e-11
allows O 0 4.955529389616409e-11
expression O 0 3.7403749542086473e-10
of O 0 1.2607608290693406e-09
full O 0 8.698727071987378e-09
- O 0 6.067030966505627e-08
length O 0 3.869990550242619e-08
ATM O 0 1.1912267154912115e-06
protein O 0 1.1301198199475948e-08
at O 0 4.251291763068821e-09
a O 0 7.245134492350758e-10
level O 0 7.838315774222337e-09
comparable O 0 1.0979728237714426e-08
with O 0 6.124610540947373e-11
that O 0 2.7607058306067245e-10
in O 0 4.574954193259373e-09
unaffected O 0 2.016262072856989e-07
individuals O 0 7.78016673308457e-09
. O 0 1.1617962769605583e-07

In O 0 8.775622717394072e-08
addition O 0 9.005410639417732e-09
, O 0 1.072774979959945e-09
we O 0 1.684091310849567e-09
have O 0 2.750079330926525e-10
studied O 0 5.017931314910129e-08
18 O 0 8.248925382758898e-07
A B-Disease 1 1.0
- I-Disease 1 0.999998927116394
T I-Disease 1 1.0
patients O 0 1.2921399061838201e-08
, O 0 2.0580491477684149e-10
in O 0 4.1890932389598845e-10
15 O 0 3.34186411876658e-09
families O 0 3.047871399708413e-10
, O 0 2.424789535826477e-10
who O 0 8.252500349748004e-10
developed O 0 5.892887884328957e-07
leukemia B-Disease 1 1.0
, O 0 0.005714770872145891
lymphoma B-Disease 1 1.0
, O 0 0.0003592100692912936
preleukemic O 1 0.9999995231628418
T O 1 0.9816328287124634
- O 0 2.7932304874411784e-05
cell O 0 5.629185034194961e-05
proliferation O 0 0.0012418872211128473
, O 0 3.477357779502199e-08
or O 0 6.741618562955409e-05
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 7.669372052987455e-07
mostly O 0 3.035841444898324e-08
in O 0 4.6163027178636185e-08
childhood O 0 0.00015217646432574838
. O 0 1.0529123528613127e-06

A O 0 3.3860590065160068e-06
wide O 0 8.570488319037395e-08
variety O 0 2.3527141124191076e-08
of O 0 1.2624921907899989e-07
ATM O 0 7.601777269883314e-06
mutation O 0 1.1049028358911528e-09
types O 0 1.032530061451098e-09
, O 0 2.0032397962665982e-10
including O 0 1.1734963001330811e-09
missense O 0 4.1352703306074545e-07
mutations O 0 2.9392959177698685e-09
and O 0 5.151437054706776e-09
in O 0 2.840634181211499e-07
- O 0 3.0506657822115812e-06
frame O 0 3.838744305539876e-05
deletions O 0 2.1013687501181266e-07
, O 0 5.230873956207915e-09
were O 0 9.942162648712838e-09
seen O 0 2.9955380398405396e-08
in O 0 3.1673890177330577e-09
these O 0 5.738945763056336e-09
patients O 0 3.745161691881549e-08
. O 0 9.682059953775024e-08

We O 0 5.771726705461333e-07
also O 0 1.0532227534554295e-08
show O 0 5.052878560007912e-09
that O 0 1.0273982359310097e-10
25 O 0 3.525426395256659e-09
% O 0 8.47054926200741e-10
of O 0 1.7518561046259151e-09
all O 0 6.4014753498042865e-09
A B-Disease 1 1.0
- I-Disease 1 0.999997615814209
T I-Disease 1 1.0
patients O 0 7.417446656887705e-09
carried O 0 4.330446667921706e-09
in O 0 1.635955904077946e-08
- O 0 2.6316507728552097e-07
frame O 0 7.76824072090676e-06
deletions O 0 4.915510203318263e-07
or O 0 4.920134344388316e-08
missense O 0 4.339660506502696e-07
mutations O 0 1.271141192304981e-09
, O 0 3.204918830324033e-10
many O 0 7.4021615226183e-11
of O 0 2.999795967184582e-09
which O 0 5.603456032510223e-10
were O 0 2.1919868142816767e-09
also O 0 6.593008916588872e-10
associated O 0 1.836198970650571e-09
with O 0 4.753904492282857e-10
expression O 0 2.9526987077588274e-08
of O 0 9.178004489740488e-08
mutant O 0 1.0503939620321034e-06
ATM O 0 4.365078348200768e-05
protein O 0 3.4376196822449856e-07
. O 0 5.484996989935098e-08

The O 0 7.959817594382912e-06
DMPK O 0 0.005595504306256771
gene O 0 3.327498347971414e-07
of O 0 2.0034715930705715e-07
severely O 0 0.0012144800275564194
affected O 0 0.00010814161214511842
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 2.6593510483507998e-05
is O 0 1.1096553009792842e-08
hypermethylated O 0 1.1778957741626073e-05
proximal O 0 3.4960701214004075e-06
to O 0 2.9347468899487694e-09
the O 0 2.3567427120951834e-08
largely O 0 5.148866648596595e-07
expanded O 0 3.0531609240824764e-07
CTG O 0 0.00033469597110524774
repeat O 0 3.382599061296787e-06
. O 0 4.5728015152235457e-07

Using O 0 6.798887284276134e-07
methylation O 0 5.898465360587579e-07
- O 0 2.2581083669592772e-07
sensitive O 0 1.4448119145527016e-07
restriction O 0 1.0073873291105429e-08
enzymes O 0 1.2988775610622838e-09
, O 0 1.5760630300842848e-10
we O 0 5.588204343709435e-10
characterized O 0 5.327404295485394e-09
the O 0 7.809112467782597e-09
methylation O 0 8.861454148245684e-08
pattern O 0 1.1289483126120103e-07
on O 0 2.4520508290493126e-08
the O 0 1.6556537474343713e-08
5 O 0 2.11252615400781e-08
side O 0 6.164522226015379e-09
of O 0 5.164376659649861e-08
the O 0 1.2388917980388214e-07
CTG O 0 0.00024853344075381756
repeat O 0 1.9993106548099604e-07
in O 0 1.1881045480777175e-08
the O 0 2.9507786436511196e-08
DMPK O 0 4.502157389651984e-05
gene O 0 7.79577824516764e-09
of O 0 1.9284462915436507e-09
normal O 0 2.6272115150050013e-08
individuals O 0 9.765505765146898e-11
and O 0 1.0207026196473734e-10
of O 0 1.622203349427309e-08
patients O 0 5.477770237405366e-09
affected O 0 1.2826812501032236e-08
with O 0 1.0885459289511346e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 1.4890491506491799e-08
showing O 0 2.5850107832070535e-08
expansions O 0 3.926333391746084e-08
of O 0 9.936266920362868e-09
the O 0 1.843843655535693e-08
repetitive O 0 6.613657319576305e-07
sequence O 0 2.405968473340181e-07
. O 0 1.3842878843206563e-07

The O 0 3.3278774935752153e-06
gene O 0 1.8449013339250087e-07
segment O 0 1.2289166306800325e-07
analyzed O 0 3.341509113852226e-08
corresponds O 0 3.5593050284887795e-08
to O 0 2.7785835854388097e-09
the O 0 4.237305262222435e-08
genomic O 0 1.5117216207727324e-06
SacI O 0 0.000536012405063957
- O 0 2.5689389531180495e-06
HindIII O 0 3.650658982223831e-05
fragment O 0 9.334312949249579e-07
carrying O 0 1.805327798365397e-07
exons O 0 1.7078163239148125e-07
11 O 0 2.09260150541013e-07
- O 0 1.2479502231599326e-07
15 O 0 2.2108157793354621e-07
. O 0 1.5553194998574327e-07

There O 0 4.680322831518424e-07
is O 0 1.8160401182854002e-08
constitutive O 0 9.261848390451632e-07
methylation O 0 1.0403161923022708e-06
in O 0 1.0270391470612594e-07
intron O 0 1.735109071887564e-05
12 O 0 2.0028487313084042e-07
at O 0 1.731966534634921e-07
restriction O 0 1.8931686440737394e-08
sites O 0 6.756354586912039e-09
of O 0 2.539803212187053e-08
SacII O 0 1.8317476133233868e-05
and O 0 4.57248745533434e-08
HhaI O 0 4.324812471168116e-05
, O 0 7.086570885661558e-09
localized O 0 1.0797242211424418e-08
1 O 0 5.813332037973851e-09
, O 0 1.0838228925447169e-10
159 O 0 1.4788449353986266e-09
- O 0 1.2196008647435974e-09
1 O 0 3.554377903114414e-09
, O 0 4.3680731254269745e-10
232 O 0 1.4026340977579821e-08
bp O 0 1.3013064403821772e-07
upstream O 0 1.891433214495919e-07
of O 0 1.8463177653416096e-08
the O 0 5.279349224451835e-08
CTG O 0 8.300645276904106e-05
repeat O 0 1.5271351117007725e-07
, O 0 1.428634655020744e-09
whereas O 0 2.487757999602991e-09
most O 0 1.8271530122238033e-10
, O 0 4.3688209300229985e-11
if O 0 6.380039552222883e-11
not O 0 9.135742856658524e-11
all O 0 2.6069227332392586e-10
, O 0 3.947550342164874e-10
of O 0 2.8475917179804355e-09
the O 0 4.461770064523307e-09
other O 0 3.7586689316526645e-10
sites O 0 2.598524506680633e-09
of O 0 3.5389629005067036e-08
SacII O 0 3.057445792364888e-05
, O 0 2.0118610777331014e-08
HhaI O 0 3.2869229471543804e-05
, O 0 4.453531321502169e-09
and O 0 3.741204679386101e-09
HpaII O 0 1.8995411664946005e-05
in O 0 7.650377220613791e-09
this O 0 1.1744906158739354e-09
region O 0 1.8841557647419904e-08
are O 0 1.160886942130901e-09
unmethylated O 0 9.394988182975794e-07
, O 0 2.3488073708222146e-09
in O 0 3.692135264188323e-09
normal O 0 7.408937818809136e-08
individuals O 0 2.060059761666011e-10
and O 0 2.1369896130440935e-10
most O 0 2.8177074562485416e-10
of O 0 5.662669444461699e-09
the O 0 3.2985187914391645e-08
patients O 0 3.4468172316337586e-08
. O 0 4.500919459360375e-08

In O 0 1.9866712364091654e-07
a O 0 1.4785014101903471e-08
number O 0 5.523194679390997e-10
of O 0 1.7365197058083481e-09
young O 0 3.522126146293658e-09
and O 0 2.9928695077785505e-09
severely O 0 2.2469946543424157e-06
affected O 0 9.873281747729834e-09
patients O 0 1.1364656993251288e-09
, O 0 5.0947676633050776e-11
however O 0 3.6996622432283743e-10
, O 0 2.0256010757613296e-10
complete O 0 6.309951228189448e-09
methylation O 0 1.3411958654785394e-08
of O 0 1.6193739682535124e-09
these O 0 1.2294330831164046e-10
restriction O 0 1.7377322913958437e-09
sites O 0 7.762211984285727e-10
was O 0 3.0750604285145755e-09
found O 0 6.863167811843596e-10
in O 0 9.967315861558745e-10
the O 0 1.3612153182407383e-08
mutated O 0 4.585658430755757e-08
allele O 0 7.073003160940061e-08
. O 0 9.188057958908757e-08

In O 0 3.6152459870208986e-07
most O 0 1.5984332746299401e-09
of O 0 1.5160240840472738e-09
these O 0 5.576353268033074e-10
patients O 0 1.5558758725831012e-09
, O 0 3.7355124549165453e-10
the O 0 3.7059215696189085e-09
onset O 0 1.3109368410368916e-05
of O 0 2.5105592271756905e-07
the O 0 2.9123016247467604e-06
disease O 1 0.9941450953483582
was O 1 0.8519421219825745
congenital O 1 1.0
. O 0 2.3613108623976586e-06

Preliminary O 0 9.299019438913092e-06
in O 0 4.3514384628906555e-07
vivo O 0 5.199424413149245e-05
footprinting O 0 0.0001580032258061692
data O 0 8.568183318402589e-08
gave O 0 5.571869632348125e-09
evidence O 0 1.0109539871905326e-08
for O 0 1.1067863292524294e-09
protein O 0 1.6882117037653188e-08
- O 0 3.143017224260802e-08
DNA O 0 3.2130074600900116e-08
contact O 0 1.195324017544408e-07
in O 0 1.3957220268423498e-08
normal O 0 1.3724222753808135e-06
genes O 0 1.9510340010242544e-08
at O 0 3.8337780949859734e-08
an O 0 2.595479564604375e-08
Sp1 O 0 4.159331638220465e-06
consensus O 0 3.8857375983525344e-08
binding O 0 1.062583354638491e-08
site O 0 8.556261832382006e-08
upstream O 0 1.8760340481094318e-07
of O 0 1.785261183329112e-08
the O 0 7.584838357388435e-08
CTG O 0 0.0001861858181655407
repeat O 0 1.9648108207093173e-07
and O 0 1.4297849570965582e-09
for O 0 6.011275366368807e-10
a O 0 1.5864841662605045e-09
significant O 0 6.705359045788839e-10
reduction O 0 4.0530689915385665e-09
of O 0 2.1150570184147455e-09
this O 0 6.069212910020383e-10
interaction O 0 1.4724228059037614e-08
in O 0 1.5355072768841183e-09
cells O 0 1.5339061132380039e-09
with O 0 2.3252307024268504e-10
a O 0 1.334270223196654e-07
hypermethylated O 0 1.752311800373718e-05
DMPK O 0 0.0008727620006538928
gene O 0 1.1515893305613645e-07
. O 0 1.2951033134811496e-08
. O 0 7.509910204817061e-08

The O 0 0.0004144713457208127
hemochromatosis B-Disease 1 1.0
gene O 0 2.429209416732192e-06
product O 0 1.6418677262208803e-07
complexes O 0 6.13981256947227e-08
with O 0 6.804823926565007e-10
the O 0 9.948578139074016e-08
transferrin O 0 2.274437792948447e-05
receptor O 0 5.400124223342573e-07
and O 0 1.517858283506257e-09
lowers O 0 1.6897743648769392e-08
its O 0 2.3719015640466523e-10
affinity O 0 2.7956799097950125e-09
for O 0 1.5578625056633655e-09
ligand O 0 1.7117820050316368e-07
binding O 0 6.206572322753345e-08
. O 0 1.6793198653886066e-07

We O 0 1.006376351142535e-06
recently O 0 2.2629632212556317e-07
reported O 0 5.796196234086892e-08
the O 0 8.617840663305287e-09
positional O 0 3.82040610702461e-07
cloning O 0 6.059768509203423e-08
of O 0 1.3404926058058209e-08
a O 0 2.0313290605145085e-08
candidate O 0 8.568248688334279e-08
gene O 0 1.31258374835852e-07
for O 0 1.202769794872438e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 1.0
HFE O 1 1.0
. O 0 1.0698090591176879e-05

The O 0 1.977025476662675e-06
gene O 0 4.842238254809672e-08
product O 0 1.1161698232342587e-08
, O 0 2.985514502285014e-09
a O 0 1.1375528075063812e-08
member O 0 1.359993007099547e-08
of O 0 1.3060956405297475e-07
the O 0 1.192487815160348e-07
major O 0 4.7012008508318104e-07
histocompatibility O 0 2.5414605261175893e-05
complex O 0 0.0004972520982846618
class O 0 1.7834016716733458e-06
I O 0 1.5509722288697958e-05
- O 0 8.851350230543176e-07
like O 0 3.0876332601792456e-08
family O 0 6.451487877257023e-08
, O 0 2.3474100441234214e-09
was O 0 9.420023161510471e-08
found O 0 2.904785967317025e-09
to O 0 1.4050619556726929e-09
have O 0 1.1302226932130566e-09
a O 0 8.667558226704841e-09
mutation O 0 6.721877499060724e-10
, O 0 1.5933497854447864e-09
Cys O 0 7.335177087952616e-06
- O 0 3.623813711328694e-07
282 O 0 4.5803216153217363e-07
- O 0 6.189744112816697e-07
- O 0 8.510969564667903e-07
> O 0 5.717271847061056e-07
Tyr O 0 1.6307147916450049e-06
( O 0 2.144691757521855e-09
C282Y O 0 4.9369706545121517e-08
) O 0 3.493595412962236e-10
, O 0 6.248040279599465e-11
in O 0 2.0962322155870794e-10
85 O 0 5.368665512150983e-09
% O 0 1.196107546341807e-09
of O 0 6.0158775738727854e-09
patient O 0 2.375549144062461e-07
chromosomes O 0 3.992929578089388e-07
. O 0 1.0936091854318875e-07

This O 0 1.303482548564716e-07
mutation O 0 4.181569224215309e-08
eliminates O 0 8.762208381085657e-08
the O 0 2.2300980617728783e-08
ability O 0 6.02062115717672e-08
of O 0 1.0316329053239315e-06
HFE O 0 0.0028197728097438812
to O 0 1.2250855263573612e-07
associate O 0 2.6655529836716596e-06
with O 0 1.1629730067852506e-08
beta2 O 0 4.902300133835524e-05
- O 0 1.1137985893583391e-05
microglobulin O 0 6.313104677246884e-05
( O 0 9.013198365437347e-08
beta2m O 0 1.6085687093436718e-06
) O 0 2.4256974207048643e-09
and O 0 1.2379280933672021e-09
prevents O 0 1.3803089338182417e-08
cell O 0 8.872410717231105e-07
- O 0 4.169226315298147e-07
surface O 0 8.51179356686771e-06
expression O 0 4.76781224278966e-06
. O 0 3.4271909044036875e-07

A O 0 1.5928566426737234e-05
second O 0 5.028892928748974e-07
mutation O 0 1.170974872621855e-08
that O 0 8.945010843142143e-10
has O 0 5.843277528505553e-10
no O 0 1.481337608133515e-09
effect O 0 1.1864536020311789e-08
on O 0 7.813615354734793e-08
beta2m O 0 2.3637043341295794e-05
association O 0 5.798014512947702e-07
, O 0 4.00562178981545e-08
H63D O 0 0.0008114065276458859
, O 0 1.425700979496014e-08
was O 0 1.368251929534381e-07
found O 0 8.727261580077084e-09
in O 0 1.7263481755236398e-09
eight O 0 1.5931947983105488e-09
out O 0 3.7778449812897463e-10
of O 0 3.2982341302556506e-09
nine O 0 4.568233791246712e-08
patients O 0 9.744578477466348e-10
heterozygous O 0 1.187336007291151e-09
for O 0 5.384794277141225e-10
the O 0 6.23457339088418e-08
C282Y O 0 2.164791658287868e-05
mutant O 0 4.721153800346656e-06
. O 0 2.8033392140969227e-07

In O 0 3.304271558590699e-07
this O 0 4.771803396863561e-09
report O 0 1.3655189867733952e-08
, O 0 4.765379757465382e-10
we O 0 9.660616751006046e-10
demonstrate O 0 5.772021527405968e-09
in O 0 5.363855137829887e-09
cultured O 0 4.222633549488819e-07
293 O 0 3.8787149492236495e-07
cells O 0 4.3902620205926723e-08
overexpressing O 0 9.254379165213322e-07
wild O 0 1.6474759334528244e-08
- O 0 5.6107023027607283e-08
type O 0 1.5708343426013016e-07
or O 0 6.577427313914086e-08
mutant O 0 7.353622208938759e-07
HFE O 0 7.328740321099758e-05
proteins O 0 1.3843157731230349e-09
that O 0 6.263121965499607e-11
both O 0 6.977841221500469e-11
the O 0 9.222621000226638e-10
wild O 0 6.114869943729673e-09
- O 0 5.2760977808929965e-08
type O 0 1.629390595780933e-07
and O 0 2.5414800930434467e-08
H63D O 1 0.9960111379623413
HFE O 0 0.007451390847563744
proteins O 0 7.199870921681395e-09
form O 0 3.322093267144055e-09
stable O 0 1.0575829492154298e-06
complexes O 0 4.348193982650628e-08
with O 0 2.8066005075544354e-09
the O 0 3.8224723653002e-07
transferrin O 0 5.353547021513805e-05
receptor O 0 7.831511538824998e-06
( O 0 8.446728116950908e-08
TfR O 0 2.49825679929927e-05
) O 0 1.957743833713721e-08
. O 0 6.317215195394965e-08

The O 0 4.137375071877614e-06
C282Y O 0 2.606697307783179e-05
mutation O 0 6.374161642952458e-08
nearly O 0 5.367347455376148e-08
completely O 0 2.0215357210418006e-07
prevents O 0 3.4001949700268597e-08
the O 0 1.1837570035311273e-08
association O 0 2.0475031448086156e-08
of O 0 8.042525934115474e-08
the O 0 4.0765087305771885e-07
mutant O 0 1.4708218259329442e-05
HFE O 0 0.0021388360764831305
protein O 0 6.40207602486953e-08
with O 0 7.683466085595114e-10
the O 0 1.206649073992594e-07
TfR O 0 0.006754257250577211
. O 0 9.344404361399938e-07

Studies O 0 5.358047019399237e-06
on O 0 2.2415572686895757e-07
cell O 0 9.254493988919421e-07
- O 0 5.034055305941365e-08
associated O 0 5.3153090817659177e-08
transferrin O 0 1.987147925319732e-06
at O 0 8.318566102616387e-08
37 O 0 1.5134014930140438e-08
degrees O 0 1.6622959719825303e-07
C O 0 1.140094596507879e-07
suggest O 0 6.0845506411055794e-09
that O 0 1.1132155613990946e-10
the O 0 3.3944131949681378e-09
overexpressed O 0 4.934664161737601e-07
wild O 0 2.9550141888989856e-08
- O 0 1.068677164539622e-07
type O 0 2.7007519065591623e-07
HFE O 0 8.699804311618209e-05
protein O 0 7.723483008703624e-08
decreases O 0 2.8974444177265468e-08
the O 0 9.154306757075403e-10
affinity O 0 1.2165022766907896e-08
of O 0 1.3582536873002482e-08
the O 0 7.009425218029719e-08
TfR O 0 0.00012206792598590255
for O 0 3.533654790999208e-08
transferrin O 0 2.3998185497475788e-05
. O 0 3.324263104786951e-07

The O 0 3.268265936640091e-05
overexpressed O 0 0.006716019008308649
H63D O 0 0.04420125111937523
protein O 0 8.074770789789909e-07
does O 0 9.2318436228922e-10
not O 0 2.0260339239630554e-10
have O 0 4.568331130050396e-11
this O 0 5.191053142894475e-11
effect O 0 2.0276120782369844e-09
, O 0 6.480192493718562e-10
providing O 0 4.351892624043785e-09
the O 0 9.627395547440187e-10
first O 0 1.8120360767426291e-09
direct O 0 1.4189398545028098e-09
evidence O 0 3.7335201596988554e-09
for O 0 4.024686972581293e-10
a O 0 3.7594598545354074e-09
functional O 0 7.932212753303247e-08
consequence O 0 6.458863310854213e-08
of O 0 2.324643411100169e-08
the O 0 1.2971284490959079e-07
H63D O 0 0.0003867869090754539
mutation O 0 1.409545831165815e-07
. O 0 7.231817988895273e-08

Addition O 0 6.91887521497847e-07
of O 0 8.028070510590624e-07
soluble O 0 5.2210066314728465e-06
wild O 0 1.0274834494339302e-06
- O 0 1.1262474799877964e-05
type O 0 9.540972678223625e-05
HFE O 1 0.9999998807907104
/ O 0 0.4190428555011749
beta2m O 0 5.853502807440236e-05
heterodimers O 0 4.89265357828117e-06
to O 0 1.2655535286398845e-08
cultured O 0 1.7182732108267373e-06
cells O 0 1.2340288435552793e-07
also O 0 1.700163898554763e-09
decreased O 0 5.325375340703431e-08
the O 0 1.6975555405807086e-09
apparent O 0 2.272352794818744e-08
affinity O 0 9.500078057556038e-09
of O 0 7.2422916552739025e-09
the O 0 2.2420270084921867e-08
TfR O 0 9.353148016089108e-06
for O 0 4.7631804056536e-10
its O 0 9.394303113197111e-10
ligand O 0 1.5013235099559097e-08
under O 0 2.0377125764525772e-08
steady O 0 1.2068809382981271e-06
- O 0 4.800193131870856e-09
state O 0 2.663806120128953e-10
conditions O 0 6.635615612538004e-09
, O 0 2.528321718653359e-10
both O 0 1.5167433975449285e-10
in O 0 1.0252649840225558e-09
293 O 0 3.006912407954587e-08
cells O 0 1.4927935554354121e-09
and O 0 4.3600073551530727e-10
in O 0 2.132468246429653e-08
HeLa O 0 0.00021227117395028472
cells O 0 3.891111646225909e-07
. O 0 8.423865693885091e-08

Furthermore O 0 5.690449597750558e-06
, O 0 1.2221233802733877e-08
at O 0 4.704272882349869e-08
4 O 0 2.489520234405518e-08
degrees O 0 1.5069441872128664e-07
C O 0 1.599285468500966e-07
, O 0 3.186146346756402e-10
the O 0 2.7734901042464344e-09
added O 0 2.8868695878259132e-08
soluble O 0 3.1813317491469206e-07
complex O 0 1.049001525643689e-06
of O 0 8.849441996972018e-07
HFE O 1 0.9859581589698792
/ O 0 0.00018838222604244947
beta2m O 0 6.700873927911744e-05
inhibited O 0 1.0381634183431743e-06
binding O 0 1.8282145575199138e-08
of O 0 4.796424946107436e-08
transferrin O 0 2.3021086690278025e-06
to O 0 4.227528904721112e-08
HeLa O 0 0.0006391904898919165
cell O 0 1.295335459872149e-05
TfR O 0 6.871699588373303e-05
in O 0 8.37573388423607e-09
a O 0 2.032526680295632e-08
concentration O 0 3.890108928317204e-06
- O 0 1.5763914973376814e-07
dependent O 0 7.769595811168983e-08
manner O 0 1.1564250002038534e-07
. O 0 8.473757162619222e-08

Scatchard O 0 0.0002095875097438693
plots O 0 1.7545406763019855e-06
of O 0 2.4079696459011757e-08
these O 0 1.0750957901706215e-09
data O 0 9.207022344526195e-08
indicate O 0 1.8427925851938198e-08
that O 0 2.058237608126845e-10
the O 0 6.218952908199071e-09
added O 0 3.053029473676361e-08
heterodimer O 0 4.7071716835489497e-07
substantially O 0 1.0636579617084863e-08
reduced O 0 8.692867536908011e-10
the O 0 1.1766745355856756e-09
affinity O 0 1.5231199412824026e-08
of O 0 5.822489868023695e-08
TfR O 0 9.472880628891289e-05
for O 0 5.356670129685881e-08
transferrin O 0 7.667305908398703e-05
. O 0 1.0112203199241776e-06

These O 0 1.4831285000127536e-07
results O 0 9.323674987626873e-08
establish O 0 1.478475439853355e-07
a O 0 7.027362869393983e-08
molecular O 0 6.982317017900641e-07
link O 0 3.8267288005044975e-07
between O 0 2.0478964302128588e-07
HFE O 1 0.6925565600395203
and O 0 1.6369764210821813e-08
a O 0 5.896688293205443e-08
key O 0 1.646678811084712e-07
protein O 0 2.623305839222212e-08
involved O 0 1.3050916791712552e-08
in O 0 1.2542782812374753e-08
iron O 0 8.00427224021405e-05
transport O 0 4.84081601825892e-06
, O 0 3.187596320231023e-08
the O 0 8.076565336523345e-07
TfR O 1 0.9997578263282776
, O 0 3.2833393781572795e-09
and O 0 8.717092603305332e-10
raise O 0 3.4779130686501958e-09
the O 0 3.014145821822467e-09
possibility O 0 1.1911631681016388e-08
that O 0 3.691710825926009e-10
alterations O 0 9.700837466652956e-09
in O 0 8.762267023065817e-10
this O 0 4.88333984360878e-10
regulatory O 0 1.0311332232504355e-08
mechanism O 0 4.460742530909556e-08
may O 0 1.0336690392520609e-09
play O 0 1.1554181611472814e-08
a O 0 1.2014355732503645e-08
role O 0 1.5514732609744897e-08
in O 0 6.693223308928964e-09
the O 0 1.5792791430158104e-07
pathogenesis O 1 0.9999785423278809
of O 1 0.9999822378158569
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.0012149647809565067
. O 0 2.476062945788726e-06

Genomic O 0 2.6250179871567525e-05
organization O 0 6.531994927172491e-07
of O 0 6.765260991414834e-07
the O 0 1.2245334346516756e-06
UBE3A O 0 0.12953434884548187
/ O 0 4.9941809265874326e-05
E6 O 0 5.36556899533025e-06
- O 0 8.877878485691326e-07
AP O 0 1.2520631571533158e-05
gene O 0 1.0140633222022188e-08
and O 0 6.433590882259921e-10
related O 0 1.2314882269492955e-07
pseudogenes O 0 4.75982506031869e-06
. O 0 7.617414325977734e-07

The O 0 2.3911417883937247e-05
UBE3A O 0 0.003942147362977266
gene O 0 6.756582138223166e-07
encodes O 0 1.6963014104476315e-07
the O 0 2.753015770906586e-08
E6 O 0 8.391118058170832e-07
- O 0 4.56280872640491e-07
AP O 0 1.0210997970716562e-05
ubiquitin O 0 1.085942926692951e-06
- O 0 6.358328050737327e-07
protein O 0 7.82942919386187e-08
ligase O 0 2.0476444717587583e-07
and O 0 3.004434256936861e-09
has O 0 9.112393062338242e-10
recently O 0 2.3300177343088535e-09
been O 0 5.607476150082391e-10
shown O 0 6.646848071945044e-10
to O 0 2.5403823489256183e-10
be O 0 1.1932205223885717e-09
mutated O 0 4.9746194719091363e-08
in O 0 1.7368206499668304e-06
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.00028920744080096483
who O 0 1.7890688042143665e-08
lack O 0 4.808475296158576e-06
15q11 O 0 0.00010098423808813095
- O 0 1.2967914699402172e-05
q13 O 0 1.95469765458256e-05
deletions O 0 6.531316216751293e-07
or O 0 1.5213234405564435e-07
chromosome O 0 1.0791537761178915e-06
15 O 0 2.149129613826517e-06
paternal O 0 0.002993765054270625
uniparental B-Disease 1 0.9999985694885254
disomy I-Disease 1 0.9785067439079285
. O 0 7.058392839098815e-06

Previous O 0 3.715019556693733e-05
UBE3A O 0 0.0003092356491833925
cDNA O 0 5.6714447964623105e-06
analysis O 0 5.887921972203003e-08
has O 0 2.81062229046114e-10
shown O 0 4.9193410456283e-10
a O 0 4.293208011318939e-09
coding O 0 8.704124354608211e-08
region O 0 8.354481551009485e-09
of O 0 6.348403047695683e-08
approximately O 0 5.3790608944837e-07
2 O 0 1.7328433159491397e-06
. O 0 2.1684188311610342e-07

6 O 0 5.431603131000884e-05
kb O 0 0.00012303223775234073
and O 0 4.243216977783959e-08
a O 0 1.287827302576261e-07
3 O 0 1.6823928206122218e-07
- O 0 1.697555518376248e-07
untranslated O 0 2.191696512454655e-05
region O 0 2.392820590557676e-07
( O 0 5.594822027887858e-08
UTR O 0 1.4523131540045142e-05
) O 0 1.9897450354022794e-09
of O 0 9.331838413118021e-09
< O 0 2.4114217467285926e-07
50 O 0 1.0292429131197878e-08
bp O 0 4.491134930617591e-08
, O 0 5.131967628635437e-10
whereas O 0 1.648971514889297e-09
Northern O 0 5.90971271918761e-09
analysis O 0 1.2265440219039192e-08
has O 0 1.3940099075071544e-10
indicated O 0 1.0694185537118983e-09
mRNA O 0 3.0883091639566373e-09
sizes O 0 8.711574239761433e-10
of O 0 9.176600812565994e-09
5 O 0 4.7115371160089126e-08
- O 0 1.0542341755126472e-07
8 O 0 5.00929616009671e-07
kb O 0 4.9664824473438784e-05
. O 0 4.4727468662131287e-07

We O 0 1.770605564388461e-07
have O 0 8.931305139903145e-10
analyzed O 0 1.0231147484773828e-08
additional O 0 1.0131140371072433e-08
cDNA O 0 4.614947215486609e-07
clones O 0 9.352936203299578e-09
and O 0 8.971781650934929e-11
provide O 0 4.5939352322221794e-10
evidence O 0 4.6497743433349115e-09
for O 0 6.260820195613803e-10
an O 0 1.800931070938816e-09
additional O 0 1.5782456230795106e-08
0 O 0 6.149575426661613e-08
. O 0 4.83046740384907e-08

5 O 0 1.2149728718213737e-05
kb O 0 3.383898001629859e-05
of O 0 9.263845299756213e-07
5 O 0 1.1999387652394944e-06
- O 0 9.010325925373763e-07
UTR O 0 2.8263008061912842e-05
and O 0 1.8904048104673166e-08
> O 0 7.099967547219421e-08
2 O 0 1.612409228357592e-08
kb O 0 7.484170509997057e-07
of O 0 5.725959439928374e-08
3 O 0 6.178927947075863e-07
- O 0 3.3201679343619617e-06
UTR O 0 0.0003666482225526124
. O 0 2.6917547302218736e-07

We O 0 4.774241233462817e-07
have O 0 3.4566978168726337e-09
established O 0 1.880780509111446e-08
the O 0 7.25550952651588e-09
genomic O 0 5.313909667847838e-08
organization O 0 1.3391789899230844e-08
of O 0 7.348393182837754e-08
UBE3A O 0 4.012387216789648e-05
and O 0 3.765200151661929e-09
the O 0 8.416345842476858e-09
sequence O 0 5.975523009738026e-08
of O 0 2.6921424023385043e-07
intron O 0 1.4889950762153603e-05
- O 0 4.104653271497227e-06
exon O 0 3.4230722576467087e-06
borders O 0 1.3750644711763016e-07
. O 0 1.6064822716543858e-07

We O 0 5.421554192253097e-07
have O 0 4.704189482396259e-09
also O 0 7.874845775468486e-10
mapped O 0 1.12050209111203e-08
two O 0 1.3941142684714691e-09
highly O 0 4.506079509525307e-09
homologous O 0 4.3025558227327565e-08
processed O 0 5.987320150779851e-08
pseudogenes O 0 4.742190640172339e-07
, O 0 2.2991912373981904e-08
UBE3AP1 O 0 0.0001287086633965373
and O 0 2.1000184347030881e-07
UBE3AP2 O 0 0.3981150984764099
, O 0 3.9837470211523396e-08
to O 0 8.215237379260998e-09
chromosomes O 0 1.3011024257991721e-08
2 O 0 8.711079857448567e-09
and O 0 3.594895492398109e-10
21 O 0 9.236674536339251e-09
, O 0 3.61702140461162e-10
respectively O 0 5.925909984938471e-09
, O 0 2.093475254261179e-10
and O 0 2.397550213917299e-10
determined O 0 1.299926744025015e-08
their O 0 4.153943411466798e-09
genomic O 0 1.5281810306078114e-07
organization O 0 8.23656307602505e-08
. O 0 1.6581034856244514e-07

These O 0 9.007647605585589e-08
results O 0 1.2195526366554077e-08
will O 0 1.1290371415562106e-10
form O 0 1.7599263713030666e-10
the O 0 8.691243280622984e-10
basis O 0 4.30279945007328e-09
for O 0 1.383787112674284e-10
studies O 0 2.9381523880545046e-09
of O 0 1.5624302962535808e-09
mutation O 0 9.269425782498786e-10
and O 0 7.767085308252319e-10
imprinting O 0 1.960273721124395e-06
of O 0 2.0961558675480774e-06
UBE3A O 1 0.7187673449516296
. O 0 2.8087767987017287e-06

Mutation O 0 6.110873869147326e-07
spectrum O 0 1.0952519602369648e-07
and O 0 1.3738370441274128e-08
genotype O 0 4.6834844624754624e-07
- O 0 2.188859156149192e-07
phenotype O 0 7.994273687472742e-08
analyses O 0 1.760313352860976e-07
in O 0 5.6865602005018445e-08
Cowden B-Disease 1 0.9986923336982727
disease I-Disease 0 0.00024087126075755805
and O 0 1.8823781999799394e-07
Bannayan B-Disease 1 1.0
- I-Disease 1 1.0
Zonana I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 2.0171441406091617e-08
two O 0 9.930908362321134e-08
hamartoma B-Disease 1 0.9989641904830933
syndromes I-Disease 0 0.0010330318473279476
with O 0 3.482383817754453e-06
germline O 1 0.9999995231628418
PTEN O 1 0.9999697208404541
mutation O 0 1.999895175686106e-06
. O 0 4.708644496531633e-07

The O 0 0.0003268187865614891
tumour B-Disease 1 1.0
suppressor O 1 0.9990231990814209
gene O 0 1.2054995750077069e-05
PTEN O 0 7.48856327845715e-05
, O 0 2.569666923690761e-09
which O 0 1.2176716301937063e-09
maps O 0 4.055351965348564e-08
to O 0 3.197704856461314e-08
10q23 O 0 3.813080184045248e-05
. O 0 1.3340212490220438e-06

3 O 0 7.953192380227847e-07
and O 0 6.049292178289534e-09
encodes O 0 2.1488366641619905e-08
a O 0 4.807275910678754e-09
403 O 0 2.0531816247171264e-08
amino O 0 1.914418135129381e-08
acid O 0 3.655224745102714e-08
dual O 0 6.28280076853116e-07
specificity O 0 9.687820465842378e-07
phosphatase O 0 0.01027334202080965
( O 0 7.152555099310121e-07
protein O 0 1.0744741985035944e-06
tyrosine O 0 8.457591889055038e-07
phosphatase O 0 2.843178663169965e-06
; O 0 1.8414143543310502e-09
PTPase O 0 1.939241656145896e-06
) O 0 2.9545168533928745e-09
, O 0 2.5002627745962513e-10
was O 0 3.796564485014642e-08
shown O 0 9.352936203299578e-09
recently O 0 1.3812226917764292e-08
to O 0 1.1596388294066173e-09
play O 0 2.8917853001075855e-08
a O 0 1.692971274280808e-08
broad O 0 9.067181672151037e-09
role O 0 3.29006155652678e-08
in O 0 3.108972634890961e-08
human O 0 1.0051305565639268e-07
malignancy B-Disease 0 0.0001445142988814041
. O 0 1.5410923026593082e-07

Somatic O 0 0.002889391500502825
PTEN O 0 0.0018048640340566635
deletions O 0 4.036261316286982e-07
and O 0 1.972292551499777e-09
mutations O 0 8.956449470964856e-10
were O 0 7.853681038838545e-10
observed O 0 2.899007478518456e-09
in O 0 2.7509095001931883e-09
sporadic B-Disease 0 5.4237254516920075e-05
breast I-Disease 0 0.3116815686225891
, I-Disease 0 2.098331833622069e-06
brain I-Disease 1 1.0
, I-Disease 0 1.588118948347983e-06
prostate I-Disease 1 0.9999731779098511
and I-Disease 1 0.5145360827445984
kidney I-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 1 0.9999995231628418
lines O 0 1.0712710718507878e-07
and O 0 1.1644840647306864e-09
in O 0 3.3811280442108682e-09
several O 0 9.918657006835474e-09
primary O 0 0.023346222937107086
tumours B-Disease 1 1.0
such O 0 2.931525955318648e-08
as O 0 5.667665755026974e-05
endometrial B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 1 0.9999938011169434
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 1.0
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 0.0026089397724717855

In O 0 8.693686481819896e-07
addition O 0 3.4967129636243044e-07
, O 0 1.1317596460003188e-07
PTEN O 0 0.000134372734464705
was O 0 2.458659480453207e-07
identified O 0 1.5358741833892964e-08
as O 0 1.2702080498527835e-09
the O 0 3.2914782011062016e-09
susceptibility O 0 4.539951348192517e-08
gene O 0 9.007588008813627e-10
for O 0 6.727187695787507e-10
two O 0 1.0701743491381421e-07
hamartoma B-Disease 1 1.0
syndromes I-Disease 1 0.9999992847442627
Cowden B-Disease 1 1.0
disease I-Disease 1 0.9999847412109375
( O 0 7.176859639912436e-07
CD B-Disease 0 6.304165435722098e-05
; O 0 4.7525677615567474e-08
MIM O 0 0.0016920343041419983
158350 O 0 1.3123641110723838e-05
) O 0 1.4994432362414045e-08
and O 0 9.29804500060527e-09
Bannayan B-Disease 0 0.0010606646537780762
- I-Disease 0 0.0006891778903082013
Zonana I-Disease 1 0.9968234300613403
( I-Disease 0 4.313222689233953e-06
BZS I-Disease 0 0.007185863796621561
) I-Disease 0 9.421046343049966e-08
or I-Disease 0 1.123912269918037e-07
Ruvalcaba I-Disease 0 2.2685288058710285e-05
- I-Disease 0 2.032769089055364e-06
Riley I-Disease 0 1.9457665985100903e-05
- I-Disease 0 0.001869489555247128
Smith I-Disease 1 0.8611136078834534
syndrome I-Disease 1 1.0
( O 0 3.662396193249151e-05
MIM O 1 0.9999269247055054
153480 O 0 0.003983073867857456
) O 0 5.358673433875083e-07
. O 0 2.789639097500185e-07

Constitutive O 0 6.847320037195459e-05
DNA O 0 8.228552133004996e-07
from O 0 3.006900683999447e-08
37 O 0 9.291649405440694e-08
CD B-Disease 0 6.216921519808238e-07
families O 0 1.1517650166936733e-09
and O 0 9.83789938402424e-10
seven O 0 4.321175239851982e-08
BZS B-Disease 0 0.004124595317989588
families O 0 7.842862359552782e-09
was O 0 7.23088007248407e-08
screened O 0 7.363658482972824e-08
for O 0 8.195411282940768e-08
germline O 0 0.0014486601576209068
PTEN O 0 0.004889090545475483
mutations O 0 1.0308116316082305e-06
. O 0 2.6895045834862685e-07

PTEN O 0 0.028228767216205597
mutations O 0 7.416642802127171e-07
were O 0 1.3789858144264144e-07
identified O 0 1.1186852333366915e-07
in O 0 1.5729684221810203e-08
30 O 0 3.0718613430735786e-08
of O 0 5.987320150779851e-08
37 O 0 3.9152130426600706e-08
( O 0 2.6538322650537793e-09
81 O 0 1.555535611430514e-08
% O 0 7.619936348568501e-10
) O 0 2.845179924992891e-10
CD B-Disease 0 1.638079005772397e-08
families O 0 1.573626923212501e-10
, O 0 1.1038531894103087e-10
including O 0 2.8276783692327e-10
missense O 0 2.3351203992660885e-07
and O 0 1.4312045770736859e-08
nonsense O 0 1.9551263903849758e-05
point O 0 8.523388714820612e-07
mutations O 0 4.90372720207688e-09
, O 0 5.30805954745972e-10
deletions O 0 1.026206586374201e-08
, O 0 1.6763644916650833e-09
insertions O 0 8.126982464773391e-08
, O 0 5.48255751908755e-09
a O 0 9.706448622637254e-08
deletion O 0 3.314397417852888e-06
/ O 0 1.4255032510845922e-05
insertion O 0 1.4934485079720616e-06
and O 0 4.075614583598508e-07
splice O 0 0.0001895888417493552
site O 0 5.0188018576591276e-06
mutations O 0 5.003266210223956e-07
. O 0 2.811757440213114e-07

These O 0 5.934260371986966e-08
mutations O 0 1.5190233071393777e-08
were O 0 1.6173745009950835e-08
scattered O 0 3.754624344765034e-08
over O 0 4.9512829392028834e-09
the O 0 1.4401506653882734e-08
entire O 0 1.637208413285407e-07
length O 0 1.1247357178945094e-07
of O 0 1.9400319217766082e-07
PTEN O 0 5.643744316330412e-06
, O 0 6.411099984227064e-10
with O 0 1.4091944278149526e-10
the O 0 5.437163608235096e-09
exception O 0 2.3073095434256174e-08
of O 0 2.4522613273347815e-08
the O 0 1.1640159947035045e-08
first O 0 1.6463859608961684e-08
, O 0 2.675315080580276e-09
fourth O 0 2.2869760130106442e-07
and O 0 1.4510888490804064e-08
last O 0 2.978259772135061e-07
exons O 0 2.44236662183539e-06
. O 0 7.021246233307465e-07

A O 0 3.7587236874969676e-05
hot O 0 3.929258582502371e-06
spot O 0 1.195198024106503e-06
for O 0 4.1802856287631585e-08
PTEN O 0 2.1018066036049277e-05
mutation O 0 7.316140138158289e-09
in O 0 3.741911225318972e-09
CD B-Disease 0 4.718687023341772e-07
was O 0 1.726912870481101e-07
identified O 0 3.21352224830207e-08
in O 0 1.1785664000285578e-08
exon O 0 7.214362085505854e-08
5 O 0 6.817610476161917e-09
that O 0 1.416699951795053e-10
contains O 0 2.365951878857686e-09
the O 0 2.2702863589074695e-08
PTPase O 0 0.0001273469824809581
core O 0 1.427366805728525e-05
motif O 0 3.0180424914760806e-07
, O 0 3.7175298950309354e-10
with O 0 5.4452012343553235e-11
13 O 0 8.926846817303158e-09
of O 0 1.0605969436028317e-08
30 O 0 9.858566407672242e-09
( O 0 1.3798318043711788e-09
43 O 0 3.267527359795963e-09
% O 0 5.16950593443255e-10
) O 0 2.504066398678617e-10
CD B-Disease 0 1.681319083957078e-08
mutations O 0 4.458161062537158e-10
identified O 0 3.211755972287733e-09
in O 0 4.096599948155699e-09
this O 0 2.870858040182611e-08
exon O 0 2.705064162000781e-06
. O 0 3.6844099327026925e-07

Seven O 0 4.367037945485208e-06
of O 0 9.138140626419045e-07
30 O 0 1.8525584266626538e-07
( O 0 1.0995844235139884e-08
23 O 0 4.263588238018201e-08
% O 0 3.213894705922371e-09
) O 0 2.623333217321999e-10
were O 0 4.512726026195679e-10
within O 0 5.202813735394329e-09
the O 0 1.371002156247414e-08
core O 0 1.4618055956816534e-06
motif O 0 9.846561255244524e-08
, O 0 3.92568533236215e-10
the O 0 2.5524771185558848e-09
majority O 0 4.140430776011783e-10
( O 0 7.726628781234979e-10
five O 0 7.869065399290776e-10
of O 0 2.859260384013851e-09
seven O 0 7.60337570682168e-09
) O 0 4.585426205405696e-10
of O 0 6.902222127180835e-10
which O 0 2.4937760190191227e-10
were O 0 4.945836629133282e-09
missense O 0 2.882694047912082e-07
mutations O 0 1.8321967276690998e-09
, O 0 1.0894691815366286e-09
possibly O 0 7.366088539129123e-08
pointing O 0 9.831470606513903e-07
to O 0 4.876845594026236e-09
the O 0 4.114738416660657e-08
functional O 0 1.304304873883666e-06
significance O 0 3.3655408060440095e-07
of O 0 3.4930522474496684e-08
this O 0 6.393665596959863e-09
region O 0 1.2801912419035943e-07
. O 0 2.1448488496389473e-07

Germline O 1 0.9999053478240967
PTEN O 0 0.008407383225858212
mutations O 0 9.250130261762024e-08
were O 0 3.5133048470470385e-08
identified O 0 2.4426169531466257e-08
in O 0 5.915125278477262e-09
four O 0 9.948858625818957e-09
of O 0 4.560903121841875e-08
seven O 0 7.820250402801321e-08
( O 0 4.347878856947318e-08
57 O 0 1.397075664044678e-07
% O 0 3.3764443685413426e-08
) O 0 3.315486551969116e-08
BZS B-Disease 0 0.006964643485844135
families O 0 4.574912892962857e-08
studied O 0 3.642909632617375e-06
. O 0 8.517246214978513e-07

Interestingly O 0 1.1036563591915183e-05
, O 0 8.776186888326265e-09
none O 0 1.1724655024636377e-08
of O 0 5.877887954142125e-09
these O 0 9.636471620666498e-10
mutations O 0 2.690230926916115e-09
was O 0 8.743077017925316e-08
observed O 0 3.269206061418117e-08
in O 0 3.491247468900838e-08
the O 0 9.540281098452397e-07
PTPase O 1 0.8737568855285645
core O 0 0.0004030342970509082
motif O 0 1.8401271518087015e-05
. O 0 3.883189663156372e-07

It O 0 1.1672258182215955e-07
is O 0 7.2831292108332946e-09
also O 0 1.0754239720967007e-09
worthy O 0 3.681392257703919e-08
of O 0 1.8428769621436913e-08
note O 0 8.60089741649972e-08
that O 0 5.733822305842295e-10
a O 0 1.0688072649145397e-08
single O 0 1.9795821870616237e-08
nonsense O 0 9.073635851564177e-07
point O 0 1.6762349730470305e-07
mutation O 0 9.942934253714952e-10
, O 0 3.9581504740482387e-10
R233X O 0 7.836854365450563e-08
, O 0 6.981332734135037e-10
was O 0 2.6281638199066037e-08
observed O 0 8.155472741577796e-09
in O 0 1.9412629281845284e-09
the O 0 1.8935297774191895e-08
germline O 0 6.928898983460385e-07
DNA O 0 1.9950322283079913e-08
from O 0 1.0041754094913813e-09
two O 0 4.0125305855731597e-10
unrelated O 0 4.621006866045718e-08
CD B-Disease 0 9.147086643679359e-07
families O 0 7.092439524569727e-09
and O 0 7.65852359307928e-09
one O 0 7.702194579906063e-07
BZS B-Disease 1 0.9417452216148376
family O 0 1.834056638472248e-05
. O 0 1.8743041891866596e-06

Genotype O 0 4.540635200100951e-05
- O 0 1.8843155658032629e-06
phenotype O 0 1.9096195558176987e-07
studies O 0 2.788172892564944e-08
were O 0 2.951396460559863e-09
not O 0 3.56001422785468e-10
performed O 0 5.78258907424356e-09
on O 0 7.685126313106139e-09
this O 0 1.7083848780075073e-09
small O 0 1.3310073931904753e-08
group O 0 1.463295706827239e-08
of O 0 5.049143396718137e-07
BZS B-Disease 1 0.9997714161872864
families O 0 3.4116226288460894e-07
. O 0 5.158046860742616e-07

However O 0 1.8614024099861126e-07
, O 0 1.1095155905138654e-08
genotype O 0 1.7005353925014788e-07
- O 0 5.964876237385397e-08
phenotype O 0 2.1553962170628438e-08
analysis O 0 9.09104524993154e-09
inthe O 0 7.112314506230177e-07
group O 0 1.284818740288074e-08
of O 0 5.1618656016216846e-08
CD B-Disease 0 5.1217430154792964e-06
families O 0 3.8288434645039615e-09
revealed O 0 3.3076918981578274e-08
two O 0 8.37301394884804e-10
possible O 0 2.45944553611821e-09
associations O 0 3.095421252652386e-09
worthy O 0 8.205014978557301e-08
of O 0 6.604606994642381e-08
follow O 0 4.491700167363888e-08
- O 0 9.010568646772299e-08
up O 0 1.661075010872537e-08
in O 0 6.5713807728684515e-09
independent O 0 7.314008598768851e-08
analyses O 0 1.0976576731991372e-06
. O 0 1.7510760130790004e-07

The O 0 1.6469062984469929e-06
first O 0 2.3665427306696074e-07
was O 0 5.31415309978911e-07
an O 0 3.0463574773875735e-08
association O 0 3.1411953926863134e-08
noted O 0 1.8436782767139448e-08
in O 0 5.8894693566458045e-09
the O 0 3.064826614718186e-08
group O 0 1.4505188161706428e-08
of O 0 3.8504794019900146e-08
CD B-Disease 0 3.197077239747159e-05
families O 0 8.110286664475552e-09
with O 0 1.826635731561055e-08
breast B-Disease 1 0.9947170615196228
disease I-Disease 1 0.7941247224807739
. O 0 2.3628697363164974e-06

A O 0 1.4809033928031567e-05
correlation O 0 1.482782295170182e-06
was O 0 8.222216507647317e-08
observed O 0 6.299537336218464e-09
between O 0 1.4144704296725763e-09
the O 0 3.3904532514839048e-09
presence O 0 2.257332631927511e-08
/ O 0 3.8613353581240517e-07
absence O 0 6.785919737239965e-08
of O 0 1.0139321204860607e-07
a O 0 2.920109238857549e-07
PTEN O 0 7.208700026239967e-06
mutation O 0 3.550845728561569e-10
and O 0 3.522035094127851e-11
the O 0 3.9683328845185883e-10
type O 0 8.268638218567048e-09
of O 0 5.171641248580272e-08
breast O 0 6.35390597381047e-06
involvement O 0 3.8886399124749005e-05
( O 0 3.6751066545548383e-07
unaffected O 0 6.464264060923597e-06
versus O 0 1.5039141544548329e-05
benign O 0 0.0003125666407868266
versus O 0 1.3816035789204761e-05
malignant O 0 0.0016717606922611594
) O 0 5.326258900595349e-08
. O 0 8.659728933935185e-08

Specifically O 0 1.0083505230795708e-06
and O 0 8.246541227663329e-09
more O 0 7.230446241734967e-10
directly O 0 1.3160552647661916e-08
, O 0 2.983283176050122e-09
an O 0 1.6942957259402647e-08
association O 0 7.127211887336671e-08
was O 0 7.844860760997108e-07
also O 0 6.159409871031585e-09
observed O 0 8.90039242307239e-09
between O 0 4.03854594210884e-09
the O 0 5.7834714795035325e-09
presence O 0 9.79652181598567e-09
of O 0 8.217858038506165e-08
a O 0 6.595768695660809e-07
PTEN O 0 0.003384126117452979
mutation O 0 7.7246468777048e-08
and O 0 8.748214241904861e-08
malignant B-Disease 1 1.0
breast I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 1.9798010271188105e-06

Secondly O 0 0.0002334804303245619
, O 0 6.628180670986694e-08
there O 0 1.7684987696497956e-08
appeared O 0 5.809898695474658e-08
to O 0 2.2067192517738476e-09
be O 0 3.8725511686266145e-09
an O 0 1.8378361943405253e-08
interdependent O 0 4.809066467714729e-06
association O 0 2.8275842112179816e-08
between O 0 7.039074034764781e-08
mutations O 0 3.259990322135309e-08
upstream O 0 7.07067499661207e-07
and O 0 1.9749915036726406e-09
within O 0 3.932666814421282e-08
the O 0 9.932726641181944e-08
PTPase O 0 0.005630833562463522
core O 0 2.968771877931431e-05
motif O 0 6.122517106632586e-07
, O 0 1.3347311034195286e-09
the O 0 2.8140514363172997e-09
core O 0 6.820917519689829e-08
motif O 0 3.100658219068464e-08
containing O 0 8.613431634607593e-10
the O 0 6.993700618629362e-10
majority O 0 1.1927853149629186e-10
of O 0 2.9762470266092578e-09
missense O 0 1.1721193970970489e-07
mutations O 0 1.3967066392339689e-09
, O 0 5.960253401937621e-10
and O 0 4.4685044553460784e-10
the O 0 7.693251369289555e-09
involvement O 0 3.213851016425906e-07
of O 0 1.0278583317813172e-07
all O 0 1.136667826528992e-08
major O 0 2.978515567519935e-07
organ O 0 0.36000025272369385
systems O 0 0.015561307780444622
( O 0 6.242644758458482e-06
central O 0 0.39830976724624634
nervous O 1 0.8635863065719604
system O 0 8.953142241807655e-05
, O 0 6.551984483849083e-07
thyroid O 1 1.0
, O 0 7.23769553587772e-05
breast O 1 1.0
, O 0 0.0012508644722402096
skin O 1 1.0
and O 1 0.9995349645614624
gastrointestinal O 1 1.0
tract O 1 1.0
) O 0 0.0011191004887223244
. O 0 1.544707265566103e-05

However O 0 3.3231569318559195e-07
, O 0 4.198558389845175e-09
these O 0 6.601754698465356e-10
observations O 0 8.623550229458488e-08
would O 0 1.730587784187776e-09
need O 0 5.0149147057254595e-09
to O 0 1.7757312287258742e-09
be O 0 2.368602425306676e-09
confirmed O 0 3.3537028709673677e-09
by O 0 8.070746848609645e-10
studying O 0 4.2875477390680317e-08
a O 0 3.3314462299927072e-09
larger O 0 4.810162268498175e-10
number O 0 4.940997611058151e-10
of O 0 6.1161413711374735e-09
CD B-Disease 0 1.5784885363245849e-06
families O 0 1.9391768191212577e-08
. O 0 7.598290352461845e-08

Molecular O 1 0.9999001026153564
defects O 1 0.9961126446723938
leading O 0 4.884165036855848e-07
to O 0 3.490499889124976e-09
human O 0 1.5349517212825958e-08
complement B-Disease 0 2.805146550599602e-06
component I-Disease 1 1.0
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.2038515251333592e-07
an O 0 1.420977202570839e-08
African O 0 6.049686618325723e-08
- O 0 2.226052941978196e-07
American O 0 5.579549906542525e-07
family O 0 3.201672313934978e-07
. O 0 1.1339355410200369e-07

Complement B-Disease 0 0.0006150185945443809
component I-Disease 1 0.9999988079071045
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 1.0103149179485627e-05
C6D B-Disease 0 0.015924988314509392
) O 0 2.5672042269775375e-08
was O 0 3.6197411645844113e-07
diagnosed O 0 3.576447511477454e-07
in O 0 5.219495236019611e-08
a O 0 1.2306219332458568e-07
16 O 0 9.215420249120143e-08
- O 0 1.0201664402131883e-08
year O 0 1.1458254789431521e-08
- O 0 2.2030700819186677e-08
old O 0 3.9973608068066824e-07
African O 0 1.5376863302662969e-06
- O 0 8.97610505035118e-07
American O 0 1.094141168778151e-07
male O 0 2.2509052399755092e-08
with O 0 2.7815001413245e-09
meningococcal B-Disease 1 0.9999998807907104
meningitis I-Disease 1 1.0
. O 0 1.5646371593902586e-06

The O 0 5.917119324294617e-06
patients O 0 2.364023146128602e-07
father O 0 1.0827764072018908e-06
and O 0 4.435697320559484e-08
two O 0 7.239975019501799e-08
brothers O 0 3.145784285152331e-05
also O 0 1.242819394065009e-07
had O 0 7.848998961890175e-07
C6D B-Disease 1 0.7363701462745667
, O 0 2.9590298211701338e-08
but O 0 3.7025300603232836e-09
gave O 0 6.498913762698066e-08
no O 0 1.1894195850459255e-08
history O 0 1.4081444987823488e-07
of O 0 7.511929425163544e-07
meningitis B-Disease 1 0.9999992847442627
or O 0 2.649757789185969e-06
other O 0 1.1277409583954068e-07
neisserial B-Disease 1 0.9997991919517517
infection I-Disease 0 0.14477014541625977
. O 0 7.365132432823884e-07

By O 0 1.836713607872298e-07
using O 0 5.7061168234895376e-08
exon O 0 1.2153235218193004e-07
- O 0 1.1884943695861239e-08
specific O 0 8.367267434472581e-10
polymerase O 0 4.601077918664487e-08
chain O 0 8.577630161710204e-09
reaction O 0 6.41561415104519e-10
( O 0 7.157435755189567e-10
PCR O 0 2.6136155462097577e-09
) O 0 5.365141664270823e-10
/ O 0 2.3409536531460162e-09
single O 0 1.754889233929191e-09
- O 0 7.187206829684101e-09
strand O 0 1.7158114928861323e-08
conformation O 0 8.265532258633357e-09
polymorphism O 0 2.5780175771927816e-09
as O 0 4.470172842996334e-11
a O 0 1.2049179709539004e-10
screening O 0 5.4607082744517754e-11
step O 0 2.8852042976978964e-10
and O 0 7.349378050580668e-11
nucleotide O 0 1.1473760608282646e-08
sequencing O 0 3.6840244188596216e-09
of O 0 2.4519979380244195e-09
target O 0 7.1608798890565595e-09
exons O 0 4.091313510201644e-09
, O 0 1.3864237535798907e-10
we O 0 3.0915783821861e-10
determined O 0 2.9989950522946174e-09
that O 0 7.010849678579234e-10
the O 0 1.204730892823136e-08
proband O 0 5.521216280612862e-06
was O 0 8.188956144294934e-07
a O 0 1.0083603996235979e-07
compound O 0 6.063399382583157e-07
heterozygote O 0 1.7882692304738157e-07
for O 0 2.1359678470389554e-09
two O 0 3.160981165706289e-08
C6 O 0 0.00031949038384482265
gene O 0 1.2789880088348582e-07
mutations O 0 4.0837061732190705e-08
. O 0 1.1484733875022357e-07

The O 0 1.7122372355515836e-06
first O 0 1.8689445369091118e-07
, O 0 1.1211112926901023e-08
1195delC O 0 4.7180481033137767e-07
located O 0 4.750782167661782e-08
in O 0 1.1826647217105801e-08
exon O 0 1.5927906815704773e-07
7 O 0 5.8163184490922504e-08
, O 0 8.424725361777519e-10
is O 0 1.0062921607101316e-09
a O 0 1.2969614271440832e-09
novel O 0 4.817160892400807e-09
mutation O 0 2.4674035037364206e-10
, O 0 9.796287392394021e-11
while O 0 3.126249537022119e-10
the O 0 5.880668840774206e-09
second O 0 3.4057965336842244e-08
, O 0 2.539627619313478e-09
1936delG O 0 1.0324600197009204e-07
in O 0 9.861989447301767e-09
exon O 0 7.415073355332424e-08
12 O 0 1.5818319099025757e-08
, O 0 1.4715123564101873e-09
has O 0 1.932222715161913e-10
been O 0 1.052326670247794e-09
described O 0 2.1252759552226053e-09
before O 0 1.1621503759329244e-08
to O 0 2.223493567043988e-08
cause O 0 1.9965757473983103e-06
C6D B-Disease 1 0.5137622356414795
in O 0 3.750794874690655e-08
an O 0 1.8797978285078898e-08
unrelated O 0 2.569646824213123e-07
African O 0 3.2045315379036765e-07
- O 0 2.724146952459705e-07
American O 0 2.5091279098887753e-07
individual O 0 2.5679094406427794e-08
. O 0 5.331188646096052e-08

Both O 0 7.90082026469463e-08
mutations O 0 2.1870432576065468e-08
result O 0 1.1755938444935055e-08
in O 0 1.9555010055682942e-08
premature O 0 5.790068939859339e-07
termination O 0 1.4610501466449932e-06
codons O 0 1.7717114815241075e-06
and O 0 3.050291468298383e-07
C6 O 0 0.0007249038317240775
null O 0 1.7307067537331022e-05
alleles O 0 4.197851808385167e-07
. O 0 4.5947243165755935e-07

Allele O 0 7.91258173649112e-07
- O 0 1.0780023274037376e-07
specific O 0 9.093819919314683e-09
PCR O 0 9.403615308656299e-08
indicated O 0 1.7196251533846407e-08
that O 0 6.100153715493661e-10
the O 0 1.3099247908598954e-08
probands O 0 6.2624653764942195e-06
two O 0 3.976004236960762e-08
brothers O 0 1.1829026789200725e-06
also O 0 8.972697251863337e-09
inherited O 0 2.8539341201394564e-07
the O 0 1.1236871699793483e-07
1195delC O 0 4.1657446558929223e-07
mutation O 0 6.918579043002637e-10
from O 0 3.003343962415528e-10
their O 0 3.956822369755031e-10
heterozygous O 0 1.7649034234068495e-08
mother O 0 8.726612321652283e-09
and O 0 4.5361209233263367e-10
the O 0 7.0970402887837736e-09
1936delG O 0 2.2559689227819035e-07
mutation O 0 1.216552747429489e-09
from O 0 8.658498917846202e-10
their O 0 1.4303578321772648e-09
homozygous O 0 8.915888471960898e-09
father O 0 3.8205226360332745e-07
. O 0 4.6809656595314664e-08
. O 0 2.695307443900674e-07

PAX6 O 0 0.03283869847655296
mutations O 0 1.0346722774556838e-05
reviewed O 0 2.92928143608151e-05
. O 0 2.7824623884953326e-06

Mutations O 0 4.258275112078991e-06
in O 0 9.259608901857064e-08
PAX6 O 0 0.00010113650205312297
are O 0 8.215738311889709e-09
responsible O 0 8.204403911804548e-08
for O 0 3.1689737056694867e-08
human O 0 1.0305933756171726e-05
aniridia B-Disease 1 1.0
and O 0 2.663794305135525e-07
have O 0 1.9692851793706723e-09
also O 0 4.81662543183603e-10
been O 0 3.9944178520379126e-10
found O 0 3.552207417101272e-10
in O 0 6.996609402953879e-10
patients O 0 4.5783213331596073e-10
with O 0 1.3560629286146764e-09
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 3.7676486499549355e-06
with O 0 0.0012384086148813367
congenital B-Disease 1 1.0
cataracts I-Disease 1 1.0
, O 0 0.0005955773522146046
with O 0 4.302409797674045e-05
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
keratitis I-Disease 1 1.0
, O 0 7.653429747733753e-07
and O 0 2.256984572568399e-07
with O 0 4.0694500057725236e-05
isolated B-Disease 1 1.0
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 0 0.10040847212076187

No O 0 9.878577657218557e-06
locus O 0 1.672818825682043e-06
other O 0 1.5844611178650325e-09
than O 0 2.8127635776087345e-09
chromosome O 0 5.7519017104823433e-08
11p13 O 0 2.3590617104218836e-07
has O 0 3.3542721933343955e-09
been O 0 1.4553851457321798e-08
implicated O 0 1.842916077521295e-07
in O 0 1.3953925304122095e-07
aniridia B-Disease 1 1.0
, O 0 1.6005580505407124e-07
and O 0 4.672758890933437e-08
PAX6 O 0 0.024899421259760857
is O 0 2.7484825082524367e-08
clearly O 0 7.454534767248333e-09
the O 0 6.7947114601452085e-09
major O 0 2.8768821991320692e-08
, O 0 2.0689878699187148e-09
if O 0 1.7376859950957169e-09
not O 0 6.830102039501185e-10
only O 0 1.7257556494953974e-09
, O 0 2.5155710847712953e-09
gene O 0 1.276404226757677e-08
responsible O 0 1.7066065538529074e-07
. O 0 8.247958476204076e-07

Twenty O 0 1.3109218343743123e-05
- O 0 5.007653385291633e-07
eight O 0 3.9157136200174136e-08
percent O 0 5.4384390324457854e-09
of O 0 2.9881579433066463e-09
identified O 0 2.2580389114068566e-08
PAX6 O 0 5.982222319289576e-06
mutations O 0 5.816515269430056e-09
are O 0 8.151083696894545e-10
C O 0 2.5590509267203743e-06
- O 0 3.0821254313195823e-06
T O 0 4.4898459350406483e-07
changes O 0 9.160301850386077e-09
at O 0 4.603360252986022e-07
CpG O 0 5.8011892178910784e-06
dinucleotides O 0 6.381496859830804e-07
, O 0 5.660723001454926e-10
20 O 0 1.011563055541842e-09
% O 0 3.623588373802278e-10
are O 0 1.5205487910452398e-11
splicing O 0 2.2464818894007976e-09
errors O 0 2.599522375135166e-08
, O 0 5.87474624502704e-10
and O 0 3.0479760382284837e-10
more O 0 4.097275643766274e-11
than O 0 4.3873255722859383e-11
30 O 0 2.4345969684702595e-09
% O 0 5.751423781674703e-10
are O 0 9.721980165355859e-11
deletion O 0 1.4395574510217557e-08
or O 0 1.1988260162354436e-08
insertion O 0 3.1965802804734267e-07
events O 0 6.525252160827222e-07
. O 0 8.733140930416994e-07

There O 0 1.9080316633335315e-06
is O 0 2.9500021980766178e-08
a O 0 5.871896036069302e-08
noticeably O 0 4.2727143068077567e-07
elevated O 0 1.5074041925799975e-07
level O 0 1.1920182174662841e-07
of O 0 2.158852296929581e-08
mutation O 0 1.259566229094844e-09
in O 0 1.6627352827924824e-09
the O 0 1.0700066610525027e-08
paired O 0 7.278521962916784e-08
domain O 0 2.5376300527568674e-07
compared O 0 2.993697290065711e-09
with O 0 1.0110417364428415e-10
the O 0 2.60134624952002e-09
rest O 0 2.588918768253734e-08
of O 0 5.590160867541272e-08
the O 0 1.1203016470062721e-07
gene O 0 1.0809362294139646e-07
. O 0 8.786609129174394e-08

Increased O 0 1.227288635163859e-07
mutation O 0 3.012099902832688e-09
in O 0 9.12091402405224e-10
the O 0 2.639334750753619e-09
homeodomain O 0 1.1061348459406872e-06
is O 0 2.9182580796316415e-09
accounted O 0 1.7005021391014452e-08
for O 0 2.934577580937514e-10
by O 0 1.973906815777582e-09
the O 0 6.805141339327747e-08
hypermutable O 0 4.9035159463528544e-05
CpG O 0 1.7295782527071424e-05
dinucleotide O 0 3.455781097727595e-06
in O 0 6.21277891355021e-08
codon O 0 8.114093930089439e-07
240 O 0 4.596788585331524e-07
. O 0 7.254572409465254e-08

Very O 0 5.376527383305074e-07
nearly O 0 3.310986684823547e-08
all O 0 2.481043370750058e-09
mutations O 0 2.8382978189966934e-09
appear O 0 8.775969284613439e-09
to O 0 6.339627933726888e-09
cause O 0 4.5350958544077e-07
loss O 0 1.8189820139014046e-06
of O 0 8.581894803683099e-07
function O 0 9.15364864795265e-07
of O 0 4.494597050097582e-08
the O 0 1.368916890953642e-08
mutant O 0 1.6635576471912827e-08
allele O 0 2.857874215056455e-10
, O 0 3.0113155025102145e-11
and O 0 1.1662966599434998e-11
more O 0 4.837003627494729e-12
than O 0 6.866617083961524e-12
80 O 0 2.3705309937227526e-10
% O 0 1.252777881433076e-10
of O 0 8.489262626198979e-10
exonic O 0 1.3074826199499512e-07
substitutions O 0 1.0777386982852022e-08
result O 0 6.4537752919591185e-09
in O 0 1.4919773860810892e-08
nonsense O 0 2.7926867005589884e-06
codons O 0 9.749335276865168e-07
. O 0 1.853007347563107e-07

In O 0 1.336881837232795e-06
a O 0 1.3543349552946893e-07
gene O 0 1.8713901539513245e-09
with O 0 1.5810279474504085e-10
such O 0 5.501598621115988e-10
extraordinarily O 0 1.3431471757030522e-07
high O 0 2.6779149564504223e-08
sequence O 0 2.1915614212275614e-08
conservation O 0 6.370221239393459e-09
throughout O 0 5.062445462833409e-10
evolution O 0 2.4510113938447375e-09
, O 0 3.345324017800522e-11
there O 0 9.335941048016494e-11
are O 0 2.0053346483361878e-10
presumed O 0 3.822399321506964e-07
undiscovered O 0 0.00018622877541929483
missense O 0 1.7731314301272505e-06
mutations O 0 2.2014055023333867e-09
, O 0 1.7218847181421637e-10
these O 0 9.87014636688599e-11
are O 0 1.359952706003753e-10
hypothesized O 0 1.1400920207904619e-08
to O 0 1.4667012049329742e-09
exist O 0 9.605138018287107e-08
in O 0 1.9678331852901465e-08
as O 0 7.65329914997892e-08
- O 0 2.760046129424154e-07
yet O 0 3.704976236917901e-08
unidentified O 0 3.5608304642664734e-06
phenotypes O 0 7.522741185539417e-08
. O 0 4.315094948026399e-09
. O 0 6.126207807710671e-08

Genetic O 0 8.380646249861456e-06
heterogeneity O 0 6.907218903506873e-07
and O 0 9.514875110028242e-09
penetrance O 0 1.6326832792401547e-06
analysis O 0 1.4236738010708905e-08
of O 0 4.207287851443198e-09
the O 0 2.4888935357125774e-08
BRCA1 O 0 1.0108021797350375e-07
and O 0 5.999835295256162e-09
BRCA2 O 0 2.1226240676242014e-07
genes O 0 1.9993329658518633e-08
in O 0 4.850205925777118e-08
breast B-Disease 1 0.9655382633209229
cancer I-Disease 1 0.965146005153656
families O 0 1.1682174090310582e-06
. O 0 1.4024060419615125e-06

The O 0 0.002690301276743412
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 1 0.9999051094055176
Consortium O 0 2.8377628041198477e-05
. O 0 1.5836710076655436e-07

The O 0 1.358479551072378e-07
contribution O 0 2.3454248321286286e-07
of O 0 1.3730124237554264e-07
BRCA1 O 0 1.5205864656309132e-07
and O 0 8.177591936942008e-09
BRCA2 O 0 9.035451853378618e-07
to O 0 1.3175565527490107e-07
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 0.000520243716891855
assessed O 0 1.4215754617907805e-07
by O 0 1.085536438516499e-09
linkage O 0 1.6757484289087188e-08
and O 0 6.282624420705929e-11
mutation O 0 9.784560661696418e-11
analysis O 0 4.273540965549216e-10
in O 0 4.848517698441412e-10
237 O 0 5.036780770240057e-09
families O 0 7.726422279752398e-10
, O 0 1.4753562260771957e-10
each O 0 3.515151503208358e-10
with O 0 2.186790748481826e-10
at O 0 1.3521513153591513e-07
least O 0 1.3251122421564787e-09
four O 0 3.6174768736074725e-10
cases O 0 1.3180208313645636e-10
of O 0 6.019504894538841e-09
breast B-Disease 0 3.202545121894218e-05
cancer I-Disease 0 2.955691797978943e-07
, O 0 5.29794430548236e-10
collected O 0 5.48412604217674e-09
by O 0 3.433416884135454e-09
the O 0 1.504870397184277e-06
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 0.000185022407094948
Consortium O 0 4.4547061861521797e-07
. O 0 2.485923644712784e-08

Families O 0 1.7217656989032548e-07
were O 0 1.8925403466596435e-08
included O 0 7.040226179810816e-09
without O 0 1.1830549873081964e-08
regard O 0 2.0278452694810767e-08
to O 0 1.7996741874526379e-09
the O 0 8.576501286938765e-09
occurrence O 0 2.3497843812947394e-06
of O 0 1.4164983440423384e-05
ovarian B-Disease 1 1.0
or I-Disease 0 0.00011994097440037876
other I-Disease 0 3.9990342770579446e-07
cancers I-Disease 0 0.4571768641471863
. O 0 2.0906736608594656e-06

Overall O 0 0.00010356957500334829
, O 0 4.703416038864816e-07
disease O 0 2.878517989302054e-06
was O 0 1.4348146351039759e-06
linked O 0 3.4317276913498063e-06
to O 0 1.5550964960198144e-08
BRCA1 O 0 2.6978680622846696e-08
in O 0 1.265719418164224e-09
an O 0 4.903070172090906e-10
estimated O 0 7.039994698310181e-10
52 O 0 2.788964170719055e-09
% O 0 6.065787871989414e-10
of O 0 2.0322505900338683e-09
families O 0 7.118375333625693e-10
, O 0 5.718728268711004e-10
to O 0 1.5503216488355065e-09
BRCA2 O 0 9.065764139393195e-09
in O 0 1.6646297673617028e-09
32 O 0 3.6235003886275763e-09
% O 0 3.573102647091986e-10
of O 0 3.6616545906476006e-10
families O 0 2.94057278527049e-10
, O 0 1.1436081248650254e-10
and O 0 1.1147709144676554e-10
to O 0 1.0973378872236594e-09
neither O 0 5.1092257535856334e-08
gene O 0 1.259198745273693e-09
in O 0 1.066204569077911e-09
16 O 0 9.618169372060947e-09
% O 0 7.418022862637486e-10
( O 0 1.631887125430609e-10
95 O 0 1.89069937484021e-09
% O 0 2.5450283547279184e-10
confidence O 0 2.5719876006746745e-08
interval O 0 6.70519796130975e-07
[ O 0 1.7401697505192715e-06
CI O 0 0.0004465006641112268
] O 0 1.6642090372442908e-07
6 O 0 2.5324411012661585e-08
% O 0 5.8534282976197e-10
- O 0 5.639439470961349e-10
28 O 0 1.7266347240862956e-09
% O 0 1.9799993589142417e-10
) O 0 6.103316463335062e-11
, O 0 5.695669283434235e-11
suggesting O 0 2.502635210177573e-09
other O 0 6.573734334658354e-10
predisposition O 0 1.0180145864069345e-06
genes O 0 1.1447445302792403e-07
. O 0 1.334681343223565e-07

The O 0 5.124475705997611e-07
majority O 0 5.7082258919649576e-09
( O 0 2.344626937045291e-09
81 O 0 2.1257877236280365e-08
% O 0 1.0271244965665005e-09
) O 0 1.9079933466503718e-10
of O 0 1.4811369908329652e-09
the O 0 2.2829229351373215e-07
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.3262385323287162e-07
were O 0 1.2276815120060292e-08
due O 0 9.43118294571832e-09
to O 0 1.883795341939276e-09
BRCA1 O 0 2.5237361089835986e-09
, O 0 4.4232881246664135e-11
with O 0 1.526849480182335e-11
most O 0 3.606660248234306e-10
others O 0 1.7841259025708212e-10
( O 0 2.8951049890757474e-10
14 O 0 7.243258881572956e-09
% O 0 2.090587258862797e-09
) O 0 7.239940313930049e-10
due O 0 2.199173998462811e-08
to O 0 5.5240324314809186e-08
BRCA2 O 0 4.051203632116085e-06
. O 0 4.1576879539206857e-07

Conversely O 0 7.755197657388635e-06
, O 0 3.939196080438023e-09
the O 0 2.643627095011425e-09
majority O 0 4.81262141249772e-10
of O 0 1.9110217408524477e-08
families O 0 8.668781248388768e-09
with O 0 2.2492043783017834e-09
male B-Disease 0 4.73857397764732e-07
and I-Disease 0 1.7290446407969284e-08
female I-Disease 0 1.8957209249492735e-05
breast I-Disease 0 3.223221210646443e-05
cancer I-Disease 0 1.3232082665126654e-06
were O 0 1.651061296570333e-07
due O 0 1.322537059422757e-06
to O 0 4.623122862312812e-08
BRCA2 O 0 7.557387249335079e-08
( O 0 3.37585048804101e-09
76 O 0 3.057586539512158e-08
% O 0 3.820279648181213e-09
) O 0 2.5991588881169037e-09
. O 0 6.204983638014028e-09

The O 0 1.4179510117173777e-06
largest O 0 2.1000165872919752e-07
proportion O 0 1.5726984159414314e-08
( O 0 1.8578470983854345e-09
67 O 0 8.278280283491313e-09
% O 0 5.65816504760619e-10
) O 0 7.081361885763471e-11
of O 0 1.0424956453647383e-09
families O 0 3.21537074743361e-10
due O 0 3.0157618624571114e-09
to O 0 6.686151077239799e-10
other O 0 5.531617941478828e-10
genes O 0 1.2718905928466029e-09
was O 0 1.969425333925301e-08
found O 0 2.6484117121583495e-09
in O 0 2.6155204668754095e-09
families O 0 7.972582594106825e-10
with O 0 2.351648320519928e-10
four O 0 1.4073451737317555e-08
or O 0 3.7205822867036886e-09
five O 0 1.249075509690556e-09
cases O 0 6.562659859987718e-10
of O 0 2.8167011123514385e-07
female O 0 0.002937417244538665
breast B-Disease 0 0.04040231183171272
cancer I-Disease 0 1.9312010408611968e-05
only O 0 8.807952411871156e-08
. O 0 1.954427659711655e-07

These O 0 7.19902217838353e-08
estimates O 0 3.303732398762804e-08
were O 0 2.384285657797136e-09
not O 0 3.01790648027378e-10
substantially O 0 6.698383181458212e-09
affected O 0 7.413553659851857e-10
either O 0 4.5335260545620315e-10
by O 0 5.677212588928171e-10
changing O 0 6.419007991809167e-09
the O 0 6.648487538285508e-09
assumed O 0 1.4206281662154652e-07
penetrance O 0 6.081322680984158e-07
model O 0 1.3421120215184601e-08
for O 0 1.0941025863075993e-09
BRCA1 O 0 5.186287843628179e-09
or O 0 5.153085180786832e-10
by O 0 2.8947622077168944e-10
including O 0 1.5909263906266347e-09
or O 0 8.644860116646669e-08
excluding O 0 1.1882425496878568e-06
BRCA1 O 0 1.4060456976494606e-07
mutation O 0 7.79912490145307e-09
data O 0 9.087390395734474e-08
. O 0 3.696442263390054e-08

Among O 0 1.8901848974905988e-08
those O 0 1.218078193865324e-09
families O 0 9.24329612850272e-10
with O 0 6.973387423059307e-10
disease O 0 4.0850235905054433e-07
due O 0 4.2477361716919404e-07
to O 0 3.753256549998696e-08
BRCA1 O 0 3.7744491976354766e-08
that O 0 1.1128907517754527e-10
were O 0 6.530992413544823e-10
tested O 0 2.48579767880841e-10
by O 0 1.4449008656214346e-10
one O 0 1.7225680604138205e-10
of O 0 3.5629013628302175e-10
the O 0 2.754231565038623e-10
standard O 0 3.915874013937781e-10
screening O 0 2.3898789197618342e-11
methods O 0 2.7412916381308605e-10
, O 0 7.086239234288527e-11
mutations O 0 5.982060680143064e-11
were O 0 5.751544240872875e-10
detected O 0 3.556439365226538e-09
in O 0 1.2125358495040928e-09
the O 0 1.889020673218056e-08
coding O 0 3.340381908856216e-07
sequence O 0 9.697529890217993e-08
or O 0 1.859535458947903e-08
splice O 0 1.4410277060505905e-07
sites O 0 3.49767081964103e-09
in O 0 3.164735973282262e-10
an O 0 6.137781394244257e-10
estimated O 0 2.1582664544439467e-09
63 O 0 1.3653159491866518e-08
% O 0 1.8322141581705864e-09
( O 0 2.5494506505907566e-09
95 O 0 2.831626488841721e-08
% O 0 6.3335603428527065e-09
CI O 0 1.0706357898015995e-05
51 O 0 4.299339906310706e-08
% O 0 3.508762835835455e-09
- O 0 5.6729505537589375e-09
77 O 0 1.1579376568704447e-08
% O 0 1.5962943189506973e-09
) O 0 1.498104640340614e-09
. O 0 1.0276324680091875e-08

The O 0 8.74068120992888e-07
estimated O 0 9.837419412406234e-08
sensitivity O 0 9.977139114880629e-08
was O 0 3.0357952596204996e-08
identical O 0 1.6655349321936797e-09
for O 0 2.4684582156098145e-10
direct O 0 1.3893680650411966e-09
sequencing O 0 1.1180464332127826e-09
and O 0 2.5162943950718386e-10
other O 0 2.6772431493959914e-10
techniques O 0 6.281698006205261e-07
. O 0 4.213265185626369e-07

The O 0 3.0243863875512034e-06
penetrance O 0 0.00010038282925961539
of O 0 1.5166168623181875e-06
BRCA2 O 0 3.6188129115544143e-07
was O 0 1.3071137061615445e-07
estimated O 0 7.395254186803868e-09
by O 0 2.7508308964030448e-09
maximizing O 0 4.785669602824782e-07
the O 0 5.6898475264688386e-08
LOD O 0 7.409686804749072e-05
score O 0 2.9157670056179086e-08
in O 0 6.739352631512929e-09
BRCA2 O 0 2.1484924062065147e-08
- O 0 1.3691937361670625e-08
mutation O 0 5.94896409911172e-10
families O 0 3.9291461750856627e-10
, O 0 1.8493750975068224e-10
over O 0 5.603338903981125e-10
all O 0 1.0510649017803075e-09
possible O 0 4.9885393593740446e-08
penetrance O 0 1.4021870811120607e-05
functions O 0 6.996675097070693e-07
. O 0 2.2180320513598417e-07

The O 0 3.26915028381336e-07
estimated O 0 3.14776862353483e-08
cumulative O 0 1.957867681312564e-07
risk O 0 4.993422564325556e-08
of O 0 1.4477691934189352e-07
breast B-Disease 0 3.861891309497878e-05
cancer I-Disease 0 3.89545220969012e-07
reached O 0 1.0051102208308293e-06
28 O 0 1.1284768675068335e-07
% O 0 1.2976246743789943e-09
( O 0 2.7450902662096155e-10
95 O 0 1.6613437292534172e-09
% O 0 7.328622708691057e-10
CI O 0 5.969770882074954e-07
9 O 0 1.6756429133124584e-08
% O 0 7.56130158485746e-10
- O 0 4.3974648922251447e-10
44 O 0 3.649884283696281e-10
% O 0 1.7058442158823794e-10
) O 0 1.5195891420183294e-11
by O 0 2.5636477316015593e-11
age O 0 8.171273102597354e-10
50 O 0 8.861327227549509e-10
years O 0 5.066473907078262e-10
and O 0 2.50490239661616e-10
84 O 0 1.4901145206636102e-08
% O 0 1.3810086407772815e-09
( O 0 7.722429917755846e-10
95 O 0 4.7381374379540375e-09
% O 0 1.9859840438840592e-09
CI O 0 1.735233013278048e-06
43 O 0 8.939557538667486e-09
% O 0 7.660141410070764e-10
- O 0 1.4419254679154392e-09
95 O 0 4.068078762742289e-09
% O 0 8.29958393677721e-11
) O 0 1.9442995824459075e-11
by O 0 6.659128110042545e-11
age O 0 2.994342551687623e-09
70 O 0 2.9530308864877952e-08
years O 0 1.9286604313606404e-08
. O 0 6.672601671198208e-08

The O 0 2.973201617351151e-06
corresponding O 1 0.7633702158927917
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 0.0003773696080315858
were O 0 4.939344080412411e-07
0 O 0 1.5483726656384533e-07
. O 0 3.521919822446762e-08

4 O 0 5.093374511488946e-06
% O 0 3.725298824974743e-08
( O 0 7.641597576935055e-09
95 O 0 3.059091469026498e-08
% O 0 3.2382985182266566e-09
CI O 0 1.5993023225746583e-06
0 O 0 2.645190733119307e-09
% O 0 2.6351984483419244e-10
- O 0 2.391425668601954e-10
1 O 0 1.4373892076591233e-09
% O 0 1.791918557980665e-10
) O 0 1.700168651697087e-11
by O 0 1.7643823901902778e-11
age O 0 3.847942797730042e-10
50 O 0 5.302524530570452e-10
years O 0 1.959478967972217e-10
and O 0 9.541253898071034e-11
27 O 0 3.3170279856165052e-09
% O 0 2.484456251838907e-10
( O 0 8.671567630624821e-11
95 O 0 8.938035866989935e-10
% O 0 3.399264481007691e-10
CI O 0 2.850563873835199e-07
0 O 0 1.0399794359017278e-09
% O 0 7.570763460584828e-11
- O 0 1.211342415263772e-10
47 O 0 4.921358875975557e-10
% O 0 1.0597102362286392e-10
) O 0 8.832042736051093e-12
by O 0 2.5661917035790793e-11
age O 0 2.6958606458293843e-09
70 O 0 1.3425856870696862e-08
years O 0 1.6302960759162488e-08
. O 0 4.951843024514346e-08

The O 0 1.2655796126637142e-06
lifetime O 0 3.2785840176075e-06
risk O 0 1.4241389862945653e-06
of O 0 3.3500721201562556e-06
breast B-Disease 1 0.9998425245285034
cancer I-Disease 0 2.9706636269111186e-05
appears O 0 9.089765029557384e-08
similar O 0 6.080707604105839e-10
to O 0 3.8986885941838523e-10
the O 0 7.832054116363452e-09
risk O 0 6.079136483094771e-08
in O 0 1.0446917997342098e-08
BRCA1 O 0 7.45575867711068e-09
carriers O 0 3.3350747163929384e-10
, O 0 1.8764573228580161e-10
but O 0 3.5987923752145434e-10
there O 0 1.491837209322e-09
was O 0 4.431824152106856e-08
some O 0 8.547118568458245e-10
suggestion O 0 1.0665183403091305e-08
of O 0 8.807932161403187e-09
a O 0 6.565517907120011e-09
lower O 0 2.374094520973813e-08
risk O 0 2.312698121897938e-08
in O 0 2.0043119164370182e-08
BRCA2 O 0 7.201645502163956e-08
carriers O 0 1.0154219687308341e-08
< O 0 2.754896968326648e-07
50 O 0 6.416351894245054e-09
years O 0 3.1551123935713576e-09
of O 0 1.6804436953066215e-08
age O 0 7.505456665057864e-07
. O 0 5.907022000428697e-07

Eye B-Disease 1 0.9793604612350464
movement I-Disease 0 9.83798145171022e-06
abnormalities I-Disease 0 0.00020847578707616776
correlate O 0 1.824216440127202e-07
with O 0 1.063117927024848e-09
genotype O 0 3.8759415588174306e-07
in O 0 8.420235531048093e-08
autosomal O 0 0.0006580436020158231
dominant O 0 0.0008422561804763973
cerebellar B-Disease 1 0.9999977350234985
ataxia I-Disease 1 1.0
type I-Disease 1 1.0
I I-Disease 1 0.9999979734420776
. O 0 2.1313562683644705e-05

We O 0 2.3457430415874114e-06
compared O 0 1.7781572978492477e-06
horizontal O 0 5.324803169060033e-06
eye O 0 1.5571105905110016e-05
movements O 0 8.281013492705824e-07
( O 0 4.618857118998676e-08
visually O 0 1.3024126133132086e-07
guided O 0 6.014136602061626e-07
saccades O 0 9.248898095393088e-06
, O 0 1.7130419749378234e-08
antisaccades O 0 1.0050575838249642e-06
, O 0 4.348407411924882e-09
and O 0 2.7844992978032224e-09
smooth O 0 9.717136606468557e-08
pursuit O 0 3.162409257129184e-06
) O 0 5.309682471477117e-09
in O 0 1.6949316394843095e-09
control O 0 1.5922811513746638e-08
subjects O 0 1.6139762237799005e-07
( O 0 1.2404388627373919e-08
n O 0 6.65051871351352e-08
= O 0 9.58676196205488e-08
14 O 0 5.901872768276917e-09
) O 0 1.8197032769506905e-10
and O 0 4.9254413048149814e-11
patients O 0 3.8240226957197976e-11
with O 0 5.7467906301733596e-12
three O 0 1.734453275448189e-10
forms O 0 4.38398428670439e-09
of O 0 8.817784873826895e-06
autosomal O 0 0.005274409428238869
dominant O 0 0.0003655478067230433
cerebellar B-Disease 1 0.9998329877853394
ataxias I-Disease 1 0.9999946355819702
type I-Disease 1 0.9999631643295288
I I-Disease 1 0.9223619699478149
spinocerebellar B-Disease 1 0.9896016716957092
ataxias I-Disease 0 0.00024120543093886226
1 I-Disease 0 1.661557348597853e-06
and I-Disease 0 2.2860289661252864e-08
2 I-Disease 0 1.8582986172077653e-07
( O 0 4.4429111056842885e-08
SCA1 B-Disease 0 3.565751285350416e-06
, O 0 7.600012175146276e-09
n O 0 1.8614203156630538e-07
= O 0 2.1660748927843088e-07
11 O 0 2.9776908050394013e-08
; O 0 8.818719643421957e-10
SCA2 B-Disease 0 7.363018426076451e-07
, O 0 1.9823660490914108e-09
n O 0 5.831736871186877e-08
= O 0 8.22449024440175e-08
10 O 0 8.869786682907943e-09
) O 0 1.7974307597867778e-09
and O 0 7.252797917800535e-09
SCA3 B-Disease 1 1.0
/ O 0 0.00023241831513587385
Machado B-Disease 0 5.072153271612478e-06
- I-Disease 0 2.342646894248901e-06
Joseph I-Disease 0 0.00011812378943432122
disease I-Disease 0 0.04233568534255028
( O 0 9.507039067102596e-07
MJD B-Disease 1 1.0
) O 0 9.879105533627808e-08
( O 0 1.2142792549241221e-08
n O 0 8.380435900789962e-08
= O 0 1.4328247743833344e-07
16 O 0 4.6403233255887244e-08
) O 0 1.8884406927099917e-08
. O 0 5.905569011588341e-08

In O 0 8.564164090785198e-06
SCA1 B-Disease 0 0.0011920689139515162
, O 0 9.968654524072917e-08
saccade O 0 1.3998384019942023e-05
amplitude O 0 2.5611768705857685e-07
was O 0 3.6410991555158034e-08
significantly O 0 2.392786635496691e-09
increased O 0 2.787639674650677e-09
, O 0 2.6061822144818336e-10
resulting O 0 9.100829423402956e-09
in O 0 4.127480224269675e-08
hypermetria B-Disease 0 4.095194162800908e-05
. O 0 4.584281043662486e-07

The O 0 1.5286754205590114e-05
smooth O 0 9.352310371468775e-06
pursuit O 0 5.2372648497112095e-05
gain O 0 1.2423362022673246e-05
was O 0 3.3299536426056875e-06
decreased O 0 7.315163657040102e-06
. O 0 2.2564380230960523e-07

In O 0 1.6240961485891603e-05
SCA2 B-Disease 0 0.0014005928533151746
, O 0 2.0545455470255547e-07
saccade O 0 4.052472286275588e-05
velocity O 0 3.2658210784575203e-06
was O 0 1.1691291774695856e-06
markedly O 0 1.374919293084531e-06
decreased O 0 6.666382432740647e-06
. O 0 2.6918806383946503e-07

The O 0 5.013540658183047e-07
percentage O 0 3.3445320468672435e-07
of O 0 2.9053913053189717e-08
errors O 0 2.339478669455275e-06
in O 0 2.1689979234906787e-07
antisaccades O 0 0.0003376522217877209
was O 0 3.0015487482160097e-06
greatly O 0 1.8920646027709154e-07
increased O 0 3.589808272863593e-08
and O 0 1.1792111731523391e-09
was O 0 2.8952511499369393e-08
significantly O 0 2.415627697871514e-09
correlated O 0 2.1530130567271044e-08
with O 0 2.556831968369977e-10
age O 0 1.1308146241617578e-07
at O 0 2.5482427190581802e-06
disease O 0 8.130383321258705e-06
onset O 0 3.8568417949136347e-05
. O 0 1.415626940115544e-07

In O 0 3.467212366103922e-07
addition O 0 4.5457046127239664e-08
, O 0 2.921582975545789e-09
a O 0 6.405750152538303e-09
correlation O 0 9.710018566977396e-09
between O 0 2.493553585836139e-09
smooth O 0 6.450257927781422e-08
pursuit O 0 8.383567546843551e-07
gain O 0 3.9550687347400526e-07
and O 0 7.36484540020399e-10
the O 0 1.4076128040940716e-09
number O 0 1.511900493689211e-09
of O 0 8.396095374507695e-09
trinucleotide O 0 4.4593152779270895e-06
repeats O 0 3.996929649474623e-07
was O 0 9.441064889870177e-07
found O 0 2.0014473989249382e-07
. O 0 1.6171377126283915e-07

In O 0 6.808155740145594e-05
SCA3 B-Disease 1 1.0
, O 0 3.20767344419437e-06
gaze B-Disease 0 0.0005944872973486781
- I-Disease 0 3.589996777009219e-05
evoked I-Disease 0 1.108696869778214e-05
nystagmus I-Disease 0 7.061954238452017e-05
was O 0 1.1498162848511129e-06
often O 0 3.8111167555143766e-09
present O 0 5.479055431578672e-09
as O 0 2.2520774578538294e-08
was O 0 9.772560360943316e-07
saccade O 0 3.6200326576363295e-05
hypometria O 0 1.6140658772201277e-05
and O 0 1.1650893583237121e-07
smooth O 0 9.61816476774402e-06
pursuit O 0 0.00014474378258455545
gain O 0 2.7889689590665512e-05
was O 0 3.823317911155755e-06
markedly O 0 3.1584374937665416e-06
decreased O 0 3.1742688406666275e-06
. O 0 1.3987261127113015e-07

Three O 0 2.7559482873584784e-07
major O 0 4.25984119090117e-08
criteria O 0 1.856848896863994e-08
, O 0 2.9094266995599583e-09
saccade O 0 1.6318271036652732e-06
amplitude O 0 7.154110903684341e-08
, O 0 9.884940643800633e-10
saccade O 0 3.1706065328762634e-07
velocity O 0 1.0499258706886394e-07
, O 0 9.298112280120563e-10
and O 0 8.057441935882537e-10
presence O 0 2.8268562601851954e-08
of O 0 1.3067450481685228e-06
gaze B-Disease 0 0.00012759544188156724
- I-Disease 0 3.741235559573397e-06
evoked I-Disease 0 7.645696769031929e-07
nystagmus I-Disease 0 1.1123189551653923e-06
, O 0 7.267389467990881e-10
permitted O 0 1.5521234297821707e-09
the O 0 1.3918267649515315e-09
correct O 0 1.7877930247323093e-08
assignment O 0 1.0159376273577436e-07
of O 0 3.968700568179884e-08
90 O 0 4.798785724346999e-08
% O 0 2.5690347627005394e-09
of O 0 3.0357472091679938e-09
the O 0 1.6678944447789945e-08
SCA1 B-Disease 0 9.752842743182555e-06
, O 0 1.3213793392807816e-09
90 O 0 4.127722164071201e-09
% O 0 3.8137545899097347e-10
of O 0 6.975462429892332e-10
the O 0 4.0330498940477355e-09
SCA2 B-Disease 0 6.225522611202905e-06
, O 0 6.442874567191836e-10
and O 0 2.0028462222043686e-10
93 O 0 1.8508520938098627e-08
% O 0 3.692570138547069e-10
of O 0 3.944577442460684e-10
the O 0 3.114104529799988e-09
patients O 0 1.56507584669896e-09
with O 0 2.7602649055324946e-09
SCA3 B-Disease 1 1.0
to O 0 2.8339281143985318e-08
their O 0 3.797366865398999e-09
genetically O 0 2.791522568657001e-10
confirmed O 0 1.8042901617221219e-09
patient O 0 1.568046847921778e-08
group O 0 9.149768720462248e-10
and O 0 5.393870905479048e-10
, O 0 1.7851139455515863e-09
therefore O 0 7.615364339130792e-09
, O 0 2.2750490380474275e-09
may O 0 1.812755989760717e-08
help O 0 1.1164875246549855e-07
orient O 0 0.0006300689419731498
diagnoses O 0 2.6233267362840706e-06
of O 0 8.160578204297053e-07
SCA1 B-Disease 0 0.27106472849845886
, O 0 7.839410898213828e-08
SCA2 B-Disease 0 0.0025350460782647133
, O 0 3.462585240754379e-08
and O 0 5.6457192698644576e-08
SCA3 B-Disease 1 1.0
at O 0 1.4208383163349936e-06
early O 0 4.107884876702883e-08
clinical O 0 4.8919961415094804e-08
stages O 0 1.946257910390159e-08
of O 0 3.4857777109209565e-08
the O 0 1.8186769068506692e-07
diseases O 0 7.08053121343255e-05
. O 0 5.025555793736203e-08
. O 0 2.0898752950415656e-07

Genetic O 0 1.1893456530742696e-06
basis O 0 8.937737305814153e-08
and O 0 6.034561184087295e-10
molecular O 0 5.8189929319496514e-08
mechanism O 0 3.9675390439697367e-07
for O 0 1.1092076874774648e-06
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 0 3.433712481637485e-05

Ventricular B-Disease 1 1.0
fibrillation I-Disease 1 0.9999270439147949
causes O 0 9.52951495492016e-07
more O 0 1.0759615420852242e-09
than O 0 7.979230054466768e-10
300 O 0 3.579748497628543e-09
, O 0 5.938137759287088e-10
000 O 0 3.745490317896838e-08
sudden O 0 3.503220824541131e-08
deaths O 0 2.967449619362128e-09
each O 0 4.0383821287015564e-10
year O 0 1.0059640898063549e-09
in O 0 4.828641042564641e-09
the O 0 1.0282309403919498e-07
USA O 0 2.496249408068252e-06
alone O 0 6.223553441486729e-07
. O 0 9.607703077563201e-08

In O 0 1.237208607562934e-06
approximately O 0 1.6675802783083782e-07
5 O 0 4.922912566485138e-08
- O 0 1.1843848568560134e-08
12 O 0 2.9507323251465323e-09
% O 0 1.1209563138825374e-10
of O 0 3.388588021291383e-11
these O 0 5.208227512459862e-12
cases O 0 2.097478961349264e-11
, O 0 2.4868255024679264e-11
there O 0 2.708796520423107e-10
are O 0 1.8672140222886213e-10
no O 0 5.390633717183846e-09
demonstrable O 0 7.0446603785967454e-06
cardiac O 0 0.0002210402744822204
or O 0 5.973551964189028e-08
non O 0 0.00013887575187254697
- O 0 0.004629955627024174
cardiac O 1 0.9999973773956299
causes O 0 9.639990850018876e-08
to O 0 9.56231871462876e-10
account O 0 1.9587410804433603e-08
for O 0 9.39618494122385e-10
the O 0 8.65586091691739e-09
episode O 0 1.9305399234781362e-07
, O 0 1.0655717280760868e-10
which O 0 9.619970618712781e-12
is O 0 1.9329220515840184e-11
therefore O 0 5.685534820720761e-10
classified O 0 6.992733148081243e-08
as O 0 1.275426342317587e-07
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 1 0.9993090629577637
IVF B-Disease 1 1.0
) O 0 8.099281103568501e-07
. O 0 2.489710766440112e-07

A O 0 4.475350579014048e-06
distinct O 0 1.1827147972098828e-07
group O 0 3.695202011044785e-08
of O 0 4.058938429807313e-06
IVF B-Disease 1 1.0
patients O 0 5.161806484466069e-07
has O 0 4.974244349753576e-10
been O 0 1.2075989097581896e-09
found O 0 9.724396843324712e-10
to O 0 3.102039181079874e-10
present O 0 4.687557009219745e-09
with O 0 2.304585855483765e-09
a O 0 2.3640681945380493e-07
characteristic O 0 8.061782637014403e-07
electrocardiographic O 0 5.722310743294656e-05
pattern O 0 1.0798459697980434e-05
. O 0 8.758663625485497e-07

Because O 0 8.607886456957203e-07
of O 0 9.403758127746187e-08
the O 0 1.4380151291959464e-08
small O 0 5.4756599254801586e-09
size O 0 4.005963560871351e-09
of O 0 1.5165452893484144e-08
most O 0 2.737593485235834e-09
pedigrees O 0 1.0264340488674861e-07
and O 0 6.958599807482813e-10
the O 0 5.908281419664263e-09
high O 0 7.483971842248138e-08
incidence O 0 4.175305434728216e-07
of O 0 1.588501596927472e-08
sudden B-Disease 0 1.9632524583812483e-07
death I-Disease 0 8.113241634077895e-09
, O 0 1.5529164065775092e-10
however O 0 2.531646281500599e-10
, O 0 5.907204586597103e-11
molecular O 0 3.3150544531679316e-09
genetic O 0 6.761894932871826e-10
studies O 0 1.6614926101610195e-09
of O 0 4.314043522413158e-08
IVF B-Disease 1 1.0
have O 0 1.2989612163671893e-10
not O 0 8.186025468592817e-11
yet O 0 2.1777137870770957e-09
been O 0 1.0919663395725365e-08
done O 0 1.9620489410954178e-07
. O 0 2.4008389232221816e-07

Because O 0 2.2349782739183865e-05
IVF B-Disease 1 1.0
causes O 0 5.632460306514986e-05
cardiac O 1 0.9999997615814209
rhythm O 1 0.9984366297721863
disturbance O 0 0.03331100568175316
, O 0 5.414230397349229e-09
we O 0 2.393653941723528e-09
investigated O 0 8.392753159114363e-08
whether O 0 1.311199504527849e-08
malfunction O 0 0.0013525871327146888
of O 0 1.2270780302969797e-07
ion O 0 2.0037057311128592e-06
channels O 0 1.4811823803029256e-06
could O 0 1.7298329879622543e-08
cause O 0 2.071735991648893e-07
the O 0 3.060539199850609e-08
disorder O 0 1.4910733625583816e-07
by O 0 5.776842892935008e-10
studying O 0 1.3918832308945639e-08
mutations O 0 3.108311108501738e-10
in O 0 6.34089447615338e-10
the O 0 8.825353781105605e-09
cardiac O 0 8.885832357918844e-06
sodium O 0 6.826748233379476e-08
channel O 0 1.389752583236259e-06
gene O 0 1.6412541015142779e-07
SCN5A O 0 9.503635374130681e-05
. O 0 4.0285777913595666e-07

We O 0 3.734761548912502e-07
have O 0 5.849759343590222e-09
now O 0 5.587599272161015e-09
identified O 0 3.282940497228992e-08
a O 0 4.482773618974534e-08
missense O 0 4.379924405384372e-07
mutation O 0 3.4368958790054194e-09
, O 0 1.1310486991433777e-09
a O 0 1.889402589938527e-08
splice O 0 3.3637019214438624e-07
- O 0 1.7488789083586198e-08
donor O 0 5.613995934794502e-09
mutation O 0 7.127450851740491e-10
, O 0 1.0691365154302801e-10
and O 0 5.328346652788696e-10
a O 0 1.4113934909687487e-08
frameshift O 0 4.216758213715366e-07
mutation O 0 6.838066779479846e-10
in O 0 4.1603959166636173e-10
the O 0 5.988402662637782e-09
coding O 0 1.396100657302668e-07
region O 0 4.5370082801809986e-08
of O 0 6.254523441384663e-07
SCN5A O 1 0.8705815672874451
in O 0 2.2771999397264153e-07
three O 0 1.3467335975292372e-06
IVF B-Disease 1 1.0
families O 0 8.896119396695212e-08
. O 0 8.486519220696209e-08

We O 0 3.297770945209777e-07
show O 0 3.176368323920542e-08
that O 0 2.91044660594153e-10
sodium O 0 6.162673149567865e-10
channels O 0 1.2251756276171477e-09
with O 0 7.893154012339476e-12
the O 0 9.59745616313512e-10
missense O 0 3.901117295868062e-08
mutation O 0 1.3734216541827493e-10
recover O 0 4.678669451863016e-09
from O 0 6.849357747640283e-10
inactivation O 0 2.1789489323964517e-08
more O 0 2.80667815377722e-11
rapidly O 0 1.4971277551012463e-09
than O 0 1.2068822330402185e-10
normal O 0 2.974561486013272e-09
and O 0 6.62122162653489e-11
that O 0 3.740244572392193e-11
the O 0 3.975463513938848e-09
frameshift O 0 2.1099856439832365e-07
mutation O 0 7.061403684005541e-10
causes O 0 5.092962718222793e-10
the O 0 5.590624074791606e-10
sodium O 0 2.010636324101256e-09
channel O 0 1.2928819792534796e-08
to O 0 3.6769326472452235e-10
be O 0 1.744260735847547e-09
non O 0 4.3788011794276827e-07
- O 0 8.563083042645303e-07
functional O 0 1.1040079698432237e-05
. O 0 3.5398514341977716e-07

Our O 0 1.121729383157799e-06
results O 0 3.097891720926782e-08
indicate O 0 1.862396459273441e-08
that O 0 2.2857127301989522e-10
mutations O 0 7.069206331422606e-10
in O 0 5.44082556785952e-09
cardiac O 0 5.603193926617678e-07
ion O 0 2.6916032425106096e-07
- O 0 4.799005637323717e-06
channel O 0 4.011341445675498e-07
genes O 0 1.3701936252275004e-09
contribute O 0 2.2830375090432398e-10
to O 0 5.1637971676399275e-11
the O 0 1.0211100853751987e-09
risk O 0 9.65509538985998e-09
of O 0 2.6033976752160015e-08
developing O 0 2.9916750463598873e-06
IVF B-Disease 1 1.0
. O 0 2.4205499826734922e-08
. O 0 2.5540172643445658e-08

Molecular O 0 6.709550507366657e-05
heterogeneity O 0 7.1588319769944064e-06
in O 0 1.5026920152649836e-07
mucopolysaccharidosis B-Disease 0 3.743995330296457e-05
IVA I-Disease 0 0.001293440698646009
in O 0 4.15878922410684e-08
Australia O 0 6.82710998844982e-09
and O 0 6.674938379802597e-10
Northern O 0 9.362181252470236e-09
Ireland O 0 6.029732269041688e-09
: O 0 7.709728966354135e-10
nine O 0 2.7875226571438816e-09
novel O 0 6.102530925033989e-09
mutations O 0 3.063894138399803e-10
including O 0 2.4285431998727347e-10
T312S O 0 5.591183480646578e-07
, O 0 6.2142815338006585e-09
a O 0 2.007054789032736e-08
common O 0 1.000589300304e-08
allele O 0 1.3673068899322516e-08
that O 0 2.082365391231633e-09
confers O 0 9.901309283577575e-08
a O 0 7.978339766623321e-08
mild O 0 4.959736088494537e-07
phenotype O 0 1.6741274748710566e-06
. O 0 2.8591318823600886e-07

Mucopolysaccharidosis B-Disease 0 0.17835380136966705
IVA I-Disease 1 0.9999645948410034
( O 0 2.2333633751259185e-05
MPS B-Disease 1 0.9999691247940063
IVA I-Disease 1 1.0
) O 0 4.0962348180073604e-08
is O 0 1.0878143941184248e-09
an O 0 1.2976154373234294e-08
autosomal B-Disease 0 0.17020352184772491
recessive I-Disease 1 0.9935477375984192
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 1 0.9986529350280762
by O 0 3.3604479199311754e-07
a O 0 9.398103429703042e-05
genetic B-Disease 1 1.0
defect I-Disease 1 0.9999990463256836
in O 0 3.277300777426717e-07
N O 0 8.311003512062598e-06
- O 0 5.020554567636282e-07
acetylgalactosamine O 0 1.2533916560641956e-05
- O 0 2.7283977033221163e-06
6 O 0 1.2044999493809883e-05
- O 0 3.158660319968476e-06
sulfate O 0 1.011666790873278e-05
sulfatase O 0 0.16658872365951538
( O 0 3.289633468739339e-06
GALNS O 0 0.001839756965637207
) O 0 2.9918155064478924e-07
. O 0 2.945892845218623e-07

Previous O 0 1.0534477041801438e-06
studies O 0 5.3315137193976625e-08
of O 0 1.186636922057005e-08
patients O 0 2.035672297395763e-09
from O 0 1.1487176765356821e-09
a O 0 1.77196284312231e-08
British O 0 3.711544138695899e-07
- O 0 1.1707474811828433e-07
Irish O 0 5.35018642722207e-08
population O 0 2.5853236218509323e-10
showed O 0 7.707258720124344e-10
that O 0 3.433544421005408e-11
the O 0 8.675459239881889e-10
I113F O 0 1.539256260230104e-07
mutation O 0 5.319248375101893e-10
is O 0 7.440493360322264e-11
the O 0 1.7494175552634772e-10
most O 0 1.7571616037215243e-11
common O 0 2.6239923428539313e-11
single O 0 2.488658445987113e-10
mutation O 0 1.8743361029915917e-10
among O 0 1.3419014788240702e-09
MPS B-Disease 1 0.9999845027923584
IVA I-Disease 1 1.0
patients O 0 1.4886991266394034e-06
and O 0 1.0640592851274278e-09
produces O 0 1.4870247255771574e-09
a O 0 5.68547253720908e-09
severe O 0 6.591795198573891e-08
clinical O 0 6.529784286612994e-07
phenotype O 0 3.4814132732208236e-07
. O 0 6.962336129845426e-08

We O 0 2.8300726739871607e-07
studied O 0 5.869040364814282e-07
mutations O 0 2.790631015159306e-08
in O 0 1.651792835843935e-08
the O 0 1.891278031962429e-07
GALNS O 0 0.0004978167125955224
gene O 0 7.489023623463709e-09
from O 0 4.556413912837343e-09
23 O 0 3.407992821280459e-08
additional O 0 4.06259061946912e-08
MPS B-Disease 1 0.9999234676361084
IVA I-Disease 1 1.0
patients O 0 3.194718374288641e-07
( O 0 1.1484131423600275e-09
15 O 0 7.38135552680319e-10
from O 0 5.334305219761859e-10
Australia O 0 1.5507091166711007e-09
, O 0 1.931916987496507e-10
8 O 0 1.529342985584492e-09
from O 0 9.624495644899866e-10
Northern O 0 5.227961619169719e-09
Ireland O 0 2.372169571884797e-09
) O 0 4.71707117810638e-10
, O 0 2.6871204913958557e-11
with O 0 1.5255307433958976e-11
various O 0 2.9044979754644373e-09
clinical O 0 1.062028604792431e-05
phenotypes O 0 8.463691756332992e-07
( O 0 1.6518463041848008e-08
severe O 0 7.125594692070081e-08
, O 0 6.288657927733254e-10
16 O 0 3.2054341403409126e-09
cases O 0 2.5414823023872657e-10
; O 0 1.2425900586254812e-10
intermediate O 0 2.734057069631035e-08
, O 0 6.280925779478252e-10
4 O 0 3.297397466184293e-09
cases O 0 3.5179281709929455e-10
; O 0 1.4635817557895336e-10
mild O 0 1.0863842270225632e-08
, O 0 5.433666849796737e-10
3 O 0 1.590417575414449e-08
cases O 0 1.3485828009862644e-09
) O 0 3.6023308780386287e-09
. O 0 2.2814205635768303e-08

We O 0 6.432885584217729e-07
found O 0 1.4047598639876924e-08
two O 0 1.3761074502127713e-09
common O 0 1.6255570223222549e-09
mutations O 0 5.915765655117866e-10
that O 0 9.925649191444563e-11
together O 0 6.709478528321711e-10
accounted O 0 6.124256657358274e-08
for O 0 1.5777330553135016e-09
32 O 0 2.5986649276887874e-08
% O 0 1.867781262987478e-09
of O 0 1.0190496224637968e-09
the O 0 2.001724341837985e-09
44 O 0 3.9435787968500335e-09
unrelated O 0 8.25503931878302e-09
alleles O 0 7.597163176331634e-11
in O 0 7.550171599035593e-11
these O 0 3.7793582152723104e-10
patients O 0 3.4617120281410507e-09
. O 0 4.675674247778261e-08

One O 0 5.851630930919782e-07
is O 0 7.317717098942467e-09
the O 0 9.975688719521258e-09
T312S O 0 9.933216915669618e-07
mutation O 0 6.991997203442679e-09
, O 0 6.577697275744754e-10
a O 0 2.183974112668352e-09
novel O 0 1.4919859125939183e-08
mutation O 0 7.202586860266535e-10
found O 0 8.786618099776433e-10
exclusively O 0 5.229487065605554e-09
in O 0 2.074294513931818e-09
milder O 0 2.9348155905495332e-08
patients O 0 2.2526316811877223e-08
. O 0 6.304444610805149e-08

The O 0 2.3871639314165805e-06
other O 0 1.9421898755922484e-08
is O 0 5.538050018571994e-09
the O 0 3.4305124074762716e-08
previously O 0 4.970223699274356e-07
described O 0 4.849405854656652e-07
I113F O 0 5.284464805299649e-06
that O 0 3.7008778264180364e-09
produces O 0 9.558785762919797e-09
a O 0 6.861368007093915e-08
severe O 0 5.737262540606025e-07
phenotype O 0 2.3573284124722704e-06
. O 0 1.8438548465837812e-07

The O 0 4.253956376487622e-06
I113F O 0 8.345075912075117e-06
and O 0 3.8457525164403705e-08
T312S O 0 1.7914064756041626e-06
mutations O 0 8.909564641612633e-09
accounted O 0 7.938297130749561e-08
for O 0 4.956375754261444e-09
8 O 0 1.0860469501494663e-07
( O 0 3.996195374611489e-09
18 O 0 1.3245924357363492e-08
% O 0 8.472552659455346e-10
) O 0 1.2110028257961147e-10
and O 0 8.350458519101878e-11
6 O 0 1.659238613171965e-08
( O 0 1.7296704069025282e-09
14 O 0 4.101275319357001e-09
% O 0 7.497280019030939e-10
) O 0 1.543631750200447e-10
of O 0 8.485361302490446e-10
44 O 0 3.544737170457779e-09
unrelated O 0 5.037743733282696e-08
alleles O 0 1.4823295924060176e-09
, O 0 1.9926087446719976e-09
respectively O 0 1.0491230284515041e-07
. O 0 1.8551362757079914e-07

The O 0 1.024682887873496e-06
relatively O 0 4.407235110193142e-07
high O 0 7.66942321206443e-07
residual O 0 2.6629448257153854e-05
GALNS O 0 0.02095063216984272
activity O 0 2.3649349714105483e-06
seen O 0 1.8950762736835713e-08
when O 0 1.1063789884246944e-09
the O 0 2.696066259133545e-09
T312S O 0 1.8886412078700232e-07
mutant O 0 3.705597961811691e-08
cDNA O 0 1.0987860576960884e-07
is O 0 5.720877105375166e-10
overexpressed O 0 5.668194447139285e-08
in O 0 2.8639091098625613e-10
mutant O 0 6.760092929880557e-09
cells O 0 1.307769670333414e-09
provides O 0 2.2156465551148585e-10
an O 0 3.065079093311773e-11
explanation O 0 5.28772803320976e-10
for O 0 4.095142627780213e-11
the O 0 2.524078057675183e-09
mild O 0 4.394610186864156e-08
phenotype O 0 2.0930821520437348e-08
in O 0 1.742159416728839e-09
patients O 0 4.686687704591463e-10
with O 0 1.081004868952462e-10
this O 0 6.7470824482995795e-09
mutation O 0 5.462633367869785e-08
. O 0 6.635808347255079e-08

The O 0 1.1789130383021984e-07
distribution O 0 9.402158163140939e-09
and O 0 5.119346058179985e-10
relative O 0 1.6402957214722846e-08
frequencies O 0 2.543282695555149e-09
of O 0 5.231133304306468e-09
the O 0 1.0367081415552093e-08
I113F O 0 6.009572643961292e-07
and O 0 2.6826065813168043e-09
T312S O 0 4.650583775855921e-07
mutations O 0 1.0562015706483407e-09
in O 0 7.31154692346081e-10
Australia O 0 1.158462770156632e-09
corresponded O 0 6.9028183169450585e-09
to O 0 5.179444650948994e-10
those O 0 2.673594678981317e-10
observed O 0 3.3841283109126152e-09
in O 0 1.88541271484155e-09
Northern O 0 6.285159503960358e-09
Ireland O 0 3.4560054817944774e-09
and O 0 4.248695562036886e-10
are O 0 5.687397428011387e-11
unique O 0 2.8870872359476607e-10
to O 0 3.511477220108361e-11
these O 0 4.0923240490764456e-11
two O 0 1.264603977091383e-10
populations O 0 1.1039669178813938e-10
, O 0 6.682297770677081e-11
suggesting O 0 1.2447042285756993e-09
that O 0 5.732091537535844e-11
both O 0 1.8045542837796802e-10
mutations O 0 1.7102358418341623e-10
were O 0 9.371109443989667e-10
probably O 0 2.029058920882676e-09
introduced O 0 1.5478861248308107e-10
to O 0 1.0957477980522157e-10
Australia O 0 6.64023391827584e-10
by O 0 5.879141062870019e-10
Irish O 0 6.45231281737324e-08
migrants O 0 1.579929254091894e-08
during O 0 1.2157832962600423e-08
the O 0 2.4158776312788177e-08
19th O 0 8.972818363872648e-07
century O 0 2.988495452882489e-06
. O 0 5.226827397564193e-07

Haplotype O 0 3.122182533843443e-05
analysis O 0 2.1522293991438346e-07
using O 0 2.2908654528919214e-08
6 O 0 1.690171558266229e-07
RFLPs O 0 7.31932277631131e-06
provides O 0 6.997547430387385e-09
additional O 0 4.67336946918806e-10
data O 0 8.887008462465928e-09
that O 0 7.834332488299012e-11
the O 0 5.5939439747021424e-09
I113F O 0 1.1728645858966047e-06
mutation O 0 9.941233614085832e-09
originated O 0 1.851233299987598e-08
from O 0 3.255707481386594e-09
a O 0 1.2345498845434122e-08
common O 0 1.2883132782803841e-08
ancestor O 0 1.0467160791449714e-06
. O 0 1.4120887215085531e-07

The O 0 3.636019698660675e-07
other O 0 2.6720259338475216e-09
9 O 0 4.421320554115482e-08
novel O 0 2.641677809833709e-08
mutations O 0 2.078924588033715e-09
identified O 0 3.00037972245093e-09
in O 0 5.182991813512672e-10
these O 0 3.197000164600894e-10
23 O 0 9.206214457435635e-08
patients O 0 2.272017907145596e-09
were O 0 3.4168170515158636e-09
each O 0 1.074257460764727e-09
limited O 0 8.345308444290822e-09
to O 0 8.858797251320993e-09
a O 0 2.0897078911730205e-07
single O 0 6.578989086847287e-07
family O 0 3.7594043078570394e-07
. O 0 1.8756618658244406e-07

These O 0 1.0449906717724389e-08
data O 0 1.800310123201143e-08
provide O 0 1.939222948887931e-10
further O 0 2.384429875768035e-10
evidence O 0 3.379535762348951e-09
for O 0 4.4294110046472213e-10
extensive O 0 3.741442000659845e-08
allelic O 0 3.4380261126898404e-07
heterogeneity O 0 6.287865517151658e-07
in O 0 5.808923830841195e-08
MPS B-Disease 0 0.38576337695121765
IVA I-Disease 1 0.9999998807907104
in O 0 9.025154668051982e-08
British O 0 1.0916080555034569e-06
- O 0 1.2900460433229455e-07
Irish O 0 1.0775089265280258e-07
patients O 0 9.644267606745416e-10
and O 0 7.206018420857774e-11
provide O 0 3.9693470732515834e-10
evidence O 0 6.6854912716962644e-09
for O 0 4.6544926246561147e-10
their O 0 1.1181360282108699e-09
transmission O 0 5.480466302998366e-09
to O 0 2.4062957182380273e-10
Australia O 0 1.1794383247831774e-09
by O 0 7.790527112305767e-10
British O 0 9.806620937524713e-08
- O 0 9.594005234703218e-08
Irish O 0 1.7650690153914184e-07
migrants O 0 3.806752602031338e-08
. O 0 5.186406415447209e-09
. O 0 3.666074732677771e-08

Identification O 0 1.3243519561001449e-06
of O 0 1.7343499791877548e-07
constitutional O 0 7.383185334219888e-07
WT1 O 0 0.0031293199863284826
mutations O 0 4.2479221917801624e-08
, O 0 6.624041870573194e-10
in O 0 1.4433756412302046e-09
patients O 0 3.608174037328382e-10
with O 0 1.386214754095505e-10
isolated O 0 1.2171822163509205e-05
diffuse B-Disease 1 0.9999639987945557
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 4.956505761377628e-10
and O 0 1.442772151749594e-10
analysis O 0 2.670079490840749e-09
of O 0 7.411903091281147e-09
genotype O 0 3.297795956314076e-07
/ O 0 2.6637079031388566e-07
phenotype O 0 7.000951374180886e-09
correlations O 0 6.490314508056372e-09
by O 0 1.922891845751451e-10
use O 0 3.490498168279288e-10
of O 0 2.755646377750054e-09
a O 0 9.656052846196417e-09
computerized O 0 1.4985575091941428e-07
mutation O 0 1.1450978831817338e-08
database O 0 2.4366613615711685e-07
. O 0 3.2413403516784456e-08

Constitutional O 0 8.59382737417036e-07
mutations O 0 4.752585880396509e-08
of O 0 6.429020515952288e-08
the O 0 2.3165506490840926e-07
WT1 O 0 4.758308205055073e-05
gene O 0 1.345154032605933e-08
, O 0 6.415063480424976e-10
encoding O 0 5.062196883898196e-09
a O 0 3.8583014116966297e-08
zinc O 0 1.575621536176186e-05
- O 0 5.638999482471263e-06
finger O 0 0.0001363131741527468
transcription O 0 0.00014080748951528221
factor O 0 3.867187388095772e-07
involved O 0 3.0224139635492975e-08
in O 0 7.955667769010688e-08
renal O 1 0.9999998807907104
and O 0 3.2682402206773986e-07
gonadal O 1 1.0
development O 1 0.9997273087501526
, O 0 2.0867947370106776e-09
are O 0 4.318358864940919e-11
found O 0 1.8624832232028155e-10
in O 0 2.467253068516584e-10
most O 0 4.1639922065961343e-10
patients O 0 3.8617800623974574e-10
with O 0 1.6170406125226577e-09
Denys B-Disease 1 1.0
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0017370650311931968
DDS B-Disease 1 1.0
) O 0 3.12467882679357e-08
, O 0 2.6510145190172807e-09
or O 0 3.176520522174542e-07
diffuse B-Disease 1 0.9715949296951294
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 0.34884878993034363
DMS B-Disease 1 0.9999765157699585
) O 0 8.346868085595816e-09
associated O 0 2.6365233551928213e-08
with O 0 1.717065423179065e-08
pseudohermaphroditism B-Disease 1 1.0
and O 0 0.0490756630897522
/ O 1 0.9999998807907104
or O 1 0.9316990375518799
Wilms B-Disease 1 1.0
tumor I-Disease 1 1.0
( O 0 0.00015019631246104836
WT B-Disease 1 1.0
) O 0 3.39860719122953e-07
. O 0 1.75629736531846e-07

Most O 0 1.340909960845238e-07
mutations O 0 4.15935232922493e-08
in O 0 1.513347314130442e-07
DDS B-Disease 1 1.0
patients O 0 5.688908913725754e-06
lie O 0 9.644503006711602e-05
in O 0 3.722713870502048e-07
exon O 0 1.7420328504158533e-06
8 O 0 2.9634080078722036e-07
or O 0 2.836167034558912e-08
exon O 0 1.1379894715446426e-07
9 O 0 6.665427321195239e-08
, O 0 4.565287259339357e-09
encoding O 0 1.4655951474651374e-07
zinc O 0 0.00021052283409517258
finger O 0 0.06017882749438286
2 O 0 0.001461233594454825
or O 0 2.147400846297387e-05
zinc O 1 0.8700317144393921
finger O 0 0.0006430938956327736
3 O 0 1.2587260016516666e-06
, O 0 3.48509798797636e-09
respectively O 0 2.0071121653586488e-08
, O 0 9.921963251002808e-10
with O 0 9.054112459772057e-10
a O 0 1.0579647380382085e-07
hot O 0 6.816390509811754e-07
spot O 0 9.423793585483509e-07
( O 0 3.650319868597762e-08
R394W O 0 9.17877230222075e-07
) O 0 1.0367892322449279e-08
in O 0 3.72699027195722e-08
exon O 0 1.3037154076300794e-06
9 O 0 2.4672401650605025e-06
. O 0 3.9517885852546897e-07

We O 0 8.32536557027197e-07
analyzed O 0 8.281045325020386e-07
a O 0 6.22002360728402e-08
series O 0 6.876667235644618e-09
of O 0 9.902154651797446e-09
24 O 0 7.072961949461387e-08
patients O 0 2.0104062858905536e-09
, O 0 3.40091815820287e-10
10 O 0 6.369808236428298e-09
with O 0 3.0791218463832593e-09
isolated B-Disease 0 0.0029566287994384766
DMS I-Disease 1 0.9999996423721313
( O 0 1.1433078725531232e-05
IDMS B-Disease 1 0.9500756859779358
) O 0 1.0360716728996522e-08
, O 0 1.0048556431385691e-09
10 O 0 6.413207298550105e-09
with O 0 8.477584856336762e-09
DDS B-Disease 1 1.0
, O 0 4.233605466197332e-08
and O 0 9.83550307864789e-09
4 O 0 3.259111451825447e-07
with O 0 1.4281994253906305e-08
urogenital B-Disease 0 0.4742421507835388
abnormalities I-Disease 1 0.9995315074920654
and O 0 4.1952648643928114e-06
/ O 1 0.9998227953910828
or O 0 0.12592104077339172
WT B-Disease 1 1.0
. O 0 1.2308148143347353e-05

We O 0 2.1716773517255206e-06
report O 0 2.1129146716702962e-06
WT1 O 0 0.00032028634450398386
heterozygous O 0 1.4588738395104883e-07
mutations O 0 3.2526228377349753e-09
in O 0 1.6676201530785306e-09
16 O 0 2.7983224626382253e-08
patients O 0 4.049359958457899e-09
, O 0 1.952667361138083e-09
4 O 0 2.039093516259527e-07
of O 0 1.7585566070010827e-07
whom O 0 1.08949521404611e-07
presented O 0 1.1209593822059105e-06
with O 0 1.4313473002403043e-06
IDMS B-Disease 1 0.9999992847442627
. O 0 7.168314368755091e-06

One O 0 3.59846421815746e-06
male O 0 2.0100550557344832e-07
and O 0 1.5723197188677318e-09
two O 0 9.381271759423271e-09
female O 0 6.639764364990697e-07
IDMS B-Disease 1 0.9999847412109375
patients O 0 4.260223107621641e-08
with O 0 4.1415626483853885e-09
WT1 O 1 0.9999997615814209
mutations O 0 3.4712131764536025e-06
underwent O 0 1.2918935681227595e-05
normal O 0 4.8508201871300116e-05
puberty O 0 6.464889884227887e-05
. O 0 1.12364865856307e-07

Two O 0 7.622864472978108e-07
mutations O 0 1.8310750249384e-07
associated O 0 1.9342903101460251e-07
with O 0 1.954553674465842e-08
IDMS B-Disease 1 0.9999998807907104
are O 0 9.738243544887837e-10
different O 0 1.1366428631642833e-10
from O 0 1.977750851978044e-09
those O 0 4.158594857361919e-10
described O 0 3.379227919708683e-08
in O 0 8.321039217662474e-07
DDS B-Disease 1 1.0
patients O 0 3.7112540667294525e-06
. O 0 4.483671318666893e-07

No O 0 4.381853068480268e-05
WT1 O 0 0.0008441097452305257
mutations O 0 8.456206757045948e-08
were O 0 1.6218940857015696e-08
detected O 0 4.121870844642217e-08
in O 0 1.0148174522939257e-09
the O 0 4.779090012618781e-09
six O 0 1.4618786181586074e-08
other O 0 5.0989328315154125e-09
IDMS B-Disease 1 1.0
patients O 0 3.3015904676858554e-08
, O 0 3.739747400643978e-10
suggesting O 0 3.95700716637748e-08
genetic O 0 8.834805953483738e-08
heterogeneity O 0 7.647579280956052e-08
of O 0 3.83192855224479e-08
this O 0 1.5652140916699864e-08
disease O 0 2.7952235086559085e-06
. O 0 1.3891852290726092e-07

We O 0 2.1405945460628573e-07
analyzed O 0 1.6105747135952697e-06
genotype O 0 4.708605047198944e-06
/ O 0 1.1454275181677076e-06
phenotype O 0 3.513117263764798e-08
correlations O 0 8.983968768916384e-08
, O 0 5.668156499716304e-10
on O 0 8.175030097312685e-10
the O 0 8.095322190371235e-10
basis O 0 1.3976828583395218e-08
of O 0 3.7763481230967955e-09
the O 0 1.6271546332546905e-09
constitution O 0 1.3937129228480671e-09
of O 0 1.4723161356755554e-08
a O 0 2.991204439695139e-08
WT1 O 0 8.600522050983272e-06
mutation O 0 5.063809371819161e-09
database O 0 1.4361293487752391e-08
of O 0 3.540682858016453e-09
84 O 0 6.632151183794122e-08
germ O 0 0.0024922119919210672
- O 0 4.3431798985693604e-05
line O 0 3.9543218122162216e-07
mutations O 0 1.301096785866207e-09
, O 0 4.3374193126055616e-11
to O 0 6.127087032181677e-11
compare O 0 1.8255340572537193e-09
the O 0 8.91765272736933e-10
distribution O 0 1.225516799152615e-09
and O 0 1.8796848799684795e-10
type O 0 2.611822935705277e-08
of O 0 3.250379521091418e-08
mutations O 0 2.423375722315768e-09
, O 0 2.2031265700661606e-10
according O 0 8.362416870077993e-10
to O 0 1.359727053173998e-10
the O 0 1.758591827716316e-09
different O 0 1.3791949804442538e-09
symptoms O 0 2.9451848604367115e-07
. O 0 1.2620394329587725e-07

This O 0 3.1797603128325136e-07
demonstrated O 0 3.2038471431405924e-07
( O 0 2.916479147074824e-08
1 O 0 3.781568835847793e-08
) O 0 1.7942555219363499e-09
the O 0 2.1744681610869065e-09
association O 0 4.551775845129669e-09
between O 0 1.9087449842913884e-08
mutations O 0 1.2235952695505148e-08
in O 0 2.844032742643776e-08
exons O 0 2.93486053237757e-08
8 O 0 2.4615584237608346e-08
and O 0 2.2151955825222558e-09
9 O 0 1.0349423718025719e-07
and O 0 1.5061361935408968e-08
DMS B-Disease 0 3.502796607790515e-05
; O 0 1.9559327490981104e-09
( O 0 3.526468672632177e-09
2 O 0 6.796215146209761e-09
) O 0 3.0191096844767173e-10
among O 0 1.524664700047751e-10
patients O 0 4.312722678978531e-10
with O 0 9.102560927232162e-10
DMS B-Disease 0 0.07810535281896591
, O 0 3.1430396063569788e-09
a O 0 2.760838890836226e-09
higher O 0 7.89659893030148e-09
frequency O 0 3.5347247351324995e-09
of O 0 1.5620548188266525e-09
exon O 0 1.730875887062666e-08
8 O 0 1.353706147178002e-09
mutations O 0 2.3770631296660127e-11
among O 0 1.0505608535882338e-11
46 O 0 3.538090487253953e-09
, O 0 2.921577424430666e-09
XY O 1 0.7711900472640991
patients O 0 1.0758635760055313e-08
with O 0 7.663780166033973e-10
female O 0 1.3649740537857724e-07
phenotype O 0 5.419220627800314e-09
than O 0 1.2925996384360872e-10
among O 0 3.776301146785066e-11
46 O 0 4.52496706770944e-09
, O 0 2.83633871944744e-09
XY O 1 0.9920360445976257
patients O 0 1.017768180844314e-08
with O 0 2.559261691459369e-10
sexual O 0 1.497871693345587e-07
ambiguity O 0 6.804569920859649e-07
or O 0 8.998752321076608e-08
male O 0 8.829175612845575e-09
phenotype O 0 7.442483851427539e-10
; O 0 1.681156255872729e-11
and O 0 1.7500784155188853e-10
( O 0 5.419383830584934e-10
3 O 0 3.5383942442734906e-09
) O 0 1.0831595342875033e-10
statistically O 0 1.7348768255320834e-10
significant O 0 1.0004393841134274e-10
evidence O 0 2.3639401547370653e-09
that O 0 8.216764768587126e-11
mutations O 0 3.198250553282378e-10
in O 0 1.3309457980170691e-09
exons O 0 9.08594799398088e-09
8 O 0 1.3464657833139881e-08
and O 0 6.123666573820685e-10
9 O 0 1.432714835658544e-08
preferentially O 0 1.0329796573671501e-08
affect O 0 4.307020073923695e-09
amino O 0 3.0293616504195597e-09
acids O 0 1.6063297914037378e-10
with O 0 1.4917844737283303e-11
different O 0 1.3908414697727522e-10
functions O 0 2.828894984929775e-08
. O 0 1.1237939467889646e-08
. O 0 7.169438021037422e-08

The O 0 1.5304580301744863e-05
185delAG O 0 7.016174640739337e-05
BRCA1 O 0 5.765960509052093e-07
mutation O 0 5.287025039990567e-09
originated O 0 2.095131002022299e-08
before O 0 2.484552341641688e-09
the O 0 5.167053895860363e-09
dispersion O 0 6.984295453094091e-08
of O 0 1.0736848565784385e-07
Jews O 0 5.517388146358826e-08
in O 0 6.830886967179595e-09
the O 0 1.527244997134858e-08
diaspora O 0 4.6493685346149505e-08
and O 0 2.2738995131277306e-09
is O 0 2.4306110457672503e-09
not O 0 6.820105036275947e-10
limited O 0 1.6327543761462948e-08
to O 0 7.539893687180665e-08
Ashkenazim O 0 4.181297117611393e-05
. O 0 1.3533889386962983e-06

The O 0 1.8438950064592063e-06
185delAG O 0 7.972489584062714e-06
mutation O 0 5.939514835517912e-08
in O 0 1.3336808102337727e-08
BRCA1 O 0 3.281350302586361e-08
is O 0 4.3150183426377e-10
detected O 0 5.136759018142811e-09
in O 0 1.2596335086101362e-09
Ashkenazi O 0 1.06556512946554e-07
Jews O 0 2.7689880610637374e-08
both O 0 1.7641518246236387e-09
in O 0 2.2109164277139826e-08
familial B-Disease 1 0.8964396715164185
breast I-Disease 1 0.9999997615814209
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 3.180818737291702e-07
in O 0 1.0553764973053603e-08
the O 0 7.348530672857123e-09
general O 0 9.322516092424848e-09
population O 0 2.9742721618930545e-09
. O 0 2.0826920632543988e-08

All O 0 2.3844555130381195e-07
tested O 0 3.006643112257734e-07
Ashkenazi O 0 1.8263624497194542e-06
mutation O 0 1.912013303240201e-08
carriers O 0 4.0053982353072115e-09
share O 0 4.571831357935707e-09
the O 0 5.253671275795568e-09
same O 0 1.2116487368984963e-08
allelic O 0 3.0632492098447983e-07
pattern O 0 5.123112600813329e-07
at O 0 1.137745698542858e-06
the O 0 4.0533575429435587e-07
BRCA1 O 0 2.477362158970209e-06
locus O 0 1.8516395812184783e-06
. O 0 7.188361195176185e-08

Our O 0 3.289062533440301e-06
previous O 0 3.7861229884583736e-07
study O 0 3.1814675338637244e-08
showed O 0 1.059559728844306e-08
that O 0 1.6420657888982504e-10
this O 0 4.874313730418578e-10
Ashkenazi O 0 9.116625676597323e-08
mutation O 0 2.6043447398649278e-09
also O 0 3.196579667630317e-10
occurs O 0 2.1071606681744015e-09
in O 0 2.718486991071245e-09
Iraqi O 0 1.8599311033540289e-06
Jews O 0 9.925000199473288e-08
with O 0 1.7430568099996435e-09
a O 0 1.53691175341919e-08
similar O 0 2.508949048518616e-09
allelic O 0 2.2227646923056454e-07
pattern O 0 1.4374757029145258e-06
. O 0 3.667292389764043e-07

We O 0 7.006129862929811e-07
extended O 0 2.53153388030114e-07
our O 0 3.256858249756078e-08
analysis O 0 8.126575856692853e-09
to O 0 5.715761752789206e-10
other O 0 6.962609377936246e-10
non O 0 6.471132962815318e-08
- O 0 3.452923635904881e-08
Ashkenazi O 0 1.0205288702991311e-07
subsets O 0 6.094855820037992e-08
354 O 0 4.5382197555454695e-08
of O 0 2.9280262658915035e-09
Moroccan O 0 1.201058097421992e-07
origin O 0 4.3481502842723785e-09
, O 0 2.0894870278453936e-09
200 O 0 1.0333777389348597e-08
Yemenites O 0 9.120893764702487e-07
and O 0 3.0058728839321702e-09
150 O 0 6.62310029042601e-08
Iranian O 0 2.145099642802961e-06
Jews O 0 5.378429932534345e-07
. O 0 3.106643475803139e-07

Heteroduplex O 0 0.0001648714969633147
analysis O 0 3.865653468437813e-07
complemented O 0 7.329733620053958e-08
by O 0 1.5183737600565905e-09
direct O 0 4.133576148035445e-09
DNA O 0 1.009522332395818e-08
sequencing O 0 5.679403169978059e-09
of O 0 8.798310524582575e-09
abnormally O 0 2.394776856817771e-07
migrating O 0 8.174066756794218e-09
bands O 0 5.865459584697419e-08
were O 0 1.6940347791205568e-07
employed O 0 5.368573511077557e-06
. O 0 7.246349582601397e-07

Four O 0 1.3553650433095754e-06
of O 0 3.499615388591337e-07
Moroccan O 0 6.85446138959378e-06
origin O 0 5.7500919581343624e-08
( O 0 3.824092154047776e-09
1 O 0 2.5923465596378037e-09
. O 0 5.022338100957313e-11
1 O 0 1.2104238722443483e-09
% O 0 2.6212826353955165e-10
) O 0 2.8925918951760998e-11
and O 0 1.9951089391678778e-11
none O 0 1.4246128721140394e-09
of O 0 2.8820377195870606e-09
the O 0 4.437067957496765e-08
Yemenites O 0 2.8516851671156473e-05
or O 0 1.0960126672898696e-07
Iranians O 0 1.92800641229951e-07
was O 0 4.9802110879682004e-08
a O 0 3.985857865984599e-09
carrier O 0 4.4299794943469806e-09
of O 0 1.3972189627509124e-08
the O 0 7.234122278987343e-08
185delAG O 0 1.0777905117720366e-05
mutation O 0 1.5389173313451465e-07
. O 0 1.940683347356753e-07

BRCA1 O 0 2.8639547963393852e-05
allelic O 0 1.401053282279463e-06
patterns O 0 2.305216497688889e-07
were O 0 2.3047629582606532e-08
determined O 0 2.9239746179854365e-09
for O 0 6.118541784339016e-10
four O 0 8.864471379155248e-10
of O 0 1.8261854251022669e-09
these O 0 7.399394985618812e-11
individuals O 0 1.0551560319926878e-10
and O 0 1.1884387918215111e-10
for O 0 4.833208833154856e-10
12 O 0 5.3910551578439936e-09
additional O 0 4.564137956464265e-09
non O 0 2.5717307039485604e-07
- O 0 1.9360030023563013e-07
Ashkenazi O 0 3.002322443990124e-07
185delAG O 0 4.150992367613071e-07
mutation O 0 3.1107503239979906e-09
carriers O 0 9.049606064515103e-10
who O 0 4.787100049696846e-09
had O 0 1.2123848136980087e-05
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 9.363697608932853e-05

Six O 0 7.367911166511476e-06
non O 0 2.8854421543655917e-05
- O 0 2.036997557297582e-06
Ashkenazi O 0 1.151121864495508e-06
individuals O 0 8.34282598560776e-09
shared O 0 7.52060387299025e-08
the O 0 2.617568206630949e-08
common O 0 1.977363339733529e-08
Ashkenazi O 0 1.378984734401456e-06
haplotype O 0 5.929270514570817e-07
, O 0 6.562387522279778e-09
four O 0 1.2597639376110692e-08
had O 0 6.560149756751343e-08
a O 0 5.417322057610363e-08
closely O 0 2.575993818254574e-08
related O 0 1.9576529552978172e-07
pattern O 0 2.0786558252439136e-06
, O 0 3.297504269639262e-09
and O 0 1.2768881507696506e-09
the O 0 2.147111821670933e-08
rest O 0 4.391300478800986e-08
( O 0 7.2165891040754104e-09
n O 0 3.582550789360539e-08
= O 0 6.607907465649987e-08
6 O 0 1.3097823270413755e-08
) O 0 2.807370169666257e-10
displayed O 0 2.838346668809777e-09
a O 0 4.929102015438502e-09
distinct O 0 8.013918417759669e-09
BRCA1 O 0 7.237586174824173e-08
allelic O 0 3.983815872743435e-07
pattern O 0 2.897928425227292e-06
. O 0 4.1126835981231125e-07

We O 0 9.346070442006749e-07
conclude O 0 1.4531003671436338e-06
that O 0 4.2299226343800456e-09
the O 0 3.213871835328064e-08
185delAG O 0 3.0757946660742164e-06
BRCA1 O 0 5.6506426204805393e-08
mutation O 0 3.909530477130829e-10
occurs O 0 4.752780391470424e-10
in O 0 2.976586199743281e-10
some O 0 4.290095501069402e-10
non O 0 1.9695458775004226e-07
- O 0 1.4121506808351114e-07
Ashkenazi O 0 2.0918334087127732e-07
populations O 0 9.697909142403205e-10
at O 0 5.944022163362206e-09
rates O 0 4.4605874549574764e-09
comparable O 0 1.0493348412410342e-08
with O 0 1.0689815005404668e-10
that O 0 4.336759562573178e-10
of O 0 1.0367580927095332e-07
Ashkenazim O 0 2.0060511815245263e-05
. O 0 6.953258662178996e-07

The O 0 2.262900835603432e-07
majority O 0 4.488563298821191e-09
of O 0 2.3276779614889165e-08
Jewish O 0 1.076486455531267e-06
185delAG O 0 1.5759435427753488e-06
mutation O 0 4.2463401683789925e-09
carriers O 0 6.6039207435864e-10
have O 0 1.476820193913042e-10
a O 0 2.408877985971003e-09
common O 0 9.008498946805332e-10
allelic O 0 3.408617033073824e-08
pattern O 0 4.1075878698393353e-07
, O 0 6.4347722705804244e-09
supporting O 0 4.6493507710465565e-08
the O 0 1.613008322465248e-07
founder O 0 1.6455592231068294e-06
effect O 0 2.452733660618378e-08
notion O 0 4.061568148472361e-08
, O 0 3.183340258061662e-10
but O 0 2.2777399411033628e-10
dating O 0 3.9193299272710647e-08
the O 0 3.374588830595826e-09
mutations O 0 7.249392197650195e-10
origin O 0 1.8373831345286362e-09
to O 0 1.053196085898378e-09
an O 0 4.803013986531823e-09
earlier O 0 2.1211787881725286e-08
date O 0 8.914395266401698e-08
than O 0 1.5444512335704985e-09
currently O 0 5.558738802591279e-09
estimated O 0 4.5930462988508225e-08
. O 0 1.8043053273686382e-07

However O 0 5.12619124037883e-07
, O 0 5.188028673330791e-09
the O 0 3.903109835334817e-09
different O 0 6.107115924081086e-10
allelic O 0 2.1210497891388513e-07
pattern O 0 4.066424708071281e-07
at O 0 3.1614848694516695e-07
the O 0 1.4779791968067002e-07
BRCA1 O 0 1.931094146812029e-07
locus O 0 2.851180269658471e-08
even O 0 1.3199806525587832e-10
in O 0 6.213871778237845e-11
some O 0 5.760698168488787e-11
Jewish O 0 3.896779787737614e-09
mutation O 0 2.34106428687042e-10
carriers O 0 2.1530191518515096e-10
, O 0 2.2873962446379181e-10
might O 0 1.171550745304728e-09
suggest O 0 1.2898425438834238e-08
that O 0 2.654681474645315e-10
the O 0 2.756066930231782e-09
mutation O 0 1.1652661058292324e-09
arose O 0 2.670203258503534e-08
independently O 0 4.786417662216991e-08
. O 0 1.7743879254794592e-08
. O 0 7.244920396942689e-08

Crystal O 0 0.0037364549934864044
structure O 0 7.500834908569232e-05
of O 0 4.238950714352541e-05
the O 0 0.0013073617592453957
hemochromatosis B-Disease 1 1.0
protein O 1 0.9999991655349731
HFE O 1 0.9999997615814209
and O 0 3.138590187745649e-08
characterization O 0 5.376116973820899e-07
of O 0 4.891912297466661e-08
its O 0 4.0520173882896415e-09
interaction O 0 4.60434357307804e-08
with O 0 2.9053068839601792e-09
transferrin O 0 1.3314513125806116e-05
receptor O 0 3.389044195500901e-06
. O 0 1.0770158098694083e-07

HFE O 1 0.9943865537643433
is O 0 1.0561698218225501e-06
an O 0 1.2151252803960233e-07
MHC O 0 4.323007487982977e-06
- O 0 3.663894676719792e-05
related O 0 1.6105033864732832e-05
protein O 0 8.722902862245974e-07
that O 0 7.473266450119809e-10
is O 0 9.183704907655965e-10
mutated O 0 1.375939584491448e-09
in O 0 5.904721600558105e-09
the O 0 4.713380121756927e-07
iron B-Disease 1 1.0
- I-Disease 1 1.0
overload I-Disease 1 1.0
disease I-Disease 1 1.0
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 1 0.9904056191444397

HFE O 0 0.014504002407193184
binds O 0 9.54590996116167e-06
to O 0 1.770102500131543e-07
transferrin O 0 1.888314181996975e-05
receptor O 0 2.551710394982365e-06
( O 0 2.897123962952719e-08
TfR O 0 8.079754479695112e-06
) O 0 6.504450866806621e-10
and O 0 1.9503808290632918e-10
reduces O 0 1.6363576049727158e-09
its O 0 9.204625950332002e-10
affinity O 0 1.020392215167476e-08
for O 0 7.598779383499732e-09
iron O 0 0.00018430226191412657
- O 0 3.4653189686650876e-06
loaded O 0 1.8607489664645982e-06
transferrin O 0 1.7050875612767413e-05
, O 0 3.112402069405107e-08
implicating O 0 0.00012403300206642598
HFE O 1 0.9689225554466248
in O 0 1.8073619685310405e-06
iron O 1 0.9993888139724731
metabolism O 1 0.9999856948852539
. O 0 3.217105813746457e-06

The O 0 2.6197008992312476e-05
2 O 0 1.97727440536255e-05
. O 0 8.718810704522184e-07

6 O 0 0.00018297307542525232
A O 0 1.2948611583851743e-05
crystal O 0 3.393444058019668e-05
structure O 0 6.103399209678173e-05
of O 0 2.3767512175254524e-05
HFE O 1 0.9999792575836182
reveals O 0 2.779332817226532e-06
the O 0 5.435310512780234e-08
locations O 0 1.1769942886985518e-07
of O 0 1.0377052603871562e-06
hemochromatosis B-Disease 1 1.0
mutations O 0 8.217704817070626e-06
and O 0 1.7527734996747313e-07
a O 0 3.673799938042066e-06
patch O 0 0.00011464133422123268
of O 0 6.516286521218717e-05
histidines O 1 0.8937447667121887
that O 0 7.108501343111584e-09
could O 0 1.2434324681009912e-09
be O 0 2.1911841230348728e-09
involved O 0 2.1508705927431038e-08
in O 0 8.581529442608371e-08
pH O 0 6.840525747975335e-05
- O 0 1.2228600098751485e-05
dependent O 0 5.315898761182325e-06
interactions O 0 1.3406444168140297e-06
. O 0 2.0262645250568312e-07

We O 0 5.389520651988278e-07
also O 0 1.0187704013731036e-08
demonstrate O 0 1.3074502192012005e-07
that O 0 1.8212052310673243e-08
soluble O 0 6.522292824229226e-05
TfR O 0 0.23474127054214478
and O 0 2.3511670121934003e-07
HFE O 0 0.0028809518553316593
bind O 0 7.849777148294379e-07
tightly O 0 1.291245212087233e-06
at O 0 7.094201492918728e-08
the O 0 1.1442726766119904e-08
basic O 0 2.2484256589905272e-07
pH O 0 1.1792165821589151e-07
of O 0 1.0172480635617376e-08
the O 0 1.620737499763436e-08
cell O 0 5.6457729158410075e-08
surface O 0 3.234695000742249e-08
, O 0 5.05830488606307e-10
but O 0 2.854904923577095e-10
not O 0 8.627489833656909e-10
at O 0 3.966951922507178e-08
the O 0 4.9205002738972325e-08
acidic O 0 1.7143972854682943e-06
pH O 0 3.0814376259513665e-06
of O 0 7.345197445829399e-07
intracellular O 0 2.6909643565886654e-05
vesicles O 0 0.00020999739354010671
. O 0 1.7168940757983364e-06

TfR O 1 0.9981661438941956
HFE O 0 0.01805027574300766
stoichiometry O 0 1.4979736988607328e-05
( O 0 1.634099362490815e-07
2 O 0 1.2349364908459393e-07
1 O 0 4.789897545265376e-08
) O 0 1.6685142156802613e-09
differs O 0 6.577450140099472e-09
from O 0 1.1302470070972959e-08
TfR O 0 3.518310040817596e-05
transferrin O 0 6.283364086812071e-07
stoichiometry O 0 8.386464145360151e-08
( O 0 1.931578896829933e-09
2 O 0 3.0295581598949184e-09
2 O 0 2.726421310939031e-09
) O 0 1.6168731631349686e-10
, O 0 5.268436728544934e-11
implying O 0 3.288597838491114e-09
a O 0 3.4137209725670914e-10
different O 0 3.3255828646439056e-11
mode O 0 3.6638221345697275e-09
of O 0 1.0757131851946156e-09
binding O 0 3.973462447959264e-09
for O 0 2.2166929625200282e-08
HFE O 0 0.0005450776079669595
and O 0 7.784696975932093e-08
transferrin O 0 1.3147417121217586e-05
to O 0 7.72115598124401e-08
TfR O 0 0.007233581505715847
, O 0 1.4378260360103923e-08
consistent O 0 1.0473476663719339e-07
with O 0 5.622877163879991e-10
our O 0 3.8180598238568564e-08
demonstration O 0 1.461080643139212e-07
that O 0 4.121342378482495e-09
HFE O 0 2.905762812588364e-05
, O 0 5.8883911080442886e-09
transferrin O 0 9.50181856751442e-07
, O 0 2.329035853065875e-09
and O 0 4.1466687861202445e-09
TfR O 0 8.401846571359783e-05
form O 0 1.7551947451011074e-08
a O 0 3.327758690829796e-07
ternary O 0 2.01701059268089e-05
complex O 0 0.00011168566561536863
. O 0 1.2342364925643778e-06

Identification O 0 6.477171154983807e-07
of O 0 3.2978519470816536e-08
three O 0 4.263464248310811e-09
novel O 0 2.9235691201279224e-08
mutations O 0 1.8176853355811318e-09
and O 0 5.087942844816951e-10
a O 0 2.872609261572734e-09
high O 0 1.2659278070259461e-08
frequency O 0 1.113165737365307e-08
of O 0 7.252106026811589e-09
the O 0 4.2072823447369956e-08
Arg778Leu O 0 5.805616456200369e-05
mutation O 0 2.97113089686718e-09
in O 0 3.815255222860969e-09
Korean O 0 3.902213938999921e-05
patients O 0 5.271537872886256e-09
with O 0 2.4476802806816522e-09
Wilson B-Disease 0 0.00036859928513877094
disease I-Disease 0 0.0001469533162890002
. O 0 2.6932158903036907e-07

Four O 0 8.028760021261405e-07
mutations O 0 3.366226764001112e-08
- O 0 1.6110496403598518e-07
- O 0 2.082402943415218e-07
R778L O 0 1.0343596841266844e-06
, O 0 1.6140463188207832e-08
A874V O 0 5.790074624201225e-07
, O 0 5.36301625331248e-09
L1083F O 0 2.474499751770054e-07
, O 0 1.892716428031349e-09
and O 0 1.1000411692663192e-09
2304delC O 0 2.676741246432357e-07
- O 0 2.2815953570898273e-07
- O 0 1.0196960431585467e-07
in O 0 9.843835080403096e-09
the O 0 3.163442130471594e-08
copper O 0 9.120170034293551e-06
- O 0 4.6590051283601497e-07
transporting O 0 1.218510874423373e-06
enzyme O 0 9.852779925267896e-08
, O 0 3.3528264609117286e-09
P O 0 7.301725872821407e-06
- O 0 2.668167269348487e-07
type O 0 2.0888442122668494e-06
ATPase O 0 0.37602904438972473
( O 0 5.3513701914198464e-08
ATP7B O 0 9.783874702407047e-06
) O 0 9.424129254753666e-10
, O 0 8.054856087680307e-11
were O 0 5.47486334045999e-10
identified O 0 7.0885310954338365e-09
in O 0 1.7741003333071603e-08
Korean O 0 0.24056345224380493
Patients O 0 1.641229090409979e-07
with O 0 4.851248736059688e-09
Wilson B-Disease 0 0.0005134058883413672
disease I-Disease 0 0.0003759578976314515
. O 0 3.406265136618458e-07

Arg778Leu O 0 0.0032238508574664593
, O 0 4.34970353069275e-08
the O 0 9.46787892530665e-09
most O 0 1.5736487668505106e-09
frequently O 0 3.5552050192677598e-09
reported O 0 4.229438577141309e-09
mutation O 0 1.8982541927226038e-10
of O 0 2.2677100197654454e-09
this O 0 8.348010616110457e-10
enzyme O 0 2.090169815005538e-08
, O 0 1.1392067289506258e-09
was O 0 9.795628130859768e-08
found O 0 7.47228678932288e-09
in O 0 2.155765344014071e-09
six O 0 4.605377856847781e-09
of O 0 8.021059372254058e-09
eight O 0 1.6085634158002904e-08
unrelated O 0 1.877746882428255e-07
patients O 0 2.481795657871544e-09
studied O 0 3.6607506359587205e-08
, O 0 7.084729469752915e-10
an O 0 7.537412916036601e-10
allele O 0 4.816698706555655e-10
frequency O 0 6.259569307331958e-09
of O 0 1.6712286665665488e-08
37 O 0 7.2899553060779e-07
. O 0 3.1851539006311214e-07

5 O 0 2.3089310161594767e-06
% O 0 3.2652987869141725e-08
, O 0 6.426330578790385e-10
which O 0 9.256982680394543e-11
is O 0 1.1118108517171876e-10
considerably O 0 2.6039077560824353e-09
higher O 0 5.168669936495007e-09
than O 0 9.608789458548372e-11
those O 0 2.983063795980456e-11
in O 0 2.0470716788345555e-10
other O 0 1.5137693876177138e-10
Asian O 0 7.003865931665132e-08
populations O 0 7.37768557357299e-09
. O 0 1.553163819778547e-08

The O 0 3.3971360835494124e-07
novel O 0 1.8095612119850557e-07
single O 0 3.519508950944328e-08
nucleotide O 0 1.1679740197223509e-07
deletion O 0 3.2129459981433683e-08
, O 0 1.2035681340449855e-09
2304delC O 0 6.029998900203282e-08
, O 0 4.351858873263836e-09
was O 0 1.616141673821403e-07
found O 0 2.0426547564511566e-08
in O 0 2.474645555139432e-08
one O 0 1.57216220486589e-07
patient O 0 2.2090275706432294e-06
. O 0 4.0919132970884675e-07

Since O 0 5.999082759444718e-07
a O 0 5.7616961868234284e-08
mutation O 0 7.378431643445538e-09
at O 0 7.82489095740857e-08
cDNA O 0 9.817565569392173e-07
nucleotide O 0 1.53917562784045e-06
2302 O 0 1.764474291121587e-05
( O 0 5.659484436648654e-09
2302insC O 0 5.129545499471533e-08
) O 0 1.7576595734425382e-09
had O 0 2.4803572529208395e-09
been O 0 1.6069986452649232e-09
previously O 0 1.0964157581838663e-08
described O 0 2.5565567440821724e-08
, O 0 6.51711740129457e-10
this O 0 7.53192286317983e-10
region O 0 7.572417359824613e-09
of O 0 6.762468274246203e-08
the O 0 5.767698780800856e-07
ATP7B O 1 0.9994875192642212
gene O 0 2.0195001226852582e-08
may O 0 2.9865909745296904e-09
be O 0 1.6177439388087578e-09
susceptible O 0 2.22729656940146e-08
to O 0 5.371123545927503e-09
gene O 0 1.0699845631734206e-07
rearrangements O 0 8.445232197118457e-06
causing O 0 0.0006911754608154297
Wilson B-Disease 1 0.9292247295379639
disease I-Disease 1 0.9590557217597961
. O 0 9.034193908519228e-07

Disruption O 0 0.00036457719397731125
of O 0 1.8337467508899863e-06
splicing O 0 1.622375634724449e-06
regulated O 0 5.067426513960527e-07
by O 0 1.988084541437729e-08
a O 0 1.85921152251467e-07
CUG O 0 0.00014454268966801465
- O 0 2.5000156256282935e-07
binding O 0 2.1189345389416303e-08
protein O 0 4.4241977548153955e-07
in O 0 2.5911720058502397e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 3.016306663994328e-06

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.8695367574691772
DM B-Disease 1 1.0
) O 0 2.3039834218252508e-07
is O 0 7.18404091770708e-09
caused O 0 2.2853271275380393e-08
by O 0 5.0846566956863626e-09
a O 0 2.079596725934607e-07
CTG O 0 0.00020627430058084428
expansion O 0 1.0567990216259204e-07
in O 0 8.016364461127523e-09
the O 0 1.1759190954307996e-08
3 O 0 7.150155312274364e-08
untranslated O 0 1.0719087185862008e-05
region O 0 9.18127867066687e-08
of O 0 2.7288533033242857e-07
the O 0 4.724541213363409e-06
DM B-Disease 1 1.0
gene O 0 2.0612587832147256e-06
. O 0 3.770362582145026e-07

One O 0 3.286972969362978e-07
model O 0 3.1727873306408583e-07
of O 0 1.3405382333075977e-06
DM B-Disease 1 1.0
pathogenesis O 1 0.9999943971633911
suggests O 0 1.9112860627501504e-06
that O 0 2.6439297418079377e-09
RNAs O 0 1.7781895849111606e-06
from O 0 4.0086618469104e-09
the O 0 2.0714556736578515e-09
expanded O 0 3.8810843427938835e-09
allele O 0 9.439600212601817e-10
create O 0 8.538124096624244e-10
a O 0 8.501922721393385e-09
gain O 0 3.855233998706353e-08
- O 0 1.7067540269977144e-08
of O 0 3.760207079039901e-08
- O 0 6.192678370098292e-08
function O 0 6.614008452032749e-09
mutation O 0 1.9024841424464256e-10
by O 0 9.842586468078451e-11
the O 0 9.578108306484978e-10
inappropriate O 0 1.699759621942576e-08
binding O 0 3.2348661527237255e-09
of O 0 1.2379854474886542e-08
proteins O 0 2.8436133447939937e-09
to O 0 7.1502204157525284e-09
the O 0 3.065142664127052e-07
CUG O 0 0.00538555346429348
repeats O 0 1.6875501387403347e-05
. O 0 8.388733476749621e-07

Data O 0 5.6963140195875894e-06
presented O 0 1.0237808822921579e-07
here O 0 4.1171958287122834e-08
indicate O 0 2.5556792238035086e-08
that O 0 1.880879063609342e-10
the O 0 2.216915984121215e-09
conserved O 0 1.3387455055635655e-07
heterogeneous O 0 4.7087880261642567e-07
nuclear O 0 1.7829486750997603e-05
ribonucleoprotein O 0 0.001458412385545671
, O 0 7.795321010917178e-08
CUG O 0 4.666269160225056e-05
- O 0 1.8353425446093752e-07
binding O 0 5.60777095870435e-08
protein O 0 1.5546758902473812e-07
( O 0 1.3784724472998278e-08
CUG O 0 3.109873432549648e-06
- O 0 5.257193151919637e-07
BP O 0 4.014497335447231e-06
) O 0 7.186151673721497e-09
, O 0 5.189857432696954e-10
may O 0 4.286335286707299e-09
mediate O 0 1.1777532904488908e-07
the O 0 2.0308185355588648e-07
trans O 0 4.315368755669624e-07
- O 0 9.099520070776634e-07
dominant O 0 1.0396293248504662e-07
effect O 0 1.5980194945086623e-08
of O 0 3.550808713725928e-08
the O 0 1.3429614398319245e-07
RNA O 0 5.362668161978945e-06
. O 0 1.1004114242041396e-07

CUG O 1 0.5508703589439392
- O 0 0.0009520198218524456
BP O 0 0.00024032439978327602
was O 0 1.0183359790971735e-06
found O 0 2.0494489660904947e-08
to O 0 1.6831247506843283e-09
bind O 0 9.598028150037408e-09
to O 0 2.9224633824043167e-09
the O 0 3.680795757077249e-08
human O 0 4.186357784874417e-07
cardiac O 0 0.00030445243464782834
troponin O 0 9.672115265857428e-05
T O 0 8.253849955508485e-06
( O 0 2.0816358414776914e-08
cTNT O 0 2.119767827934993e-07
) O 0 1.2087326695109368e-09
pre O 0 1.3130194531640882e-07
- O 0 6.282824926984176e-08
messenger O 0 1.112329996999506e-07
RNA O 0 7.095378151689147e-08
and O 0 2.3320395614589984e-10
regulate O 0 7.035068083638407e-10
its O 0 4.757106375485876e-10
alternative O 0 1.1835154190009689e-08
splicing O 0 4.127169859202695e-07
. O 0 1.3579536073393683e-07

Splicing O 0 4.601101318257861e-05
of O 0 2.4182347715395736e-06
cTNT O 0 4.2102903535123914e-05
was O 0 6.7572341322375e-06
disrupted O 0 8.677690493641421e-05
in O 0 6.413768460333813e-06
DM B-Disease 1 1.0
striated O 1 0.5977275371551514
muscle O 0 1.183884796773782e-05
and O 0 3.112105417812927e-08
in O 0 2.2182705450290996e-08
normal O 0 1.73452485796588e-06
cells O 0 6.498479621086517e-08
expressing O 0 3.176756280254267e-08
transcripts O 0 1.0507908427825896e-06
that O 0 6.281899445070849e-09
contain O 0 1.2042005437251646e-07
CUG O 0 0.00021862590801902115
repeats O 0 5.830018380947877e-06
. O 0 3.872516742831067e-07

Altered O 0 5.2384775699465536e-06
expression O 0 1.1842114133742143e-07
of O 0 3.079928134752663e-08
genes O 0 2.439301916012937e-08
regulated O 0 7.549117242433567e-08
posttranscriptionally O 0 3.967073780586361e-07
by O 0 2.25013252475037e-08
CUG O 0 0.004956686869263649
- O 0 1.1113720574940089e-05
BP O 0 8.33014382806141e-06
therefore O 0 9.23975829181245e-09
may O 0 9.946467649513124e-09
contribute O 0 6.011498498992296e-08
to O 0 1.0214397434538114e-06
DM B-Disease 1 1.0
pathogenesis O 1 0.9999288320541382
. O 0 4.1670639916446817e-07
. O 0 2.6391955998406047e-07

Identification O 0 9.268042617804895e-07
of O 0 8.301304887936567e-08
a O 0 3.5215034444036064e-08
novel O 0 1.6017979476146138e-07
nonsense O 0 1.4772957683817367e-06
mutation O 0 3.2072320355069905e-09
and O 0 2.7698410232090964e-10
a O 0 4.387698204766366e-09
missense O 0 6.7940014503165e-08
substitution O 0 4.012632004446459e-09
in O 0 3.395993708465994e-09
the O 0 2.9087738440125577e-08
vasopressin O 0 8.299783758047852e-07
- O 0 3.421443182105577e-07
neurophysin O 0 4.422056463226909e-06
II O 0 3.4650740417419e-05
gene O 0 6.018953779829417e-09
in O 0 1.0302834141384665e-09
two O 0 8.420870112324508e-10
Spanish O 0 1.413928174542889e-07
kindreds O 0 2.2934943899599602e-06
with O 0 2.670763521450681e-08
familial B-Disease 1 0.999969482421875
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
. O 0 5.286087798594963e-06

Familial B-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 0.0006127058295533061
FNDI B-Disease 1 1.0
) O 0 6.406828134686293e-08
is O 0 1.3935455012159537e-09
an O 0 1.3594433134755946e-08
autosomal B-Disease 1 0.9999144077301025
dominant I-Disease 1 0.9999929666519165
disease I-Disease 1 0.9999934434890747
caused O 0 0.00022646263823844492
by O 0 9.155962743534474e-07
deficiency O 1 1.0
in O 0 1.6864454437381937e-06
the O 0 4.638218342734035e-06
antidiuretic O 0 0.00010594162449706346
hormone O 0 9.964434610765238e-08
arginine O 0 1.6548997905374563e-07
vasopressin O 0 4.0098041154124076e-07
( O 0 7.843281579766881e-09
AVP O 0 4.7073424980226264e-07
) O 0 3.164748185735533e-10
encoded O 0 6.188716761279522e-10
by O 0 7.111861100028705e-10
the O 0 3.939077686254677e-08
AVP O 0 1.2321583199081942e-05
- O 0 4.1739878042790224e-07
neurophysin O 0 8.463260201097e-06
II O 0 0.1879754215478897
( O 0 4.681913196691312e-06
AVP O 0 0.0005104038282297552
- O 0 2.3911832158773905e-06
NPII O 0 8.619777509011328e-05
) O 0 2.2168409330447503e-08
gene O 0 5.255756274635814e-09
on O 0 2.6992424295713136e-08
chromosome O 0 6.686105393782782e-07
20p13 O 0 8.032428922888357e-06
. O 0 7.357452318501601e-07

In O 0 2.4231928819062887e-07
this O 0 3.018829186629546e-09
study O 0 1.2872226839988343e-08
, O 0 3.5465544390156367e-10
we O 0 8.189403044589483e-10
analyzed O 0 1.4234402101465093e-08
two O 0 7.482337527342509e-10
families O 0 4.0403466683436307e-10
with O 0 1.1120658838237318e-09
FNDI B-Disease 1 1.0
using O 0 1.1121390031121337e-07
direct O 0 7.404629087659487e-08
automated O 0 3.039207854271808e-07
fluorescent O 0 3.903526835102866e-09
, O 0 2.04656805391501e-10
solid O 0 8.002981388699482e-09
phase O 0 2.0215965790271184e-08
, O 0 1.1719484271921488e-09
single O 0 3.532803605210688e-09
- O 0 3.069674958666724e-09
stranded O 0 3.457271358087155e-09
DNA O 0 2.642093488436359e-10
sequencing O 0 3.766635059410106e-10
of O 0 2.357209094583368e-09
PCR O 0 4.176842338665665e-08
- O 0 2.3478551725020225e-07
amplified O 0 2.525402123865206e-06
AVP O 0 7.58225069148466e-05
- O 0 1.6536296243430115e-06
NPII O 0 5.4891424952074885e-05
DNA O 0 2.343149617445306e-06
. O 0 1.675049219329594e-07

In O 0 4.530142234671075e-07
one O 0 1.5717416701477305e-08
of O 0 2.031410595293437e-08
the O 0 1.1825609824711592e-08
families O 0 2.1060477806145173e-09
, O 0 5.237020817006055e-10
affected O 0 8.052095656907454e-10
individuals O 0 1.7948739716722173e-10
presented O 0 1.3720301339503749e-08
a O 0 3.118641345167816e-08
novel O 0 1.1570460856091813e-07
nonsense O 0 7.415362688334426e-07
mutation O 0 4.394716590638836e-09
in O 0 3.922439262282751e-09
exon O 0 4.755333193884326e-08
3 O 0 5.5262741049944e-09
of O 0 2.3423294415181317e-09
the O 0 5.870067543156665e-09
gene O 0 6.048158085469879e-10
, O 0 1.6928210222477702e-10
consisting O 0 6.90165924410735e-09
in O 0 6.6295688938566855e-09
a O 0 9.629388131315864e-08
G O 0 3.772391323764168e-07
to O 0 2.2996472281988645e-08
T O 0 5.366604227674543e-07
transition O 0 6.842051334388088e-07
at O 0 2.015922973441775e-06
nucleotide O 0 6.3756119743629824e-06
2101 O 0 1.1340656783431768e-05
, O 0 1.612777578152702e-09
which O 0 1.408106270472942e-10
produces O 0 2.103164586930717e-10
a O 0 2.904398055392221e-09
stop O 0 6.15006534587792e-09
signal O 0 5.0711097543398864e-08
in O 0 8.790125960445039e-09
codon O 0 1.3715074942410865e-07
82 O 0 6.227234621292155e-07
( O 0 1.3810337406994222e-07
Glu O 0 5.079261973151006e-05
) O 0 2.4013466770611558e-08
of O 0 1.9243472593188926e-07
NPII O 0 0.002371304901316762
. O 0 1.9785006770689506e-06

The O 0 3.0483215596177615e-06
premature O 0 4.067160716658691e-06
termination O 0 1.1146028100483818e-06
eliminates O 0 4.355797784683091e-07
part O 0 6.309857525366169e-08
of O 0 1.0956259188787953e-07
the O 0 2.357512158823738e-07
C O 0 0.0001980931410798803
- O 0 6.263408977247309e-06
terminal O 0 2.276088935104781e-06
domain O 0 1.0216512009719736e-06
of O 0 1.0121911486749013e-07
NPII O 0 0.0009861115831881762
, O 0 8.8405336384767e-09
including O 0 1.922551673416706e-09
a O 0 1.4544472293209765e-08
cysteine O 0 2.6119773011146208e-08
residue O 0 1.661522617268929e-07
in O 0 2.637623452983462e-09
position O 0 1.8263255796568956e-08
85 O 0 3.257131453437978e-08
, O 0 4.973542133690501e-10
which O 0 1.7258533491215644e-10
could O 0 4.829550093177204e-10
be O 0 9.191696292987217e-10
involved O 0 1.2189363296499778e-08
in O 0 1.0332831479331617e-08
the O 0 1.0764858870970784e-07
correct O 0 4.4633402467297856e-06
folding O 0 1.4857582755212206e-05
of O 0 1.5603961855958914e-06
the O 0 2.8472402391344076e-06
prohormone O 0 0.00646383548155427
. O 0 1.3974329249322182e-06

In O 0 1.381555534862855e-06
the O 0 1.679675563082128e-07
second O 0 6.878341878291394e-07
family O 0 2.79436818573231e-07
, O 0 4.871211434220868e-09
a O 0 2.1102911418324766e-08
G279A O 0 1.1838658053875406e-07
substitution O 0 7.178835748078427e-09
at O 0 3.151830085812435e-08
position O 0 3.2654792647690556e-08
- O 0 1.3485192518203348e-08
1 O 0 1.6674079006406828e-08
of O 0 6.285530762539793e-09
the O 0 6.858852152902273e-09
signal O 0 1.0856140875148412e-07
peptide O 0 2.3019687489522767e-08
was O 0 1.3087160688485255e-08
observed O 0 2.3147932459721687e-09
in O 0 2.9796989875485735e-10
all O 0 2.1129471783343234e-10
affected O 0 3.4604117349346097e-09
individuals O 0 4.488948768255341e-09
. O 0 8.851605315385314e-08

This O 0 4.829606154999055e-07
missense O 0 1.1208129762962926e-05
mutation O 0 2.192063064399008e-08
, O 0 2.7952800074615425e-09
which O 0 5.137219094564216e-09
replaces O 0 1.7303959793935064e-06
Ala O 0 0.0004143056576140225
with O 0 1.1830419310854268e-07
Thr O 0 0.023404506966471672
, O 0 2.7111459743878186e-08
is O 0 6.263187746213816e-09
frequent O 0 7.825439851671945e-09
among O 0 7.676804969491968e-09
FNDI B-Disease 1 1.0
patients O 0 2.749715349636972e-06
and O 0 2.3575417174015456e-09
is O 0 5.23429699583744e-09
thought O 0 6.1045102306422905e-09
to O 0 7.263619705710767e-10
reduce O 0 2.427081202682757e-09
the O 0 2.228716056151825e-08
efficiency O 0 8.469087475759807e-08
of O 0 2.0324725014120304e-08
cleavage O 0 3.884782415752852e-07
by O 0 1.305258390260633e-08
signal O 0 5.576220019065659e-07
peptidases O 0 1.0263141120958608e-05
. O 0 3.616831989461389e-08
. O 0 1.1259785281936274e-07

Genetic O 0 0.00010190455213887617
heterogeneity O 0 2.1408573957160115e-05
of O 0 1.8579048628453165e-05
Saethre B-Disease 1 1.0
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 2.3741579369129795e-08
due O 0 5.00743396969483e-07
to O 0 6.422770582048543e-08
TWIST O 0 0.00024181701883208007
and O 0 3.306027167582215e-07
FGFR O 1 0.9943747520446777
mutations O 0 2.4829535050230334e-06
. O 0 6.679770763184933e-07

Thirty O 0 0.0003613198932725936
- O 0 6.015495728206588e-06
two O 0 2.3692180661782913e-08
unrelated O 0 6.968360821701935e-07
patients O 0 3.6798810665317205e-09
with O 0 1.8046815430938778e-10
features O 0 4.0923460176145454e-08
of O 0 2.0435241822269745e-05
Saethre B-Disease 1 1.0
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 1.2857349629413761e-09
a O 0 5.516985090991966e-09
common O 0 1.887115530507799e-08
autosomal B-Disease 0 4.567980067804456e-05
dominant I-Disease 0 3.414606544538401e-05
condition I-Disease 0 0.14996328949928284
of O 0 0.24655139446258545
craniosynostosis B-Disease 1 1.0
and O 0 0.0003991202684119344
limb B-Disease 1 1.0
anomalies I-Disease 1 0.9999998807907104
, O 0 7.004119595421798e-08
were O 0 4.573324829948433e-08
screened O 0 2.74063562955007e-08
for O 0 5.093383048659916e-09
mutations O 0 6.444623501522528e-09
in O 0 8.472335366604966e-08
TWIST O 0 0.0007187130395323038
, O 0 3.0788243066126597e-07
FGFR2 O 1 0.9997989535331726
, O 0 2.1109558190346434e-07
and O 0 1.4076707657295628e-06
FGFR3 O 1 0.9999938011169434
. O 0 2.8678792659775354e-05

Nine O 0 3.8060304632381303e-06
novel O 0 6.335145599223324e-07
and O 0 2.616440042402246e-08
three O 0 2.9243274468626623e-08
recurrent O 0 1.3981360098114237e-05
TWIST O 0 2.109118941007182e-05
mutations O 0 2.5290814775758008e-08
were O 0 1.0572240860540205e-08
found O 0 2.9776836552031227e-09
in O 0 9.806336187523357e-09
12 O 0 2.735779389695381e-07
families O 0 3.5029803058250764e-08
. O 0 2.7340317387825053e-07

Seven O 0 1.8584028111945372e-06
families O 0 1.360561352470313e-08
were O 0 7.940277768625492e-09
found O 0 2.7605755459347847e-09
to O 0 8.726440681172676e-10
have O 0 8.780972060584702e-10
the O 0 8.420364139283265e-08
FGFR3 O 0 0.000361658982001245
P250R O 0 1.768129777701688e-06
mutation O 0 2.071451676854963e-09
, O 0 2.947344590609191e-10
and O 0 2.3843843566240253e-10
one O 0 1.3351130201399997e-09
individual O 0 1.7250578743244205e-09
was O 0 2.660694349287951e-07
found O 0 1.4264571746025467e-08
to O 0 2.199550319659238e-09
have O 0 2.6731370450505665e-09
an O 0 4.498207673009347e-08
FGFR2 O 0 0.00022906335652805865
VV269 O 0 3.172288779751398e-05
- O 0 4.885804173682118e-06
270 O 0 2.256901552755153e-06
deletion O 0 1.6122114629979478e-06
. O 0 1.0561319641055888e-07

To O 0 1.0120734117435859e-07
date O 0 3.015384208993055e-07
, O 0 2.988882030763307e-09
our O 0 8.689009511897439e-09
detection O 0 3.024755557134995e-08
rate O 0 2.2660248788497483e-08
for O 0 1.5505966510787061e-09
TWIST O 0 1.7780284906621091e-06
or O 0 1.505593871797828e-07
FGFR O 0 7.80669433879666e-05
mutations O 0 5.927560220442274e-09
is O 0 9.595406691431663e-10
68 O 0 2.032577128829871e-08
% O 0 8.652621397153837e-10
in O 0 1.0413708784184905e-09
our O 0 1.500223447692406e-07
Saethre B-Disease 1 0.9999916553497314
- I-Disease 1 0.9999678134918213
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 3.756921884701114e-09
, O 0 2.0276189061085859e-10
including O 0 3.61956103978045e-10
our O 0 1.6681171999266553e-08
five O 0 9.9227248639977e-09
patients O 0 5.77314196448242e-10
elsewhere O 0 1.6058282481523634e-09
reported O 0 4.6070911530193825e-09
with O 0 5.742665787344947e-10
TWIST O 0 7.00971804690198e-06
mutations O 0 1.2105310531751456e-07
. O 0 6.9537499314265e-08

More O 0 1.2407511462697585e-08
than O 0 6.96199820016119e-10
35 O 0 4.1939158812454025e-09
different O 0 2.1463766874951773e-10
TWIST O 0 2.6862235813496227e-07
mutations O 0 1.7093136905899087e-09
are O 0 2.4943563881052455e-10
now O 0 6.714215294856274e-10
known O 0 9.759849595170067e-10
in O 0 1.9817687491041625e-09
the O 0 2.9697783787696608e-08
literature O 0 1.1817039649031358e-06
. O 0 4.7305638872785494e-07

The O 0 4.310379608796211e-07
most O 0 2.63209054551794e-09
common O 0 4.055378810541299e-10
phenotypic O 0 5.888289855704443e-09
features O 0 5.3843143277276795e-09
, O 0 5.591413443362114e-10
present O 0 1.111726488645104e-09
in O 0 1.0427900765108689e-09
more O 0 1.5206162717884553e-10
than O 0 1.1380420217310672e-10
a O 0 9.35685640079953e-10
third O 0 3.6057334895645e-09
of O 0 8.1002529128682e-09
our O 0 2.390648390360184e-08
patients O 0 6.643159911057239e-10
with O 0 2.1634750935195513e-10
TWIST O 0 2.486953690095106e-06
mutations O 0 4.417028076630913e-09
, O 0 7.403040402920169e-10
are O 0 7.741202678879233e-10
coronal B-Disease 0 5.717147359973751e-06
synostosis I-Disease 0 0.00017375973402522504
, O 0 1.2037412489007693e-07
brachycephaly B-Disease 0 0.0034376904368400574
, O 0 1.0249741535517387e-06
low B-Disease 1 0.9110961556434631
frontal I-Disease 1 1.0
hairline I-Disease 1 1.0
, O 0 3.307617816972197e-06
facial B-Disease 1 0.9989801049232483
asymmetry I-Disease 1 1.0
, O 0 5.395581410994055e-06
ptosis B-Disease 1 0.9999978542327881
, O 0 4.92258436679549e-07
hypertelorism B-Disease 1 0.9993435740470886
, O 0 3.4867230169766117e-07
broad B-Disease 0 5.6402164773317054e-05
great I-Disease 1 0.9991814494132996
toes I-Disease 1 0.9999992847442627
, O 0 4.484740827592759e-07
and O 0 6.165771537780529e-07
clinodactyly B-Disease 1 0.9995933175086975
. O 0 3.5908768040826544e-05

Significant O 0 1.7097901945817284e-05
intra O 0 0.0005289019900374115
- O 0 7.904806807346176e-06
and O 0 1.1460593363210592e-08
interfamilial O 0 1.1039279343094677e-05
phenotypic O 0 4.0448853155794495e-07
variability O 0 7.496922194150102e-07
is O 0 8.098950954327222e-10
present O 0 6.807900909677755e-10
for O 0 6.87857937275993e-10
either O 0 3.579716079116224e-08
TWIST O 0 1.8942881069961004e-05
mutations O 0 1.3285703914789337e-07
or O 0 9.607208539819112e-08
FGFR O 0 0.0006163925863802433
mutations O 0 2.196942148202652e-07
. O 0 1.7131210938714503e-07

The O 0 2.903337019688479e-07
overlap O 0 1.0466128230746108e-07
in O 0 1.1041701775127422e-08
clinical O 0 1.2015300399070838e-07
features O 0 1.3174718205277713e-08
and O 0 5.842296646463296e-10
the O 0 4.270178433074534e-09
presence O 0 3.628624956064641e-09
, O 0 3.02668001772588e-10
in O 0 1.4567973216639274e-10
the O 0 7.129816737005967e-10
same O 0 7.989281458620212e-10
genes O 0 1.7854945300044278e-10
, O 0 1.382657096454798e-11
of O 0 2.2596179094502844e-10
mutations O 0 3.326737496589516e-11
for O 0 8.014475194606518e-11
more O 0 5.760873722504556e-11
than O 0 2.6329877167441396e-10
one O 0 1.637606605875419e-09
craniosynostotic B-Disease 0 2.896381943173765e-07
condition I-Disease 0 7.07584888459678e-07
- O 0 7.199777485311643e-08
such O 0 4.4674499655172895e-09
as O 0 8.366477288745955e-08
Saethre B-Disease 0 0.000235901796258986
- I-Disease 0 4.47073489340255e-06
Chotzen I-Disease 0 0.00010546275007072836
, I-Disease 0 2.5272008485899278e-08
Crouzon I-Disease 0 3.840641147689894e-05
, I-Disease 0 2.4337854398481795e-08
and I-Disease 0 7.129754919787956e-08
Pfeiffer I-Disease 0 0.30100274085998535
syndromes I-Disease 0 0.0005884898127987981
- O 0 1.823327465899638e-06
support O 0 2.1567943875311357e-08
the O 0 2.4812008447838707e-08
hypothesis O 0 5.079773757188377e-08
that O 0 1.663235660309681e-10
TWIST O 0 2.617328576093314e-08
and O 0 6.380431738506331e-10
FGFRs O 0 2.0423253772605676e-06
are O 0 2.2954686762499676e-10
components O 0 8.162055031846194e-09
of O 0 4.067163050791578e-09
the O 0 5.5584314928580625e-09
same O 0 1.2010598737788314e-08
molecular O 0 9.044799043067542e-08
pathway O 0 1.7488854808789256e-08
involved O 0 1.0353224944026351e-09
in O 0 4.149427745847589e-10
the O 0 7.418309522222444e-09
modulation O 0 1.2469938326375996e-07
of O 0 2.9762267672595044e-07
craniofacial O 1 1.0
and O 0 1.9318913473398425e-06
limb O 1 1.0
development O 0 0.11242616921663284
in O 0 2.4655906827319996e-07
humans O 0 1.7831283116720442e-07
. O 0 6.599768287429697e-09
. O 0 3.868145626029218e-08

Mutation O 0 1.464867409595172e-06
analysis O 0 2.724534056142147e-07
of O 0 7.059281870169798e-07
UBE3A O 1 0.9999978542327881
in O 0 0.1879422515630722
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.2536678612232208
. O 0 7.716428740422998e-07

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9966192245483398
AS B-Disease 1 1.0
) O 0 5.299001486491761e-07
is O 0 7.926463041485476e-09
caused O 0 2.495639073174516e-08
by O 0 2.119003106315631e-08
chromosome O 0 1.956413143489044e-06
15q11 O 0 2.0208493879181333e-05
- O 0 6.542408300447278e-06
q13 O 0 9.869584573607426e-06
deletions O 0 2.695667262742063e-07
of O 0 4.5837342810273185e-08
maternal O 0 9.630946351535385e-07
origin O 0 5.954123949436507e-08
, O 0 9.064104133926776e-09
by O 0 6.849403888509187e-08
paternal O 0 0.23615464568138123
uniparental B-Disease 1 0.9999998807907104
disomy I-Disease 1 0.9999904632568359
( O 0 0.00010218266834272072
UPD B-Disease 1 1.0
) O 0 2.135753085497072e-08
15 O 0 1.86975697147318e-08
, O 0 7.812118174577165e-10
by O 0 8.644740923102745e-09
imprinting O 0 0.19631901383399963
defects O 1 0.6838051080703735
, O 0 4.991429936040959e-09
and O 0 1.4405234782799425e-09
by O 0 7.943503632645843e-09
mutations O 0 6.574113697865869e-09
in O 0 7.134285340271163e-08
the O 0 2.827382104442222e-06
UBE3A O 1 0.9991253018379211
gene O 0 1.3486704801835003e-06
. O 0 2.2072262595429493e-07

UBE3A O 1 0.9715414047241211
encodes O 0 0.00010156037023989484
a O 0 8.419189043706865e-07
ubiquitin O 0 2.005026544793509e-06
- O 0 9.942618817149196e-07
protein O 0 8.030385600932277e-08
ligase O 0 2.526507500988373e-07
and O 0 4.799744157679697e-09
shows O 0 1.1188730297817528e-07
brain O 0 6.055148332961835e-05
- O 0 2.0728367644551327e-07
specific O 0 3.560391093060389e-08
imprinting O 0 5.482633787323721e-05
. O 0 5.424046776170144e-07

Here O 0 2.2765448193240445e-06
we O 0 1.1583831138750611e-07
describe O 0 2.7796670565294335e-06
UBE3A O 0 0.0004571993194986135
coding O 0 5.5572014389326796e-05
- O 0 7.277222948687267e-07
region O 0 3.1335240180396795e-08
mutations O 0 7.759152431674465e-09
detected O 0 8.684552632587383e-09
by O 0 1.4553233063097082e-09
SSCP O 0 0.00014920053945388645
analysis O 0 7.756344189147057e-08
in O 0 2.560044176647125e-09
13 O 0 3.521986968735291e-08
AS B-Disease 1 0.9352879524230957
individuals O 0 4.136028852741447e-09
or O 0 2.442411783931675e-08
families O 0 1.7057516288332408e-08
. O 0 9.59007167011805e-08

Two O 0 1.5297980553441448e-06
identical O 0 6.715437734783336e-07
de O 0 5.363839591154829e-06
novo O 0 3.695403393066954e-06
5 O 0 1.2869890042566112e-06
- O 0 1.4711196172356722e-06
bp O 0 4.1876783143379726e-06
duplications O 0 1.9909323327738093e-06
in O 0 9.603599693264186e-08
exon O 0 9.63023012445774e-07
16 O 0 1.9716827637239476e-07
were O 0 1.0407522665900615e-07
found O 0 2.8184746270198957e-07
. O 0 4.5325535324991506e-07

Among O 0 1.139299072860922e-07
the O 0 3.790826497152011e-08
other O 0 1.4123461289372585e-09
11 O 0 7.383978317676565e-09
unique O 0 1.9766384085073696e-09
mutations O 0 4.3421893858308636e-10
, O 0 1.6436325911417526e-10
8 O 0 9.328314121148651e-09
were O 0 3.1988747206668222e-09
small O 0 3.7300251776173354e-09
deletions O 0 1.5975562206449467e-08
or O 0 1.589768494625332e-08
insertions O 0 3.3509269314890844e-07
predicted O 0 1.5326791924508143e-07
to O 0 1.5938185882191647e-08
cause O 0 4.5569640860776417e-07
frameshifts O 0 3.301489778095856e-05
, O 0 2.9247567923107454e-08
1 O 0 1.4259148883866146e-07
was O 0 6.076643899177725e-08
a O 0 7.458048401076667e-09
mutation O 0 1.244390285259911e-10
to O 0 1.7253992679044927e-10
a O 0 4.61234028747981e-09
stop O 0 6.740163094320906e-09
codon O 0 4.783561280419235e-08
, O 0 1.7485611847334326e-09
1 O 0 4.539604958608834e-08
was O 0 1.2056126763582142e-07
a O 0 1.251453696227145e-08
missense O 0 4.584040524946431e-08
mutation O 0 2.6237637062997976e-10
, O 0 4.69494304544682e-11
and O 0 1.0860722737815465e-10
1 O 0 1.5604417313852537e-08
was O 0 1.3095467465973343e-07
predicted O 0 2.824393341427367e-08
to O 0 1.456022968859827e-09
cause O 0 8.543390883630764e-09
insertion O 0 3.39681811567516e-08
of O 0 1.2397676130149193e-07
an O 0 6.365657156948146e-08
isoleucine O 0 2.9808341423631646e-05
in O 0 6.306548527845734e-08
the O 0 2.1598660282506899e-07
hect O 0 2.4497596314176917e-05
domain O 0 1.8589487353892764e-06
of O 0 4.9590543227395756e-08
the O 0 2.1191775090301235e-07
UBE3A O 0 0.0005490828189067543
protein O 0 1.1576134539836858e-07
, O 0 2.2218124562378705e-10
which O 0 1.188601994606131e-10
functions O 0 5.9579381428420675e-09
in O 0 6.262889318264797e-09
E2 O 0 1.6996580143313622e-06
binding O 0 3.0080368418339276e-08
and O 0 5.509087852573202e-09
ubiquitin O 0 4.5251422875480785e-07
transfer O 0 1.1849247130157892e-06
. O 0 1.6551474573134328e-06

Eight O 0 1.9397930373088457e-06
of O 0 1.4739619302872597e-07
the O 0 2.0687954460640867e-08
cases O 0 9.352114638261355e-09
were O 0 8.302714604724315e-08
familial O 0 7.819212441972923e-06
, O 0 1.3129763942743011e-08
and O 0 4.8132942076506424e-09
five O 0 4.4715612546042394e-08
were O 0 1.6844204253629869e-07
sporadic O 0 1.63176518981345e-05
. O 0 8.777092830314359e-07

In O 0 1.5900163816695567e-06
two O 0 5.6458592467834023e-08
familial O 0 2.1689329514629208e-06
cases O 0 8.177060806247027e-09
and O 0 2.716620928211455e-09
one O 0 9.659073541001817e-09
sporadic O 0 1.7135656094069418e-07
case O 0 3.5961949862439724e-08
, O 0 1.0315188703202693e-08
mosaicism O 0 2.0846948245889507e-05
for O 0 3.4027188178242795e-08
UBE3A O 0 0.008388192392885685
mutations O 0 5.079376563799087e-08
was O 0 6.66237696123062e-08
detected O 0 1.9664598838176062e-08
in O 0 7.546778202360827e-10
the O 0 3.3195535209529226e-09
mother O 0 6.002138519534128e-08
of O 0 7.700095494556081e-08
three O 0 4.527585417690716e-08
AS B-Disease 1 1.0
sons O 0 0.00015951886598486453
, O 0 1.567750551600966e-08
in O 0 2.2803243737712364e-08
the O 0 2.259946114691047e-07
maternal O 0 2.5480590920778923e-05
grandfather O 0 0.00013410647807177156
of O 0 1.999841333599761e-05
two O 0 1.3188601144520362e-07
AS B-Disease 1 0.9999992847442627
first O 0 8.857074931256648e-07
cousins O 0 1.116088810704241e-06
, O 0 8.229885217758692e-09
and O 0 9.172103077048632e-09
in O 0 1.459619625165942e-07
the O 0 4.8201782192336395e-06
mother O 0 0.00012889414210803807
of O 0 0.00022336268739309162
an O 0 5.107448305352591e-05
AS B-Disease 1 1.0
daughter O 1 0.9999336004257202
. O 0 5.469192183227278e-05

The O 0 3.4109720559172274e-07
frequencies O 0 1.930441761999191e-08
with O 0 4.0382511223846507e-10
which O 0 1.1498444418833742e-09
we O 0 2.214460614879954e-09
detected O 0 1.2517473280126978e-08
mutations O 0 5.03635577686623e-10
were O 0 6.898053683812577e-09
5 O 0 1.6279159353871364e-08
( O 0 1.5954998433542755e-09
14 O 0 3.4772631440915802e-09
% O 0 4.2256789734018696e-10
) O 0 9.122579081033422e-11
of O 0 8.545569807338893e-10
35 O 0 2.7502695676417943e-09
in O 0 9.204099704618329e-10
sporadic O 0 4.6344766246875224e-08
cases O 0 4.417590460104037e-10
and O 0 4.4071629679010016e-10
8 O 0 1.1650800324503052e-08
( O 0 5.926969470770871e-10
80 O 0 1.37092037721942e-09
% O 0 1.2717031594444705e-10
) O 0 2.695426173926485e-11
of O 0 2.0359353092302968e-10
10 O 0 8.421961461557714e-10
in O 0 1.5490240201643246e-09
familial O 0 1.7741028557338723e-07
cases O 0 2.770825124898124e-09
. O 0 3.1501996566873913e-09
. O 0 4.751171900352347e-08

The O 0 5.527772009372711e-05
hemochromatosis B-Disease 1 0.9999957084655762
845 O 0 9.927432074618991e-06
G O 0 1.9825956769636832e-06
- O 0 2.2791900278207322e-07
- O 0 1.23384168659868e-07
> O 0 7.071990637541603e-08
A O 0 1.1662005583445989e-08
and O 0 1.3803495846342884e-10
187 O 0 5.132427260967631e-10
C O 0 4.503484696272153e-09
- O 0 3.890771704817553e-09
- O 0 3.898558276205222e-08
> O 0 8.408326834796753e-08
G O 0 5.67200117984612e-08
mutations O 0 7.569093685155792e-10
: O 0 1.6710963168797832e-10
prevalence O 0 2.617731365006648e-09
in O 0 1.270501259753587e-09
non O 0 2.5759354116416944e-07
- O 0 7.561148436252552e-07
Caucasian O 0 4.171534783381503e-06
populations O 0 8.335194223718645e-08
. O 0 4.368769168650033e-08

Hemochromatosis B-Disease 1 1.0
, O 0 7.00973203038302e-07
the O 0 4.9607271648710594e-05
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 1 1.0
iron I-Disease 1 1.0
metabolism I-Disease 1 1.0
, O 0 3.8889857023605146e-07
leads O 0 5.01353099480184e-07
, O 0 6.988543965746885e-09
if O 0 2.447961833240697e-08
untreated O 1 0.7658926248550415
, O 0 1.523802772851468e-08
to O 0 2.6806370101439825e-07
progressive O 1 0.9999914169311523
iron B-Disease 1 1.0
overload I-Disease 1 1.0
and O 0 9.725081326905638e-06
premature B-Disease 0 9.333834168501198e-05
death I-Disease 0 1.5988562154234387e-05
. O 0 1.4244228623283561e-06

The O 0 0.0007681531133130193
hemochromatosis B-Disease 1 1.0
gene O 0 5.067708480055444e-05
, O 0 4.2606617967066995e-07
HFE O 1 0.9996227025985718
, O 0 5.4880523236988665e-08
recently O 0 3.818292881874186e-08
has O 0 3.6808059378223845e-10
been O 0 9.578529081011311e-10
identified O 0 4.245384488399395e-09
, O 0 5.734850372363098e-10
and O 0 1.5371746098225003e-09
characterization O 0 1.300960661865247e-06
of O 0 2.851632530109782e-07
this O 0 2.6125253071995758e-08
gene O 0 6.340305169771909e-09
has O 0 1.1868937777048671e-10
shown O 0 1.1357305373937976e-10
that O 0 4.9324988538046455e-12
it O 0 2.0279956099850116e-12
contains O 0 2.1946619868651318e-11
two O 0 2.559367995313977e-11
mutations O 0 3.105826706928383e-11
that O 0 1.352852985886388e-11
result O 0 3.6204725328836673e-10
in O 0 1.368537727586272e-09
amino O 0 3.4729414899459243e-09
acid O 0 1.9367658588009817e-09
substitutions O 0 2.819396938136265e-09
- O 0 2.1104479941413956e-08
cDNA O 0 6.726654788735686e-08
nucleotides O 0 2.602105420024259e-09
845 O 0 9.985188675898371e-09
G O 0 1.0951721307606022e-08
- O 0 9.5213383843884e-09
- O 0 2.786232577989267e-08
> O 0 4.375189988081729e-08
A O 0 8.247535276950657e-08
( O 0 1.6325636398306642e-09
C282Y O 0 1.844293961994481e-08
) O 0 1.8410410695945956e-10
and O 0 1.7256032713852676e-10
187 O 0 2.205364335594595e-09
C O 0 9.264057077018606e-09
- O 0 7.977879690201917e-09
- O 0 7.517692068859105e-08
> O 0 2.3290687067856197e-07
G O 0 7.789804499225284e-07
( O 0 6.58205863146577e-08
H63D O 0 4.045672540087253e-05
) O 0 9.239708020913895e-08
. O 0 7.697246928728418e-08

Although O 0 9.601529745850712e-05
hemochromatosis B-Disease 1 1.0
is O 0 1.4619656951708748e-07
common O 0 1.997038623358094e-08
in O 0 1.1095832697094465e-08
Caucasians O 0 1.3442748070247035e-07
, O 0 4.032411293763971e-09
affecting O 0 6.642912353527208e-08
> O 0 4.3524508441805665e-08
= O 0 2.9126544731639115e-08
1 O 0 1.3962385914112474e-08
/ O 0 7.245842592595864e-09
300 O 0 9.756276897476823e-10
individuals O 0 6.328048501869077e-11
of O 0 1.0289362695203863e-09
northern O 0 3.7120742590879274e-10
European O 0 1.6386251244782102e-09
origin O 0 3.6677374470883706e-09
, O 0 2.4976698487222393e-10
it O 0 4.268887326963622e-11
has O 0 2.2307541230892625e-11
not O 0 2.8083648254129123e-11
been O 0 2.9950320001859154e-10
recognized O 0 1.5673425057816104e-10
in O 0 1.6062011443107593e-10
other O 0 1.957058543000656e-10
populations O 0 3.0023146191382466e-09
. O 0 1.918958680846572e-08

The O 0 1.2547117478334258e-07
present O 0 8.929163186621736e-09
study O 0 2.032882528979485e-09
used O 0 9.244636167693443e-10
PCR O 0 3.734730746884907e-09
and O 0 2.633243900707072e-10
restriction O 0 4.995220681536239e-09
- O 0 2.92563706594251e-09
enzyme O 0 3.411190663271668e-09
digestion O 0 7.095348752983455e-09
to O 0 1.7232482107942815e-10
analyze O 0 4.035481282471665e-09
the O 0 2.8876061541893705e-09
frequency O 0 4.6632031569515675e-09
of O 0 5.5399937970435076e-09
the O 0 6.98150914857365e-09
845 O 0 7.374777055701998e-08
G O 0 5.76755638803661e-08
- O 0 1.1515371767245597e-08
- O 0 1.869386068165113e-08
> O 0 1.372574676139493e-08
A O 0 3.2414317896467537e-09
and O 0 3.9137290630542054e-11
187 O 0 2.322823738909463e-10
C O 0 1.967802143454378e-09
- O 0 1.8358592424050357e-09
- O 0 1.0431764785323594e-08
> O 0 3.1397878075267727e-08
G O 0 5.952205128778587e-08
mutations O 0 1.2680004823906188e-09
in O 0 1.1898568796908648e-09
HLA O 0 1.1599429683428752e-07
- O 0 3.896073685893953e-09
typed O 0 2.7504754029905598e-08
samples O 0 4.6951698084996e-10
from O 0 9.71735136801044e-10
non O 0 5.4381722236485075e-08
- O 0 4.458411950736263e-08
Caucasian O 0 1.927565165260603e-07
populations O 0 2.846950897250622e-09
, O 0 2.749024896608887e-10
comprising O 0 5.050325047051274e-09
Australian O 0 6.380048489518231e-07
Aboriginal O 0 2.631931920404895e-06
, O 0 6.0459930395495576e-09
Chinese O 0 1.7234677329724946e-07
, O 0 1.5004036901800077e-09
and O 0 4.5285761807178915e-09
Pacific O 0 1.488078964939632e-06
Islanders O 0 2.6283150873496197e-06
. O 0 5.131777243150282e-07

Results O 0 2.0385152765811654e-06
showed O 0 2.747896417076845e-07
that O 0 1.4149965643639462e-09
the O 0 8.403000961720863e-09
845 O 0 1.448144786309058e-07
G O 0 3.881886527778988e-07
- O 0 5.814366090817202e-07
- O 0 6.419421083592169e-07
> O 0 1.7976412891584914e-07
A O 0 1.7482017611314404e-08
mutation O 0 6.423435394697918e-11
was O 0 3.4059943754272126e-10
present O 0 8.433918147199293e-11
in O 0 7.503113408358075e-11
these O 0 6.134360380771753e-11
populations O 0 1.643375574511552e-10
( O 0 6.329593099652087e-11
allele O 0 3.338045118095323e-11
frequency O 0 1.7207685276687812e-10
0 O 0 3.700549588980806e-11
. O 0 3.502786385597978e-12
32 O 0 1.0878552919590945e-10
% O 0 4.2741504779897355e-11
) O 0 2.3815288283102198e-11
, O 0 2.665563429704587e-11
and O 0 7.276651503573817e-11
, O 0 5.408902215009448e-10
furthermore O 0 8.77581918246051e-09
, O 0 3.1159805291558484e-10
it O 0 1.6868068053454977e-10
was O 0 1.3706752177711223e-08
always O 0 4.243312368146235e-09
seen O 0 6.678138042559567e-09
in O 0 1.967772167432713e-09
conjunction O 0 3.9565843934497025e-08
with O 0 8.793865191591976e-09
HLA O 0 6.776004011044279e-05
haplotypes O 0 4.1332791056447604e-07
common O 0 4.346798920806805e-09
in O 0 3.2571174646278678e-09
Caucasians O 0 6.512600236874277e-08
, O 0 7.810985191980535e-10
suggesting O 0 6.841958111181157e-09
that O 0 5.346947329343266e-10
845 O 0 2.7003288494142907e-08
G O 0 5.685985016157247e-08
- O 0 8.667760198477481e-08
- O 0 4.814128260477446e-07
> O 0 2.747482312770444e-07
A O 0 6.03038969870795e-08
may O 0 1.3329501946657274e-09
have O 0 4.758383617686768e-11
been O 0 1.8869265872023533e-10
introduced O 0 8.883677821147629e-11
into O 0 8.632045078726946e-11
these O 0 7.230979703898299e-11
populations O 0 2.036541213445986e-10
by O 0 2.3001418547607955e-09
Caucasian O 0 2.6566044653009158e-06
admixture O 0 2.141114237019792e-06
. O 0 2.060687478433465e-07

187 O 0 4.97670725962962e-07
C O 0 5.202608690524357e-07
- O 0 8.697221431930302e-08
- O 0 1.065939159161644e-07
> O 0 1.562467417670632e-07
G O 0 1.0360701452327703e-07
was O 0 2.4094994444112672e-08
present O 0 4.479608683993774e-09
at O 0 1.3787276209598076e-08
an O 0 1.1467846672275073e-09
allele O 0 9.155319280473861e-10
frequency O 0 6.82992329359422e-09
of O 0 1.9280205876270884e-08
2 O 0 5.461091063807544e-07
. O 0 3.181437762123096e-07

68 O 0 5.067791789770126e-06
% O 0 2.9042110938348742e-08
in O 0 1.5854738633080956e-09
the O 0 1.271985183848301e-09
two O 0 2.1198257038612667e-10
populations O 0 9.255535227126188e-11
analyzed O 0 3.75657815965269e-09
( O 0 2.69933875252093e-09
Australian O 0 2.3422998651767557e-07
Aboriginal O 0 9.902920510285185e-07
and O 0 8.576304999508011e-09
Chinese O 0 1.0132725947187282e-06
) O 0 6.8332983715890805e-09
. O 0 1.856958675716669e-08

In O 0 7.632277174707269e-07
the O 0 1.7009554653668602e-07
Australian O 0 1.0947711643893854e-06
Aboriginal O 0 1.9576958720790572e-07
samples O 0 9.617576735010402e-10
, O 0 2.8150698438977884e-10
187 O 0 8.997560474455213e-10
C O 0 6.5578333874327654e-09
- O 0 6.355463710860931e-09
- O 0 2.460446069108002e-08
> O 0 4.2531432598025276e-08
G O 0 3.5859351044109644e-08
was O 0 6.528903639946293e-09
found O 0 3.7919797857277615e-10
to O 0 6.885506748099957e-11
be O 0 5.843611705635965e-10
associated O 0 2.1421255880227363e-08
with O 0 4.8692818666040694e-08
HLA O 0 0.12071342021226883
haplotypes O 0 2.3265008621820016e-06
common O 0 7.808874435966118e-09
in O 0 8.842405030407008e-09
Caucasians O 0 2.0061330019416346e-07
, O 0 2.599044979234577e-09
suggesting O 0 1.9166176201679264e-08
that O 0 8.823577285488327e-11
it O 0 1.046942740834389e-10
was O 0 5.415242476658477e-09
introduced O 0 5.891466203777895e-10
by O 0 2.004066246286129e-09
recent O 0 1.9727410816017255e-08
admixture O 0 2.847176006071095e-07
. O 0 5.982297324180763e-08

In O 0 7.971150921548542e-07
the O 0 7.872645824136271e-08
Chinese O 0 7.344329588931942e-08
samples O 0 1.1805590949265365e-09
analyzed O 0 4.464127734138401e-09
, O 0 1.8878518193155003e-10
187 O 0 1.3582607261142243e-09
C O 0 6.336412283758364e-09
- O 0 4.546603982191755e-09
- O 0 4.283738519461622e-08
> O 0 1.166357819215591e-07
G O 0 8.984020638536094e-08
was O 0 3.4398098591736925e-08
present O 0 7.836043813824745e-09
in O 0 7.407041202611708e-09
association O 0 5.025514671075371e-09
with O 0 2.613025906761379e-10
a O 0 7.2310011312026745e-09
wide O 0 2.6219590942844206e-09
variety O 0 1.6696601878862793e-09
of O 0 3.992358301729837e-07
HLA O 0 1.3960335309093352e-05
haplotypes O 0 8.416365915309143e-08
, O 0 1.8798820833332286e-10
showing O 0 1.5043352119548103e-09
this O 0 6.166821220343621e-11
mutation O 0 5.327693841650216e-11
to O 0 5.677079639720972e-11
be O 0 2.0952248269701101e-10
widespread O 0 2.672892351895939e-09
and O 0 3.443258733693e-10
likely O 0 1.8150732028487937e-09
to O 0 1.993369025399261e-09
predate O 0 2.375184493530469e-07
the O 0 4.7273416292625825e-09
more O 0 1.3227076378630187e-10
genetically O 0 4.699416411568791e-10
restricted O 0 2.7247890610482273e-09
845 O 0 3.814056626083584e-08
G O 0 9.797310696058048e-08
- O 0 1.9653693072996248e-07
- O 0 4.358020930794737e-07
> O 0 4.6422795207945455e-07
A O 0 1.0769520741860106e-07
mutation O 0 1.0825864649177674e-08
. O 0 1.1207350603115174e-08

Genotype O 0 0.0001762688480084762
- O 0 1.1809056559286546e-05
phenotype O 0 1.994478452616022e-06
correlations O 0 3.6750473100255476e-06
in O 0 1.251964249604498e-06
attenuated B-Disease 1 0.9587142467498779
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 0.9999997615814209
. O 0 7.273654318851186e-06

Germ O 1 0.8541949391365051
- O 0 3.0108692953945138e-05
line O 0 1.9967839648415975e-07
mutations O 0 8.962675046575441e-09
of O 0 1.1727451898480012e-08
the O 0 7.542151791994911e-08
tumor B-Disease 0 1.1476995496195741e-05
suppressor O 0 5.5270847951760516e-06
APC O 0 1.434826657487065e-07
are O 0 2.606763693790981e-10
implicated O 0 4.928051922092891e-08
in O 0 2.3440919960648898e-07
attenuated B-Disease 1 0.9736528992652893
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 1 0.8780248165130615
AAPC B-Disease 1 1.0
) O 0 1.0494172641983823e-07
, O 0 1.2708503138725291e-09
a O 0 3.596250053305994e-08
variant O 0 8.520333381056844e-07
of O 0 0.06864160299301147
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.9999985694885254
FAP B-Disease 0 0.006462570745497942
) O 0 6.420884233193647e-07
. O 0 3.9045346511557e-07

AAPC B-Disease 1 1.0
is O 0 1.160613507522612e-07
recognized O 0 6.929068430139296e-09
by O 0 5.039968442588361e-10
the O 0 3.417416571949161e-09
occurrence O 0 1.1260622301279e-07
of O 0 1.7700180876545346e-07
< O 0 2.285068876517471e-05
100 O 0 7.326574404942221e-07
colonic B-Disease 0 0.00014340734924189746
adenomas I-Disease 0 1.5555700883851387e-05
and O 0 3.1504099329282553e-09
a O 0 9.198224404372013e-09
later O 0 7.330223183998896e-08
onset O 0 0.012234900146722794
of O 1 0.9985673427581787
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 8.889163609637762e-07
age O 0 2.70663349510869e-07
> O 0 9.690263169659374e-08
40 O 0 4.662758179563298e-09
years O 0 2.459764614215487e-09
) O 0 4.169239176121664e-09
. O 0 3.6462349584098774e-08

The O 0 1.008702497529157e-06
aim O 0 3.9867958889772126e-07
of O 0 2.3486743216949435e-08
this O 0 1.4511932766581026e-09
study O 0 3.3560638712515356e-09
was O 0 6.115161710340544e-09
to O 0 3.1069657957516483e-10
assess O 0 9.54254133489485e-08
genotype O 0 6.823349849582883e-07
- O 0 5.817344685965509e-07
phenotype O 0 1.8846917271275743e-07
correlations O 0 1.3538226539822062e-06
in O 0 7.734405471637729e-07
AAPC B-Disease 1 1.0
families O 0 8.780290841059468e-07
. O 0 3.0901642844582966e-07

By O 0 5.444346697913716e-07
protein O 0 1.928966497644069e-07
- O 0 5.920952972360283e-08
truncation O 0 5.028556984143506e-07
test O 0 6.312156841659089e-08
( O 0 1.6903713628835249e-07
PTT O 0 1.4686423128296155e-05
) O 0 1.597823540144816e-09
assay O 0 5.333026464882096e-09
, O 0 1.6299243899009497e-10
the O 0 9.392474575875553e-10
entire O 0 5.025172100658892e-08
coding O 0 1.1478788053409517e-07
region O 0 1.4698581907168773e-08
of O 0 3.2619432488445455e-08
the O 0 1.6938150793066598e-07
APC B-Disease 0 1.035773266266915e-06
gene O 0 2.7643640709840156e-09
was O 0 5.526790580745455e-09
screened O 0 4.057415736724579e-09
in O 0 7.48105355441453e-10
affected O 0 1.8883135055602907e-09
individuals O 0 3.932737746570325e-10
from O 0 2.486027916859257e-08
11 O 0 2.6153029466513544e-05
AAPC B-Disease 1 1.0
kindreds O 0 0.07996108382940292
, O 0 2.9361186815179963e-09
and O 0 3.4076383381709263e-10
their O 0 6.417670284086796e-10
phenotypic O 0 1.5921568063959057e-08
differences O 0 2.3963776740743015e-08
were O 0 1.0949073470101212e-07
examined O 0 1.3990611478220671e-06
. O 0 3.5964976063951326e-07

Five O 0 2.118915972459945e-06
novel O 0 5.29836233909009e-06
germ O 0 0.023919615894556046
- O 0 0.00024927433696575463
line O 0 5.386296379583655e-06
APC B-Disease 0 1.03742513601901e-06
mutations O 0 3.796034153680239e-09
were O 0 6.3627405566535344e-09
identified O 0 1.6398454150134967e-08
in O 0 3.0450330257281166e-08
seven O 0 3.8709066529918346e-07
kindreds O 0 6.546182703459635e-05
. O 0 2.8190142984385602e-06

Mutations O 0 9.703021532914136e-07
were O 0 1.0544654571731371e-07
located O 0 5.056014273918663e-08
in O 0 7.797008594323529e-10
three O 0 1.4304607498516475e-10
different O 0 8.247161981111972e-11
regions O 0 1.594371301649744e-09
of O 0 1.1371670893822738e-07
the O 0 8.383383374166442e-07
APC B-Disease 0 2.382794491495588e-06
gene O 0 4.211454740499221e-09
( O 0 1.5810377451686008e-09
1 O 0 1.2267826754452926e-08
) O 0 9.552785229516303e-10
at O 0 1.1768367613740338e-08
the O 0 1.578369079879849e-08
5 O 0 7.845289218266771e-08
end O 0 1.0017086538027797e-07
spanning O 0 9.63615548243979e-07
exons O 0 3.884107613316701e-08
4 O 0 1.027085794191862e-08
and O 0 8.555796626730228e-10
5 O 0 8.098707482417922e-09
, O 0 9.449129256822175e-10
( O 0 1.117858805521621e-09
2 O 0 6.50809095503746e-09
) O 0 4.5997744502201954e-10
within O 0 2.5323914076835763e-09
exon O 0 7.363992082787263e-09
9 O 0 3.249609026312328e-09
, O 0 1.4171268325480213e-10
and O 0 3.292789096942528e-10
( O 0 1.3667039722164986e-09
3 O 0 1.2212100664044101e-08
) O 0 5.573716488349589e-10
at O 0 8.903431769624603e-09
the O 0 4.299181899369842e-09
3 O 0 2.8293914766663875e-08
distal O 0 6.600690483082872e-08
end O 0 3.9513658123269124e-08
of O 0 5.1279709367690884e-08
the O 0 8.87441089503227e-08
gene O 0 2.7670505886590036e-08
. O 0 6.719498912843846e-08

Variability O 0 6.315327482298017e-05
in O 0 4.1149505136672815e-08
the O 0 1.3879808413719275e-08
number O 0 2.1434457764257786e-08
of O 0 7.241435014293529e-06
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 0.00010339186701457947
most O 0 1.797362148003856e-09
apparent O 0 1.0657863036556137e-08
in O 0 3.1187691318379507e-10
individuals O 0 2.5558263838654227e-11
with O 0 5.1411153112468355e-11
mutations O 0 2.4531662812243837e-10
in O 0 5.552593052016164e-09
region O 0 6.990719469968099e-08
1 O 0 2.4740115804888774e-06
, O 0 7.409118207846177e-09
and O 0 1.4093973987883146e-08
upper O 1 0.9999904632568359
- O 1 0.9293480515480042
gastrointestinal O 0 0.0024909155908972025
manifestations O 0 0.054684363305568695
were O 0 3.584513024179614e-07
more O 0 9.277597023960027e-10
severe O 0 8.373501714231679e-08
in O 0 1.2989774589300396e-08
them O 0 3.972812834263095e-08
. O 0 4.0583896065982117e-07

In O 0 1.772411621914216e-07
individuals O 0 5.36307753762344e-09
with O 0 1.3228697026690384e-09
mutations O 0 3.0676792217576576e-09
in O 0 5.361675992077153e-09
either O 0 3.1972778202771224e-08
region O 0 1.5740855019430455e-07
2 O 0 2.894791180096945e-07
or O 0 2.512915564523155e-08
region O 0 1.5894594085352765e-08
3 O 0 1.1178891590191142e-08
, O 0 2.52696696900756e-10
the O 0 4.566425571006505e-10
average O 0 3.2348044243235563e-09
number O 0 2.506613250297107e-10
of O 0 4.955043042542684e-09
adenomas B-Disease 0 1.4815185522820684e-06
tended O 0 1.0169997288755894e-08
to O 0 8.032247089673206e-10
be O 0 5.556149984542458e-10
lower O 0 4.800440489560742e-09
than O 0 1.450893571952605e-10
those O 0 3.012935734236777e-11
in O 0 4.7643593931168127e-11
individuals O 0 3.369979989509275e-11
with O 0 1.7343166833216905e-11
mutations O 0 5.720830753563888e-11
in O 0 3.385598468241824e-10
region O 0 2.4068893544892944e-09
1 O 0 3.133398607246818e-08
, O 0 5.717539219851631e-10
although O 0 5.519655843500004e-10
age O 0 2.351525196786497e-08
at O 0 1.744214159771218e-07
diagnosis O 0 2.527457070300443e-07
was O 0 7.487141573392364e-08
similar O 0 6.319864187531721e-09
. O 0 6.579259093086876e-08

In O 0 5.2435807447182015e-06
all O 0 1.5318433952415944e-06
AAPC B-Disease 1 1.0
kindreds O 0 0.001074635423719883
, O 0 3.8106755084754695e-08
a O 0 5.310606709940657e-08
predominance O 0 3.4319893984502414e-06
of O 0 3.204487256880384e-06
right O 1 0.6452503800392151
- O 1 1.0
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 0 0.37439975142478943
rectal B-Disease 1 1.0
polyp I-Disease 0 0.09545040130615234
sparing O 0 3.716885885296506e-06
was O 0 1.3791793662676355e-06
observed O 0 9.36015510433208e-07
. O 0 2.740578963766893e-07

No O 0 0.003428979776799679
desmoid B-Disease 1 0.9999995231628418
tumors I-Disease 1 1.0
were O 0 8.18801879631792e-07
found O 0 7.024642911801493e-08
in O 0 3.9935304840810204e-08
these O 0 7.577434502081815e-08
kindreds O 0 6.0239552112761885e-05
. O 0 1.7656224144957378e-06

Our O 0 1.195208255921898e-06
data O 0 2.927208129221981e-07
suggest O 0 1.682666450619763e-08
that O 0 7.198768248173337e-10
, O 0 1.8027112025365e-09
in O 0 7.26634254988312e-08
AAPC B-Disease 1 1.0
families O 0 5.8399297842015585e-08
, O 0 1.1068602701058694e-09
the O 0 6.159915244552394e-09
location O 0 1.910998719267809e-07
of O 0 6.00146279339242e-08
the O 0 3.6759547583642416e-07
APC B-Disease 0 6.203055818332359e-06
mutation O 0 6.1684857222132905e-09
may O 0 1.4811792903302035e-09
partially O 0 1.602311385795474e-07
predict O 0 2.5375033629870813e-08
specific O 0 2.556170164424998e-09
phenotypic O 0 2.1776948244678351e-07
expression O 0 3.845261744572781e-07
. O 0 2.142800354931751e-07

This O 0 2.3615940847321326e-07
should O 0 1.6054860552117134e-08
help O 0 9.527078681514922e-09
in O 0 3.379194035701971e-09
the O 0 5.1735917772077755e-09
design O 0 2.253130126916858e-08
of O 0 1.5990346824423796e-08
tailored O 0 4.3130317095574355e-08
clinical O 0 4.726704446511576e-06
- O 0 5.687643920282426e-07
management O 0 4.825872110814089e-07
protocols O 0 4.533695019404149e-08
in O 0 1.4508998447126942e-09
this O 0 8.591150013614879e-10
subset O 0 9.672425704820853e-08
of O 0 3.526483638438549e-08
FAP B-Disease 0 1.4598607549487497e-06
patients O 0 8.38417335558006e-09
. O 0 5.726939367178829e-09
. O 0 3.555613758976506e-08

Wilms B-Disease 1 0.9999958276748657
' I-Disease 0 0.00010554827167652547
tumor I-Disease 0 8.979753147286829e-06
1 O 0 1.7601941237899155e-07
and O 0 7.154068004666669e-09
Dax O 0 0.0001036349858622998
- O 0 1.3720975289288617e-07
1 O 0 3.708511187028307e-08
modulate O 0 8.057788392079601e-08
the O 0 3.93618382332761e-09
orphan O 0 7.771730281547207e-08
nuclear O 0 1.8575455840164068e-07
receptor O 0 7.585213097627275e-07
SF O 0 4.227708814141806e-06
- O 0 1.0002096040295783e-08
1 O 0 2.8330513490715248e-09
in O 0 3.2294825147438644e-10
sex O 0 1.1814511591268229e-09
- O 0 7.605010510225441e-10
specific O 0 5.299198302388675e-10
gene O 0 2.5311117646253933e-09
expression O 0 1.1748116257592756e-08
. O 0 1.6651576117965305e-08

Products O 0 7.583311116832192e-07
of O 0 1.5537036688328953e-06
steroidogenic O 0 0.00012458064884413034
factor O 0 2.6442698981554713e-06
1 O 0 2.143008828170423e-07
( O 0 1.6678914249723675e-08
SF O 0 1.0161330465052743e-05
- O 0 4.0326515460265e-08
1 O 0 3.2299972474447713e-08
) O 0 2.0852906068569155e-09
and O 0 2.4196578074509034e-09
Wilms B-Disease 0 0.000691701308824122
tumor I-Disease 0 6.9631196311092936e-06
1 O 0 2.0908959186272114e-07
( O 0 6.524309981159604e-09
WT1 O 0 5.789373176412482e-07
) O 0 1.7847590072506136e-10
genes O 0 3.178569907280604e-11
are O 0 5.430688017338259e-12
essential O 0 9.628167152442302e-10
for O 0 1.2039721442036466e-09
mammalian O 0 2.396917864189163e-07
gonadogenesis O 0 3.0352680369105656e-06
prior O 0 2.485338654878433e-07
to O 0 6.356045467725835e-09
sexual O 0 1.5506424233535654e-07
differentiation O 0 8.20113996269356e-07
. O 0 1.727487699554331e-07

In O 0 4.952655103807047e-07
males O 0 2.379970531762865e-08
, O 0 3.7501298066899835e-08
SF O 0 0.0024468363262712955
- O 0 3.144301103930047e-07
1 O 0 3.600120734859047e-08
participates O 0 3.991617258947144e-09
in O 0 3.9914399563301117e-10
sexual O 0 1.5804798580987267e-09
development O 0 1.8617631880601948e-09
by O 0 2.514984609458537e-10
regulating O 0 7.012230796021868e-09
expression O 0 2.5974244977078342e-09
of O 0 2.175210678245776e-09
the O 0 1.104321878386827e-08
polypeptide O 0 1.8561904653324746e-05
hormone O 0 7.193970645857917e-07
Mullerian O 0 5.9671467170119286e-05
inhibiting O 0 6.978003739277483e-07
substance O 0 3.3000736721078283e-07
( O 0 1.271263556645863e-07
MIS O 0 8.37413826957345e-05
) O 0 3.714896834594583e-08
. O 0 4.479414528191228e-08

Here O 0 2.6219461233267793e-06
, O 0 2.7791312362523968e-08
we O 0 2.3312413333087534e-08
show O 0 7.64144090226182e-08
that O 0 1.4742775888976212e-08
WT1 O 0 0.00010473665315657854
- O 0 3.7759324186481535e-05
KTS O 0 0.0071127456612885
isoforms O 0 8.792795824774657e-08
associate O 0 1.664177347038276e-07
and O 0 1.74192682500518e-09
synergize O 0 6.849285227872315e-07
with O 0 1.7778026162318383e-08
SF O 1 0.7740461230278015
- O 0 1.9250901459599845e-06
1 O 0 1.0476113487811745e-07
to O 0 1.0476089329358729e-08
promote O 0 3.8367340948752826e-07
MIS O 0 0.00460472609847784
expression O 0 5.932024578214623e-07
. O 0 6.666343210781633e-08

In O 0 6.820500857429579e-07
contrast O 0 6.449046168199857e-07
, O 0 1.723594351688007e-07
WT1 O 0 0.0011028674198314548
missense O 0 1.5766496289870702e-05
mutations O 0 1.9557843344841785e-08
, O 0 1.7362348225802293e-09
associated O 0 3.6216778909192726e-08
with O 0 2.1162566810062344e-08
male B-Disease 0 3.9016929804347456e-05
pseudohermaphroditism I-Disease 1 1.0
in O 0 1.4543616089213174e-05
Denys B-Disease 1 1.0
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 1.3278483379508543e-07
fail O 0 1.4071245004743105e-06
to O 0 1.1906685415397078e-07
synergize O 0 6.036629929440096e-05
with O 0 2.507317276467802e-06
SF O 1 1.0
- O 0 0.001030792249366641
1 O 0 2.4225480956374668e-05
. O 0 6.941107244529121e-07

Additionally O 0 2.846724328264827e-06
, O 0 1.9160218300839915e-08
the O 0 3.2545234063263706e-08
X O 0 3.659686626633629e-06
- O 0 2.51704648235318e-07
linked O 0 4.3790683434963285e-07
, O 0 1.4809901083268073e-09
candidate O 0 2.2588217962749013e-09
dosage O 0 4.941322728768682e-08
- O 0 5.1524320809903656e-08
sensitive O 0 1.0470760258840528e-07
sex O 0 8.796095407603843e-09
- O 0 8.930576278487479e-09
reversal O 0 5.048786988481879e-08
gene O 0 1.260835325034293e-09
, O 0 6.878592140324713e-10
Dax O 0 1.533555223431904e-05
- O 0 6.587923451206734e-08
1 O 0 4.8734726476595824e-08
, O 0 3.3438665170137938e-09
antagonizes O 0 4.810149221157189e-07
synergy O 0 2.0521544286111748e-07
between O 0 1.139279461881415e-07
SF O 0 5.415063787950203e-05
- O 0 1.0072147915707319e-07
1 O 0 3.040512197571843e-08
and O 0 2.9619364738664444e-09
WT1 O 0 5.557624717766885e-06
, O 0 1.2435320551063e-09
most O 0 2.9630706221972503e-10
likely O 0 5.737585406784262e-10
through O 0 8.211629154430966e-10
a O 0 4.243134288373085e-09
direct O 0 5.666905167345249e-09
interaction O 0 2.2574791813667616e-08
with O 0 5.292301707982006e-09
SF O 0 0.3610266447067261
- O 0 7.412241302517941e-06
1 O 0 1.7583464568815543e-06
. O 0 1.1906071506473381e-07

We O 0 1.3382875749812229e-06
propose O 0 4.228416230489529e-07
that O 0 9.810830192691355e-08
WT1 O 0 2.717833012866322e-05
and O 0 3.3256520737268147e-07
Dax O 0 0.25059089064598083
- O 0 3.39069288202154e-06
1 O 0 2.677946326912206e-07
functionally O 0 1.231168909043845e-07
oppose O 0 1.95393298763058e-10
each O 0 3.1516088350169724e-11
other O 0 3.617543764544706e-11
in O 0 6.130678742444218e-10
testis O 0 4.7006849968056486e-07
development O 0 1.6702376370858474e-08
by O 0 6.104533323281203e-09
modulating O 0 1.90092475804704e-06
SF O 0 0.0006483630859293044
- O 0 5.443287705020339e-07
1 O 0 4.552350958419993e-07
- O 0 5.279771997379612e-08
mediated O 0 3.5591426694736583e-07
transactivation O 0 5.664212494593812e-06
. O 0 9.257822064512311e-09
. O 0 3.344869625721003e-08

A O 0 7.224838100228226e-06
mouse O 0 2.7258411705588514e-07
model O 0 1.8792745137830025e-08
for O 0 2.645267827006137e-08
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 0.9999111890792847
- O 0 0.004142715595662594
centre O 0 1.30521102619241e-05
mutations O 0 1.1434767088758235e-07
. O 0 1.509386464704221e-07

Imprinting O 0 0.00023378826153930277
in O 0 4.2174860936938785e-07
the O 0 2.5894379973578907e-07
15q11 O 0 1.7740190742188133e-05
- O 0 2.8221586489962647e-06
q13 O 0 7.64757987781195e-06
region O 0 1.247785945679425e-07
involves O 0 3.497973750654637e-07
an O 0 2.988991809615982e-08
imprinting O 0 1.1377412647561869e-06
centre O 0 2.8085971734981285e-06
( O 0 4.889832183607723e-08
IC O 0 1.7097244153774227e-06
) O 0 2.1063972788226693e-09
, O 0 7.258939005438947e-10
mapping O 0 3.745247312281208e-08
in O 0 3.5665204123347394e-09
part O 0 1.2314808728319804e-08
to O 0 1.6988034090559267e-08
the O 0 2.49774444682771e-07
promoter O 0 3.0377611892618006e-06
and O 0 2.204902926905561e-08
first O 0 5.354591507966688e-07
exon O 0 2.755127979980898e-06
of O 0 9.202130399899033e-07
SNRPN O 0 0.0011686033103615046
. O 0 3.0576416065741796e-06

Deletion O 0 1.2832796528527979e-05
of O 0 2.250070849640906e-07
this O 0 3.392751324327037e-08
IC O 0 3.989365723100491e-06
abolishes O 0 1.2352545297744655e-07
local O 0 8.391452865907922e-09
paternally O 0 2.8291873377384036e-07
derived O 0 3.8834333082604644e-08
gene O 0 1.7228350968068185e-09
expression O 0 7.172317184611643e-10
and O 0 1.0196091193570567e-10
results O 0 3.072891274769063e-09
in O 0 1.0436704656058282e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9532591700553894
PWS B-Disease 1 1.0
) O 0 2.201687493652571e-06
. O 0 3.4960660855176684e-07

We O 0 1.745274147424425e-07
have O 0 7.328860296418327e-10
created O 0 1.57191792915512e-09
two O 0 1.3168807155850004e-09
deletion O 0 1.3038251367447629e-08
mutations O 0 1.4552261617950535e-09
in O 0 4.950546195203742e-09
mice O 0 1.0561215013638048e-08
to O 0 9.413858137463649e-09
understand O 0 2.8309703338891268e-05
PWS B-Disease 1 1.0
and O 0 9.034592096668348e-08
the O 0 6.165594612639325e-08
mechanism O 0 2.474405391694745e-07
of O 0 4.064884961962889e-08
this O 0 2.3714468611046868e-08
IC O 0 1.2957777471456211e-05
. O 0 2.0822797353048372e-07

Mice O 0 0.0014866003766655922
harbouring O 0 0.0003640656068455428
an O 0 1.0186036547565891e-07
intragenic O 0 2.377295277256053e-05
deletion O 0 9.892065691019525e-07
in O 0 4.9250260758526565e-08
Snrpn O 0 0.0003088988596573472
are O 0 5.804911662465884e-09
phenotypically O 0 3.446476966928458e-06
normal O 0 4.926745305056102e-07
, O 0 9.942745515800766e-10
suggesting O 0 1.5294020272449416e-08
that O 0 5.644647527169866e-10
mutations O 0 1.765097623618317e-09
of O 0 4.271825915225236e-08
SNRPN O 0 0.015194527804851532
are O 0 1.3107888108265797e-09
not O 0 9.598993822024227e-10
sufficient O 0 9.824724855889144e-08
to O 0 1.2529397963589872e-07
induce O 0 0.00011852344323415309
PWS B-Disease 1 1.0
. O 0 1.0905054296017624e-05

Mice O 0 1.658498695178423e-05
with O 0 4.663496699919278e-09
a O 0 1.7082522063560646e-08
larger O 0 7.939005008950062e-09
deletion O 0 4.745692550045533e-08
involving O 0 5.786011669783875e-08
both O 0 4.009999887699678e-09
Snrpn O 0 5.790708746644668e-05
and O 0 1.0941825223653723e-08
the O 0 2.672073833309696e-07
putative O 0 8.758530748309568e-05
PWS O 1 1.0
- O 0 0.00027837418019771576
IC O 0 5.549046181840822e-05
lack O 0 4.2352249352006766e-07
expression O 0 3.747205212789595e-08
of O 0 2.159536016677066e-08
the O 0 3.405043003112951e-08
imprinted O 0 1.1833956250484334e-06
genes O 0 1.7005319818963471e-07
Zfp127 O 0 3.3418422390241176e-05
( O 0 1.4989376495577744e-07
mouse O 0 1.1739048488834669e-07
homologue O 0 1.8799920553647098e-07
of O 0 3.310166007963744e-08
ZNF127 O 0 5.074754517409019e-05
) O 0 2.00690166707318e-08
, O 0 1.1801049915050044e-08
Ndn O 0 5.596988194156438e-05
and O 0 4.332068215262552e-08
Ipw O 0 0.00015623093349859118
, O 0 7.181396810551632e-09
and O 0 2.1895463220289457e-09
manifest O 0 3.9642145566176623e-07
several O 0 1.6029831684249984e-08
phenotypes O 0 1.1997614137726487e-06
common O 0 2.449106659696554e-07
to O 0 5.277086529531516e-06
PWS B-Disease 1 1.0
infants O 1 0.9997809529304504
. O 0 2.049869181064423e-06

These O 0 9.034110348693503e-08
data O 0 2.560769019055442e-07
demonstrate O 0 2.113932850988931e-08
that O 0 6.061693369474597e-10
both O 0 6.066470659149559e-10
the O 0 2.8300808363468377e-09
position O 0 2.0516116805424645e-08
of O 0 1.9623085378839278e-08
the O 0 2.227551476607914e-08
IC O 0 1.7465640667069238e-06
and O 0 6.119627027345587e-10
its O 0 3.3382249742253123e-10
role O 0 2.1828621132868875e-09
in O 0 3.402027271004471e-10
the O 0 6.461235435573087e-10
coordinate O 0 2.1962973661970864e-09
expression O 0 1.6215807585595599e-09
of O 0 1.3522687414280199e-09
genes O 0 4.01798316840285e-10
is O 0 1.6047986550749016e-10
conserved O 0 3.754314636950085e-09
between O 0 5.612486919659432e-09
mouse O 0 2.1952597961671927e-08
and O 0 3.2812969008588766e-10
human O 0 1.0436735919938656e-09
, O 0 1.522920956009699e-10
and O 0 2.2429487434028061e-10
indicate O 0 9.826013780411813e-09
that O 0 1.8963904058200143e-10
the O 0 1.1272803135398135e-08
mouse O 0 2.6535198927035708e-08
is O 0 1.5558751509381352e-10
a O 0 6.683142372843065e-10
suitable O 0 3.98964550285541e-09
model O 0 5.14185627409347e-09
system O 0 1.898729395932719e-09
in O 0 6.516757133923079e-10
which O 0 1.261955956399774e-10
to O 0 3.559925965124222e-10
investigate O 0 2.733900750229168e-08
the O 0 1.633595481109751e-08
molecular O 0 2.733465862547746e-07
mechanisms O 0 2.185867771231642e-07
of O 0 8.216321845111452e-08
imprinting O 0 5.041742952016648e-07
in O 0 2.9310325277975835e-09
this O 0 5.127310243047134e-10
region O 0 3.997666642163722e-09
of O 0 4.6626609240263406e-09
the O 0 1.4925950253541487e-08
genome O 0 2.1244582981694293e-08
. O 0 5.655750534572235e-09
. O 0 9.877315676476428e-08

Mutations O 0 7.889705102570588e-07
of O 0 2.7523523726813437e-07
the O 0 2.1321719145817042e-07
ATM O 0 3.94586895708926e-05
gene O 0 2.0130778821680906e-08
detected O 0 4.5499724876663095e-08
in O 0 2.0845083881226856e-08
Japanese O 1 0.9999978542327881
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 5.3678613767260686e-06
: O 0 4.386089269559079e-10
possible O 0 2.5045023832603874e-09
preponderance O 0 4.1568173401174136e-06
of O 0 7.343054875263988e-08
the O 0 1.9523628935758097e-08
two O 0 8.310617083395755e-09
founder O 0 7.995536748239829e-07
mutations O 0 8.867045764304748e-09
4612del165 O 0 4.4395230247573636e-07
and O 0 2.371162111103331e-08
7883del5 O 0 3.690288576763123e-05
. O 0 2.0882903299934696e-06

The O 0 7.784808985888958e-06
ATM O 0 0.0002536204701755196
( O 0 2.147353143300279e-06
A O 1 1.0
- O 1 0.9947063326835632
T O 1 0.9997596144676208
, O 0 3.970674899989035e-09
mutated O 0 9.39821465095747e-09
) O 0 1.2725117626288807e-09
gene O 0 3.695536654468867e-10
on O 0 2.4667650144749587e-09
human O 0 2.2886119666054583e-08
chromosome O 0 3.989762547007558e-07
11q22 O 0 9.516958925814833e-06
. O 0 4.90091565552575e-07

3 O 0 3.978640506829834e-06
has O 0 5.633980393326965e-09
recently O 0 4.7128021485320915e-09
been O 0 2.195380099934141e-09
identified O 0 6.301929200702716e-09
as O 0 5.567659666638747e-10
the O 0 2.397679610410819e-09
gene O 0 7.959864434248232e-10
responsible O 0 1.0447729348328494e-09
for O 0 4.993913060857835e-10
the O 0 1.2319323161591456e-07
human O 0 3.135122460662387e-05
recessive B-Disease 1 0.9968373775482178
disease I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999988079071045
A B-Disease 1 1.0
- I-Disease 1 0.9999995231628418
T I-Disease 1 0.9999997615814209
) O 0 2.509869716504909e-07
. O 0 6.644280858836282e-08

In O 0 3.143632625324244e-07
order O 0 1.180739861439406e-08
to O 0 3.016129790367472e-09
define O 0 1.4569460304869608e-08
the O 0 3.493657141362405e-09
types O 0 6.2623759511382104e-09
of O 0 5.112896701575664e-07
disease O 0 0.00106784887611866
- O 0 1.628731638447789e-06
causing O 0 5.832570764141565e-07
ATM O 0 2.2772768716095015e-05
mutations O 0 1.868921684078373e-09
in O 0 2.7745798991674064e-09
Japanese O 0 1.6906704331631772e-05
A B-Disease 1 1.0
- I-Disease 1 0.9872963428497314
T I-Disease 1 0.9999994039535522
patients O 0 2.2516468689559588e-09
as O 0 2.545911814699764e-10
well O 0 3.054552444314851e-10
as O 0 2.417382405361934e-10
to O 0 1.3403071708051328e-10
look O 0 2.495612605457609e-10
for O 0 1.7371017124734323e-10
possible O 0 4.173758227921098e-09
mutational O 0 7.229327820823528e-07
hotspots O 0 3.293451911190459e-08
, O 0 4.672709996711433e-10
reverse O 0 2.0030430647466346e-08
- O 0 2.738733684282124e-08
transcribed O 0 2.753988326276158e-07
RNA O 0 4.7774705080882995e-08
derived O 0 1.4259015079787218e-09
from O 0 2.402402443646423e-10
ten O 0 6.63112453835879e-09
patients O 0 5.15844478243821e-10
belonging O 0 1.3418585353974777e-08
to O 0 2.868886017637351e-09
eight O 0 1.2533102733414125e-07
unrelated O 0 3.1193665108730784e-06
Japanese O 1 0.9628973007202148
A B-Disease 1 1.0
- I-Disease 1 0.9965657591819763
T I-Disease 1 0.9998914003372192
families O 0 3.5676359644298827e-09
was O 0 5.6504023682180105e-09
analyzed O 0 3.3693150491842516e-09
for O 0 6.217831804988805e-11
mutations O 0 5.781899264922785e-11
by O 0 1.1717869730087926e-10
the O 0 2.04773642487055e-09
restriction O 0 1.1134630106823806e-08
endonuclease O 0 4.410817311395476e-08
fingerprinting O 0 1.3809408727638584e-08
method O 0 4.3135500504831725e-08
. O 0 5.421684434736562e-08

As O 0 6.030005010870809e-07
has O 0 2.8882340963320985e-09
been O 0 2.5632298505939843e-09
reported O 0 1.3748114868761263e-09
by O 0 2.5836968675641003e-10
others O 0 1.1073881811540787e-09
, O 0 7.97487853532175e-10
mutations O 0 7.516208766489285e-10
that O 0 6.462751445113213e-10
lead O 0 1.7736198287821026e-08
to O 0 4.1611937007246524e-08
exon O 0 3.0711664749105694e-06
skipping O 0 1.4750658010598272e-06
or O 0 1.6294325178023428e-07
premature O 0 3.8699988635926275e-07
protein O 0 8.189660860580261e-08
truncation O 0 1.6289880022668513e-06
were O 0 7.952179004178106e-08
also O 0 1.016346207194374e-08
predominant O 0 2.4617776261948165e-07
in O 0 4.198223990670158e-08
our O 0 3.584458454497508e-07
mutants O 0 1.9819981389446184e-06
. O 0 1.3942857890469895e-07

Six O 0 2.0990374594020977e-07
different O 0 8.303831511291548e-10
mutations O 0 2.1455754950494565e-09
were O 0 1.2658118997421752e-08
identified O 0 2.9776851206975152e-08
on O 0 2.1421094231754978e-08
12 O 0 7.360316089943808e-08
of O 0 7.558553960507197e-08
the O 0 1.6463206975458888e-07
16 O 0 3.553384146925964e-07
alleles O 0 1.4255840063981395e-08
examined O 0 9.424045401829062e-07
. O 0 3.064613736114552e-07

Four O 0 8.284916361844807e-07
were O 0 1.352370588847407e-07
deletions O 0 2.0326940841641772e-07
involving O 0 3.1571462955071183e-07
a O 0 4.748535786802677e-07
loss O 0 1.867716491688043e-05
of O 0 3.054819899261929e-05
a O 0 4.006503331765998e-06
single O 0 1.0145197393285343e-06
exon O 0 1.8834783759302809e-06
exon O 0 5.674592671311984e-07
7 O 0 3.035917188753956e-07
, O 0 1.4093060940467694e-08
exon O 0 3.10683304860504e-07
16 O 0 1.0518780868551403e-07
, O 0 2.890208250505566e-08
exon O 0 1.438992740077083e-06
33 O 0 1.2160752476120251e-06
or O 0 2.633146891639626e-07
exon O 0 5.647545549436472e-06
35 O 0 3.147753204757464e-06
. O 0 8.621787515039614e-07

The O 0 1.00929912605352e-06
others O 0 1.931270432464771e-08
were O 0 1.0841733733002457e-08
minute O 0 5.775603639790461e-08
deletions O 0 6.123917728473316e-08
, O 0 2.321761893853136e-09
4649delA O 0 4.918150011690159e-07
in O 0 6.171995181603052e-08
exon O 0 3.747219921024225e-07
33 O 0 7.914545818721308e-08
and O 0 1.2401006443951701e-08
7883del5 O 0 3.803243771471898e-06
in O 0 3.367518388586177e-07
exon O 0 9.165264600596856e-06
55 O 0 2.5095112050621537e-06
. O 0 4.0085572550196957e-07

The O 0 1.5643836377421394e-06
mutations O 0 1.2876921573479194e-07
4612del165 O 0 1.0731429256338743e-06
and O 0 1.1971123647924742e-08
7883del5 O 0 1.253919208465959e-06
were O 0 2.90591781748617e-08
found O 0 5.463526964177845e-09
in O 0 1.502459934243916e-09
more O 0 1.1387173148857954e-10
than O 0 8.738195583779529e-11
two O 0 1.6759545140576648e-10
unrelated O 0 3.3022058421039446e-09
families O 0 1.7306331367983319e-10
; O 0 1.6751812437210134e-10
44 O 0 3.3930862564091058e-09
% O 0 1.6622122567255815e-09
( O 0 7.975137772398e-10
7 O 0 9.556635482965703e-09
of O 0 5.38757083390351e-09
16 O 0 7.111077948707134e-09
) O 0 4.3308659436469554e-10
of O 0 6.606515889906461e-10
the O 0 2.2499424545685542e-09
mutant O 0 3.6215119791904726e-08
alleles O 0 9.409599766030396e-10
had O 0 1.1189082993467991e-09
one O 0 1.2213979827535582e-09
of O 0 5.1979736070961735e-09
the O 0 2.3906117974092922e-08
two O 0 1.4986198948463425e-08
mutations O 0 3.170823958953406e-08
. O 0 2.691105578378483e-07

The O 0 8.753511337999953e-07
4612del165 O 0 4.782886662724195e-06
mutations O 0 5.042018802470238e-09
in O 0 9.729776984102045e-10
three O 0 1.1623598611398833e-10
different O 0 3.4796946574155996e-11
families O 0 2.802854337513594e-10
were O 0 2.7415492098725736e-09
all O 0 4.432827882538959e-09
ascribed O 0 2.420781299861119e-07
to O 0 2.991899172855028e-09
the O 0 2.42781847958895e-08
same O 0 4.6691859267866676e-08
T O 0 1.0159745045257296e-07
- O 0 7.663305012783894e-08
- O 0 1.6401963875978254e-07
> O 0 6.468503954693006e-08
A O 0 7.796239209767464e-09
substitution O 0 1.3508663077033134e-09
at O 0 9.871925499282952e-09
the O 0 6.60141763475508e-09
splice O 0 2.7661172907755827e-07
donor O 0 8.75558825441658e-09
site O 0 3.185299135566311e-08
in O 0 2.08349462127444e-08
intron O 0 7.923706107249018e-06
33 O 0 2.381937974860193e-06
. O 0 5.606336799246492e-07

Microsatellite O 0 0.000748922408092767
genotyping O 0 2.1776335415779613e-05
around O 0 5.30376382812392e-07
the O 0 3.13807021257162e-07
ATM O 0 0.00017240707529708743
locus O 0 1.6487497305206489e-06
also O 0 2.4318538294210157e-09
indicated O 0 4.379337337212519e-09
that O 0 3.759163258454379e-10
a O 0 6.6295688938566855e-09
common O 0 5.264344071775895e-09
haplotype O 0 9.74492166960772e-08
was O 0 4.696311961538413e-08
shared O 0 9.9013997001407e-09
by O 0 1.5220271709637245e-09
the O 0 5.751503717732476e-09
mutant O 0 2.3607109156387196e-08
alleles O 0 5.747168851932827e-10
in O 0 1.631384027867e-09
both O 0 3.6291718519265714e-09
mutations O 0 3.746790611103279e-08
. O 0 1.5885643733781762e-07

This O 0 2.5430810524085246e-07
suggests O 0 1.226800776521486e-07
that O 0 3.433186235302088e-10
these O 0 4.5061204767549157e-10
two O 0 2.0062920214058977e-09
founder O 0 7.802191817063431e-07
mutations O 0 1.549473216400088e-09
may O 0 1.1796317256340672e-09
be O 0 5.51904522083646e-10
predominant O 0 2.3048771780054267e-08
among O 0 1.0166248953780155e-09
Japanese O 0 9.610560027795145e-07
ATM O 0 3.871286935464013e-06
mutant O 0 1.655417491974731e-07
alleles O 0 1.4066260156653243e-08
. O 0 2.4850510982332707e-08

W474C O 0 0.0001072014492820017
amino O 0 8.162570566128124e-07
acid O 0 3.054508823652213e-08
substitution O 0 4.81901718529798e-09
affects O 0 2.8027382636963694e-09
early O 0 3.356684930011511e-09
processing O 0 2.0283557944367203e-08
of O 0 1.3253353081665864e-08
the O 0 6.169827759805457e-09
alpha O 0 5.1776321896568334e-08
- O 0 1.4217192978449589e-09
subunit O 0 1.0663882221706444e-08
of O 0 2.210557070725372e-09
beta O 0 6.275650576981207e-08
- O 0 1.1346014794355597e-08
hexosaminidase O 0 2.0630000108212698e-07
A O 0 6.164583510326338e-08
and O 0 9.83108927599119e-10
is O 0 2.4136426191034843e-09
associated O 0 9.084579311036123e-09
with O 0 1.0231947733529978e-08
subacute O 0 0.0033083839807659388
G B-Disease 1 0.9975390434265137
( I-Disease 0 9.374455839861184e-05
M2 I-Disease 1 0.9306854009628296
) I-Disease 0 3.08519076952507e-07
gangliosidosis I-Disease 0 1.8117254512617365e-05
. O 0 3.747391588149185e-07

Mutations O 0 5.09022925143654e-07
in O 0 1.7757997738954145e-08
the O 0 3.26178160037216e-08
HEXA O 0 2.8060967451892793e-05
gene O 0 2.1091872692835523e-09
, O 0 9.727619404431564e-11
encoding O 0 1.3119838548902862e-10
the O 0 8.698622933067668e-10
alpha O 0 1.4804486525576976e-08
- O 0 1.1359564400237332e-09
subunit O 0 1.074780620058391e-08
of O 0 2.164334711451943e-09
beta O 0 3.656535341178824e-08
- O 0 1.4197905962021196e-08
hexosaminidase O 0 7.522554597017006e-07
A O 0 5.18332399224164e-07
( O 0 1.024589124654085e-08
Hex O 0 4.866719791607466e-07
A O 0 6.915102801485773e-08
) O 0 3.8592692930272676e-10
, O 0 4.7738833719446205e-11
that O 0 4.508112286250032e-11
abolish O 0 2.5342094644997815e-08
Hex O 0 3.6162293781671906e-06
A O 0 3.073215566473664e-07
enzyme O 0 1.1072792460709024e-07
activity O 0 1.2305472409934737e-06
cause O 0 5.267899177852087e-05
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9999998807907104
( O 0 4.976849936610961e-07
TSD B-Disease 0 0.027321631088852882
) O 0 2.159032508330938e-09
, O 0 1.9764527514620767e-10
the O 0 3.987272290117971e-09
fatal O 0 6.912583216944768e-07
infantile B-Disease 0 2.754870820353972e-07
form I-Disease 0 1.3196245873814405e-08
of I-Disease 0 2.0288491668907227e-06
G I-Disease 0 4.189056562609039e-05
( I-Disease 0 1.2263308235560544e-06
M2 I-Disease 0 0.0008919162210077047
) I-Disease 0 1.496329105066252e-08
gangliosidosis I-Disease 0 8.637474024908443e-07
, I-Disease 0 6.751949221950326e-09
Type I-Disease 0 8.95995754035539e-07
1 I-Disease 0 1.7019937104123528e-06
. O 0 4.332622154379351e-07

Less O 0 4.0483532757207286e-06
severe O 0 5.198479811951984e-06
, O 0 7.046475758443194e-08
subacute O 0 0.018229763954877853
( O 0 2.800530637614429e-06
juvenile O 0 0.00046848770580254495
- O 0 5.690124453394674e-06
onset O 1 0.9760075211524963
) O 0 2.6954662502021165e-08
and O 0 5.5930584608177014e-09
chronic O 1 0.985398530960083
( O 0 3.846016838338073e-08
adult O 0 1.7799614226987615e-07
- O 0 8.721524125121505e-08
onset O 0 3.682322858367115e-05
) O 0 6.281824505016687e-10
variants O 0 4.3232317725738767e-10
are O 0 1.6142439815403087e-11
characterized O 0 4.6332521153047423e-10
by O 0 1.7201154389745454e-10
a O 0 1.443061781181143e-09
broad O 0 7.902109522284206e-10
spectrum O 0 2.8246757710626014e-10
of O 0 1.6800777435932446e-09
clinical O 0 5.8291018234513103e-08
manifestations O 0 1.591120764032894e-07
and O 0 1.1794449861213252e-09
are O 0 2.077056859839388e-10
associated O 0 2.9038553783777843e-09
with O 0 7.743979346663821e-10
residual O 0 5.920340117882006e-05
levels O 0 1.1831518804683583e-06
of O 0 1.8012620728313777e-07
Hex O 0 1.2160184269305319e-05
A O 0 5.379810090744286e-07
enzyme O 0 1.1297474600269197e-07
activity O 0 1.670327520741921e-07
. O 0 2.3740991395015953e-08

We O 0 1.269752942789637e-06
identified O 0 2.5509751822028193e-07
a O 0 1.2729522325116704e-07
1422 O 0 3.1797953852219507e-06
G O 0 7.258605592141976e-07
- O 0 1.5189081636890478e-07
- O 0 2.9868320439163654e-07
> O 0 2.092631490313579e-07
C O 0 4.105947084553918e-07
( O 0 3.4142111360324634e-09
amino O 0 1.054796872068664e-08
acid O 0 4.939529674174992e-09
W474C O 0 5.561149052368819e-08
) O 0 3.310055285421498e-10
substitution O 0 7.016708880591693e-10
in O 0 8.364139381100699e-10
the O 0 2.9183582217484627e-09
first O 0 9.253302124534457e-09
position O 0 1.8274830893005856e-07
of O 0 1.2004889526906481e-07
exon O 0 2.8352428671496455e-07
13 O 0 1.6887182141545054e-07
of O 0 1.608688506848921e-07
HEXA O 0 0.0002573436067905277
of O 0 5.164608296581719e-07
a O 0 1.304980088434604e-07
non O 0 1.8314519820705755e-06
- O 0 5.803740350529552e-07
Jewish O 0 2.6974259981216164e-06
proband O 0 9.30048045120202e-05
who O 0 8.165702780615902e-08
manifested O 0 2.2599017484026263e-06
a O 0 4.3049854525634146e-07
subacute O 0 3.0217974199331366e-05
variant O 0 3.5565233247325523e-07
of O 0 5.439475899038371e-06
G B-Disease 0 0.0007349765510298312
( I-Disease 0 7.704936251684558e-06
M2 I-Disease 0 0.051587387919425964
) I-Disease 0 2.580351292635896e-07
gangliosidosis I-Disease 0 3.0302699087769724e-05
. O 0 4.19542260488015e-07

On O 0 1.8248025526190759e-06
the O 0 1.7324124712558842e-07
second O 0 2.287907676645773e-07
maternally O 0 8.659530976729002e-06
inherited O 0 8.521308245690307e-07
allele O 0 1.9536779305440177e-08
, O 0 1.2903413892928484e-09
we O 0 1.7262297147269123e-09
identified O 0 1.170684527096455e-08
the O 0 1.861558196480928e-08
common O 0 1.936098925625629e-07
infantile O 1 0.9394918084144592
disease O 0 0.17424997687339783
- O 0 2.873948233172996e-06
causing O 0 3.4343372590228682e-06
4 O 0 7.682368959649466e-06
- O 0 6.247810233617201e-07
bp O 0 9.85639530881599e-07
insertion O 0 4.21593369992479e-07
, O 0 4.4284778510927936e-08
+ O 0 1.4368138181453105e-06
TATC O 0 7.147841824917123e-05
1278 O 0 1.9561466615414247e-05
, O 0 5.75552006054636e-09
in O 0 2.556839540091005e-08
exon O 0 1.483758296672022e-06
11 O 0 9.722232334752334e-07
. O 0 1.7317483980150428e-07

Pulse O 0 0.0007210936164483428
- O 0 8.16467945696786e-06
chase O 0 1.7833335732575506e-06
analysis O 0 7.360176113024863e-08
using O 0 4.108198226049353e-08
proband O 0 1.6806154235382564e-05
fibroblasts O 0 2.1195990029809764e-06
revealed O 0 8.64713342707546e-07
that O 0 2.72021938307887e-09
the O 0 1.2403252647175123e-08
W474C O 0 3.2064880883808655e-07
- O 0 2.2965437551647483e-08
containing O 0 9.400239697754387e-09
alpha O 0 1.8341265217713953e-07
- O 0 1.882880162895617e-08
subunit O 0 8.230689019228521e-08
precursor O 0 5.831525839994356e-08
was O 0 1.373318259112466e-08
normally O 0 2.5731687891550337e-09
synthesized O 0 1.8709126692328937e-08
, O 0 8.397676998228576e-10
but O 0 2.908742968710243e-10
not O 0 6.121389506397179e-10
phosphorylated O 0 1.4649830859525537e-07
or O 0 1.296541718431854e-08
secreted O 0 1.5659963992220582e-08
, O 0 1.733252846802813e-10
and O 0 2.508301621961806e-10
the O 0 1.0408451878163305e-08
mature O 0 7.104518431333418e-07
lysosomal O 0 0.00017960468539968133
alpha O 0 2.542004722272395e-06
- O 0 9.582539206576257e-08
subunit O 0 2.53492345336781e-07
was O 0 3.61302596729729e-08
not O 0 3.065211195973916e-09
detected O 0 9.61171693347751e-08
. O 0 1.0839629993597555e-07

When O 0 4.4338619886730157e-07
the O 0 1.4258101543873636e-07
W474C O 0 7.821695362508763e-07
- O 0 3.307704332655703e-08
containing O 0 2.0301943237654996e-08
alpha O 0 2.5875175424516783e-07
- O 0 2.6970036870466174e-08
subunit O 0 1.9229787540098187e-07
was O 0 8.363573300584903e-08
transiently O 0 3.408292741369223e-07
co O 0 3.456324293438229e-07
- O 0 1.8474379359645354e-08
expressed O 0 1.675827476788072e-09
with O 0 2.815214728002502e-10
the O 0 1.406078808940947e-08
beta O 0 4.95981105075316e-08
- O 0 5.071222997088398e-09
subunit O 0 1.0682978057729997e-08
to O 0 2.5998617148026426e-10
produce O 0 7.953869785026768e-10
Hex O 0 3.4539293665147852e-06
A O 0 1.5293779824787634e-06
( O 0 1.3343091964657106e-08
alphabeta O 0 4.797595920535969e-07
) O 0 4.749429738382105e-09
in O 0 1.0053469168269658e-08
COS O 0 1.2992349184060004e-05
- O 0 1.5529690244875383e-07
7 O 0 5.1524320809903656e-08
cells O 0 1.4677898896309216e-09
, O 0 1.0814172474171713e-10
the O 0 6.533957819243597e-10
mature O 0 6.806177399454327e-09
alpha O 0 2.4123322006630588e-08
- O 0 1.8464999529399506e-09
subunit O 0 1.2697145557183376e-08
was O 0 5.1649253762775515e-09
present O 0 7.141562341494989e-10
, O 0 1.9023026209818994e-10
but O 0 2.715376534734304e-10
its O 0 7.653262468210187e-10
level O 0 7.78616708885238e-08
was O 0 3.208322851833145e-08
much O 0 3.6191485364156506e-09
lower O 0 3.5645275620055372e-09
than O 0 1.203050992160115e-10
that O 0 3.154694214191345e-11
from O 0 5.024601845704524e-10
normal O 0 9.944571388587065e-09
alpha O 0 2.8075444191699717e-08
- O 0 2.9353739439130777e-09
subunit O 0 1.707883967583257e-08
transfections O 0 4.0769354114900125e-08
, O 0 4.993710653322658e-11
although O 0 5.0941261625636614e-11
higher O 0 1.429834139976549e-09
than O 0 5.849184331330193e-11
in O 0 2.079823951950388e-10
those O 0 2.857623582208646e-10
cells O 0 2.7519484468996325e-09
transfected O 0 7.37424201702197e-08
with O 0 1.6482726294952954e-10
an O 0 1.4529879521774092e-09
alpha O 0 1.3145128718861088e-07
- O 0 1.4829213412781428e-08
subunit O 0 1.0435670105835015e-07
associated O 0 1.696329654521378e-08
with O 0 1.3944554844158574e-08
infantile O 0 0.0001511228911112994
TSD B-Disease 0 0.03857121244072914
. O 0 9.499607358520734e-07

Furthermore O 0 2.075290922221029e-06
, O 0 3.84327192293199e-09
the O 0 5.252609458494817e-09
precursor O 0 7.904181842377511e-08
level O 0 3.0842554110677156e-07
of O 0 1.5288771137988988e-08
the O 0 1.0298674801845209e-08
W474C O 0 3.4563342410365294e-07
alpha O 0 2.3820942374186416e-07
- O 0 8.269805285010534e-09
subunit O 0 2.6658421248271225e-08
was O 0 2.880010008254885e-09
found O 0 3.061247921820609e-10
to O 0 1.1795771304168312e-10
accumulate O 0 7.297395576699728e-09
in O 0 2.2970858548632123e-09
comparison O 0 1.4489647703896935e-08
to O 0 1.0073657463749441e-09
the O 0 1.966081164539446e-08
normal O 0 1.714323900614545e-07
alpha O 0 4.943099725096545e-07
- O 0 3.5267866849153506e-08
subunit O 0 3.462863560343976e-07
precursor O 0 2.803620020586095e-07
levels O 0 1.3566022971644998e-07
. O 0 3.948653670704516e-08

We O 0 7.182898684732208e-07
conclude O 0 1.4958575320633827e-06
that O 0 9.405638046189324e-09
the O 0 3.397258296899963e-08
1422 O 0 4.660747890739003e-06
G O 0 1.0978492355206981e-06
- O 0 2.7735134722206567e-07
- O 0 2.0934218980528385e-07
> O 0 1.7795913720419776e-07
C O 0 1.0943499262339174e-07
mutation O 0 8.104761306526598e-10
is O 0 2.2494521523253042e-10
the O 0 1.1777073760654844e-09
cause O 0 2.3905435853066592e-08
of O 0 1.307470256506349e-07
Hex B-Disease 0 0.0908602848649025
A I-Disease 0 0.14349910616874695
enzyme I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 3.1769204156262276e-07
the O 0 5.624968366646499e-07
proband O 0 9.394464723300189e-05
. O 0 4.914319902127318e-07

The O 0 2.92010071234472e-07
resulting O 0 5.805678071624243e-08
W474C O 0 6.145905331322865e-07
substitution O 0 7.919756228602637e-08
clearly O 0 4.297691802435111e-08
interferes O 0 1.2680954064592243e-08
with O 0 2.658238351660458e-10
alpha O 0 1.2323783771250874e-08
- O 0 1.8948367319637782e-09
subunit O 0 2.3643066171530336e-08
processing O 0 1.4276111848232631e-08
, O 0 7.481548713883512e-11
but O 0 6.643004202278036e-11
because O 0 6.541399366621903e-11
the O 0 7.123727163715898e-10
base O 0 8.091095793361092e-09
substitution O 0 6.164228238958458e-09
falls O 0 7.82769575380371e-07
at O 0 8.206234980434601e-08
the O 0 9.125355582284556e-09
first O 0 9.894848496116992e-09
position O 0 6.167276467294869e-08
of O 0 5.012354620248516e-08
exon O 0 3.200860305696551e-07
13 O 0 4.5007734428281765e-08
, O 0 2.5929149938264118e-09
aberrant O 0 5.01996062496346e-08
splicing O 0 3.213663291035118e-08
may O 0 3.850844532138353e-09
also O 0 9.013018109627069e-10
contribute O 0 1.3625479411416563e-08
to O 0 5.4284726047626464e-08
Hex B-Disease 0 0.18525655567646027
A I-Disease 0 0.001248317421413958
deficiency I-Disease 1 0.9393927454948425
in O 0 3.730005815327786e-08
this O 0 2.182043346010687e-08
proband O 0 7.21159494787571e-06
. O 0 6.02368785962426e-08
. O 0 2.1913947989560256e-07

Two O 0 3.46063842471267e-07
frequent O 0 3.8442536265392846e-07
missense O 0 7.3023379627557006e-06
mutations O 0 2.682199351511372e-07
in O 0 2.555675337134744e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 6.361280975397676e-05

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 1.5808500393177383e-05
an O 0 0.1620430201292038
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.9999899864196777
by O 0 2.840070862930588e-07
early O 1 0.9572868347167969
childhood O 1 1.0
deafness B-Disease 1 1.0
and O 1 0.9999994039535522
goiter B-Disease 1 1.0
. O 0 0.06500306725502014

A O 0 3.121812824247172e-06
century O 0 4.3973102492600447e-07
after O 0 2.2273901834068965e-08
its O 0 1.5333474490120125e-09
recognition O 0 3.0288935803923778e-09
as O 0 6.418836573374165e-09
a O 0 9.629112440734389e-08
syndrome O 0 1.8036392930298462e-06
by O 0 9.679046897304033e-09
Vaughan O 0 3.253349177612108e-06
Pendred O 0 0.0021077224519103765
, O 0 1.4035011375312934e-08
the O 0 1.4408161064238811e-07
disease O 0 4.826056738238549e-06
gene O 0 5.238834432930162e-08
( O 0 2.1255267768083286e-07
PDS O 0 1.1007596185663715e-05
) O 0 1.8912258425984874e-09
was O 0 1.5052545876415024e-08
mapped O 0 3.09580059365544e-08
to O 0 1.5210588344416465e-08
chromosome O 0 3.93048111391181e-07
7q22 O 0 2.026498259510845e-05
- O 0 4.5378299546428025e-05
q31 O 0 0.00012883046292699873
. O 0 1.936152102643973e-06

1 O 0 7.981001317602932e-07
and O 0 7.18149317791017e-09
, O 0 3.0274671658503394e-09
recently O 0 4.455205093734094e-09
, O 0 1.3057731562682307e-09
found O 0 2.05285943799538e-09
to O 0 1.5354105764586734e-09
encode O 0 6.072704650250671e-08
a O 0 1.4799594794112636e-07
putative O 0 6.993352599238278e-06
sulfate O 0 1.7001628293655813e-05
transporter O 0 0.0012138282181695104
. O 0 1.4358315638673957e-06

We O 0 1.4169006590236677e-07
performed O 0 9.373172815685393e-08
mutation O 0 6.8832286537201526e-09
analysis O 0 1.939676153028813e-08
of O 0 1.642092506415338e-08
the O 0 2.2782815278787893e-07
PDS B-Disease 0 6.168048275867477e-05
gene O 0 5.349224618811377e-09
in O 0 2.064387549793878e-09
patients O 0 9.460888739099005e-10
from O 0 5.791507717844979e-09
14 O 0 1.8589224737297627e-07
Pendred B-Disease 0 0.000688407861161977
families O 0 2.206715032926354e-09
originating O 0 9.268422473951432e-09
from O 0 9.583572824212183e-10
seven O 0 1.1429130974960344e-09
countries O 0 1.6803194252679177e-11
and O 0 2.3925844638839067e-10
identified O 0 1.1969229163355521e-08
all O 0 1.09375681844881e-08
mutations O 0 2.763643180969666e-08
. O 0 1.2299578600050154e-07

The O 0 4.4542983346218534e-07
mutations O 0 9.469215633828298e-09
include O 0 2.575294866247191e-09
three O 0 4.550525734003941e-09
single O 0 1.016385020591315e-08
base O 0 9.698916869638197e-08
deletions O 0 7.526602274765537e-08
, O 0 1.1359309937120088e-08
one O 0 4.471526793281555e-08
splice O 0 1.1286333574389573e-06
site O 0 1.0498497005073659e-07
mutation O 0 5.399020341911864e-09
and O 0 4.686546706267336e-09
10 O 0 3.3805565635702806e-07
missense O 0 7.25660993339261e-06
mutations O 0 4.111534508410841e-07
. O 0 3.5160007882950595e-07

One O 0 2.7627793315332383e-06
missense O 0 7.003704467933858e-06
mutation O 0 6.290930798513727e-08
( O 0 2.4616946703304166e-08
L236P O 0 8.521836321051524e-07
) O 0 8.208439261636613e-09
was O 0 9.211255047603117e-08
found O 0 8.985233890257405e-09
in O 0 8.627906389335749e-09
a O 0 2.4252498675991774e-08
homozygous O 0 6.1298988107694186e-09
state O 0 1.2713715635825906e-09
in O 0 3.160075312536037e-09
two O 0 5.982967898887637e-09
consanguineous O 0 2.8934327929164283e-05
families O 0 3.8141201308405925e-09
and O 0 6.492415494108172e-10
in O 0 4.215714444200103e-09
a O 0 2.0853713422752662e-08
heterozygous O 0 4.583749824149663e-09
state O 0 1.7702282695264415e-10
in O 0 1.9701820730411157e-10
five O 0 6.556003517843578e-10
additional O 0 5.155024407343944e-09
non O 0 2.0011218566651223e-06
- O 0 6.157272309792461e-06
consanguineous O 0 0.0005690492107532918
families O 0 1.3466949155827024e-07
. O 0 9.93452715647436e-08

Another O 0 1.324074219155591e-05
missense O 0 9.805414265429135e-06
mutation O 0 3.651113544833606e-08
( O 0 1.0761077362531069e-08
T416P O 0 3.528139700392785e-07
) O 0 4.177565404717143e-09
was O 0 5.816795933810681e-08
found O 0 1.0357060986621036e-08
in O 0 5.122464230566948e-09
a O 0 1.4538924730800318e-08
homozygous O 0 4.557005439664863e-09
state O 0 9.426017744118553e-10
in O 0 2.8624034253965647e-09
one O 0 9.607406425971021e-09
family O 0 7.221462983153515e-09
and O 0 4.1620387691843064e-10
in O 0 2.23779639263455e-09
a O 0 8.410985685713968e-09
heterozygous O 0 7.529955547980194e-10
state O 0 1.080926528840287e-10
in O 0 6.162838017687022e-10
four O 0 8.90433149436376e-09
families O 0 1.3867927250998946e-08
. O 0 1.9552291519175924e-07

Pendred B-Disease 0 0.3080368638038635
patients O 0 6.57850591778697e-07
in O 0 2.704024559818663e-08
three O 0 8.288881581108853e-09
non O 0 3.0865730877849273e-06
- O 0 9.038985240295005e-07
consanguineous O 0 0.0003176707250531763
families O 0 5.5077959970617485e-09
were O 0 3.912777213344043e-09
shown O 0 2.6390023499800463e-09
to O 0 2.3078015054522893e-09
be O 0 2.5213990895167626e-08
compound O 0 8.528048169864633e-07
heterozygotes O 0 8.20442025428747e-08
for O 0 6.169521782339871e-09
L236P O 0 2.969370598293608e-06
and O 0 1.4767717004815495e-07
T416P O 0 7.013813592493534e-05
. O 0 1.0729166888268082e-06

In O 0 4.2423351942488807e-07
total O 0 7.127211887336671e-08
, O 0 5.347470022343259e-09
one O 0 2.5326765129563e-09
or O 0 2.0114647725222312e-09
both O 0 4.550974874728553e-10
of O 0 3.606304366243762e-09
these O 0 4.785025708997637e-10
mutations O 0 9.407571388564406e-10
were O 0 4.809210807366071e-09
found O 0 4.946449916332085e-09
in O 0 7.890577080615913e-09
nine O 0 8.108634830250594e-08
of O 0 4.2943899103420335e-08
the O 0 3.5119448682507937e-08
14 O 0 2.2451214931606955e-07
families O 0 6.591867940386464e-09
analyzed O 0 2.4494616468473396e-07
. O 0 1.8334900175887014e-07

The O 0 3.8305773841784685e-07
identification O 0 8.268215623274955e-08
of O 0 3.8662722801063865e-08
two O 0 1.7899834503509737e-08
frequent O 0 1.7447614197863004e-07
PDS B-Disease 0 2.497192326700315e-06
mutations O 0 7.421136483110047e-10
will O 0 5.5963931405722533e-11
facilitate O 0 6.654906847813891e-09
the O 0 1.5421589338870945e-08
molecular O 0 9.638355550123379e-06
diagnosis O 0 0.0009188849944621325
of O 0 0.0075006913393735886
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.567794242873788e-05

Insertional O 0 0.0001545975828776136
mutation O 0 6.524785334249827e-08
by O 0 5.80356118717873e-09
transposable O 0 3.5145028505212395e-06
element O 0 1.9207000150345266e-06
, O 0 5.456729113006986e-08
L1 O 0 2.7857793611474335e-05
, O 0 3.827551164903298e-09
in O 0 1.2383349456968062e-08
the O 0 3.6567942629517347e-07
DMD B-Disease 1 1.0
gene O 0 2.2363979113038113e-08
results O 0 3.5400886666536735e-09
in O 0 2.2046840797429468e-08
X B-Disease 1 0.9054081439971924
- I-Disease 1 0.8135557770729065
linked I-Disease 1 0.9783162474632263
dilated I-Disease 1 0.9999794960021973
cardiomyopathy I-Disease 1 1.0
. O 0 2.2660567537968745e-06

X B-Disease 1 0.9999752044677734
- I-Disease 1 0.9996318817138672
linked I-Disease 1 0.999232292175293
dilated I-Disease 1 0.9999995231628418
cardiomyopathy I-Disease 1 1.0
( O 0 1.0572486644377932e-05
XLDCM B-Disease 1 0.9995439648628235
) O 0 1.5623475846382462e-08
is O 0 7.948228741838648e-10
a O 0 4.844157075467592e-09
clinical O 0 1.842986279143588e-07
phenotype O 0 1.4550430194049113e-07
of O 0 1.9057026179325476e-07
dystrophinopathy B-Disease 0 0.0011918656527996063
which O 0 4.762574334904457e-09
is O 0 7.023202575062726e-10
characterized O 0 2.0697259461854856e-09
by O 0 7.481781305607171e-10
preferential O 0 3.6387774571267073e-07
myocardial B-Disease 1 1.0
involvement I-Disease 0 5.414387942437315e-07
without O 0 6.590950007989704e-09
any O 0 2.4474191562262604e-09
overt O 0 3.0952396201655574e-08
clinical O 0 2.173105855263202e-07
signs O 0 1.894287180448373e-07
of O 0 3.7846351915504783e-05
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 0.001291476539336145

To O 0 5.517009071809298e-08
date O 0 1.3705556511922623e-07
, O 0 1.6785434153732126e-09
several O 0 7.975882732047523e-10
mutations O 0 1.547482586516935e-09
in O 0 2.97943913984966e-09
the O 0 1.6552958186366595e-06
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 0.999972939491272
gene O 0 1.4084655219903652e-07
, O 0 1.845958585988683e-08
DMD O 1 1.0
, O 0 2.2349555539591393e-09
have O 0 7.355323988766926e-11
been O 0 2.0466148220599223e-10
identified O 0 2.6730540003683245e-10
in O 0 1.171523877907532e-09
patients O 0 2.0334516015463322e-10
with O 0 2.5638055567434037e-10
XLDCM B-Disease 1 0.9999992847442627
, O 0 3.5201315196076166e-09
but O 0 3.1427024871355513e-10
a O 0 1.1016830780974374e-09
pathogenic O 0 6.543136588099685e-10
correlation O 0 2.1255597282276995e-09
of O 0 5.246559298122122e-10
these O 0 4.439856815530163e-10
cardiospecific O 0 8.371758895009407e-07
mutations O 0 1.074182254257039e-08
in O 0 5.5249067543172714e-08
DMD O 1 1.0
with O 0 5.304732209054919e-09
the O 0 7.774175401209504e-07
XLDCM B-Disease 1 0.9999287128448486
phenotype O 0 5.078520075585402e-07
has O 0 8.817323537968491e-10
remained O 0 4.5798543624187005e-08
to O 0 1.402732374700122e-09
be O 0 2.3112473712672e-08
elucidated O 0 7.084934622980654e-05
. O 0 7.555482852694695e-07

We O 0 7.643203048246505e-07
report O 0 2.330544077722152e-07
here O 0 1.4788060553883042e-08
the O 0 5.071580932991537e-09
identification O 0 5.669132274732647e-09
of O 0 8.038611554184172e-09
a O 0 1.3976214852107205e-08
unique O 0 1.6963522142532383e-08
de O 0 1.964859393410734e-06
novo O 0 2.5747517611307558e-06
L1 O 0 3.221094448235817e-05
insertion O 0 4.210678241634014e-07
in O 0 3.1781503651018284e-08
the O 0 8.645569238296957e-08
muscle O 0 6.238010996639787e-07
exon O 0 1.451503521820996e-06
1 O 0 5.181070719117997e-07
in O 0 1.4734320075149299e-07
DMD O 1 1.0
in O 0 4.850280177493005e-08
three O 0 1.8001109935994464e-08
XLDCM B-Disease 0 0.05533500015735626
patients O 0 7.613693675523336e-09
from O 0 3.0282811813719945e-09
two O 0 4.65114036174441e-09
unrelated O 0 7.543316087321728e-07
Japanese O 0 5.890134343644604e-05
families O 0 5.077226461480677e-08
. O 0 4.0714027704780165e-08

The O 0 2.695708190003643e-06
insertion O 0 2.0833138023590436e-06
was O 0 2.793411340462626e-06
a O 0 1.6944483149927692e-07
5 O 0 1.3665774645232887e-07
- O 0 1.3224187966898171e-08
truncated O 0 1.3801825460291184e-08
form O 0 4.809886933188068e-10
of O 0 1.6628629140313933e-08
human O 0 1.5840237566067117e-08
L1 O 0 1.9417807379795704e-06
inversely O 0 5.551113346768943e-08
integrated O 0 7.839575033585788e-08
in O 0 3.3264746512884358e-09
the O 0 6.6753234051475374e-09
5 O 0 1.963978490948648e-08
- O 0 7.636862697779634e-09
untranslated O 0 2.1583764464594424e-06
region O 0 1.2327122433930526e-08
in O 0 4.9692965298220315e-09
the O 0 2.2282824474473273e-08
muscle O 0 4.17920951178985e-08
exon O 0 6.869984048307742e-08
1 O 0 7.526713474703683e-09
, O 0 4.576878459561229e-11
which O 0 1.4106915288691901e-11
affected O 0 1.7502353732989917e-10
the O 0 2.1146535633675967e-09
transcription O 0 5.5366268014722664e-08
or O 0 4.885128412901452e-10
the O 0 2.5859414609641362e-09
stability O 0 4.03280573380016e-08
of O 0 5.32469224268084e-09
the O 0 9.57977519533415e-09
muscle O 0 6.1754548141834675e-09
form O 0 1.948292416287245e-09
of O 0 1.1738398342231449e-07
dystrophin O 0 4.614216493337153e-07
transcripts O 0 3.106424344423431e-07
but O 0 3.5227357142453286e-10
not O 0 1.286239587061644e-10
that O 0 1.2251352710102026e-10
of O 0 5.749562159707011e-09
the O 0 2.3810471816432255e-07
brain O 0 0.07756587862968445
or O 0 8.964111657405738e-07
Purkinje O 0 0.08401517570018768
cell O 0 3.329217179270927e-06
form O 0 5.776228828580088e-09
, O 0 4.039932832711202e-09
probably O 0 3.758371747153433e-08
due O 0 7.324004513975524e-08
to O 0 1.3306691304393325e-09
its O 0 8.662760508926226e-10
unique O 0 2.4879716065129287e-09
site O 0 1.8099505894042522e-08
of O 0 1.4421104310713417e-08
integration O 0 6.473157299069499e-08
. O 0 2.3105955904156872e-07

We O 0 4.848263870371738e-07
speculate O 0 4.855820066040906e-07
that O 0 1.076659539300806e-09
this O 0 5.537222902418648e-10
insertion O 0 4.7544897796569785e-08
of O 0 6.721626988337448e-08
an O 0 5.0997918776829465e-08
L1 O 0 3.502358958940022e-05
sequence O 0 4.821878860639117e-07
in O 0 4.4242904095881386e-07
DMD O 1 1.0
is O 0 2.2381305697649623e-08
responsible O 0 7.590812423075022e-09
for O 0 2.3090153400406876e-10
some O 0 1.43083461745519e-10
of O 0 1.965705154205466e-09
the O 0 3.152910821313526e-09
population O 0 2.2310529812497037e-10
of O 0 4.537282993766212e-09
Japanese O 0 3.251885118515929e-06
patients O 0 3.5222402772205896e-09
with O 0 3.981716734102747e-09
XLDCM B-Disease 0 0.0012074565747752786
. O 0 9.614027618454202e-08
. O 0 2.5441894990763103e-07

Severe O 0 0.0005245016072876751
early O 0 8.58466955833137e-05
- O 0 0.01651396043598652
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 0.0003812123031821102
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 1.1565453860384878e-05
red O 0 3.50649279425852e-05
hair O 0 0.013687456026673317
pigmentation O 1 0.58780437707901
caused O 0 8.32302903290838e-05
by O 0 7.979509746292024e-07
POMC O 1 0.9999972581863403
mutations O 0 9.592724836693378e-08
in O 0 1.6455979690022104e-08
humans O 0 2.0179952286980551e-07
. O 0 1.1965478563524812e-07

Sequential O 0 4.615788930095732e-05
cleavage O 0 9.512040378467645e-06
of O 0 3.7248625517349865e-07
the O 0 7.036980065322496e-08
precursor O 0 2.2224023155104078e-07
protein O 0 4.372061823687545e-08
pre O 0 5.540127858694177e-07
- O 0 4.5103601564733253e-07
pro O 0 7.830696517885372e-07
- O 0 1.1610889032453997e-06
opiomelanocortin O 0 2.408939690212719e-05
( O 0 1.3966705125767476e-07
POMC O 0 2.9321994588826783e-05
) O 0 3.781739810193585e-09
generates O 0 1.3181780111892749e-08
the O 0 1.4714177432040287e-08
melanocortin O 0 1.0286197721143253e-05
peptides O 0 4.346552771039569e-07
adrenocorticotrophin O 0 8.869890734786168e-06
( O 0 1.0998407162787771e-07
ACTH O 0 7.066097623464884e-06
) O 0 1.2318660758126043e-08
, O 0 2.863217218873615e-09
melanocyte O 0 4.90025604449329e-06
- O 0 1.7992481389228487e-06
stimulating O 0 2.540763716751826e-06
hormones O 0 4.968891786916174e-08
( O 0 4.194796066059325e-09
MSH O 0 2.928886146946752e-07
) O 0 9.560362917993004e-11
alpha O 0 1.1779207609308173e-09
, O 0 2.933272374994189e-11
beta O 0 3.7351349790881727e-10
and O 0 1.7238719132728342e-11
gamma O 0 3.947589810593399e-09
as O 0 1.0769382607911382e-10
well O 0 7.497805848410977e-11
as O 0 1.4832848838075563e-10
the O 0 1.5693953914208691e-09
opioid O 0 5.42862785835041e-08
- O 0 4.853630031220746e-08
receptor O 0 6.321759826732887e-08
ligand O 0 2.695739169666922e-07
beta O 0 6.016293809807394e-07
- O 0 3.5654005614560447e-07
endorphin O 0 7.025166269158944e-05
. O 0 1.6342724507012463e-07

While O 0 1.8546703586252988e-06
a O 0 3.313583363251382e-08
few O 0 3.2905367319813195e-09
cases O 0 1.888075917833021e-09
of O 0 1.5337320746766636e-07
isolated O 0 0.07704969495534897
ACTH B-Disease 1 0.9999998807907104
deficiency I-Disease 1 1.0
have O 0 1.4058562314289702e-08
been O 0 2.0447751936103487e-08
reported O 0 7.513678923487532e-08
( O 0 1.0226079183439651e-07
OMIM O 0 0.0001427790120942518
201400 O 0 2.357607172598364e-06
) O 0 2.448335401084023e-08
, O 0 2.5326520880497583e-09
an O 0 4.546953391582065e-08
inherited O 1 0.9999991655349731
POMC O 1 1.0
defect O 1 0.9999998807907104
has O 0 2.4549054344902288e-08
not O 0 2.5492028488116603e-09
been O 0 8.25527557424266e-09
described O 0 2.7250555589830583e-08
so O 0 1.8543325097652996e-08
far O 0 8.497257653061752e-08
. O 0 3.04654975025187e-07

Recent O 0 8.284600312435941e-07
studies O 0 9.902479547463372e-08
in O 0 3.9433003529154576e-09
animal O 0 8.055110356508521e-09
models O 0 5.527475810396254e-09
elucidated O 0 1.3474235629473696e-06
a O 0 1.967405260927535e-08
central O 0 1.4369815559689414e-08
role O 0 3.5162344147465774e-08
of O 0 1.515178382760496e-07
alpha O 0 6.780214789614547e-06
- O 0 1.2308465784371947e-06
MSH O 0 2.4500914150848985e-05
in O 0 1.6634300603612928e-09
the O 0 1.5023166044514369e-09
regulation O 0 3.6089742305733807e-09
of O 0 1.4934714576142483e-09
food O 0 1.410558447823007e-09
intake O 0 2.778896446287149e-09
by O 0 2.0941462453016868e-10
activation O 0 7.206451879682163e-09
of O 0 1.095859669675292e-08
the O 0 3.790204772258221e-08
brain O 0 1.2740930515064974e-06
melanocortin O 0 8.319580047100317e-07
- O 0 5.3819864120896455e-08
4 O 0 9.939473955000722e-08
- O 0 2.3076351496342795e-08
receptor O 0 2.7310653294421172e-08
( O 0 1.1906083896562336e-09
MC4 O 0 9.041701218848175e-07
- O 0 3.728185049567401e-08
R O 0 2.675755865766405e-07
; O 0 9.210702756057287e-10
refs O 0 2.32215295881133e-08
3 O 0 8.618629365741981e-09
- O 0 1.7530860096925949e-09
5 O 0 1.4438684692308357e-09
) O 0 1.1732630145200318e-10
and O 0 3.982654830925192e-11
the O 0 1.3294235712280056e-09
linkage O 0 2.0207916406889126e-07
of O 0 1.2940020610585634e-08
human O 0 1.0290118268585502e-07
obesity B-Disease 1 0.9986156225204468
to O 0 2.4279098731483373e-09
chromosome O 0 1.95734433106054e-08
2 O 0 1.5648826234837543e-08
in O 0 4.53192861016305e-09
close O 0 1.3664315190453635e-07
proximity O 0 4.038655632143673e-08
to O 0 1.9157468944541733e-09
the O 0 9.441608028737392e-08
POMC O 0 0.0006722711259499192
locus O 0 8.850252584124974e-07
, O 0 7.713965022304592e-10
led O 0 2.7947735237177085e-09
to O 0 8.898606296270373e-10
the O 0 4.370408923648483e-09
proposal O 0 6.719073741834336e-09
of O 0 1.0475770473306056e-08
an O 0 7.496140597140766e-09
association O 0 1.9277777596471424e-08
of O 0 2.2597370730181865e-07
POMC O 1 0.8422805666923523
with O 0 1.5960820221039285e-08
human O 0 1.225974119734019e-05
obesity B-Disease 1 1.0
. O 0 4.3386177139836946e-07

The O 0 1.4338570508698467e-06
dual O 0 1.042557755681628e-06
role O 0 5.583233360084705e-07
of O 0 2.0183122160233324e-06
alpha O 0 0.00014350829587783664
- O 0 4.1236689867218956e-05
MSH O 0 0.0007695917738601565
in O 0 1.601974375375903e-08
regulating O 0 1.199942829543943e-07
food O 0 1.720990105980036e-08
intake O 0 8.819484520472542e-08
and O 0 4.349087756594372e-09
influencing O 0 7.865178304200526e-06
hair O 0 1.445823727408424e-05
pigmentation O 0 5.078607864561491e-05
predicts O 0 9.290815938811647e-08
that O 0 1.408541339120717e-10
the O 0 8.379421045923152e-10
phenotype O 0 1.2982368069458516e-08
associated O 0 4.459123736921811e-09
with O 0 8.890360669866482e-10
a O 0 1.0238316150434912e-07
defect O 0 2.2418917069444433e-06
in O 0 4.050659185850236e-08
POMC O 0 0.19732071459293365
function O 0 1.4276743343089038e-07
would O 0 4.1979636433708833e-10
include O 0 1.9928604544361406e-08
obesity B-Disease 1 1.0
, O 0 7.0903971582936265e-09
alteration O 0 1.90239825315075e-05
in O 0 1.850739579367655e-07
pigmentation O 0 0.0006429149070754647
and O 0 1.4338051187223755e-05
ACTH B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 2.3286297619051766e-06

The O 0 4.178356789452664e-07
observation O 0 8.209331099351402e-06
of O 0 1.1957569157061698e-08
these O 0 1.9602650613848027e-09
symptoms O 0 7.43202193120851e-08
in O 0 1.6536148450541077e-08
two O 0 3.0921416538376434e-08
probands O 0 3.864562313538045e-05
prompted O 0 7.918109901083881e-08
us O 0 8.087501335296565e-09
to O 0 2.591277470376241e-10
search O 0 6.999736346102736e-09
for O 0 6.060144053243732e-10
mutations O 0 2.8363169590761572e-09
within O 0 3.027451001003101e-08
their O 0 7.386517353324962e-08
POMC O 0 0.015399053692817688
genes O 0 5.346198008737701e-07
. O 0 1.5533095165665145e-07

Patient O 0 0.00010848668898688629
1 O 0 3.188116863839241e-07
was O 0 9.799534694820977e-08
found O 0 4.011965870631684e-09
to O 0 1.0859900756443608e-09
be O 0 3.918244395606507e-09
a O 0 3.436989715055461e-08
compound O 0 5.796881055175618e-07
heterozygote O 0 1.1510490338650925e-07
for O 0 1.092346879616457e-09
two O 0 8.393241657245198e-10
mutations O 0 1.3073007121278124e-09
in O 0 8.027350340000794e-09
exon O 0 2.0025851199534372e-07
3 O 0 1.7023494081058743e-07
( O 0 9.425429325915502e-09
G7013T O 0 1.013470054544996e-07
, O 0 4.1583829712976694e-09
C7133delta O 0 2.8113602184021147e-06
) O 0 2.640925922392512e-09
which O 0 1.527325071970509e-10
interfere O 0 1.0103868852695541e-09
with O 0 5.666466948439641e-11
appropriate O 0 7.1932824141640594e-09
synthesis O 0 1.0193227240051783e-07
of O 0 5.508513467589182e-08
ACTH O 0 3.1200092962535564e-06
and O 0 2.4926370301159295e-08
alpha O 0 2.363129533478059e-05
- O 0 1.0941867913061287e-05
MSH O 0 0.0002896368387155235
. O 0 2.8668122808994667e-07

Patient O 0 4.3567531974986196e-05
2 O 0 4.2904846964120225e-07
was O 0 1.5026533617401583e-07
homozygous O 0 6.245783001901373e-09
for O 0 7.395842271940012e-10
a O 0 5.160396110426291e-09
mutation O 0 7.704171745004373e-10
in O 0 3.703257478449018e-09
exon O 0 9.712078252732681e-08
2 O 0 1.549677222101309e-07
( O 0 1.783232939089885e-08
C3804A O 0 6.844205131528724e-07
) O 0 6.281934972207637e-09
which O 0 2.2114046149823707e-09
abolishes O 0 6.841268600510375e-07
POMC O 0 0.00029154677758924663
translation O 0 1.6378267901018262e-05
. O 0 4.834417381971434e-07

These O 0 2.5843895912203152e-08
findings O 0 2.312671654181031e-08
represent O 0 3.859624175817089e-09
the O 0 3.3079046168893456e-09
first O 0 2.7303870275829922e-09
examples O 0 1.049859310597867e-08
of O 0 1.793749859757554e-08
a O 0 3.0523719374286884e-07
genetic B-Disease 1 0.9999986886978149
defect I-Disease 1 0.996516227722168
within O 0 2.60481822778047e-08
the O 0 4.5687301053476403e-08
POMC O 0 0.00016838857845868915
gene O 0 1.3523564490469653e-09
and O 0 8.825664504774622e-11
define O 0 3.4295617457047456e-09
a O 0 7.077601615890217e-09
new O 0 3.5210732107771037e-08
monogenic B-Disease 1 1.0
endocrine I-Disease 1 1.0
disorder I-Disease 1 0.9962555170059204
resulting O 0 4.337505004059494e-07
in O 0 3.007549054245828e-08
early O 0 1.812262780731544e-05
- O 0 0.026731926947832108
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 0.4079713523387909
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 5.0356873543933034e-05
red O 0 8.347017137566581e-05
hair O 0 0.00758355064317584
pigmentation O 0 0.05403468385338783
. O 0 6.157075063129014e-07
. O 0 1.313391749135917e-06

A O 0 1.0455248684593244e-06
European O 0 3.9734338486141496e-08
multicenter O 0 4.1284187318524346e-05
study O 0 1.7297347199018986e-07
of O 0 2.571596041889279e-06
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 2.7345265607436886e-08
classification O 0 5.473093622754277e-08
of O 0 2.27214478343285e-08
105 O 0 2.456034735587309e-07
mutations O 0 1.085816103696402e-09
and O 0 5.196117425221303e-10
a O 0 4.059165004122178e-09
general O 0 5.14668396789375e-09
system O 0 1.0974912534322812e-08
for O 0 8.934644135649705e-10
genotype O 0 5.846337458592643e-08
- O 0 5.6610740983842334e-08
based O 0 3.351939525941816e-08
prediction O 0 2.3709912966296542e-06
of O 0 1.7633007587392058e-07
metabolic O 0 0.00017776769527699798
phenotype O 0 2.3987843178474577e-06
. O 0 1.6010373826702562e-07

Phenylketonuria B-Disease 1 0.9987823367118835
( O 0 1.1283330422884319e-05
PKU B-Disease 0 0.0002341014624107629
) O 0 2.086429518044497e-08
and O 0 5.388649970683446e-09
mild B-Disease 0 2.5679772079456598e-05
hyperphenylalaninemia I-Disease 1 1.0
( O 1 1.0
MHP B-Disease 1 1.0
) O 0 1.00152526272268e-07
are O 0 1.7687812325917207e-09
allelic B-Disease 0 3.646302502602339e-05
disorders I-Disease 1 0.9999960660934448
caused O 0 6.678299087070627e-07
by O 0 6.553581677337661e-09
mutations O 0 2.112372055051992e-09
in O 0 2.1440007547113282e-09
the O 0 2.3622016342983443e-08
gene O 0 1.8689904734969787e-08
encoding O 0 8.908225623827093e-08
phenylalanine O 0 1.2733295989164617e-05
hydroxylase O 0 6.01498904870823e-05
( O 0 9.73058149611461e-07
PAH O 0 0.012324788607656956
) O 0 3.3282822187175043e-07
. O 0 3.6523434232549334e-07

Previous O 0 1.0768431820906699e-05
studies O 0 1.2397535442687513e-07
have O 0 4.91976348548917e-10
suggested O 0 1.0698468777547987e-09
that O 0 4.5644640844777484e-11
the O 0 5.018548354662755e-10
highly O 0 9.478503315563103e-09
variable O 0 7.380573379123234e-07
metabolic O 0 3.9312766602961347e-05
phenotypes O 0 4.715313480119221e-06
of O 0 0.00015335006173700094
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
correlate O 0 0.00075309764361009
with O 0 9.76961473497795e-07
PAH O 1 1.0
genotypes O 0 0.0003002359881065786
. O 0 1.0349576768931001e-06

We O 0 1.5966429600666743e-07
identified O 0 6.752183168146075e-08
both O 0 2.0126554645116812e-08
causative O 0 5.532727755053202e-06
mutations O 0 3.38512400333002e-08
in O 0 2.3993687037204836e-08
686 O 0 1.2605963775058626e-06
patients O 0 2.570975876636794e-09
from O 0 8.009848895262905e-10
seven O 0 4.652541907290697e-09
European O 0 1.6899805999059936e-08
centers O 0 1.7538853569476487e-07
. O 0 1.478389464182328e-07

On O 0 6.674905534964637e-07
the O 0 1.273187333339365e-08
basis O 0 1.1204277683418695e-07
of O 0 6.0225828768523115e-09
the O 0 4.444180135010356e-09
phenotypic O 0 4.452743596061737e-08
characteristics O 0 3.7682770681612965e-08
of O 0 3.322018571338958e-08
297 O 0 2.0887833329652494e-07
functionally O 0 8.903043635655195e-07
hemizygous O 0 1.1888728295161854e-06
patients O 0 5.4209787769821105e-09
, O 0 7.180174232956915e-10
105 O 0 2.669968957036417e-08
of O 0 4.41262448802604e-09
the O 0 4.4064596416149016e-09
mutations O 0 7.705847626660045e-10
were O 0 2.0753472274037676e-09
assigned O 0 1.471810762154746e-08
to O 0 2.596195924908784e-09
one O 0 7.488737630012565e-09
of O 0 7.145735114733043e-09
four O 0 1.1005012900966449e-08
arbitrary O 0 4.870545211588251e-08
phenotype O 0 2.7351994447144534e-08
categories O 0 1.288554472012038e-07
. O 0 8.052057864915696e-08

We O 0 2.927570790234313e-07
proposed O 0 1.729635101810345e-08
and O 0 1.6187811091583626e-09
tested O 0 2.6868209879182814e-09
a O 0 1.716170761056901e-09
simple O 0 1.152217654620813e-09
model O 0 4.3048331566097886e-10
for O 0 4.607200732031913e-11
correlation O 0 2.092865436509328e-09
between O 0 8.430158793260034e-10
genotype O 0 8.644279070324501e-09
and O 0 4.511761797498792e-10
phenotypic O 0 5.75752139297947e-08
outcome O 0 4.3658539539137564e-07
. O 0 3.938695272154291e-07

The O 0 4.767221071233507e-07
observed O 0 1.93919603930226e-07
phenotype O 0 1.1285510481684469e-07
matched O 0 4.1831729191699196e-08
the O 0 1.5285738896864132e-08
predicted O 0 7.935783941093177e-08
phenotype O 0 9.065729500434827e-09
in O 0 7.273185942402449e-10
79 O 0 1.80501729118987e-08
% O 0 8.973480847274118e-10
of O 0 8.228185355285689e-10
the O 0 6.215913894713765e-10
cases O 0 5.383243295575824e-10
, O 0 1.285597045486142e-10
and O 0 1.1150855933061976e-10
in O 0 6.148185849319532e-10
only O 0 1.7080321879081595e-10
5 O 0 8.677842333604247e-10
of O 0 6.692938980812357e-10
184 O 0 2.564961132378585e-09
patients O 0 1.5222181848351113e-10
was O 0 4.268223996461984e-09
the O 0 2.2795489940108382e-09
observed O 0 2.564643164504332e-09
phenotype O 0 7.413228364505642e-10
more O 0 1.3953047051096235e-11
than O 0 4.610233375612616e-11
one O 0 1.6303036698417372e-10
category O 0 1.1443294312130092e-08
away O 0 3.780369350891988e-09
from O 0 1.2586512943002504e-09
that O 0 3.419032001961142e-10
expected O 0 1.1321996673530066e-08
. O 0 2.512865933113062e-07

Among O 0 6.852003764379333e-08
the O 0 6.4024643364746225e-09
seven O 0 2.370889484737404e-09
contributing O 0 3.628744593697775e-08
centers O 0 4.87464113518854e-09
, O 0 1.1085477674699362e-10
the O 0 2.767137630144134e-10
proportion O 0 2.5982123119661082e-09
of O 0 2.435999624239571e-09
patients O 0 2.235491652902155e-10
for O 0 7.212852537463732e-11
whom O 0 1.1152946344239467e-09
the O 0 6.120131956777186e-09
observed O 0 2.529448117627453e-08
phenotype O 0 3.106351176285216e-09
did O 0 3.49402839994184e-10
not O 0 1.286683815049372e-10
match O 0 5.3940381050665565e-09
the O 0 3.921715574506379e-08
predicted O 0 1.470625790034319e-07
phenotype O 0 6.9302181771035976e-09
was O 0 3.6924753032963054e-08
4 O 0 1.221580436805425e-08
% O 0 5.89821247398703e-10
- O 0 6.69475197501157e-10
23 O 0 4.7006021297590905e-09
% O 0 1.471091470861552e-09
( O 0 1.7877443969638307e-09
P O 0 6.80009350162436e-07
< O 0 7.435297533220364e-08
. O 0 6.498387383757631e-10
0001 O 0 1.8292544154974166e-06
) O 0 5.282345116874865e-10
, O 0 3.5490225341883175e-11
suggesting O 0 3.8798461665656703e-10
that O 0 4.616293458603593e-12
differences O 0 1.487551748446947e-10
in O 0 1.3301025558742907e-10
methods O 0 1.6137191582998867e-09
used O 0 2.0612350715154548e-10
for O 0 1.3243106611326994e-10
mutation O 0 8.422829655962971e-10
detection O 0 1.7656743622751492e-08
or O 0 3.168573181611123e-09
phenotype O 0 1.1225171014928037e-08
classification O 0 5.579164685798332e-09
may O 0 1.0108108794426585e-09
account O 0 1.4969563366662442e-09
for O 0 1.3209629223798203e-10
a O 0 1.7210811664725156e-09
considerable O 0 1.4126349867638055e-08
proportion O 0 8.491340075522658e-09
of O 0 1.8519537903216587e-08
genotype O 0 4.649368747777771e-07
- O 0 5.843806434313592e-07
phenotype O 0 1.70544979027909e-07
inconsistencies O 0 1.339745836048678e-06
. O 0 1.3423148459423828e-07

Our O 0 1.8896244000643492e-06
data O 0 3.265411123720696e-07
indicate O 0 3.740107601402087e-08
that O 0 1.009882066860257e-09
the O 0 4.3762668155977735e-08
PAH O 0 0.0003416593244764954
- O 0 1.817818571225871e-07
mutation O 0 3.2441775932312567e-09
genotype O 0 6.01592375915061e-09
is O 0 1.4407894322054915e-10
the O 0 5.693130966655247e-10
main O 0 2.8720684497329785e-08
determinant O 0 1.4324668029530585e-07
of O 0 3.491673439270926e-08
metabolic O 0 2.7280408176011406e-05
phenotype O 0 2.370149054797821e-08
in O 0 1.8670653911811996e-09
most O 0 1.142603567316769e-09
patients O 0 9.168902082024033e-09
with O 0 8.274698188870389e-07
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.00011383827950339764

In O 0 3.6138260384177556e-07
the O 0 1.1851893688685777e-08
present O 0 5.519205981130426e-09
study O 0 4.856127500119101e-09
, O 0 2.5870106057368503e-10
the O 0 1.3854726255146943e-09
classification O 0 1.503268975966421e-08
of O 0 8.43870893163512e-08
105 O 0 6.288517761277035e-05
PAH O 1 0.999935507774353
mutations O 0 1.993712217540633e-08
may O 0 1.0699040542405669e-09
allow O 0 3.0728722344441906e-10
the O 0 5.802454072778573e-09
prediction O 0 1.9919339422358462e-07
of O 0 4.243328355357789e-09
the O 0 9.274311096874044e-09
biochemical O 0 1.259428046296307e-07
phenotype O 0 8.280364838242349e-09
in O 0 9.581634374811188e-10
> O 0 8.548297181221187e-09
10 O 0 7.297865090016842e-10
, O 0 2.010984295752749e-10
000 O 0 7.71867814108873e-09
genotypes O 0 8.72747740743307e-09
, O 0 1.6241552547313631e-10
which O 0 4.052276222910045e-11
may O 0 8.871300222201839e-11
be O 0 9.394799521666997e-11
useful O 0 1.0068514022520958e-08
for O 0 8.36129998571522e-10
the O 0 5.6656649149999794e-08
management O 0 6.218425824044971e-06
of O 0 8.410503141931258e-06
hyperphenylalaninemia B-Disease 1 1.0
in O 0 4.45164141638088e-06
newborns O 0 3.920518338418333e-06
. O 0 3.5793104302683787e-07

Somatic O 0 3.7389356293715537e-05
instability O 0 1.1722121598722879e-05
of O 0 6.455753691625432e-07
the O 0 1.0020121408160776e-06
CTG O 1 0.7293787002563477
repeat O 0 3.4279989904462127e-06
in O 0 1.0664415128758264e-07
mice O 0 1.2419474160196842e-07
transgenic O 0 2.577222524280387e-08
for O 0 2.1832702312707397e-09
the O 0 9.542574161969242e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 2.2716297110036976e-07
is O 0 1.7472175928290312e-09
age O 0 4.6614778703713e-09
dependent O 0 1.212890410329237e-08
but O 0 6.154541459801877e-11
not O 0 8.167762993727123e-11
correlated O 0 3.1951306045385763e-09
to O 0 1.881237943202052e-10
the O 0 3.0784701454678043e-09
relative O 0 6.558010454682517e-07
intertissue O 0 1.565177080919966e-05
transcription O 0 9.609808557797805e-07
levels O 0 2.699860246480057e-08
and O 0 6.893503101679244e-09
proliferative O 0 0.00017193723761010915
capacities O 0 2.4102588213281706e-05
. O 0 9.169340842163365e-07

A O 0 0.0002642083854880184
( O 0 3.805202823059517e-06
CTG O 0 0.0010972233721986413
) O 0 1.4288649197169434e-07
nexpansion O 0 1.9624153537733946e-06
in O 0 1.7270869179242254e-08
the O 0 1.805223881490292e-08
3 O 0 2.512460923753679e-07
- O 0 1.377602956154078e-07
untranslated O 0 2.8704022042802535e-05
region O 0 4.961249828738801e-07
( O 0 7.353608566518233e-08
UTR O 0 2.5849083613138646e-05
) O 0 4.0700105508051365e-09
of O 0 1.5573316858308317e-08
the O 0 3.8158327697601635e-07
DM O 1 1.0
protein O 0 5.6513817980885506e-06
kinase O 0 7.109600574040087e-06
gene O 0 1.0657618787490719e-08
( O 0 5.181284734590008e-09
DMPK O 0 5.131369562150212e-06
) O 0 2.905373275297052e-09
is O 0 3.763848677174053e-10
responsible O 0 1.1183968418038148e-08
for O 0 4.786034679682416e-08
causing O 1 0.9963709115982056
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999642372131348
DM B-Disease 1 1.0
) O 0 5.170310259927646e-07
. O 0 1.46054134120277e-07

Major O 0 5.717586827813648e-05
instability O 0 0.0001751329837134108
, O 0 8.413569396736875e-09
with O 0 4.3530276605530105e-10
very O 0 3.3275595612280995e-09
large O 0 5.661406454748885e-09
expansions O 0 3.634015399711643e-08
between O 0 1.1915722630817527e-08
generations O 0 9.807796352845344e-09
and O 0 5.55421098002995e-10
high O 0 6.388205076035547e-09
levels O 0 4.901351768893392e-09
of O 0 7.3646804210625305e-09
somatic O 0 2.291853604674543e-07
mosaicism O 0 5.053390850662254e-06
, O 0 3.400418557841789e-10
is O 0 1.927558945791219e-10
observed O 0 2.47178078005561e-09
in O 0 5.778156619840047e-09
patients O 0 1.755408973735939e-08
. O 0 9.560540803477124e-08

There O 0 6.009194635225867e-07
is O 0 1.1232796026661163e-08
a O 0 2.21910418929383e-08
good O 0 2.2943284605503322e-08
correlation O 0 2.7091816789948098e-08
between O 0 3.912717705389923e-09
repeat O 0 1.6113332890199672e-08
size O 0 3.0622029356663916e-08
( O 0 2.507255292272248e-09
at O 0 9.067562700693088e-09
least O 0 1.1729390791970218e-09
in O 0 1.3742766924451644e-09
leucocytes O 0 5.142265990798478e-07
) O 0 1.0709044762080566e-09
, O 0 1.6617325571122166e-10
clinical O 0 5.940553382544067e-09
severity O 0 1.5562152455572686e-08
and O 0 7.667025903046465e-10
age O 0 8.20158803094273e-08
of O 0 5.775834210908215e-07
onset O 0 0.0004520135116763413
. O 0 3.5430969091976294e-07

The O 0 6.091066552471602e-06
trinucleotide O 0 0.0002531592908781022
repeat O 0 3.2913094401010312e-06
instability O 0 7.348739472945454e-06
mechanisms O 0 4.757129318022635e-06
involved O 0 1.4414265478990274e-06
in O 0 2.423041223664768e-06
DM B-Disease 1 1.0
and O 0 6.6718994773395934e-09
other O 0 1.6923442647254205e-09
human O 0 4.072739159255434e-07
genetic B-Disease 1 1.0
diseases I-Disease 1 1.0
are O 0 4.820102095237644e-09
unknown O 0 2.762459007499274e-05
. O 0 1.6953131876107363e-07

We O 0 2.5305538997599797e-07
studied O 0 1.0372727956564631e-06
somatic O 0 1.0663696912160958e-06
instability O 0 1.0443409337312914e-06
by O 0 3.334639231411529e-08
measuring O 0 2.1482694137375802e-05
the O 0 3.8436226645899296e-07
CTG O 0 0.001025882549583912
repeat O 0 8.75367263120097e-08
length O 0 1.1224100759932298e-08
at O 0 4.719998614177712e-09
several O 0 1.1398386401406668e-10
ages O 0 1.882667577390862e-09
in O 0 2.0276730294810363e-10
various O 0 1.3294919609663225e-09
tissues O 0 1.939750227109016e-08
of O 0 7.199722062978253e-08
transgenic O 0 4.2825212176467176e-07
mice O 0 1.4164634798419229e-08
carrying O 0 6.241579253440932e-09
a O 0 5.1831555936132645e-08
( O 0 4.981636081424767e-08
CTG O 0 8.171591616701335e-05
) O 0 2.651010788667918e-08
55expansion O 0 7.570073421447887e-07
surrounded O 0 1.2007832594918e-07
by O 0 5.0144079999370206e-09
45 O 0 4.246228968440846e-08
kb O 0 2.2887529667059425e-06
of O 0 7.240140575959231e-08
the O 0 5.5075883409472226e-08
human O 0 4.3677695771293656e-07
DM B-Disease 1 1.0
region O 0 4.692757116231405e-08
, O 0 1.9141324081317634e-09
using O 0 2.7899165200295784e-09
small O 0 4.2958564705486424e-08
- O 0 1.7023104703639547e-07
pool O 0 4.647294645110378e-06
PCR O 0 3.576942845029407e-06
. O 0 2.21674426370555e-07

These O 0 6.254046525100421e-07
mice O 0 1.597005336861912e-07
have O 0 3.573859264083268e-10
been O 0 4.0424896763369134e-10
shown O 0 4.082106042080369e-10
to O 0 1.7999857160333477e-10
reproduce O 0 4.08892608660949e-09
the O 0 1.2611359734293615e-09
intergenerational O 0 4.541666243085274e-08
and O 0 7.890226250140131e-10
somatic O 0 4.695899846751672e-08
instability O 0 7.058851281271927e-08
of O 0 1.017098671951544e-08
the O 0 2.4920240093706525e-08
55 O 0 4.2288840518267534e-07
CTG O 0 0.0003082631155848503
repeat O 0 1.3741062332428555e-07
suggesting O 0 2.3869715093383093e-08
that O 0 8.267699719288757e-11
surrounding O 0 2.1047827925002593e-09
sequences O 0 1.5475651871099672e-09
and O 0 4.296998867836521e-10
the O 0 3.1522251475735175e-09
chromatin O 0 6.460391688278833e-08
environment O 0 1.1205191441376883e-08
are O 0 1.7990658962574457e-10
involved O 0 4.114877771854708e-09
in O 0 1.1457795601188536e-08
instability O 0 4.6102759370114654e-06
mechanisms O 0 1.261286251974525e-05
. O 0 7.352619491030055e-07

As O 0 1.9510009963141783e-07
observed O 0 1.0815136874953168e-07
in O 0 4.415486642983524e-09
some O 0 1.0381718817953356e-09
of O 0 8.461139344717594e-09
the O 0 1.9005204521249652e-08
tissues O 0 1.518974812597662e-07
of O 0 1.8603266653371975e-05
DM B-Disease 1 1.0
patients O 0 8.172229399860953e-07
, O 0 4.36028990691284e-10
there O 0 1.122674953002445e-09
is O 0 5.584954165804845e-10
a O 0 1.65387914474735e-09
tendency O 0 2.2803841037699613e-09
for O 0 3.4084965405689616e-10
repeat O 0 9.777369136543257e-09
length O 0 1.165433349825662e-08
and O 0 1.283167461174628e-09
somatic O 0 1.256519936987388e-07
mosaicism O 0 1.7547180277688312e-06
to O 0 1.4356328348341663e-09
increase O 0 1.2047255415481573e-09
with O 0 2.5320520680160996e-10
the O 0 8.65112426140513e-09
age O 0 7.655854261656714e-08
of O 0 6.892007320402627e-08
the O 0 1.4634721878792334e-07
mouse O 0 2.775789198494749e-07
. O 0 3.869060449801509e-08

Furthermore O 0 5.063695425633341e-06
, O 0 1.2088648304597882e-08
we O 0 2.9936573220368246e-09
observed O 0 1.4457183006300056e-08
no O 0 4.081648796727677e-09
correlation O 0 8.438978404967656e-09
between O 0 6.720352607736402e-10
the O 0 1.3359690020919857e-09
somatic O 0 7.978001370645416e-09
mutation O 0 3.7202255165347253e-10
rate O 0 3.7570870858871785e-09
and O 0 6.350201475768813e-10
tissue O 0 7.398713819384284e-08
proliferation O 0 1.412574238202069e-05
capacity O 0 7.82862935011508e-06
. O 0 5.565414085140219e-07

The O 0 4.7409608328052855e-07
somatic O 0 6.342822871374665e-07
mutation O 0 5.185753604308729e-09
rates O 0 1.5417258580896487e-09
in O 0 1.0689223811644055e-10
different O 0 4.864224995015931e-11
tissues O 0 1.3381034058568275e-09
were O 0 3.048506558300801e-09
also O 0 1.96171148769686e-10
not O 0 7.756199849051626e-11
correlated O 0 3.1825160284881804e-09
to O 0 1.5020294730216932e-10
the O 0 2.5542497006370013e-09
relative O 0 2.80622543868958e-07
inter O 0 3.07302116198116e-06
- O 0 8.2548831414897e-07
tissue O 0 6.912372896294983e-08
difference O 0 3.4373698554190923e-08
in O 0 3.990863639558029e-09
transcriptional O 0 6.124478346691831e-08
levels O 0 1.756171763567238e-09
of O 0 7.618686792554286e-10
the O 0 8.282792784974902e-10
three O 0 3.3311604585861687e-09
genes O 0 3.670733050853414e-09
( O 0 3.273759485722394e-09
DMAHP O 0 5.412635346146999e-06
, O 0 2.2125195897615413e-08
DMPK O 0 1.5174389773164876e-05
and O 0 2.6190862811859006e-08
59 O 0 3.22623549209311e-07
) O 0 1.0071241618447857e-08
surrounding O 0 3.453747154935627e-08
the O 0 2.8052426159774768e-08
repeat O 0 3.693225778533815e-07
. O 0 2.7440668404210555e-08
. O 0 1.2606308530394017e-07

A O 0 3.941876911994768e-06
novel O 0 9.499861448603042e-07
missense O 0 5.9224821598036215e-06
mutation O 0 1.479802147485998e-08
in O 0 2.6775150985258733e-09
patients O 0 1.7327677070966274e-09
from O 0 3.1971911784722806e-09
a O 0 6.59379466583232e-08
retinoblastoma B-Disease 0 0.01815916784107685
pedigree O 0 1.3451558515953366e-05
showing O 0 4.904973494035403e-08
only O 0 8.876958612624719e-10
mild O 0 5.99821037283732e-09
expression O 0 2.09247419391545e-09
of O 0 4.159279143323147e-09
the O 0 3.2198848032294336e-08
tumor B-Disease 0 3.180071416863939e-06
phenotype O 0 3.4043424079754914e-07
. O 0 3.064446829625922e-08

We O 0 8.139095371006988e-07
have O 0 6.268924934715869e-09
used O 0 1.073604671830708e-08
single O 0 1.552701789364619e-08
strand O 0 5.801084768108922e-08
conformation O 0 7.732529283543954e-09
polymorphism O 0 2.914675611975781e-09
analysis O 0 7.851120309432247e-10
to O 0 1.1129502180962092e-10
study O 0 1.9915638027612204e-09
the O 0 4.4208632310471785e-09
27 O 0 7.442462646167769e-08
exons O 0 1.9613468182910765e-08
of O 0 3.874427445538231e-09
the O 0 1.935263860275427e-08
RB1 O 0 6.204930832609534e-05
gene O 0 1.0448047982336561e-09
in O 0 9.369639092371429e-11
individuals O 0 5.751289375299784e-11
from O 0 1.4421014382648423e-09
a O 0 1.857840814523115e-08
family O 0 5.0553584429735565e-08
showing O 0 4.975710510279896e-08
mild O 0 9.522900690228653e-09
expression O 0 5.74642644579626e-09
of O 0 8.00310306914298e-09
the O 0 2.343036697993739e-08
retinoblastoma B-Disease 0 1.2736818462144583e-05
phenotype O 0 1.002670728666999e-06
. O 0 8.895203507108818e-08

In O 0 1.1295826141122234e-07
this O 0 6.050653755806934e-09
family O 0 1.995755383177311e-08
affected O 0 9.89188175815059e-10
individuals O 0 2.430758372362618e-10
developed O 0 2.5738916775708276e-08
unilateral B-Disease 0 3.2327234293916263e-06
tumors I-Disease 1 1.0
and O 0 1.0128923122465494e-07
, O 0 1.8702410731208374e-09
as O 0 4.781567364275929e-10
a O 0 4.5879719468011615e-10
result O 0 2.4797883191318704e-10
of O 0 1.2044315544912365e-09
linkage O 0 4.45308323548943e-08
analysis O 0 4.965847733018336e-09
, O 0 3.757220923272797e-10
unaffected O 0 3.0450507892965106e-08
mutation O 0 6.611381442311881e-10
carriers O 0 3.6540356851411104e-10
were O 0 4.04026412326175e-09
also O 0 1.4678177562288397e-09
identified O 0 1.1509750486027315e-08
within O 0 1.1170946123684189e-07
the O 0 5.015682518205722e-07
pedigree O 0 1.0887305506912526e-05
. O 0 4.488300362481823e-07

A O 0 7.423502665915294e-06
single O 0 1.1832608493023145e-07
band O 0 1.8967871540098713e-07
shift O 0 1.2975985441698867e-07
using O 0 6.726320833649879e-08
SSCP O 0 3.743727575056255e-05
was O 0 6.323001571217901e-07
identified O 0 1.0158233720858334e-07
in O 0 2.735256821040366e-08
exon O 0 1.6799126001387776e-07
21 O 0 1.4609197407366992e-08
which O 0 1.839637053802079e-10
resulted O 0 2.76957834444147e-09
in O 0 2.5829098859730948e-09
a O 0 1.0554972895704395e-08
missense O 0 6.158342813478157e-08
mutation O 0 4.840977063658158e-10
converting O 0 1.1613239259133934e-08
a O 0 2.2688144696303425e-08
cys O 0 2.8287279292271705e-06
- O 0 2.0524944375210907e-06
- O 0 2.8145468604634516e-06
> O 0 1.0277186675011762e-06
arg O 0 2.3953410277499643e-07
at O 0 4.193254454776252e-08
nucleotide O 0 9.171669290708451e-08
position O 0 7.381587607824258e-08
28 O 0 6.950673281380659e-08
in O 0 1.0066324662716397e-08
the O 0 3.0562139841094904e-07
exon O 0 5.389389571064385e-06
. O 0 2.3441367602572427e-07

The O 0 6.554859623975062e-07
mutation O 0 5.571425987227485e-08
destroyed O 0 3.354886757733766e-06
an O 0 2.628559769846106e-08
NdeI O 0 3.416798426769674e-05
restriction O 0 1.824707140940518e-07
enzyme O 0 1.5102244788067765e-07
site O 0 4.547517278297164e-07
. O 0 8.487457847650148e-08

Analysis O 0 4.787025318364613e-06
of O 0 6.347761427605292e-08
all O 0 5.793231228068407e-09
family O 0 1.6204376507289453e-08
members O 0 5.739380637415081e-10
demonstrated O 0 5.499419142296347e-09
that O 0 1.5712066370188182e-10
the O 0 7.187988426693437e-09
missense O 0 6.179581646392762e-07
mutation O 0 1.2285833683733927e-08
co O 0 2.0998293166485382e-06
- O 0 1.1735257885447936e-06
segregated O 0 9.063294470479377e-08
with O 0 1.5093246652497783e-09
patients O 0 2.728654813211051e-08
with O 0 1.0448296450249472e-07
tumors B-Disease 1 1.0
or O 1 0.9999920129776001
who O 0 5.754830567639146e-07
, O 0 8.585257837978588e-09
as O 0 2.8987310329853244e-09
a O 0 5.0106407911698625e-09
result O 0 2.43338060812448e-09
of O 0 9.539334655528364e-09
linkage O 0 1.2507180713328125e-07
analysis O 0 9.757993524317499e-09
had O 0 3.579345708715209e-09
been O 0 1.2074239386095087e-09
predicted O 0 3.1564608704570674e-09
to O 0 4.17397921781415e-10
carry O 0 6.697514098874535e-09
the O 0 6.424056664400268e-08
predisposing O 0 1.8212076611234806e-05
mutation O 0 2.2783098074796726e-07
. O 0 2.303765853639561e-07

These O 0 7.592843331849508e-08
observations O 0 6.854218668195244e-07
point O 0 1.5527541563642444e-07
to O 0 6.514893069464733e-10
another O 0 5.128584223967891e-09
region O 0 7.773521382148374e-09
of O 0 3.0936284645122214e-08
the O 0 2.4705570922378683e-07
RB1 O 0 0.00017317585297860205
gene O 0 5.4705866503468314e-09
where O 0 6.620669013024383e-10
mutations O 0 6.492473919594843e-11
only O 0 4.283160284779264e-11
modify O 0 5.768573396736087e-10
the O 0 1.930168469499449e-09
function O 0 1.6407369685111917e-08
of O 0 4.721295354670474e-09
the O 0 1.3259194631132232e-08
gene O 0 1.0457318344592181e-09
and O 0 1.2782763736396419e-10
raise O 0 1.5807632980369135e-09
important O 0 1.5430086097723006e-09
questions O 0 5.153176552141758e-09
for O 0 4.691141364254747e-10
genetic O 0 2.095258899714736e-08
counseling O 0 4.242059858938774e-08
in O 0 5.608128406109358e-10
families O 0 1.201127391992074e-10
with O 0 5.0006301183236346e-11
these O 0 4.396492336855573e-10
distinctive O 0 3.2433071339710295e-08
phenotypes O 0 2.181257343636389e-07
. O 0 8.407649687569574e-09
. O 0 7.341738239574624e-08

Maternal B-Disease 0 0.31203341484069824
disomy I-Disease 1 0.6023122668266296
and O 0 2.4643250071676448e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 0 8.084843284450471e-05
with O 0 6.685567655040359e-09
gamete O 0 1.4988482689659577e-05
complementation O 0 9.709829100756906e-06
in O 0 1.0243644155139009e-08
a O 0 3.079610877421146e-08
case O 0 3.6803672998075854e-08
of O 0 3.8945159985814826e-07
familial O 0 1.8211885617347434e-05
translocation O 0 3.333111862957594e-06
( O 0 3.03209155561035e-08
3 O 0 2.3271720550610553e-08
; O 0 3.523071834266034e-10
15 O 0 1.5696716815227774e-08
) O 0 7.883295793931211e-09
( O 0 8.084633407179354e-09
p25 O 0 2.471829816386162e-07
; O 0 1.550188533094854e-09
q11 O 0 2.5693873340060236e-07
. O 0 6.70582256390162e-09
2 O 0 1.3437954748951597e-07
) O 0 2.6045201551028185e-08
. O 0 6.043988776127662e-08

Maternal B-Disease 1 0.9998326301574707
uniparental I-Disease 1 0.9999983310699463
disomy I-Disease 1 0.9999517202377319
( I-Disease 0 0.00042666966328397393
UPD I-Disease 1 1.0
) I-Disease 0 7.336181084838245e-08
for I-Disease 0 4.551706123123722e-09
chromosome I-Disease 0 1.3598665304925817e-07
15 I-Disease 0 3.0983763110725704e-08
is O 0 2.4413113752785875e-09
responsible O 0 9.207457907223215e-09
for O 0 1.2047830511008328e-09
an O 0 3.622076638620797e-09
estimated O 0 5.060391661260155e-09
30 O 0 4.310594992062988e-09
% O 0 6.169117994225815e-10
of O 0 6.782885364486901e-10
cases O 0 7.235440024899731e-10
of O 0 9.18774048841442e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.004153309855610132
PWS B-Disease 1 1.0
) O 0 3.880228121033724e-07
. O 0 1.0104358949547532e-07

We O 0 1.6390719110859209e-06
report O 0 2.259000098092656e-07
on O 0 2.256071596207221e-08
an O 0 3.5105569562432493e-09
unusual O 0 1.654176351451042e-08
case O 0 3.171096096821202e-08
of O 0 8.607593571241523e-08
maternal B-Disease 0 7.420671863656025e-06
disomy I-Disease 0 0.00012164077634224668
15 I-Disease 0 7.817161531420425e-07
in O 0 1.48118914466977e-07
PWS B-Disease 1 1.0
that O 0 2.171794744043609e-09
is O 0 8.677826235370389e-10
most O 0 8.930021999642435e-11
consistent O 0 2.2699127022463017e-09
with O 0 7.62494858919105e-11
adjacent O 0 4.6605823200707164e-08
- O 0 5.09636919332479e-08
1 O 0 3.088788389504771e-07
segregation O 0 9.111636245506816e-08
of O 0 3.1015574109005684e-08
a O 0 6.523689677351285e-08
paternal O 0 2.950199871065706e-07
t O 0 1.3411626476056426e-08
( O 0 9.239982112774214e-10
3 O 0 3.1076072826152767e-09
; O 0 1.9046844657033546e-10
15 O 0 4.200656711361717e-09
) O 0 1.2505440016852276e-09
( O 0 1.5565051469934588e-09
p25 O 0 3.325645181462278e-08
; O 0 1.4679374382708943e-10
q11 O 0 3.649435953434477e-08
. O 0 1.5079541781926054e-10
2 O 0 3.3032074853167614e-09
) O 0 1.620386463896395e-10
with O 0 6.195600282810076e-11
simultaneous O 0 4.54683188877425e-08
maternal O 0 3.21262831448621e-07
meiotic O 0 6.101658982515801e-06
nondisjunction O 0 2.6843750674743205e-05
for O 0 1.0013629037075589e-07
chromosome O 0 1.5183795767370611e-06
15 O 0 5.073160878055205e-07
. O 0 3.5949511811850243e-07

The O 0 3.644987828010926e-06
patient O 0 1.824134415073786e-06
( O 0 2.4042890345299384e-08
J O 0 1.3326335590591043e-07
. O 0 1.2465479759526943e-09
B O 0 1.6574315964135167e-07
. O 0 1.3927641262512225e-09
) O 0 1.1215214312798594e-09
, O 0 3.353042288267716e-10
a O 0 4.691143473678494e-09
17 O 0 1.843752173158464e-08
- O 0 1.2374850477669952e-08
year O 0 1.534720439622106e-08
- O 0 4.639217365820514e-07
old O 0 7.878651899773104e-07
white O 0 9.482539553573588e-08
male O 0 4.680653020727732e-08
with O 0 3.2705826935597315e-09
PWS B-Disease 1 1.0
, O 0 2.351516137366616e-08
was O 0 1.5934911345993896e-07
found O 0 4.300690914504912e-09
to O 0 1.2694524320622236e-09
have O 0 7.376358968080865e-10
47 O 0 3.14997912198578e-08
chromosomes O 0 7.261019785431699e-09
with O 0 1.7094083926139092e-09
a O 0 1.7485578496234666e-07
supernumerary O 0 0.00015385581355076283
, O 0 1.77904748710489e-08
paternal O 0 8.51690458603116e-07
der O 0 0.00016778659482952207
( O 0 3.017897753920806e-08
15 O 0 1.046891817679807e-08
) O 0 3.4818342653508694e-10
consisting O 0 2.18707540966534e-09
of O 0 3.4186829367399696e-08
the O 0 9.861541627742554e-08
short O 0 8.705069376446772e-07
arm O 0 2.5762556106201373e-05
and O 0 5.617844678340589e-08
the O 0 3.6157327940600226e-06
proximal O 1 0.9797838926315308
long O 0 5.253050403553061e-06
arm O 0 3.9662634662818164e-05
of O 0 2.8281183404033072e-06
chromosome O 0 1.424656488779874e-06
15 O 0 2.1113785919624206e-07
, O 0 6.97925939263655e-09
and O 0 3.8846557970373397e-08
distal O 0 0.0006618288462050259
chromosome O 0 0.2956373691558838
arm O 1 0.9999617338180542
3p O 1 1.0
. O 0 9.083392069442198e-05

The O 0 1.3620313438877929e-05
t O 0 4.913485440738441e-07
( O 0 9.585368943021422e-09
3 O 0 1.3118373942688777e-08
; O 0 2.95532681660049e-10
15 O 0 7.172184179893293e-09
) O 0 5.081193243938742e-10
was O 0 6.94481361307453e-09
present O 0 1.55017076952646e-09
in O 0 4.796090746772563e-10
the O 0 3.294832406908199e-09
balanced O 0 6.235201244209065e-09
state O 0 9.35849842065295e-10
in O 0 1.4668550818441872e-09
the O 0 7.608496055411251e-09
patients O 0 2.6672852815323722e-09
father O 0 6.893189663514931e-08
and O 0 1.7331057478031653e-08
a O 0 2.986130994031555e-06
sister O 0 4.0621835069032386e-05
. O 0 5.085280463390518e-07

Fluorescent O 0 1.3514489864974166e-06
in O 0 6.537851149346352e-09
situ O 0 6.130381393631978e-07
hybridization O 0 2.0024776503646535e-08
analysis O 0 9.211023943578311e-09
demonstrated O 0 1.85755655301989e-09
that O 0 4.736355196932607e-10
the O 0 3.702856687937128e-08
PWS B-Disease 1 1.0
critical O 0 1.208677872455155e-06
region O 0 3.94448349538834e-08
resided O 0 3.9078798863556585e-07
on O 0 9.892584529325177e-09
the O 0 3.57236840109465e-09
derivative O 0 4.334911452019696e-08
chromosome O 0 3.3347649086579167e-09
3 O 0 5.280934578522078e-10
and O 0 2.6589369594987033e-11
that O 0 2.2498201218690284e-11
there O 0 3.0535446393642474e-10
was O 0 5.909659250846744e-08
no O 0 1.8422582570565282e-08
deletion O 0 3.8612167685414533e-08
of O 0 8.999284517585693e-08
the O 0 6.88055308728508e-07
PWS B-Disease 1 1.0
region O 0 4.543426257441752e-06
on O 0 1.652833674370413e-07
the O 0 3.904213841110504e-08
normal O 0 1.0040479736517227e-07
pair O 0 1.4924212976552553e-08
of O 0 1.6091526333639194e-08
15s O 0 5.73211082155467e-07
present O 0 9.736913852975704e-08
in O 0 6.414243785002327e-07
J O 0 0.00011695881403284147
. O 0 1.1872763252540608e-06

B O 0 0.000806494674179703
. O 0 6.108744855737314e-06

Methylation O 0 1.5735133274574764e-05
analysis O 0 1.6253552530542947e-06
at O 0 5.18835918228433e-07
exon O 0 3.329958815356804e-07
alpha O 0 2.2459055060153332e-07
of O 0 8.216082925116552e-09
the O 0 4.131392561390612e-09
small O 0 3.414777571819627e-09
nuclear O 0 9.211876772496908e-07
ribonucleoprotein O 0 0.000455280503956601
- O 0 1.1173219718330074e-06
associated O 0 3.619644530772348e-07
polypeptide O 0 7.857755008444656e-06
N O 0 4.838360382564133e-06
( O 0 2.9624068531575176e-08
SNRPN O 0 3.684093098854646e-05
) O 0 9.514004695176936e-09
gene O 0 1.591745957263413e-09
showed O 0 1.915754221926136e-09
a O 0 1.6206994635226124e-09
pattern O 0 1.3898405093470956e-08
characteristic O 0 6.503586558181951e-09
of O 0 1.3575517598951592e-08
only O 0 8.621337532765949e-10
the O 0 4.208780879366714e-09
maternal O 0 1.5217442239645607e-07
chromosome O 0 1.1933941834740835e-08
15 O 0 1.0403747197074154e-08
in O 0 1.5946092446483817e-08
J O 0 1.7694386770017445e-05
. O 0 5.226000325819768e-07

B O 0 0.002546322997659445
. O 0 9.742532711243257e-06

Maternal B-Disease 0 0.0014696457656100392
disomy I-Disease 0 0.00014235515845939517
was O 0 7.100176731000829e-07
confirmed O 0 7.888319331073035e-09
by O 0 5.076052023156308e-09
polymerase O 0 9.048406468536996e-08
chain O 0 7.435989157755785e-09
reaction O 0 4.167408362842906e-10
analysis O 0 4.333437608750046e-09
of O 0 1.0288229823629536e-08
microsatellite O 0 2.729790082867112e-07
repeats O 0 9.898401032160109e-08
at O 0 7.20391213349103e-08
the O 0 2.0004543799245766e-08
gamma O 0 8.171177228177839e-07
- O 0 3.000347135184711e-07
aminobutyric O 0 2.814037088683108e-06
acid O 0 2.111918320224504e-07
receptor O 0 1.9208341939247475e-07
beta3 O 0 6.774797043362923e-07
subunit O 0 5.117389036968234e-07
( O 0 2.739679239027737e-08
GABRB3 O 0 5.941473773418693e-06
) O 0 8.822058816804201e-08
locus O 0 5.018769115849864e-07
. O 0 5.0693209630026104e-08

A O 0 5.819029320264235e-05
niece O 0 1.2747135770041496e-05
( O 0 5.177908946052412e-08
B O 0 3.4504029144954984e-07
. O 0 1.0274301409651798e-09
B O 0 8.263690887133635e-08
. O 0 3.945766213764301e-10
) O 0 1.2035811236543736e-10
with O 0 4.640254153143175e-11
45 O 0 4.682079612905454e-09
chromosomes O 0 2.735970339173832e-09
and O 0 1.9520854377397256e-10
the O 0 2.6138946562781484e-09
derivative O 0 8.267206652590176e-08
3 O 0 8.317926791789887e-09
but O 0 2.453072744934559e-10
without O 0 5.806491953919135e-10
the O 0 6.678685160466102e-09
der O 0 1.0964869943563826e-05
( O 0 1.8011688140973092e-08
15 O 0 7.331939499977125e-09
) O 0 7.326372286620142e-10
demonstrated O 0 3.2036309161043164e-09
a O 0 6.439707878058698e-09
phenotype O 0 1.4562709260701467e-08
consistent O 0 7.353325504055874e-09
with O 0 1.00731145646904e-10
that O 0 1.953929240627872e-10
reported O 0 4.019188981629895e-09
for O 0 2.060045245499964e-09
haploinsufficiency O 0 8.459451237285975e-06
of O 0 2.0153154309809906e-06
distal O 0 1.1137922228954267e-05
3 O 0 1.5782532500452362e-05
p O 0 0.00015406149032060057
. O 0 4.068232328791055e-07

Uniparental B-Disease 1 1.0
disomy I-Disease 1 1.0
associated O 0 1.4618928616982885e-05
with O 0 6.597568358301942e-08
unbalanced O 0 0.00014344509690999985
segregation O 0 2.6554014311841456e-06
of O 0 5.834785383740382e-07
non O 0 6.970984395593405e-05
- O 0 3.681690577650443e-05
Robertsonian O 0 0.1609223634004593
translocations O 0 7.551113412773702e-06
has O 0 4.252532548321142e-09
been O 0 4.203798642521406e-09
reported O 0 8.786973815233523e-09
previously O 0 1.3670200971205304e-08
but O 0 1.0979868125815528e-09
has O 0 3.998061326448976e-10
not O 0 4.2047748616269587e-10
, O 0 5.986777185107428e-10
to O 0 9.35735600116061e-10
our O 0 1.413942474215446e-08
knowledge O 0 4.96574966746266e-06
, O 0 3.377550683580921e-09
been O 0 3.5585090429890442e-09
observed O 0 3.3883782446508803e-09
in O 0 2.005790866732582e-09
a O 0 8.246572313908018e-09
case O 0 4.981864165642946e-08
of O 0 1.4396268852578942e-06
PWS B-Disease 1 1.0
. O 0 6.522591320390347e-06

Furthermore O 0 9.483075700700283e-06
, O 0 1.4172012896551678e-08
our O 0 1.017779815981612e-08
findings O 0 1.0587030807585052e-08
are O 0 2.0779286624694748e-10
best O 0 1.903494251109805e-09
interpreted O 0 1.0792629900890915e-08
as O 0 3.7034624256193638e-09
true O 0 1.6440519345906068e-07
gamete O 0 8.641909516882151e-06
complementation O 0 7.210831881820923e-06
resulting O 0 2.6753349402497406e-07
in O 0 2.758990547135909e-07
maternal B-Disease 0 0.06937467306852341
UPD I-Disease 1 1.0
15 I-Disease 0 8.971722854766995e-05
and O 0 9.645298632676713e-06
PWS B-Disease 1 1.0

Schwartz B-Disease 1 0.9999830722808838
- I-Disease 1 0.9999992847442627
Jampel I-Disease 1 1.0
syndrome I-Disease 1 0.9999996423721313
type I-Disease 0 3.174855373799801e-05
2 I-Disease 0 1.408221578458324e-05
and O 0 1.325075515978824e-07
Stuve B-Disease 1 1.0
- I-Disease 1 0.9999983310699463
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 0.9999992847442627
: O 0 5.284776616321096e-09
a O 0 7.178083016867731e-09
case O 0 5.300635930183262e-09
for O 0 1.262683624325689e-09
" O 0 1.2116248626625747e-07
lumping O 0 2.0914333163091214e-06
" O 0 1.34059200718184e-06
. O 0 4.0327523720407044e-07

Recent O 0 9.872059081317275e-07
studies O 0 8.579925037111025e-08
demonstrated O 0 1.1659647469741685e-08
the O 0 3.7198299995822026e-09
existence O 0 2.9496092679437425e-07
of O 0 1.5747334103366484e-08
a O 0 8.208501434125992e-09
genetically O 0 1.8630874620839677e-10
distinct O 0 1.9997350997336127e-10
, O 0 4.984765031301741e-11
usually O 0 1.9783648330662373e-10
lethal O 0 4.034001743757898e-10
form O 0 6.069954539000832e-10
of O 0 2.5904004274934778e-08
the O 0 2.385046968811366e-07
Schwartz B-Disease 1 0.914998471736908
- I-Disease 1 0.8854645490646362
Jampel I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 5.1087372412439436e-06
SJS B-Disease 1 0.9978932738304138
) O 0 3.393450498379025e-08
of O 0 3.4934797099595016e-07
myotonia B-Disease 1 0.9999783039093018
and O 0 0.00019711621280293912
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 5.275368266666192e-07
which O 0 2.8787978223476784e-08
we O 0 7.305044391614501e-08
called O 0 1.7494280655228067e-06
SJS B-Disease 1 0.9991443157196045
type I-Disease 0 2.4082184609142132e-05
2 I-Disease 0 1.4135579476715066e-05
. O 0 7.998923479135556e-07

This O 0 3.6552221445163013e-06
disorder O 0 0.04588887840509415
is O 0 5.4413060723845774e-08
reminiscent O 0 6.597517767659156e-07
of O 0 1.0731464072932795e-07
another O 0 7.0298568743965e-08
rare O 0 1.0363942237745505e-07
condition O 0 4.385108240967384e-06
, O 0 1.2708339269806856e-08
the O 0 8.253970236182795e-07
Stuve B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999994039535522
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0003433520323596895
SWS B-Disease 1 0.9999697208404541
) O 0 5.723292506587541e-09
, O 0 6.236101635082036e-10
which O 0 6.83145706670274e-10
comprises O 0 1.1187322002115252e-07
campomelia B-Disease 0 7.521670340793207e-05
at O 0 1.2145777873229235e-05
birth O 0 9.772496923687868e-06
with O 0 6.496125593002944e-07
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 2.0171883079456165e-06
contractures B-Disease 1 0.9999282360076904
, O 0 2.439665536257962e-07
and O 0 2.539900201270484e-08
early B-Disease 0 4.877945684711449e-06
death I-Disease 0 1.2073750440322328e-05
. O 0 1.0936889793811133e-06

To O 0 3.0055019806241035e-08
test O 0 3.383999080952549e-09
for O 0 1.4244226909099211e-09
possible O 0 3.137908066719319e-08
nosologic O 0 6.605403177672997e-05
identity O 0 8.630609471538264e-08
between O 0 2.690225819890202e-09
these O 0 1.0795857541268106e-09
disorders O 0 5.645725195790874e-06
, O 0 7.017592618119295e-10
we O 0 1.0102056968719353e-09
reviewed O 0 4.785603024970442e-09
the O 0 3.4587421815501784e-09
literature O 0 1.5535816189071738e-08
and O 0 2.763582418463528e-10
obtained O 0 1.9227030634283437e-08
a O 0 3.278033178233386e-09
follow O 0 1.041998709538916e-09
- O 0 1.7410433095221833e-09
up O 0 3.0690718855197474e-09
of O 0 2.025397405347462e-09
the O 0 1.569458230044063e-09
only O 0 1.3837554713180822e-10
two O 0 1.4913015267126184e-10
surviving O 0 3.4797866987901216e-07
patients O 0 9.469174333531782e-10
, O 0 6.944704256106604e-10
one O 0 9.868179162708657e-09
with O 0 3.913100599106656e-08
SJS B-Disease 1 0.9993612170219421
type I-Disease 0 2.263890564790927e-05
2 I-Disease 0 1.364164972983417e-06
at O 0 3.22366474847513e-07
age O 0 3.910459156486468e-08
10 O 0 5.025859728391424e-09
years O 0 2.113847097362509e-09
and O 0 9.793416078096584e-10
another O 0 1.582453457160682e-08
with O 0 2.5638668077476723e-08
SWS B-Disease 0 0.02733183093369007
at O 0 1.9351870150785544e-07
age O 0 1.1185530013335665e-07
7 O 0 2.6069213276969094e-07
years O 0 6.897241178194236e-08
. O 0 7.858243833425149e-08

Patients O 0 5.329385658114916e-06
reported O 0 8.401145379366426e-08
as O 0 2.255339026646652e-09
having O 0 1.1110068243169735e-07
either O 0 1.075734689948149e-05
neonatal O 1 1.0
SJS B-Disease 1 1.0
or O 1 0.9667719006538391
SWS B-Disease 1 0.9987012147903442
presented O 0 2.4220325300916556e-08
a O 0 5.0068673651537665e-09
combination O 0 2.646482588630761e-09
of O 0 7.4206023548129e-09
a O 0 8.43363601177316e-09
severe O 0 1.3681801647180691e-07
, O 0 8.788951788574195e-09
prenatal O 0 0.07381189614534378
- O 0 0.32006534934043884
onset O 1 1.0
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 0.05370437353849411
with O 0 5.49473988940008e-05
congenital B-Disease 1 1.0
joint I-Disease 1 1.0
contractures I-Disease 1 1.0
, O 1 0.9999992847442627
respiratory O 1 1.0
and O 0 4.895759411738254e-05
feeding O 1 0.9999622106552124
difficulties O 1 1.0
, O 0 7.240553827614349e-07
tendency O 0 2.3741433778923238e-06
to O 0 9.379611043414116e-08
hyperthermia B-Disease 1 0.9999997615814209
, O 0 5.247995105150949e-08
and O 0 2.2075665739862416e-08
frequent O 0 2.7185254225514655e-07
death O 0 5.324887411006785e-07
in O 0 7.885755621828139e-07
infancy O 1 0.9504904747009277
) O 0 1.2032885798873849e-08
with O 0 7.890753050965316e-10
a O 0 8.774249948828583e-08
distinct O 0 4.053481177379581e-07
campomelic B-Disease 1 0.9999771118164062
- I-Disease 1 0.9999997615814209
metaphyseal I-Disease 1 1.0
skeletal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 0 2.270593358844053e-05

The O 0 7.099716867742245e-07
similarity O 0 2.3139341465139296e-07
of O 0 1.8021516723365494e-08
the O 0 1.7511050387497562e-08
clinical O 0 4.4078572614125733e-07
and O 0 2.1039239239684093e-09
radiographic O 0 3.999974978796672e-06
findings O 0 5.8539477265640016e-08
is O 0 7.872803520214688e-10
so O 0 2.059651338370827e-10
extensive O 0 3.327445430301168e-09
that O 0 9.236171549797945e-11
these O 0 1.4752219446023673e-09
disorders O 0 4.5313441660255194e-05
appear O 0 1.8635121890042683e-08
to O 0 4.9667288060106785e-09
be O 0 1.085212009144243e-08
a O 0 3.9369595583593764e-08
single O 0 6.744910763245571e-08
entity O 0 2.155644551748992e-06
. O 0 6.066082960387575e-07

The O 0 2.3666088964091614e-06
follow O 0 3.551385248101724e-07
- O 0 3.0128543926366547e-07
up O 0 5.7983520207471884e-08
observation O 0 3.1494739687332185e-06
of O 0 1.1523413334657562e-08
an O 0 2.58772248074024e-09
identical O 0 2.994650971643864e-09
and O 0 1.757772677413172e-10
unique O 0 1.8368364607113108e-09
pattern O 0 1.1480594963586555e-07
of O 0 1.63046604484407e-06
progressive O 1 0.999937891960144
bone B-Disease 1 1.0
dysplasia I-Disease 1 0.9999538660049438
in O 0 1.4335054743241926e-07
the O 0 1.6813454806197115e-07
two O 0 1.1841228442222018e-08
patients O 0 2.9572455595427982e-09
( O 0 8.695288378213206e-10
one O 0 2.156168132927405e-09
with O 0 4.937589448417157e-09
SJS B-Disease 1 0.9191896915435791
type I-Disease 0 8.983128282125108e-06
2 I-Disease 0 1.0432370345370146e-06
, O 0 1.7139102359564617e-09
one O 0 1.8382418920381838e-09
with O 0 2.35490804634253e-09
SWS B-Disease 0 0.11551530659198761
) O 0 1.05929300886487e-08
surviving O 0 1.7482237808508216e-06
beyond O 0 6.39372956356965e-07
infancy O 0 4.248240202286979e-06
adds O 0 2.2427199652952368e-08
to O 0 6.733978930029139e-10
the O 0 3.946498239315588e-09
evidence O 0 2.540699739483898e-08
in O 0 7.319504113922903e-09
favor O 0 8.98053986730929e-09
of O 0 4.0010327495565434e-08
identity O 0 2.930361517883284e-07
. O 0 2.128831653180896e-07

The O 0 1.7142878050435684e-06
hypothesis O 0 2.7373032480682014e-06
that O 0 1.0684998841270499e-07
SWS B-Disease 0 0.0002444783749524504
and O 0 1.4326198538583412e-07
SJS B-Disease 0 0.14407847821712494
type I-Disease 0 2.2073363652452826e-06
2 I-Disease 0 3.4581046293169493e-07
are O 0 6.020627330016737e-10
the O 0 4.9068611396307915e-09
same O 0 4.052993318737208e-08
disorder O 0 1.1249958333792165e-06
should O 0 1.0980371056845684e-09
be O 0 2.2601103211172813e-09
testable O 0 1.8491782327600959e-07
by O 0 1.6149230841477902e-09
molecular O 0 1.7890894099537036e-08
methods O 0 3.32751675102827e-08
. O 0 1.3436205925643208e-08
. O 0 9.117425747717789e-08

A O 0 2.1381601982284337e-05
mouse O 0 8.777502671364346e-07
model O 0 4.786399543377229e-08
of O 0 6.95703974429307e-08
severe O 0 0.00010055335587821901
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 0 0.0017104764701798558
defects O 1 0.9984286427497864
in O 0 5.223499215389893e-07
hemostasis O 1 0.9999901056289673
and O 0 4.0662453102413565e-06
thrombosis B-Disease 1 0.9999449253082275
. O 0 2.3371429051621817e-05

von B-Disease 1 0.9983818531036377
Willebrand I-Disease 1 1.0
factor I-Disease 1 0.7597638964653015
( I-Disease 0 4.2285097151761875e-05
vWf I-Disease 1 0.9991462230682373
) I-Disease 0 4.7150926548056304e-05
deficiency I-Disease 1 1.0
causes O 0 0.005859635770320892
severe O 1 1.0
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 0.0009997531305998564
humans O 0 8.572000297135673e-06
. O 0 1.5752448234707117e-07

We O 0 5.979001116429572e-07
generated O 0 1.6817784853628837e-07
a O 0 2.2977664215773075e-08
mouse O 0 7.806417734457227e-09
model O 0 8.246174854065202e-10
for O 0 9.134837331004064e-11
this O 0 5.972988215141584e-10
disease O 0 2.447446911801876e-09
by O 0 4.695617228378524e-10
using O 0 7.611719254896343e-09
gene O 0 8.887788283118425e-09
targeting O 0 3.007549054245828e-08
. O 0 2.8932861440011948e-08

vWf B-Disease 1 0.9991577863693237
- I-Disease 1 0.9999961853027344
deficient I-Disease 1 0.9998984336853027
mice O 0 3.0486005471175304e-06
appeared O 0 1.805716749458952e-07
normal O 0 1.2359109291537607e-07
at O 0 2.1711123565637536e-08
birth O 0 2.9526012745861863e-09
; O 0 8.51986745042943e-11
they O 0 1.6014228831906507e-10
were O 0 6.885067183048932e-09
viable O 0 4.4250205633034057e-07
and O 0 2.4419133382025393e-08
fertile O 0 9.439440873393323e-06
. O 0 6.513619155157357e-07

Neither O 0 0.0006152003188617527
vWf O 0 0.003730975789949298
nor O 0 7.986590935615823e-05
vWf O 0 0.0012452986557036638
propolypeptide O 0 0.0006425125175155699
( O 0 2.2256208467297256e-06
von B-Disease 0 0.0014036461943760514
Willebrand I-Disease 0 0.1726170778274536
antigen O 0 1.5270256881194655e-06
II O 0 0.33608219027519226
) O 0 4.697897537653262e-08
were O 0 1.142754602057039e-08
detectable O 0 1.448332653808393e-07
in O 0 4.803013986531823e-09
plasma O 0 7.426212533800935e-08
, O 0 1.1451780634885722e-09
platelets O 0 6.183035594631292e-08
, O 0 3.732331332884087e-09
or O 0 2.2461275506202583e-08
endothelial O 0 1.342655338021359e-07
cells O 0 5.523450141708963e-09
of O 0 1.0338943035037573e-08
the O 0 8.71603660357323e-08
homozygous O 0 3.452259136338398e-07
mutant O 0 2.7256928660790436e-06
mice O 0 9.258563977709855e-07
. O 0 4.169917389162947e-08

The O 0 2.6497070848563453e-06
mutant O 0 6.40932412352413e-05
mice O 0 5.891499313293025e-06
exhibited O 0 4.229636942909565e-06
defects O 0 0.0010831506224349141
in O 0 5.562273841519527e-08
hemostasis O 0 0.004333213437348604
with O 0 3.1038636105762407e-09
a O 0 3.5527531139223356e-08
highly O 0 3.3771732432796853e-07
prolonged O 1 0.984906792640686
bleeding O 1 0.7832918167114258
time O 0 2.8072130930922867e-07
and O 0 5.2351385448901055e-08
spontaneous O 0 5.6423023124807514e-06
bleeding O 0 0.0006722102407366037
events O 0 1.645786262827187e-08
in O 0 1.556285544879188e-09
approximately O 0 6.1910458981628835e-09
10 O 0 7.686064229517342e-09
% O 0 4.382579632533634e-09
of O 0 2.7838527927315226e-08
neonates O 0 3.046362735403818e-06
. O 0 2.1845508513251843e-07

As O 0 2.401649794592231e-07
in O 0 1.0751250556495506e-08
the O 0 2.125560882859645e-08
human O 0 4.550128807068177e-08
disease O 0 4.9220584941167544e-08
, O 0 3.0117133786866646e-10
the O 0 1.2869771914836292e-08
factor O 0 1.2159935636191221e-07
VIII O 0 1.0142247219846467e-06
level O 0 9.515239298707456e-07
in O 0 8.441743415410485e-10
these O 0 3.7484168546875196e-10
mice O 0 2.215123862114865e-09
was O 0 2.6239950212669783e-09
reduced O 0 9.077369411691905e-10
strongly O 0 6.680236919187621e-10
as O 0 3.2725341880812664e-10
a O 0 1.098661384091315e-09
result O 0 5.1993093164171e-10
of O 0 2.6561415289449997e-09
the O 0 1.575415353727294e-08
lack O 0 1.4233431500088045e-07
of O 0 2.7848777506278566e-08
protection O 0 6.475590197396741e-08
provided O 0 1.5976810985307566e-08
by O 0 2.033779367138777e-08
vWf O 0 1.1638399882940575e-05
. O 0 2.1190400900650275e-07

Defective O 1 0.9971129894256592
thrombosis B-Disease 1 0.9246837496757507
in O 0 1.2963237168150954e-06
mutant O 0 8.103575964923948e-05
mice O 0 1.8758349824565812e-06
was O 0 1.3856099201348115e-07
also O 0 1.0702183583788383e-09
evident O 0 3.297235551258382e-08
in O 0 1.863077692121351e-09
an O 0 1.51677592707955e-09
in O 0 2.9778710608496795e-09
vivo O 0 3.48160256180563e-07
model O 0 4.9825867876052143e-08
of O 0 9.27570965814084e-07
vascular B-Disease 1 0.9999631643295288
injury I-Disease 1 0.9997108578681946
. O 0 3.300963726360351e-05

In O 0 2.1518805226605764e-07
this O 0 5.3098241359350595e-09
model O 0 2.8673939667100967e-08
, O 0 1.9709498477737952e-09
the O 0 3.086891098291744e-08
exteriorized O 0 2.4971899620140903e-05
mesentery O 0 5.833947943756357e-05
was O 0 2.5447843654546887e-06
superfused O 0 1.9220897229388356e-05
with O 0 3.5766994699315546e-08
ferric O 0 0.00011649289081105962
chloride O 0 1.4902111615811009e-05
and O 0 6.977411715070048e-08
the O 0 2.53791085924604e-07
accumulation O 0 0.0003843538579531014
of O 0 1.9666491425596178e-05
fluorescently O 0 0.00041607284219935536
labeled O 0 5.474964837048901e-06
platelets O 0 2.0568013496813364e-06
was O 0 3.9182842215268465e-07
observed O 0 2.9092896980387195e-08
by O 0 1.7459125700725053e-08
intravital O 0 1.759050792315975e-05
microscopy O 0 6.094727268646238e-06
. O 0 8.472123340652615e-07

We O 0 6.04326885422779e-07
conclude O 0 7.95246421603224e-07
that O 0 1.4404328840811331e-09
these O 0 1.1487900630768877e-09
mice O 0 2.4082636329580964e-08
very O 0 1.4609272680488061e-09
closely O 0 4.2252075616033835e-08
mimic O 0 2.4398850655416027e-06
severe O 0 3.820977781288093e-06
human O 0 5.671596227330156e-06
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 6.490982862317196e-09
will O 0 1.3076867366734746e-10
be O 0 1.1163284185933264e-10
very O 0 2.166935936243064e-10
useful O 0 2.332481097155892e-09
for O 0 2.7036814453929026e-10
investigating O 0 2.335415949517028e-08
the O 0 9.321448501964369e-09
role O 0 1.2034807639338396e-07
of O 0 2.803547829444142e-07
vWf O 0 9.806733032746706e-06
in O 0 3.925629599166314e-08
normal O 0 1.5515729501203168e-06
physiology O 0 6.5057242863986176e-06
and O 0 1.0588480092721397e-09
in O 0 6.486354120482929e-09
disease O 0 4.752023841092523e-08
models O 0 1.6461967344838513e-09
. O 0 1.540314986669955e-09
. O 0 3.865107345291108e-08

Oral O 0 0.039280589669942856
contraceptives O 0 3.220609141862951e-05
and O 0 9.879799200973594e-09
the O 0 3.1563601510242734e-08
risk O 0 2.040357230725931e-06
of O 0 0.0667719841003418
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.023939991369843483

Hereditary B-Disease 1 1.0
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 1.0
Clinical O 1 1.0
Study O 0 0.00013026923988945782
Group O 0 1.6175339396795607e-06
. O 0 1.3162805601041327e-07

BACKGROUND O 0 0.00022550470021087676
Women O 0 6.176611577757285e-08
with O 0 1.1415384193469436e-09
mutations O 0 2.76461720183363e-09
in O 0 2.1337731581638764e-09
either O 0 2.3567068296870275e-08
the O 0 2.4088339500849543e-07
BRCA1 O 0 2.6870844749282696e-07
or O 0 6.568438237763985e-08
the O 0 2.0152988611243927e-07
BRCA2 O 0 4.404672040436708e-07
gene O 0 4.5207833032634426e-09
have O 0 1.0270925776545425e-10
a O 0 1.162832719003859e-09
high O 0 1.1665921562098447e-08
lifetime O 0 2.1070297862024745e-07
risk O 0 2.029236156886327e-06
of O 1 0.9898780584335327
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00011624532635323703

Oral O 0 0.4098827540874481
contraceptives O 0 0.0006499700248241425
protect O 0 1.1511746151882107e-06
against O 0 0.0025418095756322145
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 2.9343705136852805e-06
general O 0 2.5283804916398367e-07
, O 0 1.3686421995728892e-09
but O 0 1.3918340091567671e-10
it O 0 5.41888443839067e-11
is O 0 5.619550658142458e-11
not O 0 2.795629179541681e-11
known O 0 1.9226534253569127e-10
whether O 0 3.6922603863231984e-10
they O 0 1.4804901748988186e-09
also O 0 1.1844475400479837e-09
protect O 0 8.967496079037574e-09
against O 0 2.6042718204166704e-08
hereditary B-Disease 0 0.19326286017894745
forms I-Disease 0 8.352877193829045e-05
of I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 7.366147474385798e-05

METHODS O 0 3.1895933716441505e-06
We O 0 6.237416272369956e-08
enrolled O 0 1.8524877987147192e-07
207 O 0 2.326125354557007e-07
women O 0 2.8813120778181656e-09
with O 0 8.815613128376754e-09
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 2.3610903099324787e-06
161 O 0 3.4262626513736905e-07
of O 0 1.427063125447603e-07
their O 0 2.6083679216526434e-08
sisters O 0 3.2471252779942006e-06
as O 0 1.9158793662654716e-08
controls O 0 1.9458235911429256e-08
in O 0 3.4502292134419577e-09
a O 0 2.6582513967809973e-08
case O 0 1.7323100109933876e-07
- O 0 4.2519187104517187e-07
control O 0 2.889013330786838e-07
study O 0 3.3045111536011973e-07
. O 0 1.671369744826734e-07

All O 0 8.289391217886077e-08
the O 0 6.023274323752048e-08
patients O 0 3.2193367971444786e-09
carried O 0 4.167378886421602e-09
a O 0 2.6591222557215133e-09
pathogenic O 0 2.8361006876309602e-09
mutation O 0 6.491028825550416e-10
in O 0 1.6582824002853158e-09
either O 0 9.07572950126223e-09
BRCA1 O 0 3.652283808719403e-08
( O 0 3.4334692866622163e-09
179 O 0 1.0586223453401544e-08
women O 0 2.878055127553125e-09
) O 0 2.8121627249078074e-09
or O 0 1.2996985709889941e-08
BRCA2 O 0 4.231183581282494e-08
( O 0 6.053793466520574e-09
28 O 0 1.1471313854372056e-07
women O 0 6.809202979241036e-09
) O 0 2.028019174815654e-08
. O 0 5.263965263679893e-08

The O 0 1.5546685290246387e-06
control O 0 9.472079227634822e-07
women O 0 2.4538600040813208e-09
were O 0 4.2885761608602024e-09
enrolled O 0 2.2486007722477552e-08
regardless O 0 1.0242062309373523e-08
of O 0 2.0211340157061386e-08
whether O 0 2.7044562145306372e-09
or O 0 1.2607759281024755e-08
not O 0 1.105233682352491e-09
they O 0 1.0717791099068563e-09
had O 0 1.3402266851869626e-08
either O 0 1.816573735879956e-08
mutation O 0 3.202465848062275e-08
. O 0 9.646466025969858e-08

Lifetime O 0 2.2474583602161147e-05
histories O 0 4.051350515510421e-06
of O 0 7.829920036783733e-07
oral O 0 6.420592399081215e-05
- O 0 1.0992951501975767e-05
contraceptive O 0 4.080756070834468e-07
use O 0 8.812111595979388e-10
were O 0 3.556738015220162e-09
obtained O 0 2.0741371287158472e-08
by O 0 5.446162187894288e-09
interview O 0 9.212256912860539e-08
or O 0 3.949871985042819e-09
by O 0 5.172317019130901e-10
written O 0 1.2949987748811509e-09
questionnaire O 0 1.1787546494446133e-09
and O 0 1.4207861276371858e-10
were O 0 2.291808298693354e-09
compared O 0 4.773933248714002e-09
between O 0 7.339663099514837e-09
patients O 0 1.4243737300745352e-09
and O 0 9.398675171468085e-10
control O 0 5.604690045402094e-07
women O 0 5.221961973944644e-09
, O 0 5.486194831760827e-10
after O 0 7.817472891247235e-09
adjustment O 0 1.4890298416503356e-07
for O 0 8.630370307294299e-10
year O 0 3.4523026659627476e-09
of O 0 7.183383221587292e-09
birth O 0 2.3846780550229596e-08
and O 0 8.579724486423856e-09
parity O 0 3.371115099071176e-06
. O 0 1.3755038708040956e-07

RESULTS O 0 6.648655471508391e-06
The O 0 1.560342610673615e-07
adjusted O 0 8.59723741086782e-07
odds O 0 1.0983098945871461e-06
ratio O 0 7.028086201898986e-07
for O 0 2.4273097665172827e-07
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 1.1968518265348393e-06
with O 0 3.0487609659068937e-10
any O 0 3.7154053167398615e-09
past O 0 4.118764440619316e-09
use O 0 4.4295461743004694e-10
of O 0 5.352184029305818e-09
oral O 0 1.6953002557329455e-07
contraceptives O 0 3.6036936990058166e-07
was O 0 4.63330565025899e-07
0 O 0 8.684242658318908e-08
. O 0 3.667599557388712e-08

5 O 0 2.1477915197465336e-06
( O 0 3.3318102055091003e-08
95 O 0 6.920248551978148e-08
percent O 0 4.057740810026189e-09
confidence O 0 2.451741920594941e-08
interval O 0 1.303082370895936e-07
, O 0 2.07559258669221e-09
0 O 0 1.632999735434737e-09
. O 0 6.555950227138396e-11
3 O 0 4.285826415983962e-10
to O 0 1.8226140041655015e-10
0 O 0 8.114289795635443e-10
. O 0 1.4769949152615425e-10
8 O 0 1.1635211016880476e-08
) O 0 7.4500583480130445e-09
. O 0 2.4181412427992655e-08

The O 0 2.5714048206282314e-06
risk O 0 1.512289827587665e-06
decreased O 0 4.014709418243001e-07
with O 0 2.691112332975365e-10
increasing O 0 3.7213059300711393e-09
duration O 0 8.410733443042773e-08
of O 0 4.600189562609103e-09
use O 0 5.964392868484936e-10
( O 0 8.912076077116637e-10
P O 0 7.258031331502934e-08
for O 0 1.561458323751097e-10
trend O 0 8.252173167022647e-09
, O 0 1.826268025695299e-10
< O 0 3.6727778596201688e-09
0 O 0 5.695126314986254e-11
. O 0 1.2746238092775641e-11
001 O 0 8.532984985265557e-09
) O 0 1.8108179886122677e-11
; O 0 1.3114471531308625e-12
use O 0 1.3302820650595848e-11
for O 0 7.331246720809759e-11
six O 0 3.3646911923312928e-09
or O 0 3.7540925923451596e-09
more O 0 1.3200662785095574e-10
years O 0 3.753398036820954e-09
was O 0 9.423293789723175e-08
associated O 0 1.4793053892958596e-08
with O 0 5.934683855457479e-10
a O 0 6.254807338734736e-09
60 O 0 7.255177347786912e-09
percent O 0 1.2849774577716744e-09
reduction O 0 2.679334087929419e-09
in O 0 7.605101437491157e-09
risk O 0 1.0225693358734134e-06
. O 0 2.6035721134576306e-07

Oral O 0 0.00835932046175003
- O 0 3.989315882790834e-05
contraceptive O 0 4.40106930454931e-07
use O 0 7.448765160233961e-09
protected O 0 2.6054797217511805e-06
against O 0 0.00010046863462775946
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
both O 0 3.766521761150443e-09
for O 0 7.173685534489493e-10
carriers O 0 4.602899172923003e-10
of O 0 2.48684228765228e-09
the O 0 1.4463084951898963e-08
BRCA1 O 0 3.125680336779624e-08
mutation O 0 1.0376552950219775e-09
( O 0 2.432228585202978e-10
odds O 0 1.0686156848294104e-08
ratio O 0 3.5710672197097892e-09
, O 0 5.61734304904693e-11
0 O 0 1.6624714105351046e-10
. O 0 2.3181664920990386e-11
5 O 0 3.087435862525467e-10
; O 0 3.4910956070444144e-11
95 O 0 3.3169267332766594e-09
percent O 0 3.9877950941402673e-10
confidence O 0 4.76863704079733e-09
interval O 0 3.120759828334485e-08
, O 0 3.45098449816561e-10
0 O 0 2.5116622670573463e-10
. O 0 3.620070215815119e-11
3 O 0 9.184296378972334e-11
to O 0 2.0597209701711527e-11
0 O 0 5.6515177954130635e-11
. O 0 9.997654613902451e-12
9 O 0 3.3541874833176166e-10
) O 0 2.099151928669496e-11
and O 0 7.081344191584016e-12
for O 0 9.487139546182632e-11
carriers O 0 3.994829189668536e-10
of O 0 3.933542380707422e-09
the O 0 5.168071837147181e-08
BRCA2 O 0 1.4595501340863848e-07
mutation O 0 1.9001133999552167e-09
( O 0 8.634980508404055e-10
odds O 0 5.0854449540338464e-08
ratio O 0 6.555782139372468e-09
, O 0 1.1815902423162328e-10
0 O 0 1.685423883790449e-10
. O 0 9.41484997601938e-12
4 O 0 2.8030094911812853e-10
; O 0 2.45359548650681e-11
95 O 0 3.209061683051573e-09
percent O 0 8.665900219639866e-10
confidence O 0 5.005349024145289e-09
interval O 0 1.2918122571647928e-08
, O 0 4.5949868909822555e-10
0 O 0 4.3454786990970717e-10
. O 0 2.986935351834141e-11
2 O 0 2.807150623063137e-10
to O 0 1.3512728436193555e-10
1 O 0 2.94982060999871e-09
. O 0 6.654471973455145e-10
1 O 0 2.5259815572553634e-08
) O 0 3.2458924437150927e-09
. O 0 1.6981585915232245e-08

CONCLUSIONS O 0 7.32948028598912e-05
Oral O 0 0.0025868075899779797
- O 0 8.38507548905909e-06
contraceptive O 0 2.3182057873327722e-07
use O 0 9.424754032760774e-11
may O 0 8.52524856265191e-11
reduce O 0 4.319157878573954e-11
the O 0 8.971872134111436e-10
risk O 0 7.791000484758115e-07
of O 1 0.8050320744514465
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 9.035798598233669e-08
women O 0 3.730464825935087e-10
with O 0 1.3186035596746137e-11
pathogenic O 0 9.293289471301591e-10
mutations O 0 5.135316616389218e-10
in O 0 1.2614390643150841e-09
the O 0 3.025586536864466e-08
BRCA1 O 0 2.1250424708796345e-07
or O 0 1.578711419369938e-07
BRCA2 O 0 4.529815214482369e-06
gene O 0 2.608075192256365e-06

A O 0 6.099855454522185e-05
Japanese O 0 0.0001697258703643456
family O 0 2.2759752482670592e-07
with O 0 1.3613685290181365e-08
adrenoleukodystrophy B-Disease 1 1.0
with O 0 1.031457763644994e-08
a O 0 5.4170843810652514e-08
codon O 0 6.159788057402693e-08
291 O 0 1.8156626424570277e-08
deletion O 0 1.1581850145603312e-08
: O 0 3.0285221552794894e-10
a O 0 1.4997084685219875e-09
clinical O 0 2.5463418040772012e-08
, O 0 1.3070688975602707e-09
biochemical O 0 5.038785729993833e-06
, O 0 6.570154909013581e-08
pathological O 1 0.975548267364502
, O 0 8.614356339364804e-09
and O 0 1.0131855354700292e-08
genetic O 0 1.275544605050527e-06
report O 0 7.484056254725147e-07
. O 0 2.3112831115668087e-07

We O 0 1.6681336774126976e-06
report O 0 6.652700790255039e-07
a O 0 2.0546474388538627e-07
Japanese O 0 9.443889211979695e-06
family O 0 3.1917218734633934e-07
with O 0 1.9735132639198127e-07
adrenoleukodystrophy B-Disease 1 1.0
( O 1 0.9999998807907104
ALD B-Disease 1 1.0
) O 0 6.16306650158549e-08
with O 0 1.0353462531753621e-09
a O 0 2.5791107916006695e-08
three O 0 6.449222045290526e-09
base O 0 1.509674376620751e-07
pair O 0 3.2827156815073977e-07
deletion O 0 7.796419367878116e-07
( O 0 7.248222999578502e-08
delGAG O 0 3.3599424114072463e-06
291 O 0 1.9889081670498854e-07
) O 0 5.0254764794033235e-09
in O 0 1.4454590413492951e-08
the O 0 2.39188329942408e-06
ALD B-Disease 1 1.0
gene O 0 1.4771204405406024e-05
. O 0 7.077090913298889e-07

A O 0 1.471824134569033e-06
variety O 0 3.790927749491857e-08
of O 0 1.3964601919269626e-07
phenotypes O 0 6.238784067136294e-07
were O 0 3.832177242202306e-08
observed O 0 3.873298837220318e-08
within O 0 2.4304409151909567e-08
this O 0 3.355617650413478e-08
family O 0 3.3077679972848273e-07
. O 0 1.4537765480326925e-07

While O 0 1.8209779000244453e-06
the O 0 4.074331911851914e-07
proband O 0 1.648841134738177e-05
( O 0 9.998513661457764e-08
patient O 0 1.1545396461087876e-07
1 O 0 1.1670999811030924e-07
) O 0 3.6797898061990963e-09
was O 0 9.45524973872125e-08
classified O 0 1.291625437715993e-07
as O 0 1.866919507875764e-09
having O 0 5.7526445829125805e-09
a O 0 8.951331231799031e-09
rare O 0 4.942536158125677e-09
intermediate O 0 3.373148871332887e-08
type O 0 4.2110233522407725e-08
of O 0 1.8391202161183173e-07
adult O 0 1.108633455260133e-06
cerebral O 0 5.79143816139549e-05
and O 0 3.9948865548922186e-08
cerebello O 1 0.9999997615814209
- O 1 0.999970555305481
brain O 1 0.9982938170433044
stem O 0 3.165651492054167e-07
forms O 0 2.0200973338546646e-08
, O 0 1.9587662603015588e-09
his O 0 2.7644180278230124e-08
younger O 0 2.267382548382102e-08
brother O 0 3.241248407448438e-07
( O 0 1.2066994514725593e-08
patient O 0 1.3677947663381929e-08
2 O 0 6.53418563700825e-09
) O 0 3.0020383401385686e-10
and O 0 2.7284749459788316e-10
nephew O 0 5.893145953450585e-06
( O 0 2.7268188773632573e-07
patient O 0 9.979039532481693e-07
3 O 0 1.92257900266668e-07
) O 0 6.381482453576837e-09
had O 0 1.7353551484688978e-08
a O 0 3.309563396669546e-07
childhood O 1 0.9983693957328796
ALD B-Disease 1 1.0
type O 1 0.8437141180038452
. O 0 1.6577508858972578e-06

Another O 0 1.5767127479193732e-05
nephew O 0 8.029508171603084e-05
( O 0 7.222229783110379e-07
patient O 0 3.182487660069455e-07
4 O 0 9.978870707527676e-08
) O 0 2.2499597740477384e-09
of O 0 1.531065763060724e-08
patient O 0 9.084831731343002e-07
1 O 0 6.735846795891121e-07
was O 0 1.7728540342432098e-06
classified O 0 3.7834195154573536e-07
as O 0 8.939761819704017e-09
having O 0 7.778122323998105e-08
an O 0 1.697796037092303e-08
adolescent O 0 1.2459493063943228e-06
form O 0 1.7575054300777992e-07
. O 0 6.206560669852479e-07

The O 0 4.657264071283862e-06
tau O 0 4.563610673358198e-06
level O 0 2.1721443488331715e-07
in O 0 2.9233555576269055e-09
the O 0 1.7485453085441804e-08
cerebrospinal O 0 2.5278961857111426e-06
fluid O 0 5.093014806334395e-06
( O 0 1.8909512391473982e-06
CSF O 0 0.022393425926566124
) O 0 7.868397489119161e-08
in O 0 5.0381856908643385e-08
patient O 0 8.755824296713399e-07
1 O 0 3.260047094499896e-07
was O 0 4.5768854306516005e-07
as O 0 7.242844102250956e-09
high O 0 1.163321350361457e-08
as O 0 3.6166902805945256e-10
that O 0 5.950254872155725e-11
of O 0 2.5906112810503146e-09
patients O 0 3.890304078879581e-09
with O 0 3.275684790082778e-08
Alzheimers B-Disease 1 1.0
disease I-Disease 1 0.9999954700469971
( O 0 1.8500266207865934e-07
AD B-Disease 0 4.343828095443314e-06
) O 0 1.1935101795756964e-08
. O 0 1.3578883795162255e-08

His O 0 1.1090438420069404e-05
brain O 0 4.30900436185766e-05
magnetic O 0 4.468864517548354e-06
resonance O 0 1.8266969163960312e-06
image O 0 7.155679782044899e-07
( O 0 4.178986401370821e-08
MRI O 0 6.3535426306771114e-06
) O 0 1.0006083961400236e-08
showed O 0 7.006030244838257e-08
abnormalities B-Disease 0 2.370100673942943e-06
in I-Disease 0 5.576058725864641e-09
the I-Disease 0 3.6434059325074486e-08
bilateral I-Disease 0 3.845111859845929e-05
cerebellar I-Disease 1 0.9992857575416565
hemispheres I-Disease 0 2.6247051209793426e-05
and O 0 3.9246561556183224e-08
brain O 0 0.0009154183208011091
stem O 0 2.493417525784025e-07
, O 0 3.606646648002254e-10
but O 0 2.111396057991044e-10
not O 0 2.4500099171653744e-10
in O 0 2.315716063350237e-09
the O 0 3.801412162829365e-08
cerebral O 0 2.4200911866500974e-05
white O 0 1.2926132164636783e-08
matter O 0 5.147412807104956e-08
, O 0 6.643920413829107e-10
where O 0 3.4630046052974706e-10
marked O 0 1.821721884454064e-09
reductions O 0 2.7337427876972242e-09
of O 0 9.253337651671245e-09
the O 0 2.5088592536803844e-08
cerebral O 0 1.9604681256168988e-06
blood O 0 5.330344876597337e-08
flow O 0 7.194203703875246e-07
and O 0 6.095039584153028e-09
oxygen O 0 3.600084255594993e-06
metabolism O 0 1.6940142813837156e-05
were O 0 6.029444499233705e-09
clearly O 0 5.526000101951922e-09
demonstrated O 0 3.148079352754962e-09
by O 0 6.876532676614033e-10
positron O 0 4.977551881779618e-08
emission O 0 4.661113273130013e-09
tomography O 0 1.1023504242757554e-07
( O 0 1.2797707782397083e-08
PET O 0 6.156253107292287e-07
) O 0 1.6973816130416708e-08
. O 0 3.741491738651348e-08

In O 0 2.1751004908310279e-07
patients O 0 4.993191637936434e-09
2 O 0 8.13630052221015e-09
and O 0 7.550146619017539e-10
3 O 0 9.157979263818561e-09
, O 0 1.4472784082286694e-10
the O 0 6.723634426997194e-10
autopsy O 0 3.781381252565552e-08
findings O 0 5.76416647746214e-09
showed O 0 2.572497947994634e-08
massive O 0 7.26856001165288e-07
demyelination B-Disease 1 1.0
of I-Disease 0 2.962786857096944e-05
the I-Disease 0 5.13107079314068e-06
cerebral I-Disease 0 0.00030949580832384527
white I-Disease 0 2.617882799427207e-08
matter I-Disease 0 1.194343646204743e-08
with O 0 8.406523255288789e-10
sparing O 0 5.737985375731114e-08
of O 0 1.2981580255200242e-07
the O 0 9.45627562032314e-07
U O 1 0.9985020160675049
- O 0 1.116380462917732e-05
fibers O 0 6.402087819878943e-07
, O 0 4.334744119205425e-09
compatible O 0 9.861989447301767e-09
with O 0 1.0460605298634462e-10
the O 0 1.5282787257930863e-09
findings O 0 2.4637943241145877e-08
of O 0 1.3665565745668573e-07
childhood O 1 0.9975920915603638
ALD B-Disease 1 1.0
. O 0 5.115952717460459e-06

Oleic O 0 0.0016704328591004014
and O 0 9.766708899405785e-07
erucic O 0 0.0014951825141906738
acids O 0 2.078499164781533e-06
( O 0 2.150506048792522e-07
Lorenzos O 0 1.5100693417480215e-05
Oil O 0 6.203049906616798e-06
) O 0 3.076491950082527e-09
were O 0 1.2185057407521072e-09
administered O 0 2.3902140267040295e-09
to O 0 1.7086521086895345e-09
patients O 0 5.413763326522769e-10
1 O 0 4.219141480632516e-09
and O 0 6.811095576431114e-10
4 O 0 1.230649537831141e-08
, O 0 7.512593325209593e-11
but O 0 2.643816068848004e-11
sufficient O 0 4.906402839566226e-09
effectiveness O 0 1.9742692813906615e-08
was O 0 4.027409161722062e-08
not O 0 1.6136206815176024e-09
obtained O 0 2.964977170449856e-07
. O 0 1.2772180468800798e-07

The O 0 7.49168350466789e-07
findings O 0 2.3027246243145783e-07
in O 0 5.3192308335781036e-09
this O 0 4.730308589273591e-09
family O 0 3.247677327067322e-08
suggest O 0 8.074569457505731e-09
that O 0 2.9584623639777874e-10
delGAG291 O 0 3.8983426264849186e-08
is O 0 6.596014845428044e-10
part O 0 1.7006083208315204e-09
of O 0 1.3166177481593877e-08
the O 0 6.776826921850443e-08
cause O 0 3.3964556678256486e-07
of O 0 1.4310551250673598e-06
Japanese O 1 0.9997410178184509
ALD B-Disease 1 1.0
with O 0 6.505856742222704e-09
phenotypic O 0 2.716322740070609e-07
variations O 0 1.8200840656845685e-07
. O 0 1.687560597929405e-07

Moreover O 0 1.176189471152611e-05
, O 0 8.98098484469756e-09
although O 0 9.879040918647775e-10
the O 0 1.6542766045901658e-09
scale O 0 4.391166541495295e-08
of O 0 7.2852825994118575e-09
the O 0 5.489966259375478e-09
study O 0 2.4152588817827336e-09
is O 0 9.757946534127981e-11
limited O 0 5.377886469482007e-10
, O 0 2.8961319453735257e-10
there O 0 9.549833146493825e-10
is O 0 7.050932615548788e-10
a O 0 2.35980923690704e-09
possibility O 0 1.0960456542363772e-08
that O 0 3.974614859458825e-09
PET O 0 5.437714776235225e-07
can O 0 1.7176509103933313e-09
detect O 0 1.1324830495595961e-07
an O 0 5.846962380928744e-08
insidious B-Disease 0 6.709537046845071e-06
lesion I-Disease 0 0.00018206167442258447
which O 0 1.713887476384457e-09
is O 0 7.135720903050924e-10
undetectable O 0 2.3471963928045625e-08
by O 0 1.1806874367081832e-09
computed O 0 1.172130623672274e-07
tomogram O 0 1.3513331396097783e-06
( O 0 4.6329390102073376e-08
CT O 0 3.4902800507552456e-06
) O 0 3.9783687455496874e-09
or O 0 2.961546563540196e-09
MRI O 0 2.583138609679736e-07
analysis O 0 3.8114460920724014e-08
, O 0 7.068046703473385e-10
and O 0 2.3105044266724661e-10
that O 0 1.6691148463365835e-10
the O 0 2.9722646566199273e-09
higher O 0 4.507981543611095e-08
level O 0 6.146326825273718e-08
of O 0 5.902086375186855e-09
tau O 0 4.6592582236826274e-08
reflects O 0 2.233208507007589e-09
the O 0 2.8014168762524605e-10
process O 0 3.26649929327516e-09
of O 0 8.682718544150703e-08
neuronal B-Disease 0 0.002652352675795555
degeneration I-Disease 1 0.9999761581420898
in O 0 5.29602812093799e-06
ALD B-Disease 1 1.0
. O 0 5.674149633705383e-06

Lorenzos O 0 0.000780944072175771
Oil O 0 7.439378805429442e-06
should O 0 5.377068568179766e-09
be O 0 1.0831971986036137e-09
given O 0 3.3667646448520827e-09
in O 0 2.2777324470979465e-09
the O 0 5.691472626523364e-09
early O 0 7.077780139752576e-08
stage O 0 2.0116389976010396e-07
. O 0 2.614828531477542e-08
. O 0 1.249100449740581e-07

Nonsense O 0 0.0001533733302494511
mutation O 0 2.614582399473875e-07
in O 0 4.976223166863747e-08
exon O 0 9.528860687169072e-07
4 O 0 9.44252676049473e-08
of O 0 3.018680772015614e-08
human O 0 6.128881402389652e-09
complement O 0 1.1880686656695616e-07
C9 O 0 0.0008523107971996069
gene O 0 2.2698447565971946e-08
is O 0 1.00739261377214e-09
the O 0 4.0948813229135794e-09
major O 0 5.497135546761456e-08
cause O 0 2.0823691215809959e-07
of O 0 9.317698186350754e-07
Japanese O 0 0.0023052829783409834
complement B-Disease 0 0.00020723101624753326
C9 I-Disease 1 0.9999995231628418
deficiency I-Disease 1 0.9999979734420776
. O 0 2.1207272311585257e-06

Deficiency B-Disease 1 0.9999997615814209
of I-Disease 0 2.1112018657731824e-05
the I-Disease 0 8.748662594371126e-07
ninth I-Disease 0 9.67038704402512e-06
component I-Disease 0 1.4999545783211943e-06
of I-Disease 0 6.891941239928201e-08
human I-Disease 0 1.0924266824474671e-08
complement I-Disease 0 9.697455283230738e-08
( O 0 5.291991556077846e-08
C9 O 0 0.00012117088044760749
) O 0 1.670663718478238e-09
is O 0 1.2981908603659775e-10
the O 0 2.912957097755964e-10
most O 0 9.35717336947306e-11
common O 0 1.77679504442807e-09
complement B-Disease 1 0.9999963045120239
deficiency I-Disease 1 1.0
in O 0 1.307473098677292e-06
Japan O 0 2.077246790577192e-06
but O 0 2.719631742031936e-10
is O 0 1.957207867997468e-10
rare O 0 3.0557059660374364e-10
in O 0 1.957898704274541e-10
other O 0 2.746252669716398e-10
countries O 0 3.193191266959161e-10
. O 0 5.233940214566246e-08

We O 0 2.530433391711995e-07
studied O 0 1.6433936878001987e-07
the O 0 1.0243292436484808e-08
molecular O 0 3.5775322260178655e-08
basis O 0 9.237206199941284e-08
of O 0 2.7504395916366775e-07
C9 B-Disease 1 0.999992847442627
deficiency I-Disease 1 0.9967278242111206
in O 0 5.082729970240507e-08
four O 0 5.147913384462299e-08
Japanese O 0 1.8630769773153588e-05
C9 B-Disease 1 0.9985460042953491
- I-Disease 0 0.013857482932507992
deficient I-Disease 0 0.004229265730828047
patients O 0 7.444930449906906e-09
who O 0 1.7461780910110747e-09
had O 0 2.701575496644182e-08
suffered O 0 0.00010085816029459238
from O 0 4.539769361144863e-05
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 5.148780928720953e-06

Direct O 0 6.080980483602616e-07
sequencing O 0 7.004426549883647e-08
of O 0 1.0695540453298236e-07
amplified O 0 1.0545413715590257e-06
C9 O 0 1.9576096747186966e-05
cDNA O 0 5.726264475924836e-07
and O 0 1.2171097463209435e-09
DNA O 0 1.548637840187439e-08
revealed O 0 3.678879423318904e-08
a O 0 1.0231830493978578e-08
nonsense O 0 5.779757827895082e-08
substitution O 0 6.079805991987541e-09
( O 0 4.329439029504556e-09
CGA O 0 1.2676837002345565e-07
- O 0 3.32119540757958e-08
- O 0 1.7569372801062855e-07
> O 0 2.0015427537600772e-07
TGA O 0 4.1305250420009543e-07
) O 0 2.674828969428944e-10
at O 0 2.9119251454545747e-09
codon O 0 2.0642547227112118e-08
95 O 0 3.744261789506709e-08
in O 0 5.125836644026549e-09
exon O 0 5.5184823821718965e-08
4 O 0 3.1222004537312387e-08
in O 0 4.934218811314395e-09
the O 0 2.1757594836913086e-08
four O 0 2.272682735338094e-07
C9 B-Disease 0 0.013836762867867947
- I-Disease 0 0.0007680254057049751
deficient I-Disease 0 3.688308424898423e-05
individuals O 0 3.920033009308099e-08
. O 0 1.5876101144840504e-07

An O 0 1.5362792282758164e-07
allele O 0 1.7540569885454715e-08
- O 0 1.4445605600599265e-08
specific O 0 3.4436546947347324e-09
polymerase O 0 9.273854573166318e-08
chain O 0 1.6567339500284106e-08
reaction O 0 7.128483914264905e-10
system O 0 1.9042132315405524e-09
designed O 0 1.8832995163364785e-09
to O 0 9.044515136835685e-10
detect O 0 1.5747154691325704e-08
exclusively O 0 1.5881472137380115e-08
only O 0 2.9975082416200394e-09
one O 0 4.242460271974835e-10
of O 0 4.2244216458264816e-10
the O 0 6.869807500642366e-10
normal O 0 5.315559548080273e-09
and O 0 2.618189554048911e-10
mutant O 0 3.1382774157151516e-09
alleles O 0 4.404295331217334e-11
indicated O 0 3.196163472773961e-11
that O 0 4.1782606020890345e-12
all O 0 1.5612162604372593e-11
the O 0 1.6110518474832247e-10
four O 0 4.5703901774274414e-10
patients O 0 3.7266720959161503e-11
were O 0 3.601291764798731e-10
homozygous O 0 8.086047387223516e-10
for O 0 1.9238309556524058e-10
the O 0 3.1680535972355983e-09
mutation O 0 1.1773569896789127e-09
in O 0 6.638438687645021e-09
exon O 0 3.5146587862300294e-08
4 O 0 2.2955630285537154e-08
and O 0 3.415981386645228e-10
that O 0 1.359078821705495e-10
the O 0 2.0539874245883993e-09
parents O 0 4.794410202180188e-09
of O 0 2.976498514328796e-08
patient O 0 2.632669975355384e-07
2 O 0 2.6903049388238287e-07
were O 0 1.534530866820205e-07
heterozygous O 0 2.384887807238556e-07
. O 0 1.3667755638380186e-07

The O 0 2.0998562888507877e-07
common O 0 8.605652190851742e-09
mutation O 0 2.005710486585599e-09
at O 0 3.4063553755459e-08
codon O 0 5.189100704683369e-08
95 O 0 3.522336200489917e-08
in O 0 3.7293141907923655e-09
exon O 0 5.3964075874546324e-08
4 O 0 1.2532333393266981e-08
might O 0 8.785595584370753e-10
be O 0 3.4559113903931404e-10
responsible O 0 2.5381747814634537e-09
for O 0 2.276472788054207e-09
most O 0 2.1224170865252745e-08
Japanese O 0 0.0011733454884961247
C9 B-Disease 1 0.9999997615814209
deficiency I-Disease 1 0.9999935626983643
. O 0 9.618521090715149e-08
. O 0 2.5191306463057117e-07

BRCA1 O 0 9.062324011210876e-07
required O 0 1.6501051192108207e-08
for O 0 3.0496362768417384e-08
transcription O 0 1.5810943295946345e-05
- O 0 1.5806546116436948e-06
coupled O 0 9.399233931617346e-06
repair O 0 1.7697188013698906e-05
of O 0 1.033742364597856e-06
oxidative O 0 0.00010486176324775442
DNA O 0 0.00016292193322442472
damage O 0 0.0005534793599508703
. O 0 5.579645971920399e-07

The O 0 1.7886164641822688e-05
breast B-Disease 1 0.9999971389770508
and I-Disease 1 0.9879941940307617
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 1 0.9999990463256836
gene O 0 1.591238969922415e-06
BRCA1 O 0 2.4312413415827905e-07
encodes O 0 4.631189298720528e-08
a O 0 2.6451619561385087e-08
zinc O 0 5.941921244811965e-06
finger O 0 7.830100003047846e-06
protein O 0 8.841279708349248e-08
of O 0 7.559231818277112e-08
unknown O 0 4.200797411613166e-05
function O 0 5.97682264924515e-06
. O 0 1.9325919708990114e-07

Association O 0 6.953609954507556e-06
of O 0 1.0506264516152442e-06
the O 0 3.1378604603560234e-07
BRCA1 O 0 1.995238250174225e-07
protein O 0 7.354531650349827e-09
with O 0 1.4614198740048323e-10
the O 0 1.2913244695766934e-08
DNA O 0 5.637390358970151e-07
repair O 0 1.3268375369079877e-05
protein O 0 6.382799710991094e-07
Rad51 O 0 4.880384040006902e-06
and O 0 1.8150238256797735e-10
changes O 0 3.535464421222656e-10
in O 0 5.595915397726969e-10
the O 0 3.652790292463237e-09
phosphorylation O 0 1.5957107635244938e-08
and O 0 1.3571574974946543e-09
cellular O 0 1.5633604277809354e-07
localization O 0 4.2811086586880265e-07
of O 0 1.2885540634499648e-08
the O 0 1.7728892132140572e-08
protein O 0 2.7361229726352576e-08
after O 0 2.18641762472771e-08
exposure O 0 1.736474928293319e-07
to O 0 4.102080897183669e-09
DNA O 0 7.898829608166125e-07
- O 0 3.211522425772273e-07
damaging O 0 3.7855451751056535e-07
agents O 0 1.482562250743058e-08
are O 0 2.370847684840527e-10
consistent O 0 6.106687600038185e-09
with O 0 5.924152141068006e-11
a O 0 2.4956137156806335e-09
role O 0 1.1249563058868262e-08
for O 0 3.8786791556333355e-09
BRCA1 O 0 5.1595819172689517e-08
in O 0 5.4543878746926566e-08
DNA O 0 4.559834451356437e-06
repair O 0 0.00040387758053839207
. O 0 1.884788389361347e-06

Here O 0 3.2394236768595874e-06
, O 0 8.285767627569385e-09
it O 0 6.908530969518267e-10
is O 0 1.8052942474255929e-10
shown O 0 2.883774052886423e-10
that O 0 8.866665041074029e-11
mouse O 0 1.3115822206088978e-08
embryonic O 0 1.6040841543940587e-08
stem O 0 1.2027268780911982e-07
cells O 0 6.541607433518948e-08
deficient B-Disease 0 3.050317616271059e-07
in I-Disease 0 2.8859541423287283e-09
BRCA1 I-Disease 0 9.157979263818561e-09
are O 0 1.447391512199303e-10
defective O 0 5.695577343090008e-09
in O 0 6.963976617591072e-10
the O 0 3.817700822139614e-09
ability O 0 3.136093384981109e-09
to O 0 7.740080798512849e-10
carry O 0 3.093520550834228e-09
out O 0 8.609084112265464e-09
transcription O 0 8.384399166061485e-07
- O 0 1.5488954829834256e-07
coupled O 0 8.44344071992964e-07
repair O 0 1.3525141184800304e-06
of O 0 9.840309900255306e-08
oxidative O 0 1.3438739188131876e-06
DNA O 0 1.8913659687314066e-06
damage O 0 1.3837213373335544e-05
, O 0 2.4762873973571686e-09
and O 0 1.5317513923918114e-09
are O 0 9.88944814928061e-10
hypersensitive O 0 4.595688380959473e-07
to O 0 1.0065519084889729e-08
ionizing O 0 8.54106547194533e-05
radiation O 0 3.466759153525345e-05
and O 0 1.075354827406727e-08
hydrogen O 0 7.239836463668325e-08
peroxide O 0 2.532253802201012e-06
. O 0 4.448330059858563e-07

These O 0 1.0019034846209252e-07
results O 0 5.003614589327299e-08
suggest O 0 1.2930860293636215e-07
that O 0 4.2214431950071685e-09
BRCA1 O 0 3.105256851654303e-08
participates O 0 8.599844392165323e-09
, O 0 6.996195844877207e-10
directly O 0 5.203945274701027e-09
or O 0 5.6084417110469076e-09
indirectly O 0 3.956056104925665e-08
, O 0 1.4360409528180185e-09
in O 0 8.622411229453064e-09
transcription O 0 6.515727363876067e-06
- O 0 3.0482848956125963e-07
coupled O 0 1.2727814464597031e-06
repair O 0 3.2277234822686296e-06
of O 0 1.819520036860922e-07
oxidative O 0 6.433028829633258e-06
DNA O 0 7.334988367801998e-06
damage O 0 6.665910041192546e-05
. O 0 5.1749367457887274e-08
. O 0 1.2048876385506446e-07

Truncation O 0 0.00018583358905743808
mutations O 0 3.78533229650202e-07
in O 0 1.581457809152198e-08
the O 0 3.5967577360906944e-08
transactivation O 0 1.0011764061346184e-05
region O 0 1.7343069202979677e-07
of O 0 6.725820185238263e-07
PAX6 O 0 0.004982038401067257
result O 0 2.0859886262769578e-07
in O 0 4.128677133508063e-08
dominant O 0 3.7547286524386436e-07
- O 0 1.236151376815542e-07
negative O 0 4.6258925578968046e-08
mutants O 0 7.4225442858733e-07
. O 0 7.053401418488647e-08

PAX6 O 0 0.005029389634728432
is O 0 2.771033678072854e-07
a O 0 3.186451067449525e-07
transcription O 0 1.9434555724728853e-06
factor O 0 4.918023321920373e-08
with O 0 1.7953293018901917e-10
two O 0 2.661984188634392e-09
DNA O 0 9.605962247860589e-08
- O 0 7.823099679171719e-08
binding O 0 1.3275288424097198e-08
domains O 0 2.5849720941550913e-07
( O 0 3.7071514746855883e-09
paired O 0 1.190668008632656e-08
box O 0 1.0363785207800902e-07
and O 0 4.281702103980933e-09
homeobox O 0 2.598605988168856e-06
) O 0 3.039478224664549e-09
and O 0 8.741201096285067e-10
a O 0 2.5989077556687334e-08
proline O 0 3.658807088413596e-07
- O 0 3.0349789881256584e-07
serine O 0 1.720708496577572e-06
- O 0 1.446418309569708e-06
threonine O 0 4.554949100565864e-06
( O 0 1.5599958658185642e-07
PST O 0 2.1600653781206347e-05
) O 0 5.7493899419114314e-08
- O 0 1.0106710135460162e-07
rich O 0 2.1954613771413278e-07
transactivation O 0 0.0003793981159105897
domain O 0 1.1622229976637755e-05
. O 0 3.2743236033638823e-07

PAX6 O 1 0.9999918937683105
regulates O 0 0.00048030386096797884
eye O 0 9.094866982195526e-05
development O 0 2.497263267287053e-07
in O 0 5.156972182618347e-09
animals O 0 1.4178440643775048e-09
ranging O 0 1.6872107266863168e-08
from O 0 8.38674818481877e-09
jellyfish O 0 7.897834386483282e-09
to O 0 9.35466260010287e-10
Drosophila O 0 2.668299181607381e-08
to O 0 7.580593930356372e-10
humans O 0 3.216361577074167e-08
. O 0 3.693095251833256e-08

Heterozygous O 0 1.0049664524558466e-05
mutations O 0 2.8903793136692002e-08
in O 0 2.7421034332064664e-09
the O 0 1.7006026808985553e-08
human O 0 2.8997609646808087e-08
PAX6 O 0 0.00019637915829662234
gene O 0 3.612803611829918e-09
result O 0 2.5690921612309126e-10
in O 0 1.4913528745275073e-10
various O 0 6.057266910275416e-10
phenotypes O 0 1.4210204568598783e-08
, O 0 4.0397765688204856e-10
including O 0 4.106057716057876e-09
aniridia B-Disease 1 1.0
, O 0 4.0003999401960755e-07
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 3.9753146552357066e-07
autosomal B-Disease 0 0.0016269742045551538
dominant I-Disease 0 0.0005321242497302592
keratitis I-Disease 1 0.9990659356117249
, O 0 5.293657636684657e-07
and O 0 4.2208754166495055e-05
familial B-Disease 1 1.0
foveal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 0 0.00819778349250555

It O 0 4.645999851504712e-08
is O 0 3.4966505246813995e-09
believed O 0 1.726303011650998e-08
that O 0 2.773076213102854e-10
the O 0 3.0644158321990744e-09
mutated O 0 5.860178564631724e-09
allele O 0 5.543407954888835e-09
of O 0 3.206365306596126e-08
PAX6 O 0 6.61689045955427e-05
produces O 0 1.828702878015065e-08
an O 0 8.97307383951329e-09
inactive O 0 8.904588639779831e-07
protein O 0 2.3196479048692709e-07
and O 0 1.830758478149619e-08
aniridia B-Disease 1 1.0
is O 0 1.6908776956370275e-07
caused O 0 2.1380482451149874e-07
due O 0 1.2696690987468173e-07
to O 0 8.115612359915758e-08
genetic O 0 6.838660283392528e-06
haploinsufficiency O 0 0.0010153371840715408
. O 0 1.4364355820362107e-06

However O 0 1.8729234341208212e-07
, O 0 3.871081677431221e-09
several O 0 3.3904599128220525e-09
truncation O 0 5.098328301755828e-07
mutations O 0 3.8732381746342526e-09
have O 0 2.0006241108205813e-10
been O 0 6.749409364736891e-10
found O 0 3.140102344811879e-10
to O 0 8.711369819947024e-11
occur O 0 6.136072205897847e-10
in O 0 1.2698665452504088e-09
the O 0 5.13630133980314e-08
C O 0 0.0002942633582279086
- O 0 6.251034960769175e-07
terminal O 0 2.753226624463423e-07
half O 0 1.0192445998313815e-08
of O 0 2.138361843151415e-08
PAX6 O 0 2.6123714633286e-05
in O 0 7.304999272150781e-09
patients O 0 6.968361998538342e-10
with O 0 2.649880870286836e-10
Aniridia B-Disease 1 1.0
resulting O 0 1.7053001499789389e-07
in O 0 2.316480340880389e-09
mutant O 0 6.543140251835666e-09
proteins O 0 7.75157091292833e-11
that O 0 2.213820619878515e-11
retain O 0 5.88146253921451e-10
the O 0 1.8629398468306135e-08
DNA O 0 1.5042232348605467e-07
- O 0 1.4182477414692585e-08
binding O 0 9.220866736825428e-09
domains O 0 5.630954191815363e-08
but O 0 6.416716047397131e-10
have O 0 9.321942107121117e-10
lost O 0 5.561371381190838e-07
most O 0 2.4633513007188412e-09
of O 0 2.9557638114852125e-08
the O 0 2.427471770261036e-07
transactivation O 0 0.00024495902471244335
domain O 0 3.1548690458294004e-05
. O 0 3.180260819135583e-07

It O 0 2.7237929245416126e-08
is O 0 1.360007884088077e-09
not O 0 1.3722538383387217e-10
clear O 0 1.4752810084672774e-09
whether O 0 4.215720550426738e-10
such O 0 1.8070831497851714e-09
mutants O 0 5.270555902825436e-07
really O 0 1.282226804733e-07
behave O 0 8.166757936578506e-09
as O 0 6.268530139408313e-09
loss O 0 4.4267468979342084e-07
- O 0 1.4653714686119201e-07
of O 0 1.7846402897703229e-06
- O 0 2.706568693611189e-06
function O 0 4.2765262264765624e-07
mutants O 0 1.1588196002776385e-07
as O 0 5.012734227705096e-09
predicted O 0 7.643554766900706e-08
by O 0 2.097278084534082e-08
haploinsufficiency O 0 4.995657582185231e-05
. O 0 9.12713232992246e-07

Contrary O 0 1.3369453881750815e-05
to O 0 7.97520272044494e-09
this O 0 3.101490397838802e-09
theory O 0 1.1581435188645628e-07
, O 0 8.308964627445903e-10
our O 0 2.8834947762845786e-09
data O 0 2.2193496818090352e-08
showed O 0 1.3366622253485616e-09
that O 0 3.743313645165891e-11
these O 0 8.125559947114169e-11
mutants O 0 6.847166833523488e-09
are O 0 1.7959801701383782e-10
dominant O 0 4.5391526093396806e-09
- O 0 5.81209080863232e-09
negative O 0 4.699149513953671e-09
in O 0 1.4931267333651022e-09
transient O 0 5.661181603500154e-07
transfection O 0 4.7565896466039703e-07
assays O 0 1.489267908993952e-08
when O 0 5.902176525296454e-09
they O 0 2.034236112891108e-09
are O 0 8.820788544028346e-10
coexpressed O 0 5.621917011922051e-07
with O 0 5.369249489461936e-09
wild O 0 5.128435986989643e-07
- O 0 8.376779078389518e-06
type O 0 1.6921545466175303e-05
PAX6 O 0 0.16455873847007751
. O 0 1.38799362048303e-06

We O 0 1.6651695489144913e-07
found O 0 1.3423193223616181e-08
that O 0 3.470886911216553e-10
the O 0 1.2376148106341134e-08
dominant O 0 5.7243322970634836e-08
- O 0 1.6484314357967378e-08
negative O 0 6.733801960479013e-09
effects O 0 8.844143195574361e-09
result O 0 1.0773806291553e-09
from O 0 8.974609944090162e-10
the O 0 1.516041403526458e-09
enhanced O 0 4.695467126225594e-09
DNA O 0 4.187545421530103e-09
binding O 0 7.348232022863499e-10
ability O 0 6.290889476012751e-10
of O 0 3.852821173211396e-09
these O 0 2.224077588763862e-09
mutants O 0 4.364280243862595e-07
. O 0 7.935148005344672e-08

Kinetic O 0 2.7505036996444687e-05
studies O 0 4.308867289637419e-07
of O 0 5.4853213526939726e-08
binding O 0 1.7536990526423324e-08
and O 0 2.7648912048761076e-09
dissociation O 0 2.751452257143683e-07
revealed O 0 9.453410854121103e-08
that O 0 4.0656875088807e-10
various O 0 1.2130632054407897e-09
truncation O 0 2.8008167873849743e-07
mutants O 0 7.898831455577238e-08
have O 0 4.094652950037414e-10
3 O 0 7.034977489439598e-09
- O 0 3.016716876302894e-09
5 O 0 1.4614157883841017e-08
- O 0 5.227582366984507e-09
fold O 0 8.319720912197681e-09
higher O 0 3.805930237632538e-09
affinity O 0 9.847210824531771e-10
to O 0 5.658917084927495e-11
various O 0 4.102853612408808e-10
DNA O 0 9.104059728315406e-09
- O 0 1.4252108382351025e-09
binding O 0 6.811238795201291e-10
sites O 0 1.2183128950127298e-09
when O 0 6.228232374283493e-10
compared O 0 7.336132812341134e-10
with O 0 5.440643421894542e-11
the O 0 5.9325935275467145e-09
wild O 0 1.528357387314827e-07
- O 0 6.573012569788261e-07
type O 0 4.746371814690065e-06
PAX6 O 0 0.001247807522304356
. O 0 8.505541586600884e-07

These O 0 8.682486907218845e-08
results O 0 4.165529077226893e-08
provide O 0 5.681721759742686e-09
a O 0 4.627760841202644e-09
new O 0 1.5723137236633988e-09
insight O 0 5.485823706408155e-08
into O 0 2.1369011005134553e-09
the O 0 6.175620015369532e-09
role O 0 3.214325161593479e-08
of O 0 1.5079190518463292e-07
mutant O 0 2.9074981284793466e-06
PAX6 O 0 0.0006449813372455537
in O 0 2.9988368055455794e-07
causing O 0 3.599236379159265e-06
aniridia B-Disease 1 1.0
. O 0 2.3240785651523765e-07
. O 0 5.073857778370439e-07

Reversal O 0 6.94826667313464e-05
of O 0 5.139313088875497e-06
severe O 1 0.9998055100440979
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
and O 0 4.3570733510023274e-07
excellent O 0 3.911342901119497e-06
neuropsychologic O 0 2.3554683139082044e-05
outcome O 0 4.2525917365310306e-07
in O 0 6.582887124295667e-08
very B-Disease 0 7.879841490421313e-08
- I-Disease 0 7.759909408378007e-07
long I-Disease 0 5.158470344213129e-07
- I-Disease 0 3.0002672701812116e-07
chain I-Disease 0 1.8935809009690274e-07
acyl I-Disease 0 2.820587781116046e-07
- I-Disease 0 3.340180967370543e-07
coenzyme I-Disease 0 2.5428655590076232e-06
A I-Disease 0 7.361779717030004e-05
dehydrogenase I-Disease 0 0.0003580128541216254
deficiency I-Disease 0 0.07407777011394501
. O 0 5.533258331524848e-07

Very B-Disease 0 2.3647160105610965e-06
- I-Disease 0 1.3009407666686457e-06
long I-Disease 0 2.3361293699508678e-07
- I-Disease 0 1.576059389662987e-07
chain I-Disease 0 7.142249813796298e-08
acyl I-Disease 0 7.318167405401255e-08
- I-Disease 0 7.884697339477498e-08
coenzyme I-Disease 0 1.2400042237459274e-07
A I-Disease 0 5.805223963761819e-07
dehydrogenase I-Disease 0 1.6785001832886337e-07
( I-Disease 0 8.840921772446109e-09
VLCAD I-Disease 0 0.0002311193966306746
) I-Disease 0 3.420900895889645e-08
deficiency I-Disease 0 9.859415513346903e-06
is O 0 2.1976298558712415e-09
a O 0 4.003949172215471e-08
disorder O 0 0.00023952008632477373
of O 0 1.1623271348071285e-05
fatty O 0 4.8290719860233366e-05
acid O 0 2.7551872335607186e-05
beta O 0 3.7537192838499323e-06
oxidation O 0 5.397506885884695e-09
that O 0 2.9101082654747756e-10
reportedly O 0 4.224907090843999e-09
has O 0 4.4122327319540133e-11
high O 0 1.7787708805894198e-10
rates O 0 5.909450706553798e-10
of O 0 2.134082466298537e-09
morbidity O 0 4.793973857886158e-07
and O 0 3.700059147959678e-09
mortality O 0 3.060421704503824e-06
. O 0 6.551634612605994e-08

We O 0 4.362341314845253e-07
describe O 0 4.4346947447593266e-07
the O 0 8.09861901984732e-08
outcome O 0 1.5126691721434327e-07
of O 0 2.3824372874514665e-07
a O 0 6.517123551930126e-08
5 O 0 3.4526404846246805e-08
- O 0 4.621639515534071e-09
year O 0 5.30458077463436e-09
- O 0 1.0235446268325177e-07
old O 0 6.306723321358731e-07
girl O 0 3.951395683543524e-06
with O 0 5.299749545883969e-07
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 1.7196141470776638e-06
was O 0 3.434871132412809e-06
first O 0 2.3152564665451791e-07
seen O 0 9.465047412504646e-08
at O 0 1.0575450914984685e-07
5 O 0 2.0997115157683766e-08
months O 0 2.9621680663893812e-09
of O 0 2.5374293777247203e-09
age O 0 4.2449574522152034e-08
with O 0 1.3477375659931567e-08
severe O 1 0.9999806880950928
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
, O 0 0.0006082720938138664
hepatomegaly B-Disease 1 1.0
, O 0 0.11593598127365112
encephalopathy B-Disease 1 0.9974339604377747
, O 0 1.2622600706890807e-06
and O 0 3.127809031866491e-05
hypotonia B-Disease 1 0.999984860420227
. O 0 0.0001400188630213961

Biochemical O 0 0.012006537057459354
studies O 0 0.0016034012660384178
indicated O 1 0.9095619320869446
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 6.658336496911943e-05
by O 0 7.644804789208592e-09
a O 0 1.2097320478687834e-08
stable O 0 1.3576143942373164e-07
yet O 0 2.075023530778708e-08
inactive O 0 2.7388648504711455e-06
enzyme O 0 1.687628014224174e-06
. O 0 3.2212952305599174e-07

Molecular O 0 5.697763481293805e-05
genetic O 0 1.060638396666036e-06
analysis O 0 1.2330195886534057e-07
of O 0 9.195299099928889e-08
her O 0 2.2364633878169116e-06
VLCAD O 1 0.9976595640182495
gene O 0 1.3475170135279768e-07
revealed O 0 8.621212259640743e-07
a O 0 1.3228797968167783e-07
T1372C O 0 1.6796127511042869e-06
( O 0 7.888262842925542e-08
F458L O 0 2.6887657895713346e-06
) O 0 5.3242985131873866e-08
missense O 0 8.741756687413726e-07
mutation O 0 2.0221095908823372e-08
and O 0 2.1016669293771884e-08
a O 0 1.9352971776243066e-06
1668 O 1 0.9364995956420898
ACAG O 1 0.9999949932098389
1669 O 1 0.9728986024856567
splice O 0 0.0006349998875521123
site O 0 8.174012691597454e-06
mutation O 0 4.086379590262368e-07
. O 0 2.820582665208349e-07

After O 0 2.4612916149635566e-07
initial O 0 1.422821895857851e-07
treatment O 0 1.396808624321011e-08
with O 0 2.131564258434082e-09
intravenous O 0 1.7691000664399326e-07
glucose O 0 4.842819976147439e-07
and O 0 2.097705120718274e-09
carnitine O 0 1.7593646362001891e-06
, O 0 3.3351146289106737e-09
the O 0 1.654848702514755e-08
patient O 0 9.474057947045367e-07
has O 0 8.354302249991008e-10
thrived O 0 5.3956462409132655e-08
on O 0 1.1709347269572845e-08
a O 0 2.8347230340841634e-08
low O 0 5.852144795426284e-07
- O 0 1.1716857528654145e-07
fat O 0 9.94976989687757e-09
diet O 0 2.440817992166444e-09
supplemented O 0 2.6742590364392527e-09
with O 0 1.0949204737320528e-10
medium O 0 1.445881565587115e-07
- O 0 4.775821480507147e-07
chain O 0 9.036953940722015e-08
triglyceride O 0 2.5242772494493693e-07
oil O 0 2.2601810201194894e-07
and O 0 6.1323661704193455e-09
carnitine O 0 2.166224930988392e-06
and O 0 1.2963710993574296e-08
avoidance O 0 1.2360363825791865e-06
of O 0 4.6337785875039117e-07
fasting O 0 5.055294877820415e-06
. O 0 3.522753502238629e-07

Her O 0 0.0022638512309640646
ventricular O 1 0.9894534349441528
hypertrophy O 0 0.0016639361856505275
resolved O 0 4.834560058952775e-06
significantly O 0 1.2442794172784488e-07
over O 0 6.650884731840279e-09
1 O 0 1.023179141412811e-08
year O 0 1.3202583470928175e-09
, O 0 3.1952504531140846e-10
and O 0 9.454177440915146e-10
cognitively O 0 7.5849698077945504e-06
, O 0 5.479859677137711e-09
she O 0 9.659515853854828e-09
is O 0 1.9198582723589652e-09
in O 0 8.676585006028859e-10
the O 0 1.8029278070486043e-09
superior O 0 2.545341537540935e-08
range O 0 6.473256064509769e-08
for O 0 1.0674503947427638e-08
age O 0 2.255862227684702e-06
. O 0 5.093094159747125e-07

Clinical O 0 0.0004119416989851743
recognition O 0 2.9175084819144104e-06
of O 1 0.9721818566322327
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 1.4352880270962487e-06
important O 0 1.8595461170889394e-08
because O 0 1.4162540584727878e-10
it O 0 2.8012391017906424e-11
is O 0 7.072183810796773e-11
one O 0 1.8144767632843894e-10
of O 0 4.989181290326883e-10
the O 0 3.447953034196871e-09
few O 0 3.4026392814467954e-09
directly O 0 2.736989479501517e-08
treatable O 0 2.6144925868720748e-05
causes O 0 1.0320264891561237e-06
of O 0 0.00017096911324188113
cardiomyopathy B-Disease 1 1.0
in O 0 1.7160231209345511e-06
children O 0 9.441571791057868e-08
. O 0 3.0140896001285e-08
. O 0 2.4374074314437166e-07

Cloning O 0 1.2654259990085848e-05
of O 0 8.057511280412655e-08
a O 0 3.27545990330691e-08
novel O 0 6.002230179547041e-08
member O 0 3.7127719565432926e-08
of O 0 4.580308754498219e-08
the O 0 6.517322503896139e-08
low O 0 2.692886937438743e-06
- O 0 1.1112459787909756e-06
density O 0 4.5558036276815983e-07
lipoprotein O 0 2.1808547899127007e-05
receptor O 0 2.0036295609315857e-06
family O 0 2.5499340949863836e-07
. O 0 5.448336537483556e-08

A O 0 8.716294360056054e-06
gene O 0 1.342724544883822e-07
encoding O 0 4.384923002476171e-08
a O 0 2.931436604569626e-08
novel O 0 2.9280761282279855e-07
transmembrane O 0 2.709802174649667e-06
protein O 0 3.2068179223188054e-08
was O 0 1.436970631374379e-08
identified O 0 9.038824688722968e-10
by O 0 8.545550378435962e-11
DNA O 0 9.565457315119374e-10
sequence O 0 6.617727477120638e-10
analysis O 0 3.8952990832896717e-10
within O 0 3.439320495068898e-10
the O 0 1.2961206552475346e-09
insulin B-Disease 0 4.4139821397948253e-07
- I-Disease 0 8.765750862949062e-06
dependent I-Disease 0 0.3963088393211365
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 1.4113704310148023e-05
IDDM B-Disease 1 0.9208527207374573
) O 0 1.152598940734606e-07
locus O 0 5.3538923339147e-07
IDDM4 O 0 1.0289435522281565e-05
on O 0 3.7558709209406516e-07
chromosome O 0 2.474889697623439e-06
11q13 O 0 1.7612395822652616e-05
. O 0 7.411439355564653e-07

Based O 0 1.220636931975605e-06
on O 0 9.881726015237291e-08
its O 0 8.013673280515832e-09
chromosomal O 0 1.2478288624606648e-07
position O 0 7.943780389041422e-08
, O 0 1.0153865526163486e-09
this O 0 9.60403090388695e-10
gene O 0 5.113695578096156e-10
is O 0 1.9390676564423615e-10
a O 0 1.1710480363191778e-09
candidate O 0 3.6048308782454797e-10
for O 0 4.135466691312928e-10
conferring O 0 3.7189880686128163e-07
susceptibility O 0 2.041967036348069e-06
to O 0 2.034839212683437e-07
diabetes B-Disease 1 0.9999985694885254
. O 0 1.354445089418732e-06

The O 0 2.3175614387582755e-06
gene O 0 1.0623669055576102e-07
, O 0 4.5530259562553965e-09
termed O 0 1.6217276765928546e-07
low O 0 1.983401034522103e-06
- O 0 9.085082979254366e-07
density O 0 1.3111025509715546e-07
lipoprotein O 0 5.779146249551559e-06
receptor O 0 3.1611986628377053e-07
related O 0 4.861588820403995e-08
protein O 0 3.254740477132145e-08
5 O 0 2.4510361740226472e-08
( O 0 4.4498800200187816e-09
LRP5 O 0 3.4102899917343166e-06
) O 0 2.6432793731601123e-09
, O 0 3.2722718978916987e-10
encodes O 0 5.128368840701114e-09
a O 0 1.0923760784820047e-09
protein O 0 4.921342888764002e-09
of O 0 8.696503961402868e-09
1615 O 0 1.3290828974277247e-05
amino O 0 1.7095061366489972e-07
acids O 0 6.7216374688428004e-09
that O 0 2.510498475771783e-10
contains O 0 2.5249831114848575e-09
conserved O 0 1.0806868289137128e-07
modules O 0 1.1334014970998396e-07
which O 0 1.982871644656825e-10
are O 0 5.845281203509245e-11
characteristic O 0 1.7419733433499118e-09
of O 0 5.146379322695793e-09
the O 0 3.212523580486959e-08
low O 0 2.121416855516145e-06
- O 0 5.138496703693818e-07
density O 0 6.129258167675289e-08
lipoprotein O 0 6.826078333688201e-06
( O 0 1.1861870774509953e-07
LDL O 0 7.678208021388855e-06
) O 0 7.63521601498951e-09
receptor O 0 9.420417512728818e-08
family O 0 2.0917291010391637e-08
. O 0 3.1912829712155144e-08

These O 0 2.2626396400937665e-07
modules O 0 2.0425104594323784e-06
include O 0 7.558683989827841e-08
a O 0 2.255065396639111e-07
putative O 0 3.313746447020094e-06
signal O 0 3.401791843771207e-07
peptide O 0 9.16023257246934e-09
for O 0 7.627948828137221e-10
protein O 0 5.375540901297882e-09
export O 0 8.571285015079866e-09
, O 0 7.19138526505958e-10
four O 0 8.967325548780991e-09
epidermal O 0 1.4392012417374644e-06
growth O 0 2.5840838802082544e-08
factor O 0 5.344402964624351e-08
( O 0 1.0063388344860869e-08
EGF O 0 9.875674322756822e-07
) O 0 4.659546637419965e-10
repeats O 0 2.6359838756206955e-09
with O 0 1.6937835856101202e-10
associated O 0 5.0358607950329315e-08
spacer O 0 6.682384537270991e-06
domains O 0 2.5535996428516228e-06
, O 0 1.3085663219669641e-08
three O 0 6.04432273121347e-08
LDL O 0 1.6176130884559825e-05
- O 0 2.0150157524767565e-06
receptor O 0 1.5288311487893225e-06
( O 0 2.417772293483722e-08
LDLR O 0 8.621602319180965e-06
) O 0 9.438129389138794e-09
repeats O 0 2.539803212187053e-08
, O 0 5.774297706651055e-10
a O 0 5.43715295009406e-09
single O 0 2.590479475372831e-08
transmembrane O 0 2.155381480406504e-06
spanning O 0 3.0294554562715348e-06
domain O 0 6.195506557560293e-06
, O 0 7.148270420032077e-09
and O 0 1.1344845951555271e-08
a O 0 5.615647751255892e-07
cytoplasmic O 0 7.150733290472999e-05
domain O 0 5.805095861433074e-05
. O 0 5.554904305427044e-07

The O 0 1.9674744180520065e-06
encoded O 0 1.5687908216932556e-06
protein O 0 5.67474955914804e-08
has O 0 5.282678183782252e-10
a O 0 1.6294745552869472e-09
unique O 0 6.86531764770848e-09
organization O 0 3.195619768803226e-08
of O 0 1.3294820746523328e-06
EGF O 0 0.003991955425590277
and O 0 1.568647967076231e-08
LDLR O 0 0.0002369556314079091
repeats O 0 1.1817429168559102e-07
; O 0 1.2639775892608895e-09
therefore O 0 8.810704166251071e-09
, O 0 4.2437249270221855e-09
LRP5 O 0 4.031707067042589e-05
likely O 0 1.8209343366493158e-08
represents O 0 8.442005317021994e-09
a O 0 2.079111105501852e-09
new O 0 1.5067934677759354e-09
category O 0 1.5528682695276075e-07
of O 0 7.684338498847865e-08
the O 0 6.154844527372916e-07
LDLR O 1 0.9791589975357056
family O 0 6.359823146340204e-06
. O 0 7.552457077508734e-07

Both O 0 1.5779271507199155e-06
human O 0 6.30536419521377e-07
and O 0 1.8847565286250756e-07
mouse O 0 3.0178632641764125e-06
LRP5 O 0 0.03610018640756607
cDNAs O 0 1.784452615538612e-05
have O 0 1.0290147622882273e-09
been O 0 1.440166430555223e-09
isolated O 0 3.598807918336888e-09
and O 0 4.9805357754673096e-11
the O 0 8.770460468987551e-10
encoded O 0 7.91383314435734e-09
mature O 0 2.6368036643020787e-09
proteins O 0 1.9365321846098738e-10
are O 0 1.115883566105147e-10
95 O 0 6.700606292042721e-09
% O 0 8.980980403805461e-10
identical O 0 1.918869951822444e-09
, O 0 7.789101030830636e-10
indicating O 0 2.5380646917483318e-08
a O 0 2.8290501052907757e-09
high O 0 3.205097742764451e-09
degree O 0 2.8825485287597985e-07
of O 0 9.452902460793666e-09
evolutionary O 0 7.097178666981563e-08
conservation O 0 9.761754071746509e-09
. O 0 1.2011004413281512e-09
. O 0 1.3255225361774592e-08

The O 0 1.0799952178786043e-05
APC B-Disease 0 1.1614683899097145e-05
variants O 0 2.32605884775694e-07
I1307K O 0 1.6370645425922703e-06
and O 0 1.9890935121225084e-08
E1317Q O 0 1.7612095462027355e-06
are O 0 4.7899311184096405e-09
associated O 0 2.6032892037619604e-06
with O 1 0.9968320727348328
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 0.1438070684671402
but O 0 2.177719160556535e-08
not O 0 3.081601196441852e-09
always O 0 1.3701733969639918e-08
with O 0 1.2429629547838772e-09
a O 0 9.805779654925573e-08
family O 0 3.458975470493897e-07
history O 0 3.7928302845102735e-06
. O 0 4.7013531911943574e-07

Classical O 1 0.9999979734420776
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.9614046216011047
FAP B-Disease 0 0.00017016920901369303
) O 0 2.078112970593793e-08
is O 0 1.9376524829084474e-09
a O 0 3.0749447432754096e-08
high O 0 0.0006580875487998128
- O 1 0.999996542930603
penetrance O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 0.9999972581863403
disease I-Disease 1 0.6589064598083496
that O 0 2.6036146572039343e-09
predisposes O 0 1.3645718865973322e-07
to O 0 2.7608757502406434e-09
hundreds O 0 4.8751340742114735e-09
or O 0 7.642909416460952e-09
thousands O 0 1.8495992293310337e-08
of O 0 0.02360420674085617
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9999997615814209
carcinoma I-Disease 1 1.0
and O 0 6.248535466824023e-09
that O 0 2.4745391846714426e-10
results O 0 6.806485930432871e-10
from O 0 2.240743368631115e-09
truncating O 0 2.188454146789809e-07
mutations O 0 1.902869861680756e-09
in O 0 3.765595391058696e-09
the O 0 2.0103733788801037e-07
APC B-Disease 0 3.219693326173001e-06
gene O 0 1.8039129656699515e-07
. O 0 9.32290973310046e-08

A O 0 4.110811460122932e-06
variant O 0 6.4609696437401e-07
of O 0 3.061499853629357e-07
FAP B-Disease 0 2.9554725188063458e-05
is O 0 4.6401640929616406e-07
attenuated B-Disease 0 0.011190127581357956
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999991655349731
coli I-Disease 1 0.997523844242096
, O 0 2.9957134550784303e-09
which O 0 4.160276845244226e-10
results O 0 2.3612680699613975e-09
from O 0 2.1989055909443778e-08
germ O 0 0.008679070509970188
- O 0 6.568722255906323e-06
line O 0 2.3969772655618726e-07
mutations O 0 2.1199562105778114e-09
in O 0 2.276703048309514e-09
the O 0 7.306894200809211e-09
5 O 0 1.4752113308702519e-08
and O 0 4.4712752944597867e-10
3 O 0 8.493656444841235e-09
regions O 0 1.1688588985592219e-09
of O 0 3.5335197878794133e-08
the O 0 2.9943387858111237e-07
APC B-Disease 0 3.8063967622292694e-06
gene O 0 7.981901717357687e-08
. O 0 6.564781074303028e-08

Attenuated B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
patients O 0 1.7527414456708357e-05
have O 0 6.512793082613655e-10
" O 0 1.4584223606561864e-08
multiple O 0 2.3214359146095376e-07
" O 1 0.9999586343765259
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 8.78858728015075e-08
typically O 0 7.808408919451892e-10
fewer O 0 4.967377204012635e-11
than O 0 3.6013997339878756e-11
100 O 0 8.693314956786935e-10
) O 0 7.535295998284397e-11
without O 0 3.267313641863723e-10
the O 0 4.6223624927677065e-09
florid O 0 6.437002753045817e-07
phenotype O 0 6.073920388871556e-08
of O 0 1.1477638395263057e-07
classical O 0 2.3226737539516762e-05
FAP B-Disease 0 1.556629649712704e-05
. O 0 2.1689027107640868e-07

Another O 0 1.4485524388874182e-06
group O 0 2.8547065156203644e-08
of O 0 3.334740839022743e-08
patients O 0 5.647795120466981e-09
with O 0 1.9318735500206685e-09
multiple O 0 1.3890979744246579e-06
adenomas B-Disease 1 0.6759172081947327
has O 0 3.6096627908932533e-09
no O 0 1.763960089107286e-09
mutations O 0 1.0426284141606956e-10
in O 0 7.786248867880374e-10
the O 0 1.8470856844032824e-08
APC B-Disease 0 1.4433135220315307e-07
gene O 0 9.929744804182405e-10
, O 0 9.671950740308688e-11
and O 0 1.204272376265081e-10
their O 0 1.147740902318617e-09
phenotype O 0 9.451893490108887e-09
probably O 0 5.306321160247762e-09
results O 0 1.1343650463402355e-09
from O 0 1.7362645765572893e-09
variation O 0 2.4000463838547148e-08
at O 0 1.3705164292332483e-07
a O 0 6.074684932855234e-08
locus O 0 4.2370785990897275e-08
, O 0 3.027234296570924e-10
or O 0 5.274673475774705e-10
loci O 0 1.5537584552305361e-09
, O 0 3.1094024577349444e-10
elsewhere O 0 3.977890905559889e-09
in O 0 6.247558026473143e-09
the O 0 9.766507247377376e-08
genome O 0 3.2763634294497024e-07
. O 0 2.846404925094248e-07

Recently O 0 4.738348252431024e-06
, O 0 1.1123018950343067e-08
however O 0 6.3730771771020045e-09
, O 0 2.285866607110165e-09
a O 0 2.1866595645292364e-08
missense O 0 2.4025774791880394e-07
variant O 0 4.524046204323895e-08
of O 0 1.2558148227981292e-06
APC B-Disease 0 2.7843841508001788e-06
( O 0 7.846860938798272e-08
I1307K O 0 1.5803110500201e-06
) O 0 1.8822088776460077e-08
was O 0 1.1199577443221642e-07
described O 0 5.082409870738047e-08
that O 0 3.983104679416982e-10
confers O 0 1.1862567816933733e-08
an O 0 5.76621916881237e-10
increased O 0 9.994924887735124e-09
risk O 0 2.5081567400775384e-06
of O 1 0.9999971389770508
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 3.458943183431984e-06
including O 0 1.7147451458754404e-08
multiple O 0 3.640731733867142e-07
adenomas B-Disease 0 9.951589163392782e-05
, O 0 6.206510860806702e-09
in O 0 7.072233643157233e-08
Ashkenazim O 0 7.286073378054425e-05
. O 0 1.442109919480572e-06

We O 0 7.802020149938471e-07
have O 0 6.343256586660573e-09
studied O 0 8.330172107662293e-08
a O 0 1.4733779529763069e-08
set O 0 5.487181375940509e-09
of O 0 3.95057986324332e-09
164 O 0 5.223558829925423e-08
patients O 0 1.9755037605762027e-09
with O 0 1.2279712802154563e-09
multiple O 0 0.015856778249144554
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9954971075057983
/ I-Disease 1 1.0
or I-Disease 1 0.5682393908500671
carcinoma I-Disease 1 1.0
and O 0 1.1979940595097105e-08
analyzed O 0 2.573399058292125e-07
codons O 0 1.8136039159344364e-07
1263 O 0 7.208033821370918e-06
- O 0 4.4614662897402013e-07
1377 O 0 4.8909882934822235e-06
( O 0 6.685621656288276e-08
exon O 0 2.1707320740915748e-07
15G O 0 8.267094813163567e-07
) O 0 2.6369644245960444e-09
of O 0 5.192553054200744e-09
the O 0 5.324126206573965e-08
APC B-Disease 0 1.101881252907333e-06
gene O 0 1.1497901297730095e-08
for O 0 1.495182289090735e-08
germ O 0 0.1360463947057724
- O 0 0.00106582953594625
line O 0 9.368788596475497e-06
variants O 0 9.638057463234873e-07
. O 0 2.1255330295844033e-07

Three O 0 1.4158484873405541e-06
patients O 0 1.6751860343333647e-08
with O 0 1.7684507191972898e-09
the O 0 7.729214956953001e-08
I1307K O 0 2.9819816518283915e-06
allele O 0 1.4090937305866191e-08
were O 0 6.659096829508826e-09
detected O 0 1.8392668721389782e-08
, O 0 7.289740477922635e-10
each O 0 8.305827137178312e-10
of O 0 8.882589952463604e-08
Ashkenazi O 0 1.1869687114085536e-05
descent O 0 2.4194565412472002e-05
. O 0 1.6556036825932097e-06

Four O 0 7.85476640885463e-06
patients O 0 2.405454608833679e-07
had O 0 1.6026109506128705e-07
a O 0 2.617418886075029e-07
germ O 0 0.0016756791155785322
- O 0 7.320044824155048e-05
line O 0 2.9098002869432094e-06
E1317Q O 0 1.1605948202486616e-05
missense O 0 3.3869828257593326e-06
variant O 0 1.037604775433465e-07
of O 0 1.893700130040088e-07
APC O 0 1.5503171368891344e-07
that O 0 1.1896412743794826e-09
was O 0 5.361770760714535e-08
not O 0 4.6117304419723837e-10
present O 0 6.952527442649625e-09
in O 0 1.4121636304764706e-08
controls O 0 5.2776677250676585e-08
; O 0 2.802362786269441e-10
one O 0 2.754320660436349e-10
of O 0 1.9731616340834535e-09
these O 0 3.315748786647532e-10
individuals O 0 6.987993517171276e-10
had O 0 3.962670191981488e-09
an O 0 1.525695347837086e-09
unusually O 0 6.605309632590206e-09
large O 0 7.615635899682616e-10
number O 0 1.5297981770245883e-09
of O 0 4.283509724700707e-08
metaplastic B-Disease 0 0.00015534811245743185
polyps I-Disease 0 1.3314576108314213e-06
of I-Disease 0 2.934721408109908e-07
the I-Disease 0 1.7153915905510075e-06
colorectum I-Disease 0 0.0005651700776070356
. O 0 1.8848405716198613e-06

There O 0 3.909497650056437e-07
is O 0 4.0473908669014236e-09
increasing O 0 2.6390376550722294e-09
evidence O 0 9.716576876428462e-09
that O 0 1.1972778324320643e-10
there O 0 4.6205791970344023e-10
exist O 0 1.159612939005683e-08
germ O 0 2.4049370495049516e-06
- O 0 7.991971529008879e-08
line O 0 1.1811678746198595e-08
variants O 0 1.6521670698210755e-09
of O 0 1.9717094623672438e-09
the O 0 2.1639806391249294e-08
APC B-Disease 0 3.5920965046898345e-07
gene O 0 1.6246364253902357e-09
that O 0 6.287191600673481e-11
predispose O 0 1.1633789931408955e-08
to O 0 2.378688357396186e-10
the O 0 1.8648302901880243e-09
development O 0 1.3014889077567204e-07
of O 0 7.915902529020968e-07
multiple O 1 0.9999865293502808
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9999991655349731
carcinoma I-Disease 1 1.0
, O 0 5.156568505526593e-09
but O 0 2.5994650876270953e-10
without O 0 8.542783702658596e-10
the O 0 4.091469829603511e-09
florid O 0 3.5074137372248515e-07
phenotype O 0 2.6969113164909686e-08
of O 0 1.1680882927578295e-08
classical O 0 3.7013958262832602e-06
FAP B-Disease 0 7.489211384381633e-07
, O 0 7.183119099529733e-10
and O 0 1.6114454215454543e-10
possibly O 0 6.346741798779476e-09
with O 0 2.45885312111227e-10
importance O 0 6.190781277837232e-06
for O 1 0.7266298532485962
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 1 0.9997050166130066
in O 0 1.0112587212063318e-08
the O 0 5.475847775215925e-09
general O 0 6.189794454769526e-09
population O 0 2.1677749872939245e-10
. O 0 5.208431463898933e-10
. O 0 1.266357685381081e-08

Genomic O 0 8.62320484884549e-06
structure O 0 5.455021891975775e-07
of O 0 2.8935079399161623e-07
the O 0 1.368290099890146e-06
human O 1 0.909853458404541
congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 1.0
CLD B-Disease 1 1.0
) O 0 3.0871383387420792e-06
gene O 0 3.469226612651255e-07
. O 0 1.42185342610901e-07

Congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9999996423721313
CLD B-Disease 1 1.0
) O 0 6.791603937017499e-07
is O 0 6.938960961377916e-09
caused O 0 2.56591174974119e-08
by O 0 5.269306768695969e-09
mutations O 0 7.536567814270256e-09
in O 0 7.731969731139543e-09
a O 0 8.066876233669973e-08
gene O 0 7.359611142732092e-09
which O 0 1.8174322047315172e-09
encodes O 0 4.8907459415659105e-08
an O 0 5.260007984730919e-09
intestinal O 0 1.9174881344952155e-06
anion O 0 0.0001627582823857665
transporter O 0 0.0028522643260657787
. O 0 1.3611318081530044e-06

We O 0 4.775370143761393e-07
report O 0 1.4005787818405224e-07
here O 0 1.2396442095052862e-08
the O 0 3.93615406935055e-09
complete O 0 2.367844764705751e-08
genomic O 0 6.454072831729718e-08
organization O 0 1.1677229849738069e-08
of O 0 6.385209871950792e-08
the O 0 4.2953729462169576e-07
human O 0 3.2840225685504265e-06
CLD B-Disease 1 0.9999850988388062
gene O 0 4.392540375874887e-08
which O 0 1.3775097729151753e-09
spans O 0 4.5513264268493003e-08
approximately O 0 6.518277473333001e-09
39kb O 0 4.293149231671123e-07
, O 0 2.305012403169826e-09
and O 0 1.926736548085728e-09
comprises O 0 9.024052616268818e-08
21 O 0 1.262428668269422e-06
exons O 0 1.9611470634117723e-06
. O 0 1.743919710861519e-07

All O 0 2.4336172828043345e-06
exon O 0 2.2169559088069946e-05
/ O 0 2.6720431378635112e-06
intron O 0 2.2686622287437785e-06
boundaries O 0 5.057480478853904e-08
conform O 0 6.18208062519443e-08
to O 0 1.060522070162051e-08
the O 0 3.6483052667790616e-07
GT O 0 4.4753312977263704e-05
/ O 0 3.2509418815607205e-05
AG O 0 0.00020274864800740033
rule O 0 2.188795633628615e-06
. O 0 6.296386345638894e-07

An O 0 9.463730066272547e-08
analysis O 0 1.1027205459868128e-07
of O 0 3.053990482726476e-08
the O 0 1.5716794621312147e-07
putative O 0 9.380285519000608e-06
promoter O 0 4.698328211816261e-06
region O 0 2.0415704682363867e-07
sequence O 0 1.0717999430198688e-06
shows O 0 3.4952125815834734e-07
a O 0 5.939287461842468e-07
putative O 0 2.952390605059918e-05
TATA O 0 5.0642978749237955e-05
box O 0 4.5139097437640885e-07
and O 0 6.969601340500731e-09
predicts O 0 1.6152233683897066e-07
multiple O 0 7.701799376036433e-08
transcription O 0 6.117315479059471e-06
factor O 0 1.0432286501327326e-07
binding O 0 1.4213892285397378e-08
sites O 0 5.816085391074921e-08
. O 0 6.530375173952052e-08

The O 0 7.017932830422069e-07
genomic O 0 4.115782985536498e-07
structure O 0 2.137106491773011e-07
was O 0 1.0968114594334111e-07
determined O 0 1.6781729783588162e-08
using O 0 2.2910344732451904e-09
DNA O 0 3.6592127106160888e-09
from O 0 3.980545337789465e-10
several O 0 2.145525423991046e-10
sources O 0 1.939634675096613e-09
including O 0 1.1540293720635475e-10
multiple O 0 9.023528591001195e-10
large O 0 9.315779259111423e-09
- O 0 1.7167371879622806e-07
insert O 0 4.951068035552453e-07
libaries O 0 4.211523901176406e-06
and O 0 3.3519442776963615e-09
genomic O 0 5.5924751052316424e-08
DNA O 0 3.667641479410122e-08
from O 0 1.4840504825031076e-08
Finnish O 0 0.002907773246988654
CLD B-Disease 1 0.9999998807907104
patients O 0 2.653849833222921e-07
and O 0 2.3755349687348826e-08
controls O 0 2.9270796630953555e-07
. O 0 2.1220209589500882e-07

Exon O 0 1.8858183466363698e-05
- O 0 8.412610696950651e-08
specific O 0 2.1045178932865838e-09
primers O 0 4.494939886967586e-08
developed O 0 1.9929431438470147e-09
in O 0 4.078907211990668e-10
this O 0 8.635273052171044e-11
study O 0 3.240379076174804e-10
will O 0 1.2025021603467856e-11
facilitate O 0 3.391079084202886e-10
mutation O 0 3.975596241101442e-11
screening O 0 8.253235594946062e-11
studies O 0 5.683919446219932e-10
of O 0 4.826373745103751e-10
patients O 0 1.5071319192649923e-10
with O 0 7.252085043596423e-11
the O 0 5.438824928205577e-07
disease O 0 0.00514610530808568
. O 0 1.5577658984966547e-07

Genomic O 0 2.730159621933126e-06
sequencing O 0 1.705331129642218e-07
of O 0 3.107336965513241e-07
a O 0 1.6694910982550937e-06
BAC O 0 0.08741705119609833
clone O 0 0.0004683925653807819
H O 1 1.0
_ O 0 7.330278606332286e-08
RG364P16 O 0 9.257319106836803e-07
revealed O 0 1.8533359025241225e-07
the O 0 1.646203706684446e-08
presence O 0 5.489966259375478e-09
of O 0 1.1217722750700432e-08
another O 0 1.5798388375287686e-08
, O 0 1.0287459772939656e-09
highly O 0 8.357525338453797e-09
homologous O 0 3.103545509475225e-08
gene O 0 1.88579774018649e-09
3 O 0 7.4879231704017e-09
of O 0 1.4485226351723668e-08
the O 0 4.874597721027385e-07
CLD B-Disease 1 0.999972939491272
gene O 0 3.2391898940886676e-08
, O 0 3.3336947091733293e-10
with O 0 1.0806729122680991e-10
a O 0 2.4687651922761233e-09
similar O 0 8.530490203106922e-10
genomic O 0 3.3087964368405665e-08
structure O 0 2.2725095050191157e-07
, O 0 2.764058315563034e-09
recently O 0 4.278902121512829e-09
identified O 0 4.8221617809929285e-09
as O 0 7.64821717069708e-09
the O 0 1.8622100697029964e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 1.5735031411168166e-06
( O 0 4.572945613290358e-07
PDS B-Disease 0 6.6173688537674025e-06
) O 0 2.0149975021865885e-09
. O 0 1.6736297903108266e-09
. O 0 3.935045000957871e-08

The O 0 3.4174686334154103e-06
APCI1307K O 0 0.0004108463763259351
allele O 0 1.7632351045904215e-07
and O 0 2.587482228477711e-08
cancer B-Disease 0 2.409385842838674e-06
risk O 0 5.685843689207104e-07
in O 0 1.3893078687488014e-08
a O 0 1.1491680851349884e-07
community O 0 2.3263011517116183e-09
- O 0 2.2873059002392893e-09
based O 0 1.36153144314477e-09
study O 0 1.0949340989441225e-08
of O 0 1.8169687976410387e-08
Ashkenazi O 0 9.840541679295711e-07
Jews O 0 4.5212854615783726e-07
. O 0 1.5545455767096428e-07

Mutations O 0 1.3511912584363017e-06
in O 0 6.496905768926808e-08
APC O 0 7.701805770921055e-07
are O 0 1.2465716237031188e-09
classically O 0 2.6377213089290308e-06
associated O 0 1.1688081258398597e-06
with O 0 5.5781529226806015e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.9999779462814331
FAP B-Disease 0 0.00016659540415275842
) O 0 2.899538387168832e-09
, O 0 2.3178846342286619e-10
a O 0 6.507693495194644e-09
highly O 0 2.532520920794923e-05
penetrant O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.9981189370155334
by O 0 1.5399390349557507e-06
multiple O 0 0.17068786919116974
intestinal O 1 0.9999996423721313
polyps B-Disease 0 1.4672996258013882e-05
and O 0 2.655788300387485e-08
, O 0 1.1905772367981626e-08
without O 0 3.1949133472153335e-07
surgical O 1 0.9447832703590393
intervention O 0 0.04428248107433319
, O 0 1.981157460306804e-08
the O 0 2.136258672180702e-07
development O 1 0.9827893376350403
of O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 1 0.9999998807907104
CRC B-Disease 1 0.9999961853027344
) O 0 3.069530691846012e-07
. O 0 1.621948797492223e-07

APC B-Disease 0 0.0001433916186215356
is O 0 3.7902921690147195e-07
a O 0 1.2783480087819044e-06
tumour O 1 1.0
- O 0 0.00010981706873280928
suppressor O 0 5.99663917455473e-06
gene O 0 7.767119392099175e-09
, O 0 2.494541795350358e-10
and O 0 5.005747483188827e-10
somatic O 0 1.9094775893790938e-07
loss O 0 4.161906872468535e-06
occurs O 0 4.243088085331692e-07
in O 0 2.5318383904959774e-06
tumours B-Disease 1 1.0
. O 0 1.0014113286160864e-05

The O 0 4.801358500117203e-06
germline O 0 1.5361019904958084e-05
T O 0 1.8500668375054374e-06
- O 0 6.919285056028457e-08
to O 0 1.3621763272908538e-08
- O 0 2.109611330070038e-07
A O 0 3.5052872249252687e-07
transversion O 0 8.784110150372726e-07
responsible O 0 2.4730177017318056e-08
for O 0 1.7024907039697723e-09
the O 0 3.9432947573914134e-08
APC O 0 2.294609373620915e-07
I1307K O 0 1.1158105905906268e-07
allele O 0 1.514255498769046e-09
converts O 0 3.210921528662425e-10
the O 0 2.805100596248167e-10
wild O 0 1.0480262213619085e-09
- O 0 3.2601754629268953e-09
type O 0 4.749583393248713e-09
sequence O 0 1.6273105529762688e-08
to O 0 4.202949099862963e-09
a O 0 1.218827634374975e-07
homopolymer O 0 0.0002485216245986521
tract O 0 0.00200263736769557
( O 0 1.1312509968774975e-06
A8 O 0 1.8855304006137885e-05
) O 0 7.682278702070278e-10
that O 0 2.996882256245392e-11
is O 0 1.7422184528381734e-10
genetically O 0 1.286281969825609e-09
unstable O 0 7.540604656242067e-07
and O 0 1.5512572559828186e-08
prone O 0 7.102960921656631e-07
to O 0 1.875875987877862e-08
somatic O 0 1.7959036995307542e-06
mutation O 0 6.510303052209565e-08
. O 0 8.503808146542724e-08

The O 0 4.546369382296689e-06
I1307K O 0 3.235231270082295e-05
allele O 0 2.547348003645311e-07
was O 0 3.3558487189111474e-07
found O 0 4.039425860469237e-08
in O 0 4.8606985103560874e-08
6 O 0 2.972901029352215e-06
. O 0 7.648008022442809e-07

1 O 0 2.272072379128076e-06
% O 0 4.084796856318462e-08
of O 0 3.6714698836703974e-08
unselected O 0 0.001123298890888691
Ashkenazi O 0 5.651748324453365e-06
Jews O 0 8.906068416081325e-08
and O 0 1.1980848535486643e-09
higher O 0 2.774528340410143e-08
proportions O 0 4.583087687137777e-08
of O 0 1.9044180987748405e-07
Ashkenazim O 0 4.584434918797342e-06
with O 0 1.8731407536165534e-08
family O 0 9.987197699956596e-07
or O 0 1.1123363208298542e-07
personal O 0 6.918505732755875e-06
histories O 0 9.750722711032722e-06
of O 0 0.00010354913683841005
CRC B-Disease 0 0.19631943106651306
( O 0 7.988052175278426e-07
ref O 0 1.295737888540316e-06
. O 0 5.006113301675441e-09
2 O 0 1.1772996799663815e-07
) O 0 3.789019231703605e-08
. O 0 1.241080695990604e-07

To O 0 1.4822998650743102e-07
evaluate O 0 6.901200890752079e-07
the O 0 1.3382232566527819e-07
role O 0 4.892528409072838e-07
of O 0 4.416984609179053e-07
I1307K O 0 1.4701542568218429e-05
in O 0 1.1205965222416125e-07
cancer B-Disease 0 2.832043435319065e-07
, O 0 5.1459374539319924e-09
we O 0 6.565645094269712e-08
genotyped O 0 1.5222903130052146e-05
5 O 0 5.586733209383965e-07
, O 0 1.7952970665646717e-08
081 O 0 4.23685742134694e-05
Ashkenazi O 0 4.882255097982124e-07
volunteers O 0 8.346553670435242e-08
in O 0 1.3927436093297274e-08
a O 0 5.405792435908552e-08
community O 0 2.8933632378880247e-08
survey O 0 6.016799147801066e-07
. O 0 1.019167257254594e-07

Risk O 0 2.2980369976721704e-05
of O 0 1.2400046216498595e-06
developing O 0 0.0694926455616951
colorectal B-Disease 1 1.0
, I-Disease 0 6.9088396230654325e-06
breast I-Disease 0 0.1440291553735733
and I-Disease 0 9.328530836683058e-08
other I-Disease 0 7.586904438028341e-09
cancers I-Disease 0 8.890656317817047e-06
were O 0 5.4819327743871327e-08
compared O 0 5.0775071258613025e-08
between O 0 1.8390458933481568e-08
genotyped O 0 8.455221518488543e-07
I1307K O 0 2.508548959667678e-07
carriers O 0 6.223043746977908e-10
and O 0 5.420242032982969e-10
non O 0 6.926838125309587e-08
- O 0 8.012286656366996e-08
carriers O 0 2.2948218880713966e-09
and O 0 1.0735078381785002e-09
their O 0 3.105634194255913e-09
first O 0 1.0081181756049773e-07
- O 0 1.681483325910449e-07
degree O 0 1.2871393664681818e-05
relatives O 0 7.948005986690987e-07
. O 0 8.622563285598517e-08

Sperm O 0 3.2895018193812575e-06
DNA O 0 1.4792468050472962e-07
analysis O 0 2.6859204638185474e-08
in O 0 9.823746260906319e-09
a O 0 3.261160372858285e-07
Friedreich B-Disease 1 0.7276240587234497
ataxia I-Disease 1 0.9929361939430237
premutation O 0 0.028298215940594673
carrier O 0 1.0610925755827338e-06
suggests O 0 2.2356394424605242e-07
both O 0 1.0096166569439902e-08
meiotic O 0 4.119020559301134e-06
and O 0 6.041096156650383e-08
mitotic O 0 3.1015863442007685e-06
expansion O 0 3.035951863239461e-07
in O 0 5.0489695979649696e-08
the O 0 3.1726875704407576e-07
FRDA B-Disease 0 0.009102589450776577
gene O 0 2.750056410150137e-06
. O 0 2.8330646273388993e-07

Friedreich B-Disease 1 1.0
ataxia I-Disease 1 1.0
is O 0 2.7226401471125428e-06
usually O 0 1.8076877950079506e-07
caused O 0 1.1763187757196647e-07
by O 0 4.02743793870286e-09
an O 0 6.993704282365343e-09
expansion O 0 1.9259186956332996e-07
of O 0 1.0224806601399905e-06
a O 0 1.8088794604409486e-06
GAA O 0 5.296637027640827e-05
trinucleotide O 0 9.103521733777598e-06
repeat O 0 3.762327764889051e-07
in O 0 3.943445037180027e-08
intron O 0 1.7834100844993372e-06
1 O 0 4.8971497079719484e-08
of O 0 4.278838972027188e-08
the O 0 2.612264324852731e-07
FRDA B-Disease 0 0.00512892659753561
gene O 0 1.3979754385218257e-06
. O 0 2.7476920649860404e-07

Occasionally O 0 2.74889862339478e-05
, O 0 5.419627058245169e-08
a O 0 6.609647584809863e-08
fully O 0 1.7966847565276112e-07
expanded O 0 7.06322822452421e-08
allele O 0 1.8500296405932204e-08
has O 0 6.915241157479102e-10
been O 0 4.5882259103180445e-10
found O 0 4.6553272348148766e-10
to O 0 2.5406149406492773e-10
arise O 0 2.497567486159369e-08
from O 0 2.6853006929172807e-08
a O 0 9.959988744867587e-08
premutation O 0 4.085251930519007e-06
of O 0 5.231435693531239e-07
100 O 0 4.942124292028893e-07
or O 0 2.0798577082814518e-08
less O 0 2.7229408061657523e-08
triplet O 0 5.804299689771142e-06
repeats O 0 2.1926125555182807e-06
. O 0 4.477091124499566e-07

We O 0 5.436252763502125e-07
have O 0 4.827867439161082e-09
examined O 0 4.336929393389255e-08
the O 0 9.877877182873362e-09
sperm O 0 6.194450463681278e-08
DNA O 0 2.5045560292369373e-08
of O 0 1.7000187924054444e-08
a O 0 7.927917522465577e-08
premutation O 0 1.724663161439821e-05
carrier O 0 7.898814828877221e-07
. O 0 5.544255827771849e-07

This O 0 6.153964022814762e-07
mans O 0 4.7080256990739144e-06
leucocyte O 0 3.340896000736393e-06
DNA O 0 2.347676115732611e-07
showed O 0 1.5391059093872173e-08
one O 0 2.8834068466210283e-09
normal O 0 9.233415809717371e-09
allele O 0 4.927689367661969e-10
and O 0 1.333615856635717e-10
one O 0 7.246461208865185e-10
allele O 0 1.7086878578709275e-09
of O 0 9.5791552467972e-09
approximately O 0 7.300183568759167e-08
100 O 0 2.47133243647113e-07
repeats O 0 1.4644550105913368e-07
. O 0 9.08881219174873e-08

His O 0 3.0676801543449983e-06
sperm O 0 8.134175573104585e-07
showed O 0 2.885262340157624e-08
an O 0 6.227804938419013e-10
expanded O 0 1.7860470880037838e-09
allele O 0 1.1870348037845702e-09
in O 0 9.873728501474943e-10
a O 0 1.4700152206614803e-08
tight O 0 1.0518941451209685e-07
range O 0 7.268907609159214e-08
centering O 0 5.020315256842878e-07
on O 0 6.199423641106705e-09
a O 0 2.223263351197602e-09
size O 0 1.0258401905716141e-09
of O 0 3.500327139249748e-09
approximately O 0 4.164806099993257e-08
320 O 0 2.3177150865194562e-07
trinucleotide O 0 9.62737794907298e-06
repeats O 0 2.4471644337609177e-06
. O 0 5.934474529567524e-07

His O 0 5.397921268013306e-05
affected O 0 8.153303497238085e-06
son O 0 5.0880073104053736e-05
has O 0 5.78325405342639e-08
repeat O 0 1.3823117228639603e-07
sizes O 0 5.6743814980109164e-08
of O 0 4.6962847477516334e-07
1040 O 0 3.712078751050285e-06
and O 0 1.0524721005822357e-07
540 O 0 8.944163710111752e-06
. O 0 4.41955052110643e-07

These O 0 8.520465399897148e-08
data O 0 1.458308958035559e-07
suggest O 0 5.169596750675964e-09
that O 0 1.4565167127944534e-10
expansion O 0 7.349609365547849e-09
occurs O 0 4.5718748786782726e-09
in O 0 1.4438134021688143e-09
two O 0 1.0424479057746794e-09
stages O 0 3.092507228075192e-08
, O 0 2.434290324870858e-09
the O 0 1.1833326318821946e-08
first O 0 2.3607288568427975e-08
during O 0 8.544405005750377e-08
meiosis O 0 2.978160296152055e-07
followed O 0 5.103285261043311e-08
by O 0 8.28365021021682e-09
a O 0 4.2227259910987414e-08
second O 0 1.41835656108924e-07
mitotic O 0 1.988638132388587e-06
expansion O 0 1.4933232250768924e-06
. O 0 4.402723163821065e-07

We O 0 1.2780384395227884e-06
also O 0 1.4318161767334914e-08
show O 0 7.694498371790814e-09
that O 0 1.7258533491215644e-10
in O 0 6.004686192717656e-10
all O 0 8.861344436006391e-10
informative O 0 8.217011071565139e-08
carrier O 0 9.019180069458343e-09
father O 0 2.0644515430490173e-08
to O 0 1.580663822053907e-09
affected O 0 6.5523568792968945e-09
child O 0 3.968586526070794e-08
transmissions O 0 6.030999344375232e-08
, O 0 2.1866115862412272e-10
with O 0 6.545767400334412e-11
the O 0 3.750206367669762e-09
notable O 0 2.1334404465278567e-08
exception O 0 1.976741081932687e-08
of O 0 3.3380118225068145e-08
the O 0 1.0752341950137634e-07
premutation O 0 5.43854184797965e-06
carrier O 0 1.0839092112746584e-07
, O 0 3.77657105588014e-09
the O 0 8.961785091798902e-09
expansion O 0 4.315311130653754e-08
size O 0 4.6135212983244855e-08
decreases O 0 1.5471563585833792e-07
. O 0 7.600751139591466e-09
. O 0 6.228594884305494e-08

The O 0 1.5325930462495307e-06
R496H O 0 1.8693966922000982e-05
mutation O 0 9.264060452096601e-08
of O 0 1.5277059617346822e-07
arylsulfatase O 0 0.00019491104467306286
A O 0 2.8909009415656328e-05
does O 0 2.3517314318155513e-08
not O 0 6.02631899937478e-08
cause O 0 3.247961649321951e-05
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
. O 0 5.000970759283518e-06

Deficiency B-Disease 1 1.0
of I-Disease 0 0.00034364641760475934
arylsulfatase I-Disease 1 0.9742192029953003
A I-Disease 0 0.017107071354985237
( O 0 6.956522156542633e-06
ARSA O 1 0.961139440536499
) O 0 6.231233129483371e-08
enzyme O 0 1.5721592205864e-07
activity O 0 1.3938220035925042e-06
causes O 0 4.831909336644458e-06
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 0.0018274072790518403
MLD B-Disease 1 1.0
) O 0 1.0535320598137332e-06
. O 0 1.2246520952885476e-07

A O 0 1.7814603552324115e-06
number O 0 1.4070231202367722e-08
of O 0 1.9546065743725194e-07
ARSA O 0 0.012620908208191395
gene O 0 6.799238150279052e-08
mutations O 0 7.559588510730464e-09
responsible O 0 5.549832238216368e-08
for O 0 3.8659410961372487e-07
MLD B-Disease 1 1.0
have O 0 3.939119608276087e-07
been O 0 1.7719739275889879e-07
identified O 0 6.608128160223714e-07
. O 0 2.745355516253767e-07

Recently O 0 4.702039859694196e-06
, O 0 1.1146487288726803e-08
the O 0 1.5954002563489666e-08
R496H O 0 2.264879185531754e-06
mutation O 0 5.855075713157021e-08
of O 0 7.121056455616781e-07
ARSA O 0 0.3419342637062073
was O 0 7.578199756608228e-07
proposed O 0 1.2513510228018276e-08
to O 0 2.5232980149780815e-09
be O 0 3.265913539607368e-09
a O 0 3.096680600833679e-08
cause O 0 2.2270423016834684e-07
of O 0 2.0273622794775292e-05
MLD B-Disease 1 1.0
( O 0 5.9136709751328453e-05
Draghia O 0 0.0016128555871546268
et O 0 2.0434226826182567e-05
al O 0 2.865540864149807e-06
. O 0 2.7753845888156548e-09
, O 0 1.7774491878341792e-09
1997 O 0 6.363447369039932e-08
) O 0 1.903251778401227e-08
. O 0 4.1388165783473596e-08

We O 0 5.225382437856751e-07
have O 0 4.8671902064256756e-09
investigated O 0 1.1355978557503477e-07
the O 0 3.3305838087471784e-08
R496H O 0 8.730159493097744e-07
mutation O 0 1.1317198289617636e-09
and O 0 1.3034633095099224e-10
found O 0 5.863418084395278e-10
this O 0 6.741522340369954e-10
mutation O 0 6.390077911255787e-10
at O 0 8.497171855026409e-09
a O 0 2.1804278382830944e-09
relatively O 0 9.764914432608407e-10
high O 0 9.708718273770955e-10
frequency O 0 5.695607319111673e-10
in O 0 1.3795625752877072e-10
an O 0 3.663205572213002e-10
African O 0 1.7349602865479596e-09
American O 0 1.496282764357204e-09
population O 0 2.756505614043281e-11
( O 0 4.962150135234822e-11
f O 0 1.4472155696054756e-09
= O 0 1.8436564497292807e-09
0 O 0 1.3267781318049288e-10
. O 0 2.393984663284776e-11
09 O 0 7.680641900265073e-09
, O 0 2.4821544819531027e-10
n O 0 1.711373087687207e-08
= O 0 6.17604598573962e-08
61 O 0 1.536893989850796e-08
subjects O 0 1.4897486266818305e-07
) O 0 2.4451527025348696e-08
. O 0 4.7295447558326487e-08

The O 0 1.6311647414113395e-05
ARSA O 0 0.18055325746536255
enzyme O 0 9.175866466648586e-07
activity O 0 2.9474861662492913e-07
in O 0 2.2751140971166706e-09
subjects O 0 4.430513911302114e-08
with O 0 5.778076905826879e-10
and O 0 2.3373309954166643e-09
without O 0 2.9192394279675682e-08
the O 0 1.0578718701026446e-07
R496H O 0 1.422837158315815e-06
mutation O 0 3.088703737219589e-09
was O 0 1.274511429727454e-08
determined O 0 1.2581430119951165e-08
and O 0 1.5889310978067783e-09
found O 0 5.645382383789865e-09
to O 0 1.4449457186316295e-09
be O 0 1.929149817669895e-08
normal O 0 1.2700121487796423e-06
. O 0 3.389734786196641e-07

It O 0 1.1817992628948559e-07
is O 0 4.412523235686194e-09
therefore O 0 6.442619771007685e-09
concluded O 0 5.7335437730898775e-08
that O 0 8.458667100086359e-10
the O 0 1.152024875494817e-08
R496H O 0 2.3320210402744124e-06
mutation O 0 1.9299484677048895e-08
of O 0 1.5210578396818164e-07
ARSA O 0 0.0021838797256350517
does O 0 5.163645067085554e-09
not O 0 1.928652126892416e-09
negatively O 0 2.745134786152903e-08
influence O 0 2.15256967805999e-08
the O 0 1.6015283321735296e-08
activity O 0 9.538534868624993e-07
of O 0 1.7976719846046763e-07
ARSA O 0 0.004208818078041077
and O 0 6.133372032479656e-09
is O 0 8.16858136687415e-09
not O 0 3.6388132507170212e-09
a O 0 1.494423003123302e-07
cause O 0 2.1081805243738927e-06
of O 0 5.6095930631272495e-05
MLD B-Disease 1 1.0

Down O 0 0.00015041227743495256
- O 0 2.546945324866101e-06
regulation O 0 2.3291620721010986e-07
of O 0 2.5249605073440762e-08
transmembrane O 0 6.7581559051177464e-06
carbonic O 0 0.0001613639760762453
anhydrases O 0 0.07709038257598877
in O 0 6.49100766167976e-05
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999996423721313
lines O 0 4.062343350597075e-07
by O 0 2.1892386570243616e-08
wild O 0 6.701324082314386e-07
- O 0 2.5253082185372477e-06
type O 0 1.5171958693827037e-05
von B-Disease 1 0.9999821186065674
Hippel I-Disease 1 0.9999997615814209
- I-Disease 1 0.9983081817626953
Lindau I-Disease 1 0.9990253448486328
transgenes O 0 0.000564564426895231
. O 0 2.113168420692091e-06

To O 0 7.655093554603809e-07
discover O 0 4.2534779822744895e-06
genes O 0 1.203194983645517e-07
involved O 0 1.1383432507727775e-07
in O 0 1.4055041219762643e-07
von B-Disease 1 0.9999284744262695
Hippel I-Disease 1 1.0
- I-Disease 1 0.9999996423721313
Lindau I-Disease 1 0.9999994039535522
( O 0 1.4321433809527662e-05
VHL B-Disease 0 0.001193273114040494
) O 0 1.4529504710480978e-07
- O 0 2.0632538166864833e-07
mediated O 0 8.700869784661336e-07
carcinogenesis O 0 0.0005521819111891091
, O 0 6.114111439359249e-09
we O 0 1.4322641739283881e-08
used O 0 2.0692357338703005e-06
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999998807907104
lines O 0 1.6205762221943587e-05
stably O 0 8.595859253546223e-05
transfected O 0 7.065585577947786e-06
with O 0 6.647371098011945e-09
wild O 0 2.3705341334334662e-07
- O 0 3.4709546525846235e-06
type O 0 1.1761760106310248e-05
VHL O 1 0.9927115440368652
- O 0 1.4053022823645733e-05
expressing O 0 6.091462978474738e-07
transgenes O 0 3.166243914165534e-05
. O 0 2.94733155214999e-07

Large O 0 1.229285203407926e-06
- O 0 4.308263044094929e-07
scale O 0 7.208433316918672e-07
RNA O 0 9.569987469149055e-07
differential O 0 5.24130321366556e-08
display O 0 1.2393652326636584e-08
technology O 0 1.1728685933576344e-07
applied O 0 8.262427186878085e-09
to O 0 9.688702062859988e-10
these O 0 2.060803749870388e-09
cell O 0 2.2917663500265917e-07
lines O 0 4.0689944746929996e-09
identified O 0 1.6137068348243133e-09
several O 0 1.1199027122321681e-10
differentially O 0 2.2009617239859836e-08
expressed O 0 6.168364707903606e-10
genes O 0 9.857094029896984e-10
, O 0 7.264765872205814e-11
including O 0 9.818435647845902e-11
an O 0 4.100000339235521e-09
alpha O 0 4.373538615709549e-07
carbonic O 0 1.4484042367257643e-05
anhydrase O 0 7.771072705509141e-05
gene O 0 6.714361688864301e-08
, O 0 6.738992919252951e-09
termed O 0 1.263428316633508e-06
CA12 O 0 0.0017408179119229317
. O 0 2.520693442420452e-06

The O 0 1.4613510757044423e-06
deduced O 0 7.795923920639325e-06
protein O 0 1.5820437226921058e-07
sequence O 0 1.134387659362801e-07
was O 0 1.825904689667368e-07
classified O 0 9.639072118261538e-08
as O 0 5.9885394421144156e-09
a O 0 2.7580874473187578e-08
one O 0 1.3961001243956161e-08
- O 0 1.2050828956944315e-07
pass O 0 9.228259756355328e-08
transmembrane O 0 4.2276627937098965e-05
CA O 0 9.81643552222522e-06
possessing O 0 8.585988098275266e-07
an O 0 1.427263214281993e-07
apparently O 0 2.303410838067066e-06
intact O 0 3.902928438037634e-05
catalytic O 0 8.548021241949755e-07
domain O 0 1.1272909432591405e-06
in O 0 2.170909496612694e-08
the O 0 2.5413160642528965e-07
extracellular O 0 0.002589515643194318
CA O 0 0.30194494128227234
module O 0 0.0894559770822525
. O 0 2.984860884680529e-06

Reintroduced O 0 2.2065828488848638e-06
wild O 0 4.1068162204283e-07
- O 0 1.0460694284120109e-06
type O 0 8.388597620978544e-07
VHL B-Disease 0 0.0005958782276138663
strongly O 0 7.318167405401255e-08
inhibited O 0 1.7058792423085833e-07
the O 0 5.165516459015862e-09
overexpression O 0 2.7726981599585088e-08
of O 0 2.640120122521239e-09
the O 0 7.798083956345181e-09
CA12 O 0 8.772441105975304e-06
gene O 0 3.0273572537709015e-09
in O 0 5.505209621503582e-10
the O 0 2.3567515938793804e-08
parental O 0 2.8009233574266545e-05
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999992847442627
lines O 0 1.7464924894738942e-05
. O 0 1.037146262206079e-06

Similar O 0 1.8097441056852404e-07
results O 0 4.9810850555331854e-08
were O 0 2.2101829699749942e-08
obtained O 0 1.1127904286922785e-07
with O 0 9.123632516150337e-09
CA9 O 0 0.015367922373116016
, O 0 1.1897236085189888e-08
encoding O 0 2.562043377452028e-08
another O 0 1.0772767211619794e-07
transmembrane O 0 1.9186358258593827e-05
CA O 0 2.2965016341913724e-06
with O 0 2.1349049195151792e-09
an O 0 1.0087182289453267e-07
intact O 0 0.00023547143791802227
catalytic O 0 1.2298127330723219e-05
domain O 0 4.755758345709182e-05
. O 0 3.9328847378783394e-07

Although O 0 2.129152250063271e-07
both O 0 2.1131345562253046e-08
domains O 0 1.9421052854795562e-07
of O 0 7.084019415515286e-08
the O 0 1.7835058940818271e-07
VHL B-Disease 0 0.00011175075633218512
protein O 0 4.357750427175233e-08
contribute O 0 1.1742172789652727e-09
to O 0 3.97640226301732e-10
regulation O 0 1.0242647618952105e-08
of O 0 3.650863078519251e-08
CA12 O 0 0.00033125237678177655
expression O 0 4.8385729201072536e-08
, O 0 9.37958599678268e-10
the O 0 9.568088543687736e-09
elongin O 0 1.2502450772444718e-06
binding O 0 2.7804672342313097e-08
domain O 0 3.647766106951167e-07
alone O 0 1.444582675702577e-08
could O 0 1.4933289049778864e-09
effectively O 0 1.2675423022301402e-07
regulate O 0 1.0456644758960465e-06
CA9 O 1 0.9927541613578796
expression O 0 2.3479992705688346e-06
. O 0 2.858660366200638e-07

We O 0 2.8584768188011367e-06
mapped O 0 1.1003722647728864e-05
CA12 O 0 0.002125686267390847
and O 0 2.506636064936174e-06
CA9 O 1 0.9426189064979553
loci O 0 9.881373443931807e-07
to O 0 2.9781736188283503e-08
chromosome O 0 2.436559043417219e-07
bands O 0 3.273458730745915e-07
15q22 O 0 8.587096999690402e-06
and O 0 3.883574777319154e-07
17q21 O 0 0.0001492079463787377
. O 0 3.8133223370095948e-06

2 O 0 1.0650363719832967e-06
respectively O 0 2.067697550955927e-07
, O 0 1.8985413241523474e-09
regions O 0 3.874656595570514e-09
prone O 0 9.224986996514417e-08
to O 0 2.682545297005845e-09
amplification O 0 2.4563436795688176e-07
in O 0 8.883263014070053e-09
some O 0 1.2010919370197826e-08
human O 0 3.157917092266871e-07
cancers B-Disease 0 1.963901740964502e-05
. O 0 4.1497412439639447e-07

Additional O 0 1.1400011601381266e-07
experiments O 0 1.9369632298094075e-07
are O 0 1.0005029027482237e-09
needed O 0 6.8073200409912715e-09
to O 0 1.8343576657642302e-09
define O 0 2.1419948481593565e-08
the O 0 3.305383700080711e-08
role O 0 2.93384260885432e-07
of O 0 1.4256269196266658e-06
CA O 0 2.1075869881315157e-05
IX O 0 1.0121240848093294e-05
and O 0 5.012651271840696e-08
CA O 0 4.561909008771181e-06
XII O 0 1.016767964756582e-05
enzymes O 0 1.0861915811233303e-08
in O 0 1.4413754634290399e-09
the O 0 2.6797888352803056e-09
regulation O 0 1.5631165695140226e-08
of O 0 1.2628312617835036e-08
pH O 0 1.579408603902266e-07
in O 0 6.6325158698532505e-09
the O 0 4.5536534543089147e-08
extracellular O 0 1.5007291040092241e-05
microenvironment O 0 2.555315768404398e-05
and O 0 1.534807503311697e-09
its O 0 1.3705334644953382e-09
potential O 0 1.0243624615213776e-08
impact O 0 4.493636751590202e-08
on O 0 8.743443657976968e-08
cancer B-Disease 0 3.310221245556022e-06
cell O 0 6.744737220287789e-06
growth O 0 3.0518131666212867e-07
. O 0 9.229844266656073e-08

A O 0 5.646209956466919e-06
gene O 0 9.564881509049883e-08
encoding O 0 5.023179028285085e-08
a O 0 3.379073021392287e-08
transmembrane O 0 8.670221518514154e-07
protein O 0 1.636233548651944e-08
is O 0 1.7705727162198315e-10
mutated O 0 3.551434979431889e-10
in O 0 3.7046757328518254e-10
patients O 0 2.4419726241120543e-09
with O 0 3.6801222336180217e-07
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
( O 1 1.0
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 1.4432089301408269e-07
. O 0 5.410640824266011e-08

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0021687173284590244
WFS B-Disease 1 0.9999995231628418
; O 0 2.1563651841915998e-07
OMIM O 1 0.6926867365837097
222300 O 0 6.904881502123317e-06
) O 0 5.526948676504162e-09
is O 0 1.918430747593902e-09
an O 0 8.358725267498812e-08
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 1.0
defined O 0 6.008706805005204e-06
by O 0 4.520052598877555e-08
young O 0 1.2960418871443835e-06
- O 0 4.0692601032787934e-05
onset O 1 0.999996542930603
non O 1 0.9999996423721313
- O 1 0.5479152202606201
immune O 0 1.8501077647670172e-05
insulin B-Disease 0 0.07648656517267227
- I-Disease 0 0.2509317398071289
dependent I-Disease 1 0.9999938011169434
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 0.0029968866147100925
progressive O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 0.9999958276748657
. O 0 2.348397629248211e-06

Linkage O 0 0.0005316216265782714
to O 0 3.7342451264521515e-07
markers O 0 3.689649247462512e-06
on O 0 8.766886594457901e-07
chromosome O 0 5.7860611377691384e-06
4p O 0 0.24509917199611664
was O 0 6.13988640907337e-06
confirmed O 0 1.1996706916761468e-07
in O 0 1.8362802833848946e-08
five O 0 9.060166661356561e-08
families O 0 6.076481184891236e-08
. O 0 2.0645035192501382e-07

On O 0 7.157358936638047e-07
the O 0 2.9592726491500798e-08
basis O 0 1.6277924430596613e-07
of O 0 1.0804703265421267e-07
meiotic O 0 2.3104128558770753e-05
recombinants O 0 0.0020092937629669905
and O 0 4.051177882047341e-07
disease O 0 0.00016347560449503362
- O 0 4.330779574956978e-07
associated O 0 5.544763439502276e-07
haplotypes O 0 6.588023779841023e-07
, O 0 3.2617988310335022e-09
the O 0 1.3868196901967167e-07
WFS B-Disease 0 0.04507903754711151
gene O 0 2.383222863500123e-08
was O 0 7.986515981883713e-08
localized O 0 1.0196377786542143e-07
to O 0 2.099307216951729e-08
a O 0 1.2583250281750225e-06
BAC O 0 0.017293108627200127
/ O 0 3.399371780687943e-05
P1 O 0 0.00013382008182816207
contig O 0 5.153138317837147e-06
of O 0 2.6505761141493167e-08
less O 0 3.726597697095713e-09
than O 0 1.6715370199094082e-09
250 O 0 6.80001619457471e-08
kb O 0 1.1998679838143289e-05
. O 0 4.102029151908937e-07

Mutations O 0 8.204293067137769e-07
in O 0 1.4007786042213866e-08
a O 0 1.5398017083612103e-08
novel O 0 6.706567035053013e-08
gene O 0 1.627549650606852e-08
( O 0 8.779317717255708e-09
WFS1 O 0 1.2630533092305996e-05
) O 0 7.65017205139884e-09
encoding O 0 2.64352273404711e-08
a O 0 3.7355306403696886e-08
putative O 0 9.063983270607423e-07
transmembrane O 0 7.06855132648343e-07
protein O 0 2.0074184092777614e-08
were O 0 4.836457456747212e-09
found O 0 6.521332918119072e-10
in O 0 3.336945442189432e-10
all O 0 4.3239489766477845e-10
affected O 0 2.2703847690763723e-09
individuals O 0 9.137804402037375e-10
in O 0 9.481468943306481e-09
six O 0 2.7209271138417535e-06
WFS B-Disease 1 0.9999997615814209
families O 0 2.1527779558994098e-09
, O 0 7.999035461780934e-11
and O 0 2.947292410127034e-11
these O 0 5.143096712401096e-11
mutations O 0 2.438890200906485e-10
were O 0 3.290235417452436e-09
associated O 0 9.458908323267678e-09
with O 0 1.1618749296005149e-09
the O 0 1.5924231320241233e-06
disease O 0 3.501734317978844e-05
phenotype O 0 3.29389223452381e-07
. O 0 1.1209321826299856e-07

WFS1 O 0 0.0027382674161344767
appears O 0 5.250669232736982e-07
to O 0 4.30836788467559e-09
function O 0 2.7426697357668672e-08
in O 0 4.485320115321656e-09
survival O 0 3.37930714522372e-06
of O 0 1.8384484690159297e-07
islet O 0 6.499876235466218e-06
beta O 0 2.1499658942047972e-06
- O 0 1.1366098107146172e-07
cells O 0 3.903094736301682e-09
and O 0 1.2489682621463771e-09
neurons O 0 2.304047228562922e-07
. O 0 8.560012254577032e-09
. O 0 5.993066309883943e-08

Stable O 0 0.0003894358524121344
interaction O 0 7.856630190872238e-07
between O 0 1.0387013027468583e-08
the O 0 2.4241988416662252e-09
products O 0 6.504364269410701e-10
of O 0 6.885920278421054e-09
the O 0 2.3038444041389994e-08
BRCA1 O 0 7.066408613809472e-08
and O 0 5.6370974554909026e-09
BRCA2 O 0 2.0040371850882366e-07
tumor B-Disease 0 3.205317113952333e-07
suppressor O 0 1.5327553626320878e-07
genes O 0 4.5979239859939014e-10
in O 0 9.161573166771575e-10
mitotic O 0 5.529998858833096e-08
and O 0 9.116465804481777e-09
meiotic O 0 3.737776933121495e-05
cells O 0 1.7785202999220928e-06
. O 0 3.267538772888656e-07

BRCA1 O 0 1.018862531054765e-05
and O 0 1.6847089057137055e-08
BRCA2 O 0 2.269541710120393e-08
account O 0 1.8182678696021526e-09
for O 0 8.616483915258044e-11
most O 0 7.156462228374849e-11
cases O 0 2.774875051958503e-10
of O 0 7.548666580703411e-09
familial O 0 1.0943433153443038e-05
, O 0 7.448196726045353e-09
early O 0 1.17800880161667e-06
onset O 1 0.9784985184669495
breast B-Disease 0 0.00034066601074300706
and I-Disease 0 0.00028708280296996236
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 2.610060789720592e-07
encode O 0 2.087341144374477e-08
products O 0 7.767292364846412e-10
that O 0 6.20865997502662e-11
each O 0 1.8219468989055798e-10
interact O 0 9.595333416712037e-10
with O 0 7.283458280937793e-10
hRAD51 O 0 2.0941818092978792e-06
. O 0 1.8986840188972565e-07

Results O 0 4.496667997955228e-07
presented O 0 1.544879921766551e-07
here O 0 7.539721025295876e-08
show O 0 4.425167787758255e-08
that O 0 1.384173220486673e-09
BRCA1 O 0 3.050846331120738e-08
and O 0 2.346819183429716e-09
BRCA2 O 0 1.464777739101919e-07
coexist O 0 8.519068472878644e-08
in O 0 8.0510247357779e-09
a O 0 2.9696991532546235e-08
biochemical O 0 7.569965418952052e-07
complex O 0 6.588390988326864e-06
and O 0 3.933956804758054e-08
colocalize O 0 3.869994543492794e-05
in O 0 1.2798689397186536e-07
subnuclear O 0 7.413545245071873e-05
foci O 0 2.637881516420748e-05
in O 0 1.129212723327555e-08
somatic O 0 1.0350292711791553e-07
cells O 0 6.541991837138994e-09
and O 0 8.024131359363196e-10
on O 0 1.3333730564113466e-08
the O 0 1.3988776359497024e-08
axial O 0 3.1907106290418596e-08
elements O 0 1.3984294611191217e-08
of O 0 7.896677090002413e-08
developing O 0 6.912715093676525e-07
synaptonemal O 0 0.0004983918624930084
complexes O 0 2.1624313376378268e-05
. O 0 8.05337549536489e-07

Like O 0 1.5356537915067747e-05
BRCA1 O 0 1.6959606000455096e-05
and O 0 7.679794293835585e-07
RAD51 O 0 0.003909436985850334
, O 0 2.473730660312867e-07
BRCA2 O 0 6.159776830827468e-07
relocates O 0 5.787060217699036e-07
to O 0 8.119216410307217e-09
PCNA O 0 2.045461951638572e-05
+ O 0 3.532785797233373e-07
replication O 0 3.966898987073364e-08
sites O 0 7.676215219021287e-10
following O 0 1.1870483485054706e-09
exposure O 0 7.215036390562091e-08
of O 0 1.362979844543588e-07
S O 0 1.990142663998995e-06
phase O 0 1.0276912689732853e-06
cells O 0 5.295384042369733e-08
to O 0 8.824024178011314e-09
hydroxyurea O 0 1.5141456515266327e-06
or O 0 1.2598653142958938e-07
UV O 0 4.7394139983225614e-05
irradiation O 0 6.030376880516997e-06
. O 0 7.440390703550293e-08

Thus O 0 2.78280731436098e-06
, O 0 5.671849834243403e-08
BRCA1 O 0 6.623984205589295e-08
and O 0 2.1449126919037553e-09
BRCA2 O 0 9.48997236349669e-09
participate O 0 6.617163261779524e-09
, O 0 1.2347682876168165e-09
together O 0 2.4274793286593876e-09
, O 0 3.633334522135101e-09
in O 0 1.8985494065759667e-08
a O 0 9.938829492739387e-08
pathway O 0 1.184326592351681e-07
( O 0 6.04305316898035e-09
s O 0 1.7945094299420816e-08
) O 0 6.200910895870493e-10
associated O 0 4.292413979811727e-09
with O 0 1.342037037055377e-09
the O 0 6.241497629844162e-08
activation O 0 1.6137298075591389e-07
of O 0 1.3758489103565807e-07
double O 0 5.9227598825373207e-08
- O 0 1.6768809985023836e-07
strand O 0 2.807941541504988e-07
break O 0 3.7484997505998763e-07
repair O 0 5.616351245407714e-06
and O 0 1.4989062435688538e-07
/ O 0 2.1473251763381995e-05
or O 0 6.251589752537257e-07
homologous O 0 1.450670424674172e-06
recombination O 0 1.3547008848036057e-06
. O 0 2.714028539685387e-07

Dysfunction O 1 0.9999895095825195
of O 0 3.5357354590814793e-06
this O 0 1.702463094943596e-07
pathway O 0 2.2553028884431114e-06
may O 0 4.134325326532462e-09
be O 0 6.142805153430686e-10
a O 0 3.468049847299426e-09
general O 0 5.833213911898838e-09
phenomenon O 0 1.0792469851139685e-07
in O 0 3.939336634672941e-10
the O 0 9.009048507202522e-10
majority O 0 6.997379758955091e-11
of O 0 7.447510941283042e-10
cases O 0 3.354519995113492e-10
of O 0 9.474602791215148e-08
hereditary B-Disease 1 0.9999997615814209
breast I-Disease 1 0.9999961853027344
and I-Disease 1 0.9991596937179565
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.644998630785267e-06
. O 0 2.8325132461759495e-07

A O 0 1.6016030713217333e-05
novel O 0 3.484243961793254e-06
Arg362Ser O 0 3.195110912201926e-05
mutation O 0 1.4648036561482058e-08
in O 0 9.476334383862195e-09
the O 0 4.0401349821195254e-08
sterol O 0 9.085499073080427e-07
27 O 0 1.4117240425548516e-06
- O 0 6.10867118666647e-07
hydroxylase O 0 3.9252659007615875e-06
gene O 0 3.3672094446046685e-08
( O 0 7.462872098074058e-09
CYP27 O 0 2.7852925086335745e-06
) O 0 1.5060634961372443e-09
: O 0 1.3181768176995234e-10
its O 0 1.0175536802048413e-10
effects O 0 3.0493962910327355e-09
on O 0 4.5171462126347706e-09
pre O 0 2.3005297578038153e-07
- O 0 4.6083677318620175e-08
mRNA O 0 7.204296537111077e-08
splicing O 0 2.1559429796980112e-08
and O 0 4.386189744742808e-10
enzyme O 0 6.9060970275813816e-09
activity O 0 1.1593225224260095e-07
. O 0 3.7257393614709144e-08

A O 0 7.732495760137681e-06
novel O 0 1.6538236877750023e-06
C O 0 2.7680805487761972e-06
to O 0 6.512945738279541e-09
A O 0 6.750097014673884e-08
mutation O 0 8.980158283655726e-10
in O 0 1.2112367775429789e-09
the O 0 2.238143181898522e-08
sterol O 0 5.943412588749197e-07
27 O 0 4.239152531226864e-07
- O 0 4.093931238458026e-07
hydroxylase O 0 1.7248668200409156e-06
gene O 0 2.0912263920536134e-08
( O 0 6.548209086076895e-09
CYP27 O 0 3.3916146549017867e-06
) O 0 1.2465098953029496e-09
was O 0 5.5393809539339145e-09
identified O 0 1.3709701152109233e-09
by O 0 7.16526171729015e-10
sequencing O 0 3.149270000335491e-08
amplified O 0 7.464795999112539e-07
CYP27 O 0 1.3412821317615453e-05
gene O 0 8.318513877725309e-09
products O 0 1.0888356882787775e-09
from O 0 4.798142771988978e-09
a O 0 6.112598072149922e-08
patient O 0 1.666693094648508e-07
with O 0 2.6407963815699986e-08
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 1.0
( O 0 0.0002193075488321483
CTX B-Disease 0 0.2169068157672882
) O 0 1.5323402635658567e-07
. O 0 1.0704805930572547e-07

The O 0 8.277697816083673e-07
mutation O 0 7.923034672785434e-08
changed O 0 9.975673265216756e-08
the O 0 1.0019130769478579e-07
adrenodoxin O 0 1.4594372260035016e-05
cofactor O 0 1.672700818744488e-06
binding O 0 2.8525672490786746e-08
residue O 0 7.099100685081794e-07
362Arg O 0 5.796040909444855e-07
to O 0 2.676444310623083e-08
362Ser O 0 4.081658062204951e-06
( O 0 9.367557822770323e-07
CGT O 0 2.6017154596047476e-05
362Arg O 0 6.1067066781106405e-06
to O 0 1.5264272690274083e-07
AGT O 0 4.0047572838375345e-05
362Ser O 0 7.032551820884692e-07
) O 0 2.8863504919485194e-09
, O 0 1.9359781833205858e-10
and O 0 1.7266206520094585e-10
was O 0 7.947189573087599e-08
responsible O 0 3.227632703328709e-07
for O 0 3.2145405270966876e-07
deficiency O 1 0.9999417066574097
in O 0 1.6559242794755846e-06
the O 0 2.349190708628157e-06
sterol O 0 4.4632083699980285e-06
27 O 0 1.3197148973631556e-06
- O 0 7.635932206540019e-07
hydroxylase O 0 3.7419883938127896e-06
activity O 0 6.740705202901154e-07
, O 0 3.5612571225307477e-10
as O 0 1.4296533401569889e-10
confirmed O 0 1.0140158851479342e-10
by O 0 1.259647386397944e-10
expression O 0 8.839449727737758e-10
of O 0 5.033457650682749e-09
mutant O 0 4.994413416170573e-08
cDNA O 0 7.489740738719775e-08
into O 0 9.064345718456934e-09
COS O 0 9.00740360521013e-06
- O 0 4.0306761661668133e-07
1 O 0 4.0368544773627946e-07
cells O 0 1.3412309840532544e-07
. O 0 4.868538994173832e-08

Quantitative O 0 1.946000338648446e-06
analysis O 0 1.2181281761058926e-07
showed O 0 6.55613208166983e-09
that O 0 9.748831603095809e-11
the O 0 1.357017720415854e-09
expression O 0 1.520026238210903e-08
of O 0 2.5225006083928747e-08
CYP27 O 0 1.5620023987139575e-05
gene O 0 9.999844508001843e-09
mRNA O 0 2.341647054038276e-08
in O 0 9.663214672883669e-10
the O 0 1.6710078876158718e-09
patient O 0 9.837847869675898e-09
represented O 0 4.1381591486810976e-09
52 O 0 5.165519496586057e-07
. O 0 3.5732432479562704e-07

5 O 0 4.343417913332814e-06
% O 0 6.017877041131214e-08
of O 0 4.732061853474079e-08
the O 0 4.767911931935487e-08
normal O 0 1.4068064047023654e-06
level O 0 2.869785248549306e-06
. O 0 2.11316347531465e-07

As O 0 1.9224175673571153e-07
the O 0 4.489250926553723e-08
mutation O 0 5.910287814714366e-09
occurred O 0 2.4238491391770367e-07
at O 0 2.7201380703445466e-08
the O 0 3.031952644505509e-08
penultimate O 0 2.3397842596750706e-06
nucleotide O 0 4.16808148884229e-07
of O 0 2.2413820488509373e-07
exon O 0 8.15222591654674e-08
6 O 0 5.560926297221158e-08
( O 0 2.8533222451443407e-09
- O 0 4.579397749893133e-09
2 O 0 1.614372635572181e-08
position O 0 4.19215879787771e-08
of O 0 1.1681711953315244e-07
exon O 0 2.3737149490443699e-07
6 O 0 9.954363804354216e-07
- O 0 7.420222800647025e-07
intron O 0 3.81972449758905e-06
6 O 0 4.744362058772822e-07
splice O 0 6.805115049246524e-07
site O 0 2.945043675595116e-08
) O 0 4.5019712957561353e-10
of O 0 7.632183773864654e-10
the O 0 4.0202161599722785e-09
gene O 0 5.010163395269274e-09
, O 0 1.1254106535574238e-09
we O 0 4.354457683319879e-09
hypothesized O 0 4.439675294065637e-08
that O 0 1.595788223784922e-10
the O 0 2.5828899019586515e-09
mutation O 0 1.161498341950562e-09
may O 0 1.256370341096158e-09
partially O 0 7.39649905767692e-08
affect O 0 4.33783764464124e-09
the O 0 8.260898631817781e-09
normal O 0 3.7249865414423766e-08
splicing O 0 1.5553069943052833e-08
efficiency O 0 1.4640606949001267e-08
in O 0 1.757931245016664e-09
exon O 0 2.0031270864251383e-08
6 O 0 5.3413438116933776e-09
and O 0 1.7036365373979123e-10
cause O 0 1.2760335010852941e-09
alternative O 0 1.7291229559290855e-09
splicing O 0 1.211771127884731e-08
elsewhere O 0 7.0644516902973464e-09
, O 0 3.1810215572747325e-10
which O 0 1.6067709662781482e-10
resulted O 0 7.227415999011555e-09
in O 0 5.825297577644051e-09
decreased O 0 2.645548647706164e-06
transcript O 0 1.1975791949225822e-06
in O 0 7.076899510849444e-09
the O 0 5.9232458937685806e-08
patient O 0 5.457019938148733e-07
. O 0 8.694700426303825e-08

Transfection O 0 0.0020748295355588198
of O 0 3.0735955078853294e-06
constructed O 0 2.789791142276954e-05
minigenes O 0 7.117479981388897e-05
, O 0 1.697763529762142e-08
with O 0 8.740734247503212e-10
or O 0 1.0717878140553694e-08
without O 0 1.1984008452259332e-08
the O 0 1.8924573907952436e-08
mutation O 0 1.3899299489139594e-09
, O 0 5.651304979537031e-10
into O 0 1.0292390051347411e-08
COS O 0 0.0002592514210846275
- O 0 2.0681466139649274e-06
1 O 0 3.916311470675282e-07
cells O 0 5.220448517917475e-09
confirmed O 0 1.4345407084448425e-09
that O 0 1.2126509518761708e-10
the O 0 5.7756226468086425e-09
mutant O 0 1.3796487507988786e-07
minigene O 0 1.925002152347588e-06
was O 0 9.209919937802624e-08
responsible O 0 6.282091291609504e-09
for O 0 4.958293220447274e-10
a O 0 1.0243976333867977e-08
mRNA O 0 5.458675644831601e-08
species O 0 3.838954987234189e-10
alternatively O 0 1.091884982429292e-08
spliced O 0 1.008379655331737e-07
at O 0 1.1861282445124743e-07
an O 0 2.1335708311198687e-08
activated O 0 5.163086598258815e-07
cryptic O 0 3.0973922093835426e-06
5 O 0 9.956244184650132e-07
splice O 0 2.821509951900225e-06
site O 0 6.000352641422069e-07
88 O 0 3.4256026992807165e-07
bp O 0 1.5799222410350922e-06
upstream O 0 9.45597776080831e-07
from O 0 1.999523746576415e-08
the O 0 5.239524014655217e-08
3 O 0 1.2802557591840014e-07
end O 0 1.041246733279877e-07
of O 0 3.689948187002301e-07
exon O 0 2.5696715511003276e-06
6 O 0 1.98201701095968e-06
. O 0 2.6580795520203537e-07

Our O 0 1.1573677056730958e-06
data O 0 2.0668201727858104e-07
suggest O 0 1.3993499692332989e-08
that O 0 2.41288183877586e-10
the O 0 3.68546526630098e-09
C O 0 1.8213411578926753e-07
to O 0 2.2217501172150378e-09
A O 0 3.6540953374242235e-08
mutation O 0 5.833611371741654e-10
at O 0 3.4653850899957206e-09
the O 0 1.9738015666348474e-09
penultimate O 0 2.3566714446587866e-07
nucleotide O 0 2.106957310843427e-07
of O 0 2.51197622702648e-08
exon O 0 4.8008363506824026e-08
6 O 0 1.1061685789570674e-08
of O 0 5.426740834479915e-09
the O 0 1.5306452993968378e-08
CYP27 O 0 5.485604197019711e-05
gene O 0 4.0359200426109965e-09
not O 0 1.535948868092163e-10
only O 0 9.94452742375529e-10
causes O 0 3.7742022840348e-09
the O 0 8.948803476016565e-09
deficiency B-Disease 0 9.553518611937761e-05
in I-Disease 0 4.8589654966235685e-08
the I-Disease 0 2.0957871527116367e-07
sterol I-Disease 0 6.523976594507985e-07
27 I-Disease 0 4.4480668748292373e-07
- I-Disease 0 5.40607096866097e-08
hydroxylase I-Disease 0 3.554722809440136e-07
activity I-Disease 0 1.4769406675441132e-07
, O 0 2.1381883763549325e-10
but O 0 1.3775511287228426e-10
also O 0 2.7314742134798564e-10
partially O 0 1.8998861150976154e-08
leads O 0 7.991994288580884e-10
to O 0 3.249929492188386e-10
alternative O 0 2.0069466089012167e-09
pre O 0 1.1254353182721388e-07
- O 0 3.233079226561131e-08
mRNA O 0 6.800638630011235e-08
splicing O 0 2.8388297934611728e-08
of O 0 3.358651134988122e-09
the O 0 1.563763696310616e-08
gene O 0 9.441068016258214e-08
. O 0 1.823256354782643e-07

To O 0 3.637406962297973e-07
our O 0 2.4173070301003463e-07
knowledge O 0 2.522439217500505e-06
, O 0 5.1384052568437255e-09
this O 0 1.2574443708501803e-09
is O 0 2.4621288341464265e-10
the O 0 4.1238956693945283e-10
first O 0 8.269028795027111e-10
report O 0 1.057052112507506e-09
regarding O 0 2.0794799215906323e-09
effects O 0 9.539244061329555e-09
on O 0 5.24398036105822e-09
pre O 0 1.8150331015931442e-07
- O 0 3.866862385848435e-08
mRNA O 0 5.7239830653088575e-08
splicing O 0 1.2931040238584046e-08
of O 0 3.196946929406863e-09
a O 0 2.370374119209373e-09
mutation O 0 2.9580224381042797e-10
at O 0 9.681280666029579e-09
the O 0 1.4836032846687885e-08
- O 0 1.1649726872065003e-07
2 O 0 1.8097992438015353e-07
position O 0 2.0770794151303562e-07
of O 0 1.347506781712582e-07
a O 0 1.7065040935904108e-07
5 O 0 5.783054461971915e-07
splice O 0 4.769995030073915e-06
site O 0 8.290195410154411e-07
. O 0 1.0674833816892715e-07

ATM O 0 0.0009296545758843422
germline O 0 4.160499156569131e-05
mutations O 0 5.0490466918517996e-08
in O 0 2.7096055177366907e-08
classical O 1 0.999765932559967
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 0.0020501562394201756
in O 0 6.871973656785713e-09
the O 0 3.2194794385986825e-08
Dutch O 0 1.1165018804604188e-05
population O 0 5.716375373054916e-09
. O 0 4.078631121728904e-08

Germline O 0 0.0007278610137291253
mutations O 0 7.92725174392217e-08
in O 0 7.884167985139356e-09
the O 0 1.303812791064729e-08
ATM O 0 1.1251288469793508e-06
gene O 0 3.7046968270892933e-10
are O 0 1.2253378867121967e-11
responsible O 0 3.6378605683395904e-10
for O 0 4.876361536787499e-09
the O 1 0.9999709129333496
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999998807907104
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 3.5977093375549885e-06
. O 0 9.888765362120466e-07

In O 0 2.1840173758391757e-07
our O 0 3.642800905367949e-08
study O 0 6.221302584208388e-09
, O 0 1.0274060768811211e-10
we O 0 1.8623731723454995e-10
have O 0 2.2229388468852918e-11
determined O 0 1.233546598200519e-09
the O 0 7.144508984424647e-09
ATM O 0 7.186208677012473e-07
mutation O 0 7.226447773511779e-10
spectrum O 0 5.595691132675995e-10
in O 0 1.0308770503897335e-09
19 O 0 4.004353826303486e-08
classical O 0 2.9614369850605726e-05
A B-Disease 1 1.0
- I-Disease 1 0.9998612403869629
T I-Disease 1 0.9999998807907104
patients O 0 2.808549837141072e-09
, O 0 4.3735397248223506e-11
including O 0 2.400821035031253e-11
some O 0 2.2100699742511054e-11
immigrant O 0 2.649390706821464e-10
populations O 0 1.2791349923713113e-10
, O 0 2.682450268853831e-11
as O 0 2.1057494636878005e-10
well O 0 2.4265198184103554e-10
as O 0 2.1532778338162473e-10
12 O 0 6.158184517879306e-10
of O 0 4.736969705376737e-10
Dutch O 0 8.19330097101556e-08
ethnic O 0 3.731832620701425e-09
origin O 0 1.0050654708493312e-07
. O 0 8.038446708269475e-08

Both O 0 2.643891434672696e-07
the O 0 2.17575603755904e-07
protein O 0 1.0836838981731489e-07
truncation O 0 4.665340611609281e-07
test O 0 4.6586183799490755e-08
( O 0 2.274243797728559e-07
PTT O 0 3.13182026729919e-05
) O 0 1.6772409017207224e-09
and O 0 3.0503430337169846e-10
the O 0 5.093936827904599e-09
restriction O 0 1.2399373972016292e-08
endonuclease O 0 1.6907003441701818e-07
fingerprinting O 0 1.930154702733944e-08
( O 0 6.896895943242498e-09
REF O 0 3.354357431817334e-07
) O 0 8.498168835302522e-11
method O 0 4.2738998451419263e-10
were O 0 2.8908836435803664e-10
used O 0 3.099111800519694e-10
and O 0 1.9870438627833664e-10
compared O 0 2.6452362522633166e-09
for O 0 1.4004299109249274e-10
their O 0 2.4357196815039117e-10
detection O 0 1.4808382964304201e-08
efficiency O 0 4.040302314933797e-09
, O 0 4.989216678685793e-11
identifying O 0 8.300600762289889e-10
76 O 0 4.308597478797083e-09
% O 0 1.766720103546504e-10
and O 0 4.1761750307900414e-11
60 O 0 1.7555120690460058e-09
% O 0 2.4116947328067795e-10
of O 0 3.789391578301604e-10
the O 0 2.464338288987733e-09
mutations O 0 1.2261737181162857e-09
, O 0 1.4261054559483455e-09
respectively O 0 1.5237162642733892e-07
. O 0 3.219603001980431e-07

Most O 0 2.839626631612191e-07
patients O 0 1.776240132755902e-08
were O 0 7.110712019198218e-09
found O 0 1.0368822245254705e-08
to O 0 7.3230785879729865e-09
be O 0 2.027969543405561e-07
compound O 0 0.00011251925025135279
heterozygote O 0 0.00021718339121434838
. O 0 2.5187612209265353e-06

Seventeen O 0 1.0248440958093852e-05
mutations O 0 8.566352960315271e-08
were O 0 2.279241506641938e-08
distinct O 0 7.154191017377798e-09
, O 0 1.405616734118098e-09
of O 0 2.322241599017616e-08
which O 0 1.6328096652529211e-09
10 O 0 1.1914131015089424e-08
were O 0 1.3922549335632084e-08
not O 0 6.493026116771716e-09
reported O 0 1.4898395761520078e-07
previously O 0 1.2183203352833516e-06
. O 0 6.071465463719505e-07

Mutations O 0 2.3867542040534317e-06
are O 0 4.627972671755742e-09
small O 0 1.6838832550547522e-08
deletions O 0 1.1071103500626123e-07
or O 0 4.225763561294116e-08
point O 0 1.3081977385809296e-06
mutations O 0 1.8678605329114362e-08
frequently O 0 1.333882266862929e-07
affecting O 0 6.539549417539092e-07
splice O 0 4.272264504834311e-06
sites O 0 4.961935360370262e-07
. O 0 4.154096870934154e-07

Moreover O 0 2.5973076844820753e-05
, O 0 5.388508839132555e-08
a O 0 1.4785148039209162e-07
16 O 0 4.4337392068882764e-07
. O 0 1.2387405945446517e-07

7 O 0 2.1517096683965065e-05
- O 0 1.7748975551512558e-06
kb O 0 1.3038823453825898e-05
genomic O 0 1.8711754989908513e-07
deletion O 0 4.312463985911563e-08
of O 0 2.2175090208520487e-08
the O 0 1.6224539933773485e-08
3 O 0 2.75380358516486e-08
end O 0 1.262850535255211e-08
of O 0 1.2465343424139519e-08
the O 0 5.664711366648589e-09
gene O 0 8.636924508920174e-10
, O 0 5.674221509321953e-11
most O 0 5.171051434271767e-11
likely O 0 1.817448691543433e-10
a O 0 2.5483812837734376e-09
result O 0 4.395102504162196e-09
of O 0 1.7091092985310752e-08
recombination O 0 3.578785934266193e-09
between O 0 2.486083561237251e-09
two O 0 1.3201802984141864e-09
LINE O 0 9.98684868136479e-08
elements O 0 6.450454748119228e-08
, O 0 1.0944246398025825e-08
was O 0 6.221720241228468e-07
identified O 0 1.0473371503394446e-06
. O 0 5.261777005216572e-07

The O 0 2.4791768282739213e-07
most O 0 1.591199616512995e-09
frequently O 0 1.5157695099077273e-09
found O 0 8.982881660735131e-10
mutation O 0 2.721494696267257e-10
, O 0 1.1989986781202333e-10
identified O 0 4.429582478593375e-09
in O 0 2.1560038199197606e-09
three O 0 4.6235086870183295e-09
unrelated O 0 5.050010258855764e-07
Turkish O 0 1.588124541740399e-05
A B-Disease 1 1.0
- I-Disease 1 0.9999693632125854
T I-Disease 1 0.9999996423721313
individuals O 0 2.026144052535983e-08
, O 0 1.886650391469402e-09
was O 0 5.836154670646465e-08
previously O 0 9.93875026722435e-09
described O 0 6.873310365307361e-09
to O 0 1.4753569477221617e-09
be O 0 2.616064254112871e-09
a O 0 6.42372626202814e-08
Turkish O 0 3.770323019125499e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999716281890869
T I-Disease 1 0.9999994039535522
founder O 0 0.0003089345118496567
mutation O 0 2.691752456485119e-07
. O 0 1.0236597347557108e-07

The O 0 1.4250858839659486e-06
presence O 0 9.579049020658204e-08
of O 0 1.9827834307761805e-07
a O 0 1.641363667204132e-07
founder O 0 7.935827284200059e-07
mutation O 0 3.1267266553669515e-10
among O 0 2.4038175963636554e-11
relatively O 0 3.1912064657468875e-10
small O 0 1.2235799873305808e-10
ethnic O 0 6.007638830851647e-11
population O 0 5.284872192645729e-11
groups O 0 1.87339171953127e-11
in O 0 2.5652191482095077e-10
Western O 0 1.160697227220453e-08
Europe O 0 5.13738607210712e-09
could O 0 1.5158245769697487e-09
indicate O 0 8.040589527524844e-09
a O 0 1.0149722173835585e-09
high O 0 1.1097415208993766e-09
carrier O 0 3.047941343758964e-10
frequency O 0 7.310974603491616e-10
in O 0 2.867938109218926e-10
such O 0 8.525073980081288e-10
communities O 0 1.8378152333298203e-08
. O 0 2.694793295177078e-07

In O 0 2.4461235170747386e-07
patients O 0 1.1740387328984525e-08
of O 0 1.624255929755236e-08
Dutch O 0 3.1862400646787137e-06
ethnic O 0 1.2884950884028967e-08
origin O 0 1.852151498837884e-08
, O 0 1.5812458009634156e-09
however O 0 6.429361931736821e-09
, O 0 2.621914019229621e-09
no O 0 1.1235067098880336e-08
significant O 0 4.587889179674676e-08
founder O 0 7.922911891000695e-07
effect O 0 2.584843095121414e-08
could O 0 2.5254840441135684e-09
be O 0 5.918115775216393e-09
identified O 0 3.125618093235971e-07
. O 0 2.2003136734838336e-07

The O 0 2.911316698828159e-07
observed O 0 1.7170007993172476e-07
genetic O 0 4.8957485176970295e-08
heterogeneity O 0 5.755764931336671e-08
including O 0 2.154285416722246e-09
the O 0 1.0792300386697207e-08
relative O 0 1.45449371302675e-06
high O 0 2.077194238836455e-07
percentage O 0 2.818555060457584e-07
of O 0 1.0969516495151765e-07
splice O 0 3.4602530831762124e-06
- O 0 3.4081367061844503e-07
site O 0 2.0509629905518523e-07
mutations O 0 4.9148325409476e-09
had O 0 1.4672028036954998e-08
no O 0 1.7789625772479667e-08
reflection O 0 2.3656536995986244e-07
on O 0 5.463206775857543e-08
the O 0 1.9036535547911626e-07
phenotype O 0 1.5215555322356522e-06
. O 0 2.4080162575046415e-07

All O 0 8.637147175249993e-08
patients O 0 4.456811364406121e-09
manifested O 0 1.3198906856359827e-07
classical O 0 6.52832823107019e-05
A B-Disease 1 1.0
- I-Disease 1 0.5791805386543274
T I-Disease 1 0.9648628234863281
and O 0 5.932061508673314e-09
increased O 0 7.18550978717758e-08
cellular O 0 2.1204712652433955e-07
radioresistant O 0 2.861657094399561e-06
DNA O 0 3.934025016860687e-07
synthesis O 0 9.048774813891214e-07
. O 0 8.062922773888204e-08

Determination O 0 4.965982043358963e-06
of O 0 2.2246818787152733e-07
the O 0 3.584307606274706e-08
genomic O 0 1.150273192251916e-07
structure O 0 1.620577450012206e-07
of O 0 5.983951467669613e-08
the O 0 7.791872036477798e-08
COL4A4 O 0 0.0008163898601196706
gene O 0 1.163072305132573e-09
and O 0 7.409973329375319e-11
of O 0 2.3913446778323078e-09
novel O 0 9.130614557761874e-07
mutations O 0 1.3946304306955426e-06
causing O 0 7.373315747827291e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 2.81412030744832e-05

Autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 3.665530243779358e-07
a O 0 4.603738489095122e-06
progressive O 1 0.9999206066131592
hematuric B-Disease 1 1.0
glomerulonephritis I-Disease 1 1.0
characterized O 0 0.002076205099001527
by O 0 4.950954007654218e-06
glomerular B-Disease 1 1.0
basement I-Disease 1 1.0
membrane I-Disease 1 0.9998500347137451
abnormalities I-Disease 1 0.9995070695877075
and O 0 2.1284494167161938e-08
associated O 0 1.9088257374733075e-07
with O 0 8.727327305280141e-09
mutations O 0 2.0169903081068696e-08
in O 0 6.876381775100526e-08
either O 0 4.788125238519569e-07
the O 0 1.3723562915401999e-05
COL4A3 O 1 0.9999661445617676
or O 0 8.138583211803052e-07
the O 0 4.4839026713816565e-07
COL4A4 O 0 0.05769820883870125
gene O 0 1.1795154186700074e-08
, O 0 1.52983026247e-09
which O 0 1.0903361546965584e-09
encode O 0 5.345338394135979e-09
the O 0 3.1963086399855456e-08
alpha3 O 0 7.3275077738799155e-06
and O 0 6.66003927562997e-08
alpha4 O 0 0.0007570746238343418
type O 0 0.001696953782811761
IV O 1 0.9999998807907104
collagen O 1 0.99980229139328
chains O 0 0.0013941804645583034
, O 0 1.9811503193523095e-07
respectively O 0 6.629692506976426e-06
. O 0 1.2579663462020108e-06

To O 0 4.8928548324056464e-08
date O 0 9.911474307955359e-08
, O 0 7.714023864124897e-10
mutation O 0 3.0971203379692724e-10
screening O 0 3.6749134291191865e-10
in O 0 4.60013444003593e-10
the O 0 1.3887269112444756e-09
two O 0 5.906926059395801e-10
genes O 0 1.3099490381307533e-09
has O 0 1.4185033703206784e-10
been O 0 8.699618803120757e-10
hampered O 0 9.070852513559657e-08
by O 0 8.432715636885746e-10
the O 0 1.0623907975571001e-08
lack O 0 6.28748821895897e-08
of O 0 3.036501539099845e-08
genomic O 0 1.015085402400473e-07
structure O 0 2.918227437476162e-07
information O 0 5.664292643814406e-07
. O 0 1.7592947187949903e-07

We O 0 7.296256967492809e-07
report O 0 1.27064296862045e-07
here O 0 1.3078227389939912e-08
the O 0 1.7297109522473875e-08
complete O 0 9.639587261744964e-08
characterization O 0 5.608978881355142e-07
of O 0 8.936203244047647e-08
the O 0 3.4951515459624716e-08
48 O 0 1.1570394775617387e-07
exons O 0 2.618042316271385e-08
of O 0 5.244960465944359e-09
the O 0 3.2769094104878604e-08
COL4A4 O 0 0.00032231048680841923
gene O 0 6.158399568079176e-09
, O 0 3.530969405751705e-10
a O 0 2.3262298753934374e-09
comprehensive O 0 1.2503037716271592e-08
gene O 0 5.350395682057751e-10
screen O 0 3.952027149978221e-09
, O 0 3.9222425307627873e-10
and O 0 1.512384245616616e-10
the O 0 2.1474590994330356e-09
subsequent O 0 1.5977999368033124e-08
detection O 0 1.0148159645950727e-08
of O 0 5.228307786708797e-10
10 O 0 4.462014646655632e-10
novel O 0 2.1417609907814494e-09
mutations O 0 7.115629613307917e-11
in O 0 3.91890547790652e-11
eight O 0 2.727846615258045e-09
patients O 0 1.0376399295353167e-08
diagnosed O 0 4.5850288188376e-07
with O 0 1.6373050470974704e-07
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.6717884136596695e-05

Furthermore O 0 3.352417706992128e-06
, O 0 9.115075805254946e-09
we O 0 9.011492885235839e-09
identified O 0 2.9266319145904163e-08
a O 0 1.5054268942549243e-08
glycine O 0 5.0372442217394564e-08
to O 0 3.5879170745545252e-09
alanine O 0 1.3339483473373548e-07
substitution O 0 2.586727099185282e-08
in O 0 1.840617969151026e-08
the O 0 1.0789773341457476e-07
collagenous O 0 0.00011726301454473287
domain O 0 5.36237450887711e-07
that O 0 3.7618391734994816e-10
is O 0 7.840973426098685e-10
apparently O 0 4.198720660042454e-08
silent O 0 2.142064801091692e-07
in O 0 5.491306076521596e-09
the O 0 1.873823229914251e-08
heterozygous O 0 9.660916511222695e-09
carriers O 0 1.2412666450245524e-09
, O 0 1.6258050461459561e-09
in O 0 1.959656614758387e-08
11 O 0 1.6467209889015066e-06
. O 0 5.859666885044135e-07

5 O 0 6.683141009489191e-07
% O 0 1.4483900301343056e-08
of O 0 3.955360483587356e-09
all O 0 4.403928055563e-10
control O 0 6.804814933758507e-09
individuals O 0 9.286130753238808e-10
, O 0 2.003308491316247e-10
and O 0 1.8167797821710963e-10
in O 0 1.875227528813639e-09
one O 0 3.078311383575283e-09
control O 0 2.523153908029485e-09
individual O 0 3.0446406507067536e-10
homozygous O 0 7.975000659854459e-10
for O 0 2.0198025196815905e-10
this O 0 1.516157088765624e-09
glycine O 0 1.49155695794434e-07
substitution O 0 1.9010248308859445e-07
. O 0 1.655935335520553e-07

There O 0 1.3664513289768365e-06
has O 0 5.068118813511546e-09
been O 0 6.600007651513806e-09
no O 0 3.563474182399773e-09
previous O 0 1.3545953692073454e-08
finding O 0 4.0349984686827156e-08
of O 0 1.9929593975120952e-08
a O 0 1.5001184294760606e-08
glycine O 0 2.6103586847625593e-08
substitution O 0 4.088902993970578e-09
that O 0 4.016251498040191e-10
is O 0 1.174731978359489e-10
not O 0 3.196687706208401e-11
associated O 0 4.972053324614478e-10
with O 0 1.0696586671965491e-10
any O 0 7.157643810984382e-09
obvious O 0 1.0146285944756528e-07
phenotype O 0 1.811905647741696e-08
in O 0 2.064683091163033e-09
homozygous O 0 7.415876357441675e-09
individuals O 0 2.6583868439900016e-09
. O 0 6.808686237036454e-08

Founder O 0 0.014443127438426018
BRCA1 O 0 9.952068467100617e-06
and O 0 1.8497191334176932e-08
BRCA2 O 0 1.1285349188483451e-07
mutations O 0 2.1012611650661484e-09
in O 0 1.2860734699415843e-09
French O 0 2.64535674432409e-06
Canadian O 1 0.9933650493621826
breast B-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 0.00014190991350915283
. O 0 5.357109671422222e-07

We O 0 2.0681650880760571e-07
have O 0 1.8107577659520757e-09
identified O 0 2.3996422626737512e-09
four O 0 6.940678032307801e-10
mutations O 0 6.564922216956148e-11
in O 0 6.917203615453005e-11
each O 0 1.3138594379125124e-10
of O 0 1.068456700892284e-08
the O 0 1.1137368574054562e-06
breast B-Disease 1 0.6578746438026428
cancer I-Disease 0 0.0028618797659873962
- O 0 6.81224773870781e-05
susceptibility O 0 3.955577085434925e-06
genes O 0 1.2712461305852685e-08
, O 0 8.019908070977522e-10
BRCA1 O 0 3.797019143547686e-09
and O 0 5.486037735202842e-10
BRCA2 O 0 4.5208694565701535e-09
, O 0 6.793900858559354e-11
in O 0 3.3618541284141656e-10
French O 0 1.3000314424971293e-07
Canadian O 0 0.0001692857767920941
breast B-Disease 1 0.9995842576026917
cancer I-Disease 0 0.00453314371407032
and O 0 0.0003647722187452018
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 5.655850259245199e-07
from O 0 6.474515856780272e-08
Quebec O 0 8.054435625126644e-07
. O 0 1.849582105251102e-07

To O 0 2.714618574373162e-07
identify O 0 5.103314038024109e-07
founder O 0 1.2700636943918653e-05
effects O 0 8.677403457113542e-06
, O 0 6.8009868847696e-09
we O 0 3.785853408544426e-09
examined O 0 3.719172170235652e-08
independently O 0 3.181243002359224e-08
ascertained O 0 3.541657918049168e-07
French O 0 1.4131732939404174e-07
Canadian O 0 7.907949566288153e-07
cancer B-Disease 0 5.669350571224641e-07
families O 0 5.880228526322639e-10
for O 0 8.585019500850777e-11
the O 0 1.2430364515481074e-09
distribution O 0 2.0992581006851196e-09
of O 0 8.360379943894714e-09
these O 0 7.810925795048718e-10
eight O 0 3.61491458988894e-08
mutations O 0 2.356329353858655e-08
. O 0 5.455855145442001e-08

Mutations O 0 6.234859029063955e-07
were O 0 3.7891783932764156e-08
found O 0 6.639730099067265e-09
in O 0 4.2894021667905236e-09
41 O 0 1.1081751694064224e-07
of O 0 1.2202582411191543e-07
97 O 0 2.7175115974387154e-05
families O 0 1.417877797393885e-07
. O 0 3.0957656349528406e-07

Six O 0 1.5151047136896523e-06
of O 0 1.1357082740914848e-07
eight O 0 4.1205424849977135e-08
mutations O 0 3.6262104430306863e-09
were O 0 1.4281913429670112e-08
observed O 0 2.7990214590545293e-08
at O 0 2.8253799655431067e-07
least O 0 2.9429603642938673e-08
twice O 0 1.1773704500228632e-07
. O 0 1.87631655990117e-07

The O 0 8.413430805376265e-06
BRCA1 O 0 8.576997061027214e-06
C4446T O 0 2.3025104383123107e-06
mutation O 0 5.505842448627618e-09
was O 0 1.481629308131005e-08
the O 0 1.696040974330515e-09
most O 0 1.7540852104147575e-10
common O 0 2.67681432575273e-10
mutation O 0 3.081294108753241e-10
found O 0 1.0340870382208323e-09
, O 0 1.921927478276686e-10
followed O 0 4.61234028747981e-09
by O 0 4.111920137717107e-09
the O 0 1.648050300673276e-07
BRCA2 O 0 8.800058139968314e-07
8765delAG O 0 1.538060359962401e-06
mutation O 0 4.347331739040783e-08
. O 0 4.4190443304614746e-08

Together O 0 6.92708795213548e-07
, O 0 4.095217054356226e-09
these O 0 4.256328345331184e-10
mutations O 0 6.730563328893879e-10
were O 0 2.656587394511689e-09
found O 0 1.4355945321398167e-09
in O 0 2.934220866279702e-09
28 O 0 6.94471040674216e-08
of O 0 8.545138996396417e-08
41 O 0 1.2789732295459544e-07
families O 0 2.384863195814546e-09
identified O 0 3.5957821165055748e-09
to O 0 1.6837026217686457e-09
have O 0 1.9687669272627772e-09
a O 0 4.866812020054567e-08
mutation O 0 3.5854288427117353e-08
. O 0 9.634127451363383e-08

The O 0 2.361484348512022e-06
odds O 0 9.869452696875669e-06
of O 0 6.891112747098305e-08
detection O 0 9.624834262922377e-08
of O 0 1.365860224922244e-08
any O 0 1.0054428400962934e-08
of O 0 4.95442158410242e-08
the O 0 3.5792588448657625e-08
four O 0 1.072757527253998e-07
BRCA1 O 0 5.627239119121441e-08
mutations O 0 2.7523159307207834e-09
was O 0 1.7134708230059914e-07
18 O 0 3.843553031401825e-07
. O 0 1.4777889134620636e-07

7x O 0 0.003831513226032257
greater O 0 4.7389630708494224e-07
if O 0 7.82346987193705e-09
one O 0 2.9610720542194713e-09
or O 0 2.363113871250988e-10
more O 0 8.007687395117369e-12
cases O 0 1.6973927818852985e-10
of O 0 1.1204143447685055e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 0.0001047619225573726
also O 0 2.4523769681650265e-09
present O 0 1.761935819466487e-09
in O 0 9.713018833679143e-09
the O 0 1.3564573464464047e-07
family O 0 1.3727194527746178e-06
. O 0 3.77363619463722e-07

The O 0 1.988202029679087e-06
odds O 0 6.44989177089883e-06
of O 0 7.966646364820917e-08
detection O 0 2.5056414187929477e-07
of O 0 2.690083533707366e-08
any O 0 1.1580237213593136e-08
of O 0 2.9209379803774027e-08
the O 0 5.934192159884333e-08
four O 0 6.57292531514031e-08
BRCA2 O 0 5.388827162278176e-08
mutations O 0 1.2897434231717853e-09
was O 0 2.232288096593038e-07
5 O 0 5.587345413005096e-07
. O 0 9.39852213832637e-08

3x O 0 0.0002248412638437003
greater O 0 1.6406031022597745e-07
if O 0 9.106108755929654e-09
there O 0 5.06683361933824e-09
were O 0 7.97683075148825e-09
at O 0 1.890516543312515e-08
least O 0 3.811478355153497e-10
five O 0 2.446726987681558e-10
cases O 0 1.1360208607147371e-10
of O 0 2.444686408864527e-08
breast B-Disease 0 0.0008530860068276525
cancer I-Disease 0 4.4690918002743274e-05
in O 0 1.0394106766398181e-06
the O 0 1.9038301616092212e-05
family O 0 1.8587892554933205e-05
. O 0 2.002703638481762e-07

Interestingly O 0 2.09427707886789e-05
, O 0 3.0014174257075865e-08
the O 0 1.287993800502818e-08
presence O 0 2.1116036919011094e-08
of O 0 3.0958926799939945e-07
a O 0 2.1640280465362594e-06
breast B-Disease 0 5.689977842848748e-05
cancer I-Disease 0 7.493404723390995e-07
case O 0 1.9806648765552382e-07
< O 0 8.260703339146858e-07
36 O 0 2.051105951750287e-09
years O 0 3.1562846780630593e-10
of O 0 1.2219223410880886e-09
age O 0 1.0158171193097587e-08
was O 0 2.956547540122756e-08
strongly O 0 1.0650216264451728e-09
predictive O 0 6.076629421869484e-09
of O 0 6.472509195276643e-10
the O 0 8.058241851571779e-10
presence O 0 6.393833240636582e-10
of O 0 3.564711414938415e-09
any O 0 1.5314270962463183e-09
of O 0 9.023980673816823e-09
the O 0 9.382596033447044e-09
eight O 0 3.12121812839905e-08
mutations O 0 3.779143664672802e-09
screened O 0 1.29676109850152e-07
. O 0 9.248524435179206e-08

Carriers O 0 7.101415917531995e-07
of O 0 3.46815056673222e-08
the O 0 9.658336352913466e-09
same O 0 3.898564138182792e-09
mutation O 0 4.776317119592477e-10
, O 0 4.621159011009013e-11
from O 0 6.755652287582237e-11
different O 0 4.008129939059302e-11
families O 0 3.8679942582220406e-10
, O 0 9.75670030878284e-11
shared O 0 2.3324855380479903e-09
similar O 0 9.83099601725712e-10
haplotypes O 0 3.4295180029175754e-08
, O 0 5.737322839038939e-10
indicating O 0 1.2204812271932042e-08
that O 0 6.477272884719554e-11
the O 0 1.7044662348197903e-09
mutant O 0 1.1613084716088906e-08
alleles O 0 3.2401811789206647e-10
were O 0 9.033309100736631e-10
likely O 0 3.498016043490537e-10
to O 0 1.050958209347641e-10
be O 0 2.1691731744155618e-10
identical O 0 1.5742401826557284e-09
by O 0 1.5528578423129602e-09
descent O 0 7.977229188327328e-08
for O 0 1.6466614738419594e-09
a O 0 8.737954360071853e-09
mutation O 0 6.456295498225018e-10
in O 0 2.265211351826224e-09
the O 0 2.8042904887115583e-08
founder O 0 1.2943549336341675e-05
population O 0 7.368066601287637e-09
. O 0 2.0820804635945933e-08

The O 0 5.580530171300779e-08
identification O 0 8.850757460265868e-09
of O 0 1.579956254715853e-08
common O 0 4.2057898497205315e-08
BRCA1 O 0 2.1060694166408211e-07
and O 0 2.246821750873096e-08
BRCA2 O 0 1.6263430779872579e-07
mutations O 0 1.4994482322450153e-09
will O 0 1.6099983846107335e-10
facilitate O 0 1.2159687479140757e-08
carrier O 0 1.3113846009105146e-08
detection O 0 5.7159535771234005e-08
in O 0 2.6057609403551396e-09
French O 0 2.012066261158907e-06
Canadian O 0 0.027392596006393433
breast B-Disease 1 0.9999980926513672
cancer I-Disease 1 0.5008885860443115
and O 0 7.840760372346267e-05
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 6.737543003509927e-07
. O 0 8.126222894588864e-08

Are O 0 4.805646653949225e-07
Dp71 O 0 0.0001146314971265383
and O 0 1.3476699223247124e-07
Dp140 O 0 0.00035509635927155614
brain O 0 0.0003624091623350978
dystrophin O 0 3.903443030139897e-06
isoforms O 0 3.5699112999054705e-08
related O 0 2.6500908134607926e-08
to O 0 3.030910411538912e-09
cognitive B-Disease 0 0.0022502343636006117
impairment I-Disease 1 0.9999797344207764
in O 0 0.0006362815038301051
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
? O 0 2.137346746167168e-05

Molecular O 0 1.969836557691451e-05
study O 0 4.4323311243488206e-08
and O 0 1.0617844381499708e-09
neuropsychological O 0 9.489541241691768e-08
analysis O 0 1.1348308959213682e-08
were O 0 2.172751756290836e-09
performed O 0 3.0532785189052447e-09
concurrently O 0 2.7154465342960066e-08
on O 0 1.1629664342649448e-08
49 O 0 6.118091988582819e-08
patients O 0 1.5825855070872308e-09
with O 0 7.324978845701935e-09
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 2.4119604859151877e-05
DMD B-Disease 1 1.0
) O 0 1.0047176424166082e-09
in O 0 1.244390285259911e-10
order O 0 5.422919890918365e-10
to O 0 2.6850469070360816e-10
find O 0 7.731349782602592e-09
a O 0 5.9864158075129126e-09
molecular O 0 1.0667664973595947e-08
explanation O 0 2.383480746104283e-09
for O 0 1.051934858664616e-10
the O 0 5.345124787226041e-09
cognitive B-Disease 0 2.064510772470385e-05
impairment I-Disease 0 7.138250566640636e-06
observed O 0 4.0074866092254524e-08
in O 0 8.160903952614262e-09
most O 0 4.539856135465925e-08
DMD B-Disease 1 1.0
patients O 0 8.556168609175074e-07
. O 0 1.0934151362107514e-07

Complete O 0 1.8396233372186543e-06
analysis O 0 2.7051083861806546e-07
of O 0 5.04402244416724e-08
the O 0 7.195864526465812e-08
dystrophin O 0 2.0483448679442517e-06
gene O 0 2.76483991257237e-08
was O 0 7.67849215321803e-08
performed O 0 7.357324083301364e-09
to O 0 2.2824684364763925e-09
define O 0 4.01737452193629e-08
the O 0 3.212780796957304e-08
localization O 0 3.8123730519146193e-06
of O 0 3.8113004308115705e-08
deletions O 0 4.236287054482091e-08
and O 0 3.1123765786844615e-09
duplications O 0 2.515789105927979e-07
in O 0 1.9574375897946084e-08
relation O 0 3.995020563252183e-07
to O 0 4.784836082905031e-09
the O 0 6.028388099821314e-08
different O 0 4.315697879064828e-07
DMD B-Disease 1 1.0
promoters O 0 0.0002495242515578866
. O 0 1.3362699746721773e-06

Qualitative O 0 5.337962647899985e-05
analysis O 0 1.0307437605661107e-06
of O 0 1.6391065571497165e-07
the O 0 1.000396920858293e-07
Dp71 O 0 4.5587363274535164e-05
transcript O 0 1.6771798527770443e-06
and O 0 1.5451525614551542e-09
testing O 0 1.0594096711002976e-09
for O 0 6.844682598483587e-10
the O 0 5.3503064201265715e-09
specific O 0 6.202061531013214e-09
first O 0 6.705019472974527e-08
exon O 0 2.0550000101593469e-07
of O 0 1.1419728451755873e-07
Dp140 O 0 2.5898775675159413e-06
were O 0 8.796637018804176e-08
also O 0 9.955901880687179e-09
carried O 0 5.457457774582508e-08
out O 0 8.632452619394826e-08
. O 0 3.088788389504771e-07

Neuropsychological O 0 6.412259244825691e-05
analysis O 0 1.512338826614723e-06
assessed O 0 1.4620928823205759e-06
verbal O 0 2.6894633720075944e-06
and O 0 1.2727932130474073e-07
visuospatial O 0 0.2940218448638916
intelligence O 0 8.288891694974154e-05
, O 0 7.827144088423665e-08
verbal O 0 1.2718988728011027e-05
memory O 1 0.8110753297805786
, O 0 5.0927543071566106e-08
and O 0 3.7453617096616654e-08
reading O 0 2.5846446078503504e-05
skills O 0 0.0008981930441223085
. O 0 5.522816991287982e-06

Comparison O 0 4.3651143641909584e-06
of O 0 1.581437203412861e-07
molecular O 0 8.000037041711039e-07
and O 0 1.0451640441999643e-08
psychometric O 0 6.301742359937634e-06
findings O 0 7.117309053228382e-08
demonstrated O 0 2.4260501163553272e-08
that O 0 1.1466753102595817e-09
deletions O 0 6.157835574782666e-09
and O 0 1.1564671442698682e-09
duplications O 0 4.930900487920553e-08
that O 0 3.420518868146871e-10
were O 0 7.397708667866709e-09
localized O 0 1.0198380806514251e-07
in O 0 1.1649555098358633e-08
the O 0 9.462322481113006e-08
distal O 0 3.0296891964098904e-06
part O 0 1.485520897404058e-07
of O 0 1.929759037011536e-06
the O 0 1.068299638973258e-06
gene O 0 2.069182158948024e-08
seemed O 0 1.0689234386518365e-08
to O 0 2.2176252501004967e-10
be O 0 3.2869407196045586e-10
preferentially O 0 6.710275446408787e-09
associated O 0 1.4645047841099768e-08
with O 0 9.801193634473293e-09
cognitive B-Disease 1 0.9998407363891602
impairment I-Disease 1 0.99998939037323
. O 0 3.08412495542143e-06

Two O 0 1.2340929060883354e-06
altered O 0 8.412656029577192e-07
Dp71 O 0 4.0044284105533734e-05
transcripts O 0 3.061052211705828e-06
and O 0 5.4095550261479275e-09
two O 0 4.09339762086347e-09
deleted O 0 1.7084778392018052e-07
Dp140 O 0 1.3502544504717662e-07
DNA O 0 9.388074317939754e-09
sequences O 0 4.308910117600817e-09
were O 0 1.9495860481555383e-09
found O 0 8.082038371881595e-10
in O 0 6.193700552437065e-10
four O 0 3.237316636983678e-09
patients O 0 1.1442699010544288e-09
with O 0 2.1072934508481467e-09
severe O 1 0.9999986886978149
cerebral B-Disease 1 1.0
dysfunction I-Disease 1 1.0
. O 0 7.699382695136592e-05

These O 0 4.410741638594118e-08
findings O 0 7.54743254560708e-08
suggest O 0 1.833204343881789e-08
that O 0 1.4063374076389579e-10
some O 0 1.2805702331863955e-10
sequences O 0 2.5335846753904434e-09
located O 0 8.723217703732189e-09
in O 0 1.1398283428221134e-09
the O 0 1.8617500430195832e-08
distal O 0 3.969378212786978e-07
part O 0 3.974374251924928e-08
of O 0 9.036953940722015e-08
the O 0 3.924252212073043e-08
gene O 0 7.934156665001524e-10
and O 0 1.5891665761103013e-10
, O 0 1.0437784664363292e-10
in O 0 1.7012498354507244e-10
particular O 0 1.4373700008007972e-09
, O 0 7.688406022943184e-10
some O 0 3.6047846929676552e-09
DMD B-Disease 1 1.0
isoforms O 0 1.9801902340077504e-08
expressed O 0 8.048748334488209e-10
in O 0 1.218559253501894e-09
the O 0 2.137354648823475e-08
brain O 0 4.19138586948975e-06
may O 0 6.101806282465816e-10
be O 0 1.1171058522663202e-10
related O 0 2.7641635647057683e-09
to O 0 2.462490489296698e-10
the O 0 9.734719697007677e-09
cognitive B-Disease 0 0.32683590054512024
impairment I-Disease 0 0.0004590155149344355
associated O 0 4.4780395569432585e-07
with O 0 7.045562000485006e-08
DMD B-Disease 1 1.0
. O 0 9.324155314516247e-08
. O 0 1.2946667027335934e-07

I1307K O 0 0.00032651450601406395
APC O 0 1.0775458576972596e-05
and O 0 2.400572718386229e-08
hMLH1 O 0 9.287322200179915e-07
mutations O 0 1.3101745466315151e-08
in O 0 4.3039980468506656e-09
a O 0 2.464903836596477e-08
non O 0 5.616008365905145e-06
- O 0 1.12346378955408e-06
Jewish O 0 3.56219584318751e-06
family O 0 8.232965598153896e-08
with O 0 1.244891856266861e-09
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.003930732142180204

We O 0 9.188055969389097e-07
describe O 0 9.479182381255669e-07
a O 0 1.9647059446015191e-07
French O 0 8.804154276731424e-07
Canadian O 0 9.108166523219552e-06
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 1 1.0
HNPCC B-Disease 1 1.0
) O 0 1.7242405192519072e-07
kindred O 0 3.4058402889058925e-06
which O 0 1.1320629988986752e-09
carries O 0 3.208933119225321e-09
a O 0 6.103345828734064e-09
novel O 0 8.38022842231112e-08
truncating O 0 2.3139880340750096e-06
mutation O 0 3.44334125657042e-08
in O 0 6.761088400253357e-08
hMLH1 O 0 1.292063643631991e-05
. O 0 7.636886039108504e-07

Interestingly O 0 9.078916264115833e-06
, O 0 1.755127776448262e-08
the O 0 5.317833640106073e-08
I1307K O 0 6.4487967392778955e-06
APC O 0 1.2469490684452467e-06
polymorphism O 0 1.3428191891762253e-07
, O 0 4.730947300579658e-10
associated O 0 2.4498569839437323e-09
with O 0 7.90303933406733e-11
an O 0 2.6323263568883704e-09
increased O 0 5.818526815914993e-08
risk O 0 4.226378678140463e-06
of O 1 0.9999105930328369
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 6.225346282917599e-07
is O 0 2.818724809117157e-09
also O 0 1.186423043142426e-10
present O 0 5.867009100768428e-10
in O 0 2.6140991593592844e-09
this O 0 1.552891149003699e-08
family O 0 2.581838316473295e-07
. O 0 1.6206809050345328e-07

The O 0 2.736755277510383e-06
I1307K O 0 1.3785080227535218e-05
polymorphism O 0 9.517208354736795e-07
has O 0 2.00107175274411e-09
previously O 0 1.7885595227085105e-09
only O 0 1.7522060191677014e-10
been O 0 4.374785256278102e-10
identified O 0 1.1472397476453011e-09
in O 0 1.2173326791042882e-09
individuals O 0 1.068101607160088e-09
of O 0 5.625086600957729e-07
self O 0 0.00017696534632705152
- O 0 1.2287014214962255e-05
reported O 0 1.6859791003298596e-06
Ashkenazi O 0 2.670539970495156e-06
Jewish O 0 9.871173460851423e-07
origins O 0 1.7367577811455703e-06
. O 0 4.086262777036609e-07

In O 0 2.8902007898068405e-07
addition O 0 5.6535533587975806e-08
, O 0 2.7907784971858973e-09
in O 0 5.846111594820513e-09
this O 0 1.2847037211827228e-08
family O 0 6.412586373016893e-08
, O 0 1.713710839901239e-09
there O 0 9.604658401940469e-09
appears O 0 2.4819959421051863e-08
to O 0 1.5989393142845643e-09
be O 0 6.3056924126669855e-09
no O 0 2.6100799743744574e-08
relationship O 0 3.8490256315526494e-08
between O 0 6.349623493662193e-09
the O 0 8.169858567441679e-09
I1307K O 0 2.844036259830318e-07
polymorphism O 0 3.2202166266870336e-08
and O 0 3.077646471005835e-10
the O 0 1.1312645264993648e-09
presence O 0 4.146953447303758e-09
or O 0 1.2287403095001537e-08
absence O 0 4.2173815018031746e-07
of O 0 1.3388403203862254e-06
cancer B-Disease 0 2.53202188105206e-06
. O 0 3.53570399624914e-08
. O 0 1.6753672582581203e-07

Identification O 0 2.4221678813773906e-06
of O 0 1.0968093278052038e-07
a O 0 2.211131722162918e-08
novel O 0 6.597040425049272e-08
mutation O 0 5.584914308798261e-09
of O 0 4.0216139751692026e-08
the O 0 4.165911491327279e-07
CPO O 0 0.00017037543875630945
gene O 0 6.290606791026221e-08
in O 0 1.7972052290815554e-08
a O 0 4.059221794250334e-07
Japanese O 0 0.0020036688074469566
hereditary B-Disease 1 0.9999978542327881
coproporphyria I-Disease 1 0.9999799728393555
family O 0 2.8742590075125918e-05
. O 0 7.138585260690888e-07

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 0.9999998807907104
( O 0 0.008398415520787239
HCP B-Disease 1 1.0
) O 0 3.709173199695215e-07
is O 0 9.157401947845756e-09
an O 0 6.81528646850893e-08
autosomal B-Disease 1 0.9999994039535522
dominant I-Disease 1 0.9999998807907104
disease I-Disease 1 0.9999954700469971
characterized O 0 5.335272703632654e-07
by O 0 2.431595547136567e-08
a O 0 8.45046486119827e-07
deficiency B-Disease 1 0.8342177271842957
of I-Disease 0 0.00036579984589479864
coproporphyrinogen I-Disease 1 0.7230212092399597
oxidase I-Disease 0 3.0602116112277145e-06
( O 0 1.422554589680658e-07
CPO O 0 1.6464431610074826e-05
) O 0 1.0202910516454722e-08
caused O 0 1.399731619500244e-08
by O 0 2.121962605627914e-09
a O 0 1.8139077795353842e-08
mutation O 0 1.6310914841000113e-09
in O 0 8.644427396120591e-09
the O 0 3.33962674403665e-07
CPO O 0 0.00022198435908649117
gene O 0 7.615394679305609e-07
. O 0 2.44895716150495e-07

Only O 0 3.691722270104947e-07
11 O 0 1.5317792190217006e-07
mutations O 0 6.645191064080791e-09
of O 0 2.685362154863924e-08
the O 0 7.063201934442986e-08
gene O 0 1.278175254526559e-08
have O 0 7.528705436854466e-10
been O 0 8.20199108630959e-09
reported O 0 4.4907924490189544e-08
in O 0 6.751913161906486e-08
HCP B-Disease 1 1.0
patients O 0 4.286487182980636e-06
. O 0 7.703561095695477e-07

We O 0 6.568563435394026e-07
report O 0 1.318553302098735e-07
another O 0 2.195661785719949e-08
mutation O 0 3.894625066891422e-09
in O 0 8.433828746490235e-09
a O 0 1.0715550757822712e-07
Japanese O 0 0.00010753644164651632
family O 0 1.99513669940643e-06
. O 0 3.9135747442742286e-07

Polymerase O 0 6.363902502926067e-05
chain O 0 5.953884851805924e-07
reaction O 0 2.0559834723599124e-08
- O 0 2.6489182403111045e-08
single O 0 9.198803496701657e-09
strand O 0 1.4640829881784612e-08
conformational O 0 2.0869697081593586e-09
polymorphism O 0 1.969319152195226e-09
and O 0 2.2609790775729444e-11
direct O 0 3.291777683767094e-10
sequence O 0 9.315774818219325e-10
analyses O 0 4.96358465440494e-09
demonstrated O 0 3.2703582064641523e-09
a O 0 8.344480662003662e-09
C O 0 5.4657498083088285e-08
to O 0 4.072177262059995e-09
T O 0 1.723006981535491e-08
substitution O 0 1.5893493188201546e-09
in O 0 5.003087277799523e-09
exon O 0 2.915427899097267e-08
1 O 0 9.561995639728593e-09
of O 0 4.471609749145955e-09
the O 0 2.9321187255959558e-08
CPO O 0 2.745203573795152e-06
gene O 0 1.1303936453543884e-08
at O 0 3.166363526929672e-08
nucleotide O 0 8.18800529600594e-08
position O 0 4.052266788789893e-08
85 O 0 1.4020590022312263e-08
, O 0 3.5473868287283494e-10
which O 0 1.7251490513903178e-10
lies O 0 2.2987263648133194e-08
in O 0 2.3127675330414377e-09
the O 0 1.663506843385676e-08
putative O 0 4.0774418152977887e-07
presequence O 0 6.282129447754414e-07
for O 0 3.3155227452397185e-09
targeting O 0 2.2496605467381414e-08
to O 0 1.1264098098706654e-08
mitochondria O 0 1.1465980378488894e-06
. O 0 3.7334797298171907e-07

This O 0 2.988421599070534e-08
mutation O 0 1.4265678638381019e-09
changes O 0 3.332067399774985e-10
the O 0 1.385552006460955e-09
codon O 0 1.3458289593870632e-08
for O 0 8.380172111799311e-10
glutamine O 0 4.417165300196757e-08
to O 0 2.212683147817529e-09
a O 0 1.0713769427184161e-08
termination O 0 2.589284804344061e-07
codon O 0 8.442997341262526e-07
at O 0 2.929844526988745e-07
amino O 0 3.358807134645758e-07
acid O 0 1.1298013191662903e-07
position O 0 7.451139936165418e-07
29 O 0 4.489782895689132e-06
. O 0 2.644801782025752e-07

MaeI O 0 0.0008476267103105783
restriction O 0 9.617876912670908e-07
analysis O 0 1.3520559605240123e-07
showed O 0 2.9073149221403582e-08
two O 0 5.846733652781211e-10
other O 0 3.6355854438063773e-10
carriers O 0 1.27517219006279e-09
in O 0 9.275797019370202e-09
the O 0 3.714451111136441e-07
family O 0 4.483775228436571e-06
. O 0 1.290661657549208e-06

The O 0 9.494132427789737e-06
C O 0 0.0995546355843544
- O 0 0.0023888791911303997
T O 0 1.3559825674747117e-05
mutation O 0 1.8371002497019617e-08
is O 0 1.088439005592079e-09
located O 0 5.98061777878911e-09
within O 0 2.7279456471518415e-09
a O 0 9.24825638293214e-09
recently O 0 2.203081495011361e-09
proposed O 0 1.6774007738362684e-09
putative O 0 9.355989760706507e-08
alternative O 0 1.045961806056539e-08
translation O 0 1.4989034013979108e-07
initiation O 0 4.160487065973939e-08
codon O 0 2.965527556852976e-08
( O 0 3.910703316734043e-09
TIC O 0 1.8969481629937945e-07
- O 0 1.690983353341835e-08
1 O 0 2.28110721423036e-08
) O 0 5.775642186733876e-10
, O 0 2.406851107306096e-10
supporting O 0 5.510906397887538e-09
that O 0 1.620900524912372e-09
TIC O 0 1.2296898148633773e-06
- O 0 9.335009565347718e-08
1 O 0 5.865548757810757e-08
is O 0 2.014394206995007e-09
the O 0 8.489429603741883e-09
real O 0 1.0292458227922907e-06
TIC O 0 7.610409284097841e-06
rather O 0 3.6121232227515065e-08
than O 0 5.068892416915105e-09
TIC O 0 1.7165797316920361e-06
- O 0 6.989385781253077e-08
2 O 0 4.326420466327363e-08
. O 0 3.3195153292808754e-09
. O 0 3.128221237602702e-08

Human B-Disease 0 7.016835184003867e-07
complement I-Disease 0 1.8438036022416782e-06
factor I-Disease 0 0.0015811093617230654
H I-Disease 1 1.0
deficiency I-Disease 1 1.0
associated O 0 0.02106962539255619
with O 0 0.00012008757767034695
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.016065340489149094

This O 0 1.4637375045367662e-07
study O 0 4.573360001813853e-08
reports O 0 1.4208904275392342e-08
on O 0 2.2283237477438433e-09
six O 0 1.5208896364526936e-09
cases O 0 3.7886976889112134e-10
of O 0 1.9036766829572116e-08
deficiency B-Disease 0 0.03589685261249542
in I-Disease 0 2.1473043787523238e-08
the I-Disease 0 5.7174904810608496e-08
human I-Disease 0 4.712918943994282e-09
complement I-Disease 0 7.457606976402076e-09
regulatory I-Disease 0 2.879314031645208e-08
protein I-Disease 0 4.3462868859478476e-08
Factor I-Disease 0 3.079987607179646e-07
H I-Disease 0 0.10492367297410965
( O 0 1.3956900524192406e-08
FH O 0 2.516826043574838e-06
) O 0 2.1797573468429476e-10
in O 0 5.957864063210749e-11
the O 0 1.8187178152384575e-10
context O 0 3.7239331618366123e-09
of O 0 2.2555541878688246e-09
an O 0 4.0997914396712076e-08
acute B-Disease 1 1.0
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.00010356128768762574

Five O 0 3.0184799015842145e-07
of O 0 3.428687378459472e-08
the O 0 6.055987711306443e-09
cases O 0 1.2398280180292431e-09
were O 0 2.951103583725967e-09
observed O 0 2.140527533001091e-09
in O 0 5.766978561361213e-10
children O 0 7.780830424408691e-10
presenting O 0 2.3931850279268474e-08
with O 0 1.8814066606864799e-06
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 1.0
HUS B-Disease 1 1.0
) O 0 0.00027646057424135506
. O 0 5.11805637870566e-06

Two O 0 6.424215825973079e-08
of O 0 1.568612084668075e-08
the O 0 2.00850625020621e-08
children O 0 8.911331228489416e-09
exhibited O 0 5.155666826794914e-07
a O 0 1.6419850226156996e-06
homozygous O 0 6.32292676527868e-06
deficiency O 1 0.8492218255996704
characterized O 0 2.4197359493882686e-07
by O 0 7.786817413091285e-09
the O 0 3.47690018998037e-08
absence O 0 1.2203163635149394e-07
of O 0 5.246724299468042e-08
the O 0 8.36690450256583e-09
150 O 0 8.36548430527273e-09
- O 0 3.888961153108994e-09
kD O 0 3.901121772287297e-07
form O 0 2.233949691898829e-09
of O 0 1.1513576225752331e-07
Factor O 0 8.187899766198825e-06
H O 1 0.999997615814209
and O 0 2.6416260290318405e-09
the O 0 6.195086221794099e-09
presence O 0 4.65122917958638e-09
, O 0 1.0455364352068841e-09
upon O 0 3.5106388907024666e-08
immunoblotting O 0 1.6614686728644301e-06
, O 0 2.6925306428893236e-09
of O 0 1.1384210019116381e-08
the O 0 1.2103044788602801e-08
42 O 0 4.17816536923965e-08
- O 0 3.6436073713730366e-08
kD O 0 3.7479785532923415e-05
Factor O 0 2.44670136453351e-05
H O 1 0.9956081509590149
- O 0 3.211387706869573e-07
like O 0 6.457937296033833e-09
protein O 0 2.2666993615416686e-08
1 O 0 3.1403928346662724e-08
( O 0 2.3069828269939308e-09
FHL O 0 3.0891536084709514e-07
- O 0 1.2027792095636869e-08
1 O 0 8.501030990260006e-09
) O 0 2.335324711388864e-10
and O 0 1.1519248749314315e-10
other O 0 3.3021285705814307e-10
FH O 0 5.1067786444036756e-06
- O 0 7.342858765468918e-08
related O 0 1.4040425355688058e-07
protein O 0 1.9105922888229543e-07
( O 0 1.4046151797231232e-08
FHR O 0 1.0172335350944195e-05
) O 0 1.2603190491233818e-08
bands O 0 1.104107454352743e-07
. O 0 2.565197974035982e-07

Southern O 0 6.320533429970965e-06
blot O 0 3.474651066426304e-06
and O 0 5.514460443833968e-09
PCR O 0 5.831447680293422e-08
analysis O 0 4.177979739949933e-09
of O 0 2.3117576741782386e-09
DNA O 0 6.81067069407959e-09
of O 0 3.9778149663050044e-09
one O 0 3.3674902866209777e-09
patient O 0 2.0680142043261185e-08
with O 0 1.8680521574054865e-09
homozygous O 0 1.3017101991863456e-06
deficiency O 0 0.05967884138226509
ruled O 0 2.822169165028754e-08
out O 0 1.9778112481105836e-09
the O 0 2.228621287514443e-09
presence O 0 1.6816100734118322e-09
of O 0 3.1082476592558805e-09
a O 0 1.1017041723349053e-09
large O 0 8.032124410028985e-10
deletion O 0 8.51005044211206e-09
of O 0 1.1622057982663136e-08
the O 0 4.679742815483223e-08
FH O 0 0.00012432668881956488
gene O 0 4.616599991180692e-09
as O 0 5.825927518188223e-10
the O 0 6.644151451240532e-09
underlying O 0 4.271699071978219e-05
defect O 0 1.1415463632147294e-06
for O 0 8.945271190441417e-09
the O 0 1.0588383929643896e-06
deficiency O 1 0.9999908208847046
. O 0 7.933913366287015e-06

The O 0 1.8885276631408487e-07
other O 0 7.494106446515048e-10
four O 0 1.519503745051054e-09
children O 0 3.512664881188954e-10
presented O 0 5.572252437247016e-09
with O 0 7.707438243187426e-09
heterozygous O 0 9.693970241642091e-06
deficiency O 1 0.6520988345146179
and O 0 1.232749813340206e-08
exhibited O 0 2.3596180653839838e-06
a O 0 1.203237843583338e-06
normal O 0 4.957275450578891e-06
immunoblotting O 0 6.155140908958856e-06
pattern O 0 1.059851157947378e-07
of O 0 1.7670858554197366e-08
proteins O 0 5.327048580028304e-09
of O 0 3.090927691573597e-07
the O 0 1.568802326801233e-05
FH O 1 0.9999988079071045
family O 0 4.337254267738899e-06
. O 0 4.089311289590114e-07

Factor B-Disease 1 0.9999995231628418
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
is O 0 1.3852250013712819e-08
the O 0 1.602946397838423e-08
only O 0 4.826958743819887e-08
complement B-Disease 1 0.9999988079071045
deficiency I-Disease 1 1.0
associated O 0 0.0003491270763333887
with O 0 7.694192163398839e-07
HUS B-Disease 1 1.0
. O 0 6.939559170859866e-06

These O 0 6.118629158891054e-08
observations O 0 1.112019731408509e-06
suggest O 0 8.302001930360348e-08
a O 0 2.3783549352174305e-08
role O 0 4.602798142627762e-08
for O 0 1.2989154640763445e-08
FH O 0 2.7157084332429804e-05
and O 0 1.0699416463921807e-07
/ O 0 1.3395258974924218e-05
or O 0 3.105816972492903e-07
FH O 0 8.291783888125792e-05
receptors O 0 2.2618451112066396e-08
in O 0 8.581766408610747e-10
the O 0 1.211761979647008e-08
pathogenesis O 0 0.000246612326009199
of O 0 6.696687705698423e-06
idiopathic O 1 0.9999978542327881
HUS B-Disease 1 1.0
. O 0 4.688793637797062e-07
. O 0 5.648885803566372e-07

Further O 0 1.628407346743188e-07
evidence O 0 1.4165695461088035e-07
for O 0 2.3001505145003875e-09
a O 0 5.698826743838481e-09
major O 0 7.87749332431531e-09
ancient O 0 1.1810662954303552e-06
mutation O 0 1.2806176528101787e-06
underlying O 1 0.7516875863075256
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 1.6200181107706157e-07
linkage O 0 2.3334450816037133e-06
disequilibrium O 0 1.792190801097604e-06
studies O 0 3.241822810196027e-08
in O 0 2.0809161060952874e-09
the O 0 1.2046205810634092e-08
Japanese O 0 2.9978868951729964e-06
population O 0 5.2858957211299185e-09
. O 0 3.0748861234997094e-08

The O 0 0.00025113290757872164
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0006853959639556706
DM B-Disease 1 1.0
) O 0 1.617788036867296e-08
mutation O 0 1.3118442998560909e-09
is O 0 5.083306553466116e-10
an O 0 2.2671089450199133e-09
unstable O 0 3.3075768897106173e-06
( O 0 5.602819896921574e-07
CTG O 0 0.0010276498505845666
) O 0 5.723764573417611e-08
n O 0 2.1259951665797416e-07
repeat O 0 8.49116617018808e-08
, O 0 5.473488329243992e-09
present O 0 1.2473310384564229e-08
at O 0 1.9611528045970772e-07
a O 0 1.4269741832606542e-08
copy O 0 2.6860536905815025e-08
number O 0 1.1309235770085024e-09
of O 0 3.8181453554386735e-09
5 O 0 9.517344246035009e-09
- O 0 9.824177915618293e-09
37 O 0 1.3581214375335549e-08
repeats O 0 1.1278953770954558e-08
on O 0 4.610845039110245e-09
normal O 0 2.3269901561207007e-08
chromosomes O 0 3.6894038935031404e-09
but O 0 3.9603254009534794e-10
amplified O 0 1.765799062525275e-08
to O 0 2.0339645523392846e-09
50 O 0 2.6444908485245833e-08
- O 0 2.8203610114019284e-08
3000 O 0 8.24259771547986e-08
copies O 0 1.528719728582928e-08
on O 0 2.0757961749495735e-07
DM B-Disease 1 0.9994852542877197
chromosomes O 0 7.49079731576785e-07
. O 0 1.0716757259388032e-07

Previous O 0 1.1492614930830314e-06
findings O 0 5.367971667169513e-08
in O 0 9.209179197000594e-09
Caucasian O 0 7.02416002695827e-07
populations O 0 1.0039289399799145e-08
of O 0 1.0831238483888228e-07
a O 0 1.919283386087045e-05
DM B-Disease 1 1.0
founder O 0 0.22450897097587585
chromosome O 0 5.928947757638525e-06
raise O 0 2.2566524648937047e-08
a O 0 4.5673078652441745e-09
question O 0 1.1173519887108796e-08
about O 0 9.692878721878628e-10
the O 0 1.7320672673903914e-09
molecular O 0 2.615916017134623e-08
events O 0 7.045358074719843e-09
involved O 0 5.665251379127767e-09
in O 0 5.7565632261002975e-09
the O 0 2.1797553984015394e-08
expansion O 0 4.39714682443082e-07
mutation O 0 1.0650185799931933e-07
. O 0 8.11304303738325e-08

To O 0 2.5268377612519544e-07
investigate O 0 2.7089214427178376e-07
whether O 0 4.759697702638732e-08
a O 0 1.6105043698644295e-07
founder O 0 3.284329523012275e-06
chromosome O 0 2.7282027303954237e-07
for O 0 4.655400509534502e-09
the O 0 4.1839192022052885e-07
DM B-Disease 1 1.0
mutation O 0 6.854588896487712e-09
exists O 0 4.657052077305934e-09
in O 0 2.558373513039669e-10
the O 0 1.0833955954581143e-09
Japanese O 0 1.342263544756861e-07
population O 0 5.542271155900558e-11
, O 0 3.1776119929771696e-11
we O 0 5.376440403992433e-10
genotyped O 0 3.266102908128232e-07
families O 0 9.958346369742799e-10
using O 0 1.2355479972470107e-09
polymorphic O 0 1.3130014409057367e-08
markers O 0 1.8660802680869892e-08
near O 0 1.7546433639381576e-07
the O 0 9.73396154790862e-08
( O 0 4.4040754687557637e-07
CTG O 0 0.0004449574917089194
) O 0 2.3852239294797073e-08
n O 0 1.2903350921078527e-07
repeat O 0 9.926685606842511e-08
region O 0 1.4677353021852468e-07
and O 0 2.7817032233201644e-08
constructed O 0 3.0106366466498002e-05
haplotypes O 0 3.09661882056389e-05
. O 0 9.527134352538269e-07

Six O 0 1.466062258259626e-06
different O 0 8.253700833904531e-09
haplotypes O 0 3.106619885784312e-07
were O 0 1.901528356995641e-08
found O 0 2.738733684282124e-08
and O 0 1.213800402410925e-07
DM B-Disease 1 1.0
alleles O 0 7.537276758284861e-08
were O 0 1.7857217926575686e-07
always O 0 6.731017947458895e-07
haplotype O 0 2.0753423086716793e-06
A O 0 4.465720394364325e-06
. O 0 9.770901669980958e-07

To O 0 1.4145230409212672e-07
find O 0 6.225744186849624e-08
an O 0 2.6342601433526625e-09
origin O 0 5.5334039572585425e-09
of O 0 4.4505611640488496e-08
the O 0 1.8932884415789886e-07
( O 0 1.8733021533989813e-07
CTG O 0 5.765044261352159e-05
) O 0 1.1014105183448919e-08
n O 0 3.002510950977921e-08
repeat O 0 1.9966575948160425e-08
mutation O 0 8.24222801121266e-10
and O 0 1.6219077469958876e-10
to O 0 3.306679097203613e-10
investigate O 0 2.3204217214356504e-08
the O 0 1.0413415907351009e-08
mechanism O 0 5.153243591848877e-07
of O 0 3.005926174637352e-08
the O 0 3.3012235167717563e-09
expansion O 0 1.796776949447576e-08
mutation O 0 3.041181750873534e-10
in O 0 1.7504656057987233e-10
the O 0 6.396565499500184e-10
Japanese O 0 6.531197982440062e-08
population O 0 6.62910698556729e-11
we O 0 5.62925921154811e-11
have O 0 4.4984838770689706e-11
studied O 0 1.006622873944707e-08
90 O 0 4.1156489771765337e-08
Japanese O 0 7.719586392340716e-06
DM B-Disease 1 1.0
families O 0 3.903183998232862e-09
comprising O 0 1.2303538632352229e-08
190 O 0 3.9682838348653604e-08
affected O 0 3.6315537244036022e-09
and O 0 9.6318775177906e-10
130 O 0 5.564958627246597e-08
unaffected O 0 7.748033681309607e-07
members O 0 2.1570823349748025e-08
. O 0 1.6786073331331863e-07

The O 0 9.902742021949962e-07
results O 0 9.690540281326321e-08
suggest O 0 9.728393024488469e-08
that O 0 6.010449915549998e-10
a O 0 4.529967068123142e-09
few O 0 1.7142895991639762e-09
common O 0 1.966068863268333e-09
ancestral O 0 4.81359563764272e-07
mutations O 0 8.06042399492668e-10
in O 0 6.972283306261318e-10
both O 0 6.918447481574219e-10
Caucasian O 0 2.8339886171124817e-07
and O 0 1.691572881767911e-09
Japanese O 0 4.2417223085067235e-06
populations O 0 7.822749115149463e-10
have O 0 3.175939719546328e-11
originated O 0 1.3431382672735026e-09
by O 0 9.724187427506692e-11
expansion O 0 4.346185189518792e-09
of O 0 7.4140662498223264e-09
an O 0 3.494750266952451e-09
ancestral O 0 2.7661198487294314e-07
n O 0 5.8902813293570944e-08
= O 0 5.359848387342936e-08
5 O 0 3.918221747056805e-09
repeat O 0 2.6745345937939646e-09
to O 0 1.5520672524971246e-09
n O 0 1.127334527950552e-07
= O 0 2.015914191133561e-07
19 O 0 9.654473132059138e-08
- O 0 5.6883610710656285e-08
37 O 0 9.280314117177113e-08
copies O 0 1.1756346651736749e-07
. O 0 7.056953421624712e-08

These O 0 2.1916534365118423e-08
data O 0 7.234646659526334e-08
support O 0 5.955597348616948e-09
multistep O 0 1.8470298357442516e-07
models O 0 2.687432143488877e-08
of O 0 4.259231900505256e-08
triplet O 0 3.2085667953651864e-06
repeat O 0 2.3068527355007973e-07
expansion O 0 2.609025386846042e-07
that O 0 1.1791481124845404e-09
have O 0 2.5437033035480283e-10
been O 0 2.7063484786538083e-10
proposed O 0 1.8347873220747601e-10
for O 0 7.029515303180744e-10
both O 0 6.112994554996476e-08
DM B-Disease 1 1.0
and O 0 1.2092289125575917e-06
Friedreichs B-Disease 1 0.9999812841415405
ataxia I-Disease 1 0.7826715707778931
. O 0 2.1565379881849367e-07
. O 0 5.84454255658784e-07

The O 0 4.3401320226621465e-07
molecular O 0 9.205720630234282e-07
basis O 0 3.493510575935943e-06
of O 0 0.0005886623403057456
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 4.6112691620692203e-07
the O 0 2.8507072258321386e-08
western O 0 2.748493166393473e-08
Cape O 0 3.5509856388671324e-07
, O 0 2.486733263751262e-09
South O 0 7.492155873478623e-08
Africa O 0 9.047508342518995e-08
. O 0 9.915294185702805e-08

Deficiency B-Disease 1 0.9999998807907104
of I-Disease 0 3.0051351131987758e-05
the I-Disease 0 1.2077906603735755e-06
sixth I-Disease 0 1.1870275557157584e-05
component I-Disease 0 6.014807240717346e-06
of I-Disease 0 1.7555321107920463e-07
human I-Disease 0 2.8589020928393438e-08
complement I-Disease 0 2.0250860188752995e-07
( O 0 1.7472292768161424e-07
C6 O 0 6.626766116824001e-05
) O 0 2.8897328974153424e-09
has O 0 1.0144046713733701e-10
been O 0 2.6375265860245634e-10
reported O 0 1.2087743028743603e-09
in O 0 3.765183997916921e-10
a O 0 1.0480901702081269e-09
number O 0 4.683595733467882e-10
of O 0 2.3155217743209278e-09
families O 0 6.340362124213073e-10
from O 0 1.622818435187412e-09
the O 0 7.206946595061936e-09
western O 0 1.4214244892229999e-08
Cape O 0 2.3853220909586526e-07
, O 0 4.018736454725058e-09
South O 0 5.454502272073114e-08
Africa O 0 8.876593682316525e-08
. O 0 1.607800470537768e-07

Meningococcal B-Disease 1 0.9999889135360718
disease I-Disease 1 0.9808400273323059
is O 0 4.872989123327898e-08
endemic O 0 5.6763301614637385e-08
in O 0 1.2623585510240787e-09
the O 0 4.753997639994623e-09
Cape O 0 3.080586736814439e-07
and O 0 3.8170147598215465e-10
almost O 0 3.1971119085483224e-09
all O 0 3.566899553497649e-10
pedigrees O 0 7.932605683436122e-08
of O 0 6.400391328043042e-08
total O 0 4.928249109070748e-05
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 6.893005320307566e-06
C6Q0 O 0 0.4295993447303772
) O 0 6.288157106126846e-09
have O 0 6.458151374788557e-11
been O 0 5.160727956088351e-10
ascertained O 0 7.021280623575876e-08
because O 0 1.780886771385326e-09
of O 0 1.1001134225807618e-07
recurrent O 1 0.9998304843902588
disease O 1 0.9835531711578369
. O 0 1.1345731536493986e-06

We O 0 2.4480090132783516e-07
have O 0 5.2944519879361e-09
sequenced O 0 2.6963455468376196e-08
the O 0 1.2080143108050834e-08
expressed O 0 7.37016092600129e-09
exons O 0 7.589989792222696e-08
of O 0 3.7222022797323007e-08
the O 0 5.691247650929654e-08
C6 O 0 1.4625287803937681e-05
gene O 0 3.610735044290436e-10
from O 0 3.0394870648153827e-11
selected O 0 4.7954661075433336e-11
cases O 0 7.268467078214158e-11
and O 0 1.1156940649126312e-10
have O 0 8.156491454469617e-11
found O 0 1.4711588613991466e-09
three O 0 5.572911021545224e-09
molecular O 0 2.0155261154286563e-05
defects O 0 6.0788283008150756e-05
leading O 0 1.7536328300593595e-07
to O 0 1.2872079402370673e-08
total O 0 1.5011785762908403e-05
deficiency O 1 0.9999977350234985
879delG O 0 4.581233224598691e-05
, O 0 2.276629107456074e-09
which O 0 2.516356845116974e-10
is O 0 7.260932965991174e-10
the O 0 3.711976948039819e-09
common O 0 2.0027641767228488e-08
defect O 0 4.1149590401801106e-07
in O 0 5.49004974814693e-09
the O 0 2.8712248578699473e-08
Cape O 0 1.1096668686150224e-06
and O 0 4.550829491023478e-09
hitherto O 0 1.2593311566888588e-06
unreported O 0 1.6077989357654587e-06
, O 0 6.590054058008832e-10
and O 0 7.49969752966706e-10
1195delC O 0 1.076586499948462e-07
and O 0 3.105610435483186e-09
1936delG O 0 4.6654832885906217e-07
, O 0 4.55224435924606e-09
which O 0 3.7270861397153965e-10
have O 0 1.133000013253671e-10
been O 0 8.23463797150481e-10
previously O 0 1.5396109276366587e-08
reported O 0 3.5198915782075346e-08
in O 0 1.2556354178627771e-08
African O 0 6.39641257293988e-07
- O 0 1.5859212680879864e-06
Americans O 0 2.8743875191139523e-07
. O 0 3.543158015872905e-07

We O 0 7.949575433485734e-07
also O 0 1.7133197971475056e-08
show O 0 6.848603462117353e-09
that O 0 1.8802621959412846e-10
the O 0 4.757961580281744e-09
879delG O 0 3.683415741306817e-07
and O 0 7.93776422369774e-09
1195delC O 0 1.614367647562176e-05
defects O 0 1.0135614502360113e-05
are O 0 7.814457969601563e-10
associated O 0 6.569024879610197e-09
with O 0 9.666888622916758e-09
characteristic O 0 0.06460690498352051
C6 O 1 1.0
/ O 1 0.9863558411598206
C7 O 0 0.0026071895845234394
region O 0 1.4063756736959476e-07
DNA O 0 7.421779741889623e-07
marker O 0 1.6607116037903324e-07
haplotypes O 0 5.259248680999917e-08
, O 0 1.5700651889716255e-10
although O 0 3.0160768327291976e-10
small O 0 1.0244557424599066e-09
variations O 0 1.308628760909869e-08
were O 0 8.569572429451e-08
observed O 0 3.178441545514943e-07
. O 0 3.659983178749826e-07

The O 0 8.0203953984892e-06
1936delG O 0 4.832974445889704e-05
defect O 0 1.8116890714736655e-05
was O 0 2.0516496590516908e-07
observed O 0 1.7422799203359318e-08
only O 0 2.603177673421442e-09
once O 0 1.000240068549374e-08
in O 0 2.282446454060505e-09
the O 0 1.3794508646469694e-08
Cape O 0 7.809255748725263e-07
, O 0 8.408479468258179e-10
but O 0 3.543626503343944e-10
its O 0 1.2056864395759703e-09
associated O 0 4.2479868511691166e-08
haplotype O 0 1.78452665977602e-07
could O 0 9.370684672660445e-09
be O 0 4.681224652358651e-08
deduced O 0 9.927725841407664e-06
. O 0 7.049204100439965e-07

The O 0 2.3347953970187518e-07
data O 0 1.2097117974008142e-07
from O 0 4.286335286707299e-09
the O 0 5.558601134936225e-09
haplotypes O 0 8.725301370304805e-08
indicate O 0 3.1805074129920285e-09
that O 0 4.6986518842384584e-11
these O 0 1.9514152793664863e-10
three O 0 2.313998548331142e-09
molecular O 0 9.663311857366352e-07
defects O 0 7.920954203655128e-07
account O 0 2.4189345637637416e-08
for O 0 5.174490169679302e-09
the O 0 4.569898521822324e-07
defects O 0 1.2198317563161254e-05
in O 0 2.5598405173354877e-08
all O 0 8.425243613885414e-09
the O 0 5.4460091547525735e-08
38 O 0 1.7208334668339376e-07
unrelated O 0 3.8642087929474656e-07
C6Q0 O 0 0.00018960186571348459
individuals O 0 4.139848908124577e-09
we O 0 2.027882972654993e-09
have O 0 4.558063093629272e-10
studied O 0 3.668473880225065e-08
from O 0 2.77634963907758e-08
the O 0 1.2663653592426272e-07
Cape O 0 6.3496654547634535e-06
. O 0 3.049724170978152e-07

We O 0 1.0103431122843176e-06
have O 0 5.862895502417587e-09
also O 0 1.7058419121696033e-09
observed O 0 1.2287075357164667e-08
the O 0 2.27653469409006e-08
879delG O 0 1.80672429905826e-06
defect O 0 9.106439051720372e-07
in O 0 1.886579426013668e-08
two O 0 3.628619893447649e-08
Dutch O 1 0.8854928016662598
C6 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
kindreds O 0 1.603360396984499e-05
, O 0 1.6555455895073123e-09
but O 0 5.04158381708919e-10
the O 0 1.5652945606348112e-08
879delG O 0 1.231589749295381e-06
defect O 0 1.0682364290914848e-06
in O 0 2.2019694512209753e-08
the O 0 7.999276618875228e-08
Cape O 0 3.931743776774965e-06
probably O 0 2.0641414266719949e-07
did O 0 1.0280520434946538e-08
not O 0 6.854389278387885e-10
come O 0 7.959454761952145e-10
from O 0 1.7489181214358496e-09
The O 0 2.8120998862846136e-08
Netherlands O 0 8.639799631282585e-08
. O 0 2.75343072786427e-08
. O 0 1.5425686683556705e-07

Complement B-Disease 1 0.9999992847442627
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 5.717752316058977e-08
seven O 0 1.1264249089038003e-08
further O 0 1.0219816104495294e-08
molecular O 0 1.2979397070012055e-05
defects O 0 9.806143680179957e-06
and O 0 2.2381207998023456e-09
their O 0 3.002888959713346e-08
associated O 0 4.712876943813171e-06
marker O 0 1.5310040907934308e-05
haplotypes O 0 1.1843105312436819e-05
. O 0 5.293677531881258e-07

Seven O 0 4.4110743147030007e-07
further O 0 3.0952929108707394e-08
molecular O 0 5.454985512187704e-07
bases O 0 1.0015879752245382e-06
of O 0 0.009656216017901897
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 2.4805484599710326e-07
described O 0 1.3321346159500536e-06
. O 0 3.933034804504132e-07

All O 0 2.8432461718352897e-08
these O 0 1.6820110859683268e-09
new O 0 8.082505331685752e-09
molecular O 0 1.1927043033210794e-06
defects O 0 8.779118729762558e-07
involve O 0 4.864529401515938e-08
single O 0 1.992329146105476e-07
- O 0 2.4166939738279325e-07
nucleotide O 0 4.7314847506640945e-07
events O 0 2.4707309975724456e-08
, O 0 8.039879872967504e-10
deletions O 0 4.194507852162133e-09
and O 0 5.559276927691315e-10
substitutions O 0 2.2816948330728337e-08
, O 0 1.9969843556566502e-09
some O 0 7.123971412781316e-10
of O 0 1.2681002914405326e-08
which O 0 6.912594052721488e-09
alter O 0 2.557435152539256e-07
splice O 0 8.765515531194978e-07
sites O 0 3.687337368774024e-08
, O 0 1.3671732634890077e-09
and O 0 3.6391532010071614e-09
others O 0 4.825218979931378e-08
codons O 0 3.1127101465244778e-06
. O 0 1.8578163007987314e-06

They O 0 4.7293912786017245e-08
are O 0 7.414839853225885e-10
distributed O 0 1.9063137735031432e-09
along O 0 1.494862900131011e-08
the O 0 9.97346703002222e-08
C7 O 0 6.265424599405378e-05
gene O 0 5.096794097880775e-09
, O 0 1.9265666839629603e-10
but O 0 1.5945650355675411e-10
predominantly O 0 5.28942278865685e-10
towards O 0 1.4107986778810755e-08
the O 0 1.9480628665746735e-08
3 O 0 7.023544412732008e-08
end O 0 1.0860117072297726e-07
. O 0 8.50053254453087e-08

All O 0 2.4481818172716885e-07
were O 0 6.214331449427846e-08
found O 0 2.659762543544275e-08
in O 0 1.4611231335948105e-08
compound O 0 3.296382374173845e-06
heterozygous O 0 1.47746476386601e-07
individuals O 0 1.3372111418163968e-08
. O 0 1.3305610480074392e-07

The O 0 0.00038517476059496403
C6 O 1 0.9999886751174927
/ O 0 0.00571209192276001
C7 O 0 0.0008858112269081175
marker O 0 1.1965939847868867e-06
haplotypes O 0 3.577443976610084e-07
associated O 0 5.7059100555534314e-08
with O 0 1.5440692280321855e-08
most O 0 5.869196684216149e-07
C7 B-Disease 1 1.0
defects I-Disease 1 0.5871490836143494
are O 0 5.853285856005641e-09
tabulated O 0 5.625914582196856e-06
. O 0 1.463341021690212e-07
. O 0 3.9716920241517073e-07

A O 0 2.5373130938532995e-06
genome O 0 6.011613606915489e-08
- O 0 1.9804620166041786e-08
wide O 0 8.642185633789268e-09
search O 0 2.221085892983865e-08
for O 0 7.823659498029656e-10
chromosomal O 0 5.798484608021681e-07
loci O 0 4.2048593940080536e-08
linked O 0 2.4642650942041655e-07
to O 0 1.202464883220955e-08
mental O 1 0.9999926090240479
health O 0 4.239247573423199e-06
wellness O 0 1.0598490916891024e-05
in O 0 3.124939640386515e-09
relatives O 0 7.684612945979552e-09
at O 0 5.433566041546101e-09
high O 0 2.1794935634034118e-08
risk O 0 3.2523954018870427e-07
for O 0 5.915534870837291e-07
bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
among O 0 7.752661446147613e-08
the O 0 1.8461915374246018e-07
Old O 0 1.4779519005969632e-05
Order O 0 5.722126843465958e-07
Amish O 0 2.289538679178804e-05
. O 0 2.5520458279970626e-07

Bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
( O 1 0.9999977350234985
BPAD B-Disease 1 1.0
; O 1 0.999829888343811
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 1.0
) O 0 5.086629244033247e-05
is O 0 6.041913991339243e-08
characterized O 0 3.4182917829639337e-08
by O 0 8.120796479715864e-09
episodes O 0 1.4627594282501377e-06
of O 0 1.9602941392804496e-05
mania B-Disease 0 0.111174076795578
and O 0 0.00018845716840587556
/ O 1 1.0
or O 1 0.9995649456977844
hypomania B-Disease 1 1.0
interspersed O 0 0.00042523365118540823
with O 0 3.542907123232908e-08
periods O 0 0.20529033243656158
of O 1 0.8314369916915894
depression B-Disease 1 1.0
. O 0 1.668311597313732e-05

Compelling O 0 7.123934665287379e-06
evidence O 0 3.03059437101183e-07
supports O 0 8.680263618998652e-09
a O 0 1.5601433478451554e-09
significant O 0 1.5197935132604812e-09
genetic O 0 6.796318174906446e-09
component O 0 3.680507631997898e-08
in O 0 9.675922285623528e-10
the O 0 2.360327933104145e-08
susceptibility O 0 8.375801030524599e-08
to O 0 2.026793310960784e-08
develop O 0 5.851547484780895e-06
BPAD B-Disease 1 1.0
. O 0 1.6786738342489116e-05

To O 0 2.724333292292158e-08
date O 0 6.141979014273602e-08
, O 0 9.424416802517044e-10
however O 0 6.198179747229915e-10
, O 0 4.85968376651158e-10
linkage O 0 7.939856772054554e-08
studies O 0 3.2520395265578372e-09
have O 0 6.318399276006303e-11
attempted O 0 9.657489918879492e-09
only O 0 9.187944849387009e-10
to O 0 4.4833248225017996e-10
identify O 0 3.6905319689140015e-08
chromosomal O 0 1.4862621355860028e-06
loci O 0 5.3667331911810834e-08
that O 0 1.4066787734634545e-09
cause O 0 3.7722752921354186e-08
or O 0 8.26827495359339e-09
increase O 0 2.2477892880345962e-09
the O 0 6.960474863149102e-09
risk O 0 6.965497334476822e-08
of O 0 1.7929225748503086e-07
developing O 0 1.2178428733022884e-05
BPAD B-Disease 1 1.0
. O 0 4.7350690692837816e-06

To O 0 4.5010484228669156e-08
determine O 0 1.8104616472669477e-08
whether O 0 4.40338432383669e-09
there O 0 6.306113409237923e-09
could O 0 3.4171820928463603e-09
be O 0 3.941405424257027e-09
protective O 0 3.064662834617593e-08
alleles O 0 5.39109423769446e-10
that O 0 7.578276894903979e-11
prevent O 0 1.103384383860373e-09
or O 0 4.250010565698403e-09
reduce O 0 3.147869298558703e-09
the O 0 3.646200497087193e-08
risk O 0 3.443112177592411e-07
of O 0 1.1223205831356609e-07
developing O 0 1.9034143406315707e-05
BPAD B-Disease 1 1.0
, O 0 3.0683753315940976e-09
similar O 0 8.91312509909703e-11
to O 0 5.517758125406225e-11
what O 0 1.0617738632756613e-10
is O 0 4.111939261308706e-11
observed O 0 2.1604153188636843e-10
in O 0 1.1628588370005133e-10
other O 0 2.62776644888163e-09
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 3.213024291071065e-09
we O 0 2.247150465706227e-09
used O 0 4.458879843127761e-08
mental O 1 0.9303135871887207
health O 0 4.277982270650682e-07
wellness O 0 3.7604440876748413e-06
( O 0 2.231905327221284e-09
absence O 0 4.7575898776131e-09
of O 0 2.747841731931544e-09
any O 0 1.2665218207530415e-08
psychiatric B-Disease 1 0.9947957396507263
disorder I-Disease 0 0.00018168399401474744
) O 0 2.6074611358950506e-09
as O 0 5.288938731418114e-10
the O 0 2.2870834115451544e-09
phenotype O 0 8.785046468062774e-09
in O 0 1.9518631155790445e-09
our O 0 2.8520288353206524e-08
genome O 0 2.3078730038150752e-08
- O 0 3.398217529593239e-08
wide O 0 4.673124109899618e-08
linkage O 0 4.499731005580543e-07
scan O 0 7.334278961934615e-08
of O 0 1.220001699664408e-08
several O 0 1.3918347585573088e-09
large O 0 2.0730732686047304e-08
multigeneration O 0 3.3598716981941834e-05
Old O 0 6.597734227398178e-06
Order O 0 1.944698198030892e-07
Amish O 0 2.5909373562171822e-06
pedigrees O 0 1.7265770679841808e-07
exhibiting O 0 4.003101494731709e-08
an O 0 3.4524476610897636e-09
extremely O 0 5.85271955344524e-08
high O 0 2.133616021637863e-07
incidence O 0 9.18619662115816e-06
of O 0 2.077748104056809e-05
BPAD B-Disease 1 1.0
. O 0 1.435661852156045e-05

We O 0 8.7378060698029e-07
have O 0 1.0586102661136465e-08
found O 0 4.086485816401364e-09
strong O 0 5.650661272227353e-09
evidence O 0 9.44202227515234e-08
for O 0 9.59038004566537e-09
a O 0 2.231202671509891e-07
locus O 0 1.1519719009811524e-06
on O 0 1.0477752709903143e-07
chromosome O 0 9.051337883647648e-07
4p O 0 0.0002810639562085271
at O 0 4.486255875235656e-06
D4S2949 O 0 4.639377493731445e-06
( O 0 8.999507628004721e-08
maximum O 0 2.3065931031851505e-07
GENEHUNTER O 0 1.0989481779688504e-05
- O 0 3.563095845038333e-07
PLUS O 0 3.5419080290921556e-07
nonparametric O 0 5.048093498771777e-07
linkage O 0 9.9120036622935e-08
score O 0 2.8752639380513756e-08
= O 0 5.202261377235118e-08
4 O 0 1.0586788334876474e-08
. O 0 7.687819825186182e-10
05 O 0 2.949451811673498e-07
, O 0 6.355900250554214e-09
P O 0 1.915391749207629e-06
= O 0 7.863971518418111e-08
5 O 0 7.932194456827801e-09
. O 0 1.6504307642772886e-10
22 O 0 2.169558976916619e-09
x O 0 3.502450995895856e-09
10 O 0 2.2216144479614286e-09
( O 0 1.1735881155772176e-09
- O 0 4.497218597521169e-09
4 O 0 1.3634734230549839e-08
) O 0 1.1775814767744919e-09
; O 0 4.996476010710182e-10
SIBPAL O 0 2.2256845113588497e-06
Pempirical O 0 4.173500656179385e-06
value O 0 5.733510874961212e-07
< O 0 1.085241407849935e-07
3 O 0 5.765716348804517e-09
x O 0 4.523560637181845e-09
10 O 0 9.347188578701093e-10
( O 0 1.7555412679115534e-10
- O 0 5.343847586658512e-10
5 O 0 1.1394131194109036e-09
) O 0 1.321411591259647e-10
) O 0 3.8707967386919506e-11
and O 0 1.9748086846349544e-11
suggestive O 0 8.020156982979643e-09
evidence O 0 2.358595274642994e-08
for O 0 5.457205354275629e-09
a O 0 1.212070941392085e-07
locus O 0 5.810995844512945e-07
on O 0 4.7719879603391746e-08
chromosome O 0 1.3808969470119337e-06
4q O 0 5.231423529039603e-06
at O 0 1.5089260330114485e-07
D4S397 O 0 8.296776172755926e-07
( O 0 1.0723971932691256e-08
maximum O 0 7.495400211610104e-08
GENEHUNTER O 0 5.5699979384371545e-06
- O 0 1.2021627071590046e-07
PLUS O 0 5.280890604808519e-07
nonparametric O 0 1.0678983244361007e-06
linkage O 0 2.4499945538991597e-07
score O 0 1.744255051505661e-08
= O 0 2.5982435758464817e-08
3 O 0 3.035260931483208e-09
. O 0 1.738649779703394e-10
29 O 0 3.4518881086853526e-09
, O 0 1.951695471902326e-09
P O 0 7.974070399541233e-07
= O 0 4.783825602316938e-08
2 O 0 6.440568078858178e-09
. O 0 1.3010588439943405e-10
57 O 0 1.3139176413545783e-09
x O 0 2.5637481027018794e-09
10 O 0 1.2073249067157121e-09
( O 0 6.1949645413506e-10
- O 0 2.9798428169414137e-09
3 O 0 8.123677730509371e-09
) O 0 3.589783748036979e-10
; O 0 3.659099412356426e-10
SIBPAL O 0 1.9410661025176523e-06
Pempirical O 0 1.3841574855177896e-06
value O 0 1.1616344863796257e-07
< O 0 3.9088781988994015e-08
1 O 0 2.5679569581882333e-09
x O 0 2.058792247794372e-09
10 O 0 5.028906735482508e-10
( O 0 8.339141877033995e-11
- O 0 1.7076151603845346e-10
3 O 0 1.320721754183296e-09
) O 0 1.1388411741419802e-10
) O 0 2.8670284896170628e-11
that O 0 7.97189050882885e-12
are O 0 5.378191642035901e-11
linked O 0 7.510895905227244e-09
to O 0 4.162072464453104e-09
mental O 1 0.9993929862976074
health O 0 1.1197425010323059e-05
wellness O 0 0.00035238181590102613
. O 0 3.159637174121599e-07

These O 0 2.0013931845141997e-08
findings O 0 2.581108660137943e-08
are O 0 3.7979802636201043e-10
consistent O 0 6.39874064845003e-09
with O 0 6.151115033992127e-11
the O 0 1.5471992576010507e-09
hypothesis O 0 6.967514565303645e-09
that O 0 1.1184740633662926e-11
certain O 0 9.551596319434807e-11
alleles O 0 1.0986985626848522e-10
could O 0 1.7591611500833437e-10
prevent O 0 3.6421115012785776e-09
or O 0 5.686166648644075e-09
modify O 0 3.654114344442405e-09
the O 0 1.1173008296339049e-08
clinical O 0 8.214627200686664e-07
manifestations O 0 2.624612989166053e-06
of O 0 8.966147106548306e-06
BPAD B-Disease 1 1.0
and O 0 1.1542793387775419e-08
perhaps O 0 1.0389667792765067e-08
other O 0 1.2139474980799037e-09
related O 0 9.351739208796062e-06
affective B-Disease 1 0.9998619556427002
disorders I-Disease 1 1.0
. O 0 3.3619041914789705e-06

Segregation O 0 0.0015123607590794563
distortion O 0 0.004436034709215164
in O 0 2.9777202144032344e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 1.1041827747249044e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.8436921238899231
DM B-Disease 1 1.0
) O 0 9.314965154771926e-08
is O 0 4.5980752538810066e-09
an O 0 1.8270956303467756e-08
autosomal B-Disease 0 0.0932488664984703
dominant I-Disease 1 0.9586617946624756
disease I-Disease 0 0.03011818788945675
which O 0 3.4241500745935127e-09
, O 0 9.421396995890063e-10
in O 0 4.476012893661618e-09
the O 0 7.952041869430104e-08
typical O 0 6.723743808834115e-06
pedigree O 0 8.491722951475822e-07
, O 0 8.978633947442916e-10
shows O 0 4.458835078935408e-09
a O 0 2.8671136576008394e-09
three O 0 3.0341669177147423e-09
generation O 0 1.1403958666278413e-07
anticipation O 0 8.887332683116256e-07
cascade O 0 1.5132091903069522e-05
. O 0 4.6771279471613525e-07

This O 0 1.749719658050708e-08
results O 0 2.5580737528230202e-08
in O 0 7.576769434081143e-08
infertility B-Disease 1 0.9999942779541016
and O 0 4.778465518029407e-05
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.00874362699687481
CDM B-Disease 0 0.013857587240636349
) O 0 9.509065757029589e-10
with O 0 6.661401985574855e-11
the O 0 7.966248105617524e-09
disappearance O 0 8.747963875066489e-06
of O 0 1.1744409675884526e-05
DM B-Disease 1 1.0
in O 0 2.841035211531562e-07
that O 0 3.918410840242359e-08
pedigree O 0 9.107272489927709e-06
. O 0 3.6718276419378526e-07

The O 0 3.7590820056720986e-07
concept O 0 4.900522867501422e-07
of O 0 4.505102424445795e-07
segregation O 0 8.329757292813156e-07
distortion O 0 2.1544813080254244e-06
, O 0 1.6495377286318558e-09
where O 0 6.660376694611614e-10
there O 0 5.13620757036648e-10
is O 0 1.0717334658627564e-10
preferential O 0 1.4463547026721812e-09
transmission O 0 1.0888943968723197e-08
of O 0 1.1820529000061697e-09
the O 0 3.3324885073682253e-09
larger O 0 3.2925266957306576e-09
allele O 0 3.023635120058543e-09
at O 0 6.339158886703444e-08
the O 0 5.665421554112982e-07
DM B-Disease 1 1.0
locus O 0 1.1700292361638276e-06
, O 0 7.19100112789306e-10
has O 0 1.7397477902747482e-10
been O 0 2.7906441046887664e-10
put O 0 8.535731010894665e-10
forward O 0 7.975065052789887e-09
to O 0 7.172731297799828e-09
explain O 0 1.576128454416903e-07
partially O 0 1.5304561884477152e-06
the O 0 1.4665934600088804e-07
maintenance O 0 0.00010381994798080996
of O 0 1.4833260138402693e-05
DM B-Disease 1 1.0
in O 0 1.0146963091983707e-07
the O 0 1.1278571321327036e-07
population O 0 6.92671608959472e-09
. O 0 1.7848833522293717e-08

In O 0 7.983879299899854e-07
a O 0 1.872744803677051e-07
survey O 0 6.362973863360821e-07
of O 0 9.917523584590526e-07
DM B-Disease 1 1.0
in O 0 8.571877430085806e-08
Northern O 0 1.0935320204907839e-07
Ireland O 0 4.3633477275761834e-08
, O 0 1.1326511284437402e-08
59 O 0 3.070572915930825e-07
pedigrees O 0 1.6423608713012072e-06
were O 0 2.398367655587208e-07
ascertained O 0 1.0303241651854478e-05
. O 0 5.030432248531724e-07

Sibships O 0 0.0004994614864699543
where O 0 1.945519869650525e-07
the O 0 1.857189069198739e-08
status O 0 1.0975351294462143e-08
of O 0 1.3461703751715959e-08
all O 0 1.2795112747099324e-09
the O 0 3.2868106014660725e-09
members O 0 8.690861919014026e-10
had O 0 5.097610777937689e-09
been O 0 2.1505577318947644e-09
identified O 0 3.003293835845966e-09
were O 0 1.0514218384827245e-09
examined O 0 5.932117908002965e-09
to O 0 1.7990658962574457e-10
determine O 0 4.354283600349618e-09
the O 0 2.0717214610499468e-08
transmission O 0 2.1215595324974856e-07
of O 0 1.0258175109356671e-07
the O 0 9.383599035572843e-07
DM B-Disease 1 1.0
expansion O 0 3.4990679864677077e-07
from O 0 2.339571381071437e-08
affected O 0 1.1455260739978712e-08
parents O 0 1.5943955045116809e-09
to O 0 1.2169845131637658e-09
their O 0 9.797417988011148e-09
offspring O 0 2.1433972108297894e-07
. O 0 8.07163118565768e-08

Where O 0 4.51946380053414e-06
the O 0 1.4728224186910666e-06
transmitting O 0 0.05397731065750122
parent O 0 1.6765428881626576e-05
was O 0 1.9143733879900537e-05
male O 0 6.083967605263751e-07
, O 0 1.0316997922643623e-08
58 O 0 5.29836484020052e-07
. O 0 2.4284537403218565e-07

3 O 0 1.097070480682305e-06
% O 0 1.1908451114095442e-08
of O 0 3.3957798795114513e-09
the O 0 2.600155646348412e-09
offspring O 0 1.7322687728693609e-09
were O 0 2.0048347426637747e-09
affected O 0 7.236695687140582e-10
, O 0 2.8600008472601246e-10
and O 0 3.6608305276075725e-10
in O 0 3.006749960121624e-09
the O 0 6.110824291027939e-09
case O 0 1.737401689183571e-08
of O 0 5.296495331208462e-08
a O 0 1.3433482592972723e-07
female O 0 8.98482568345571e-08
transmitting O 0 1.7160608649646747e-06
parent O 0 4.6775699047429953e-07
, O 0 2.322276770883036e-08
68 O 0 1.6881914461919223e-06
. O 0 4.964406343788141e-07

7 O 0 7.534734322689474e-06
% O 0 4.462214420186683e-08
were O 0 3.766638556612634e-08
affected O 0 1.2530173876257322e-07
. O 0 1.62475870979506e-07

Studies O 0 4.260436071490403e-06
on O 0 9.700526248934693e-08
meiotic O 0 5.130249064677628e-06
drive O 0 5.545027761399979e-07
in O 0 1.206764181915787e-07
DM B-Disease 1 1.0
have O 0 1.2545718908185677e-09
shown O 0 1.461509802069827e-09
increased O 0 2.461998604985638e-09
transmission O 0 1.4039776452534625e-08
of O 0 1.385308867618562e-09
the O 0 7.484136088642401e-10
larger O 0 3.9964906384248877e-10
allele O 0 4.102876927092325e-10
at O 0 5.8315894335692064e-09
the O 0 2.9428592895897054e-08
DM B-Disease 1 0.9999964237213135
locus O 0 1.992557230323655e-07
in O 0 5.848197481839179e-09
non O 0 1.0047690466308268e-06
- O 0 9.595371011528187e-06
DM O 1 0.9999998807907104
heterozygotes O 0 6.7026940087089315e-06
for O 0 1.389340127389005e-07
CTGn O 0 0.0006507135694846511
. O 0 2.3815928216208704e-06

This O 0 3.954366434300027e-08
study O 0 1.5592933166885814e-08
provides O 0 1.6146921577586681e-09
further O 0 1.3496991024819494e-10
evidence O 0 6.35064090204196e-09
that O 0 1.2776725233365482e-09
the O 0 1.0642813919048422e-07
DM B-Disease 1 1.0
expansion O 0 4.075746460330265e-07
tends O 0 1.197625607574082e-07
to O 0 1.2821498307502566e-09
be O 0 3.404820647645579e-09
transmitted O 0 6.429180388067834e-08
preferentially O 0 2.518249289096275e-07
. O 0 1.3350275196444272e-07

Diagnosis O 1 0.9999980926513672
of O 0 0.006452552508562803
hemochromatosis B-Disease 1 1.0
. O 0 0.0003393143997527659

If O 0 6.85361010255292e-05
untreated O 1 0.9999997615814209
, O 0 4.194913344690576e-06
hemochromatosis B-Disease 1 1.0
can O 0 7.334379915846512e-06
cause O 1 0.7784281373023987
serious O 1 0.9994682669639587
illness O 1 0.999717652797699
and O 0 1.3692120326425083e-08
early B-Disease 0 4.694950348493876e-07
death I-Disease 0 2.3691050898833055e-08
, O 0 2.783791530625024e-10
but O 0 4.402685160886932e-10
the O 0 2.2716074354889315e-08
disease O 0 6.463367299147649e-07
is O 0 7.190123496592093e-10
still O 0 1.689003270577416e-09
substantially O 0 1.200066002127187e-08
under O 0 1.1158333563798806e-06
- O 0 0.0005914345965720713
diagnosed O 0 2.0008581486763433e-05
. O 0 3.482093973161682e-07

The O 0 3.5003070024686167e-06
cornerstone O 0 2.260421751998365e-05
of O 0 1.34858666456239e-07
screening O 0 1.1547307110504335e-08
and O 0 1.0008883721823736e-09
case O 0 5.883541209783516e-09
detection O 0 4.5582503105379146e-08
is O 0 4.95140317635645e-10
the O 0 2.6620501358820547e-09
measurement O 0 3.7560897681032657e-07
of O 0 5.427602900454076e-08
serum O 0 3.2538766845391365e-06
transferrin O 0 2.221951035608072e-05
saturation O 0 1.0033097623818321e-06
and O 0 1.8073245122707249e-09
the O 0 1.639038416101357e-08
serum O 0 1.180102572106989e-06
ferritin O 0 1.5657862604712136e-05
level O 0 3.2230911983788246e-06
. O 0 2.841452442226e-07

Once O 0 4.04017691835179e-06
the O 0 2.104666094737695e-07
diagnosis O 0 4.501259809330804e-06
is O 0 1.3980454127704434e-08
suspected O 0 3.4731692721834406e-07
, O 0 1.5443629708400408e-09
physicians O 0 5.365921929012529e-09
must O 0 2.462759551846716e-09
use O 0 7.972905891051596e-09
serum O 0 2.3229264115798287e-05
ferritin O 0 0.12655635178089142
levels O 0 2.7545249395188875e-05
and O 0 4.140806098007488e-08
hepatic O 0 0.0009692475432530046
iron O 0 0.010222573764622211
stores O 0 1.2979822372471972e-07
on O 0 2.100456697462505e-08
liver O 0 4.570691203298338e-08
biopsy O 0 1.6620797183009017e-08
specimens O 0 2.7872304464438002e-09
to O 0 3.0575658671594397e-10
assess O 0 7.138150692753698e-08
patients O 0 3.0274553974862783e-09
for O 0 9.624605556979304e-10
the O 0 9.67329256695848e-08
presence O 0 6.390583280335704e-07
of O 0 1.7839556676335633e-05
iron B-Disease 1 0.9999995231628418
overload I-Disease 1 0.9999897480010986
. O 0 2.765109684332856e-06

Liver O 1 0.9982434511184692
biopsy O 0 0.003881474258378148
is O 0 2.953368927194333e-08
also O 0 9.128292566273899e-10
used O 0 1.7632872939543631e-09
to O 0 8.275370944055283e-10
establish O 0 3.780717605650352e-08
the O 0 4.086168559069847e-08
presence O 0 3.3898022167022646e-08
or O 0 1.436893803941075e-08
absence O 0 1.0624702184713897e-07
of O 0 1.4053568975214148e-06
cirrhosis B-Disease 1 0.9999872446060181
, O 0 2.250478914334053e-09
which O 0 1.9594716127446787e-10
can O 0 5.444788508945919e-10
affect O 0 2.4346631377625272e-08
prognosis O 0 2.639187550812494e-05
and O 0 4.165664080346687e-08
management O 0 3.240412115701474e-05
. O 0 6.101661256252555e-07

A O 0 4.975377578375628e-06
DNA O 0 1.8622583297656092e-07
- O 0 1.2890112088825845e-08
based O 0 1.028820473258918e-09
test O 0 9.863038163970828e-10
for O 0 9.923667443345607e-10
the O 0 3.198973885787382e-08
HFE O 0 0.00011468004959169775
gene O 0 2.3223996059584806e-09
is O 0 5.4740045829504425e-11
commercially O 0 1.7039028521459443e-10
available O 0 1.1456690457434249e-10
, O 0 1.7219463702145e-11
but O 0 2.1772838740274914e-11
its O 0 6.265499924440476e-11
place O 0 1.0293955687856737e-09
in O 0 3.983887386649343e-10
the O 0 1.1208120653805054e-08
diagnosis O 0 7.130976882763207e-06
of O 0 3.474737241049297e-06
hemochromatosis B-Disease 1 1.0
is O 0 5.872489055036567e-07
still O 0 1.7710068078713448e-08
being O 0 2.0395324540345428e-08
evaluated O 0 4.1310880760647706e-07
. O 0 2.8095809057049337e-07

Currently O 0 4.5935456682855147e-07
, O 0 2.007363830713871e-09
the O 0 2.314899161248718e-09
most O 0 4.4593090331446206e-10
useful O 0 8.077203794698562e-09
role O 0 7.132391122155468e-09
for O 0 2.7397129009898435e-10
this O 0 4.3239489766477845e-10
test O 0 8.666495299181065e-10
is O 0 9.824397961821774e-10
in O 0 9.57862011929933e-10
the O 0 5.405088820964465e-09
detection O 0 7.364963607869868e-07
of O 0 3.3406029160687467e-06
hemochromatosis B-Disease 1 1.0
in O 0 5.114411578688305e-06
the O 0 9.548718935548095e-07
family O 0 1.140556804557491e-07
members O 0 5.175484485420156e-10
of O 0 6.493050985767468e-09
patients O 0 4.4620487860136393e-10
with O 0 8.327682293751693e-11
a O 0 1.813004857353917e-08
proven O 0 6.320119609881658e-07
case O 0 1.8020141823171798e-08
of O 0 2.356311235018893e-08
the O 0 1.7957873410523462e-07
disease O 0 6.070884865039261e-06
. O 0 1.4966923345127725e-07

It O 0 3.136214488108635e-08
is O 0 6.060032031740548e-09
crucial O 0 1.6129190782976366e-07
to O 0 9.355775887343043e-08
diagnose O 1 0.9999983310699463
hemochromatosis B-Disease 1 1.0
before O 1 1.0
hepatic B-Disease 1 1.0
cirrhosis I-Disease 1 1.0
develops O 0 0.0021744032856076956
because O 0 3.587823016459879e-08
phlebotomy O 1 0.9995675683021545
therapy O 0 7.301674486370757e-05
can O 0 7.922331679566241e-10
avert O 0 9.434566550226009e-07
serious O 1 0.9999885559082031
chronic O 1 1.0
disease O 1 1.0
and O 0 1.1715959757907513e-08
can O 0 5.53971934991182e-09
even O 0 7.203318830306671e-09
lead O 0 1.5948799614307063e-08
to O 0 2.4113326890784492e-09
normal O 0 1.3985661553306272e-06
life O 0 1.559273101747749e-07
expectancy O 0 2.467195088229346e-07
. O 0 1.3486651795346916e-09
. O 0 1.4793703151383397e-08

Prevalence O 0 0.0001613571948837489
of O 0 2.0162677571988752e-07
the O 0 2.2470193528079108e-07
I1307K O 0 1.2832208994950633e-05
APC B-Disease 0 1.2614707429747796e-06
gene O 0 4.623588178986893e-09
variant O 0 2.9990636640775392e-09
in O 0 5.287688065180873e-10
Israeli O 0 2.703328050301934e-08
Jews O 0 1.5544224796215644e-09
of O 0 2.41955983026898e-10
differing O 0 6.379589218008519e-11
ethnic O 0 5.02286476300462e-11
origin O 0 2.243260993628482e-10
and O 0 1.92548282873517e-10
risk O 0 4.172280299030717e-08
for O 0 1.3036532209298457e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00012929220974911004

BACKGROUND O 0 0.0010545399272814393
& O 0 8.33999874885194e-05
AIMS O 0 7.4259742177673616e-06
Israeli O 0 2.3877923922555055e-06
Jews O 0 1.2526912485100183e-07
of O 0 2.8332799217878346e-08
European O 0 5.820499637820831e-09
birth O 0 9.670004352813066e-09
, O 0 7.847287819551241e-10
i O 0 3.9282039843158145e-09
. O 0 6.883907333055106e-10
e O 0 6.891057502400599e-09
. O 0 2.243376456823043e-10
, O 0 6.022108922643099e-10
Ashkenazim O 0 1.5576173950648808e-07
, O 0 7.145390945595409e-10
have O 0 2.1311039044569213e-10
the O 0 7.3285284507562665e-09
highest O 1 0.8765659332275391
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 1 0.9981908202171326
of O 0 6.540222585726951e-08
any O 0 7.410743574354228e-09
Israeli O 0 2.8728470624628244e-07
ethnic O 0 6.9317911410848865e-09
group O 0 4.0865113959398514e-08
. O 0 4.876848080925811e-08

The O 0 2.055948607448954e-05
I1307K O 0 0.0006253636674955487
APC B-Disease 0 4.760223237099126e-05
gene O 0 9.473536266568772e-08
variant O 0 5.7861551994164984e-08
was O 0 2.5627772970437945e-07
found O 0 1.4020563376959672e-08
in O 0 3.078594801309009e-08
6 O 0 2.6685518150770804e-06
. O 0 4.4085717831876536e-07

1 O 0 5.866287438038853e-07
% O 0 5.954597703805575e-09
of O 0 3.983478880087432e-09
American O 0 6.337403490874749e-09
Jews O 0 7.199238982735778e-09
, O 0 3.2914138081707733e-10
28 O 0 7.185767536554977e-09
% O 0 1.997944476528346e-09
of O 0 4.78264627901126e-09
their O 0 1.03162349773811e-07
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 1.0607247531879693e-05
, O 0 3.254861380419527e-10
but O 0 1.3147091748599848e-10
not O 0 2.2088909867878925e-10
in O 0 3.9412926255977254e-09
non O 0 9.132895684160758e-07
- O 0 4.500147099406604e-07
Jews O 0 6.90172726081073e-07
. O 0 3.2180187758967804e-07

We O 0 3.6092620803174214e-07
assessed O 0 1.091108515538508e-06
the O 0 1.1288212675708564e-07
I1307K O 0 4.849123342864914e-06
prevalence O 0 2.767333739939204e-07
in O 0 1.1238747710251573e-09
Israeli O 0 4.649049500926594e-08
Jews O 0 2.473700355665187e-09
of O 0 2.509320806698412e-10
differing O 0 4.559617267085869e-11
ethnic O 0 6.790532719458398e-11
origin O 0 7.06051120347162e-11
and O 0 1.3570067292079102e-10
risk O 0 1.4336470677278612e-08
for O 0 1.0945237818305031e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 6.930902600288391e-05

METHODS O 0 5.387241799326148e-06
DNA O 0 4.388253103115858e-07
samples O 0 3.247689761565198e-08
from O 0 3.3238627850096236e-08
500 O 0 3.9260562800791377e-08
unrelated O 0 6.20434761344768e-08
Jews O 0 1.6002703162598664e-08
of O 0 1.5148367893402792e-08
European O 0 3.971659001678063e-09
or O 0 6.982748157469132e-09
non O 0 4.49989805417772e-08
- O 0 1.9030077513804144e-09
European O 0 1.1099425822891362e-09
origin O 0 3.0603040102050727e-09
, O 0 2.3054860798232824e-10
with O 0 1.312722153201662e-10
or O 0 4.437759493214344e-09
without O 0 9.254326194252371e-09
a O 0 3.1914961340362424e-08
personal O 0 1.957804158791987e-07
and O 0 6.279982756041136e-09
/ O 0 1.625017375772586e-06
or O 0 7.741047625131614e-08
family O 0 1.0588388477117405e-07
history O 0 4.4164622181597224e-07
of O 0 3.0699172270942654e-07
neoplasia B-Disease 0 3.960012327297591e-05
, O 0 3.267826675923402e-09
were O 0 1.1307192515630504e-08
examined O 0 1.2453371311949013e-07
for O 0 6.718791745186081e-09
the O 0 1.2381228486901819e-07
I1307K O 0 1.2088299854440265e-06
variant O 0 6.775932259728279e-09
by O 0 9.46881351104878e-10
the O 0 2.9292106518141736e-09
allele O 0 6.282159792370123e-10
- O 0 1.5621561821888008e-09
specific O 0 1.2461389697904224e-09
oligonucleotide O 0 3.2366270374950545e-07
( O 0 1.2040443664318445e-07
ASO O 0 6.723494152538478e-06
) O 0 7.813597768802083e-09
method O 0 5.5430302126069364e-08
. O 0 5.835932270770172e-08

RESULTS O 0 2.7313890313962474e-06
In O 0 4.78480224330724e-08
persons O 0 5.0624702652157794e-08
at O 0 5.8962047688737584e-08
average O 0 1.6570633931678458e-07
risk O 0 9.782147714076928e-08
for O 0 1.0655707001205883e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 6.445021881518187e-06
I1307K O 0 2.6658919523470104e-05
was O 0 4.6530502118002914e-07
found O 0 6.011920739013021e-09
in O 0 7.009008040625986e-09
5 O 0 1.3957730971014826e-07
. O 0 4.387834451335948e-08

0 O 0 3.736357427897019e-07
% O 0 1.1341125372155147e-08
of O 0 6.089276194387594e-09
120 O 0 7.289758574557936e-09
European O 0 1.1857403947601597e-09
and O 0 5.006284720110443e-09
1 O 0 3.118237543731084e-07
. O 0 1.4241291523831023e-07

6 O 0 5.58783222004422e-06
% O 0 4.16281302761945e-08
of O 0 2.7886303044510896e-08
188 O 0 3.473241250162573e-08
non O 0 5.545261316797223e-08
- O 0 1.0620261114979712e-08
European O 0 4.372735062929678e-09
Jews O 0 2.440409474502303e-08
( O 0 4.175924495086747e-09
P O 0 3.1382137422042433e-07
= O 0 2.9568973047844338e-08
0 O 0 1.5589117774439387e-09
. O 0 2.0896692709548859e-10
08 O 0 6.201637603453491e-08
) O 0 6.605511249091478e-09
. O 0 1.0949361417544878e-08

It O 0 3.5625623695523245e-07
occurred O 0 2.1060504877823405e-06
in O 0 4.750655335783449e-08
15 O 0 7.679933560211794e-07
. O 0 2.9146170277272176e-07

4 O 0 2.3512550342275063e-06
% O 0 1.4383965130093657e-08
of O 0 8.876928525580752e-09
52 O 0 4.050597723903593e-08
Ashkenazi O 0 2.3137003779538645e-07
Israelis O 0 7.145152380871878e-08
with O 0 3.865459063945309e-09
familial O 0 1.075537693395745e-05
cancer B-Disease 0 1.8804990986609482e-06
( O 0 1.506699902620312e-07
P O 0 8.99020378710702e-05
= O 0 2.2505581398490904e-07
0 O 0 2.227210638139354e-09
. O 0 1.0750419998650784e-10
02 O 0 6.82377958582947e-08
) O 0 2.4904436846107103e-10
and O 0 5.961955928945883e-11
was O 0 1.506342961477003e-08
not O 0 8.352342706352545e-10
detected O 0 7.166304438754878e-09
in O 0 3.4758373956833566e-09
51 O 0 7.81796813953406e-08
non O 0 2.7236505957262125e-06
- O 0 1.4029021144779108e-07
European O 0 1.8603513396442395e-08
Jews O 0 6.88224659484149e-08
at O 0 9.161511371758024e-08
increased O 0 2.9290220027178293e-08
cancer B-Disease 0 3.455230057625158e-07
risk O 0 1.596487635424637e-07
. O 0 6.742904190559784e-08

Colorectal B-Disease 1 0.9999805688858032
neoplasia I-Disease 1 0.9999970197677612
occurred O 0 0.02813377045094967
personally O 0 2.940468675660668e-06
or O 0 1.1755965090287646e-07
in O 0 1.5135169562086048e-08
the O 0 6.843539779310959e-08
families O 0 1.6330719887491796e-08
of O 0 6.433964472307707e-08
13 O 0 2.2477631489437044e-07
of O 0 3.099056300470693e-07
20 O 0 4.3425541207398055e-07
Ashkenazi O 0 7.559287951153237e-07
I1307K O 0 5.6191402109107e-07
carriers O 0 8.738087586834808e-09
, O 0 3.177893947992061e-09
8 O 0 9.350959118137325e-08
of O 0 4.612447810359299e-07
whom O 0 2.8679582442237006e-07
also O 0 9.484909213597348e-08
had O 0 3.009761542216438e-07
a O 0 5.467469463837915e-07
personal O 0 3.932236722903326e-05
or O 0 2.556635365635884e-07
family O 0 3.081832744555868e-07
history O 0 2.680128318388597e-06
of O 0 2.2678234017803334e-05
noncolonic O 1 0.9873669147491455
neoplasia B-Disease 1 0.9999682903289795
. O 0 3.368366742506623e-05

CONCLUSIONS O 0 5.812074596178718e-05
The O 0 3.8308289731503464e-06
I1307K O 0 0.00015091295063029975
APC O 0 4.902340606349753e-06
variant O 0 3.613866539353694e-08
may O 0 2.5143096493707162e-09
represent O 0 2.1146777662295335e-09
a O 0 4.449093182756769e-08
susceptibility O 0 4.831554747397604e-07
gene O 0 1.049586995094387e-08
for O 0 1.0952933671148912e-08
colorectal B-Disease 1 1.0
, I-Disease 0 6.892966553095903e-08
or I-Disease 0 1.2624272471839504e-07
other I-Disease 0 1.0066127931196434e-09
, I-Disease 0 2.7997462126450046e-09
cancers I-Disease 0 7.237957788674976e-07
in O 0 4.381010398901708e-08
Ashkenazi O 0 1.8742020984063856e-05
Jews O 0 2.2953884126764024e-07
, O 0 1.5427142896484725e-09
and O 0 2.016174116548086e-09
partially O 0 3.123554961348418e-06
explains O 0 6.18401472252117e-08
the O 0 6.6872511972349e-09
higher O 0 7.097733600858191e-08
incidence O 0 2.7295868676446844e-06
of O 0 8.9753681095317e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 2.8349340936983936e-06
European O 0 1.9136302853439702e-07
Israelis O 0 5.409102641351637e-07
. O 0 3.470294629437376e-08

Systematic O 0 1.6012709238566458e-06
analysis O 0 9.179387205904277e-08
of O 0 7.213179031850814e-08
coproporphyrinogen O 0 0.00015956175047904253
oxidase O 0 3.222673694835976e-05
gene O 0 2.960350684588775e-06
defects O 0 0.00014275245484896004
in O 0 1.5917566997813992e-07
hereditary B-Disease 1 0.9999984502792358
coproporphyria I-Disease 1 0.9999884366989136
and O 0 8.910348014978808e-07
mutation O 0 4.1759867031032627e-07
update O 0 2.041624384219176e-06
. O 0 9.159037404060655e-07

Hereditary B-Disease 1 0.9999996423721313
coproporphyria I-Disease 1 0.9999086856842041
( O 0 3.290428867330775e-05
HC B-Disease 1 1.0
) O 0 1.0925183460130938e-06
is O 0 2.8146541097839872e-08
an O 0 1.1903505736654552e-07
acute O 1 1.0
hepatic B-Disease 1 1.0
porphyria I-Disease 1 1.0
with O 0 0.0013606506399810314
autosomal O 1 1.0
dominant O 1 0.9976122379302979
inheritance O 0 0.04329413175582886
caused O 0 8.762407560425345e-06
by O 0 1.5370119399449322e-07
deficient B-Disease 0 0.0052286977879703045
activity I-Disease 0 1.3366139683057554e-05
of I-Disease 0 2.9620960049214773e-06
coproporphyrinogen I-Disease 0 0.0003903874312527478
III I-Disease 1 0.9998302459716797
oxidase I-Disease 0 1.1541092135303188e-05
( O 0 6.736964337505924e-07
CPO O 0 5.0898710469482467e-05
) O 0 1.7435772292628826e-07
. O 0 4.576693299895851e-07

Clinical O 0 0.0007645429577678442
manifestations O 0 9.58553846430732e-06
of O 0 4.1988405996562506e-07
the O 0 5.324786229721212e-07
disease O 0 9.397063695359975e-05
are O 0 1.2663611825836085e-10
characterized O 0 2.5884727694602816e-09
by O 0 1.2878899058321736e-09
acute O 0 0.00013974396279081702
attacks O 0 5.178639739256141e-08
of O 0 2.3414262614096515e-05
neurological B-Disease 1 1.0
dysfunction I-Disease 1 1.0
often O 0 3.462096742623544e-08
precipitated O 0 7.713487093496951e-08
by O 0 7.618425335031986e-10
drugs O 0 3.1323210691880377e-09
, O 0 2.10755057850065e-09
fasting O 0 2.244362576675485e-06
, O 0 2.517761110709671e-08
cyclical O 0 0.03000769205391407
hormonal O 0 2.0961015252396464e-05
changes O 0 7.484296737914065e-09
, O 0 8.855654876072094e-09
or O 0 1.4725288792760693e-06
infectious B-Disease 1 0.9998319149017334
diseases I-Disease 1 0.9999997615814209
. O 0 3.1421321182278916e-05

Skin O 1 1.0
photosensitivity O 1 0.9999996423721313
may O 0 3.2046614251157735e-06
also O 0 2.5757186605801508e-08
be O 0 1.1574562641669672e-08
present O 0 1.6974632899291464e-07
. O 0 1.406760816280439e-06

The O 0 2.624653006932931e-06
seven O 0 8.462506002615555e-07
exons O 0 3.1227429531099915e-07
, O 0 3.727273156783895e-09
the O 0 7.303442117745362e-08
exon O 0 1.6608349824309698e-06
/ O 0 1.0873336577787995e-06
intron O 0 1.3148630841897102e-06
boundaries O 0 1.1215562700783721e-08
and O 0 9.350006324737592e-10
part O 0 7.155650738610575e-09
of O 0 6.788405215729654e-08
3 O 0 1.6514376000031916e-07
noncoding O 0 5.624496566269954e-07
sequence O 0 5.0641311588606186e-08
of O 0 2.4520740993239087e-08
the O 0 5.5705658752458476e-08
CPO O 0 5.004596459912136e-06
gene O 0 5.828264537655059e-09
were O 0 5.499628752403396e-09
systematically O 0 2.961401257550733e-08
analyzed O 0 1.041474639862372e-08
by O 0 1.9566044340280087e-09
an O 0 3.6763805333350774e-09
exon O 0 3.6745735343401975e-08
- O 0 1.672430727239771e-08
by O 0 1.716872333190622e-08
- O 0 5.894382866244996e-07
exon O 0 9.069293014363211e-07
denaturing O 0 1.756323763402179e-05
gradient O 0 1.5898662013569265e-06
gel O 0 8.646160267744563e-07
electrophoresis O 0 4.123273356526624e-06
( O 0 1.2773057278536726e-07
DGGE O 0 4.3654283217620105e-05
) O 0 4.412548548771156e-09
strategy O 0 2.842111435086281e-09
followed O 0 6.508036887176161e-10
by O 0 1.4800942416126617e-10
direct O 0 8.259475881011724e-10
sequencing O 0 7.791121636735454e-10
in O 0 4.276215492815538e-10
seven O 0 1.1344326367179747e-08
unrelated O 0 2.32007707268167e-07
heterozygous O 0 8.852939714643071e-08
HC B-Disease 1 0.8678064942359924
patients O 0 1.4400742998077476e-07
from O 0 1.5786248752647225e-08
France O 0 2.2546089439856587e-08
, O 0 6.746748049124562e-09
Holland O 0 1.3620676497794193e-07
, O 0 2.5819837379259525e-09
and O 0 2.0830011049355335e-09
Czech O 0 8.866836651577614e-07
Republic O 0 1.3985561054141726e-05
. O 0 2.477295993230655e-06

Seven O 0 1.3277993957672152e-06
novel O 0 3.1378962717099057e-07
mutations O 0 7.4333237343182645e-09
and O 0 5.417564175047573e-10
two O 0 6.469744184833814e-10
new O 0 4.2966323832160924e-09
polymorphisms O 0 2.9423270575534843e-07
were O 0 1.9963118802479585e-07
detected O 0 1.9845970200549345e-06
. O 0 5.243218197392707e-07

Among O 0 6.321398160480385e-08
these O 0 2.137663379642163e-09
mutations O 0 3.1925233567875466e-09
two O 0 1.0765384139688194e-09
are O 0 8.116611271979934e-10
missense O 0 2.1449285725338996e-07
( O 0 3.770088952137485e-08
G197W O 0 3.9521503936157387e-07
, O 0 9.375583864823511e-09
W427R O 0 3.867984048611106e-07
) O 0 1.127794213573452e-08
, O 0 1.0501692848663424e-09
two O 0 1.2617085154431606e-09
are O 0 2.7769520016818205e-09
nonsense O 0 1.9308008631924167e-06
( O 0 1.8645472721345868e-07
Q306X O 0 2.515870846764301e-06
, O 0 2.258435038982043e-08
Q385X O 0 1.5174473446677439e-06
) O 0 1.1324394755263256e-08
, O 0 1.2382351810558134e-09
two O 0 1.1550606027199706e-09
are O 0 5.041468353894629e-10
small O 0 3.990802799336279e-09
deletions O 0 4.7035996431077365e-08
( O 0 4.188050795050913e-08
662de14bp O 0 1.239930043084314e-06
; O 0 1.654138515050363e-08
1168del3bp O 0 4.515572982199956e-06
removing O 0 7.296152375602105e-07
a O 0 2.5381237378496735e-07
glycine O 0 3.4737655596472905e-07
at O 0 1.9771924542055785e-07
position O 0 1.1888122486425345e-07
390 O 0 4.1051197996466726e-08
) O 0 2.813593802386549e-10
, O 0 9.723909177861145e-11
and O 0 2.569307822053446e-10
one O 0 2.2056885207177857e-09
is O 0 2.4560047329202916e-09
a O 0 1.1534165622606452e-08
splicing O 0 4.039164025471109e-08
mutation O 0 2.674871213415031e-09
( O 0 4.284594012915477e-09
IVS1 O 0 1.2069742751918966e-06
- O 0 1.0544996342787272e-07
15c O 0 9.218863397109089e-07
- O 0 1.2015988204439054e-07
- O 0 1.4092528033415874e-07
> O 0 2.416350639578013e-07
g O 0 3.8643850786002076e-08
) O 0 7.866589601945861e-10
which O 0 1.6374183953171695e-10
creates O 0 5.685830029023009e-09
a O 0 7.3807395750691285e-09
new O 0 1.2836381735326086e-08
acceptor O 0 4.4838941448688274e-07
splice O 0 1.715127109491732e-05
site O 0 3.9910132727527525e-06
. O 0 5.114023338137486e-07

The O 0 2.566783678048523e-06
pathological O 0 0.00013706916070077568
significance O 0 1.5803260566826793e-06
of O 0 3.2849141007318394e-07
the O 0 1.1744512562472664e-07
point O 0 7.155803132263827e-07
mutations O 0 5.3789150911143224e-09
G197W O 0 2.1696847340990644e-07
, O 0 3.6775233969166266e-09
W427R O 0 4.0132545109372586e-07
, O 0 4.793084595888786e-09
and O 0 3.025943051682134e-09
the O 0 3.745747534367183e-08
in O 0 2.5255729951823014e-07
- O 0 6.075636065361323e-07
frame O 0 4.202957825327758e-06
deletion O 0 1.7326999568467727e-07
390delGly O 0 1.9148315288930462e-07
were O 0 1.2583439845670341e-09
assessed O 0 5.316086681972365e-09
by O 0 1.550530814853346e-10
their O 0 1.9651492932926118e-10
respective O 0 5.901771515937071e-09
expression O 0 2.558023570742307e-09
in O 0 1.8896970654935785e-09
a O 0 4.070189518756706e-09
prokaryotic O 0 7.1191119666025315e-09
system O 0 1.5772035899530579e-09
using O 0 3.9269454354950994e-09
site O 0 2.036007771266668e-07
- O 0 1.0368648162284444e-07
directed O 0 2.985442506542313e-07
mutagenesis O 0 3.265290433773771e-05
. O 0 1.479270963500312e-06

These O 0 3.241581580937236e-08
mutations O 0 1.3212187788269603e-08
resulted O 0 6.255717011072193e-08
in O 0 6.63894494934425e-09
the O 0 1.9640534532072706e-08
absence O 0 3.895704594469862e-07
or O 0 3.9687986230774186e-08
a O 0 1.773609703548118e-08
dramatic O 0 4.621341886945629e-08
decrease O 0 1.1370109120889538e-07
of O 0 3.5150117128068814e-07
CPO O 0 0.0003430771466810256
activity O 0 3.665903932414949e-05
. O 0 6.289886869126349e-07

The O 0 1.8211292740488716e-07
two O 0 1.08131112952492e-08
polymorphisms O 0 3.895154065958195e-08
were O 0 2.6851560974705535e-09
localized O 0 2.74687899093351e-08
in O 0 5.4225810508512495e-09
noncoding O 0 2.543177970437682e-07
part O 0 2.164121148950926e-08
of O 0 5.0811888030466434e-08
the O 0 1.1143957756587497e-08
gene O 0 3.933645353892956e-10
1 O 0 3.429797335030571e-09
) O 0 1.393842402608314e-10
a O 0 1.1063093774410504e-09
C O 0 6.989319700778651e-08
/ O 0 3.37348353696143e-08
G O 0 1.1654294240770469e-07
polymorphism O 0 1.919068459699247e-08
in O 0 1.894381318479077e-09
the O 0 1.5798990560256243e-08
promotor O 0 1.8702099623624235e-05
region O 0 1.4066506537346868e-07
, O 0 2.5625958244290814e-08
142 O 0 2.0996020566599327e-07
bp O 0 1.252453898814565e-06
upstream O 0 1.2171589105491876e-06
from O 0 2.3454958864022046e-08
the O 0 5.8618471854288146e-08
transcriptional O 0 7.960250059113605e-07
initiation O 0 5.1041514126382026e-08
site O 0 2.893815853610704e-08
( O 0 1.5282582976894332e-09
- O 0 3.931952541336159e-09
142C O 0 2.1244022718747146e-07
/ O 0 1.2692139250702894e-07
G O 0 1.447539972332379e-07
) O 0 8.401922491074743e-10
, O 0 2.1272945904815543e-10
and O 0 6.143684450066189e-10
2 O 0 4.9221146269928795e-08
) O 0 1.5150585230827573e-09
a O 0 6.123623386145027e-09
6 O 0 2.0632667130371374e-08
bp O 0 1.0234274583353908e-07
deletion O 0 8.37854674529126e-09
polymorphism O 0 4.893542904227388e-09
in O 0 2.1066534627856015e-10
the O 0 1.476083144602569e-09
3 O 0 1.4131524395111228e-08
noncoding O 0 1.1712489111914692e-07
part O 0 1.3210197380431055e-08
of O 0 2.2947356015379228e-08
the O 0 3.244191759677051e-08
CPO O 0 6.182709967106348e-06
gene O 0 3.235873791140875e-08
, O 0 4.265782393986228e-09
574 O 0 3.736756752914516e-07
bp O 0 4.7522595991722483e-07
downstream O 0 3.9323896317000617e-07
of O 0 2.4831182443563193e-08
the O 0 1.5590195800996298e-08
last O 0 1.2741688593109757e-08
base O 0 4.5314731522694274e-08
of O 0 1.473434174670274e-08
the O 0 1.4389508251611005e-08
normal O 0 1.2211266664508003e-07
termination O 0 8.198038159434873e-08
codon O 0 1.4167829931466258e-07
( O 0 1.2209375732652461e-08
+ O 0 5.632908894881439e-08
574 O 0 2.47831167143886e-07
delATTCTT O 0 2.2119936602393864e-06
) O 0 4.654372887102909e-08
. O 0 7.244035771236668e-08

Five O 0 1.0110571565746795e-05
intragenic O 0 0.00011840822116937488
dimorphisms O 0 5.665169010171667e-05
are O 0 7.66270247254397e-09
now O 0 9.220586072444803e-09
well O 0 7.687339653728031e-09
characterized O 0 2.6370415184828744e-08
and O 0 6.766681659442497e-10
the O 0 1.1302383917666248e-08
high O 0 3.608742105143392e-08
degree O 0 4.498928376506228e-07
of O 0 2.3531942616727974e-08
allelic O 0 1.3876611149044038e-07
heterogeneity O 0 6.587892471543455e-07
in O 0 5.0101466086971413e-08
HC B-Disease 1 0.9999988079071045
is O 0 2.0147761858879676e-07
demonstrated O 0 1.893948819997604e-08
with O 0 1.5905039785213404e-10
seven O 0 1.2763086143507962e-09
new O 0 3.698375980465407e-11
different O 0 3.4512854379942226e-11
mutations O 0 2.625155093305409e-10
making O 0 3.7144398667976475e-10
a O 0 2.141282928747046e-09
total O 0 3.0698623643132805e-09
of O 0 1.660200865671868e-08
nineteen O 0 5.236894139670767e-06
CPO O 0 0.15523304045200348
gene B-Disease 0 1.07861305878032e-05
defects I-Disease 0 2.1460087737068534e-05
reported O 0 8.38011615655887e-08
so O 0 1.3938299403548626e-09
far O 0 1.1887436812685337e-08
. O 0 7.605057916748592e-09
. O 0 5.866253971475999e-08

Coincidence O 0 0.00011949165491387248
of O 0 2.0545415679862344e-07
two O 0 1.5836009836789344e-08
novel O 0 4.981641268386738e-07
arylsulfatase O 0 8.977390280051623e-06
A O 0 2.503181519841746e-07
alleles O 0 1.7801430329811296e-09
and O 0 7.603820906254555e-10
mutation O 0 3.7081131498695186e-09
459 O 0 7.113983429007931e-07
+ O 0 1.8582202301331563e-06
1G O 0 1.692751538939774e-05
> O 0 1.872623300869236e-07
A O 0 2.7640911781645627e-08
within O 0 1.1954147893789013e-08
a O 0 2.9582285065998803e-08
family O 0 1.9549936780549615e-08
with O 0 5.95342841691604e-09
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
: O 0 8.942303786341199e-09
molecular O 0 9.262360656236979e-09
basis O 0 1.3452925884394062e-08
of O 0 5.217780429944696e-09
phenotypic O 0 2.554724574110878e-07
heterogeneity O 0 1.020757008518558e-05
. O 0 7.31047236968152e-07

In O 0 8.979668564279564e-06
a O 0 1.7954104123418801e-06
family O 0 9.246707577403868e-08
with O 0 1.4181442686833634e-09
three O 0 1.4153913596715029e-08
siblings O 0 4.601525631642289e-07
, O 0 1.1152095913402604e-09
one O 0 1.2908755175899955e-09
developed O 0 7.57035234499881e-09
classical O 0 1.555923154228367e-05
late O 0 0.0005268088425509632
infantile O 1 0.9995135068893433
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 4.004573929705657e-05
MLD B-Disease 1 1.0
) O 0 1.299171117352671e-07
, O 0 9.027767866598424e-09
fatal O 0 1.4713019709233777e-06
at O 0 9.694992968434235e-07
age O 0 7.42770623674005e-07
5 O 0 2.0038307013692247e-07
years O 0 2.282526168073673e-08
, O 0 1.8685439862053954e-09
with O 0 4.3014538597674346e-09
deficient O 0 0.00020743205095641315
arylsulfatase O 0 0.0005888607120141387
A O 0 0.0002524053561501205
( O 0 5.757564736086351e-07
ARSA O 0 0.00033942487789317966
) O 0 3.261618308769698e-09
activity O 0 1.4948515314472388e-08
and O 0 9.255909927396999e-10
increased O 0 1.713685726656422e-08
galactosylsulfatide O 0 2.765959652606398e-05
( O 0 1.8168459519074531e-06
GS O 1 0.9999854564666748
) O 0 2.0117688848131365e-08
excretion O 0 1.6487655329910922e-07
. O 0 2.9587930328034417e-08

The O 0 4.260948117007501e-06
two O 0 4.846950929504601e-08
other O 0 1.3842108792516683e-08
siblings O 0 8.616099762548401e-07
, O 0 2.4817969901391734e-08
apparently O 0 1.9655508367577568e-06
healthy O 0 1.1387276543928238e-07
at O 0 1.4562770900283795e-07
12 O 0 4.726046043401766e-08
( O 0 2.625947681522689e-09
1 O 0 2.593465531219863e-08
/ O 0 8.604602363959657e-09
2 O 0 9.92906734609278e-09
) O 0 3.2004535133189904e-10
and O 0 8.722875893818482e-11
15 O 0 1.1109148045918005e-09
years O 0 1.7451026179671203e-09
, O 0 5.018921944710542e-10
respectively O 0 1.0080811740920126e-08
, O 0 1.2127671089601222e-09
and O 0 2.7599053598059697e-10
their O 0 1.1769348828849502e-09
father O 0 1.3044076752066758e-07
, O 0 4.410579457214681e-09
apparently O 0 8.591290168169508e-08
healthy O 0 4.668471831337229e-09
as O 0 6.220587378535924e-10
well O 0 9.55622914133869e-10
, O 0 6.524604745372642e-10
presented O 0 2.045366898073553e-07
ARSA O 1 0.6159412264823914
and O 0 5.075638682683348e-07
GS O 1 0.9999994039535522
values O 0 1.545462779972695e-08
within O 0 2.308800928219057e-09
the O 0 1.1229662755241065e-09
range O 0 1.3276224564151562e-08
of O 0 2.613697347442212e-07
MLD B-Disease 1 1.0
patients O 0 5.425979452411411e-06
. O 0 4.6249266461018124e-07

Mutation O 0 1.5726870117305225e-07
screening O 0 6.6729302083956554e-09
and O 0 1.886059503020121e-10
sequence O 0 6.59881171927168e-09
analysis O 0 1.2969127993756047e-08
disclosed O 0 1.0752936674407465e-07
the O 0 7.637488863565522e-09
involvement O 0 4.4567965318265124e-08
of O 0 9.568124959002944e-09
three O 0 1.4125669522968565e-09
different O 0 1.3792186281946783e-09
ARSA O 0 0.0001963280519703403
mutations O 0 3.1203772898891202e-09
being O 0 3.1588036630836314e-09
the O 0 3.1418649903969254e-09
molecular O 0 1.5314279622202775e-08
basis O 0 2.417929145792641e-08
of O 0 5.2158426910864364e-08
intrafamilial O 0 2.890294672397431e-05
phenotypic O 0 2.5980532427638536e-06
heterogeneity O 0 2.417828181933146e-05
. O 0 7.849762369005475e-07

The O 0 9.887284022624954e-07
late O 0 2.4441314963041805e-05
infantile O 0 0.018251482397317886
patient O 0 4.738425104733324e-06
inherited O 0 9.432260412722826e-06
from O 0 3.960651042689278e-07
his O 0 1.1455979347374523e-06
mother O 0 2.8998222205700586e-06
the O 0 9.388095634221827e-08
frequent O 0 1.5979066958493604e-08
0 O 0 6.388570117366044e-09
- O 0 1.416646577823144e-09
type O 0 6.658919193824886e-09
mutation O 0 1.4744679921463444e-09
459 O 0 8.672341067494926e-08
+ O 0 1.0372406933356615e-07
1G O 0 5.832843612552097e-07
> O 0 2.519783670607012e-08
A O 0 1.2545390504214993e-08
, O 0 2.0500176556303984e-10
and O 0 4.5652934210771434e-10
from O 0 6.866601509614156e-09
his O 0 5.115369106079015e-08
father O 0 9.57202360041265e-07
a O 0 5.509500766720521e-08
novel O 0 3.8464786911163173e-08
, O 0 1.0353343737889986e-09
single O 0 1.4304594841973994e-08
basepair O 0 1.4499538565360126e-06
microdeletion O 0 3.781925897783367e-06
of O 0 5.618990144284908e-07
guanine O 0 1.9901654013665393e-06
at O 0 1.2394430086715147e-06
nucleotide O 0 9.276071750718984e-07
7 O 0 2.3716873442936048e-07
in O 0 2.420485323284538e-08
exon O 0 1.7086780701447424e-07
1 O 0 5.3645326403284344e-08
( O 0 7.03289826375908e-09
7delG O 0 1.8110267774318345e-07
) O 0 2.180770053428205e-08
. O 0 5.858125007307535e-08

The O 0 7.12683117853885e-07
two O 0 5.6976666940045106e-08
clinically O 0 3.445691618253477e-05
unaffected O 0 3.3292676562268753e-06
siblings O 0 3.305907227968419e-07
carried O 0 1.1544444511457641e-08
the O 0 1.1550545409022561e-08
maternal O 0 7.841234861416524e-08
mutation O 0 2.132251486486325e-09
459 O 0 4.5119040947838585e-08
+ O 0 5.824545112886881e-08
1G O 0 5.63441801659792e-07
> O 0 2.04211705323587e-08
A O 0 1.5296297561917527e-08
and O 0 3.8159808646298643e-10
, O 0 3.4539540672007263e-10
on O 0 2.669086729412129e-09
their O 0 6.451433276488672e-10
paternal O 0 4.9017845782373115e-08
allele O 0 8.796494643803499e-10
, O 0 1.1553861339885785e-10
a O 0 7.200787188743618e-10
novel O 0 8.138007601132813e-09
cytosine O 0 1.5834769939715443e-08
to O 0 1.6576877648333266e-09
thymidine O 0 2.3187587316897407e-07
transition O 0 1.3606563697976526e-07
at O 0 4.2031675206999353e-07
nucleotide O 0 2.1936291432211874e-06
2435 O 0 1.318170234299032e-05
in O 0 1.903041457751442e-08
exon O 0 4.518595986269247e-08
8 O 0 7.006348390348194e-09
, O 0 1.1484563994246244e-10
resulting O 0 8.998161105111535e-10
in O 0 9.71462688070801e-10
substitution O 0 1.0978408404582751e-08
of O 0 1.249064780495246e-07
alanine O 0 3.0489700293401256e-06
464 O 0 1.5817736311873887e-06
by O 0 9.958393576425806e-08
valine O 0 3.688955257530324e-05
( O 0 3.2812570793794293e-07
A464V O 0 1.1369602361810394e-05
) O 0 1.4304383455510106e-07
. O 0 1.9702918052644236e-07

The O 0 6.69779910822399e-06
fathers O 0 9.66592415352352e-06
genotype O 0 4.5612770804837055e-07
thus O 0 1.430086342679715e-07
was O 0 2.820942427206319e-06
7delG O 0 3.291727989562787e-05
/ O 0 3.5841942008119076e-05
A464V O 0 7.965158147271723e-05
. O 0 1.1352290130162146e-06

Mutation O 0 1.0754659342637751e-05
A464V O 0 8.528108082828112e-06
was O 0 6.596699790861749e-07
not O 0 3.1219131724213867e-09
found O 0 9.475882301046568e-09
in O 0 1.4656867719509137e-08
18 O 0 5.503807756213064e-07
unrelated O 0 0.0006442228914238513
MLD B-Disease 1 1.0
patients O 0 9.49895093071973e-06
and O 0 2.499874263151014e-08
50 O 0 5.824683739774628e-07
controls O 0 8.525079806531721e-07
. O 0 2.4573327550569957e-07

A464V O 0 4.2433064663782716e-05
, O 0 2.2912235664307445e-08
although O 0 1.1247503373112977e-08
clearly O 0 1.911913756202921e-07
modifying O 0 1.7598125623408123e-06
ARSA O 0 0.43152305483818054
and O 0 3.721361736097606e-06
GS O 1 1.0
levels O 0 3.742481112567475e-06
, O 0 8.55975024194322e-09
apparently O 0 1.2318029973812372e-07
bears O 0 4.211842608015104e-08
little O 0 1.5354642002307628e-08
significance O 0 3.2814877926057306e-08
for O 0 2.9296016723634466e-09
clinical O 0 5.429279212876281e-07
manifestation O 0 5.658813279296737e-06
of O 0 7.399959031317849e-06
MLD B-Disease 1 1.0
, O 0 2.8315653821664455e-07
mimicking O 0 3.734929350684979e-06
the O 0 3.6868422625957464e-07
frequent O 0 1.8615033923197188e-06
ARSA O 0 0.00918230228126049
pseudodeficiency O 0 0.00013050483539700508
allele O 0 2.195035449403804e-06
. O 0 8.107140274660196e-07

Our O 0 1.6213052731472999e-06
results O 0 3.872404974458732e-08
demonstrate O 0 1.8085462016870224e-08
that O 0 9.463735350934144e-11
in O 0 2.524471742759715e-10
certain O 0 4.0493269848340674e-10
genetic O 0 1.3486942229690158e-08
conditions O 0 2.9305095949894167e-07
MLD B-Disease 1 1.0
- O 0 0.0001309588406002149
like O 0 9.784125865053284e-08
ARSA O 0 0.01955225132405758
and O 0 4.304148149003595e-08
GS O 1 0.9999995231628418
values O 0 1.0270113648402912e-08
need O 0 5.171547079463323e-10
not O 0 4.325720684428269e-11
be O 0 2.9002059087623877e-10
paralleled O 0 3.275734883345649e-08
by O 0 2.371346230489735e-09
clinical O 0 1.1078302122768946e-05
disease O 0 1.336675268248655e-06
, O 0 6.005247410456604e-10
a O 0 2.247390495924151e-09
finding O 0 5.499104283046563e-09
with O 0 1.722840758944244e-10
serious O 0 5.169994565790148e-08
diagnostic O 0 1.162186293868217e-07
and O 0 1.4783520185801535e-08
prognostic O 0 0.00016018080350477248
implications O 0 1.5385503502329811e-06
. O 0 8.938587825468858e-07

Moreover O 0 1.1687338883348275e-05
, O 0 4.7913321310488755e-08
further O 0 1.9155218922151107e-07
ARSA O 0 0.0015430011553689837
alleles O 0 5.3800668808889895e-08
functionally O 0 3.946767890283809e-07
similar O 0 3.1695521762742374e-09
to O 0 2.5721531571321066e-09
A464V O 0 4.1775916770347976e-07
might O 0 8.329564593623218e-09
exist O 0 7.4214234757619124e-09
which O 0 5.395105473482431e-10
, O 0 2.1299742525293652e-10
together O 0 7.566004489589773e-10
with O 0 1.2182617137312945e-09
0 O 0 6.336837543585716e-08
- O 0 1.978491326326548e-08
type O 0 1.2379784308791386e-08
mutations O 0 2.8578430733006144e-09
, O 0 3.7823294496419635e-10
may O 0 8.041570964678613e-09
cause O 0 5.709991910407552e-07
pathological O 1 0.9987801909446716
ARSA O 1 0.9999945163726807
and O 0 1.1417630503274268e-06
GS O 1 1.0
levels O 0 7.355026099276074e-08
, O 0 1.475815025742122e-10
but O 0 3.812923587975803e-11
not O 0 5.922423662596543e-11
clinical O 0 7.94129206838079e-09
outbreak O 0 2.628227635526059e-09
of O 0 7.697507520276758e-09
the O 0 1.888398060145846e-07
disease O 0 2.0834568204008974e-06
. O 0 4.996221214526031e-09
. O 0 4.9540251012558656e-08

Human O 1 0.9795597791671753
MLH1 O 1 1.0
deficiency O 1 1.0
predisposes O 0 0.0006344551802612841
to O 0 2.2942329280795093e-07
hematological B-Disease 1 0.9999996423721313
malignancy I-Disease 1 0.9999997615814209
and O 0 8.212919055949897e-07
neurofibromatosis B-Disease 1 0.9999926090240479
type I-Disease 0 0.09526970237493515
1 I-Disease 0 0.00043091102270409465
. O 0 1.1287431789241964e-06

Heterozygous O 0 9.217244951287284e-06
germ O 0 9.364716242998838e-05
- O 0 1.1330571396683808e-06
line O 0 5.631136446027085e-08
mutations O 0 9.020190150366147e-10
in O 0 2.40483688518367e-10
the O 0 4.405652731520604e-09
DNA O 0 2.698661205613462e-07
mismatch O 0 0.013434813357889652
repair O 0 0.012581215240061283
genes O 0 5.708984645025339e-07
lead O 0 9.774107638804708e-07
to O 0 1.868256731540896e-07
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.002310614800080657

The O 0 2.0017384940729244e-06
disease O 0 1.1237230864935555e-05
susceptibility O 0 2.438818569316936e-07
of O 0 9.616833551717718e-08
individuals O 0 1.1345906436588393e-08
who O 0 6.784506290102854e-09
constitutionally O 0 1.1724324622264248e-07
lack O 0 6.785881367932234e-08
both O 0 1.2939864735272977e-09
wild O 0 9.425572322641074e-09
- O 0 1.6388915113907387e-08
type O 0 1.27874111299775e-08
alleles O 0 9.973629699899789e-10
is O 0 1.426157192341293e-09
unknown O 0 5.762827299804485e-07
. O 0 1.5972095468441694e-07

We O 0 4.4830986212218704e-07
have O 0 4.054321323110344e-09
identified O 0 2.0316159421440716e-08
three O 0 4.012700838273986e-09
offspring O 0 1.623791412441733e-08
in O 0 6.7962666605581035e-09
a O 0 4.7013037374199484e-07
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 1 1.0
who O 0 1.6496731802817521e-07
developed O 0 4.424604412633926e-06
hematological B-Disease 1 0.9999991655349731
malignancy I-Disease 1 0.9999996423721313
at O 0 1.8666853065951727e-05
a O 0 7.129700918540038e-08
very O 0 8.942110940601822e-10
early O 0 1.8411411062402294e-08
age O 0 8.193269707135187e-08
, O 0 1.945158700777938e-09
and O 0 2.4399706699540502e-09
at O 0 6.648641033280001e-07
least O 0 7.725497574995188e-09
two O 0 5.335099029224466e-10
of O 0 3.606483112150727e-09
them O 0 8.963815800733244e-10
displayed O 0 2.4779569685051683e-07
signs O 0 7.626589137998963e-08
of O 0 7.613928119099e-07
neurofibromatosis B-Disease 0 0.38149747252464294
type I-Disease 0 0.0003921928000636399
1 I-Disease 0 0.00030951175722293556
( O 0 7.434743451995018e-07
NF1 B-Disease 0 0.00025798476417548954
) O 0 1.185076712317823e-07
. O 0 7.351729180982147e-08

DNA O 0 2.0714969650725834e-07
sequence O 0 4.2909753972253384e-08
analysis O 0 1.2373858382375147e-08
and O 0 1.2123271830866145e-10
allele O 0 1.7409294839065836e-10
- O 0 1.0982298404016433e-09
specific O 0 4.657378926964384e-10
amplification O 0 1.5478464732154862e-08
in O 0 2.461285175670014e-09
two O 0 5.861419349884045e-09
siblings O 0 1.848171535812071e-07
revealed O 0 4.287760191346024e-07
a O 0 1.7881076530557038e-07
homozygous O 0 7.177277439041063e-08
MLH1 O 0 5.7635152188595384e-06
mutation O 0 5.261352686858345e-09
( O 0 2.444209279417464e-09
C676T O 0 6.542992281310944e-08
- O 0 7.436871101162978e-07
- O 0 4.255506610206794e-06
> O 0 3.897353963111527e-06
Arg226Stop O 0 0.00015945376071613282
) O 0 1.1294211077483851e-07
. O 0 1.1050028803083478e-07

Thus O 0 3.1126894555200124e-06
, O 0 3.006809023986534e-08
a O 0 4.44271641697469e-08
homozygous O 0 6.939625762925061e-08
germ O 0 0.0006454422255046666
- O 0 5.5593216529814526e-05
line O 0 1.8606230014484026e-06
MLH1 O 0 0.0007482375949621201
mutation O 0 1.5572751976833388e-08
and O 0 1.1081064954510111e-09
consequent O 0 3.4985965612577274e-05
mismatch O 1 1.0
repair O 1 1.0
deficiency O 1 1.0
results O 0 1.094187723538198e-06
in O 0 3.1275767753413675e-08
a O 0 1.2456008846584155e-07
mutator O 0 0.0002615140110719949
phenotype O 0 9.830929315057801e-08
characterized O 0 4.580664292319625e-09
by O 0 2.6688067311653185e-09
leukemia B-Disease 1 0.9461275339126587
and O 0 7.317335985135287e-05
/ O 1 1.0
or O 1 1.0
lymphoma B-Disease 1 1.0
associated O 1 0.9999998807907104
with O 0 3.3892465580720454e-05
neurofibromatosis B-Disease 1 1.0
type I-Disease 1 0.9994606375694275
1 I-Disease 0 0.0005642131436616182
. O 0 5.9596796830874155e-08
. O 0 1.9923025718071585e-07

Missense O 0 0.0004741244774777442
mutations O 0 2.769918410194805e-07
in O 0 1.1469559524357464e-08
the O 0 7.327465745277095e-09
most O 0 1.9135848461360183e-09
ancient O 0 2.829648622082459e-07
residues O 0 7.550858640570368e-07
of O 0 2.288614524559307e-07
the O 0 8.444197305834678e-07
PAX6 O 0 0.45371195673942566
paired O 0 2.11095698432473e-06
domain O 0 3.114325636488502e-06
underlie O 0 5.428813096841623e-07
a O 0 1.2144552030690647e-08
spectrum O 0 2.3700769347101414e-08
of O 0 1.2553406349979923e-06
human O 1 0.9999806880950928
congenital B-Disease 1 1.0
eye I-Disease 1 1.0
malformations I-Disease 1 1.0
. O 0 0.000422431156039238

Mutations O 0 9.530587590234063e-07
of O 0 2.0666981015438068e-07
the O 0 1.4215171972864482e-07
human O 0 3.7993430623828317e-07
PAX6 O 1 0.6942459940910339
gene O 0 5.811893515783595e-06
underlie O 0 0.36976486444473267
aniridia B-Disease 1 1.0
( O 1 0.9999765157699585
congenital B-Disease 1 1.0
absence I-Disease 0 0.00018708876450546086
of I-Disease 0 8.124482701532543e-05
the I-Disease 0 6.974856205488322e-06
iris I-Disease 0 5.037468872615136e-05
) O 0 9.536754674854819e-08
, O 0 8.403609363938358e-09
a O 0 2.0736632677653688e-07
rare O 0 4.4339427404338494e-05
dominant O 1 0.9999998807907104
malformation B-Disease 1 1.0
of I-Disease 1 0.9999998807907104
the I-Disease 1 0.9999959468841553
eye I-Disease 1 1.0
. O 0 1.6210353351198137e-05

The O 0 4.20964653358169e-07
spectrum O 0 1.8386781164281274e-07
of O 0 3.8377004329959163e-07
PAX6 O 0 0.0069336919113993645
mutations O 0 2.163242669439569e-07
in O 0 5.7305374667748765e-08
aniridia B-Disease 1 1.0
patients O 0 2.6404235242694085e-08
is O 0 2.0097457031909016e-10
highly O 0 8.741417589774869e-10
biased O 0 1.2196713861101216e-08
, O 0 2.0386749233214374e-10
with O 0 7.96631580146645e-11
92 O 0 7.957063985486457e-08
% O 0 1.981160124842063e-09
of O 0 1.951260042432068e-09
all O 0 1.074546451818037e-09
reported O 0 2.3668153659173186e-08
mutations O 0 1.1499650121038485e-09
leading O 0 1.6771137367754818e-08
to O 0 2.316506764188375e-09
premature O 0 1.408489680443381e-07
truncation O 0 2.6061456992465537e-06
of O 0 3.907175596395973e-07
the O 0 1.6848863992890983e-07
protein O 0 2.463156079102191e-07
( O 0 8.419492658617855e-09
nonsense O 0 1.3112750707477971e-07
, O 0 1.5523485830115646e-09
splicing O 0 1.3012562583014642e-08
, O 0 9.171153836362578e-10
insertions O 0 2.2917657105381295e-08
and O 0 1.8611454599692934e-09
deletions O 0 2.0568895919836905e-08
) O 0 2.998623127581368e-09
and O 0 1.8956536340652974e-09
just O 0 6.559549348139626e-08
2 O 0 1.7536095242576266e-07
% O 0 6.221124060346028e-09
leading O 0 1.393279602801556e-09
to O 0 8.305094806315694e-11
substitution O 0 9.740900308585765e-10
of O 0 1.475214173041195e-08
one O 0 3.8009755343182405e-09
amino O 0 1.0411926432141172e-08
acid O 0 5.773827194133219e-09
by O 0 3.067813780788242e-09
another O 0 8.450708577356636e-08
( O 0 7.101078125515414e-08
missense O 0 9.64981154538691e-07
) O 0 5.753646448170002e-08
. O 0 1.4128754344255867e-07

The O 0 2.174619169181824e-07
extraordinary O 0 3.944250579479558e-07
conservation O 0 6.782878614330912e-08
of O 0 1.6086556087202553e-08
the O 0 4.759107952168051e-08
PAX6 O 0 2.8803558961953968e-05
protein O 0 6.539038110986439e-08
at O 0 1.0150095874905674e-08
the O 0 2.9130360346130146e-09
amino O 0 1.6428131743850827e-08
acid O 0 6.675476171835726e-09
level O 0 2.736002890912914e-08
amongst O 0 4.43417462747675e-08
vertebrates O 0 5.782729317616031e-07
predicts O 0 5.5644914453978345e-08
that O 0 7.70314367848357e-10
pathological O 0 5.255646101431921e-06
missense O 0 7.90887781931815e-07
mutations O 0 1.5472642056479913e-09
should O 0 3.6874744924197955e-10
in O 0 9.85066694880743e-10
fact O 0 9.588368321544749e-09
be O 0 2.1323898202751934e-09
common O 0 1.4525861624647973e-09
even O 0 7.470102869611139e-10
though O 0 4.27192753393868e-10
they O 0 2.9095698073078324e-10
are O 0 6.359510140718783e-10
hardly O 0 6.554934373070864e-08
ever O 0 4.9728356543710106e-08
seen O 0 7.1051829308999e-08
in O 0 1.9915997029329446e-07
aniridia B-Disease 1 1.0
patients O 0 3.373163508513244e-06
. O 0 5.68545317491953e-07

This O 0 1.605786934533171e-07
indicates O 0 1.7227216630999465e-07
that O 0 5.33600497121256e-10
there O 0 1.3096391748845804e-09
is O 0 2.106357088749178e-09
a O 0 1.0533975469684265e-08
heavy O 0 5.231295858720841e-07
ascertainment O 0 6.45883847028017e-05
bias O 0 1.9263211470388342e-07
in O 0 1.4387853131125894e-09
the O 0 4.5936901504894934e-10
selection O 0 2.352509576031281e-10
of O 0 2.708911539528458e-09
patients O 0 1.0273714101671771e-09
for O 0 6.404426988737555e-10
PAX6 O 0 1.72786367329536e-05
mutation O 0 1.7712017408300085e-09
analysis O 0 3.36425465263801e-09
and O 0 7.492702291944653e-11
that O 0 1.2038842145400963e-10
the O 0 2.0535928513254476e-08
missing O 0 1.964666080311872e-05
PAX6 O 0 0.48327553272247314
missense O 0 9.396992390975356e-05
mutations O 0 9.309992066164341e-08
frequently O 0 1.947661765200337e-08
may O 0 2.0080081597484423e-08
underlie O 0 3.0418168535106815e-06
phenotypes O 0 1.196461539620941e-06
distinct O 0 8.363652881371308e-08
from O 0 3.4352535749349045e-07
textbook O 0 0.00027614051941782236
aniridia B-Disease 1 1.0
. O 0 5.018337105866522e-06

Here O 0 1.3643951888298034e-06
we O 0 1.2995572618024198e-08
present O 0 2.540646448778716e-08
four O 0 4.923917629184871e-08
novel O 0 3.3264620924455812e-06
PAX6 O 0 0.0010812897235155106
missense O 0 1.7388263586326502e-05
mutations O 0 2.9810550472575414e-08
, O 0 9.905910536289753e-10
two O 0 7.90738641232025e-10
in O 0 4.385940943762989e-09
association O 0 1.2355745759862202e-08
with O 0 5.020762472440765e-09
atypical O 0 5.348035756469471e-06
phenotypes O 0 7.069650109770009e-06
ectopia B-Disease 0 0.00024895870592445135
pupillae I-Disease 0 0.00019051629351451993
( O 0 1.3082609484627028e-07
displaced B-Disease 0 1.2239399893587688e-07
pupils I-Disease 0 6.959508880299836e-08
) O 0 7.37858911747935e-08
and O 0 6.663736371592677e-07
congenital B-Disease 1 1.0
nystagmus I-Disease 1 0.9934013485908508
( O 0 8.081048690655734e-06
searching B-Disease 0 0.00014854017354082316
gaze I-Disease 0 3.8099868106655777e-05
) O 0 4.547681697886219e-08
, O 0 2.993679970586527e-09
and O 0 3.4036127249947867e-09
two O 0 9.34644450722999e-09
in O 0 5.468137942443718e-08
association O 0 1.0919083592852985e-07
with O 0 3.823661831603431e-09
more O 0 2.036830615281815e-08
recognizable O 0 9.28072495298693e-06
aniridia B-Disease 1 1.0
phenotypes O 0 4.913870361633599e-05
. O 0 8.631017749394232e-07

Strikingly O 0 1.1014988558599725e-05
, O 0 9.802988643059507e-09
all O 0 1.3418349764648951e-09
four O 0 3.867155484726936e-09
mutations O 0 1.6425615312343211e-09
are O 0 5.122324786555055e-10
located O 0 2.2610340266737694e-08
within O 0 5.2737938460722944e-08
the O 0 3.777445556352177e-07
PAX6 O 0 0.0008120530983433127
paired O 0 3.2952559081422805e-07
domain O 0 1.8258873524246155e-07
and O 0 6.806420427274418e-10
affect O 0 4.460357860835984e-09
amino O 0 6.69975008804613e-09
acids O 0 2.2609900618419942e-09
which O 0 1.9641563375749627e-10
are O 0 4.700274197633192e-11
highly O 0 1.9292114572522223e-09
conserved O 0 4.392917318796208e-08
in O 0 7.391587342198136e-09
all O 0 1.1927137499867513e-08
known O 0 2.0489414964686148e-07
paired O 0 7.987055141711608e-07
domain O 0 3.208622047168319e-06
proteins O 0 1.7740113378295064e-07
. O 0 5.365146193980763e-07

Our O 0 1.7094569102482637e-06
results O 0 4.7047841178482486e-08
support O 0 6.587871137497814e-09
the O 0 3.2671472194323314e-09
hypothesis O 0 1.620876588503961e-08
that O 0 2.14870239656495e-11
the O 0 1.0712961767689322e-10
under O 0 1.6529330126857644e-09
- O 0 3.314978735957652e-09
representation O 0 1.76108250204976e-09
of O 0 7.784263900134647e-09
missense O 0 6.335151851999399e-07
mutations O 0 6.253566553482415e-09
is O 0 9.293732450288417e-10
caused O 0 5.8799738411607905e-09
by O 0 2.387475550591489e-09
ascertainment O 0 0.0012580851325765252
bias O 0 1.8975304101331858e-06
and O 0 5.7112532481085054e-09
suggest O 0 2.892491579586931e-08
that O 0 2.888585204363636e-10
a O 0 1.5363774696908195e-09
substantial O 0 1.8804612977874058e-08
burden O 0 2.631527706853376e-07
of O 0 1.7326780152870924e-06
PAX6 B-Disease 1 0.9999523162841797
- I-Disease 0 0.0004418841272126883
related I-Disease 0 0.057392511516809464
disease I-Disease 1 0.9230331182479858
remains O 0 5.285081670081127e-07
to O 0 1.7597393542345685e-09
be O 0 4.490053218120238e-09
uncovered O 0 6.857233074697433e-06
. O 0 3.8402259150416285e-08
. O 0 5.826834126310132e-08

The O 0 1.0375982810728601e-06
chromosomal O 0 3.6224389532435453e-06
order O 0 4.52756800939369e-08
of O 0 3.7153651533117227e-07
genes O 0 1.3524699227218662e-07
controlling O 0 2.137017872883007e-06
the O 0 6.960795531085751e-07
major O 0 3.952153292630101e-06
histocompatibility O 0 0.020327309146523476
complex O 0 0.00036346184788271785
, O 0 6.748138048351393e-09
properdin O 0 1.6023952866817126e-06
factor O 0 3.364469023381389e-07
B O 0 1.5459455653399345e-06
, O 0 1.8008039504024964e-09
and O 0 9.646186960310388e-09
deficiency B-Disease 1 0.995288610458374
of I-Disease 0 0.0005660024471580982
the I-Disease 0 7.20922980690375e-06
second I-Disease 0 1.9328053895151243e-06
component I-Disease 0 2.1698142518289387e-06
of I-Disease 0 1.3595047221315326e-07
complement I-Disease 0 6.662218083874905e-07
. O 0 4.2404869304846216e-07

The O 0 6.548386295435193e-07
relationship O 0 2.99598411857005e-07
of O 0 2.328970438725264e-08
the O 0 1.4479867971317617e-08
genes O 0 4.606484527158727e-09
coding O 0 2.2613274808236383e-08
for O 0 1.0961371810225273e-09
HLA O 0 5.199840558134383e-08
to O 0 2.2054556791939461e-10
those O 0 3.064168918598398e-10
coding O 0 1.654132297801425e-08
for O 0 9.220334495907423e-10
properdin O 0 1.8117384570359718e-06
Factor O 0 9.120727781919413e-07
B O 0 7.199680567282485e-07
allotypes O 0 7.964836186147295e-07
and O 0 2.44869369225853e-09
for O 0 5.214258358421375e-09
deficiency B-Disease 0 0.0032244545873254538
of I-Disease 0 3.536551503202645e-06
the I-Disease 0 1.708236538888741e-07
second I-Disease 0 2.3618149214144069e-07
component I-Disease 0 3.7006827824370703e-07
of I-Disease 0 2.9835518944310024e-08
complement I-Disease 0 1.815175068031749e-07
( O 0 7.220529596452252e-08
C2 O 0 3.092058932452346e-06
) O 0 5.840001815471396e-10
was O 0 2.0617119123045313e-09
studied O 0 5.427641003308281e-09
in O 0 3.3986224945437016e-10
families O 0 1.494239870725167e-10
of O 0 1.8904577903100517e-09
patients O 0 3.024713812749269e-09
with O 0 1.2777707780742276e-08
connective O 1 1.0
tissue O 1 1.0
disorders O 1 1.0
. O 1 0.8947245478630066

Patients O 0 8.44456792492565e-07
were O 0 1.2198620780168312e-08
selected O 0 2.6795077268104706e-09
because O 0 1.3515828456434065e-09
they O 0 1.0934266825302075e-09
were O 0 1.6340317543495075e-08
heterozygous O 0 3.8466918539370454e-08
or O 0 5.892528065487568e-08
homozygous O 0 4.4004733013025543e-07
for O 0 4.575899765768554e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.00017431264859624207

12 O 0 2.4280791421915637e-06
families O 0 1.7512322258994573e-08
with O 0 1.806204519283483e-09
15 O 0 7.157018444559071e-08
matings O 0 5.947732461208943e-06
informative O 0 1.9983181118732318e-05
for O 0 7.483723948098486e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 5.482452252181247e-06
found O 0 7.491175892937463e-07
. O 0 3.4382657077003387e-07

Of O 0 4.7062030716915615e-06
57 O 0 8.464022585030762e-07
informative O 0 9.415169870408135e-07
meioses O 0 2.3857096493884455e-06
, O 0 4.4692565204229595e-09
two O 0 5.961003912702267e-10
crossovers O 0 4.968367939284235e-09
were O 0 1.9395716144288144e-09
noted O 0 6.709149236172607e-09
between O 0 2.476727800626577e-08
the O 0 1.2082227840437554e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 2.782000407819396e-08
and O 0 2.3900041945523753e-09
the O 0 9.174294035574349e-08
HLA O 0 7.764616611893871e-07
- O 0 4.485395095343847e-07
B O 0 3.1101051263249246e-06
gene O 0 6.445779021646558e-09
, O 0 1.2224461720666824e-10
with O 0 8.24635984497668e-11
a O 0 2.2009059019723054e-09
recombinant O 0 1.2061924792305945e-09
fraction O 0 5.775028011356653e-09
of O 0 2.3403655902143328e-08
0 O 0 7.883480179771141e-08
. O 0 3.9895791559274585e-08

035 O 0 0.07758666574954987
. O 0 6.619490886805579e-05

A O 0 4.7102530515985563e-05
lod O 0 0.00015244456881191581
score O 0 1.7990475953411078e-07
of O 0 4.173728740397564e-08
13 O 0 4.350450311108034e-08
was O 0 2.9147104285698333e-08
calculated O 0 5.83942849630148e-08
for O 0 3.8761203136061795e-09
linkage O 0 1.220902390741685e-06
between O 0 1.5786662288519437e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 2.872562276934332e-07
HLA O 0 2.860527501979959e-06
- O 0 1.1358425666685434e-07
B O 0 4.938261213283113e-07
at O 0 1.5512423345853676e-08
a O 0 9.430854985836845e-10
maximum O 0 1.254899850700042e-09
likelihood O 0 1.876651500865023e-09
value O 0 2.2788100295656477e-09
of O 0 6.942293961920143e-10
the O 0 3.5856509428278116e-10
recombinant O 0 4.5103767942755724e-10
fraction O 0 3.0003395323774384e-09
of O 0 5.556078264135067e-09
0 O 0 1.5577505507735623e-08
. O 0 1.0206686162916867e-08

04 O 0 0.007861573249101639
. O 0 2.667336411832366e-05

18 O 0 1.7670644183453987e-06
families O 0 1.3422707390020605e-08
with O 0 6.752151615607715e-10
21 O 0 5.8903371069618515e-08
informative O 0 6.936316765404626e-08
matings O 0 9.030750902638829e-08
for O 0 5.630292898572975e-10
both O 0 9.360373587341542e-10
properdin O 0 7.81432902385859e-07
Factor O 0 4.5430869022311526e-07
B O 0 1.934924966917606e-07
allotype O 0 3.0430652486757026e-07
and O 0 1.6162427840527016e-08
HLA O 0 9.55906102717563e-07
- O 0 1.6735324948058405e-07
B O 0 9.869440873444546e-07
were O 0 6.591267265321221e-08
found O 0 1.209646995903313e-07
. O 0 1.195349170757254e-07

Of O 0 9.463092283112928e-06
72 O 0 6.491130534413969e-06
informative O 0 1.735307364469918e-06
meioses O 0 4.967379027220886e-06
, O 0 5.582326600972465e-09
three O 0 4.042854051533595e-09
recombinants O 0 6.007933848195535e-07
were O 0 2.961519918187605e-08
found O 0 1.1052911474962457e-08
, O 0 1.2345681144054765e-09
giving O 0 4.874250780773082e-09
a O 0 5.909915667956511e-09
recombinant O 0 1.962124018817235e-09
fraction O 0 1.7248087402776946e-08
of O 0 4.421809762789053e-08
0 O 0 1.9347515944900806e-07
. O 0 7.207663799135844e-08

042 O 0 0.011664257384836674
. O 0 2.6630310458131135e-05

A O 0 2.4487462724209763e-05
lod O 0 4.6926776121836156e-05
score O 0 1.0860283339297894e-07
of O 0 3.298386630490313e-08
16 O 0 2.736352655574592e-08
between O 0 1.653403636225903e-08
HLA O 0 1.427018219146703e-07
- O 0 1.6615567588473823e-08
B O 0 9.039332127258604e-08
and O 0 6.77572220553202e-10
Factor O 0 3.2947437489383447e-07
B O 0 4.6844670009704714e-07
allotypes O 0 6.282740514507168e-07
was O 0 2.5637202583084218e-08
calculated O 0 7.239643196044199e-08
at O 0 8.81980000144722e-09
a O 0 4.770526751407544e-10
maximum O 0 5.579438577818507e-10
likelihood O 0 1.291648787926647e-09
value O 0 1.7184766942790475e-09
of O 0 1.0562781760370399e-09
the O 0 8.550999353040822e-10
recombinant O 0 8.345892865690985e-10
fraction O 0 6.117261364124715e-09
of O 0 6.950299891173017e-09
0 O 0 2.902760165568452e-08
. O 0 1.9525938199649318e-08

04 O 0 0.006259391084313393
. O 0 1.977323518076446e-05

A O 0 1.1452394574007485e-05
crossover O 0 7.635889005541685e-07
was O 0 1.8250482014536829e-07
shown O 0 1.0017732421374603e-08
to O 0 1.7473642532905842e-09
have O 0 3.303779194663292e-10
occurred O 0 1.2244730562827044e-08
between O 0 8.214072755308166e-10
genes O 0 2.2896004536754333e-10
for O 0 4.217135807227379e-10
Factor O 0 1.9823177765943e-08
B O 0 2.8176621924558276e-08
and O 0 2.840648161139825e-09
HLA O 0 1.2252490932951332e-07
- O 0 4.7669114877635366e-08
D O 0 2.7925833023800806e-07
, O 0 2.8785658301444528e-09
in O 0 1.7625004788968113e-09
which O 0 2.292682488302944e-09
HLA O 0 7.370445587184804e-08
- O 0 2.294026657523318e-08
D O 0 2.2962335322063154e-07
segregared O 0 1.0541351684878464e-06
with O 0 1.8109174604319378e-08
HLA O 0 1.5898252740953467e-06
- O 0 6.620246040256461e-08
A O 0 9.056658711870114e-08
and O 0 2.7755326925671397e-09
B O 0 1.4670064274469041e-06
. O 0 1.293879137165277e-07

These O 0 3.6180118456741184e-08
studies O 0 5.7801219810471594e-08
suggest O 0 5.00288699356588e-09
that O 0 7.035440285907413e-11
the O 0 4.659342356383434e-10
genes O 0 3.476624821363572e-10
for O 0 3.901217404678192e-10
Factor O 0 4.1387897908862215e-07
B O 0 4.976391574018635e-05
and O 0 4.762431672133971e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 1.074587885341316e-08
located O 0 8.77424621847922e-09
outside O 0 4.239760542645854e-09
those O 0 2.498651285876008e-10
for O 0 3.095350420423415e-09
HLA O 0 2.3782065454724943e-06
, O 0 8.677709661952804e-10
that O 0 1.2502236745870476e-10
the O 0 1.7244262684457112e-09
order O 0 2.246863362032059e-09
of O 0 3.999087283546032e-08
genese O 0 1.2173562708994723e-06
is O 0 1.7272547836455487e-08
HLA O 0 4.21190691213269e-08
- O 0 7.231745868807593e-09
A O 0 5.4468298316123764e-08
, O 0 2.073233390520457e-10
- O 0 1.0975764741516514e-09
B O 0 3.219774313834023e-08
, O 0 3.6691913396502684e-10
- O 0 3.96008603686937e-09
D O 0 5.5777633178877295e-08
, O 0 2.0737012107474584e-09
Factor O 0 3.2216055956268974e-07
B O 0 3.3344724670314463e-06
allotype O 0 0.00035055220359936357
, O 0 4.002966761618154e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 2.0932846567234265e-09
that O 0 2.869457622900473e-11
the O 0 1.2128157367286008e-09
genes O 0 3.467910847376743e-09
coding O 0 7.730276507800227e-08
for O 0 3.725298824974743e-08
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 1.8924995970337477e-07
Factor O 0 6.157988991617458e-06
B O 0 1.3140720511728432e-06
allotypes O 0 3.6417458204596187e-07
are O 0 4.517763940725672e-10
approximately O 0 7.914991440038932e-10
3 O 0 1.6739170050072971e-09
- O 0 1.9631798409136536e-09
- O 0 6.447241851503804e-09
5 O 0 1.2041426522557686e-08
centimorgans O 0 1.4786911606279318e-07
from O 0 7.240716914935774e-09
the O 0 1.521279280325416e-08
HLA O 0 4.639951711737922e-08
- O 0 5.409668268896439e-09
A O 0 4.9267171675637655e-08
and O 0 7.738559792969113e-10
HLA O 0 6.50203872964994e-08
- O 0 1.2802785498422509e-08
B O 0 1.2298241358621453e-07
loci O 0 5.553154380777414e-09
, O 0 1.0915757880924915e-10
and O 0 7.888883296613969e-11
that O 0 1.1131646299178399e-10
the O 0 2.9464692907765766e-09
apparent O 0 3.06850637343814e-07
lack O 0 1.3881111726732343e-07
of O 0 2.1732544652763863e-08
recombinants O 0 3.0032558129278186e-07
between O 0 5.027835037196837e-09
the O 0 1.2708266439176441e-08
Factor O 0 5.405709657679836e-07
B O 0 2.3435561615769984e-06
gene O 0 1.5075939074904454e-07
and O 0 1.417859039065661e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 3.831790422736958e-07
suggests O 0 6.152599762998534e-09
that O 0 4.238042208837278e-11
these O 0 3.920027150106087e-11
two O 0 5.798843627502492e-10
genes O 0 4.057052027661712e-09
lie O 0 1.465415039092477e-06
in O 0 1.1334965677178843e-07
close O 0 1.2003831216134131e-05
proximity O 0 2.354641083002207e-06
to O 0 2.2559595080906547e-08
one O 0 7.15532593176249e-08
another O 0 3.785852129567502e-07
. O 0 3.6509993606159696e-07

Distribution O 0 2.571203594925464e-06
of O 0 1.3109140581946122e-06
emerin O 0 0.0002245306532131508
and O 0 2.2334869242968125e-07
lamins O 0 0.002856683451682329
in O 0 1.7609866631573823e-07
the O 0 3.8413034531004087e-07
heart O 0 6.334327736112755e-06
and O 0 5.222948296079721e-09
implications O 0 1.03820454455672e-07
for O 0 4.920237728356369e-08
Emery B-Disease 1 0.7794472575187683
- I-Disease 1 0.9999996423721313
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 0.9999995231628418
. O 0 2.012745426327456e-06

Emerin O 0 0.0049914526753127575
is O 0 4.763294612075697e-07
a O 0 4.631340004834783e-07
nuclear O 0 7.283663762791548e-06
membrane O 0 1.025920755637344e-05
protein O 0 2.219439210193741e-07
which O 0 2.2161295021305705e-09
is O 0 2.6694686461326e-09
missing O 0 5.615390819002641e-07
or O 0 1.0985009879505014e-07
defective O 0 1.6493237353643053e-06
in O 0 6.413044388864364e-07
Emery B-Disease 1 0.9999582767486572
- I-Disease 1 1.0
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 8.038135274546221e-05
EDMD B-Disease 1 1.0
) O 0 4.919805860481574e-07
. O 0 1.4306974094324687e-07

It O 0 8.048971267271554e-08
is O 0 1.2806522065034187e-08
one O 0 3.1334026484586275e-09
member O 0 2.5599186770364213e-08
of O 0 1.834822711543893e-07
a O 0 4.640765780550282e-07
family O 0 4.5261174363986356e-07
of O 0 1.2722086921712616e-06
lamina O 1 0.9998908042907715
- O 0 0.009689250029623508
associated O 0 1.5032225064715021e-06
proteins O 0 1.6540754543825642e-08
which O 0 1.627350143529327e-09
includes O 0 8.42273717438502e-09
LAP1 O 0 0.0003794440708588809
, O 0 4.8984198031121196e-08
LAP2 O 0 0.0004652545030694455
and O 0 7.12993184492916e-08
lamin O 0 8.486523438477889e-05
B O 0 9.050588414538652e-05
receptor O 0 1.8875582100008614e-05
( O 0 4.583026793625322e-07
LBR O 0 0.00011733616702258587
) O 0 5.70001468247483e-08
. O 0 7.920556299723103e-08

A O 0 2.495409171388019e-05
panel O 0 4.3950461758868187e-07
of O 0 1.3922182517944748e-07
16 O 0 1.5990536894605611e-07
monoclonal O 0 3.594487907321309e-08
antibodies O 0 3.2338358657568733e-09
( O 0 1.2084706568771253e-08
mAbs O 0 3.8673496760566195e-07
) O 0 1.48593604087921e-09
has O 0 9.666583505874016e-11
been O 0 8.51208756258437e-11
mapped O 0 1.8566568282807339e-09
to O 0 1.115540854135233e-10
six O 0 5.528612012639655e-10
specific O 0 1.108000288740918e-10
sites O 0 1.4991393681995646e-09
throughout O 0 9.66275393032845e-10
the O 0 4.5126680170426425e-09
emerin O 0 6.511718879664841e-07
molecule O 0 1.8114633348886855e-08
using O 0 7.507243715565437e-09
phage O 0 4.9132882651292675e-08
- O 0 5.331795893681601e-09
displayed O 0 8.915394644759544e-09
peptide O 0 2.362886597495617e-08
libraries O 0 7.1925416733620295e-09
and O 0 1.7460906331923098e-10
has O 0 1.2837103602336697e-10
been O 0 6.620340942120606e-10
used O 0 1.6801321445214512e-09
to O 0 8.473381107876321e-09
localize O 0 1.3308419511304237e-05
emerin O 0 0.00014077646483201534
in O 0 1.1841865443784627e-07
human O 0 1.0813527495656672e-07
and O 0 5.9198576707331085e-08
rabbit O 0 2.3298394808080047e-05
heart O 0 8.744109800318256e-05
. O 0 6.786598873986804e-07

Several O 0 7.129686423468229e-07
mAbs O 0 4.067889676662162e-06
against O 0 3.110681134899096e-08
different O 0 6.694933940565306e-09
emerin O 0 7.634951543877833e-06
epitopes O 0 7.884018486947753e-07
did O 0 1.4078069376921576e-08
not O 0 1.6642138778166782e-09
recognize O 0 6.567308918903336e-09
intercalated O 0 2.7839541871799156e-06
discs O 0 3.3700416679494083e-06
in O 0 2.941708743264826e-08
the O 0 6.71196715984479e-08
heart O 0 3.4464276268408867e-06
, O 0 2.231752116443886e-09
though O 0 2.000308363392378e-09
they O 0 5.897244914621069e-10
recognized O 0 1.1118798326492652e-08
cardiomyocyte O 0 6.640619290010363e-07
nuclei O 0 4.2914749087685777e-07
strongly O 0 1.972733620903e-08
, O 0 2.549387589922958e-09
both O 0 3.1635005726116106e-09
at O 0 5.76520221784449e-07
the O 0 2.564718499797891e-07
rim O 0 1.2001756886093062e-06
and O 0 4.053199997855472e-09
in O 0 1.2448925446051362e-08
intranuclear O 0 7.589941105834441e-06
spots O 0 6.11156679042324e-07
or O 0 1.4553843641351705e-07
channels O 0 1.1422596344345948e-06
. O 0 3.959937373565481e-07

A O 0 9.485246118856594e-05
polyclonal O 0 0.00011477346561150625
rabbit O 0 3.27648081110965e-06
antiserum O 0 9.75726197793847e-06
against O 0 1.1521736809072536e-07
emerin O 0 1.4575719433196355e-05
did O 0 3.6189295116173525e-08
recognize O 0 4.642737749804837e-09
both O 0 3.554235350478052e-09
nuclear O 0 1.5623364788552863e-06
membrane O 0 2.4303960799443303e-06
and O 0 3.6558365223982037e-09
intercalated O 0 1.643996938582859e-06
discs O 0 2.8539315621856076e-07
but O 0 1.373233859958134e-09
, O 0 2.2300064572711165e-10
after O 0 4.364194783335051e-09
affinity O 0 1.923055137353913e-08
purification O 0 6.986147127463482e-08
against O 0 7.483996533608206e-09
a O 0 3.437632045688588e-08
pure O 0 1.2612252930921386e-06
- O 0 1.8683812186282012e-07
emerin O 0 2.2405365598388016e-06
band O 0 6.418961362442133e-08
on O 0 2.3929201731220928e-08
a O 0 1.9529924344396932e-08
western O 0 8.005362595042698e-09
blot O 0 6.473397888839827e-07
, O 0 3.355775879398948e-09
it O 0 1.311168840167909e-09
stained O 0 2.645087135988433e-07
only O 0 1.1530470800380499e-08
the O 0 7.600116447292748e-08
nuclear O 0 1.466363846702734e-05
membrane O 0 6.272239988902584e-05
. O 0 4.6087239979897276e-07

These O 0 6.342218483723627e-08
results O 0 9.699985703548464e-09
would O 0 1.3863291625781926e-09
not O 0 1.0338543354748708e-09
be O 0 1.765770973882752e-09
expected O 0 2.0054427007920594e-09
if O 0 1.0356863811011863e-08
immunostaining O 0 2.8108988772146404e-06
at O 0 3.745183505543537e-07
intercalated O 0 5.976064585411223e-06
discs O 0 2.2691360754834022e-06
were O 0 5.4928175785562416e-08
due O 0 3.300104722825381e-08
to O 0 2.2511270625358293e-09
a O 0 5.768114874626917e-09
product O 0 1.4998657871245769e-09
of O 0 5.542255543389274e-09
the O 0 2.637886709067061e-08
emerin O 0 6.854748335172189e-06
gene O 0 2.975577118036199e-09
and O 0 3.572727946821175e-10
, O 0 1.5676414333309907e-10
therefore O 0 2.6791295848482832e-09
, O 0 4.086842531059176e-10
cast O 0 1.8625944120387317e-09
some O 0 1.3231921114353895e-10
doubt O 0 1.6807059077805775e-09
upon O 0 2.1811681349959144e-09
the O 0 1.9766648318153557e-09
hypothesis O 0 2.559430534176954e-08
that O 0 1.5387234819641549e-09
cardiac B-Disease 0 0.0027327516581863165
defects I-Disease 0 1.316788257099688e-05
in O 0 9.033469154928753e-07
EDMD B-Disease 1 1.0
are O 0 2.9959213065922086e-07
caused O 0 2.5535067038617854e-07
by O 0 7.524273648584767e-09
absence O 0 7.656188927285257e-07
of O 0 1.1287356755929068e-06
emerin O 0 0.00023642551968805492
from O 0 7.120349891920341e-07
intercalated O 0 0.0003044570912607014
discs O 0 4.933534364681691e-05
. O 0 7.188099857557972e-07

Although O 0 3.357031118866871e-06
emerin O 0 4.0222334064310417e-05
was O 0 6.64092283386708e-07
abundant O 0 1.3552549660289515e-07
in O 0 8.491712222280512e-09
the O 0 3.4775435864276005e-08
membranes O 0 4.5460427600119147e-07
of O 0 2.7573756256060733e-07
cardiomyocyte O 0 4.9252888857154176e-05
nuclei O 0 4.6233972170739435e-06
, O 0 1.2983011998812799e-08
it O 0 4.4343220761966506e-10
was O 0 4.7544716608172166e-08
absent O 0 2.339861282507627e-08
from O 0 9.402441047967613e-10
many O 0 2.2660573417709884e-10
non O 0 5.460268681645175e-08
- O 0 9.110610932339114e-08
myocyte O 0 5.0750983064062893e-05
cells O 0 3.255901503962377e-08
in O 0 8.58087023658527e-09
the O 0 1.559073865564642e-07
heart O 0 1.4778644072066527e-05
. O 0 5.53184463569778e-07

This O 0 7.940523261140697e-08
distribution O 0 8.03974984364686e-08
of O 0 2.730506309944758e-07
emerin O 0 4.5345776015892625e-05
was O 0 5.229759381109034e-07
similar O 0 3.078311383575283e-09
to O 0 1.1475701500174296e-09
that O 0 8.023702258164178e-10
of O 0 6.011865849586684e-08
lamin O 0 9.731315913086291e-06
A O 0 9.69421535046422e-07
, O 0 8.066637913195507e-10
a O 0 1.7414617525801646e-09
candidate O 0 1.1274172706521313e-09
gene O 0 3.4288605288423923e-10
for O 0 1.659907905571245e-10
an O 0 8.453380218043094e-09
autosomal O 0 9.458587868493851e-08
form O 0 8.72986234412565e-08
of O 1 0.9535506367683411
EDMD B-Disease 1 1.0
. O 0 6.066117202863097e-05

In O 0 1.5950647593854228e-06
contrast O 0 1.0897887250393978e-06
, O 0 2.7153126325174526e-07
lamin O 0 0.0003363292198628187
B1 O 0 0.008372528478503227
was O 0 3.1513006888417294e-06
absent O 0 1.073590169653471e-06
from O 0 6.973460386916486e-08
cardiomyocyte O 0 5.663380761689041e-06
nuclei O 0 1.9807716853392776e-06
, O 0 1.8395827083850236e-08
showing O 0 5.5941063692444e-07
that O 0 8.212604818425007e-09
lamin O 0 1.1638411706371699e-05
B1 O 0 7.445157825713977e-05
is O 0 1.19301801770888e-09
not O 0 1.2124889980924536e-10
essential O 0 8.02312527525828e-09
for O 0 1.8925900846511468e-09
localization O 0 3.14540670842689e-06
of O 0 2.634978102378227e-07
emerin O 0 1.5200096640910488e-05
to O 0 4.7444164152921076e-08
the O 0 4.7167614525278623e-07
nuclear O 0 0.0007055433816276491
lamina O 1 0.9999526739120483
. O 0 1.0051993740489706e-05

Lamin O 1 0.9999752044677734
B1 O 1 0.9996496438980103
is O 0 2.770002183183351e-08
also O 0 7.73388297847788e-10
almost O 0 5.034245020851813e-09
completely O 0 4.606030472587008e-07
absent O 0 2.262213229187182e-06
from O 0 6.897923867654754e-07
skeletal O 1 0.9798973202705383
muscle O 0 1.7455153283663094e-05
nuclei O 0 0.0010222858982160687
. O 0 4.295067810744513e-06

In O 0 2.4380598915740848e-05
EDMD B-Disease 1 1.0
, O 0 2.4969386558382212e-08
the O 0 4.5892609712439025e-09
additional O 0 5.461390895078466e-09
absence O 0 7.654846712057406e-08
of O 0 2.0913108755848953e-07
lamin O 0 0.0007648059981875122
B1 O 1 0.9976741671562195
from O 0 1.1227889444853645e-06
heart O 0 0.0012628338299691677
and O 0 1.4177077218846534e-06
skeletal O 1 1.0
muscle O 0 0.026927616447210312
nuclei O 1 0.8823017477989197
which O 0 4.9356057019167565e-08
already O 0 1.1727899540403541e-08
lack O 0 3.0173001164257585e-07
emerin O 0 2.065276703433483e-06
may O 0 4.325626079548783e-09
offer O 0 3.6837768946362814e-10
an O 0 4.666759756410954e-10
alternative O 0 2.0484396401343474e-09
explanation O 0 1.2197597598628818e-08
of O 0 2.792636788484515e-09
why O 0 2.3893114153850092e-09
these O 0 3.103850232388794e-10
tissues O 0 6.5940564120126055e-09
are O 0 4.258610131202545e-10
particularly O 0 3.7033209832060265e-09
affected O 0 1.1420659973282454e-08
. O 0 9.206491569102582e-09
. O 0 1.7916458716626948e-07

Genetic O 0 1.3568725989898667e-05
mapping O 0 4.878759682469536e-06
of O 0 7.619892130605876e-07
the O 0 2.245388031951734e-06
copper B-Disease 1 0.999737560749054
toxicosis I-Disease 1 0.9999997615814209
locus O 0 0.0002914017532020807
in O 0 1.2052247484461986e-06
Bedlington O 0 0.039848990738391876
terriers O 0 4.3468175135785714e-05
to O 0 2.8272388874484022e-08
dog O 0 2.2366417340435873e-07
chromosome O 0 1.7297141496896984e-08
10 O 0 3.4964171558016233e-09
, O 0 2.1288612539471785e-10
in O 0 9.40825417572455e-10
a O 0 2.1211908673990365e-08
region O 0 6.238736460772998e-08
syntenic O 0 1.8771213945001364e-05
to O 0 2.9780316879168822e-08
human O 0 8.062568923605795e-08
chromosome O 0 1.2790610526280943e-07
region O 0 4.834182121271624e-08
2p13 O 0 2.0474722987273708e-05
- O 0 8.45806334837107e-06
p16 O 0 1.5093968613655306e-05
. O 0 4.139212137488357e-07

Abnormal O 1 1.0
hepatic B-Disease 1 1.0
copper I-Disease 1 0.9999977350234985
accumulation I-Disease 1 0.9999916553497314
is O 0 8.923412053718494e-08
recognized O 0 1.0869687372405679e-08
as O 0 7.373732735516114e-09
an O 0 4.812810630028252e-07
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 1 0.9925811290740967
man O 1 0.9997337460517883
, O 0 1.366446213069139e-06
mouse O 0 1.354173400613945e-05
, O 0 2.0435439296306868e-07
rat O 0 0.00011259695020271465
and O 0 3.5383629892749013e-07
dog O 0 0.000356060394551605
. O 0 2.103104179695947e-06

The O 0 5.229846919974079e-06
major O 0 2.2939361770113464e-06
cause O 0 1.2202586731291376e-05
of O 0 5.4323179938364774e-05
hepatic B-Disease 1 1.0
copper I-Disease 1 1.0
accumulation I-Disease 1 1.0
in O 0 1.991674434975721e-05
man O 0 0.00014558427210431546
is O 0 7.051571060401329e-08
a O 0 2.1190118104641442e-07
dysfunctional O 0 0.00010827378719113767
ATP7B O 1 0.8185386061668396
gene O 0 2.0104384645946993e-07
, O 0 1.0889337431763124e-08
causing O 0 2.4455616767227184e-06
Wilson B-Disease 0 0.007960138842463493
disease I-Disease 1 0.9998606443405151
( O 0 0.00014660677697975188
WD B-Disease 1 0.9999788999557495
) O 0 5.251731067801302e-07
. O 0 3.2339337963094295e-07

Mutations O 0 1.69470524724602e-06
in O 0 9.348943308395974e-08
the O 0 1.8631251919032366e-07
ATP7B O 0 0.4569474756717682
genes O 0 9.434353387405281e-08
have O 0 6.623372406089345e-10
also O 0 5.155257887246023e-10
been O 0 2.343777394386848e-09
demonstrated O 0 3.559128458618943e-08
in O 0 1.0146053597281934e-07
mouse O 0 7.620132009833469e-07
and O 0 9.314626936429704e-08
rat O 0 3.1598676287103444e-05
. O 0 2.9518096766878443e-07

The O 0 1.1246321264479775e-05
ATP7B O 0 0.005364422686398029
gene O 0 1.0597056387950943e-07
has O 0 1.3896966910564856e-09
been O 0 1.3304281010206864e-09
excluded O 0 9.041864146297485e-09
in O 0 5.259383484279567e-10
the O 0 3.807549386891651e-09
much O 0 1.557070206104072e-08
rarer O 0 3.6702525108012196e-07
human O 0 1.9615251289906155e-07
copper B-Disease 1 0.9999873638153076
overload I-Disease 1 1.0
disease O 1 0.9982482194900513
non B-Disease 0 0.03849082067608833
- I-Disease 0 5.421598871180322e-06
Indian I-Disease 0 1.552280446048826e-05
childhood I-Disease 1 0.9969147443771362
cirrhosis I-Disease 1 0.9999997615814209
, O 0 5.607628583703672e-09
indicating O 0 1.3070837212580955e-07
genetic O 0 1.442669628204385e-07
heterogeneity O 0 4.947490879203542e-07
. O 0 6.267863028597276e-08

By O 0 2.6503138883526844e-07
investigating O 0 2.1497280613402836e-06
the O 0 2.3069669907727075e-07
common O 0 6.375304906214296e-07
autosomal O 0 0.00010050024866359308
recessive O 0 2.141004370059818e-05
copper B-Disease 1 0.999998927116394
toxicosis I-Disease 1 1.0
( O 0 0.0016075415769591928
CT B-Disease 1 0.9999796152114868
) O 0 1.607910888878905e-07
in O 0 8.01765196456472e-08
Bedlington O 1 0.6664793491363525
terriers O 0 5.374816828407347e-05
, O 0 4.704575395919619e-09
we O 0 2.5989110863378073e-09
have O 0 3.2371974545419846e-10
identified O 0 3.855871621993856e-09
a O 0 2.7518332057496764e-09
new O 0 9.172571036053512e-10
locus O 0 4.22094643681703e-08
involved O 0 9.404184986294695e-09
in O 0 1.9918313398648024e-07
progressive O 1 1.0
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 3.317184382467531e-05

We O 0 3.0211467105800693e-07
examined O 0 6.8295213395686e-07
whether O 0 4.4345974004045274e-08
the O 0 4.575366858716734e-07
WD B-Disease 0 0.0023682161699980497
gene O 0 3.4753958289002185e-07
ATP7B O 0 1.9833441911032423e-05
was O 0 2.6727465751719137e-07
also O 0 3.5499334583022346e-09
causative O 0 1.3227877104782237e-07
for O 0 3.313626040224449e-09
CT B-Disease 0 7.023328635114012e-06
by O 0 1.0217554802238737e-08
investigating O 0 8.068066108535277e-07
the O 0 5.042060138293891e-07
chromosomal O 0 6.107428362156497e-06
co O 0 2.564528949733358e-05
- O 0 1.6608919395366684e-05
localization O 0 0.00019809012883342803
of O 0 3.5708859513761126e-07
ATP7B O 0 0.00042595257400535047
and O 0 1.544266581277043e-08
C04107 O 0 7.21520109436824e-07
, O 0 8.703070486504316e-10
using O 0 1.4509690116071283e-09
fluorescence O 0 1.086728218524513e-08
in O 0 2.520796682503601e-09
situ O 0 1.8382747839496005e-06
hybridization O 0 1.5698249455908808e-07
( O 0 8.21727397237737e-09
FISH O 0 1.5334101988173643e-07
) O 0 1.187800879876022e-08
. O 0 2.832425849419451e-08

C04107 O 0 0.00025713289505802095
is O 0 2.0735208750011225e-07
an O 0 4.801477615501426e-08
anonymous O 0 2.2451995391747914e-06
microsatellite O 0 7.273828032339225e-06
marker O 0 9.884719247565954e-07
closely O 0 3.8742010133319127e-07
linked O 0 2.1961157017358346e-06
to O 0 3.4182795616288786e-07
CT B-Disease 1 0.9998416900634766
. O 0 3.7767142657685326e-06

However O 0 4.630042440112447e-06
, O 0 4.1374201487087703e-07
BAC O 0 0.0004986095591448247
clones O 0 7.203506129371817e-07
containing O 0 1.0077490486537499e-07
ATP7B O 0 6.495243724202737e-05
and O 0 4.0885460350637004e-08
C04107 O 0 4.689876732300036e-06
mapped O 0 3.2765009905233455e-07
to O 0 7.30826021921871e-09
the O 0 1.5756775439967896e-07
canine O 0 1.4999344557509176e-06
chromosome O 0 3.051210626381362e-07
regions O 0 2.347769623156637e-08
CFA22q11 O 0 0.00017048692097887397
and O 0 7.853299166526995e-08
CFA10q26 O 0 0.0006345032597891986
, O 0 6.8405876518795594e-09
respectively O 0 5.172272921072363e-08
, O 0 1.2035750174277382e-09
demonstrating O 0 7.634113075027926e-08
that O 0 7.07602243465999e-09
WD B-Disease 0 8.29868804430589e-06
cannot O 0 2.5881977450126215e-08
be O 0 7.232104692889152e-09
homologous O 0 5.471715880389638e-08
to O 0 6.526514795268668e-08
CT B-Disease 0 0.0020434772595763206
. O 0 2.1603987079288345e-06

The O 0 9.695357221062295e-06
copper O 0 0.00027040697750635445
transport O 0 8.888239790394437e-06
genes O 0 2.400661060164566e-06
CTR1 O 0 0.07410432398319244
and O 0 2.7697495852407883e-07
CTR2 O 1 0.8254339694976807
were O 0 2.527616231873253e-07
also O 0 5.42056488583853e-09
excluded O 0 1.3966194423176148e-08
as O 0 3.846014617892024e-09
candidate O 0 4.203157377702382e-09
genes O 0 1.2436222052158996e-09
for O 0 1.4449016427775518e-09
CT B-Disease 0 8.472834451822564e-05
since O 0 2.890974748481767e-08
they O 0 6.330235780005466e-10
both O 0 1.4386756230777564e-09
mapped O 0 5.6361866285215e-08
to O 0 3.156558747718918e-08
canine O 0 3.5991640743304743e-06
chromosome O 0 1.4963097783038393e-06
region O 0 6.048499017197173e-07
CFA11q22 O 0 0.006672930903732777
. O 0 2.2572762645722833e-06

2 O 0 2.077145836665295e-05
- O 0 5.312579105520854e-06
22 O 0 2.023363322223304e-06
. O 0 2.8728089773721877e-07

5 O 0 0.0001345612108707428
. O 0 7.729974640824366e-06

A O 0 9.063465768122114e-06
transcribed O 0 2.0507686713244766e-06
sequence O 0 7.30175671037614e-08
identified O 0 1.9248863836196506e-08
from O 0 6.581327482990673e-09
the O 0 3.6542765258218424e-08
C04107 O 0 1.7671687828624272e-06
- O 0 2.053154730674578e-07
containing O 0 1.5547620080269553e-07
BAC O 0 0.000143121273140423
was O 0 9.15124260814082e-08
found O 0 2.2178803238404043e-09
to O 0 3.651339508525808e-10
be O 0 7.685957426062373e-10
homologous O 0 1.0545072370859998e-08
to O 0 1.2204806054683104e-09
a O 0 1.1692920409700491e-08
gene O 0 8.079864555199379e-10
expressed O 0 4.889668669960656e-10
from O 0 5.294573224290389e-09
human O 0 6.350773684715705e-09
chromosome O 0 2.6939911634826785e-08
2p13 O 0 6.774467351533531e-07
- O 0 1.72129290376688e-07
p16 O 0 1.1489357376603948e-07
, O 0 2.793589248817341e-10
a O 0 5.742818998122345e-10
region O 0 1.8233974330428282e-09
devoid O 0 2.5386125912518764e-07
of O 0 6.252135698048278e-09
any O 0 8.35570901358551e-09
positional O 0 3.7500228700082516e-07
candidate O 0 1.568535026308382e-07
genes O 0 1.5052422952521738e-07
. O 0 3.0244157755987544e-07

Molecular O 0 1.449172486900352e-05
analysis O 0 3.7253562368277926e-07
of O 0 7.107446720056032e-08
the O 0 1.2614559352641663e-07
APC B-Disease 0 3.7593829915749666e-07
gene O 0 7.365716925278321e-10
in O 0 2.190740228114052e-10
205 O 0 2.6156503629692907e-09
families O 0 2.4928059616513565e-10
: O 0 5.67575042520474e-10
extended O 0 1.8945522484159483e-08
genotype O 0 1.2517311631654593e-07
- O 0 5.953771875510938e-08
phenotype O 0 3.4262686909869444e-08
correlations O 0 1.5647296436327451e-07
in O 0 9.566719860742978e-09
FAP B-Disease 0 1.1462827842478873e-07
and O 0 1.6885934317478757e-10
evidence O 0 1.0181662624120236e-08
for O 0 3.912648538495489e-10
the O 0 3.4206968368977186e-09
role O 0 1.619600276114852e-08
of O 0 5.648067258334777e-08
APC B-Disease 0 2.8304773991294496e-07
amino O 0 8.363378434239621e-09
acid O 0 4.753163196369314e-09
changes O 0 2.075624339070714e-09
in O 0 3.943448518839432e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 1.0
. O 0 6.0674183259834535e-06

BACKGROUND O 0 0.0029477193020284176
/ O 0 6.141413177829236e-05
AIMS O 0 2.0402287645993056e-06
The O 0 9.22285821047808e-08
development O 0 2.2139795419207076e-06
of O 0 0.012053812853991985
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 3.281060756421539e-09
a O 0 1.7637279414728368e-09
variable O 0 7.715494909632525e-10
range O 0 3.489047106786103e-10
of O 0 1.7536478935653577e-09
extracolonic O 0 1.5727786149000167e-06
manifestations O 0 5.345272256818134e-06
in O 0 3.3207568321813596e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 7.55395958549343e-05
FAP B-Disease 0 5.012956080463482e-06
) O 0 2.5122051106052368e-09
is O 0 4.096066541503518e-10
the O 0 1.137248517579792e-09
result O 0 9.322266514288913e-09
of O 0 1.1897967766572037e-07
the O 0 4.779721507475188e-07
dominant O 0 2.5476263544987887e-05
inheritance O 0 0.00027039949782192707
of O 1 0.5119860172271729
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 0.00011747565440600738
APC B-Disease 0 2.0785408196388744e-05
) O 0 1.8339517282583984e-07
gene O 0 1.0463233479640621e-07
mutations O 0 9.83361090334256e-08
. O 0 3.0919005666874e-07

In O 0 1.1494157092784008e-07
this O 0 8.781943505731249e-10
study O 0 2.470946336430302e-09
, O 0 6.241334532530729e-11
direct O 0 3.1742819484037454e-10
mutation O 0 5.424013668764438e-11
analysis O 0 6.840023547560747e-10
of O 0 1.8320605033039783e-09
the O 0 1.3297741574547217e-08
APC B-Disease 0 1.8998575512796378e-07
gene O 0 8.858521693966281e-10
was O 0 8.884720514856781e-09
performed O 0 2.8486455416754097e-09
to O 0 2.7530183688284637e-10
determine O 0 2.1453884002653467e-08
genotype O 0 2.2470452165634924e-07
- O 0 1.2550013650525216e-07
phenotype O 0 2.5677135084833935e-08
correlations O 0 4.996137903390263e-08
for O 0 9.891825136776333e-10
nine O 0 5.02413683989289e-08
extracolonic O 0 2.1809962618135614e-06
manifestations O 0 3.0136246209622186e-07
and O 0 1.0542975381611086e-09
to O 0 1.0955288898273352e-09
investigate O 0 1.6614235320844273e-08
the O 0 1.6588588280797012e-08
incidence O 0 3.738499856353883e-07
of O 0 4.0314983351663614e-08
APC B-Disease 0 1.5363055183570395e-07
mutations O 0 4.3845505004469487e-10
in O 0 2.1889368095884265e-09
non O 0 5.349469211068936e-05
- O 1 0.9999003410339355
FAP O 1 0.9999991655349731
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 5.935702574788593e-06

METHODS O 0 3.3293195883743465e-05
The O 0 2.321968395335716e-06
APC B-Disease 0 3.851012479572091e-06
gene O 0 8.409108964713141e-09
was O 0 1.2769910462395728e-08
analysed O 0 3.833273609643584e-08
in O 0 5.050498685932325e-09
190 O 0 6.536868113471428e-08
unrelated O 0 1.0310196074669875e-07
FAP B-Disease 0 5.500911370859285e-08
and O 0 5.570804373355998e-10
15 O 0 5.9091181725534625e-08
non O 0 0.001097400556318462
- O 1 0.9998806715011597
FAP O 1 0.999998927116394
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 3.7835306443412264e-08
using O 0 4.109254270190377e-09
denaturing O 0 2.5124585590674542e-05
gradient O 0 1.1791013321271748e-06
gel O 0 1.4604133014017862e-07
electrophoresis O 0 1.409134569030357e-07
, O 0 1.172827279738442e-09
the O 0 3.5268519216202776e-09
protein O 0 7.800657009227052e-09
truncation O 0 4.9936989654497665e-08
test O 0 2.0401693667793097e-09
, O 0 8.800903755767919e-11
and O 0 3.9959113795617895e-10
direct O 0 1.2365176438322578e-08
sequencing O 0 6.262210661134304e-08
. O 0 1.1921659393010486e-07

RESULTS O 0 7.689652557019144e-05
Chain O 0 1.1109121260233223e-05
terminating O 0 6.480791512331052e-07
signals O 0 6.048948364423268e-08
were O 0 1.423925533039494e-09
only O 0 2.375994678782689e-10
identified O 0 1.5091777827436204e-09
in O 0 3.101928269799714e-09
patients O 0 1.747740840940537e-09
belonging O 0 1.87711492571907e-07
to O 0 2.8086530434734414e-08
the O 0 1.956465439434396e-06
FAP B-Disease 0 4.512396117206663e-06
group O 0 2.128360065967172e-08
( O 0 3.3820504174997268e-09
105 O 0 8.391760530912507e-08
patients O 0 4.711031564852419e-09
) O 0 4.471917058879171e-09
. O 0 6.859692547322993e-08

Amino O 0 5.279477591102477e-06
acid O 0 5.031118277543101e-08
changes O 0 1.2444526520383192e-09
were O 0 2.812806432217485e-09
identified O 0 6.277180109037772e-09
in O 0 2.0802017886012436e-09
four O 0 6.641364347359513e-09
patients O 0 1.453630993353272e-09
, O 0 2.5642457601726676e-10
three O 0 1.313043340722686e-09
of O 0 2.574560085122357e-07
whom O 0 1.7675485253221268e-07
belonged O 0 7.116930646589026e-05
to O 0 5.942199976516349e-08
the O 0 4.3117981363138824e-07
non O 0 0.00013066473184153438
- O 0 7.3806822911137715e-06
FAP O 0 1.3094110045130947e-06
group O 0 1.954095196765593e-08
of O 0 7.346637630689656e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.01097689475864172
. O 0 2.7878866148967063e-07

Genotype O 0 0.00041340928873978555
- O 0 1.4598061170545407e-05
phenotype O 0 8.043903676480113e-07
correlations O 0 7.702121251895733e-07
identified O 0 1.0957869278627186e-07
significant O 0 2.8107486116368818e-08
differences O 0 1.4254181834871815e-08
in O 0 4.955392540750836e-09
the O 0 5.492993171429816e-09
nature O 0 3.4551703720353544e-08
of O 0 2.9710347515532476e-09
certain O 0 1.4406279502665598e-09
extracolonic O 0 1.2041642776239314e-06
manifestations O 0 2.4396237563450995e-07
in O 0 4.6211127369133465e-08
FAP B-Disease 0 1.006883167065098e-06
patients O 0 1.1408788358480138e-09
belonging O 0 2.0541373046967237e-08
to O 0 8.398750028781876e-10
three O 0 7.37069560940995e-09
mutation O 0 1.8301964388456327e-08
subgroups O 0 2.8995953016419662e-06
. O 0 1.9461731426417828e-07

CONCLUSIONS O 0 2.6926176360575482e-05
Extended O 0 4.864538368565263e-06
genotype O 0 5.7755428315431345e-06
- O 0 5.676075147675874e-07
phenotype O 0 8.746229696043883e-08
correlations O 0 8.074680835079562e-08
made O 0 3.1761184793310804e-09
in O 0 1.7929554507745138e-09
this O 0 8.730603462403508e-10
study O 0 2.5218789279080056e-09
may O 0 1.1371704689011608e-09
have O 0 6.235242877572489e-11
the O 0 1.1013426837180873e-09
potential O 0 1.5782537499120508e-09
to O 0 8.881119450965258e-11
determine O 0 3.4240259516593596e-09
the O 0 2.6809239273006824e-09
most O 0 1.3011011712471543e-10
appropriate O 0 4.717395363229571e-10
surveillance O 0 7.494653786466188e-09
and O 0 2.3057103448742566e-10
prophylactic O 0 1.5927892604850058e-07
treatment O 0 9.864698391481852e-09
regimens O 0 2.101057638981274e-08
for O 0 1.415576128538376e-10
those O 0 1.8721924011089186e-10
patients O 0 2.2361311413643392e-10
with O 0 5.828136584451471e-11
mutations O 0 1.2959872064399747e-09
associated O 0 2.9073815355218358e-08
with O 0 5.476203046583805e-09
life O 0 2.986143226735294e-05
threatening O 0 1.3282832469485584e-06
conditions O 0 6.827881861681817e-06
. O 0 7.379475164270843e-07

This O 0 3.398846359914387e-08
study O 0 4.103708928226979e-09
also O 0 1.1108654274227803e-10
provided O 0 8.067960743929348e-10
evidence O 0 2.1856410015175243e-09
for O 0 3.0471158929401554e-10
the O 0 1.1650977960186992e-08
pathological O 0 7.074850145727396e-06
nature O 0 9.295761316252538e-08
of O 0 2.8247272965131742e-08
amino O 0 2.7318259654407484e-08
acid O 0 4.251591967374679e-09
changes O 0 7.256599210414549e-10
in O 0 7.483226482918326e-09
APC O 0 9.526646493895896e-08
associated O 0 5.2963713415010716e-09
with O 0 6.735841329152947e-10
both O 0 1.4658265712341745e-08
FAP B-Disease 0 4.292825792617805e-07
and O 0 1.688978379377204e-08
non O 1 0.9625397324562073
- O 1 0.9999997615814209
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 7.141539299482247e-06
. O 0 1.1571340330363e-08
. O 0 1.110151046646024e-07

Inherited B-Disease 1 1.0
colorectal I-Disease 1 1.0
polyposis I-Disease 1 1.0
and O 0 3.111128899035975e-05
cancer B-Disease 1 0.9483316540718079
risk O 0 9.265761764254421e-05
of O 0 0.00014585367171093822
the O 0 1.9763036107178777e-05
APC O 0 2.4871174900908954e-05
I1307K O 0 1.6177304132725112e-05
polymorphism O 0 3.66126437256753e-06
. O 0 2.716812446124095e-07

Germ O 0 0.03687736764550209
- O 0 2.5060047846636735e-05
line O 0 4.1986405108218605e-07
and O 0 3.311483975920737e-09
somatic O 0 3.70035770913546e-08
truncating O 0 2.385713457897509e-07
mutations O 0 1.6465798724496494e-09
of O 0 4.618370574860364e-09
the O 0 1.9293080910642857e-08
APC B-Disease 0 2.2635676089066692e-07
gene O 0 5.698954086419405e-10
are O 0 3.18998161219497e-11
thought O 0 2.9332416495719826e-09
to O 0 1.7068930713293184e-09
initiate O 0 9.329168619842676e-07
colorectal B-Disease 1 1.0
tumor I-Disease 1 0.9997774958610535
formation O 1 0.9409241676330566
in O 1 0.9970961809158325
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 1.9965029423474334e-05
sporadic O 1 1.0
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 4.312063083489193e-06
respectively O 0 8.481119584757835e-05
. O 0 5.6367307479376905e-06

Recently O 0 1.8374089449935127e-06
, O 0 9.72837099766366e-09
an O 0 2.8487884051742185e-08
isoleucine O 0 3.3051680929929717e-06
- O 0 5.540035090234596e-06
- O 0 7.450199063896434e-06
> O 0 2.4292467060149647e-06
lysine O 0 5.489544037118321e-07
polymorphism O 0 8.948499896632711e-08
at O 0 5.882354514596955e-08
codon O 0 7.722142214561245e-08
1307 O 0 1.5690122836531373e-06
( O 0 1.0643866232840082e-08
I1307K O 0 1.373549451955114e-07
) O 0 1.130884830224943e-09
of O 0 8.614192914535579e-09
the O 0 8.21007120066497e-08
APC B-Disease 0 8.890571052688756e-07
gene O 0 2.3579689312214214e-09
has O 0 1.2346829114662228e-10
been O 0 2.6128169072769936e-10
identified O 0 1.0416052464989889e-09
in O 0 1.8010580804528331e-09
6 O 0 5.3996718207827143e-08
% O 0 3.3281246647476337e-09
- O 0 1.6545227410347252e-09
7 O 0 1.1898734442183923e-08
% O 0 5.156369220493673e-10
of O 0 5.327259189336075e-10
the O 0 2.024659773169901e-09
Ashkenazi O 0 4.228472860745569e-08
Jewish O 0 4.238913575704828e-08
population O 0 1.0037349840175125e-09
. O 0 8.583882049606473e-09

To O 0 8.821167085670822e-08
assess O 0 3.669247803372855e-07
the O 0 5.838359129484161e-08
risk O 0 7.11995724600456e-08
of O 0 1.3416435962199103e-08
this O 0 3.765631362284694e-09
common O 0 1.0469317857086935e-08
APC B-Disease 0 1.5416743792684429e-07
allelic O 0 6.595241330842327e-08
variant O 0 7.215876252075759e-08
in O 0 7.392239353976038e-08
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 5.047631645993533e-08
we O 0 5.984006623549476e-09
have O 0 2.455722569738583e-10
analyzed O 0 6.440862510004308e-09
a O 0 1.4389747171605904e-09
large O 0 9.305314851992819e-10
cohort O 0 8.786911109837092e-08
of O 0 4.572077827447174e-08
unselected O 0 0.0005162102752365172
Ashkenazi O 0 5.2225004765205085e-06
Jewish O 0 4.4459545733843697e-07
subjects O 0 8.186636932805413e-07
with O 0 3.8221909193225656e-08
adenomatous B-Disease 0 0.0008143192972056568
polyps I-Disease 0 2.03776107809972e-06
and O 0 1.4234457168527115e-08
. O 0 2.2361874130183423e-07
or O 1 0.9999996423721313
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 3.50059076481557e-06
for O 0 1.2734598442420975e-07
the O 0 5.33894990439876e-06
APC O 0 3.0515409889630973e-05
I1307K O 0 2.6464356778888032e-05
polymorphism O 0 2.845921017069486e-06
. O 0 3.5241916407358076e-07

The O 0 5.702569251297973e-05
APC O 0 5.779796265414916e-05
I1307K O 0 1.5662222722312436e-05
allele O 0 1.8983362792823755e-07
was O 0 1.8340968210850406e-07
identified O 0 3.114676516702275e-08
in O 0 1.021079398810798e-08
48 O 0 4.150745880338036e-08
( O 0 3.1594906690912694e-09
10 O 0 2.054222569825015e-09
. O 0 1.4240335299842144e-10
1 O 0 7.426521175801781e-09
% O 0 5.324689578145581e-10
) O 0 1.1393495175093804e-10
of O 0 2.0401693667793097e-09
476 O 0 1.1110661546354095e-07
patients O 0 1.53905599376003e-08
. O 0 3.027122019716444e-08

Compared O 0 2.932771394625888e-07
with O 0 3.970392348229268e-10
the O 0 1.2041718733257767e-09
frequency O 0 1.6973613625737016e-09
in O 0 1.6570295136020263e-10
two O 0 3.071880250171688e-11
separate O 0 2.604626792024334e-10
population O 0 4.9448417582809157e-11
control O 0 6.337448343884944e-10
groups O 0 1.191800547140076e-10
, O 0 3.1623406671066334e-10
the O 0 2.187927883312568e-08
APC O 0 4.60257496115446e-07
I1307K O 0 1.785849406132911e-07
allele O 0 1.4702639106189963e-09
is O 0 2.146761657328966e-10
associated O 0 4.943712661464872e-10
with O 0 1.792379265841415e-11
an O 0 7.598079942994218e-10
estimated O 0 2.6424324950369282e-09
relative O 0 1.0618280299468097e-07
risk O 0 5.406668890373112e-08
of O 0 9.688156410447846e-08
1 O 0 2.841069772330229e-06
. O 0 3.170527804741141e-07

5 O 0 2.7708389097824693e-05
- O 0 9.025091458170209e-06
1 O 0 4.337523023423273e-06
. O 0 4.810213454220502e-07

7 O 0 8.399097168876324e-06
for O 0 3.0210719614842674e-07
colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.9857067465782166
( O 0 2.032348447755794e-06
both O 0 1.4932791714272753e-07
P O 0 0.0017886449350044131
= O 0 3.2769464723969577e-06
. O 0 1.2330908738533708e-08
01 O 0 3.61903767043259e-06
) O 0 2.7757193876709607e-08
. O 0 3.3694838919018366e-08

Furthermore O 0 3.5165680856152903e-06
, O 0 1.1387489173841914e-08
compared O 0 1.195946186527408e-08
with O 0 2.063238246918786e-09
noncarriers O 0 5.756145037594251e-05
, O 0 1.350761920093646e-07
APC O 0 1.485244752075232e-06
I1307K O 0 8.670502325003326e-07
carriers O 0 2.9201956408542173e-09
had O 0 2.040352331533768e-09
increased O 0 1.5180871004716323e-09
numbers O 0 2.810875754377662e-09
of O 0 5.739714836749954e-08
adenomas B-Disease 1 0.9759637117385864
and O 0 3.6831875149800908e-06
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9886004328727722
per O 0 3.6943674786016345e-06
patient O 0 7.567705893052334e-07
( O 0 9.373580134308668e-09
P O 0 3.9374813241011e-06
= O 0 5.1709413639855484e-08
. O 0 3.1706148817534086e-10
03 O 0 1.4585954488666175e-07
) O 0 1.900279100741642e-10
, O 0 6.874942282131258e-11
as O 0 2.7808250147032254e-10
well O 0 1.3069193505188537e-09
as O 0 2.613276484098037e-09
a O 0 1.8540919910492448e-08
younger O 0 1.2715006825203545e-08
age O 0 1.5657133189961314e-07
at O 0 3.2603377349005314e-06
diagnosis O 0 2.083311483147554e-05
. O 0 2.804633538744383e-07

We O 0 1.2102279924874892e-06
conclude O 0 2.6887041713052895e-06
that O 0 1.4218827004697232e-08
the O 0 3.218890753942105e-07
APC O 0 5.630836767522851e-06
I1307K O 0 3.1853405744186603e-06
variant O 0 1.9617439761532296e-07
leads O 0 3.1152765700426244e-08
to O 0 4.480403603679406e-09
increased O 0 2.3240720281592075e-07
adenoma B-Disease 1 1.0
formation O 0 6.60011721720366e-07
and O 0 1.07079056732573e-08
directly O 0 3.650584190495465e-08
contributes O 0 8.502474280192018e-09
to O 0 5.405508818334681e-10
3 O 0 5.239641165388775e-09
% O 0 7.011625169361935e-10
- O 0 4.163467903772755e-10
4 O 0 1.4475552978510109e-09
% O 0 6.147045372717486e-11
of O 0 1.4005527293470266e-10
all O 0 5.265023972356175e-10
Ashkenazi O 0 9.64661012403667e-07
Jewish O 0 0.012113616801798344
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 5.638343282043934e-06

The O 0 1.715696242854392e-07
estimated O 0 2.6220002169452528e-08
relative O 0 3.744048058251792e-07
risk O 0 5.91141784411775e-08
for O 0 1.7715260369755015e-09
carriers O 0 3.0250080218507946e-09
may O 0 1.8984434024815755e-09
justify O 0 3.055866670820251e-08
specific O 0 5.727264218435835e-10
clinical O 0 1.0509432435412691e-08
screening O 0 4.744221682173588e-10
for O 0 1.279093359007888e-10
the O 0 1.8638310894658616e-09
360 O 0 9.201540862591173e-09
, O 0 5.3719376169603095e-11
000 O 0 2.770064178037046e-09
Americans O 0 3.8026121140788405e-10
expected O 0 1.559547352369961e-10
to O 0 4.734846958953653e-10
harbor O 0 1.44522815048731e-07
this O 0 1.103504398969335e-09
allele O 0 1.5590307933521785e-09
, O 0 1.8491422282274073e-10
and O 0 1.8003083745998794e-10
genetic O 0 2.409309862727582e-09
testing O 0 7.127369250348181e-10
in O 0 1.0766204594503392e-09
the O 0 5.0160342546234915e-09
setting O 0 1.9010030882782303e-07
of O 0 5.809068071016554e-08
long O 0 2.3229059564755516e-08
- O 0 9.96671190023335e-09
term O 0 2.372003393702471e-08
- O 0 3.875292531319019e-09
outcome O 0 2.1950492534728028e-09
studies O 0 9.117608890107931e-10
may O 0 6.055254214709649e-11
impact O 0 6.602736690730637e-10
significantly O 0 4.208829285090587e-09
on O 0 1.9863870193148614e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 9.488422074355185e-05
in O 0 4.105906725726527e-10
this O 0 3.3506641905489687e-10
population O 0 1.7270125607371511e-10
. O 0 2.5437678630169103e-09

Localization O 0 0.00027277000481262803
of O 0 6.326873744910699e-07
human O 0 1.2294206896967808e-07
BRCA1 O 0 3.3666442078583714e-08
and O 0 4.130439545946274e-09
its O 0 3.856849950523156e-09
loss O 0 2.0176527470994188e-07
in O 0 3.504370127416223e-08
high O 0 1.4812897006777348e-06
- O 0 9.680634320829995e-07
grade O 0 2.786084769468289e-05
, O 0 1.2419391737239494e-07
non B-Disease 0 0.01763404719531536
- I-Disease 0 0.20042508840560913
inherited I-Disease 1 1.0
breast I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 7.4830741141340695e-06

Although O 0 1.408489680443381e-07
the O 0 3.358998768021593e-08
link O 0 1.872109010037093e-07
between O 0 3.046572416565141e-08
the O 0 3.046166341391654e-07
BRCA1 O 0 6.627208676945884e-06
tumour B-Disease 1 1.0
- O 0 4.84456104459241e-05
suppressor O 0 1.6663938367855735e-05
gene O 0 1.129701754365442e-08
and O 0 2.514535024644715e-09
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 2.2632445961789927e-06
established O 0 7.007941604797452e-08
, O 0 2.3973720231218465e-10
the O 0 1.390311754612128e-09
role O 0 2.107161911624189e-08
, O 0 4.4957929046240963e-10
if O 0 3.2831060092775033e-10
any O 0 1.9170518505973178e-09
, O 0 6.115811745921462e-10
of O 0 5.023150251304287e-08
BRCA1 O 0 5.9060642598751656e-08
in O 0 1.0241499381891117e-07
non B-Disease 1 0.9997274279594421
- I-Disease 1 0.9952706694602966
familial I-Disease 1 0.9999310970306396
cancers I-Disease 1 0.9700924754142761
is O 0 5.809256009570163e-08
unclear O 0 1.2913658338220557e-06
. O 0 2.788436859191279e-07

BRCA1 O 0 1.421338674845174e-05
mutations O 0 4.146694010387364e-08
are O 0 2.115874975228138e-10
rare O 0 2.0496473407405347e-09
in O 0 4.498591277268815e-09
sporadic B-Disease 0 0.00042736108298413455
cancers I-Disease 0 0.28929969668388367
, O 0 1.1556981149851708e-08
but O 0 5.206149289449513e-09
loss O 0 4.395206815388519e-06
of O 0 7.583375918329693e-07
BRCA1 O 0 2.5557328697800585e-08
resulting O 0 1.4629434330615254e-09
from O 0 2.595066106447774e-10
reduced O 0 4.294368749491184e-10
expression O 0 1.2137645333254454e-09
or O 0 7.522461542563974e-10
incorrect O 0 1.59655098030953e-08
subcellular O 0 1.0950050182145787e-06
localization O 0 3.99645728066389e-07
is O 0 9.37175337334395e-10
postulated O 0 1.679751804317675e-08
to O 0 3.947301929763114e-10
be O 0 7.118362010949397e-10
important O 0 5.135857517046816e-09
in O 0 1.5395873020906947e-08
non B-Disease 0 0.0011874064803123474
- I-Disease 0 0.15206044912338257
familial I-Disease 1 0.9999994039535522
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 8.762039942666888e-05

Epigenetic O 0 0.0010101260850206017
loss O 0 3.161211498081684e-05
, O 0 3.37220988910758e-08
however O 0 2.2253644260672445e-08
, O 0 2.0999308958380425e-09
has O 0 3.6598180042091144e-10
not O 0 8.012748103913836e-11
received O 0 5.44028322391199e-10
general O 0 3.366366518875452e-09
acceptance O 0 9.767825659423579e-09
due O 0 5.6732350373067675e-08
to O 0 2.999366754963262e-09
controversy O 0 1.5372606299024483e-08
regarding O 0 1.3721741076722083e-08
the O 0 1.5303241340802742e-08
subcellular O 0 8.119999620248564e-06
localization O 0 1.8137506003768067e-06
of O 0 2.0010153534144592e-08
BRCA1 O 0 1.2718864184080303e-08
proteins O 0 1.2927086068259541e-09
, O 0 7.242785815542163e-10
reports O 0 4.996087987763076e-09
of O 0 8.315056199137416e-09
which O 0 6.914819272729744e-10
have O 0 2.8627514248036334e-10
ranged O 0 6.906416416541106e-08
from O 0 3.587369734603385e-09
exclusively O 0 2.323446501861781e-08
nuclear O 0 6.017246505507501e-07
, O 0 2.1428150365210286e-09
to O 0 1.4261952729910377e-09
conditionally O 0 2.5806263792560458e-08
nuclear O 0 2.5890034294207e-07
, O 0 1.9021513253392186e-09
to O 0 1.3048444547081317e-09
the O 0 8.58542605897128e-08
ER O 0 0.002371713286265731
/ O 0 2.675143605301855e-06
golgi O 0 6.389392183336895e-06
, O 0 3.4545093452464926e-09
to O 0 2.559472855878653e-09
cytoplasmic O 0 7.725043360551354e-07
invaginations O 0 3.227419028917211e-06
into O 0 3.254430325227986e-08
the O 0 1.183987734520997e-07
nucleus O 0 4.613249075191561e-06
. O 0 4.3778783265224774e-07

In O 0 1.290400746256637e-06
an O 0 5.871951813674059e-08
attempt O 0 1.536324560902358e-07
to O 0 6.091855020429193e-09
resolve O 0 1.1367941255002734e-07
this O 0 4.2569228142497195e-09
issue O 0 8.758427760824361e-09
, O 0 7.526667067381254e-10
we O 0 1.864869592083096e-09
have O 0 3.587792007930801e-10
comprehensively O 0 2.086211310370345e-07
characterized O 0 7.913927646541197e-08
19 O 0 2.1817317019667826e-07
anti O 0 1.5375076145573985e-07
- O 0 2.008799128816463e-06
BRCA1 O 0 1.9219353930566285e-07
antibodies O 0 1.2814439287467394e-08
. O 0 4.0521506150525965e-08

These O 0 8.550485830483012e-08
reagents O 0 2.491440227458952e-07
detect O 0 1.9145940655107552e-07
a O 0 7.005001378956877e-08
220 O 0 1.454704374737048e-07
- O 0 9.251981936131415e-08
kD O 0 2.1548803488258272e-05
protein O 0 3.860951736101015e-08
localized O 0 3.037943940853438e-08
in O 0 7.608956242854958e-10
discrete O 0 1.6700623106657986e-08
nuclear O 0 4.017796300104237e-07
foci O 0 4.255477961123688e-06
in O 0 1.9837653741916483e-09
all O 0 2.869640969294096e-09
epithelial O 0 7.402552455459954e-07
cell O 0 1.3961594049760606e-06
lines O 0 4.628202265877235e-09
, O 0 6.167832911074811e-11
including O 0 3.648379168219584e-11
those O 0 9.114126814369072e-11
derived O 0 1.5819042076259393e-08
from O 0 1.9767907133427798e-07
breast B-Disease 0 9.326164581580088e-05
malignancies I-Disease 0 0.00027410636539570987
. O 0 3.613901355947746e-07

Immunohistochemical O 0 0.009867072105407715
staining O 0 3.354166619828902e-05
of O 0 1.3338407143237418e-06
human O 0 7.844225251574244e-07
breast O 0 2.9518762403313303e-06
specimens O 0 5.914948246754648e-07
also O 0 1.0201237188312007e-08
revealed O 0 1.2147306733822916e-06
BRCA1 O 0 9.091083086332219e-08
nuclear O 0 2.3716834220977034e-06
foci O 0 3.1839997973293066e-05
in O 0 2.7026990423451025e-08
benign O 0 0.010395669378340244
breast O 0 2.48242595262127e-05
, O 0 1.7308634880919271e-07
invasive B-Disease 0 0.1567598134279251
lobular I-Disease 1 1.0
cancers I-Disease 1 0.999687671661377
and O 0 1.7352545000903774e-06
low B-Disease 1 1.0
- I-Disease 1 0.9999957084655762
grade I-Disease 1 1.0
ductal I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 1.2531705579021946e-05

Conversely O 0 3.25838518620003e-05
, O 0 1.1053127479954128e-07
BRCA1 O 0 1.3569606949204172e-07
expression O 0 1.0476329137532048e-08
was O 0 2.7248217904229932e-08
reduced O 0 5.042538386845763e-09
or O 0 2.3521788961033963e-09
undetectable O 0 5.053565388379866e-08
in O 0 1.0244557424599066e-09
the O 0 2.6442121825454024e-09
majority O 0 1.9715354349081338e-10
of O 0 1.1172391012337357e-08
high O 0 7.421921282002586e-07
- O 0 2.362313352932688e-06
grade O 0 0.0073945363983511925
, O 0 2.0084657990082633e-06
ductal B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 0 1.900817636624197e-08
suggesting O 0 2.6392857677137727e-08
that O 0 4.891002047813231e-10
absence O 0 4.901990280359314e-08
of O 0 1.9847699661568186e-07
BRCA1 O 0 5.6394881653432094e-08
may O 0 2.0607289208385282e-09
contribute O 0 6.223094040080923e-09
to O 0 4.396796260408564e-09
the O 0 7.00941171771774e-08
pathogenesis O 0 0.00016595998022239655
of O 0 4.2819742418487294e-08
a O 0 3.351809940710382e-09
significant O 0 1.7495587201210583e-09
percentage O 0 1.8449554772814736e-08
of O 0 9.946695023188568e-09
sporadic B-Disease 0 2.6617310140863992e-05
breast I-Disease 0 0.10811371356248856
cancers I-Disease 0 0.0006367831956595182
. O 0 8.666586381878005e-08
. O 0 4.2409035927448713e-07

